Department of Defense Fiscal Year (FY) 2024 Budget Estimates

March 2023



Chemical and Biological Defense Program

Defense-Wide Justification Book Volume 4 of 5

Research, Development, Test & Evaluation, Defense-Wide

UNCLASSIFIED

THIS PAGE INTENTIONALLY LEFT BLANK

UNCLASSIFIED

Chemical and Biological Defense Program • Budget Estimates FY 2024 • RDT&E Program

Table of Volumes

Defense Advanced Research Projects Agency	olume 1
Missile Defense Agency	olume 2
Office of the Secretary Of Defense	olume 3
Chemical and Biological Defense Program	olume 4
Defense Contract Management Agency	olume 5
DoD Human Resources Activity	olume 5
Defense Information Systems Agency	
Defense Logistics Agency	olume 5
Defense Security Cooperation Agency	olume 5
Defense Security Service	olume 5
Defense Technical Information Center	olume 5
Defense Threat Reduction Agency	olume 5
The Joint Staff	olume 5
United States Special Operations Command	olume 5
Washington Headquarters ServiceVo	olume 5
Operational Test and Evaluation, Defense	olume 5

Chemical and Biological Defense Program • Budget Estimates FY 2024 • RDT&E Program

Defense Geospatial Intelligence Agency	(see) NIP	and MIP	Justification Books)
Defense Intelligence Agency	(see	NIP	and MIP	Justification Books)
National Security Agency	(see	NIP	and MIP	Justification Books)

Chemical and Biological Defense Program • Budget Estimates FY 2024 • RDT&E Program

Volume 4 Table of Contents

Introduction and Explanation of Contents	Volume 4 - v
Comptroller Exhibit R-1	Volume 4 - xv
Program Element Table of Contents (by Budget Activity then Line Item Number)	Volume 4 - xxiii
Program Element Table of Contents (Alphabetically by Program Element Title)	Volume 4 - xxvii
Exhibit R-2s	Volume 4 - 1

THIS PAGE INTENTIONALLY LEFT BLANK

UNCLASSIFIED

<u>Chemical and Biological Defense Program</u> <u>Fiscal Year 2024 Budget Overview</u>

The Chemical and Biological Defense Program (CBDP) is vital to the Department of Defense's ability to counter current and future chemical and biological threats. By providing the Joint Force with the capabilities it needs to fight and win in any chemical- and/or biological-contested environment, the CBDP enables a resilient Joint Force able to defend the homeland, deter aggression and strategic attacks against the U.S., Allies, and partners, and prepared to prevail in conflict when necessary. The need for modernized chemical and biological defenses is underscored by many factors. We continue to witness the gradual erosion of international norms against the use of weapons of mass destruction, especially chemical weapons. The COVID-19 pandemic highlighted the critical need for responsive biological defense capabilities to address emerging and advanced biological threats, whether naturally occurring, accidental, or deliberate in nature. Additionally, the sophistication with which chemical and biological weapons can be designed and engineered increases with rapid advances in science and technology, creating new potential risks for the Joint Force. Finally, increased competition with major powers, including the People's Republic of China as the pacing challenge and the Russian Federation as an acute threat, challenges the chemical and biological (CB) defense paradigm. In this new era, it is imperative that the Joint Force has modernized, resilient, and integrated chemical and biological defense capabilities.

The U.S. government clearly recognizes the need to address these CB defense challenges, as evidenced by the 2022 *National Security Strategy* (*NSS*), 2022 *National Defense Strategy* (*NDS*), 2022 *National Biodefense Strategy and Implementation Plan* (*NBS*), 2022-2026 *DoD Strategic Management Plan* (*SMP*), and the Secretary of Defense's 2021 *Biodefense Vision Memo*. Congressional legislation and joint statements with allies and partners similarly recognize this need.

We are in a decisive decade for chemical and biological defense. To stay ahead of chemical and biological threats, the CBDP is pivoting in its approach to defense capability development, moving to a threat- and risk-informed portfolio approach to modernization. This budget request is essential to execute the program pivot. The fiscal year 2024 (FY24) request of \$1,790.3 Million (M) is \$213.8M more than the FY23 enacted, which itself was an increase from FY22. We will not use these funds to do more of what we've always done. Instead, this request aims to transform how the Department researches, develops, and acquires chemical and biological defense capabilities. The CBDP must change faster than the threat.

This change includes reforming our organization and business processes to better deliver capabilities to the warfighter. The CBDP is implementing a new governance framework that ensures alignment to White House and Departmental strategic objectives, strengthens the



warfighter demand signal, and provides better oversight of the CBDP Enterprise. This new framework enables us to pursue a portfolio-based approach to close capability gaps more quickly. The overriding priority is to shrink the time from concept origination to capability delivery. By focusing on innovative system solutions that can be fielded incrementally, we will buy down risk and mitigate single-approach vulnerabilities. These changes will not be easy, but a failure to modernize our chemical and especially biological defense capabilities presents unacceptable risks to the Joint Force and the nation we defend. The CBDP's mission remains unchanged; how we achieve this mission is evolving quickly.

Strategic Overview

The 2022 NSS and 2022 NDS acknowledge an increasingly complex global security environment. The NSS identifies two strategic challenges: the competition between major powers and transboundary issues. Both strategic challenges impact the CBDP. The NSS further identifies the danger of catastrophic biological risks, arguing a "narrow window of opportunity" exists to take "steps nationally and internationally to prepare for the next pandemic and strengthen our biodefense." To address the competition with major powers, the Department has adopted Integrated Deterrence backed by combat-credible military forces. As part of this effort, the NDS calls for improving the Joint Force's ability to operate in the face of limited chemical and biological attacks to deny adversaries the benefits of possessing and using these weapons.

As mentioned above, these geopolitical and scientific factors are transforming the CB threat landscape. The *NDS* identifies the People's Republic of China (PRC) as the pacing challenge, and Russia as an acute threat. The same document lists North Korea and Iran as persistent challenges. All these are actors are pursuing destabilizing weapons of mass destruction (WMD) activities, to include cyber and disinformation. For example, the Department of State's April 2022 Compliance Report is unable to certify that the PRC is in compliance with the Chemical Weapons Convention (CWC). The same report raises concerns about Beijing's compliance with Biological Weapons and Toxins Convention (BWC), pointing to the PRC's dual-use activities. Chinese publications have described biology as a new domain of warfare and PRC leaders aspire to make their country a world leader in genetic engineering, precision-medicine, and brain sciences, among other scientific disciplines. The State Department has also assessed the Russian Federation and Democratic People's Republic of Korea (DPRK) maintain offensive chemical and biological weapons as an asymmetric advantage and relish their potential deterrent threat. To deny them these advantages, the Department must ensure the Total Force is prepared to fight and win in CB contested environments. The CBDP's investments must reflect this objective. The program will focus on being able to manufacture at scale while reducing unit cost. At the same time, CB defense capabilities



must be easy to use and unencumber the warfighter. In every instance, the CBDP will seek to utilize existing Joint Force equipment such as wearables or command and control networks. The program will focus on far forward capabilities that have minimal logistical burdens.

Alongside the geopolitical changes, scientific and technological advancements are transforming the threat landscape. Diverse sciences and technologies—including computational and cognitive science, nanotechnology, physics, and others-- are being applied to the physical and life sciences. The National Intelligence Council has called this bioconvergence and it has enormous implications for the CBDP. Among other effects, bioconvergence has the potential to create exponentially more biological threats and transformative chemical processes, forcing the Department away from only developing countermeasures against a definite list of known threat agents. Instead, the Department must seek broad-spectrum treatments and the ability to rapidly produce countermeasures as new threats emerge.

Bioconvergence could also challenge our ability to attribute the origins of an attack. For that reason, the *NDS* and the Secretary of Defense's *Biodefense Vision* direct the Department to be postured against the full spectrum of biological threats, whether naturally occurring, accidental, or deliberate. The *Biodefense Vision* also asked the Department to conduct the first-of-its kind Biodefense Posture Review (BPR). The BPR will establish the Department's approach to biodefense, to include clarifying biodefense priorities, roles, responsibilities, authorities, capabilities, and posture. As such, the CBDP participated in the BPR as a significant enabler and integrator of CB defense capabilities for the Department and our warfighters.

In many cases, the technologies underpinning bioconvergence have the potential to enhance CB defense. This budget request allows the CBDP to exploit these new technologies to achieve our mission of enabling the Joint Force to fight and win in CB-contested environments.

FY 2024 Portfolio Overview

The FY 2024 budget request of \$1,790.3M supports the Department's strategic priorities and guidance and will enable the continued development of capabilities to increase the resiliency of our warfighters. Enhanced resource levels in the CBDP portfolio also support the Federal preparedness and response efforts to ensure the Nation and the DOD are able to address emerging biological threats. The CBDP investments are aligned to the following portfolios (Figure 1):

• <u>Understand Portfolio (\$725.9M)</u> - Reduces the risk from emerging threats resulting from advances in technology and the increased proliferation of WMD to prevent surprise to the Department and the nation. Efforts focus on accelerating characterization and early assessment of possible CB hazards by leveraging advances in technology and artificial intelligence. Capabilities development seeks to improve tactical and operational commanders' decisions through improved detection, diagnosis and identification capabilities to



support assigned missions. Developmental efforts focus on increasing detection accuracy, range and effectiveness, ensuring that data integrates seamlessly with other non-CB sensor systems and relevant information systems, and integration of sensors onto Service-fielded unmanned platforms.

Protect Portfolio (\$466.5M) – Enhances mission performance and provides effective protection against current and emerging threats by rapidly developing and fielding modernized protection Developmental efforts capabilities. focus on advances in materials and engineering to enhance systems protective properties against a broader array of hazards, while reducing CWMD operational challenges and logistical burdens. Approaches focus on modular and customizable collective protection solutions that are effective against a broad range of challenges in varied environments. Investments seek to improve delivery of medical countermeasures (MCM) the to




Figure 1

warfighter through a platform-based development approach to enable cost effective and agile delivery of prophylactic capabilities for known and emerging threats. Developmental efforts focus on advanced medical countermeasures that provide safe and effective medical defenses against biological agents (bacteria, toxins, and viruses), emerging infectious diseases, and chemical agents.

• <u>Mitigate Portfolio (\$383.1M)</u> – Preserves combat power by developing and fielding systems that mitigate exposure to CB hazards and restore combat readiness of critical personnel and platforms. Developmental efforts address personnel decontamination and materiel decontamination including sensitive equipment and aircraft. Novel decontamination approaches focus on broad decontaminant applicability to CB hazards, while minimizing harm to individuals, equipment, and platforms. Medical countermeasure efforts focus



Volume 4 - ix

on discovery and development of therapeutic products treating biological agents (bacteria, toxins, and viruses), emerging infectious diseases, and chemical agents.

• <u>Enabling Investments (\$214.9M)</u> – Provides fundamental knowledge, support to Research, Development, Testing, and Evaluation (RDT&E) infrastructure, technology demonstrations, and overarching RDT&E support functions as portfolio enablers key to responding to emerging threats. Dedicated funding in this portfolio supports National and Departmental incident response and preparedness to CB threats.

Modernized Chemical and Biological Defense

The CBDP is leaning forward to address the current and future threat landscape while building an agile and adaptable program to ensure execution of Department CB defense priorities. The Department's *SMP* identifies CB defense as a priority (Figure 2) within Strategic Objective 1.4 "Modernize and sustain the nuclear deterrent and protect against chemical and biological threats." Understanding and anticipating threats is central to the CBDP's contribution to implement the *NDS*, *SMP*, the Secretary's *Biodefense Vision*, and to address the threats posed by our adversaries.

Strengthening the focus on countering CB threats, the FY2024 budget request includes increased resources to modernize biodefense approaches. At this pivotal time, the

Department can no longer rely on a static list of historical bio-weapons agents; instead, the Department must aggressively assess, predict,

Strategic Objective 1.4: Modernize and sustain the nuclear deterrent and protect against chemical and biological threats Strategic Objective Lead: Office of the Under Secretary of Defense for Acquisition & Sustainment (OUSD(A&S))

To ensure that the U.S. nuclear deterrent remains safe, secure, reliable, and effective, OUSD(A&S) will continue guiding and directing the highly complex and interdependent set of nuclear modernization and sustainment programs. As growing chemical and biological threats emerge and converge, we will similarly reform approaches to surveillance, detection, preparedness, and response, as well as advance development of revolutionary defense capabilities.












prepare for, respond to, and recover from the full spectrum of biological threats whether naturally occurring, accidental, or deliberate. The FY2024 budget request will allow the Department to make vital investments in novel and advanced biodefense capabilities.

The CBDP's biodefense modernization efforts aligns to clear operational capability end states. These strategic investments will focus on technologies that enable a more agile and responsive Joint Force, while addressing the dynamic and evolving biological threat landscape.



Further, these investments will enable the Department to change its approach to biological defense by modernizing the current operating paradigms including novel sciences and technologies that drive the United States' dynamic private industry. These additional resources will allow the Department to prioritize and support Joint All-Domain Operations and integrate the Department's biodefense capabilities with interagency investments. Ultimately, this approach will posture the Department to quickly detect and identify emerging biological threats, reduce risks, and prepare for, respond to, and recover from any type of biological threat-based event.

The enhanced investment levels are focused on advancing five key overarching goals aligned to the *NBS* and 2021 American Pandemic Preparedness Plan:

(1) Enhancing Rapid Response Vaccine Platforms Research and Manufacturing

- Establish key partnerships and exploit successful vaccine platforms, prototypes, and manufacturing capabilities
- Enhance the discovery or development of rapid response vaccine platforms research and manufacturing

(2) Expediting Surveillance and Pathogen Characterization (including diagnostics and detection)

- Enhance the flow of surveillance data and samples through a network of laboratories
- Expands deployable analytical capabilities, wearable technologies and leverages data analysis and modeling with machine learning/artificial intelligence





(3) Expanding Protection & Hazard Mitigation Capabilities

 Accelerates prototyping and delivery of low-burden biothreat respiratory protection, collective protection, isolation systems, and improved disinfection

(4) Evolving Therapeutics Research and Development

• Focused on delivering or making available Food and Drug Administration (FDA) approved MCM products or tests to the warfighter that can either be immediately deployed in far-forward settings or included with the warfighter prior to deployment

(5) Enhancing Biodefense Workforce and Biosafety

• Adds critical technical expertise enhancing the CBDP biodefense and biosecurity activities and supply chain resiliency

FY 2024 Budget Request Highlights

This budget shifts to an integrated portfolio approach that will reduce risk in research, development, and acquisition and more quickly deliver capabilities into the warfighter's hands. FY 2024 investments continue to invest in Service and Combatant Commander priorities, to include focused efforts providing rapid capability for the Special Operations Forces.

RDT&E

The FY 2024 RDT&E budget request of \$1,398.6 million supports key efforts including:

- \$355.5 million supporting enhanced biodefense and pandemic preparedness efforts. Efforts are focused on accelerating characterization and situational awareness of emerging biothreats, optimizing MCM manufacturing, and accelerating delivery of improved protection from and mitigation of biothreats, including rapid repurposing of available therapeutics and development of new vaccines.
- \$560.6 million to implement the new approach to research, development, and acquisition of MCMs, such as vaccines and therapeutics, addressing high-priority biological and chemical hazards.
- \$333.9 million supporting RDT&E efforts advancing environmental detection and medical diagnostic capabilities providing enhanced situational awareness of traditional and non-traditional chemical hazards, as well as traditional and emerging biological hazards.
- \$101.9 million supporting integrated early warning, warning & reporting, decision support, and modeling and simulation capabilities.





- \$112.6 million supporting RDT&E for personnel protection, respiratory and ocular protection, collective protection, and hazard mitigation capabilities against traditional and non-traditional CB agents.
- \$79.0 million supporting basic research and threat agent sciences, advancing fundamental knowledge and experimental research in the life and physical sciences.
- \$54.5 million supporting improved domestic incident preparedness and response to include dedicated efforts improving capabilities to address potential future pandemic and biological incidents. Additionally, these resources provide funding supporting the DoD Medical Countermeasures Advanced Development and Manufacturing capability.
- \$41.1 million supporting concepts development, technology demonstrations, enhanced capability demonstrations, and Special Operations Forces Rapid Capability Development and Deployment to enhance military operational capabilities with technologies and equipment. Resources a dedicated innovation fund to rapidly address emerging threats.

Procurement

The FY 2024 Procurement budget request of \$391.7 million supports key efforts including:

- \$85.9 million to procure improved air crew and ground forces protective ensembles to increase protection against advanced chemical and biological threats and decrease physiological burden.
- \$84.5 million to procure systems providing improved diagnostic, detection and identification capabilities with decreased operational costs and increased reliability for detection and diagnosis of biological and agents. Includes efforts providing portable chemical detection capabilities and improved multi-phase sampling and detection.
- \$60.5 million to procure CBRN Dismounted Reconnaissance Sets, Kits, and Outfits which allows warfighters to perform CBRN dismounted reconnaissance, surveillance, and site assessment of WMD suspect areas not accessible by traditional CBRN reconnaissance-mounted platforms.
- \$49.5 million to procure near-term urgent CBD requirements providing Special Operations Forces (SOF) critical life-saving protective capabilities and systems to safely operate in a CB-contaminated environment.
- \$24.1 million to procure the Advanced Anticonvulsant System providing a midazolam autoinjector for treatment against nerve induced seizures supporting operational readiness.



Summary

The last several years have demonstrated the increased probability and expansion of CB threats and technologies as the greatest challenges facing the United States of America, so the Department must prioritize improving our ability to counter these new and emerging threats. Currently, the erosion of international norms regarding the use of CB weapons, acceleration and advances in science and technology, and the re-emergence of strategic competition all worsen the current CB threat environment. The CBDP \$1,790.3M request focuses on key efforts across the Understand, Protect, Mitigate and Enable portfolios to provide new CB defense capabilities. Amid this new technological revolution, the United States must continue modernizing our defensive capabilities and reinvest in the Department's scientific and technological edge.



THIS PAGE INTENTIONALLY LEFT BLANK

UNCLASSIFIED

Department of Defense FY 2024 President's Budget Exhibit R-1 FY 2024 President's Budget Total Obligational Authority (Dollars in Thousands)

Appropriation	 FY 2022 Actuals	FY 2023 Less Supplementals Enactment	FY 2023 Supplementals Enactment*	FY 2023 Total Enactment	FY 2024 Request
Research, Development, Test and Evaluation, Defense-Wide	1,050,175	1,257,964		1,257,964	1,398,625
Total Research, Development, Test, & Evaluation	1,050,175	1,257,964		1,257,964	1,398,625

*Includes enacted funding in the Ukraine Supplemental Appropriation Act, 2023 (Division B of Public Law 117-180) and Additional Ukraine Supplemental Appropriation Act, 2023 (Division M of Public Law 117-328).

Volume 4 - xv

Department of Defense FY 2024 President's Budget Exhibit R-1 FY 2024 President's Budget Total Obligational Authority (Dollars in Thousands)

	FY 2022 Actuals	FY 2023 Less Supplementals Enactment	FY 2023 Supplementals Enactment*	FY 2023 Total Enactment	FY 2024 Request
Summary Recap of Budget Activities					<i>v</i> .
Basic Research	35,327	39,734		39,734	36,235
Applied Research	205,018	244,364		244,364	240,610
Advanced Technology Development	191,695	226,225		226,225	240,010
Advanced Component Development & Prototypes	133,902	252,010			
				252,010	316,853
System Development & Demonstration	291,122	301,611		301,611	382,977
Management Support	137,752	128,432		128,432	74,382
Operational Systems Development	55,359	65,588		65,588	80,495
Total Research, Development, Test, & Evaluation	1,050,175	1,257,964		1,257,964	1,398,625
Summary Recap of FYDP Programs					
Research and Development	1,050,175	1,257,964		1,257,964	1,398,625
Total Research, Development, Test, & Evaluation	1,050,175	1,257,964		1,257,964	1,398,625

*Includes enacted funding in the Ukraine Supplemental Appropriation Act, 2023 (Division B of Public Law 117-180) and Additional Ukraine Supplemental Appropriation Act, 2023 (Division M of Public Law 117-328).

Defense-Wide FY 2024 President's Budget Exhibit R-1 FY 2024 President's Budget Total Obligational Authority (Dollars in Thousands)

	FY 2022 Actuals	FY 2023 Less Supplementals Enactment	FY 2023 Supplementals Enactment*	FY 2023 Total Enactment	FY 2024 Request
Summary Recap of Budget Activities					
Basic Research	35,327	39,734		39,734	36,235
Applied Research	205,018	244,364		244,364	240,610
Advanced Technology Development	191,695	226,225		226,225	267,073
Advanced Component Development & Prototypes	133,902	252,010		252,010	316,853
System Development & Demonstration	291,122	301,611		301,611	382,977
Management Support	137,752	128,432		128,432	74,382
Operational Systems Development	55,359	65,588		65,588	80,495
Total Research, Development, Test, & Evaluation	1,050,175	1,257,964		1,257,964	1,398,625
Summary Recap of FYDP Programs					
Research and Development	1,050,175			1,257,964	1,398,625
Total Research, Development, Test, & Evaluation	1,050,175	1,257,964		1,257,964	1,398,625

*Includes enacted funding in the Ukraine Supplemental Appropriation Act, 2023 (Division B of Public Law 117-180) and Additional Ukraine Supplemental Appropriation Act, 2023 (Division M of Public Law 117-328).

Defense-Wide FY 2024 President's Budget Exhibit R-1 FY 2024 President's Budget Total Obligational Authority (Dollars in Thousands)

Appropriation	FY 2022 Actuals	FY 2023 Less Supplementals Enactment	FY 2023 Supplementals Enactment*	FY 2023 Total Enactment	FY 2024 Request
Chemical and Biological Defense Program	1,050,175	1,257,964		1,257,964	1,398,625
Total Research, Development, Test and Evaluation, Defense-Wide	1,050,175	1,257,964		1,257,964	1,398,625

*Includes enacted funding in the Ukraine Supplemental Appropriation Act, 2023 (Division B of Public Law 117-180) and Additional Ukraine Supplemental Appropriation Act, 2023 (Division M of Public Law 117-328).

Page 4

Defense-Wide FY 2024 President's Budget Exhibit R-1 FY 2024 President's Budget Total Obligational Authority (Dollars in Thousands)

Appropriation: 0400D Research, Development, Test and Evaluation, Defense-Wide

Line <u>No</u>	Program Element <u>Number</u>	Item	Act	<u>Se</u> C	FY 2022 Actuals	FY 2023 Less Supplementals Enactment	FY 2023 Supplementals Enactment	FY 2023 Total Enactment
8	0601384BP	Chemical and Biological Defense Program	01	U	35,327	39,734		39,734
	Basic Resear	rch			35,327	39,734		39,734
17	0602384BP	Chemical and Biological Defense Program	02	υ	205,018	244,364		244,364
	Applied Rese	earch			205,018	244,364		244,364
49	0603384BP	Chemical and Biological Defense Program - Advanced Developmen	t 03	U	191,695	226,225		226,225
	Advanced Tec	chnology Development		200	191,695	226,225		226,225
79	0603884BP	Chemical and Biological Defense Program - Dem/Val	04	U	133,902	252,010		252,010
	Advanced Cor	mponent Development & Prototypes			133,902	252,010		252,010
132	0604384BP	Chemical and Biological Defense Program - EMD	05	U	291,122	301,611		301,611
	System Devel	lopment & Demonstration		_	291,122	301,611		301,611
163	0605384BP	Chemical and Biological Defense Program	06	U	116,573	126,432		126,432
164	0605502BP	Small Business Innovative Research - Chemical Biological Def	06	U	21,179	2,000		2,000
	Management S	Support			137,752	128,432		128,432
		Chemical and Biological Defense (Operational Systems						
208	0607384BP	Development)	07	U _	55,359	65,588		65,588
	Operational	Systems Development			55,359	65,588		65,588
Total	Research, Dev	velopment, Test and Evaluation, Defense-Wide			1,050,175	1,257,964		1,257,964

*Includes enacted funding in the Ukraine Supplemental Appropriation Act, 2023 (Division B of Public Law 117-180) and Additional Ukraine Supplemental Appropriation Act, 2023 (Division M of Public Law 117-328).

Page 5

Volume 4 - xix

Defense-Wide FY 2024 President's Budget Exhibit R-1 FY 2024 President's Budget Total Obligational Authority (Dollars in Thousands)

Appropriation: 0400D Research, Development, Test and Evaluation, Defense-Wide

	Program				
Line	Element			Se	FY 2024
No	Number	Item	Act	<u> </u>	Request
8	0601384BP	Chemical and Biological Defense Program	01	υ	36,235
	Basic Resear	ch			36,235
17	0602384BP	Chemical and Biological Defense Program	02	U	240,610
	Applied Resea	arch		22	240,610
49	0603384BP		0.0		0.62 0.20
49		Chemical and Biological Defense Program - Advanced Development	03	U	267,073
	Advanced Tech	hnology Development			267,073
79	0603884BP	Chemical and Biological Defense Program - Dem/Val	04	υ	316,853
	Advanced Com	ponent Development & Prototypes			316,853
132	0604384BP	Chemical and Biological Defense Program - EMD	05	U	382,977
	System Devel	opment & Demonstration			382,977
163	0605384BP	Chemical and Biological Defense Program	06	U	74,382
164	0605502BP	Small Business Innovative Research - Chemical Biological Def	06	U	
	Management S				74,382
		Chemical and Biological Defense (Operational Systems			
208	0607384BP	Development)	07	U .	80,495
	Operational :	Systems Development			80,495
Total	Research, Dev	elopment, Test and Evaluation, Defense-Wide			1,398,625

Volume 4 - xx

Chemical and Biological Defense Program FY 2024 President's Budget Exhibit R-1 FY 2024 President's Budget Total Obligational Authority (Dollars in Thousands)

Appropriation: 0400D Research, Development, Test and Evaluation, Defense-Wide

Line <u>No</u>	Program Element <u>Number</u>	Item	Act		FY 2022 Actuals	FY 2023 Less Supplementals Enactment	FY 2023 Supplementals Enactment	FY 2023 Total Enactment
8	0601384BP	Chemical and Biological Defense Program	01	U	35,327	39,734		39,734
	Basic Resear	rch			35,327	39,734		39,734
17	0602384BP	Chemical and Biological Defense Program	02	U	205,018	244,364		244,364
	Applied Rese	earch			205,018	244,364		244,364
49	0603384BP	Chemical and Biological Defense Program - Advanced Development	t 03	U	191,695	226,225		226,225
	Advanced Tec	chnology Development		-	191,695	226,225		226,225
79	0603884BP	Chemical and Biological Defense Program - Dem/Val	04	U	133,902	252,010		252,010
	Advanced Con	mponent Development & Prototypes			133,902	252,010		252,010
132	0604384BP	Chemical and Biological Defense Program - EMD	05	U	291,122	301,611		301,611
	System Devel	Lopment & Demonstration			291,122	301,611		301,611
163	0605384BP	Chemical and Biological Defense Program	06	U	116,573	126,432		126,432
164	0605502BP	Small Business Innovative Research - Chemical Biological Def	06	U	21,179	2,000		2,000
	Management S	Support Chemical and Biological Defense (Operational Systems			137,752	128,432		128,432
208	0607384BP	Development)	07	υ	55,359	65,588		65,588
	Operational	Systems Development		200	55,359	65,588		65,588
Total	Chemical and	Biological Defense Program			1,050,175	1,257,964		1,257,964

*Includes enacted funding in the Ukraine Supplemental Appropriation Act, 2023 (Division B of Public Law 117-180) and Additional Ukraine Supplemental Appropriation Act, 2023 (Division M of Public Law 117-328).

Page 7

Volume 4 - xxi

Chemical and Biological Defense Program FY 2024 President's Budget Exhibit R-1 FY 2024 President's Budget Total Obligational Authority (Dollars in Thousands)

Appropriation: 0400D Research, Development, Test and Evaluation, Defense-Wide

	Program				
Line	Element			Se	FY 2024
No	Number	Item	Act	<u> </u>	Request
8	0601384BP	Chemical and Biological Defense Program	01	υ	36,235
	Basic Resear	ch			36,235
17	0602384BP	Chemical and Biological Defense Program	02	U	240,610
	Applied Rese	arch		-	240,610
49	0603384BP	Chemical and Biological Defense Program - Advanced Development	03	υ	267,073
	Advanced Tec	hnology Development			267,073
79	0603884BP	Chemical and Biological Defense Program - Dem/Val	04	U	316,853
	Advanced Com	ponent Development & Prototypes			316,853
132	0604384BP	Chemical and Biological Defense Program - EMD	05	U	382,977
	System Devel	opment & Demonstration		_	382,977
163	0605384BP	Chemical and Biological Defense Program	06	U	74,382
164	0605502BP	Small Business Innovative Research - Chemical Biological Def	06	υ	
	Management S	upport			74,382
		Chemical and Biological Defense (Operational Systems			
208	0607384BP	Development)	07	U	80,495
	Operational	Systems Development			80,495
Total	Chemical and	Biological Defense Program			1,398,625

Chemical and Biological Defense Program • Budget Estimates FY 2024 • RDT&E Program

Program Element Table of Contents (by Budget Activity then Line Item Number)

Appropriation 0400: Research, Development, Test & Evaluation, Defense-Wide

Line #	Budget Activity	Program Element Number	Program Element Title	Page
8	01	0601384BP	Chemical and Biological Defense Program	Volume 4 - 1
Appropria	tion 0400: Researc	h, Development, Test & Evaluatio	on, Defense-Wide	
Line #	Budget Activity	Program Element Number	Program Element Title	Page
17	02	0602384BP	Chemical and Biological Defense Program	Volume 4 - 9
Appropria		h, Development, Test & Evaluatio Program Element Number	on, Defense-Wide Program Element Title	Page
49	03	0603384BP	Chemical and Biological Defense Program - Advanced Development	Volume 4 - 63

Chemical and Biological Defense Program • Budget Estimates FY 2024 • RDT&E Program

Appropriation 0400: Research, Development, Test & Evaluation, Defense-Wide

Line #	Budget Activit	y Program Element Number	Program Element Title	Page
79	04	0603884BP	Chemical and Biological Defense Program - Dem/ValVolume	4 - 133

Appropriation 0400: Research, Development, Test & Evaluation, Defense-Wide

Line #	Budget Activity	/ Program Element Number	Program Element Title	Page
132	05	0604384BP	Chemical and Biological Defense Program - EMD Volum	e 4 - 247

Appropriation 0400: Research, Development, Test & Evaluation, Defense-Wide

Line #	Budget Activi	ty Program Element Number	Program Element Title	Page
163	06	0605384BP	Chemical and Biological Defense Program	/olume 4 - 405
164	06	0605502BP	Small Business Innovative Research - Chemical Biological Def	/olume 4 - 427

Chemical and Biological Defense Program • Budget Estimates FY 2024 • RDT&E Program

Appropriation 0400: Research, Development, Test & Evaluation, Defense-Wide

Line #	Budget Activity	y Program Element Number	Program Element Title	Page
208	07	0607384BP	Chemical and Biological Defense (Operational Systems Development)Volum	e 4 - 431

THIS PAGE INTENTIONALLY LEFT BLANK

UNCLASSIFIED

Volume 4 - xxvi

Chemical and Biological Defense Program • Budget Estimates FY 2024 • RDT&E Program

Program Element Table of Contents (Alphabetically by Program Element Title)

Program Element Title	Program Element Number	Line #	BA Page
Chemical and Biological Defense (Operational Systems Development)	0607384BP	208	07Volume 4 - 431
Chemical and Biological Defense Program	0601384BP	8	01Volume 4 - 1
Chemical and Biological Defense Program	0602384BP	17	02Volume 4 - 9
Chemical and Biological Defense Program	0605384BP	163	06 Volume 4 - 405
Chemical and Biological Defense Program - Advanced Development	0603384BP	49	03 Volume 4 - 63
Chemical and Biological Defense Program - Dem/Val	0603884BP	79	04 Volume 4 - 133
Chemical and Biological Defense Program - EMD	0604384BP	132	05 Volume 4 - 247
Small Business Innovative Research - Chemical Biological Def	0605502BP	164	06 Volume 4 - 427

THIS PAGE INTENTIONALLY LEFT BLANK

UNCLASSIFIED

Volume 4 - xxviii

Exhibit R-2, RDT&E Budget Iten	n Justificat	ion: PB 202	24 Chemica	l and Biolog	gical Defens	e Program				Date: Marc	ch 2023	
Appropriation/Budget Activity 0400: <i>Research, Development, Te</i> <i>Research</i>	est & Evalua	ation, Defen	se-Wide I B			am Element 34BP / Chen			fense Progr	ram		
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
Total Program Element	0.000	35.327	39.734	36.235	0.000	36.235	37.812	43.264	49.270	50.188	Continuing	Continuing
LF1: Life Sciences (Basic Research)	-	19.114	19.199	20.335	0.000	20.335	21.125	26.206	29.030	29.575	Continuing	Continuing
PS1: Physical Sciences (Basic Research)	-	16.213	20.535	15.900	0.000	15.900	16.687	17.058	20.240	20.613	Continuing	Continuing

A. Mission Description and Budget Item Justification

This program element (PE) resources basic research efforts directed at promoting theoretical and experimental research in Life and Physical Sciences. These efforts are part of an integrated portfolio addressing emerging chemical and biological (CB) threats, and are a key enabler supporting the Understand, Protect, and Mitigate portfolios. Basic research focuses on pursuing fundamental science to advance a greater understanding of threats, improve situational awareness of emerging threats, and support transformative research in emerging research areas that can potentially foster paradigm shifts in the CB defense research arena to a rapid response capability.

Individual projects include:

- Life Sciences (LF1): fundamental efforts to understand living systems' response to biological or chemical agents to support detection, diagnostics, protection, and medical treatment (e.g., microbiology, biochemistry, pathogenic mechanisms, cell and molecular biology, immunology, nanoscale science, and information science).

- Physical Sciences (PS1): fundamental scientific phenomena to support the investigation of physical and chemical properties and interactions for enhanced functionalities important to detection, diagnostics, protection, and decontamination (e.g., chemistry, physics, materials science, nanotechnologies, nanoscale science, and environmental science).

ibit R-2, RDT&E Budget Item Justification: PB 2024 C	hemical and Biolog	gical Defense P	rogram	Date	: March 2023	
propriation/Budget Activity 0: Research, Development, Test & Evaluation, Defense-Wassearch			Element (Number/Name) I Chemical and Biologica			
Program Change Summary (\$ in Millions)	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024	Total
Previous President's Budget	37.208	34.734	35.341	-	3	5.341
Current President's Budget	35.327	39.734	36.235	-	3	6.235
Total Adjustments	-1.881	5.000	0.894	-		0.894
 Congressional General Reductions 	-	-				
 Congressional Directed Reductions 	-	-				
 Congressional Rescissions 	-	-				
 Congressional Adds 	-	5.000				
 Congressional Directed Transfers 	-	-				
 Reprogrammings 	-1.022	-				
 SBIR/STTR Transfer 	-0.859	-				
Other Adjustments	-	-	0.894	-		0.894
Congressional Add Details (\$ in Millions, and Inclu	ides General Red	<u>uctions)</u>		ſ	FY 2022	FY 2023
Project: PS1: Physical Sciences (Basic Research)					t	
Congressional Add: Physical Sciences				-	2.500	5.00
			Congressional Add Subto	tals for Project: PS1	2.500	5.0
			Congressional Add T	otals for all Projects	2.500	5.0

Change Summary Explanation

Funding: FY 2022 (+\$2.500 Million): Congressional Add for chemically resistant, high-performance military cordage, rope and webbing is included in the Previous President's Budget total.

FY 2022 (-\$1.022 Million): Below threshold reprogramming to support priority protection and hazard mitigation efforts within Advanced Technology Development. FY 2022 (-\$0.859 Million): Transfer of funding to support Small Business Innovative Research/Small Business Technology Transfer efforts.

FY 2023 (+\$5.000 Million): Congressional Add for waterless solutions for decontamination.

FY 2024 (+\$0.894 Million): Basic Research enhancements for strategic competition (+\$0.722 Million) and Departmental inflation rate adjustments (+\$0.172 Million).

Schedule: N/A

Technical: N/A

Exhibit R-2A, RDT&E Project J	ustification	: PB 2024 C	Chemical and	d Biologica	l Defense P	rogram				Date: Marc	ch 2023	
Appropriation/Budget Activity 0400 / 1						34BP / Cher	t (Number/ nical and Bi	,	Project (N LF1 / Life S		,	rch)
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
LF1: Life Sciences (Basic Research)	-	19.114	19.199	20.335	0.000	20.335	21.125	26.206	29.030	29.575	Continuing	Continuing

A. Mission Description and Budget Item Justification

This Project (LF1) focuses on fundamental efforts to understand living systems' responses to biological or chemical agents to support detection, protection, diagnostics, and medical treatment. Research focuses on studying factors that influence the behavior of chemicals, toxins, and pathogens in relation to the host or target. Understanding host/agent interactions can drive the exploration of novel approaches to detect, diagnose or protect against threats. Research also focuses on medical countermeasures for improved efficacy against a wide array of current and future threat agents. This project is a key enabler supporting the Understand, Protect, and Mitigate portfolios.

Individual efforts in this Project include:

- Research to understand threats focused on illuminating pathogen/host interactions, innate and targeted immune responses, and drug/pathogen interactions that enable the development of new medical countermeasures and diagnostic platforms.

- Research in advancing countermeasures to understand underpinnings necessary to advance translational animal models for human disease, to explore artificial intelligence/machine learning (AI/ML) and novel structural biology approaches for enhancing rapid medical defense capabilities, to seek platform technologies with broad flexibility for drug development, and to improve protective factors for increasing therapeutic efficacy.

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2022	FY 2023	FY 2024
Title: 1) Life Sciences	19.114	19.199	20.335
Description: Focuses on fundamental efforts to understand living systems' responses to biological agents, providing knowledge and capabilities that support medical countermeasure development for prophylaxis and therapeutic interventions.			
 FY 2023 Plans: Organoid Technology - Investigate cellular toxicity and metabolic profiles in organoids and evaluate relevance to animal model data. Determine inflammatory signaling in mouse models that are relevant to human cells. Pathogenesis - Assess peptide protection against multiple subtype viral insult in mouse model. Assess influence of gene expression following viral infection. Structural Biology - Investigate efficacy of inhibitor molecules in mouse models. Evaluate anti-alphavirus peptide for efficacy of reduced viral load in animal models. Design synthesis loop for production and testing of small molecules and validate machine-learning predictions. 			

Exhibit R-2A, RDT&E Project Justif	fication: PB 2	2024 Chemic	cal and Biolo	ogical Deten	se Program				Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 1				PE 06	rogram Eler 01384BP / C se Program				t (Number/I ife Sciences	Name) s (Basic Rese	arch)
B. Accomplishments/Planned Prog	<u>ırams (\$ in M</u>	lillions)							FY 2022	FY 2023	FY 2024
 Artificial Intelligence (AI) for Early D selection. Evaluate model response generate therapeutic Monoclonal ant Biomarkers - Begin testing machine binders to expanded data set of path Inflammation Mapping - Validate ge integrate machine learning for predict 	to changing c ibodies agains learning moc ogens. ne protection	conditions an st bacterial to del to predict against che	nd extend for argets and s t cellular bin mical toxicit	recasting to screen for ef iding site tar	additional di fficacy. gets. Demo s neuron reg	seases. Us nstrate scree generation.	e Al model to ening framew				
 Organoid Technology - Continue to animal model data. Determine prima Pathogenesis - Continue to assess 	ry metabolite peptide protect	production i ction agains	in mouse ce	ells.	-						
of transcriptional changes on neurona - Structural biology - Continue investi alphavirus peptide to describe mecha machine-learning predictions. - Artificial Intelligence (AI) for Early D Continue to evaluate model response combine small molecule and therape - Biomarkers - Begin iterative improve learning architecture and sampling fo - Inflammation Mapping - Begin testir molecules and demonstrate molecula	gating efficacy anism of action rug Discovery to changing utic Monoclon ement of mach or iterative exp ng of novel me ar design agai	y of inhibitor n. Generate / - Develop a conditions a nal antibodie hine-learning perimental de edical counte inst in vitro d	experiment active learnin and extend for a against ba g model to p esign. ermeasures	al data for te ng strategy f orecasting to acterial targe oredict cellul	esting of sma to guide sele additional o ets and scree ar binding si	all molecules ection and m diseases. Us en for efficac te targets. I	and validate olecular scre e Al model to y. ntegrate mac	ening. o chine-			
 Structural biology - Continue investi alphavirus peptide to describe mecha machine-learning predictions. Artificial Intelligence (AI) for Early D Continue to evaluate model response combine small molecule and therape Biomarkers - Begin iterative improve learning architecture and sampling fo Inflammation Mapping - Begin testir 	gating efficacy anism of action rug Discovery to changing utic Monoclon ement of mach or iterative exp ng of novel me ar design agai	y of inhibitor n. Generate / - Develop a conditions a hal antibodie hine-learning perimental de edical counte inst in vitro d	experiment active learnin and extend for a against ba g model to p esign. ermeasures	al data for te ng strategy t orecasting to acterial targe oredict cellul in an in vitro	esting of sma to guide sele o additional o ets and scree ar binding si o nerve mod	all molecules ection and m diseases. Us en for efficac te targets. I el. Begin va	and validate olecular scre te Al model to y. ntegrate mac lidation of se	ening. o chine- lect			
 Structural biology - Continue investi alphavirus peptide to describe mecha machine-learning predictions. Artificial Intelligence (AI) for Early D Continue to evaluate model response combine small molecule and therape Biomarkers - Begin iterative improve learning architecture and sampling for Inflammation Mapping - Begin testir molecules and demonstrate molecula 	gating efficacy anism of action rug Discovery to changing utic Monoclon ement of mach or iterative exp ng of novel me ar design agai	y of inhibitor n. Generate / - Develop a conditions a hal antibodie hine-learning perimental de edical counte inst in vitro d	experiment active learnin and extend for a against ba g model to p esign. ermeasures	al data for te ng strategy t orecasting to acterial targe oredict cellul in an in vitro	esting of sma to guide sele o additional o ets and scree ar binding si o nerve mod	all molecules ection and m diseases. Us en for efficac te targets. I el. Begin va	and validate olecular scre e Al model to y. ntegrate mac	ening. o chine- lect	19.114	19.199	20.33
 Structural biology - Continue investi alphavirus peptide to describe mecha machine-learning predictions. Artificial Intelligence (AI) for Early D Continue to evaluate model response combine small molecule and therape Biomarkers - Begin iterative improve learning architecture and sampling for Inflammation Mapping - Begin testir molecules and demonstrate molecula 	gating efficacy anism of action rug Discovery to changing utic Monoclon ement of mach or iterative exp ng of novel me ar design agai case Stateme n adjustments.	y of inhibitor n. Generate / - Develop a conditions a hal antibodie hine-learning berimental de edical counte inst in vitro d ent:	experiment active learnin and extend for s against ba g model to p esign. ermeasures lata.	al data for te ng strategy to orecasting to acterial targe oredict cellul in an in vitro Accon	esting of sma to guide sele o additional o ets and scree ar binding si o nerve mod	all molecules ection and m diseases. Us en for efficac te targets. I el. Begin va	and validate olecular scre te Al model to y. ntegrate mac lidation of se	ening. o chine- lect	19.114		
 Structural biology - Continue investi alphavirus peptide to describe mecha machine-learning predictions. Artificial Intelligence (AI) for Early D Continue to evaluate model response combine small molecule and therape Biomarkers - Begin iterative improve learning architecture and sampling for Inflammation Mapping - Begin testir molecules and demonstrate molecula FY 2023 to FY 2024 Increase/Decree Minor change due to routine program 	gating efficacy anism of action rug Discovery to changing utic Monoclon ement of mach or iterative exp ng of novel me ar design agai case Stateme n adjustments.	y of inhibitor n. Generate / - Develop a conditions a hal antibodie hine-learning berimental de edical counte inst in vitro d ent:	experiment active learnin and extend for a against ba g model to p esign. ermeasures	al data for te ng strategy t orecasting to acterial targe oredict cellul in an in vitro	esting of sma to guide sele o additional o ets and scree ar binding si o nerve mod	all molecules ection and m diseases. Us en for efficac te targets. I el. Begin va	and validate olecular scre te Al model to y. ntegrate mac lidation of se	ening. o chine- lect		19.199 <u>Cost To</u> 8 <u>Complete</u> 0.000	Total Cos

PE 0601384BP: Chemical and Biological Defense Program Chemical and Biological Defense Program Page 4 of 8

Volume 4 - 4

Exhibit R-2A, RDT&E Project Justi	fication: PB	2024 Chemi	ical and Biol	ogical Defer	se Program				Date: Ma	rch 2023	
Appropriation/Budget Activity					rogram Eler	•	,		Number/Na		
0400 / 1					01384BP / C se Program	hemical and	l Biological	LF1 / Life	Sciences (Basic Resea	arch)
C. Other Program Funding Summa	ry (\$ in Milli	ons <u>)</u>									
			<u>FY 2024</u>	<u>FY 2024</u>	<u>FY 2024</u>					<u>Cost To</u>	<u>.</u>
Line Item	FY 2022	FY 2023	Base	000	<u>Total</u>	FY 2025	FY 2026	FY 2027	FY 2028	<u>Complete</u>	Total Cost
• PT2: Protect (Applied Research)	-	58.091	55.057	-	55.057	56.153	57.817	61.452	61.452	Continuing	Continuing
 TM2: Techbase Medical 	107.608	-	-	-	-	-	-	-	-	0.000	107.608
Defense (Applied Research)											
UN2: Understand	-	112.952	119.182	-	119.182	111.773	107.842	107.193	107.193	Continuing	Continuing
(Applied Research)										-	-
<u>Remarks</u>											

D. Acquisition Strategy

N/A

Appropriation/Budget Activity 0400 / 1	ustification	: PB 2024 (inemical an	a Biologica	I Detense P R-1 Progra PE 060138 <i>Defense Pi</i>	am Elemen 4BP / Cher	•			Date: Mar umber/Nar sical Science		Research)
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
PS1: Physical Sciences (Basic Research)	-	16.213	20.535	15.900	0.000	15.900	16.687	17.058	20.240	20.613	Continuing	Continuin
A. Mission Description and Buc This Project (PS1) advances fun- nanotechnology that could poten supporting the Understand, Prote Individual efforts in this Project in - Innovative materials focuses or would enable novel, advanced ca - Novel sensing research to impr detection, diagnostics, hazard mi - Modeling sciences research to	damental so tially lead to ect, and Miti nclude: n understand apabilities fo ove the und itigation and explore the	cientific know b transforma gate portfol ding the phy or decontam lerstanding d protection. potential of	wledge in ph tional CB do ios. vsics, physic ination, pro of elementa Artificial Inte	efensive ca cal propertie tection and ry physics o elligence/M	pabilities en es, fabricatic detection o or fundamer achine Lear	hancing Wa on pathways f chemical a ntal materia	arfighter per s, and chara and biologic ls properties	formance ar acterization n al (CB) threa s to construc	nd safety. nethods re ats. ct novel pla	This project lated to ma tforms and	tt is a key en terial classe approaches	nabler es that
physio-monitoring, rational and ra	apid design	of medical (countermea	sures, and						azaro mitiga	ation, stand	-off
B Accomplishments/Planned F	Programs (S	t in Million	s)	,	novel mater					-	r	
B. Accomplishments/Planned F <i>Title:</i> 1) Physical Sciences	Programs (S	<u>\$ in Million</u>	<u>s)</u>		novel mater					-	ation, stand [.] FY 2023 15.535	-off FY 2024 15.90

Exhibit R-2A, RDT&E Project Justif	ication: PB	2024 Chemi	cal and Biol	ogical Defen	se Program				Date: Ma	arch 2023	
Appropriation/Budget Activity 0400 / 1				PE 06		nent (Numb Chemical and				umber/Name) sical Sciences (Basic Re	
B. Accomplishments/Planned Prog	rams (\$ in N	<u>/lillions)</u>						F	Y 2022	FY 2023	FY 2024
 Novel Destruction - Continue develor surrogates. Continue investigating no 											
FY 2024 Plans: -Multifunctional Materials - Begin dev Establish design, methodology and a -Design Rules for Materials - Comple design of metal organic framework w -Biomimetic - Investigate scalability o coating to nylons and characterization -Photocatalysis - Characterize individ Continue studies of aerogels using si -Novel Destruction - Investigate bindi photochemical activity and determine	ssembly prof te characteri ith high adso f protein des n of mechani lual compone mulants and ng specificity	cocols for fus zation and te rption capaci igns and tes cal propertie ents of hybrid model energy of enzymes	sion tag syst esting of bi-f city and sele t membrane es. d catalysts a getic effects. s for catalytic	em and surfa functional ma ctivity. e-protein aga and their inter	ace binding f aterials. Deve inst simulan ractions with	unctionality a elop syntheti ts. Begin syn simulants, ir	at various der c process for thesis of poly n light and da	mer rk.			
FY 2023 to FY 2024 Increase/Decree Minor change due to routine program											
				Accon	nplishment	s/Planned P	rograms Sub	ototals	13.713	15.535	15.900
							FY 2022	FY 2023			
Congressional Add: Physical Scien	ces						2.500	5.00	0		
FY 2022 Accomplishments: Chemic	cally resistan	t, high-perfo	rmance mili	tary cordage	, rope, and v	vebbing.					
FY 2023 Plans: Waterless solutions	for decontam	nination.									
				Cong	ressional A	dds Subtota	l s 2.500	5.00	0		
C. Other Program Funding Summa	ry (\$ in Milli	ons)									
Line Item • CB2: Chemical Biological Defense (Applied Research) • MT2: Mitigate (Applied Research)	<u>FY 2022</u> 97.410	FY 2023	FY 2024 Base - 66.371	<u>FY 2024</u> <u>OCO</u> -	FY 2024 Total - 66.371	FY 2025	FY 2026 - 51.426	FY 2027 - 59.920	- 64.824	Cost To Complete 0.000 Continuing	97.410 Continuing
PT2: Protect (Applied Research) PE 0601384BP: Chemical and Biolog	- ical Defense	58.091	55.057		55.057	56.153	57.817	61.452	61.452	Continuing	Continuing

Chemical and Biological Defense Program

Volume 4 - 7

Exhibit R-2A, RDT&E Project Just	tification: PB	2024 Chemi	cal and Biol	ogical Defen	se Program				Date: Ma	rch 2023	
Appropriation/Budget Activity					ogram Elen	•	,	Project (N		,	
0400 / 1					01384BP / C	chemical and	l Biological	PS1 I Phy	sical Scien	ces (Basic F	Research)
				Defens	se Program						
C. Other Program Funding Summ	ary (\$ in Milli	ons <u>)</u>									
			FY 2024	<u>FY 2024</u>	FY 2024					Cost To	
Line Item	FY 2022	FY 2023	Base	000	<u>Total</u>	FY 2025	FY 2026	FY 2027	FY 2028	Complete	Total Cost
 TM2: Techbase Medical 	107.608	-	-	-	-	-	-	-	-	0.000	107.608
Defense (Applied Research)											
UN2: Understand	-	112.952	119.182	-	119.182	111.773	107.842	107.193	107.193	Continuing	Continuing
(Applied Research)											
<u>Remarks</u>											

D. Acquisition Strategy

N/A

Exhibit R-2, RDT&E Budget Item	n Justificat	i on: PB 202	24 Chemica	I and Biolog	logical Defense Program					Date: March 2023		
Appropriation/Budget Activity 0400: Research, Development, Te Applied Research	est & Evalua	tion, Defen	se-Wide I B	A 2:	-		t (Number/ nical and Bi		fense Progr	ram		
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
Total Program Element	0.000	205.018	244.364	240.610	0.000	240.610	231.758	217.085	228.565	233.469	Continuing	Continuing
UN2: Understand (Applied Research)	-	0.000	112.952	119.182	0.000	119.182	111.773	107.842	107.193	107.193	Continuing	Continuing
PT2: Protect (Applied Research)	-	0.000	58.091	55.057	0.000	55.057	56.153	57.817	61.452	61.452	Continuing	Continuing
MT2: <i>Mitigate (Applied</i> <i>Research)</i>	-	0.000	73.321	66.371	0.000	66.371	63.832	51.426	59.920	64.824	Continuing	Continuing
CB2: Chemical Biological Defense (Applied Research)	-	97.410	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	97.410
TM2: Techbase Medical Defense (Applied Research)	-	107.608	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	107.608

A. Mission Description and Budget Item Justification

This program element (PE) resources Applied Research across the Understand, Protect, and Mitigate portfolios. Chemical and Biological Defense Program (CBDP) investments provide an integrated, layered capability to enable combating weapons of mass destruction (CWMD) missions ranging from combat operations to Department of Defense (DoD) support to domestic incident prevention and response. The Projects in this PE support applied research in the areas of physical technologies, non-traditional agent (NTA) medical and physical defense technologies, and medical technologies. These investments are a key component to sustaining the core physical and intellectual chemical and biological (CB) defense infrastructure of the Department and support the delivery of capabilities, assessments of emerging threats, and the ability to surge unique capabilities in response to a CB event. FY24 funding accelerates characterization and situational awareness of emerging biothreats and accelerates delivery of improved protection from and mitigation of biothreats, including rapid repurposing of available therapeutics and development of new vaccines.

Individual Projects include:

- Understand (UN2): Development of next-generation chemical and biological hazard detectors, point-of-need diagnostic devices, next-generation diagnostics systems, decision support tools, algorithms, and software.

- Protect (PT2): Development of antidotes, disease surveillance medical technologies, vaccines, nerve agent pretreatments, and respiratory and ocular protection. Improvement of protection technologies and biological weapon/agent surveillance.

- Mitigate (MT2): Improvement of CB defense material, including contamination avoidance and decontamination. Development of drug treatments, therapeutics, patient decontamination technologies, and individual protection advancements.

Exhibit R-2, RDT&E Budget Item Justification: PB 2024 C	hemical and Biolo	gical Defense Pr	ogram	Date	: March 2023	
Appropriation/Budget Activity			Element (Number/Name)			
0400: Research, Development, Test & Evaluation, Defense-V	<i>Vide I</i> BA 2:	PE 0602384BP	I Chemical and Biologic	al Defense Program		
Applied Research						
- Chemical Biological Defense (CB2) and Techbase Medical	l Defense (TM2) a	re no longer activ	ve Projects due to budget	t restructuring.		
CBDP Science and Technology (S&T) Applied Research Pe CBC), United States Army Medical Research Institute of Infe (USAMRICD), United States Army Natick Soldier Systems C such as Pacific Northwest National Laboratory (PNNL), amo interagency for mission success across the enterprise throug Efforts under this PE will transition to or will provide risk redu	ectious Diseases (Center, Naval Rese ong others. The in gh collaborative pl	USAMRIID), Unit earch Lab (NRL), tent is to maintain anning and progr	ted States Army Medical Air Force Research Lab n strategic partnerships v ramming maintaining buc	Research Institute of ((AFRL), and Departm vith the DoD Service c lget assurance.	Chemical Defe ent of Energy ommunities &	nse Laboratori the
Prototypes (PE 0603884BP), and System Development and	Demonstration (F	PE 0604384BP) a	activities.			
B. Program Change Summary (\$ in Millions)	<u>FY 2022</u>	FY 2023	FY 2024 Base	<u>FY 2024 OCO</u>	<u>FY 2024</u>	
Previous President's Budget	209.956	256.197	248.726	-		48.726
Current President's Budget	205.018	244.364	240.610	-		40.610
Total Adjustments	-4.938	-11.833	-8.116	-		-8.116
 Congressional General Reductions 	-	-0.273				
 Congressional Directed Reductions 	-	-11.560				
 Congressional Rescissions 	-	-				
 Congressional Adds 	-	-				
 Congressional Directed Transfers 	-	-				
 Reprogrammings 	-1.500	-				
 SBIR/STTR Transfer 	-3.438	-				
Other Adjustments	-	-	-8.116	-		-8.116
Congressional Add Details (\$ in Millions, and Inclu	udes General Rec	<u>luctions)</u>			FY 2022	FY 202
Project: TM2: Techbase Medical Defense (Applied R	esearch)					
Congressional Add: Biological Warfare Defense T	Therapeutics				3.000	
		(Congressional Add Subto	otals for Project: TM2	3.000	
			Congressional Add	Totals for all Projects	3.000	
Change Summary Explanation Funding: FY 2022 (+\$3.000 Million): Congressional A FY 2022 (-\$1.500 Million): Reprogrammed prior year					•	

FY 2022 (-\$1.500 Million): Reprogrammed prior year execution balances to RDT&E Management Support, Budget Activity 6 in support of the Departments higher priorities.

PE 0602384BP: *Chemical and Biological Defense Program* Chemical and Biological Defense Program

chibit R-2, RDT&E Budget Item Justification: PB 2024 Chemical and Bio	ological Defense Program	Date: March 2023
opropriation/Budget Activity 000: Research, Development, Test & Evaluation, Defense-Wide I BA 2: oplied Research	R-1 Program Element (Number/Name PE 0602384BP <i>I Chemical and Biologic</i>	
FY 2022 (-\$3.438 Million): Transfer of funding to support Small Busir	ness Innovative Research/Small Business T	echnology Transfer efforts.
FY 2023 (-\$0.273 Million): Congressional General Reductions to sup FY 2023 (-\$11.560 Million): Congressional Directed Reductions.	oport Federally Funded Research and Deve	lopment Centers (FFRDCs).
FY 2024 (-\$8.116 Million): Departmental inflation rate adjustments (+ Advanced Technology Development (-\$9.283 Million).	+\$1.167 Million) and a reduction in Applied F	Research due to technology progressing to
Schedule: N/A		
Technical: N/A		

Exhibit R-2A, RDT&E Project Ju	hibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program							Date: March 2023				
Appropriation/Budget Activity 0400 / 2				R-1 Program Element (Number/Name) PE 0602384BP <i>I Chemical and Biological</i> <i>Defense Program</i>				Project (Number/Name) UN2 / Understand (Applied Research)				
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
UN2: Understand (Applied Research)	-	0.000	112.952	119.182	0.000	119.182	111.773	107.842	107.193	107.193	Continuing	Continuing

A. Mission Description and Budget Item Justification

The Understand Applied Research Project provides the Joint Force with the abilities to detect, identify, and characterize chemical and biological (CB) threat agents. This includes classification and/or identification of the threat and potentially the amount of chemical, biological, radiological, and nuclear (CBRN) hazards in all physical states. Efforts provide the ability to characterize the CBRN hazard to a commander and develop a clear understanding of the current and predicted CBRN situation; collect, query, and assimilate information from sensors, intelligence and medical communities, etc., in near real time to inform decisions; and provide actual and potential impacts of CBRN hazards. In FY 2023, the Chemical Biological Defense Program (CBDP) RDT&E Projects have been restructured to align with the CBDP portfolio construct. UN2 efforts in FY 2022 remain in Projects CB2 and TM2. This restructuring provides standardization and alignment across CBDP research, development and acquisition efforts.

Thrust Areas included in this Project are:

(1) Chemical, Biological, Radiological, and Nuclear (CBRN) Battlespace Sensing, Alerting & Response

- (2) CBRN Decision Aids
- (3) CBRN Situational Awareness
- (4) Chemical Diagnostics
- (5) Diagnostic Building Blocks
- (6) Emerging Threats
- (7) Distributed CB Reconnaissance
- (8) Emerging and Enhanced Biothreat Sensing
- (9) Employment Characterization
- (10) Environmental Response
- (11) First Look (Chemical and Biological)
- (12) Host Response
- (13) Technical Surprise
- (14) Expeditionary Analytical Toolkit (ExAnT)
- (15) Unattended Perimeter Monitoring
- (16) Unconventional Detection Modalities

CBRN Battlespace Sensing, Alerting & Response: Development of algorithms that generate and disseminate warning to personnel in time to prevent exposure to or limit the impact of CBRN threats. This thrust area conducts data collection trials to support algorithm development; leverage Artificial Intelligence (AI) to identify key

	nd Biological Defense Program	Date: March 2023
Appropriation/Budget Activity 0400 / 2	R-1 Program Element (Number/Name) PE 0602384BP <i>I Chemical and Biological</i> <i>Defense Program</i>	Project (Number/Name) UN2 I Understand (Applied Research)
indicators, combinations of indicators, and sensing modalities to rec and analysis for application in Warfighter chemical and biological th		e; explore remote and contactless monitoring
CBRN Decision Aids: Providing tools that assess risk from CBRN h the dynamic discovery, querying, and control of sensors through sta tactical edge to enable sharing of information and capabilities acros	andard protocols; allow for dynamic discovery and integ	
CBRN Situational Awareness: Providing operationally relevant cont and mitigate their effects on mission success. This thrust area prov generated during the course of technology development and hazard	vides the analytic framework to determine optimal defe	nse postures by extrapolating scientific data
Chemical Diagnostics: Discovers innovative and integrated capabili by investing in diagnostics for exposure to traditional and nontradition coordinating with Threat Agent Science and the Intelligence Comm	onal Chemical Warfare Agents (CWA), including pharn	
Diagnostic Building Blocks: Develops foundational capabilities for the development pipeline for diagnostics; and exploits areas in artificial for utilization. Efforts accelerate assay development timelines and development for emerging threats. Efforts include additional invest	intelligence synthetic biology and machine learning to optimize test parameters by leveraging novel concepts	develop novel and rapid diagnostic tests and tools that readily allow a pivot to assay
Emerging Threats: Efforts to push beyond the boundaries of the tra diagnostic systems that leverage novel approaches to characterize administering the appropriate antibiotic, antiviral, or vaccine to a me pandemic preparedness.	the pathogen or the host response enables the deliver	y of actionable information, such as
Distributed CB Reconnaissance: Enhances early warning and situa reconnaissance tools to include low-cost point sensors and sensing payloads for manned and unmanned aerial and ground platforms to	g/collection systems for unmanned platforms. Efforts in	clude developing threat sensing and sampling
Enhanced and Emerging Biothreat Sensing: Establishes a capabilit	ty to rapidly develop advanced, agile, pathogen-agnost ross all force echelons (presumptive, field confirmatory,	

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologi	ical Defense Program	Date:	March 2023	
Appropriation/Budget Activity 0400 / 2	R-1 Program Element (Number/Name) PE 0602384BP / Chemical and Biological Defense Program	Project (Number/ UN2 / Understand	(Applied Rese	,
Employment Characterization: Conduct studies to help refine threat assessing strategy, and capabilities. Studies will include both laboratory, chamber-bas determine risks posed by an agent employed in a similar fashion by an adverted and the strategy of	sed dissemination characterization and full-scale			
Environmental Response: Evaluate CB threats that have been released into environmental conditions (e.g., ozone, ultraviolet, humidity, etc.) have on the environment (to include soil, water, and plants) on clothing, on and in structu	ose agents. Identify and characterize behavior	of chemical and biolo	ogical agents i	n the
First Look (Chemical and Biological): Provide the initial characterization of p Evaluate agents and develop both methods and capabilities to quickly and a development and modeling for CB defense community stakeholders.				
Host Response: Characterize effects (acute vs. chronic) from exposure to to scenarios, exposure routes, and appropriate assessment methods and mode mortality of agents and provide adverse health effects information and other capabilities for identifying the human response to chemical and biological the	lels. Improve understanding of the mechanisms relevant data. Data from host response studies	of action, infectivity	, morbidity, an	d
Technical Surprise: Mitigate technical surprise by providing technology over- knowledge, with a focus on breakthroughs that can/will overcome bottleneck scanning capabilities allowing for continuous, real-time monitoring to identify echnological convergence. Efforts include additional investments in enhanc	ks and enable the development of capabilities of amerging threats, maintain situational awarene	f concern. Improve tl	hreat awarene	SS
Expeditionary Analytical Toolkit (ExAnT): Provides general and specialized f enhancing detection capabilities for non-traditional, emerging, and mixed ch		chnologies for tradition	onal threats wh	hile
Unattended Perimeter Monitoring: Invests in efforts supporting Integrated Ea through developing and implementing automated and integrated technologie				apability
Unconventional Detection Modalities: Develops disruptive technologies push sensors that operate in complex threat environments with high fidelity.	hing the boundaries of currently fielded sensors	and detection techn	ologies to dev	elop novel
8. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
Title: 1) CBRN Battlespace Sensing, Alerting, and Response		-	8.000	7.25
Description: Improve the Department of Defense's capability to detect, iden and naturally occurring outbreaks of chemical and biological threat agents. F				
PE 0602384BP: Chemical and Biological Defense Program	JNCLASSIFIED			olumo 4 14

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical	and Biological Defense Program	Date: N	Aarch 2023	
Appropriation/Budget Activity)400 / 2	R-1 Program Element (Number/Name) PE 0602384BP <i>I Chemical and Biological</i> <i>Defense Program</i>	Project (Number/ UN2 / Understand		earch)
3. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
of chemical and biological (CB) agent / agent proxy exposures. S solating indicators of respiratory infection, determining severity of exposure, and examining physiological effects on human tissue in early implementation of countermeasures such as isolation, quara transmission, morbidity, and mortality rates. Mature algorithms an sensitivity and specificity.	f infection, predicting return to mission readiness after n multi-organ-chips after exposure to CB threat agents. Ena antine, and removal from an area, thus potentially reducing			
FY 2023 Plans: Continue wearable device-based non-invasive biomarker analyschemical or biological exposure. Continue to develop predictive algorithms and analytic tools utilizapid response to emerging threats and detection of genetically encontinue development of AI-based drug discovery algorithms for Continue the advancement of standoff physiological monitoring of Utilize a multi-organ chip system to characterize the effects of bissues and conduct multi-omics analysis (e.g. proteomics, metabohysiological responses from exposure to high, mid, and low multi-organ chip system to characterize to high, mid, and low multi-organ chip system to high mide system high syst	zing artificial intelligence (AI) and ML techniques to allow fo ngineered pathogens. r Emerging Threats. capabilities. iological threat agents on several different cultured human olomics) to identify potential biomarkers associated with			
FY 2024 Plans: - Continue wearable device-based non-invasive algorithm enhance exposure. - Continue to develop predictive algorithms and analytic tools utilizer rapid response to emerging threats and detection of genetically effect - Continue development of AI-based drug discovery algorithms for - Continue the advancement of standoff physiological monitoring at which physiological data can be captured. - Continue work with multi-organ chip system to characterize the enuman tissues and conduct multi-omics analysis (e.g. proteomics bysiological responses from exposure to high, mid, and low multi-	cements for pre-symptomatic indication of chemical or biolo zing artificial intelligence (AI) and ML techniques to allow fo ngineered pathogens. r Emerging Threats. capabilities to include efforts that increase the standoff dista effects of biological threat agents on several different cultures, metabolomics) to identify potential biomarkers associated	r ance ed		
FY 2023 to FY 2024 Increase/Decrease Statement: Winor change due to routine program adjustments.				
Title: 2) CBRN Decision Aids				

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	I Defense Program		Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 2	R-1 Program Element (Number/Name) PE 0602384BP / Chemical and Biological Defense Program		ct (Number/N Understand	Name) (Applied Rese	earch)
B. Accomplishments/Planned Programs (\$ in Millions)			FY 2022	FY 2023	FY 2024
Description: In order to unencumber the Warfighter at the tactical edge, efforts technology for CBRN Decision Aids on End User Devices (EUDs) in both connectilizing automation, reducing the burden experienced by the warfighter, while p a Contamination Avoidance Decision Aid to inform the warfighter on how to avoid Develop an Autonomous Asset Guidance capability to optimize their use and reto operate them. Fuse and utilize data from Autonomous Assets to improve an	ected and disconnected operations. Focus on providing accurate, actionable information. De bid, respond to and plan routes around CB haz educe the burden incurred by the warfighter in	velop ards.			
FY 2023 Plans: - Continue development of warning and decision aids for tactical users leveragi - Continue development of AR-based technologies to incorporate CB threat situ					
 FY 2024 Plans: Continue development of warning and reporting decision aids for tactical users EUDs. Continue development of Augmented Reality (AR) based technologies to inco -Initiate the development of tools that support the interoperability, integration, an need for manual user inputs. 	rporate CB threat situational awareness in EU	Ds.			
FY 2023 to FY 2024 Increase/Decrease Statement: Decrease due to change in program/project technical parameters. Decrease due transitioning to Budget Activity 3.	e to efforts within this area maturing and				
Title: 3) CBRN Situational Awareness			-	11.812	15.880
Description: Expand on the types of threats that can be modeled with hazard a rotary-wing drones of interests and allow for airborne CB releases from single of Virtual Reality (VR) and Augmented Reality (AR) technologies to develop CB for that will be integrated into systems widely used by the Joint Force. Develop vir and account for hazard source terms and plumes generated by transport and d for tactical use to maximize warfighter CB situational awareness on the battlefie adopting a modular framework and integrating across Service command and contended to support operations in urban and mixed environments. Leverage new state-ot techniques and their use of computing resources to increase both modeling spectrum and analytic tools to support force readiness and facilitate m agents. Develop epidemiological models to quantify and visualize mission operations.	drones and swarms to be modeled. Leverage boused training and mission rehearsal capabili- tual training environments to implement, visual ispersion (T&D) models. Explore AR application eld. Modernize hazard modeling capabilities b pontrol systems to operationalize reachback sup eling capability and improve urban T&D model f-the-art computational fluid dynamics modeling eed and accuracy. Develop CB health effect redical planning against chemical and biological	ties lize ons y oport. ing ig al			

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program Date: March 2023						
Appropriation/Budget Activity 0400 / 2		•	Number/Notestand	lame) (Applied Rese	earch)	
B. Accomplishments/Planned Programs (\$ in Millions)			Y 2022	FY 2023	FY 2024	
infectious biological threat agents. Leverage threat agent science (TAS) data and host pathogen interactions from exposures to traditional and non-tradition accurate casualty estimates accounting for human health effects.						
 FY 2023 Plans: Complete development of models to provide operationally relevant outputs to Continue to develop Machine Learning (ML) algorithms for disease prediction Continue to enhance CB situational awareness capabilities for integration int Initiate efforts to expand focus on emerging threat hazard modeling, leveragi characterize new CB hazards and mitigate their effects on mission success. Explore new areas for targeted investment in synthetic environments to provide chelon training and mission readiness capability. Explore in-host modeling capabilities leveraging ML/Artificial Intelligence (AI) chemical and biological exposure prior to onset of symptoms. 	n and forecasting for mobile platforms. o Heads up Display (HUD) technologies. ng TAS data to ensure the Joint Force is able to ide a CBRN-specific cognitive, collective, multi-					
 FY 2024 Plans: Continue to develop Machine Learning (ML) algorithms for disease prediction Continue to enhance CB situational awareness capabilities for integration integration integration integrates and emerging threat hazard modeling, leveraging TAS characterize new CB hazards and mitigate their effects on mission success. Continue the development of VR-based synthetic environments in order to prechelon training and mission readiness capability. Continue the development of in-host modeling capabilities leveraging ML and characterize predictive biomarkers of chemical and biological exposure prior to the development of the de	o Heads up Display (HUD) technologies. S data to ensure the Joint Force is able to rovide a CBRN-specific cognitive, collective, mu d Artificial Intelligence (AI) techniques to	lti-				
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to change in program/project technical parameters.						
<i>Title:</i> 4) Chemical Diagnostics			-	0.693	0.698	
Description: Provide innovative and integrated capabilities to the Warfighter to spectrum. Enhance force protection by investing in diagnostics for exposure to Agents (CWAs), including pharmaceutical based agents (PBAs). Leverage the monitors blood, indicating whether a Warfighter has been exposed to nerve agents.	o traditional and nontraditional Chemical Warfa e development of a chemical diagnostic that					
FY 2023 Plans:						

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical a	nd Biological Defense Program		Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 2	R-1 Program Element (Number/Name) PE 0602384BP <i>I Chemical and Biological</i> <i>Defense Program</i>	-	t (Number/I Understand	Name) (Applied Res	earch)
B. Accomplishments/Planned Programs (\$ in Millions)			FY 2022	FY 2023	FY 2024
 Continue the development of integrated capabilities that address Diagnostic System Increment 2 Chemical Diagnostic (NGDS 2 CH of CWAs, resulting in more informed treatment decisions. 					
FY 2024 Plans: - Continue the development of integrated capabilities that address Diagnostic System Increment 2 Chemical Diagnostic (NGDS 2 CH of CWAs, resulting in more informed treatment decisions.					
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.					
<i>Title:</i> 5) Diagnostic Building Blocks			-	1.693	3.83
Description: Develop novel, state of the art capabilities that lay the portfolio. This includes exploiting areas such as synthetic biology a utilization in the event of an outbreak of an unknown threat. Invest and optimized test parameters through leveraging artificial intellige and develop assays for emerging threats and speed up development.	and chemistry to develop novel and rapid diagnostic tests in efforts that lead to accelerated assay development tim nce (AI) and machine learning (ML) to allow us to quickly	for elines			
FY 2023 Plans: - Continue efforts to collect the baseline data required for future de breath as a non-invasive sampling mechanism offers Warfighters li opportunity for earlier diagnosis/indication of infection or chemical of	ittle-to-no interruption to mission activities and provides th				
 FY 2024 Plans: Continue field validation studies for diagnostics prototypes using a gold standard diagnostic methods and integrate enzymes to create burdens. Continue efforts to collect the baseline data required for future de breath as a non-invasive sampling mechanism offers Warfighters li opportunity for earlier diagnosis/indication of infection or chemical e - Initiate efforts to identify and establish testing methods utilizing lo sweat or interstitial fluid could significantly expand field-forward test collect and administer testing. 	e inexpensive, on-demand, diagnostics with reduced logist velopment of a whole breath diagnostic platform the use of ittle-to-no interruption to mission activities and provides th exposure. w to minimally invasive clinical matrices. Matrices like bre	tical of e eath,			
FY 2023 to FY 2024 Increase/Decrease Statement:					

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical an	nd Biological Defense Program		Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 2	R-1 Program Element (Number/Name) PE 0602384BP <i>I Chemical and Biological</i> <i>Defense Program</i>		ct (Number/I Understand	Name) (Applied Rese	earch)
B. Accomplishments/Planned Programs (\$ in Millions)			FY 2022	FY 2023	FY 2024
Increase due to change in program/project technical parameters.					
<i>Title:</i> 6) Emerging Threats			-	2.773	2.443
Description: Push beyond the boundaries of the traditional threat I Development of diagnostic systems that leverage novel approaches the classification of threat (e.g., bacterial vs viral) from an unknown actionable information, such as administering the appropriate media medic or primary care provider greatly improves turnaround time for	s to characterize pathogen or host response and can ider sample. Invest in diagnostic tests that enable the deliver cal countermeasure (e.g. antibiotic, antiviral, vaccine), by	ntify Ty of			
 FY 2023 Plans: Complete efforts on several complementary approaches to address of contamination (POC) and initiate validation of these prototypes for forward responses to emerging threats. Complete the development of a universal blood sample preparation improving the speed of sample preparation tools at low pathogen conchallenges holding back diagnostics in point-of-care, outbreak, and 	or potential use as a threat agnostic capability to enable fi on platform to be compatible with several diagnostic syste oncentrations (i.e. pre-symptomatic levels) is one of the b	eld- ms,			
<i>FY 2024 Plans:</i> - Initiate efforts to identify novel platforms that are capable of identify platforms will ideally enable the diagnosis of exposure to toxins as a capability in the hands of the warfighter. - Begin preliminary research efforts to diagnose biological threats the changes in infected individuals.	well as other biological threats, resulting in a broad-spect				
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.					
Title: 7) Diagnostic Building Blocks - Enhanced Biodefense (ENBD)		-	6.500	4.100
Description: This effort will focus on Assay Development and Delivi Diagnostics (BioAID) Efforts as well as developing novel, state of the areas within the diagnostics portfolio. This includes exploiting areas and rapid diagnostic tests for utilization in the event of an outbreak assay development timelines and optimized test parameters throug (ML) to allow us to quickly pivot and develop assays for emerging the	he art capabilities that lay the foundation for modernizing of s such as synthetic biology and chemistry to develop nov of an unknown threat. Invest in efforts that lead to accele h leveraging artificial intelligence (AI) and machine learning	el erated ng			
FY 2023 Plans:					

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biol	ogical Defense Program		Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 2	R-1 Program Element (Number/Name) PE 0602384BP <i>I Chemical and Biological</i> <i>Defense Program</i>	Project (I UN2 / Und		Name) (Applied Rese	earch)
B. Accomplishments/Planned Programs (\$ in Millions)		F	Y 2022	FY 2023	FY 2024
 Expand work with collection & analysis of individual's breath, skin emissi offers Warfighters little-to-no interruption to mission activities and provides infection or chemical exposure. 		nich			
FY 2024 Plans: - Continue collection & analysis of individual's breath, skin emissions or of possible prototypes which offers Warfighters little-to-no interruption to mis diagnosis/indication of infection or chemical exposure.					
FY 2023 to FY 2024 Increase/Decrease Statement: Decrease due to change in program/project technical parameters.					
Title: 8) Emerging Threats - Enhanced Biodefense (ENBD)			-	8.000	5.200
Description: This effort will focus on Novel Non-Invasive Screening and 0 the traditional threat list in the field of diagnostics to better prepare for surp novel approaches to characterize pathogen or host response and can idea from an unknown sample. Invest in diagnostic tests that enable the deliver appropriate medical countermeasure (e.g. antibiotic, antiviral, vaccine), by turnaround time for soldier wellness and return to duty.	prise. Development of diagnostic systems that leven ntify the classification of threat (e.g., bacterial vs vin ery of actionable information, such as administering	erage ral) the			
FY 2023 Plans:					
- Complete training and development efforts by the Army Medical Researce become an authorized developer of assays for the Cepheid Flex Cart tech (MPDS).		stem			
- Initiate efforts to explore innovative methods to investigate genetically m biomarkers or synthetic biology approaches. Novel methods will allow for from months to weeks.	rapid assay fielding potentially cutting developmen				
 Accelerate next generation diagnostic platform development to meet the diagnostics that would address detection and identification technology nee platform for emerging pathogens. 	eds with a combined affinity based and molecular				
 Initiate effort to predict disease severity to provide agnostic disease scre decision making support for the Warfighter in field forward environments. Expand agnostic biomimetic sensing to explore additional panels of sma 					
of activity, and tested in both clinical and aerosol sample matrices to inclu					
FY 2024 Plans:					

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and	d Biological Defense Program	Date:	March 2023	
Appropriation/Budget Activity 0400 / 2	R-1 Program Element (Number/Name) PE 0602384BP <i>I Chemical and Biological</i> <i>Defense Program</i>	Project (Numbe UN2 / Understan	,	earch)
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
 Continue efforts to explore innovative methods to investigate genet biomarkers or synthetic biology approaches. Novel methods will allo from months to weeks. Continue next generation diagnostic platform development to meet diagnostics that would address detection and identification technolog platform for emerging pathogens. Continue effort to predict disease severity to provide agnostic diseas resource decision making support for the Warfighter in field forward - Continue agnostic biomimetic sensing to explore additional panels of activity, and tested in both clinical and aerosol sample matrices to 	ow for rapid assay fielding potentially cutting development the evolving needs of the CBDP enterprise, providing gy needs with a combined affinity based and molecular ase screening tool that enhances triage, transport and environments. of small and large molecular weight toxins with various in	nt time		
FY 2023 to FY 2024 Increase/Decrease Statement: Decrease due to change in program/project technical parameters.				
Title: 9) Unconventional Detection Modalities - Enhanced Biodefens	e (ENBD)	-	2.000	1.00
Description: Develop disruptive technologies to identify unknown or complex threat environments with high fidelity. This thrust area supp (e.g., expeditionary, perimeter defense, or unmanned reconnaissance)	ports others as appropriate to the Joint Force mission ne			
FY 2023 Plans: - Expand Assays on Demand (AoD) for emerging biological threat de reducing supply chain constraints typically seen in currently fielded s		g		
FY 2024 Plans: - Continue Assays on Demand (AoD) for emerging biological threat or reducing supply chain constraints typically seen in currently fielded s		ng		
FY 2023 to FY 2024 Increase/Decrease Statement: Decrease due to change in program/project technical parameters.				
Title: 10) Distributed CB Reconnaissance - Biological Detection		-	3.614	1.31
Description: Developing capability to warn and inform the Joint Ford sensing payloads on manned and unmanned systems (e.g. UAS, UC remotely sense threats relevant to mission environment at presumpt Early Warning.	GS). Point sensors on manned and unmanned assets with			

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	I Defense Program		Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 2	R-1 Program Element (Number/Name) PE 0602384BP <i>I Chemical and Biological</i> <i>Defense Program</i>		ct (Number/I Understand	Name) (Applied Rese	earch)
B. Accomplishments/Planned Programs (\$ in Millions)		[FY 2022	FY 2023	FY 2024
 FY 2023 Plans: Continue to invest in low size, weight, power, and cost technologies for near-redistributed biological and chemical sensing for hazard awareness and assessmenter in innovative technologies to increase situational awareness using man operational advantages to the Warfighter. Explore application of advanced computational tools, Artificial Intelligence (All sensor technologies to provide improved early warning and integrated threat awareness. 	nent of operational environments. nned and unmanned platforms and provide) and Machine Learning (ML), to connect multi				
FY 2024 Plans: - Continue to explore fundamental science and novel technologies to increase specificity; low size, weight, and power; and reduced consumables and life-cyc- - Continue developing biological threat sensing and sampling systems, to inclue - Continue to evaluate the use of computational tools, like machine learning interfalse reporting due to environmental factors.	le costs of fielded biological sensors. de unmanned and manned platforms.				
FY 2023 to FY 2024 Increase/Decrease Statement: Decrease due to change in program/project technical parameters.					
Title: 11) Emerging and Enhanced Biothreat Sensing			-	10.753	12.922
Description: Establish a capability to rapidly develop advanced, agile, pathoge capabilities to detect emerging and enhanced biological threats across all force validation, and definitive identification). Further, multi-omics and data sciences will be used to modernize laboratory capabilities and leverage synthetic biology sensing/detection capabilities to the Joint Force.	e echelons (presumptive, field confirmatory, the s (MODS) - multiple biological measurements -	eater			
 FY 2023 Plans: Continue development of detection algorithms and laboratory workflows to ide Continue automated computational tools to design and expedite assay develor Continue applied research component of far-forward pathogen agnostic sensitive Pursue advanced biological measurements and data processing techniques in response to emerging threats with emerging pathogen targeted detection capa FY 2024 Plans: 	opment for biological detection. ing toolkit development. nto sensor development to enable an agile bilities.				
- Continue development of detection algorithms, laboratory workflows, and imp identify threats in unknown samples	iementation of bioinformatics analysis tools to				

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	al Defense Program		Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 2	R-1 Program Element (Number/Name) PE 0602384BP <i>I Chemical and Biological</i> <i>Defense Program</i>		: (Number/N Inderstand (lame) Applied Rese	earch)
B. Accomplishments/Planned Programs (\$ in Millions)			FY 2022	FY 2023	FY 2024
 Continue incorporating advanced biological measurements and data process Continue to leverage Assays on Demand (AoD) to develop computational too biological detection. 		or			
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to change in program/project technical parameters.					
Title: 12) Unattended Perimeter Monitoring - Biological Detection			-	4.871	1.771
Description: Aims to enhance situational awareness against potential biologic to provide continuous, synchronous information of the operational environmen developed here will focus on autonomy and improved accuracy and reliance the synchronous information of the operational environment of the operational en	t and dynamic threat landscape. Capabilities	nter.			
<i>FY 2023 Plans:</i> - Continue to evaluate the use of computational tools, like machine learning, in false reporting due to environmental factors. - Continue to make technological improvements to enhance early warning of a	-	uce			
FY 2024 Plans: - Continue to make technological improvements to enhance early warning of a	erosolized biological threats.				
FY 2023 to FY 2024 Increase/Decrease Statement: Decrease due to change in program/project technical parameters.					
Title: 13) Unconventional Detection Modalities - Biological Detection			-	5.581	5.276
Description: Focuses on developing and evaluating novel, disruptive sensor a modernize existing biological detection technologies that go beyond current terms					
 FY 2023 Plans: Continue refinement of novel optical detector for bioaerosols modernizing cure. Explore innovative detection methods such as synthetic or organ on a chip bioidentify an unknown as hazardous to a human. Continue to integrate advanced computational tools, Artificial Intelligence (AI) improve speed of detection, reduce false alarms and enable integration of data Initiate Assays on-Demand efforts aimed to rapidly deliver novel assay solution <i>FY 2024 Plans:</i> 	osensors to provide agent agnostic techniques /Machine Learning (ML) into sensor developme a from multiple detection sources.				

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical	and Biological Defense Program	Date: I	March 2023							
Appropriation/Budget Activity 0400 / 2							PE 0602384BP / Chemical and Biological UN2 / Un			
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024						
 Continue Assays on Demand (AoD) to augment targeted detectidevelopment solutions. Continue investigating alternative optical detection development biological activity. Continue evaluating the feasibility of organ-on-a-chip technological activity. 	not reliant on fluorescence for real-time detection of anoma	alous								
FY 2023 to FY 2024 Increase/Decrease Statement:										
Minor change due to routine program adjustments. <i>Title:</i> 14) Employment Characterization			4.657	5.35						
Description: Employment Characterization studies refine threat a outdoor releases of threat agents on CBDP operations, strategy, a threat space by determining how CB agents behave when release knowledge gaps and informing on the type, extent and magnitude environment. Employment Characterization will: review state of k to identify gaps and TAS assessment opportunities; continue coor resources; develop closer linkages to hazard prediction modelers evaluation of potential munitions for applicability to potential future chamber tests and operational trials as appropriate for compound	and capabilities. These studies directly define the Warfight ed. This effort reduces risk to the CBDP Enterprise by closi- of a potential hazard a warfighter may face in an operation mowledge on agent employment (laboratory and outdoors) rdination with international partners to leverage skills and to identify knowledge gaps and TAS opportunities; prepare e threats based on performance characteristics; and continu	er ing nal								
FY 2023 Plans: - Continue to review state of knowledge on agent employment (lal assessment opportunities. - Continue studying scale employment methods and feasibility for - Begin Toxin Dissemination Efficiency and Anti-Material Efficacy	emerging threat agents.	ience								
FY 2024 Plans: - Continue to assess state of knowledge on agent employment (la opportunities Continue studying different scale employment methods and their - Continue Toxin Dissemination Studies and Anti-Material Efficacy	r feasibility for use with emerging threat agents.	sience								
FY 2023 to FY 2024 Increase/Decrease Statement:										
Minor change due to routine program adjustments.										

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	al Defense Program		Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 2	-	t (Number/N Understand	lame) (Applied Rese	earch)	
B. Accomplishments/Planned Programs (\$ in Millions)			FY 2022	FY 2023	FY 2024
Description: Environmental Response evaluates CB threats to understand ho persistence, degradation, decomposition), along with the effects of environmer etc.) on those agents; evaluates CB threat agents on soil, water, and plants, an and equipment; reduces risk to the CBDP Enterprise by closing knowledge gap of a potential hazard a warfighter may face in an operational environment. Sm predict the larger-scale behavior and fate of the agents in outdoor and operation operationally relevant substrates refines our understanding of their environmer from Environmental Response is used to inform operators, predictive model defined as the statement of the statement o	ntal conditions (e.g., ozone, ultraviolet, humidit nd operational surfaces such as clothing, struct ps and informing on the type, extent and magn nall-scale laboratory measurements are used to onal settings, while examining agents deposite ntal persistence and hazards. Knowledge obta	tures, iitude o d on			
 FY 2023 Plans: Continue evaluating stability of toxin and viral threats, including exploring the stability in the environment. Continue closing knowledge gaps associated with aerosol biology and its imp threats. Continue environmental characterization of chemical threats, increasing evalue byproducts for detection, diagnostics and other applications. 	plications with the outdoor release of biological				
 FY 2024 Plans: Continue evaluating stability of toxin and viral threats, including exploring the stability in the environment. Continue closing knowledge gaps associated with aerosol biology and its impathreats. Continue environmental characterization of chemical threats, and increasing byproducts for detection, diagnostics and other applications. 	plications with the outdoor release of biological				
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.					
<i>Title:</i> 16) First Look (Chemical and Biological)			-	9.850	9.910
Description: First Look provides the initial evaluation of known and emerging to the Warfighter. For both chemical and biological agents, this initial fundame synthesis and toxicity screening for chemicals and toxins and growth and/or via and feasibility of weaponization for all agents; evaluates threat agents and devacurately characterize chemical, biological, and toxin threat agent properties.	ental risk assessment includes evaluation of rulence for biological agents as well as produc relop methods and capabilities to quickly and	tion			

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	I Defense Program		Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 2	R-1 Program Element (Number/Name) PE 0602384BP <i>I Chemical and Biological</i> <i>Defense Program</i>		Number/N nderstand	lame) (Applied Rese	earch)
B. Accomplishments/Planned Programs (\$ in Millions)			Y 2022	FY 2023	FY 2024
planning, requirements generation, capability development, model developmen other government stakeholders about known or emerging agent threats.	it, the larger CBDP Enterprise, Intelligence and	1			
 FY 2023 Plans: Continue developing innovative laboratory tools and approaches to enable exbiological threats (to include highly infectious and novel organisms), including u gene modification/expression and the ability to assess toxin activity. Continue developing advanced methods for threat agent characterization, inclucions. Continue evaluating findings of technological advancement implications to discovere the second secon	inderstanding enabling technologies' impact to luding more complex chemical agent mixtures				
 FY 2024 Plans: Continue developing innovative laboratory tools and approaches to enable exbiological threats (to include highly infectious and novel organisms), including us gene modification/expression and the ability to assess toxin activity. Continue developing advanced methods for threat agent characterization, inclusions. Continue evaluating findings of technological advancement implications to discuss the advancement implications to discuss the advancement implications to discuss the advancement implications in the advancement implications to discuss the advancement implications in the adv	inderstanding enabling technologies' impact to luding complex chemical agent mixtures or				
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.					
<i>Title:</i> 17) Host Response			-	12.643	13.500
Description: Host Response assesses the human response of exposure to CE exposure scenarios (acute versus chronic) and exposure routes (e.g., inhalatio assessment methods and models. Data from host response studies is used to information (e.g., mechanism of action) to inform Warfighter mission planning, r model development, the larger CBDP Enterprise, Intelligence and other govern predictive capabilities for rapidly assessing the human response to chemical arknowledge gaps associated with traditional threats, including exploring synergies exposures; assesses bioavailability of threats that are encapsulated to understate to encapsulated versus un-encapsulated threats.	n, dermal, ingestion, etc.) and appropriate develop quantitative exposure limits and quali- requirements generation, capability development ment stakeholders. Host Response includes and biological threat agents; works to close know stic effects associated with combinatorial agen	nt, vn t			
FY 2023 Plans: - Continue to build on and develop predictive methods and technologies for CB	agent characterizations.				

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical ar	nd Biological Defense Program	Date: I	March 2023	
Appropriation/Budget Activity 0400 / 2	Adget Activity R-1 Program Element (Number/Name) Project (Numb PE 0602384BP / Chemical and Biological UN2 / Understa Defense Program			
B. Accomplishments/Planned Programs (\$ in Millions) - Continue studies to address host response areas identified by gap - Deliver IOC (initial operating capacity) for CRISTAL (Computation incorporating results into future host response. Continue to enhance Continue to enhance	al Rapid Identification and Scientific Threat Analysis) e and modernize CRISTAL methods and tools.	FY 2022	FY 2023	FY 2024
 Continue to assess the human (host) response to novel and emer FY 2024 Plans: Continue to build on and further develop predictive methods and to Continue studies to address host response areas identified by gap Begin improvements/upgrades for CRISTAL (Computational Rapid enhance and modernize CRISTAL methods and tools. Continue to assess the human (host) response to novel and emer 	echnologies for CB agent characterizations. analysis studies for traditional biological agents. d Identification and Scientific Threat Analysis). Continue to			
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.				
<i>Title:</i> 18) Technical Surprise <i>Description:</i> Technical Surprise assesses technological advancem agent use and release. Include horizon scanning to identify potenti of emerging technological advancements (e.g., biotechnology, artifi develops capabilities to evaluate and assess technical enhancemen evaluates emerging technologies and convergence of technologies more likely to survive being released; identifies the limitations and b implications, and identify and assess former technology hurdles that increasing potential threat.	al areas of concern and conduct technical assessments cial intelligence, machine learning, quantum computing); nts that may alter the nature or magnitude of a threat ager that improve the ease of threat use and make threats parriers associated with synthetic biology and assess the	nt;	4.007	4.50
 FY 2023 Plans: Continue identifying and assessing technological advancements the including potential threats that are not specifically chemical or biological defense capabilities. Continue a horizon scanning capability to provide situational awar can affect the chemical and biological threat space, while keeping a - Continue the assessment of synthetic biological tools and other bi space. Enhance evaluation of converging technologies and their implication. 	gical in nature, but have implications to chemical and biolo eness in assessing technological growth and convergence abreast of changes in the nature of future threats. otechnology developments that can enhance or alter the t	e that		
FY 2024 Plans:				

PE 0602384BP: *Chemical and Biological Defense Program* Chemical and Biological Defense Program

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical a	and Biological Defense Program	Date	March 2023	
Appropriation/Budget Activity 0400 / 2	R-1 Program Element (Number/Name) PE 0602384BP <i>I Chemical and Biological</i> <i>Defense Program</i>	Project (Numbe UN2 / Understan	,	earch)
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
 Continue identifying and assessing technological advancements including potential threats that are not specifically chemical or biol and biological defense capabilities. Continue a horizon scanning capability to provide situational awa may affect the chemical and biological threat space, while keeping Continue the assessment of synthetic biological tools and other I space. Enhance evaluation of converging technologies and their implication. 	ogical in nature but have implications with respect to chem areness in assessing technological growth and convergence g abreast of changes in the nature of future threats. biotechnology developments that can enhance or alter the	e that		
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.				
Title: 19) Technical Surprise - Enhanced Biodefense (ENBD)		-	1.500	3.50
Description: This effort will focus on Advanced Pathogen and Emhost responses and pathogen signatures using multi-omic analyse characterize known and emerging threats. This effort will include to identify patterns of response that allow for the prediction of nove Evaluations of pathogenesis and viral transmission to understand this program, efforts to characterize synthetic and natural viral patterning threat agnostic tools to provide better characterization cap	es and enabling technologies to develop the ability to understanding the host response to various pathogen insu el threat agents based on the host responses they generat differences in disease severity will also be conducted. Wit hogens to compare varying gene expressions between the rize emerging threats and will generate more robust data s	lts e. thin e two		
<i>FY 2023 Plans:</i> - Begin the development of a robust characterization pipeline capa - Begin the development of robust threat agnostic tools to characterization				
 FY 2024 Plans: Continue the development of a robust characterization pipeline of continue the development of robust threat agnostic tools to characterization pipeline of continue the development of robust threat agnostic tools to characterization pipeline of continue the development of robust threat agnostic tools to characterization pipeline of continue the development of robust threat agnostic tools to characterization pipeline of continue the development of robust threat agnostic tools to characterization pipeline of continue the development of robust threat agnostic tools to characterization pipeline of continue the development of robust threat agnostic tools to characterization pipeline of continue the development of continue	apable of characterizing emerging pathogens.			
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to fact of life change in the program/project.				
Title: 20) Distributed CB Reconnaissance - Chemical Detection		-	-	
				2.32

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical	and Biological Defense Program	Date: N	/larch 2023	
Appropriation/Budget Activity 0400 / 2	R-1 Program Element (Number/Name) PE 0602384BP <i>I Chemical and Biological</i> <i>Defense Program</i>	Project (Number/ UN2 / Understand		earch)
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
 Continue to explore fundamental science and novel technologies specificity; reduced size, weight, and power; and reduced consum Continue developing chemical threat sensing and sampling syst Continue to evaluate the use of computational tools, like maching false reporting due to environmental factors. 	nables and life-cycle costs of fielded chemical sensors. ems, to include unmanned and manned platforms.			
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project funding transferred from another funding line.				
Title: 21) Expeditionary Analytical Toolkit (ExAnT) - Chemical Dev	tection	-	3.296	3.616
Description: Provide general and specialized forces with the abil while enhancing detection capabilities for non-traditional, emergin		ts		
FY 2023 Plans: - Continue to support expeditionary forces in leveraging reach-bac detection capabilities to address opioids and emerging chemical t - Continue to invest in improvements of current detection technolo environments.	hreats.	y		
FY 2024 Plans: - Continue to invest in novel detection capabilities to address opic analogue agnostic capabilities. - Continue to invest in improvements of current detection technolo by improving currently-fielded detectors to provide early warning of battlespace.	ogies for chemical hazards in obscurant-heavy environmen	ts		
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.				
Title: 22) Unattended Perimeter Monitoring - Chemical Detection		-	-	3.054
Description: Establish a layered defense capability by developing enabling unattended monitoring for chemical threats. These techn liquid hazards and unencumber the Warfighter by reducing logisti capability at fixed or expeditionary sites will enhance the overall p technologies can be miniaturized for portability and operational su	nologies will provide early warning of vapor, aerosol, solid, a cs and operator burden. Providing a reliable detect-to-warn rotective posture of ground and maneuver forces as robust	and		

Appropriation/Budget Activity	tification: PB	2024 Chemic	al and Biol	ogical Defen	se Program				Date: Ma	arch 2023	
0400 / 2				PE 06		nent (Numb Chemical and			Number/N derstand (/	ame) Applied Rese	earch)
B. Accomplishments/Planned Pr	<u>ograms (\$ in N</u>	<u>lillions)</u>						F	Y 2022	FY 2023	FY 2024
FY 2024 Plans: - Continue to make technological ir	nprovements to	o enhance ea	rlv warning	of vapor. ae	rosol. solid.	and liquid h	azards.				
FY 2023 to FY 2024 Increase/Dec Program/project funding transferre	crease Stateme	ent:	, ,	• •		·					
Title: 23) Unconventional Detection	n Modalities - C	hemical Dete	ection						-	-	2.443
that can operate in complex threat Force mission needs (e.g., expedit utilizing machine learning and othe alarms, and enable mapping of has	ionary, perimete r advanced cor	er defense, o nputational to	r unmanne ools to incre	d reconnaiss ase detectio	ance). This on and identi	thrust area v fication accu	vill also expl	ore			
FY 2024 Plans: - Continue pursuing advances in pl but keeping the selectivity and sen - Incorporate early warning and thr analyze sensor data in real-time. - Continue library-less detection to be updated to detect emerging three	sitivity of a tradi eat mapping us surmount curre eats.	itional sensoi sing machine ent sustainme	r. learning (M ent limitation	IL)/artificial in	ntelligence (based or an	AI) tools to a	ggregate an	d			
- Continue development in ML and											
- Continue development in ML and FY 2023 to FY 2024 Increase/Dec											
- Continue development in ML and				Accon	nplishment	s/Planned P	rograms Su	btotals		112.952	119.182
- Continue development in ML and FY 2023 to FY 2024 Increase/Dec Program/project funding transferred	d from another	funding line.	FY 2024	Accon	nplishment FY 2024	s/Planned P	rograms Su	btotals	-	112.952 <u>Cost To</u>	119.182
- Continue development in ML and FY 2023 to FY 2024 Increase/Dec	d from another	funding line.	FY 2024 Base 83.825		<u>.</u>	5/Planned P <u>FY 2025</u> 81.392	rograms Su <u>FY 2026</u> 87.384	btotals <u>FY 2027</u> 73.515			Total Cos

PE 0602384BP: Chemical and Biological Defense Program Chemical and Biological Defense Program

Volume 4 - 30

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program									Date: March 2023			
Appropriation/Budget Activity 0400 / 2				R-1 Progra PE 060238 Defense Pl	84BP / Cher	•	,		ect (Number/Name) I Protect (Applied Research)			
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
PT2: Protect (Applied Research)	-	0.000	58.091	55.057	0.000	55.057	56.153	57.817	61.452	61.452	Continuing	Continuing

A. Mission Description and Budget Item Justification

The Protect Applied Research Project provides the Joint Force the ability to prevent the effects from exposure to chemical and biological hazards. PT2 emphasizes increasing protection capability and reducing physiological effects, preventing or reducing individual and collective exposures, applying prophylaxis to prevent or mitigate negative physiological effects, and protecting critical equipment in Chemical, Biological, Radiological, and Nuclear (CBRN) environments. In FY 2023, the Chemical Biological Defense Program (CBDP) RDT&E Projects have been restructured to align with the CBDP portfolio construct. PT2 efforts in FY 2022 remain in Projects CB2 and TM2. This restructuring provides standardization and alignment across CBDP research, development and acquisition efforts.

Thrust Areas included in this Project are:

- (1) Biological Warfare Defense Prophylaxis
- (2) Air Purification Enhancements
- (3) All-Hazards & Respiratory Protection
- (4) Dynamic Multifunctional Materials for Second Skin
- (5) Enhanced Survivability Coatings
- (6) Lightweight Protective Garments
- (7) Multifunctional Materials for Protection
- (8) Nerve Agent Prophylaxis/Pretreatments
- (9) Reactivators of AChE as Therapeutics (ReACT)

Biological Warfare Defense Prophylaxis: Provides the Warfighter protection against biothreat agents through the pre-exposure administration of prophylactics against known bacterial, viral and toxin agents of interest and emerging infectious threats. Medical countermeasure (MCM) strategies against broader classes of biological agents will be pursued with emphasis on broad-spectrum protection based on mechanism of action. Platform technologies will be utilized and adapted to maximize flexibility, increase stability, shelf life, and expand storage conditions. Efforts will also be adapted to maximize delivery flexibility through modifying delivery routes, which will allow for dose and reagent sparing. Efforts include additional investments in enhanced biodefense and pandemic preparedness.

Air Purification Enhancements: Optimizes and extends filter life and reduces lifecycle costs while maintaining or enhancing protection against all chemical weapons agents and toxic industrial chemicals/materials. Improves integration of collective protection into developmental Service major combat platforms. Investigates existing filtration performance against emerging and non-traditional threats and identify and develop countermeasures.

All Hazards and Respiratory Protection: Develops next generation general purpose mask that unencumbers the Warfighter, integrates with existing system technology, and closes capability gaps in current technologies. Supports special purpose units (e.g., special operations, Civil Support Teams, Explosive Ordnance Disposal) and

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologic	al Defense Program	Date: N	/larch 2023	
Appropriation/Budget Activity 0400 / 2	R-1 Program Element (Number/Name) PE 0602384BP <i>I Chemical and Biological</i> <i>Defense Program</i>	Project (Number/ PT2 / Protect (App	,)
modernization efforts to insert new, scalable protection technologies into curre range of military operations.	ent respirator programs of record that protect	against the full spect	rum of threats	for the full
Dynamic Multifunction Materials for Second Skin: Efforts support percutaneous protective suits that adapt to the environment by synthesizing scaled samples and integrate with current combat garments. These technologies include inter selectivity on demand, and membranes with higher moisture vapor transfer ra	via roll-to-roll manufacture which exhibit mate penetrating polymer networks that will change	erials properties that	reduce therma	al burden
Lightweight Protective Garments: Advances garment material and ensemble a garment designs and fabrication for thermal burden reduction. Incorporates st methods that provide operationally relevant, comparable test data on garment performance evaluation.	ate-of-the-art threat protection technologies a	nd supporting test m	ethodologies a	and
Enhanced Survivability Coatings: Addresses materiel surface ease of deconta coatings that resist chemical agent absorption and are quickly decontaminate	•	•	durable tempo	orary
Multifunctional Materials for Protection: Supports Protection and Hazard Mitig engineer, and integrate novel, reactive/catalytic materials into next generation reactivity, and service life while unencumbering the warfighter. Characterizes generation filters and protective garments that reactively decontaminate chem	CB defense systems. Engineers and scales materials using state-of-the-art ambient press	material manufacturi	ng to maximize	e sorption,
Nerve Agent Prophylaxis/Pretreatments: Obtain the first prophylactic MCMs d the need for additional individual physical protective equipment.	esigned to prevent severe morbidity and mort	ality upon exposure t	o nerve agent	s without
Reactivators of AChE as Therapeutics (ReACT): Provide rapid acting MCMs	to counter adverse effects from exposure to ne	erve agents and mai	ntain force leth	ality.
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
<i>Title:</i> 1) Biological Warfare Defense Prophylaxis		-	26.032	22.116
Description: The ultimate protection of the warfighter is achieved by pretreati with no adverse side effects from the pretreatment. Such pretreatment would environment, absent of any personal protective equipment, facilitating the war support innovative concepts in prophylaxis that support needs specific to the vortex onset to protection, fewer doses required, no cold chain required, and needle-	enable the warfighter to work in a less restrict fighter to operate at peak performance. Effort varfighter such as broad spectrum protection,	ive s		
FY 2023 Plans:				

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	Date: March 2023				
Appropriation/Budget Activity 0400 / 2	R-1 Program Element (Number/Name) PE 0602384BP <i>I Chemical and Biological</i> <i>Defense Program</i>		t (Number/N Protect (Appl	lame) ied Research	n)
B. Accomplishments/Planned Programs (\$ in Millions)			FY 2022	FY 2023	FY 2024
 Bacterial: Continue development of nanobodies. Continue plague and melioidosis human surveillance. Continue non-human primate (NHP) model development for co-infection model. Continue NHP melioidosis neurological model. Initiate development of plaque Messenger Ribonucleic Acid (mRNA) vaccine. Continue to evaluate protective efficacy of Anthrax vaccines against novel Ba 					
Viral: - Conduct nonclinical studies for vaccines and pretreatments for Crimean Cong - Complete Marburg virus infection studies of bats. - Continue immune correlate identification for Ebola.	go Hemorrhagic Fever viruses.				
Toxins: - Increase half-life of monoclonal antibodies (mAb) and scale up manufacturing - Continue evaluation of naturally occurring anti-toxins to protect against marine - Continue to develop novel antitoxin technologies including exploring the use of - Continue evaluation of toxins and antitoxin prophylaxis in animal models. - Continue to develop functional assays to determine biological activity for vario	e toxins. of cell membrane coated nanosponges.				
Broad Spectrum: - Continue novel pan virus nanosponge platform development and animal testin applications of nanosponge technology to include emerging toxin and bacterial - Continue development of a prototype broad spectrum neuronal nanosponge p - Continue exploration of additional strategies and platforms for broad spectrum threats.	threats. platform technology.				
FY 2024 Plans: Viral: - Continue nonclinical studies for vaccines and pretreatments for Crimean Cong - Discovery and development of broadly protective strategies and nontraditiona antibody, and immunomodulators) against new and emerging viral threats. - Explore the use of production pipelines for mosaic and/or engineered antigens platforms.	al approaches (e.g., host-directed, nucleic acio				

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program			Date: March 2023			
Appropriation/Budget Activity 0400 / 2		Project (Number PT2 / Protect (Ap _l		h)		
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024		
 Continue immune correlate identification for Ebola. Continue animal model development for viral families to support Emerging Test protective vaccine/therapeutic layered defense approaches to preven 						
 Toxins: Continue half-life extension of monoclonal antibodies (mAb) and scale up Continue evaluation of naturally occurring anti-toxins to protect against ma Continue development of animal models for evaluation of toxins and antite Continue development of functional assays to determine biological activity Continue evaluation of aptmers as MCM against conotoxins. Continue characterization of toxin-host cell interactions for the continued of Evaluate genetic and genomics approaches to address previously unfores so that they no longer are amenable for detection and neutralization Broad Spectrum: Initial Prototype Development of Broad-spectrum Neuronal Nanosponges Evaluate broad spectrum protection strategies based on mechanisms of a Expand nanosponge platform to target multiple toxin families. Continue layered defense testing with candidate vaccine/antibiotic/antiboo interference between medical countermeasure. Continue to evaluate multiple novel broad spectrum platform strategies for pathogens will be used for test & evaluation, emphasis on broad-spectrum 	arine toxins. poxin prophylaxis. r for various toxins. development of pretreatment strategies. seen threat of deliberate manipulation of threat age to protect against multiple types of neurotoxins. action. dy combinations to broaden protection and avoid r potential use to respond to EID, appropriate protoc					
FY 2023 to FY 2024 Increase/Decrease Statement: Decrease due to change in program/project technical parameters. Decreas past FY23 and all work associated with plague mRNA vaccine has been ca	ncelled.	ng				
<i>Title:</i> 2) Biological Warfare Defense Prophylaxis - Enhanced Biodefense (E	NBD)	-	16.000	20.000		
Description: This effort will focus on Innate Immune Training and Adjuvant enhance immune response. Investments include efforts to strengthen and to or stimulation to increase the ability to resist disease progression and spreas relative to the way a pathogen or toxin causes disease and how the host im- matching of a disease indication with the most appropriate vaccine platform	une the host immune system through enhancemer ad. Characterization of vaccine platform technolog imune system responds will be executed to optimiz	es				
FY 2023 Plans:						

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical a	and Biological Defense Program	Date: I	March 2023				
Appropriation/Budget Activity 0400 / 2	R-1 Program Element (Number/Name) PE 0602384BP <i>I Chemical and Biological</i> <i>Defense Program</i>		Project (Number/Name) PT2 I Protect (Applied Research)				
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024			
 Develop a predictive capability to rapidly identify the optimal vaccord or emerging biological threat. Initiation of projects that identify and evaluate adjuvants/encapsu combined with vaccines to stimulate a customized immunogenicity 	lation formulations/mucosal delivery technologies that can						
FY 2024 Plans: - Continue to develop a predictive capability to rapidly identify the current, novel or emerging biological threat. - Continue to identify and evaluate adjuvants/immune modulation to customized immunogenicity profile without compromising vaccine	echnologies that can be combined with vaccines to stimul						
FY 2023 to FY 2024 Increase/Decrease Statement: Additional investment in enhanced biodefense and pandemic prep	aredness.						
Title: 3) Air Purification Enhancements		-	4.705	1.16			
Description: Existing Collective Protection (ColPro) systems have life. Efforts will focus on optimizing and extending filter life to redu							
FY 2023 Plans: - Continue materials testing for effectiveness against novel threats - Complete and publish report on computational modeling for filter - Complete and publish report on design of high air flow collective advanced agents delivered in all states of matter (vapor, aerosol, a - Continue to engineer novel filter bed materials for chemical agen develop methods to assess filter performance in an operationally-r - Develop low-cost, continuous operation collective protection engine of unprotected facilities during pandemic/bio warfare attack.	protection against advanced agents. protection systems that increase the performance against and liquid) in operationally relevant environments. t destruction, integrate them into next generation filters, ar elevant environment.	nd					
FY 2024 Plans: - Integrate new filtration technologies with more stable, reactive material extending filter operational life. - Continue to assess and mitigate impact of advanced threats on continue to assess and mitigate impact of advanced threats on contransition Residual Life Indicator System to Modernization Collection	surrent and developing filtration technologies.	nd					
FY 2023 to FY 2024 Increase/Decrease Statement:							

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	I Defense Program		Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 2	R-1 Program Element (Number/Name) PE 0602384BP <i>I Chemical and Biological</i> <i>Defense Program</i>	-	ct (Number/N Protect (Appl	lame) lied Research _,)
PE 0602384BP / Chemical and Biological Defense Program ccomplishments/Planned Programs (\$ in Millions) ram/project transitioned to Advanced Development. Decrease due to transition of Residual Life Indicator System to project transition Collective Protection program of record in early FY24. (4) All-Hazards & Respiratory Protection rription: Efforts will improve chemical and biological agent protection while maintaining warfighter capability through rated research on respirator, seams, closures, and new manufacturing techniques and materials; perform early surveys for juser jury input with frequent user operational evaluation; focus on low burden next generation protective mask. D23 Plans: noplete evaluate and assess systems that provide chemical biological respiratory protection technologies in support of tac zard, full spectrum respirator fit testing system to the Joint Service Mask Leakage Tester (JSMLT). nsition operationally-relevant respirator fit testing system to the Joint Service Mask Leakage Tester (JSMLT). nsition operationally-relevant prototypes for a low-encumbrance, next generation protective mask. D24 Plans: elop use of innovative, low burden respirator prototypes. elop use of innovative manufacturing techniques for respirators, such as 3D facial scanning and additive manufacturing. abilsh operationally-relevant protocols for next generation respirator prototype testing. neilop use of innovative, low burden respirator prototypes. elop use of innovative manufacturing techniques for respirators, such a			FY 2022	FY 2023	FY 2024
Program/project transitioned to Advanced Development. Decrease due to trans Modernization Collective Protection program of record in early FY24.	sition of Residual Life Indicator System to				
Title: 4) All-Hazards & Respiratory Protection			-	1.482	1.026
integrated research on respirator, seams, closures, and new manufacturing tec	chniques and materials; perform early surveys	for			
 all hazard, full spectrum respiratory protection system. Transition operationally-relevant respirator fit testing system to the Joint Servi Transition specification for anti-fog lenses in respirators as a Ground Mask mediate 	ice Mask Leakage Tester (JSMLT). odification work order.	ctical			
- Establish operationally-relevant protocols for next generation respiratory prote	ection prototype testing.				
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project transitioned to Advanced Development.					
Title: 5) Dynamic Multifunction Materials for Second Skin			-	1.793	-
environment by synthesizing scaled samples via roll-to-roll manufacture which burden and integrate with current combat garments. These technologies include	exhibit materials properties that reduce therm de interpenetrating polymer networks that will				
<i>FY 2023 Plans:</i> - Continue development and testing of protective garment materials that respon Warfighter protection.	nd to the presence of chemical agents to incre	ase			

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	al Defense Program		Date: N	1arch 2023	
Appropriation/Budget Activity 0400 / 2		-	t (Number/N Protect (Appl)	
B. Accomplishments/Planned Programs (\$ in Millions)			FY 2022	FY 2023	FY 2024
- Begin integration of responsive systems into protective suit paradigms for who	ole system testing.				
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project funding transferred to another funding line. Project funding tra Multifunctional Materials for Protection thrust areas starting in FY24.	nsfers to the Lightweight Protective Garments a	and			
<i>Title:</i> 6) Enhanced Survivability Coatings			-	1.178	1.881
Description: Efforts seek to produce enhanced coatings that increase chemical decontaminatability of military materiel to levels comparable to that of stainless absorption and be quickly decontaminated in field, to rapidly return materiel to	steel. Improved coatings will resist chemical a	igent			
 FY 2023 Plans: Continue to characterize bio-inspired surface treatments for materiel coatings Evaluate and incorporate new or commercially-available appliques (to include coatings, novel coatings characterization, thin film overcoats, strippable coat, no CBRN Coatings, Coverings, and Protective Overlays Program of Record. Advance thin repellent film coating systems from fundamental research to apply 	e chemical transport studies in current military eactive coat, and lock-down coats) in support o				
 FY 2024 Plans: Increase chemical agent resistance of current military coatings through develoreduce the spread of contamination and ease decontamination of military asse Continue to improve equipment coatings through bio-inspired surface treatment equipment coatings. Develop and verify test methods for chemical decontamination efficiency of each other series. 	ts. ents to repel agents of interest from current milit				
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.					
Title: 7) Lightweight Protective Garments			-	-	0.234
Description: Efforts will advance garment material and ensemble technologies designs and fabrication for thermal burden reduction, state-of-the-art threat promethodologies and methods that provide operationally relevant, comparable data	tection technologies, and supporting test	t			
FY 2024 Plans: - Manufacture scaled responsive/reactive textile swatch samples that adapt or thermal burden and integrate with current combat garments.	react to the threat and environment while reduc	cing			

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologic		Date: March 2023			
Appropriation/Budget Activity 0400 / 2	R-1 Program Element (Number/Name) PE 0602384BP <i>I Chemical and Biological</i> <i>Defense Program</i>	Project (N PT2 / Prote		Name) lied Research,)
B. Accomplishments/Planned Programs (\$ in Millions)		FY	2022	FY 2023	FY 2024
- Test scaled responsive/reactive textile swatch samples using whole system	test methods.				
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project funding transferred from another funding line. Project funding Materials for Second Skin thrust area which ends in FY23.	g transferred from the Dynamic Multifunctional				
Title: 8) Multifunctional Materials for Protection			-	2.743	5.087
Description: Efforts will discover, develop and integrate novel, reactive/cataly with maximum sorption and reactivity. They will characterize materials using s spectroscopies for eventual integration into next generation decontaminants, reactively decontaminate chemical warfare agents.	state-of-the-art in operando and ambient pressu	re			
 FY 2023 Plans: Continue to engineer reactive/catalytic nano-structure materials from basic refeed air purification enhancement. Continue to integrate engineered reactive/catalytic nano-structure materials materials in an operationally-relevant environment for personnel decontaminational - Advance next generation materials to design reactive, regenerative protective thermal burden. 	into filters, decontaminants, and textiles to asse ition.				
 FY 2024 Plans: Generate prototype next generation reactive and regenerative protective gat thermal burden for whole system testing. Incorporate novel materials into individual and collective protection filtration conventional and advanced threats delivered in all states of matter (vapor, ae - Begin demonstration of enhanced filter bed performance towards emerging/materials in operationally-relevant environments. Develop scaled manufacturing techniques for novel materials for incorporation 	systems and test for increased performance aga rosol, and liquid) in laboratory. advanced threats and toxic industrial chemicals,	ainst			
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project funding transferred from another funding line. Project funding Materials for Second Skin thrust area which ends in FY23.	g transferred from the Dynamic Multifunctional				
Title: 9) Nerve Agent Prophylaxis/Pretreatments			-	4.158	2.576
Description: Develop pretreatments and prophylactics that counter chemical agents (OPNA), using targeted and innovative science and technology efforts					

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and I	Date: N	March 2023		
Appropriation/Budget Activity 0400 / 2	• • • •	Project (Number/ PT2 / Protect (App	,	n)
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
route of administration, lower dose requirements, and reduced operation countermeasures (MCM) will protect the lives and effectiveness of our capability.				
FY 2023 Plans: - Continue efforts to develop catalytic enzymes for use against selecte - Complete expanded pre-clinical studies of lead catalytic scavengers - Continue efforts to develop capability for rapid development of medic - Continue efforts to explore and further develop novel non-enzyme ne - Continue new approaches to identify pretreatment and prophylaxis ag threats.	to support future investigative new drug (IND) filing. al countermeasures. rve agent prophylaxis.			
 FY 2024 Plans: Continue exploration of the therapeutic efficacy of atipamezole and o opioid-based pharmaceutical based agents (PBAs). Continue cross-toxidromic and pathway analysis to determine possib and development. Finish a paper study to identify previous accomplishments, current st discovering, developing, and fielding therapeutic MCMs for a broad scored statement of the statement of the	le targets for multi-toxidromic therapeutic MCM discover ate of the science and outline a path forward for	у		
FY 2023 to FY 2024 Increase/Decrease Statement: Decrease due to change in program/project technical parameters.				
Title: 10) Reactivators of AChE as Therapeutics (ReACT)		-	-	0.968
Description: Provide rapid acting MCMs to counter adverse effects fro	om exposure to nerve agents and maintain force lethality	<i>.</i>		
FY 2024 Plans: - Initiate efforts that utilize modelling and structural activity relationship and broad spectrum capabilities.	s in order to develop prophylactics with both centrally ac	ting		
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to change in program/project technical parameters.				
	Accomplishments/Planned Programs Subto	otals -	58.091	55.057

				UNCLAS							
Exhibit R-2A, RDT&E Project Jus	tification: PB	2024 Chem	ical and Biol	ogical Defen	se Program				Date: Ma	arch 2023	
Appropriation/Budget Activity 0400 / 2						ment (Numb Chemical and		Project (Number/Name) PT2 I Protect (Applied Research)			
C. Other Program Funding Summ	ary (\$ in Milli	ons)									
	2 .		FY 2024	FY 2024	FY 2024					Cost To	
Line Item	<u>FY 2022</u>	FY 2023	Base	000	Total	FY 2025	FY 2026	FY 2027	FY 2028		
• PT3: <i>Protect (ATD)</i> Remarks	-	32.113	29.261	-	29.261	48.969	42.794	46.159	52.561	Continuing	Continuin
D. Acquisition Strategy N/A											

Exhibit R-2A, RDT&E Project J	hibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program								Date: March 2023			
Appropriation/Budget Activity 0400 / 2					R-1 Progra PE 060238 <i>Defense Pl</i>	84BP / Cher	•	,	Project (Number/Name) MT2 <i>I Mitigate (Applied Research)</i>			
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
MT2: <i>Mitigate (Applied</i> <i>Research)</i>	-	0.000	73.321	66.371	0.000	66.371	63.832	51.426	59.920	64.824	Continuing	Continuing

A. Mission Description and Budget Item Justification

The Mitigate Applied Research Project emphasizes the ability to conduct decontamination and medical actions that enable the quick restoration of combat power, maintain/recover essential functions that are free from the effects of Chemical, Biological, Radiological, and Nuclear (CBRN) hazards, and facilitate the return to preincident operational capability as soon as possible. In FY 2023, the Chemical Biological Defense Program (CBDP) RDT&E Projects have been restructured to align with the CBDP portfolio construct. MT2 efforts in FY 2022 remain in Projects CB2 and TM2. This restructuring provides standardization and alignment across CBDP research, development and acquisition efforts.

Thrust Areas included in this Project are:

- (1) Biological Warfare Defense Therapeutics
- (2) Discovery of Medical Countermeasures Against New and Emerging (DOMANE)
- (3) Chemically Reactive Ocular Wound and Dermal Therapeutics (CROWD)
- (4) Emerging and Pharmaceutical-based Agent Threats (EMPATH)
- (5) Enabling Science
- (6) Reactivators of AChE as Therapeutics (ReACT)
- (7) Enhanced Survivability Coatings
- (8) Equipment Decontamination
- (9) Multifunctional Materials for Protection
- (10) Personnel Decontamination

Biological Warfare Defense Therapeutics: Discovers broad-spectrum bacterial, toxin and viral therapeutics, and label expansion (repurposing) of medical countermeasures that are U.S. Food & Drug Administration (FDA) approved or in advanced stages of clinical development. These efforts are coordinated with Interagency and Department, to leverage public and force/defense health related investments made to minimize risk and speed approval of novel antibiotic countermeasures.

DOMANE: Provides innovative and rapid medical countermeasures (MCMs) development capabilities that reduce developmental risks, cost and schedule associated with MCM fielding, and afford protection against and allow the Joint Force to rapidly respond to traditional, new and emerging biological warfare threat exposures to allow freedom of action.

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and			Date: March 2023	
Appropriation/Budget Activity 0400 / 2	R-1 Program Element (Number/Name) PE 0602384BP / Chemical and Biological Defense Program	•	Imber/Name) ate (Applied Researd	ch)
Chemically Reactive Ocular Wound and Dermal Therapeutics (CRC that has breached the skin. Collect the data that the Food and Drug		e Warfighter th	nat can treat a chem	ical agent
Emerging and Pharmaceutical-based Agent Threats (EMPATH): As development into fieldable drug products. Activities focus on assess non-opioid sedatives.				
Enabling Science: Leverage technological advances and innovative (MCM) to the Warfighter. Modernize the chemical MCM developme therapeutics before regulatory submission and to cultivate technolog MCM testing more cost-effectively with fewer animals.	ent process to allow for an earlier assessment of both th	ne safety and e	fficacy of candidate	
Reactivators of AChE as Therapeutics (ReACT): Develops broad-sp morbidity, and decrease neurological damage.	pectrum, centrally-acting acetylcholinesterase (AChE) r	eactivators, tha	at increase survival,	reduce
Enhanced Survivability Coatings: Develops temporary coatings that regeneration of combat power.	resist chemical agent absorption and are quickly deco	ntaminated in t	he field and allow th	e rapid
Equipment Decontamination: Addresses the limited capability to dec hazardous waste. Efforts within this thrust seek to develop deconta unit-level decontamination with rapid unmasking, reduce logistic nee to develop improved test methods.	minant formulations and procedures that reduce or elir	ninate residual	contamination haza	rds, enable
Multifunctional Materials for Protection: Discovers, develops, and in sorption and reactivity, and characterize materials using state-of-the decontaminants that reactively decontaminate chemical warfare age	e-art in operando and ambient pressure spectroscopies			
Personnel Decontamination: Develops personnel decontaminants w to Warfighters for mass casualty decontamination.	vith lower lifecycle costs and storage constraints and de	etermines time,	, efficacy, and logisti	cs burdens
B. Accomplishments/Planned Programs (\$ in Millions)		FY	2022 FY 2023	FY 2024
Title: 1) Biological Warfare Defense Therapeutics			- 31.034	31.36
Description: This effort funds biomedical research focused on the e against known and emerging biological warfare (BW) threats for whi BW defense therapeutics mitigate and reverse the effects of known a	ch FDA-approved therapeutics are limited or lacking.			
PE 0602384BP: Chemical and Biological Defense Program	UNCLASSIFIED			olume 4 - 42
Chemical and Biological Defense Program	Page 34 of 53 R-1 Line	#17	V	olullic 4 - 42

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	I Defense Program		Date: N	larch 2023		
Appropriation/Budget Activity 0400 / 2	vity R-1 Program Element (Number/Name) Project PE 0602384BP / Chemical and Biological MT2 / I Defense Program Defense Program					
B. Accomplishments/Planned Programs (\$ in Millions)		Γ	FY 2022	FY 2023	FY 2024	
warfighters diagnosed with BW disease. They are the last line of defense again symptomatic Warfighters to service. Biomedical research is focused on discove therapeutic candidates and therapeutic platforms that target viruses, bacteria o by modulating the immune system) and/or relieve BW disease symptoms. Broa to be both safe and efficacious against BW threats in small animal models will a can be accelerated for use against emerging infectious diseases during an out and evaluation of novel small molecules (chemically synthesized), novel biolog and drug/vaccine combinations (aka layered defense), and repurposing of drug included in this research. Development of appropriate animal models and assa also included. Projects leverage interagency and commercial sector investmer	ery and development of broad-spectrum r toxins directly, enhance the host response (ad-spectrum therapeutic candidates that are s advance for additional pre-clinical evaluation, preak. Therapeutic target identification discov- ic molecules (isolated from natural sources), is approved by the FDA for other indications, ays in which to evaluate therapeutic candidate	shown and very drug are es is				
<i>FY 2023 Plans:</i> Viral Therapeutics: - Evaluate conserved targets, including host targets and processes of pathoger - Continue drug discovery and development efforts to prepare for emerging thre action conserved targets and platform technologies. Upon establishment of pro therapeutic candidates to advanced technology development.	eats by focusing on broad spectrum mechanis					
 Bacterial Therapeutics: Evaluate conserved therapeutic targets, with a focus on circumventing or over spectrum treatment. Continue to discover therapeutic candidates that employ novel strategies and delivery methods, or modulating the immune response, to overcome current an in bacterial infections. Upon establishment of proof of concept in small animal i development. Establish proof of concept efficacy of biologics to treat intracellular bacterial bi expansion of investments in biologic therapeutic class. 	mechanisms, such as new pathogen targets, d emerging mechanisms of antibiotic resistar models, transition to advanced technology	nce				
Toxin Therapeutics: - Continue evaluation of repurposed small molecule drug for efficacy in the trea (BoNT) in small animal models; evaluate repurposed drug in combination with b FY 2024 Plans:		rotoxin				

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica		Date: N	larch 2023		
Appropriation/Budget Activity 0400 / 2	R-1 Program Element (Number/Name) PE 0602384BP <i>I Chemical and Biological</i> <i>Defense Program</i>				
B. Accomplishments/Planned Programs (\$ in Millions)		F	Y 2022	FY 2023	FY 2024
Viral Therapeutics: - Continue to evaluate conserved targets, including host targets and processes - Continue drug discovery and development efforts to prepare for emerging threation conserved targets and platform technologies. Upon establishment of pro- therapeutic candidates to advanced technology development.	n of				
 Bacterial Therapeutics: Continue to evaluate conserved therapeutic targets, with a focus on circumve broad-spectrum treatment. Continue to discover therapeutic candidates that employ novel strategies and delivery methods, or modulating the immune response, to overcome current an in bacterial infections. Upon establishment of proof of concept in small animal development. Continue to establish proof of concept efficacy of biologics to treat intracellula groundwork for future expansion of investments in biologic therapeutic class. Toxin Therapeutics: Continue evaluation of repurposed small molecule drug for efficacy in the treat (BoNT) in small animal models in combination with botulinum antitoxin. 	mechanisms, such as new pathogen targets, ad emerging mechanisms of antibiotic resistance models, transition to advanced technology r bacterial biothreat infections to lay the	drug :e			
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.					
Title: 2) Discovery of Medical Countermeasures Against New and Emerging (D	OOMANE)		-	4.334	-
Description: Develop and successfully transition emerging technology platform platforms that will support transition to applied programs for clinical trials. These provide a knowledge foundation and broad candidate pipeline that will underpiped Access, Compassionate Use and Emergency Use authorities) of BW MCM to the freedom of action.					
FY 2023 Plans:					

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical a	and Biological Defense Program	Date:	March 2023	
Appropriation/Budget Activity 0400 / 2	R-1 Program Element (Number/Name) PE 0602384BP <i>I Chemical and Biological</i> <i>Defense Program</i>	Name) plied Researd	ch)	
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
 Pursuing high-throughput 3D structural biology, combined with o technologies to transition to applied programs to address mechani countermeasure identification. 				
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project terminated in FY 2024.				
Title: 3) Chemical Reactive Ocular Wound and Dermal Therapeut	ics (CROWD)	-	6.351	5.639
Description: Focuses on therapeutic strategies to effectively treat eyes, and large areas of intact skin. This effort involves the development those routes of exposure, to decrease the toxic load of agent	opment of products capable of removing or neutralizing CV	VA		
<i>FY 2023 Plans:</i> - Continue advanced preclinical studies to validate safety and effic - Continue assessment of candidate products for advanced develor - Refine pathway to regulatory approval and licensure.				
FY 2024 Plans: - Initiate proof of concept test of candidate decontamination produ - Determination of dosing strategies for use of candidate products				
FY 2023 to FY 2024 Increase/Decrease Statement: Decrease due to change in program/project technical parameters.				
Title: 4) Emerging and Pharmaceutical-based Agent Threats (EM	PATH)	-	5.586	3.753
Description: The Warfighter requires effective MCMs that preven Agents (PBAs) and Emerging Chemical Threats (ECTs), while still fentanyl) by Joint Force Medical Staff for their originally intended p to develop MCMs that are efficacious against a range of toxidrome therapeutic benefit to minimize the potential for re-intoxication and	l allowing for the use of FDA approved drugs (e.g. morphin ourposes of pain management and sedation. This portfolio es, are fast-acting, and have a prolonged protective and/or	seeks		
<i>FY 2023 Plans:</i> - Continue to assess drug products for use against other priority P	BA emerging threats (e.g., non-opioids).			
FY 2024 Plans: - Continue exploration of the therapeutic efficacy of atipamezole a opioid-based PBAs.	nd other FDA-approved and developmental MCMs for non	-		

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Bio	logical Defense Program		Date: N	larch 2023		
Appropriation/Budget Activity 0400 / 2	R-1 Program Element (Number/Name) PE 0602384BP <i>I Chemical and Biological</i> <i>Defense Program</i>	Project (Number/Name) MT2 / Mitigate (Applied Research)				
B. Accomplishments/Planned Programs (\$ in Millions)		F	FY 2022	FY 2023	FY 2024	
 Continue cross-toxidromic and pathway analysis to determine possible t and development. Finish a paper study to identify previous accomplishments, current state discovering, developing, and fielding therapeutic MCMs for a broad scope 	of the science and outline a path forward for	very				
FY 2023 to FY 2024 Increase/Decrease Statement: Decrease due to change in program/project technical parameters.						
<i>Title:</i> 5) Enabling Science			-	12.877	13.878	
Description: Focus on protection of the Warfighter against CWA to main emerging technologies to support modernization of chemical medical cou cMCMs more rapidly to the Warfighter. Efforts include: 1) development o to more efficiently identify cMCMs and assess their safety and efficacy for screening-based sampling of large chemical spaces with the aim of provid selectivity, minimal toxicity, and decreased expense and fielding times to MCMs across the blood brain barrier (BBB) into the brain; 4) maturation of 5) development of well characterized or FDA qualified animal models, as under the FDA animal rule.	Intermeasure (cMCM) pipeline, and develop and de of Artificial Intelligence/Machine Learning (AI/ML) too r regulatory submission; 2) Al/ultra-high throughput ding broad spectrum cMCMs with improved efficacy the warfighter; 3) development of technologies to d of cMCMs with innovative mechanisms of actions; a	ploy ols y and leliver ind				
 FY 2023 Plans: Continue to employ Al/ML-based tools for drug design and predictive drue. Continue to maintain screening and safety databases for drug candidate. Continue to perform select animal and safety studies for lead therapeutic CWAs. Continue to investigate technologies for delivering therapeutics (e.g. 2-p. Continue to support the therapeutic candidate pipeline. Develop well characterized or FDA qualified animal models to support the FDA animal rule that provide protection for the Warfighter against CWAs. Continue to test the safety and efficacy of candidate resurrectors of age. Develop naturally derived MCM with innovative mechanism of action ag (OPNA) threats. 	es ic candidates, including anticholinergics, for treatme byridine aldoxime methyl chloride/2-PAM) to the bra he development of MCMs requiring licensure under ed/inhibited enzyme in animal models.	in. the				
 Continue to employ AI/ML-based tools for drug design and predictive drug Continue to maintain screening and safety databases for drug candidate 						

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical	and Biological Defense Program	Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 2	R-1 Program Element (Number/Name) PE 0602384BP <i>I Chemical and Biological</i> <i>Defense Program</i>	Project (Number/ MT2 / Mitigate (Ap		h)
 B. Accomplishments/Planned Programs (\$ in Millions) Continue to perform select animal and safety studies for lead the Continue to investigate technologies for delivering therapeutics (Continue to support the therapeutic candidate pipeline. Continue to develop well characterized or FDA qualified animal r under the FDA animal rule that provide protection for the Warfight Continue to develop naturally derived MCMs with innovative mediate 	e.g. 2-PAM) to the brain. models to support the development of MCMs requiring licer er against CWAs.		FY 2023	FY 2024
 FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments. Title: 6) Reactivators of AChE as Therapeutics (ReACT) Description: The Warfighter requires rapid acting medical counter to Nerve Agents (NAs) and maintain force lethality. Utilize modelli prophylactics or therapeutics for acetylcholinesterase enzyme real 	ng and structural activity relationships in order to develop	ure -	3.779	4.87
 capabilities. Develop potential candidates that will ultimately be suidentify previously licensed products for new uses in the treatment FY 2023 Plans: Continue to down select generated chemical libraries to the most safety and efficacy assessments. Continue drug formulation efforts for MCMs with a longer shelf-lic chemical composition. Continue development screening for novel broad spectrum enzy Transition critical in vivo data to advanced developer for lead real 	t of chemical warfare casualties. t promising broad spectrum therapeutic candidates for follo fe and with feasibility of an auto-injector containing materia me reactivators that are effective in the brain.	ow on		
 FY 2024 Plans: Continue efforts that utilize modelling and structural activity relat acting and broad spectrum capabilities. Continue to down select generated chemical libraries to the most safety and efficacy assessments. Continue development screening for novel broad spectrum enzy FY 2023 to FY 2024 Increase/Decrease Statement: 	t promising broad spectrum therapeutic candidates for follo			
Minor change due to routine program adjustments. <i>Title:</i> 7) Enhanced Survivability Coatings			1.071	

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	al Defense Program	C	Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 2	•	Project (Nu MT2 / <i>Mitiga</i>		Name) blied Researc	h)
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2	022	FY 2023	FY 2024
Description: Efforts seek to produce enhanced coatings that increase chemical decontaminatability of military materiel to levels comparable to that of stainless absorption and be quickly decontaminated in field, to rapidly return materiel to	steel. Improved coatings will resist chemical a	gent			
 FY 2023 Plans: Continue to characterize bio-inspired surface treatments for equipment coating equipment coatings. Evaluate and incorporate new or commercially-available appliques (to include coatings, novel coatings characterization, thin film overcoats, strippable coat, re CBRN Coatings, Coverings, and Protective Overlays Program of Record. Advance thin repellent film coating systems from fundamental research to application. 	e chemical transport studies in current military eactive coat, and lock-down coats) in support o				
 FY 2024 Plans: Continue evaluating polymer coatings as potential temporary or permanent m burden of decontamination. Increase chemical agent resistance of current military coatings through develor reduce the spread of contamination and enable more facile decontamination of Continue to improve equipment coatings through bio-inspired surface treatment equipment coatings. 	opment and testing of novel temporary coatings f military assets.	to			
FY 2023 to FY 2024 Increase/Decrease Statement: Decrease due to change in program/project technical parameters.					
Title: 8) Equipment Decontamination			-	5.774	2.925
Description: The Warfighter has a limited capability to decontaminate personal facilities; Sensitive equipment (weapon system optics, electronic equipment, in Efforts seek to develop decontaminant formulations and procedures that reduce enable unit-level decontamination with rapid unmasking; reduce logistic needs dirty to rapidly return high-value equipment to normal use; and develop improved.	terior spaces, and aircraft); and hazardous was e or eliminate residual contamination hazards; (need for water); enable rapid sorting of clean				
FY 2023 Plans: - Transition methodology for testing for effective decontamination of complex s Equipment Decontamination System or Tactical Contamination Mitigation Syste - Finish development and demonstration of an autonomous decontamination pl operational decontamination.	em programs of record.				

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical	and Biological Defense Program	Date	: March 2023		
Appropriation/Budget Activity 0400 / 2	R-1 Program Element (Number/Name) PE 0602384BP <i>I Chemical and Biological</i> <i>Defense Program</i>	Project (Numb MT2 / Mitigate (e r/Name) Applied Research)		
B. Accomplishments/Planned Programs (\$ in Millions)		FY 202	2 FY 2023	FY 2024	
- Develop bioagent disclosure spray and bio contamination mapp	ing technologies into prototypes to demonstrate.				
 FY 2024 Plans: Refine autonomous equipment decontamination platform to reduce decontamination. Transition hot air decontamination technologies to Joint Biologic Decontamination Systems programs of record in early FY24. 		t			
FY 2023 to FY 2024 Increase/Decrease Statement: Decrease due to change in program/project technical parameters	i.				
Title: 9) Multifunctional Materials for Protection			- 1.823	2.22	
Description: Efforts will discover, develop and integrate novel, rewith maximum sorption and reactivity, and characterize materials spectroscopies, for eventual integration into next generation decomposition decomposition and reactivity.	using state-of-the-art in operando and ambient pressure				
FY 2023 Plans: - Develop and characterize novel reactive/catalytic materials that materials into next generation decontaminants and coatings.	decontaminate biological and chemical threats and integral	e			
FY 2024 Plans: Integrate reactive materials into decontamination systems for er Continue ambient pressure characterization of reactive chemica Scale materials manufacturing processes for cost-efficiency and 	al decontamination mechanisms.	ons.			
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to change in program/project technical parameters.					
Title: 10) Personnel Decontamination			- 0.692	1.17	
Description: Efforts will develop decontaminants for decontamination constraints and determination of time, efficacy and logistics burded Decrease Warfighter burden in the event of a CWA exposure by i decontamination process as well as possible substitutions for current of a CWA exposure by the contamination process as well as possible substitutions for current of a CWA exposure by the contamination process as well as possible substitutions for current of a CWA exposure by the contamination process as well as possible substitutions for current of a CWA exposure by the current of a CWA	ens to warfighters for mass casualty decontamination. identifying science and technology gaps in the mass persor				
FY 2023 Plans: - Develop and use laboratory and animal models to assess physic skin decontamination lotion (RSDL).	cal removal technologies for potential replacement of reacti	ve			

Exhibit R-2A, RDT&E Project Jus				-	-					March 2023	
Appropriation/Budget Activity 400 / 2				PE 060		ment (Numb Chemical and		Project (Number/Name) MT2 / Mitigate (Applied Research)			:h)
B. Accomplishments/Planned Pro	ograms (\$ in I	Millions)							FY 2022	FY 2023	FY 2024
 Continue to integrate new dry dec process and procedure improveme device. 											
FY 2024 Plans: - Generate efficacy and safety data device package for FDA considerat	•			nontraditiona	al agents rec	ุ่นired to sub	mit a medic <i>e</i>	I£			
FY 2023 to FY 2024 Increase/Dec Increase due to accelerated develo		ent:									
				Accon	nplishments	s/Planned P	Programs Su	btotals	-	73.321	66.371
C. Other Program Funding Summ	<u>nary (\$ in Milli</u>	ions)									
l inc léan	EV 2022	EV 2022	<u>FY 2024</u>	FY 2024	<u>FY 2024</u>	EV 2025	EV 2026	EV 204	~7 EV 201	Cost To	
Line Item • MT3: <i>Mitigate (ATD)</i>	<u>FY 2022</u>	<u>FY 2023</u> 86.157	<u>Base</u> 100.791	<u>000</u>	<u>Total</u> 100.791	<u>FY 2025</u> 89.511	<u>FY 2026</u> 91.704	FY 202 85.79		28 <u>Complete</u> 30 Continuing	
Remarks		<u> </u>	••••				<u> </u>				
D. Acquisition Strategy N/A											

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program									Date: March 2023			
Appropriation/Budget Activity 0400 / 2					R-1 Program Element (Number/Name) PE 0602384BP / Chemical and Biological Defense ProgramProject (Number/Name) CB2 / Chemical Biological De 				,	e (Applied		
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
CB2: Chemical Biological Defense (Applied Research)	-	97.410	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	97.410

A. Mission Description and Budget Item Justification

Project CB2 provides physical science applied research to develop future, multi-disciplinary, and multi-functional capabilities in life sciences, physical sciences, environmental sciences, mathematics, cognitive sciences, and engineering. Efforts in this project support the seamless integration of state-of-the-art-technologies into a collection of systems across the spectrum of capabilities required to support chemical and biological defense missions. After FY 2022, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. CB2 efforts in FY 2022 progress to Projects MT2, PT2, and UN2. This restructuring provides standardization and alignment across CBDP research, development and acquisition efforts.

Individual efforts in this Project include:

- Protection and hazard mitigation focuses on providing technologies that protect from and reduce the impact of chemical/biological threat or hazard to the Warfighter, weapons platforms, and structures.

- Detection focuses on developing technologies for remote and point detection and identification of chemical and biological agents.

- Decision analysis and management focuses on advanced hazard prediction, medical and epidemiological modeling of biological agents, operational effects and risk assessment, and systems performance modeling.

- Warning and reporting focuses on methods of alerting to chemical or biological threat agent releases and exposures.

- Threat agent science is devoted to characterizing threat agents and the hazards they present in terms of agent fate in the environment, toxicology, and pathogenicity, and focuses on the horizontal integration of threat agent information across CB defensive technologies in support of the Joint Services.

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2022	FY 2023	FY 2024
Title: 1) Unattended Perimeter Monitoring	4.114	-	-
Description: Develop automated technologies to improve detection of aerosolized hazards while minimizing or removing user intervention to enable a reliable detect-to-warn capability, providing a capability for unattended monitoring of perimeters for temporary defense positioning, including base camps, to enable early indication of threats. This thrust area will evaluate current and novel technologies to provide improved chemical threat detection and automated biological detection capabilities.			
Title: 2) Unconventional Detection Modalities	3.997	-	-
Description: Develop disruptive technologies to identify unknown or emerging threats and develop sensors that can operate in complex threat environments with high fidelity. This thrust area supports others as appropriate to the Joint Force mission needs (e.g., expeditionary, perimeter defense, or unmanned reconnaissance.			

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical	and Biological Defense Program	Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 2	PE 0602384BP / Chemical and Biological	Project (Number/N CB2 I Chemical Bio Research)		nse (Applied
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
Title: 3) Distributed CB Reconnaissance		3.328	-	-
Description: Develop threat sensing and sampling payloads for platforms to enhance early warning and situational awareness of support dismounted reconnaissance and surveillance missions by collection systems that are rugged, rapid and accurate.	biological and chemical threats. Sensor development will			
Title: 4) Enhanced/Emerging Biothreat Sensing		7.825	-	-
Description: Establish a capability responsive to detecting emerge (presumptive, field confirmatory, theater validation, and definitive coupled with advanced computational tools that produce a field re- and enhanced biological threats across all force echelons. Further data processing sciences to understand if a biological sample pre- Leveraged modern laboratory capabilities and synthetic biology n Joint Force.	identification) through a pathogen-agnostic laboratory workflo eady test. field forward detection capabilities to detect emergi er, advanced biological measurement approaches and esents threat characteristics that could harm the warfighter.	w ng		
<i>Title:</i> 5) Expeditionary Analytical Toolkit (ExAnT)		2.903	-	-
Description: Provide general and specialized forces with the abi while enhancing detection capabilities for non-traditional, emerging the set of the set				
Title: 6) Air Purification Enhancements		0.393	-	-
Description: This effort supports the Expeditionary Collective Productive by maintenance and limited service life. Efforts will focus of while maintaining or improving protection.				
Title: 7) All-Hazards & Respiratory Protection		1.380	-	-
Description: This effort supports the Respiratory and Ocular Pro protection while maintaining warfighter capability through integrat perform early surveys for end-user jury input; frequent user operaprotection.	ed research on respirator, seams, closures, and new materia			
Title: 8) Dynamic Multifunction Materials for Second Skin		1.839		

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	I Defense Program	Date:	March 2023		
Appropriation/Budget Activity 0400 / 2	R-1 Program Element (Number/Name) PE 0602384BP <i>I Chemical and Biological</i> <i>Defense Program</i>		e ct (Number/Name) I Chemical Biological Defense earch)		
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024	
Description: This effort supports the Percutaneous Protection. Efforts will utili biological protective suits that adapt to the environment by synthesizing scaled materials properties that reduce thermal burden and integrate with current com interpenetrating polymer networks that will change moisture permeability and m with higher moisture vapor transfer rates than existing fabrics.	samples via roll-to-roll manufacture which exhibit garments. These technologies include	nibit			
<i>Title:</i> 9) Enhanced Survivability Coatings		2.436	-	-	
Description: This effort supports the Materiel Contamination Mitigation. Militar logistically intensive to decontaminate. Efforts within this thrust seek to produc warfare agent survivability and decontaminability of military equipment to levels coatings will resist chemical agent absorption and be quickly decontaminated in operations level.	e enhanced coatings that increase chemical s comparable to that of stainless steel. Improv	ed			
Title: 10) Equipment Decontamination		2.523	-	-	
Description: This effort supports the Materiel Contamination Mitigation. The V personal equipment, weapons, vehicles, ships, and facilities; Sensitive equipment interior spaces, and aircraft); and hazardous waste. Efforts within this thrust seprocedures that reduce or eliminate residual contamination hazards; enable un reduce logistic needs (need for water); enable rapid sorting of clean from dirty t use; and develop improved realistic test methods.	ent (weapon system optics, electronic equipme eek to develop decontaminant formulations an it-level decontamination with rapid unmasking	ent, d ;			
Title: 11) Multifunctional Materials for Protection		4.677	-	-	
Description: This effort supports the Respiratory and Ocular Protection, Percur Protection, Materiel Contamination Mitigation, and Personnel Contamination M integrate novel, reactive/catalytic materials and scale material manufacturing w characterize materials using state-of-the-art in operando and ambient pressure generation decontaminants, coatings, filters, and protective garments that reac	itigation. Efforts will discover, develop and vith maximum sorption and reactivity, and spectroscopies, for eventual integration into r				
<i>Title:</i> 12) Personnel Decontamination		1.180	-	-	
Description: This effort supports the Personnel Contamination Mitigation. Effort decontamination of unbroken skin with lower lifecycle costs and storage construit logistics burdens to warfighters for mass casualty decontamination. Decrease	aints and determination of time, efficacy and				

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	l Defense Program		Date: M	arch 2023	
Appropriation/Budget Activity 0400 / 2	R-1 Program Element (Number/Name) PE 0602384BP <i>I Chemical and Biological</i> <i>Defense Program</i>	Project (N CB2 I Che Research)	mical Bio	a me) logical Defer	nse (Applied
B. Accomplishments/Planned Programs (\$ in Millions)			2022	FY 2023	FY 2024
Warfare Agent (CWA) exposure by identifying science and technology gaps in well as possible substitutions for current approved personnel decontamination		as			
<i>Title:</i> 13) Employment Characterization			4.159	-	-
Description: Employment Characterization studies refine threat assessments a outdoor releases of threat agents on CBDP operations, strategy, and capabilitie threat space by determining how chemical and biological agents behave when CBDP Enterprise by closing knowledge gaps and informing on the type, extent may face in an operational environment. Employment Characterization will: review state of knowledge on agent employr and threat agent science (TAS) assessment opportunities; continue coordination resources; develop closer linkages to hazard prediction modelers to identify knowledge to potential munitions for applicability to potential future threats base chamber tests and operational trials as appropriate for compounds of interest.	es. These studies directly define the Warfighter released. This thrust area reduces risk to the and magnitude of a potential hazard a warfight ment (laboratory and outdoors) to identify gaps on with international partners to leverage skills owledge gaps and TAS opportunities; prepare	iter and			
<i>Title:</i> 14) Environmental Response			6.467	-	-
Description: Environmental Response evaluates CB threats to understand how persistence, degradation, decomposition), along with the effects of environment those agents. Studies include evaluations of chemical and biological threat age surfaces such as clothing, structures, and equipment. This thrust area reduces gaps and informing on the type, extent and magnitude of a potential hazard a w Small-scale laboratory measurements are used to predict the larger-scale beha operational settings, while examining agents deposited on operationally relevant environmental persistence and hazards. Knowledge obtained from Environment predictive model development, and capability development.	tal conditions (e.g. ozone, UV, humidity, etc.) ents on soil, water, and plants, and operational s risk to the CBDP Enterprise by closing knowl varfighter may face in an operational environm avior and fate of the agents in outdoor and nt substrates refines our understanding of their	l edge ent.			
<i>Title:</i> 15) First Look (Chemical and Biological)			9.850	-	-
Description: First Look provides the initial evaluation of known and emerging to the Warfighter. For both chemical and biological agents, this initial fundamental and toxicity screening for chemicals and toxins and growth and/or virulence for feasibility of weaponization for all agents. Investments in this area are used to evaluate threat agents as well as develop characterize chemical, biological, and toxin threat agent properties. First Look	al risk assessment includes evaluation of synth biological agents as well as production and methods and capabilities to quickly and accura	esis ately			

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	I Defense Program		Date: M	larch 2023	
Appropriation/Budget Activity 0400 / 2	R-1 Program Element (Number/Name) PE 0602384BP <i>I Chemical and Biological</i> <i>Defense Program</i>		ct (Number/N Chemical Bio arch)		nse (Applied
B. Accomplishments/Planned Programs (\$ in Millions)		Γ	FY 2022	FY 2023	FY 2024
requirements generation, capability development, model development, the larg government stakeholders about known or emerging agent threats.	er CBDP Enterprise, Intelligence and other				
Title: 16) Host Response			15.199	-	-
Description: Host Response assesses the human response of exposure to bid operationally relevant exposure scenarios (acute versus chronic) and exposure etc.) and appropriate assessment methods and models. Data from host response exposure limits (e.g. LD50 or ID50) and qualitative information (e.g. mechanism requirements generation, capability development, model development, the larg government stakeholders. The program, known as CRISTAL (Computational Rapid Identification and Scie predictive capabilities for rapidly assessing the human response to chemical ar response will be working to close known knowledge gaps associated with tradit associated with combinatorial agent exposures. Bioavailability of threats that a differences between exposures to encapsulated versus un-encapsulated threat	e routes (e.g., .inhalation, dermal, ingestion, nse studies are used to develop quantitative n of action) to inform warfighter mission planni er CBDP Enterprise, Intelligence and other entific Threat Analysis) is modernizing to includ nd biological threat agents. In addition, host tional threats, including exploring synergistic e are encapsulated to understand host response	le			
<i>Title:</i> 17) Technical Surprise			4.500	-	-
Description: Technical Surprise assesses technological advancements for polagent use and release. Technical Surprise includes horizon scanning to identifit technical assessments of emerging technological advancements (e.g. biotechn quantum computing). This program develops capabilities to evaluate and assest nature or magnitude of a threat agent. The technical surprise program will be evaluating emerging technologies and c of threat use and make threats more likely to survive being released. Identify the biology and assess the implications. These efforts will identify and assess form overcome and assess implications of increasing potential threat.	fy potential areas of concern as well as conduct ology, artificial intelligence, machine learning, ass technical enhancements that may alter the onvergence of technologies that improve the e he limitations and barriers associated with syn	ease thetic			
<i>Title:</i> 18) CBRN Battlespace Surveillance, Alerting & Response			9.459	-	-
Description: Improve the Department of Defense's capability to detect, identify and naturally occurring outbreaks of chemical and biological threat agents. Cu JSTO are based on large in-hospital datasets from patients with comorbidities. these algorithms will focus on large, real-time human data collects of chemical Additionally, studies will focus on examining the feasibility of specifically isolating	rrent predictive algorithms in development by Improving on the applicability and efficacy of and biological agent / agent proxy exposures.	ng			

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	I Defense Program	Date:	March 2023	
Appropriation/Budget Activity 0400 / 2	R-1 Program Element (Number/Name) PE 0602384BP <i>I Chemical and Biological</i> <i>Defense Program</i>	Project (Number CB2 I Chemical E Research)	,	nse (Applied
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
severity of infection, and predicting return to mission readiness after exposure. of countermeasures such as isolation, quarantine, and removal from an area, the and mortality rates. The maturation of algorithms will incorporate Machine Lea specificity.	hus potentially reducing transmission, morbidit	у,		
<i>Title:</i> 19) CBRN Decision Aids		3.10) -	-
Description: In order to unencumber the warfighter at the tactical edge, contin on End User Devices (EUDs) in both connected and disconnected operations. reducing the burden experienced by the warfighter, while providing accurate, a focus will be put on developing a Contamination Avoidance Decision Aid to info plan routes around CB hazards.	Capabilities will focus on utilizing automation, ctionable information. During this time period,			
Another area of focus will be the development of Autonomous Asset Guidance, other capabilities developed under the CBRN Decision Aids portfolio to optimiz burden incurred by the warfighter in order to operate them. This capability will Autonomous Assets to improve and refine other CBRN Decision Aids.	e the use of Autonomous Assets and reduce the	ne		
Title: 20) CBRN Situational Awareness		8.08	1 -	-
Description: To enhance CB Situational Awareness, efforts will expand the typ assessment capabilities to include fixed-wing and rotary-wing drones of interes and swarms to be modeled.				
Virtual Reality (VR) and Augmented Reality (AR) technologies will be leveraged rehearsal capabilities that will be integrated into systems widely used by the Jo developed to implement, visualize and account for hazard source terms and plu models Augmented Reality applications will also be explored for tactical use to the battlefield.	int Force. Virtual training environments will be umes generated by transport and dispersion (1	&D)		
Modernize hazard modeling capabilities by adopting a modular framework and systems to operationalize Reachback support. Further enhance hazard model modeling capability and improve urban T&D modeling to support operations in art computational fluid dynamics modeling techniques and their exploitation of t increase both speed and accuracy.	ing by creating a seamless indoor-to-outdoor T urban and mixed environments. New state-of-	&D the-		

Exhibit R-2A, RDT&E Project Jus	stification: PB	2024 Chemi	ical and Biol	ogical Defen	se Program				Date: M	arch 2023	
Appropriation/Budget Activity 0400 / 2				PE 06	r ogram Ele r 02384BP / C se Program			Project (Number/Name) CB2 / Chemical Biological Defense (App Research)			
B. Accomplishments/Planned Pr	ograms (\$ in I	<u>Aillions)</u>							FY 2022	FY 2023	FY 2024
Develop CB health effect modeling chemical and biological agents. Ef impacts from exposure to, and spre leverage Threat Agent Science (TA exposures to traditional and non-tra accounting for human health effect	pidemiological ead of, infection AS) data to enh aditional CB ag	models will k us biological ance capabi	be developed threat agen ilities for mo	d that quanti ts to DoD rel deling health	fy and visual levant popula r effects and	lize mission ations. Addi host pathog	operational tionally, effor en interactior	ts will ns from			
				Accor	nplishment	s/Planned P	rograms Su	btotals	97.410	-	-
C. Other Program Funding Summ Line Item • CB3: Chemical	mary (\$ in Milli <u>FY 2022</u> 28.484	<u>ons)</u> FY 2023 -	<u>FY 2024</u> <u>Base</u> -	<u>FY 2024</u> <u>OCO</u> -	<u>FY 2024</u> <u>Total</u> -	<u>FY 2025</u>	<u>FY 2026</u>	FY 202	27 FY 2028	Cost To <u>Complete</u> 0.000	Total Cos
Biological Defense (ATD) • MT3: Mitigate (ATD) • PT3: Protect (ATD) • UN3: Understand (ATD) Remarks	- - -	86.157 32.113 68.415	100.791 29.261 83.825	- - -	100.791 29.261 83.825	89.511 48.969 81.392	91.704 42.794 87.384	85.79 46.15 73.51	59 52.58 ²	Continuing Continuing Continuing	Continuin
<u>D. Acquisition Strategy</u> N/A											

Exhibit R-2A, RDT&E Project Ju	stification	: PB 2024 C	Chemical an	d Biologica	l Defense P	rogram				Date: Marc	ch 2023	
Appropriation/Budget Activity 0400 / 2	R-1 Program Element (Number/Name) Project (Number/Name) PE 0602384BP / Chemical and Biological TM2 / Techbase Medical Defense (A Defense Program Research)						Applied					
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
TM2: Techbase Medical Defense (Applied Research)	-	107.608	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	107.608

A. Mission Description and Budget Item Justification

Project TM2 provides for applied research for innovative technology approaches to advance medical systems designed to rapidly identify, diagnose, prevent, and treat disease due to exposure to chemical and biological threat agents. After FY 2022, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. TM2 efforts in FY 2022 progress to Projects MT2, PT2, and UN2. This restructuring provides standardization and alignment across CBDP research, development and acquisition efforts.

Individual efforts in this Project include:

- Core science efforts in Medical Chemical, Medical Biological, Diagnostics, and Medical Countermeasures.

- Supports applied research for the investigation of new medical countermeasures to include prophylaxes, pretreatments, antidotes, skin decontaminants, and therapeutic drugs against identified and emerging biological and chemical warfare agents.

- Medical Science and Technology (S&T) efforts in this Budget Activity refine promising medical initiatives identified in Budget Activity 1, resulting in the development of countermeasures to protect against and treat the effects of exposure to chemical and biological (CB) agents.

- Diagnostic research focuses on providing high quality data closer to the point-of-need comprising device innovation, panels of biomarkers driven by bioinformatics, and epidemiological modeling tools.

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2022	FY 2023	FY 2024
Title: 1) Chemical Diagnostics	0.699	-	-
Description: Provide innovative and integrated capabilities to the Warfighter that are able to diagnose threats across the chemical spectrum. Enhance force protection by investing in diagnostics for exposure to traditional and nontraditional Chemical Warfare Agents (CWAs), including pharmaceutical based agents (PBAs). Leverage the development of a chemical diagnostic that monitors blood, indicating whether a Warfighter has been exposed to nerve agents within minutes.			
Title: 2) Diagnostic Building Blocks	4.446	-	-
Description: Develop novel, state of the art capabilities that lay the foundation for modernizing other areas within the diagnostics portfolio. This includes exploiting areas such as synthetic biology and chemistry to develop novel and rapid diagnostic tests for utilization in the event of an outbreak of an unknown threat. Invest in efforts that lead to accelerated assay development timelines and optimized test parameters through leveraging artificial intelligence (AI) and machine learning (ML) to allow us to quickly pivot and develop assays for emerging threats and speed up development to days instead of weeks.			

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical a	and Biological Defense Program	Date: N	arch 2023		
Appropriation/Budget Activity 0400 / 2	R-1 Program Element (Number/Name) PE 0602384BP <i>I Chemical and Biological</i> <i>Defense Program</i>	Project (Number/N TM2 / Techbase Me Research)		ense (Applied	
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024	
Title: 3) Emerging Threats		4.110	-	-	
Description: Push beyond the boundaries of the traditional threat Development of diagnostic systems that leverage novel approaches the classification of threat (e.g., bacterial vs viral) from an unknown actionable information, such as administering the appropriate med medic or primary care provider greatly improves turnaround time for	es to characterize pathogen or host response and can ider n sample. Invest in diagnostic tests that enable the deliver ical countermeasure (e.g. antibiotic, antiviral, vaccine), by	ntify ry of			
Title: 4) Bacterial Therapeutics		14.456	-	-	
Description: Discover and develop therapeutic countermeasures to the warfighter.	to mitigate the effects of known and emerging bacterial the	reats			
<i>Title:</i> 5) Toxin Therapeutics		0.250	-		
Description: Discover and develop therapeutic countermeasures	to protect the warfighter against biotoxin threats.				
<i>Title:</i> 6) Viral Therapeutics		14.457	-	-	
Description: Discover and develop therapeutic countermeasures warfighter.	to mitigate the effects of known and emerging viral threats	to the			
Title: 7) Bacterial/Viral/Toxins/Broad Spectrum Prophylaxis		35.512	-		
Description: The ultimate protection of the Warfighter is achieved threat with no adverse side effects from the pretreatment. Such prestrictive environment, absent of any personal protective equipmed Investments in this Program Element support innovative concepts such as broad spectrum protection, rapid onset to protection, fewer administration.	retreatment would enable the Warfighter to work in a less ent, facilitating the Warfighter to operate at peak performar in prophylaxis that support needs specific to the warfighte				
Title: 8) Chemical Reactive Ocular Wound and Dermal Therapeut	ics (CROWD)	6.679	-	-	
Description: Focuses on therapeutic strategies to effectively treat skin. This effort involves the development of products capable of to decrease the toxic load of agent and allow optimal effectiveness	removing or neutralizing CWAs from those routes of expos				
Title: 9) Enabling Science		10.214	_		

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical a	nd Biological Defense Program	Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 2	PE 0602384BP / Chemical and Biological	P roject (Number / M2 / Techbase M Research)	,	se (Applied
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
Description: Protection of the Warfighter against Chemical Warfar goal of the Enabling Sciences portfolio. The portfolio leverages in modernization of chemical medical countermeasure (cMCM) pipelin more rapidly to the warfighter.	novative approaches and emerging technologies to support			
Portfolio elements include: 1) development of Artificial Intelligence/ cMCMs and assess their safety and efficacy for regulatory submiss large chemical spaces with the aim of providing broad spectrum cM and decreased expense and fielding times to the warfighter; 3) dev brain barrier (BBB) into the brain; 4) maturation of cMCMs with inner characterized or FDA qualified animal models, as needed, to suppor rule.	sion; 2) Al/ultra-high throughput screening-based sampling of MCMs with improved efficacy and selectivity, minimal toxicity relopment of technologies to deliver MCMs across the blood ovative mechanisms of actions; and 5) development of well	,		
Title: 10) Nerve Agent Prophylaxis/Pretreatments		3.282	-	-
Description: Develop pretreatments and prophylactics that counter agents (OPNA), using targeted and innovative science & technolog of administration, lower dose requirements, and reduced operation the lives and effectiveness of our warfighters, thus maintaining for	gy efforts that will offer broad-spectrum protection, flexible ro al and logistical burden. The use of these MCMs will protect	ute		
Title: 11) Pharmaceutical Based Agents (PBAs)		6.673	-	-
Description: Focuses on therapeutic strategies to effectively minin Agents (PBAs). This effort involves the evaluation FDA approved to novel drug products to enhance level of protection and/or operation to develop drug candidates that will ultimately be submitted for Foc previously licensed products for new uses in the treatment of chem	therapeutics for operational use, as well as generation of nal utility for the Warfighter. Efforts in this area are designed and Drug Administration (FDA) licensure or to identify			
<i>Title:</i> 12) Reactivators of AChE as Therapeutics (ReACT)		3.830	-	-
Description: The warfighter requires rapid acting medical counterrest exposure to Nerve Agents (NAs) and maintain force lethality. This acetylcholinesterase enzyme reactivation. Efforts in this area are a submitted for U.S. Food and Drug Administration (FDA) licensure of treatment of chemical warfare casualties.	effort involves the development of improved therapies for designed to develop potential candidates that will ultimately			
			L	L

Exhibit R-2A, RDT&E Project Justif Appropriation/Budget Activity 0400 / 2		2024 Chem	ical and Biol	R-1 Pr PE 06	ogram Eler	n ent (Numbe Chemical and I					
B. Accomplishments/Planned Prog	rams (\$ in N	<u>/lillions)</u>						[FY 2022	FY 2023	FY 2024
				Accon	nplishments	s/Planned Pro	ograms Sul	ototals	104.608	-	-
							FY 2022	FY 20	023		
Congressional Add: Biological Warf	are Defense	Therapeutio	CS				3.000	C	-		
FY 2022 Accomplishments: For PU of concept small animal efficacy studis studies, and Good Manufacturing Prato advanced development. This is a hMCMs.	ies will be co actice (GMP) nost directed	mpleted witl manufactur therapeutic	h options for ing. The can and fits with	non human didate will th our broad s	primate pha len be ready pectrum stra	rmacokinetics to transition					
	ogomony and					dds Subtotals	s 3.000	<u>ר</u>			
C. Other Program Funding Summa Line Item	FY 2022	<u>FY 2023</u>	<u>FY 2024</u> <u>Base</u>	<u>FY 2024</u> OCO	<u>FY 2024</u> <u>Total</u>	<u>FY 2025</u>	<u>FY 2026</u>	FY 202	27 FY 2028	<u>Cost To</u> Complete	
• EN3: Enabling Investments (ATD)	<u></u>	39.540	43.196	-	43.196	43.198	44.449	44.44		Continuing	
• MT2: <i>Mitigate (Applied Research)</i>	-	73.321	66.371	-	66.371	63.832	51.426	59.92		Continuing	
• MT3: <i>Mitigate (ATD)</i>	-	86.157	100.791	-	100.791	89.511	91.704	85.79		Continuing	
• PT2: Protect (Applied Research)	-	58.091	55.057	-	55.057	56.153	57.817	61.45		Continuing	
• PT3: Protect (ATD)	-	32.113	29.261	-	29.261	48.969	42.794	46.15		Continuing	
• TM3: Techbase	144.779	-	-	-	-	-	-			0.000	
Medical Defense (ATD)											
UN2: Understand	-	112.952	119.182	-	119.182	111.773	107.842	107.19	93 107.193	Continuing	Continuin
(Applied Research)										-	
• UN3: Understand (ATD)	-	68.415	83.825	-	83.825	81.392	87.384	73.51	15 71.015	Continuing	Continuin
<u>Remarks</u>											
D. Acquisition Strategy N/A											
					SIFIED						

THIS PAGE INTENTIONALLY LEFT BLANK

Exhibit R-2, RDT&E Budget Item	n Justificat	ion: PB 202	24 Chemica	I and Biolog	gical Defens	e Program				Date: March 2023			
Appropriation/Budget Activity 0400: Research, Development, Te Advanced Technology Developme		ation, Defen	se-Wide I B	3A 3:			t (Number/ nical and B	gram - Advanced Development					
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost	
Total Program Element	0.000	191.695	226.225	267.073	0.000	267.073	273.070	276.331	259.918	263.525	Continuing	Continuing	
UN3: Understand (ATD)	-	0.000	68.415	83.825	0.000	83.825	81.392	87.384	73.515	71.015	Continuing	Continuing	
PT3: Protect (ATD)	-	0.000	32.113	29.261	0.000	29.261	48.969	42.794	46.159	52.581	Continuing	Continuing	
MT3: Mitigate (ATD)	-	0.000	86.157	100.791	0.000	100.791	89.511	91.704	85.795	85.480	Continuing	Continuing	
EN3: Enabling Investments (ATD)	-	0.000	39.540	43.196	0.000	43.196	43.198	44.449	44.449	44.449	Continuing	Continuing	
ET3: Emerging Threats (ATD)	-	0.000	0.000	10.000	0.000	10.000	10.000	10.000	10.000	10.000	Continuing	Continuing	
CB3: Chemical Biological Defense (ATD)	-	28.484	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	28.484	
NT3: Non-Traditional Agents Defense (ATD)	-	10.843	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	10.843	
TM3: Techbase Medical Defense (ATD)	-	144.779	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	144.779	
TT3: Technology Transition (ATD)	-	7.589	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	7.589	

A. Mission Description and Budget Item Justification

This program element (PE) resources Advanced Technology Development across the Understand, Protect, Mitigate, and Enabling Investments portfolios. Chemical and Biological Defense Program (CBDP) investments provide an integrated, layered capability to enable Countering Weapons of Mass Destruction (CWMD) missions ranging from combat operations to Department of Defense (DoD) support to domestic incident prevention and response. The Projects in this PE demonstrate technologies supporting the transition to advanced component development for physical capabilities, which cover chemical and biological (CB) detection, situational awareness and effects modeling, and protection and hazard mitigation. FY24 funding accelerates characterization and situational awareness of emerging biothreats and accelerates delivery of improved protection from and mitigation of biothreats, including rapid repurposing of available therapeutics and development of new vaccines.

Individual Projects include:

- Understand (UN3): Demonstration of enhanced chemical detection capabilities for aerosols and non-traditional agents, expanded capabilities for biosurveillance in pathogen detection and diagnosis, produce biological diagnostic arrays and reagents and diagnostic device platforms.

- Protect (PT3): Production of pretreatment candidates for bacterial, viral, and toxin threats.

Exhibit R-2, RDT&E Budget Item Justification: PB 2024 C	chemical and Biolog	gical Deletise FIO	gram	Date:	March 2023
Appropriation/Budget Activity 400: Research, Development, Test & Evaluation, Defense-N Advanced Technology Development (ATD)	<i>Wide I</i> BA 3:		ement (Number/Name) Chemical and Biologica		Advanced Development
Mitigate (MT3): Production of therapeutic candidates for ba	acterial, viral, and to	oxin threats.			
Enabling Investments (EN3): Demonstrations of CB defense and the continued efforts to enhance the military					nation, including non-
Emerging Threats (ET3): identify and develop scientific sol	utions or to moder	nize capabilities th	nat allow for a more rapi	d response to emergin	ng threats.
 Chemical Biological Defense (CB3), Non-Traditional Agent active FY24 Projects due to budget restructuring. 	ts (NTA) Defense (NT3), Techbase N	Medical Defense (TM3),	and Technology Trans	sition (TT3) are no longe
CBDP Science and Technology (S&T) Applied Research Pe CBC), United States Army Medical Research Institute of Infe	ectious Diseases (l	JSAMRIID), Unite	d States Army Medical	Research Institute of C	Chemical Defense
(USAMRICD), United States Army Natick Soldier Systems (such as Pacific Northwest National Laboratory (PNNL), amo nteragency for mission success across the enterprise throu Work conducted under this PE will transition to and will prov Development and Demonstration (PE 0604384BP) activities	ng others. The int gh collaborative pla ide risk reduction f	ent is to maintain anning and progra	strategic partnerships wamming maintaining bud	vith the DoD Service co lget assurance.	ommunities & the
such as Pacific Northwest National Laboratory (PNNL), and nteragency for mission success across the enterprise throu Work conducted under this PE will transition to and will prov Development and Demonstration (PE 0604384BP) activities	ng others. The int gh collaborative pla ide risk reduction f	ent is to maintain anning and progra	strategic partnerships wamming maintaining bud	vith the DoD Service co lget assurance.	ommunities & the
Such as Pacific Northwest National Laboratory (PNNL), and nteragency for mission success across the enterprise throu Nork conducted under this PE will transition to and will prov Development and Demonstration (PE 0604384BP) activities B. Program Change Summary (\$ in Millions)	ng others. The int gh collaborative pla ide risk reduction fo <u>FY 2022</u>	ent is to maintain anning and progra or Advanced Com <u>FY 2023</u>	strategic partnerships wamming maintaining bud apponent Development an <u>FY 2024 Base</u>	vith the DoD Service co lget assurance. nd Prototypes (PE 060	ommunities & the 3884BP) and System <u>FY 2024 Total</u>
uch as Pacific Northwest National Laboratory (PNNL), and nteragency for mission success across the enterprise throu Vork conducted under this PE will transition to and will prov Development and Demonstration (PE 0604384BP) activities <u>Program Change Summary (\$ in Millions)</u> Previous President's Budget	ng others. The int gh collaborative pla ide risk reduction fo <u>FY 2022</u> 197.824	ent is to maintain anning and progra or Advanced Com	strategic partnerships w amming maintaining bud nponent Development ar	vith the DoD Service co lget assurance. nd Prototypes (PE 060	ommunities & the 3884BP) and System
uch as Pacific Northwest National Laboratory (PNNL), and nteragency for mission success across the enterprise throu Vork conducted under this PE will transition to and will prov Development and Demonstration (PE 0604384BP) activities . Program Change Summary (\$ in Millions) Previous President's Budget Current President's Budget	ng others. The int gh collaborative pla ide risk reduction fo <u>FY 2022</u>	ent is to maintain anning and progra or Advanced Com <u>FY 2023</u> 238.407	strategic partnerships w amming maintaining bud nponent Development an <u>FY 2024 Base</u> 248.071	vith the DoD Service co lget assurance. nd Prototypes (PE 060	ommunities & the 3884BP) and System <u>FY 2024 Total</u> 248.071
uch as Pacific Northwest National Laboratory (PNNL), and iteragency for mission success across the enterprise throu Vork conducted under this PE will transition to and will prov evelopment and Demonstration (PE 0604384BP) activities Program Change Summary (\$ in Millions) Previous President's Budget	ng others. The int gh collaborative pla ide risk reduction for <u>FY 2022</u> 197.824 191.695	ent is to maintain anning and progra or Advanced Com <u>FY 2023</u> 238.407 226.225	strategic partnerships w amming maintaining bud nponent Development an <u>FY 2024 Base</u> 248.071 267.073	vith the DoD Service co lget assurance. nd Prototypes (PE 060	ommunities & the 3884BP) and System <u>FY 2024 Total</u> 248.071 267.073
uch as Pacific Northwest National Laboratory (PNNL), and interagency for mission success across the enterprise throu Vork conducted under this PE will transition to and will prov Development and Demonstration (PE 0604384BP) activities Program Change Summary (\$ in Millions) Previous President's Budget Current President's Budget Total Adjustments	ng others. The int gh collaborative pla ide risk reduction for <u>FY 2022</u> 197.824 191.695 -6.129	ent is to maintain anning and progra or Advanced Com <u>FY 2023</u> 238.407 226.225 -12.182	strategic partnerships w amming maintaining bud nponent Development an <u>FY 2024 Base</u> 248.071 267.073	vith the DoD Service co lget assurance. nd Prototypes (PE 060	ommunities & the 3884BP) and System <u>FY 2024 Total</u> 248.071 267.073
uch as Pacific Northwest National Laboratory (PNNL), and interagency for mission success across the enterprise throu Work conducted under this PE will transition to and will prov bevelopment and Demonstration (PE 0604384BP) activities Program Change Summary (\$ in Millions) Previous President's Budget Current President's Budget Total Adjustments • Congressional General Reductions	ng others. The int gh collaborative pla ide risk reduction fo <u>FY 2022</u> 197.824 191.695 -6.129	ent is to maintain anning and progra or Advanced Com <u>FY 2023</u> 238.407 226.225 -12.182 -0.182	strategic partnerships w amming maintaining bud nponent Development an <u>FY 2024 Base</u> 248.071 267.073	vith the DoD Service co lget assurance. nd Prototypes (PE 060	ommunities & the 3884BP) and System <u>FY 2024 Total</u> 248.071 267.073
uch as Pacific Northwest National Laboratory (PNNL), and interagency for mission success across the enterprise throu Work conducted under this PE will transition to and will prov evelopment and Demonstration (PE 0604384BP) activities Program Change Summary (\$ in Millions) Previous President's Budget Current President's Budget Total Adjustments • Congressional General Reductions • Congressional Directed Reductions	ng others. The int gh collaborative pla ide risk reduction fo <u>FY 2022</u> 197.824 191.695 -6.129	ent is to maintain anning and progra or Advanced Com <u>FY 2023</u> 238.407 226.225 -12.182 -0.182	strategic partnerships w amming maintaining bud nponent Development an <u>FY 2024 Base</u> 248.071 267.073	vith the DoD Service co lget assurance. nd Prototypes (PE 060	ommunities & the 3884BP) and System <u>FY 2024 Total</u> 248.071 267.073
uch as Pacific Northwest National Laboratory (PNNL), and iteragency for mission success across the enterprise throu lovek conducted under this PE will transition to and will prov lovelopment and Demonstration (PE 0604384BP) activities Program Change Summary (\$ in Millions) Previous President's Budget Current President's Budget Total Adjustments • Congressional General Reductions • Congressional Directed Reductions • Congressional Rescissions	ng others. The int gh collaborative pla ide risk reduction fo <u>FY 2022</u> 197.824 191.695 -6.129	ent is to maintain anning and progra or Advanced Com <u>FY 2023</u> 238.407 226.225 -12.182 -0.182 -0.182 -17.000	strategic partnerships w amming maintaining bud nponent Development an <u>FY 2024 Base</u> 248.071 267.073	vith the DoD Service co lget assurance. nd Prototypes (PE 060	ommunities & the 3884BP) and System <u>FY 2024 Total</u> 248.071 267.073
uch as Pacific Northwest National Laboratory (PNNL), and iteragency for mission success across the enterprise throu Vork conducted under this PE will transition to and will prov revelopment and Demonstration (PE 0604384BP) activities Program Change Summary (\$ in Millions) Previous President's Budget Current President's Budget Total Adjustments • Congressional General Reductions • Congressional Directed Reductions • Congressional Rescissions • Congressional Adds	ng others. The int gh collaborative pla ide risk reduction fo <u>FY 2022</u> 197.824 191.695 -6.129	ent is to maintain anning and progra or Advanced Com <u>FY 2023</u> 238.407 226.225 -12.182 -0.182 -0.182 -17.000	strategic partnerships wamming maintaining bud apponent Development an <u>FY 2024 Base</u> 248.071 267.073	vith the DoD Service co lget assurance. nd Prototypes (PE 060	ommunities & the 3884BP) and System <u>FY 2024 Total</u> 248.071 267.073
uch as Pacific Northwest National Laboratory (PNNL), and interagency for mission success across the enterprise throu Work conducted under this PE will transition to and will prov bevelopment and Demonstration (PE 0604384BP) activities Program Change Summary (\$ in Millions) Previous President's Budget Current President's Budget Total Adjustments • Congressional General Reductions • Congressional Directed Reductions • Congressional Rescissions • Congressional Adds • Congressional Directed Transfers	ong others. The int gh collaborative pla ide risk reduction for <u>FY 2022</u> 197.824 191.695 -6.129 - - - - - - - -	ent is to maintain anning and progra or Advanced Com <u>FY 2023</u> 238.407 226.225 -12.182 -0.182 -0.182 -17.000	strategic partnerships wamming maintaining bud apponent Development an <u>FY 2024 Base</u> 248.071 267.073	vith the DoD Service co lget assurance. nd Prototypes (PE 060	ommunities & the 3884BP) and System <u>FY 2024 Total</u> 248.071 267.073
such as Pacific Northwest National Laboratory (PNNL), and interagency for mission success across the enterprise throu Work conducted under this PE will transition to and will prov Development and Demonstration (PE 0604384BP) activities 5. Program Change Summary (\$ in Millions) Previous President's Budget Current President's Budget Total Adjustments • Congressional General Reductions • Congressional Directed Reductions • Congressional Rescissions • Congressional Adds • Congressional Directed Transfers • Reprogrammings	ng others. The int gh collaborative pla ide risk reduction for	ent is to maintain anning and progra or Advanced Com <u>FY 2023</u> 238.407 226.225 -12.182 -0.182 -0.182 -17.000	strategic partnerships wamming maintaining bud apponent Development an <u>FY 2024 Base</u> 248.071 267.073	vith the DoD Service co lget assurance. nd Prototypes (PE 060	ommunities & the 3884BP) and System <u>FY 2024 Total</u> 248.071 267.073
such as Pacific Northwest National Laboratory (PNNL), and interagency for mission success across the enterprise throu Work conducted under this PE will transition to and will prov Development and Demonstration (PE 0604384BP) activities Program Change Summary (\$ in Millions) Previous President's Budget Current President's Budget Total Adjustments • Congressional General Reductions • Congressional Directed Reductions • Congressional Rescissions • Congressional Adds • Congressional Directed Transfers • Reprogrammings • SBIR/STTR Transfer	ng others. The int gh collaborative pla ide risk reduction for	ent is to maintain anning and progra or Advanced Com <u>FY 2023</u> 238.407 226.225 -12.182 -0.182 -0.182 -17.000 - 5.000 - - -	strategic partnerships w amming maintaining bud aponent Development an <u>FY 2024 Base</u> 248.071 267.073 19.002	vith the DoD Service co lget assurance. nd Prototypes (PE 060	ommunities & the 3884BP) and System <u>FY 2024 Total</u> 248.071 267.073 19.002
Such as Pacific Northwest National Laboratory (PNNL), and nteragency for mission success across the enterprise throu Work conducted under this PE will transition to and will prov Development and Demonstration (PE 0604384BP) activities 3. Program Change Summary (\$ in Millions) Previous President's Budget Current President's Budget Total Adjustments • Congressional General Reductions • Congressional Directed Reductions • Congressional Rescissions • Congressional Directed Transfers • Reprogrammings • SBIR/STTR Transfer • Other Adjustments	ng others. The int gh collaborative pla ide risk reduction for	ent is to maintain anning and progra or Advanced Com <u>FY 2023</u> 238.407 226.225 -12.182 -0.182 -0.182 -17.000 - 5.000 - - -	strategic partnerships w amming maintaining bud aponent Development an <u>FY 2024 Base</u> 248.071 267.073 19.002	vith the DoD Service co lget assurance. nd Prototypes (PE 060	5 mmunities & the 3884BP) and System FY 2024 Total 248.071 267.073 19.002

Exhibit R-2, RDT&E Budget Item Justification: PB 2024 Chemical and Bio	blogical Defense Program Da	te: March 2023	
Appropriation/Budget Activity 0400: Research, Development, Test & Evaluation, Defense-Wide I BA 3: Advanced Technology Development (ATD)	R-1 Program Element (Number/Name) PE 0603384BP <i>I Chemical and Biological Defense Program</i>	- Advanced De	velopment
Congressional Add Details (\$ in Millions, and Includes General R	eductions)	FY 2022	FY 2023
Congressional Add: Broad Spectrum Small Molecule Anti-viral De	evelopment	-	5.000
	Congressional Add Subtotals for Project: MT	- 3	5.000
	Congressional Add Totals for all Project	s -	5.000
FY 2023 (-\$0.182 Million): Congressional General Reductions to sup FY 2023 (-\$17.000 Million): Congressional Directed Reductions. FY 2023 (+\$5.000 Million): Congressional Add for broad spectrum su			
	Dranbulavia and Theranautica and CRDN Warning and Design	n Cunnart offart	- (1040.000
Schedule: N/A	Prophylaxis and Therapeutics and CBRN Warning and Decision pabilities (+\$5.700 Million), and Departmental inflation rate adju		

Technical: N/A

Exhibit R-2A, RDT&E Project Ju	stification	: PB 2024 C	chemical and	d Biologica	l Defense P	rogram				Date: Marc	ch 2023	
Appropriation/Budget Activity 0400 / 3			R-1 Program Element (Number/Name) PE 0603384BP <i>I Chemical and Biological</i> <i>Defense Program - Advanced Development</i>			Project (Number/Name) UN3 / Understand (ATD)						
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
UN3: Understand (ATD)	-	0.000	68.415	83.825	0.000	83.825	81.392	87.384	73.515	71.015	Continuing	Continuing
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

The Understand Advanced Technology Development (ATD) Project supports freedom of maneuver and informs commanders' decisions by predicting, locating, identifying, analyzing, and warning of chemical and biological (CB) hazards. In FY 2023, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. UN3 efforts in FY 2022 remain in Projects CB3, NT3, and TM3. This restructuring provided standardization and alignment across CBDP research, development and acquisition efforts.

Thrust Areas included in this Project are:

(1) Chemical, Biological, Radiological, and Nuclear (CBRN) Battlespace Sensing, Alerting & Response

- (2) CBRN Decision Aids
- (3) CBRN Situational Awareness
- (4) Battlefield Readiness
- (5) Chemical Diagnostics
- (6) Clinical Evaluation
- (7) Diagnostic Building Blocks
- (8) Emerging Threats
- (9) Emerging and Enhanced Biothreat Sensing
- (10) Distributed CB Reconnaissance
- (11) Expeditionary Analytical Toolkit (ExAnT)
- (12) Unconventional Detection Modalities
- (13) Technical Surprise
- (14) Unattended Perimeter Monitoring

CBRN Battlespace Sensing, Alerting & Response: Development of algorithms that generate and disseminate warning to personnel in time to prevent exposure to or limit the impact of CBRN threats. This thrust area conducts data collection trials to support algorithm development; leverage Artificial Intelligence (AI) to identify key indicators, combinations of indicators, and sensing modalities to reduce false alarms and predict the likelihood of exposure; explore remote and contactless monitoring and analysis for application in Warfighter chemical and biological threat exposure alerting. Efforts include additional investments in enhanced biodefense and pandemic preparedness.

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program			Date: March 2023
Appropriation/Budget Activity	R-1 Program Element (Number/Name)	Project (N	umber/Name)
0400 / 3	PE 0603384BP / Chemical and Biological	UN3 I Und	lerstand (ATD)
	Defense Program - Advanced Development		
CRDN Decision Aide, Dreviding tools that access risk from CRDN becaude and	Lidentify any many of action to limit immedia. This		a manualta anno activity (an abiling

CBRN Decision Aids: Providing tools that assess risk from CBRN hazards and identify courses of action to limit impact. This thrust area permits connectivity, enabling the dynamic discovery, querying, and control of sensors through standard protocols; allow for dynamic discovery and integration between networked devices at the tactical edge to enable sharing of information and capabilities across connected components. Efforts include additional investments in enhanced biodefense and pandemic preparedness.

CBRN Situation Awareness: Providing operationally relevant context to CB-specific phenomena data to ensure the Joint Force is able to characterize new CB hazards and mitigate their effects on mission success. This thrust area provides the analytic framework to determine optimal defense postures by extrapolating scientific data generated during the course of technology development and hazard assessment data into an assessment to help inform operational utility. Efforts include additional investments in enhanced biodefense and pandemic preparedness.

Battlefield Readiness: Provides innovative capabilities to the Warfighter that increase the speed of relevancy, enhance troop preparedness, aid with triage support, and provides diagnosis at lower roles of care. Develops field forward medical diagnostics to provide multiplexed detection of biological and toxin threats and leverages immunodiagnostics to identify specific targets using current or novel approaches to enable broader and more accurate diagnosis for a range of targets and across a wider window following exposure.

Chemical Diagnostics: Discovers innovative and integrated capabilities that are able to diagnose threats across the chemical spectrum and enhance force protection by investing in diagnostics for exposure to traditional and nontraditional Chemical Warfare Agents (CWA), including pharmaceutical based agents. Efforts include coordinating with Threat Agent Science and the Intelligence Community and to understand the chemical threat space.

Clinical Evaluation: Provides independent verification and validation of diagnostic tests in real world patients to decrease development costs, collecting initial clinical data sets to support pre-submission discussions with the Food and Drug Administration (FDA). De-risks diagnostic platform development through third party, real world, and austere environment testing and evaluation prior to transition and establishes clinical and performance parameters therefore de-risking diagnostic platforms through real world populations.

Diagnostic Building Blocks: Develops foundational capabilities for the entire diagnostics portfolio; invests in innovative, cutting-edge technologies to improve the development pipeline for diagnostics; and exploits areas in artificial intelligence synthetic biology and machine learning to develop novel and rapid diagnostic tests for utilization. Efforts accelerate assay development timelines and optimize test parameters by leveraging novel concepts and tools that readily allow a pivot to assay development for emerging threats.

Emerging Threats: Invests in diagnostic tests that enable the delivery of actionable information, such as administering the appropriate medical countermeasure, to greatly advance efficacy rates and turnaround time for Warfighter wellness. Efforts focus on better preparing for surprise by developing diagnostic systems that leverage novel approaches to characterize pathogens or host response and can identify the classification of threat (e.g., bacterial vs viral) from an unknown sample.

Emerging and Enhanced Biothreat Sensing: Establishes a capability to rapidly develop advanced, agile, pathogen-agnostic laboratory and field forward detection capabilities to detect emerging and enhanced biological threats across all force echelons (presumptive, field confirmatory, theater validation, and definitive identification).

	ogical Defense Program	Date: N	March 2023		
Appropriation/Budget Activity 0400 / 3	R-1 Program Element (Number/Name) PE 0603384BP <i>I Chemical and Biological</i> <i>Defense Program - Advanced Development</i>	Biological UN3 I Understand (ATD)			
Further, multiple biological measurements will be used to modernize labor biothreat sensing/detection capabilities to the Joint Force.	atory capabilities and leverage synthetic biology m	ethods and tools to	deliver enhan	nced	
Distributed CB Reconnaissance: Enhances early warning and situational a reconnaissance tools to include low-cost point sensors and sensing/collec payloads for manned and unmanned aerial and ground platforms to enhance the sense of the sens	tion systems for unmanned platforms. Efforts inclu	de developing threa			
Expeditionary Analytical Toolkit (ExAnT): Provides general and specialized enhancing detection capabilities for non-traditional, emerging, and mixed of		nnologies for traditio	onal threats wh	nile	
Unconventional Detection Modalities: Develops disruptive technologies to operate in complex threat environments with high fidelity. Efforts include a identification accuracy, reduce false alarms, and enable mapping of hazar	utilizing machine learning and other advanced com	putational tools to i			
Technical Surprise: Encompasses horizon scanning to identify potential an Efforts assess technological advancements for potential implications to the assess technical enhancements that may alter the nature or magnitude of	e threat space, including agent use and release an	d develops capabili			
	a threat agent. These enorts include additional in	vestments in Biodel	ense Improve	ment.	
Unattended Perimeter Monitoring: Invests in efforts supporting Integrated through developing and implementing automated and integrated technology	Early Warning and Integrated Layered Defense by	establishing a laye	·		
	Early Warning and Integrated Layered Defense by	establishing a laye	·		
through developing and implementing automated and integrated technolog	Early Warning and Integrated Layered Defense by	establishing a laye	red defense ca	apability	
through developing and implementing automated and integrated technolog B. Accomplishments/Planned Programs (\$ in Millions)	Early Warning and Integrated Layered Defense by gies enabling unattended monitoring for biothreats entify, alert, and responds to deliberate releases a pand on the development of predictive CB exposu on the applicability and efficacy of these algorithn I agent / agent proxy exposures. Studies will focus fection, determining severity of infection, and predi of countermeasures such as isolation, quarantine,	establishing a laye FY 2022 	red defense ca	apability FY 2024	

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical a	and Biological Defense Program	Date:	March 2023	
Appropriation/Budget Activity 0400 / 3	R-1 Program Element (Number/Name) PE 0603384BP <i>I Chemical and Biological</i> <i>Defense Program - Advanced Development</i>	Project (Number) UN3 / Understand		
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
 Continue the advancement of standoff physiological monitoring of Leverage a data and AI platform that supports access to harmon development and validation of models to continue to develop pred Threats. 	ized physiological status monitoring data and support			
FY 2024 Plans: - Continue the improvement of algorithms that leverage non-invasi chemical and biological threats and/or exposure. - Continue the advancement of standoff physiological monitoring of - Expand and further develop a data and Artificial Intelligence (AI) status monitoring data and development and validation of models rapid response to Emerging Threats.	apabilities. platform to support the access to harmonized physiologica			
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.				
Title: 2) CBRN Decision Aids		-	3.000	3.50
Description: Unencumber the warfighter at the tactical edge by co on End User Devices (EUDs) in both connected and disconnected experienced by the warfighter, while providing accurate, actionable Aid to inform the warfighter on how to avoid, respond to and plan r Guidance for use in conjunction with other capabilities developed Asset use and reduce the burden incurred by the warfighter in ord Autonomous Assets to improve and refine other CBRN Decision A	l operations. Focus on utilizing automation, reducing the b e information. Develop a Contamination Avoidance Decisi routes around CB hazards. Develop of Autonomous Asset under the CBRN Decision Aids portfolio to optimize Autono er to operate them. Incorporate, fuse and utilize data from	urden on omous		
FY 2023 Plans: - Continue developing new decision support plug-ins for integration Windows OS, and virtual and augmented reality versions, to further and develop a rapid and iterative software capability. - Complete development of Graphical Processing Unit (GPU)-base modeling capabilities and continue user testing. - Finalize the development of approaches to translate raw sensor	er enhance the TAK infrastructure and cross-community to ed faster-than-real-time, high resolution hazard prediction			
FY 2024 Plans:				

Appropriation/Budget Activity R-1 Program Element (Number/Name) PE 0603384BP / Chemical and Biological Defense Program - Advanced Developme B. Accomplishments/Planned Programs (\$ in Millions) Continue developing new decision support plug-ins for integration with TAK, including the Android, web, Windows OS, a and augmented reality versions, to further enhance the TAK infrastructure and cross-community tools and develop a rapid terative software capability. FY 2023 to FY 2024 Increase/Decrease Statement: ncrease due to change in program/project technical parameters.	ent FY 2022		FY 2024
Continue developing new decision support plug-ins for integration with TAK, including the Android, web, Windows OS, a and augmented reality versions, to further enhance the TAK infrastructure and cross-community tools and develop a rapic terative software capability. FY 2023 to FY 2024 Increase/Decrease Statement: ncrease due to change in program/project technical parameters.	ind virtual	FY 2023	FY 2024
ncrease due to change in program/project technical parameters.			
<i>Title:</i> 3) CBRN Situational Awareness Description: To enhance chemical and biological (CB) Situational Awareness, Science & Technology will expand the typ CB threats that can be modeled with hazard assessment capabilities to include those from fixed-wing and rotary-wing dro interests and allow for airborne CB releases from single drones and swarms to be modeled. Leverage Virtual Reality (VR Augmented Reality (AR) technologies to develop CB focused training and mission rehearsal capabilities that will be integr into systems widely used by the Joint Force. Modernize hazard modeling capabilities by adopting a modular framework an integrating across Service command and control systems. Enhance hazard modeling by creating a seamless indoor- to-co ransport and dispersion (T&D) modeling capability and improve urban T&D modeling to support operations in urban and environments. Leverage new state-of-the-art computational fluid dynamics modeling techniques and their use of computi esources to increase both modeling speed and accuracy. Develop CB health effect modeling software and analytic tools support force readiness and facilitate medical planning against chemical and biological agents. Develop epidemiological hat quantify and visualize mission operational impacts from exposure to, and spread of, infectious biological threat agents everage Threat Agent Science (TAS) data to enhance modeling health effects and host pathogen interactions from expo o traditional and non-traditional CB agents, providing the warfighter with more accurate casualty estimates accounting for health effects.	nes of e) and rated nd outdoor mixed ng s to models s. osures	3.888	6.690
FY 2023 Plans: Continue configuration management of science and technology prototype for transition of upgraded capabilities. Continue improvement of performance enhancements for T&D models, particularly for urban environments. Continue the development of comprehensive infectious disease epidemiological modeling applications for disease predie orecasting, medical planning and treatment. Continue to enhance CB situational awareness capabilities for integration into Head up Display (HUD) technologies for t use. Build out pipelines for ingestion and storage of disparate chemical and biological threat datasets and advanced analytic development to support the CBDP medical enterprise.	actical		

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	I Defense Program	Date: N	/larch 2023	
Appropriation/Budget Activity 0400 / 3	R-1 Program Element (Number/Name) PE 0603384BP <i>I Chemical and Biological</i> <i>Defense Program - Advanced Development</i>	Project (Number/ UN3 / Understand		
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
 Complete development of a digital environment prototype for science and tech Development, Security, and Operations (DevSecOps) framework. Continue improvement of performance enhancements for T&D models, partic release from drone platforms and alternate types of delivery mechanisms. Continue the development of comprehensive infectious disease epidemiologic forecasting, medical planning and treatment. Continue to enhance CB situational awareness capabilities for integration into use. Continue work to ingest and store disparate chemical and biological threat dat support the CBDP medical enterprise. Expedite the development of a CB Defense Digital Laboratory capability enco end Al/ML data analysis, model development and training, and agile software of FY 2023 to FY 2024 Increase/Decrease Statement: 	ularly for urban environments and for hazard cal modeling applications for disease prediction b Heads up Display (HUD) technologies for tac tasets and advanced analytic development to mpassing a DevSecOps environment for end-	tical		
Title: 4) CBRN Battlespace Surveillance, Alerting & Response - Enhanced Bio	defense (ENBD)	-	2.400	2.500
Description: Focus on a passive, wearable, contactless screening capability we to seek medical treatment at the earliest indication of exposure. This area includata; competitive prototyping to further develop algorithms that are able to non-courses of action, prior to the onset of symptoms; expansion of efforts to develop support; and S&T for an advanced, integrated cloud based data environment to characteristics.	udes data collection and analysis of exposure invasively identify afflicted personnel and infor op analytic resources for early warning/decisio	n		
 FY 2023 Plans: Examine feasibility of isolating indicators of respiratory infection, determining a mission readiness after exposure. Leverage competitive prototyping to explore and evaluate alternative concepts and non-invasive techniques to enhance our ability to quickly identify afflicted p to the onset of symptoms. Development of an advanced, integrated cloud based data environment to stocharacteristics; capability would support automated data ingestion, collection, or FY 2024 Plans: 	s for providing remote sensing and/or minimall personnel and inform courses of action, ideally pre a dynamic knowledge base of biothreat	prior		

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	I Defense Program		Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 3	R-1 Program Element (Number/Name) PE 0603384BP <i>I Chemical and Biological</i> <i>Defense Program - Advanced Development</i>	-	t (Number/N Understand	,	
B. Accomplishments/Planned Programs (\$ in Millions)		Γ	FY 2022	FY 2023	FY 2024
 Continue to isolate and identify indicators of respiratory infection that can be upredicting return to mission readiness after exposure. Continue competitive prototyping to evaluate alternative concepts for providin invasive techniques to enhance our ability to quickly identify afflicted personnel onset of symptoms. Continue the development and expansion of an advanced, integrated cloud b knowledge base of biothreat characteristics; capability would support automate advanced analytics of data. 	g remote sensing and/or minimally and non- and inform courses of action, ideally prior to the ased data environment to store a dynamic				
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.					
Title: 5) CBRN Decision Aids - Enhanced Biodefense (ENBD)			-	-	1.000
Description: Focus on improved solutions for comprehensive biothreat charact modernization goals, to include leveraging a cloud based data environment of l created and curated under the CBRN Battlespace Sensing, Alerting, and Resp will be leveraged and data streams will be translated into actionable information (EUDs).	biothreat characteristics, data sources, reposite onse thrust area. Cloud based data environme	nt			
FY 2024 Plans: -Explore and initiate efforts that will utilize data streams from a cloud based data about biological threats and exposures on EUDs.	ta environment to provide actionable information	'n			
FY 2023 to FY 2024 Increase/Decrease Statement: Additional investment in enhanced biodefense and pandemic preparedness.					
Title: 6) CBRN Situational Awareness - Enhanced Biodefense (ENBD)			-	3.000	2.500
Description: Focus on exploring solutions for comprehensive biothreat charact modernization goals, including the development of data analytics using machin efforts to provide a suite of analytic tools for biological threat agent modeling, for defense postures. Utilize scientific data generated during the course of techno to help inform operational utility. Develop epidemiological models that quantify accounting for medically relevant inputs from exposure to and spread of CB three the course of the c	e learning and artificial intelligence (ML/AI) and precasting, and prediction to determine optima logy development and hazard assessment dat risk and visualize mission operational impacts				
<i>FY 2023 Plans:</i> - Expand development of analytic tools for biological threat agent surveillance,	modeling, forecasting, and prediction.				

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologic	al Defense Program	Date:	March 2023	
Appropriation/Budget Activity 0400 / 3	R-1 Program Element (Number/Name) PE 0603384BP / Chemical and Biological Defense Program - Advanced Development	Project (Number/ UN3 / Understand		
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
 Accelerate and expand efforts to develop data analytics using ML/AI to prediagent exposure based on advanced omics, epigenetics, host immune respons Explore feasibility of mathematical models for innate immune recognition bas patterns associated with bacterial vs. viral pathogens. 	ses, and wearables data sources.	В		
FY 2024 Plans: - Continue the development of analytic tools for biological threat agent surveill - Continue efforts to develop data analytics using ML/AI to predict individual w based on advanced omics, epigenetics, host immune responses, and wearab - Continue to explore mathematical models for innate immune recognition bas patterns associated with bacterial vs. viral pathogens.	arfighter susceptibility to acute CB agent exposiles data sources.	ure		
FY 2023 to FY 2024 Increase/Decrease Statement: Decrease due to change in program/project technical parameters.				
Title: 7) Battlefield Readiness		-	6.700	5.08
Description: Develop platforms to prepare the Warfighter with rapid and easy healthy and ready for movement. Platforms developed with affinity-based ide to the pathogen may leverage immunodiagnostics to identify specific targets u approaches. This will enable broader and more accurate diagnosis for a range exposure. Investments in this area will provide capabilities to the Warfighter to preparedness, aid with triage support, and provide diagnosis at lower roles of	ntification of either pathogen or host response using antibodies, or explore other innovative le of targets and across a wider window followir hat increase the speed of relevancy, enhance t	g		
<i>FY 2023 Plans:</i> - Complete the development and evaluation of a customizable, lightweight, co algorithms to detect disease onset by monitoring a Warfighter's health state. - Complete the development of vertical flow assay technologies that are rapid a faster sample to answer and more sensitive detection level than traditional la - Complete the program to identify biological indicators that predict disease se diagnostic that alerts medical personnel that a patient's condition may worsen - Continue a wearable effort for developing and testing a microneedle-based p or bacterial infection, this focus on minimally invasive testing techniques along mission readiness.	, capable of multiplexing, portable, and may res ateral flow diagnostics. everity, which will lead to the development of a or require immediate intensive care. patch intended to screen for the presence of a v	iral		

xhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Bi	ological Defense Program	Date:	March 2023	
Appropriation/Budget Activity 400 / 3	R-1 Program Element (Number/Name) PE 0603384BP <i>I</i> Chemical and Biological Defense Program - Advanced Development	Project (Number/ UN3 / Understand		
8. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
Continue the development of a POC diagnostic platform that can provie respective of whether the underlying pathogens are viral, bacterial, or p		tion,		
EY 2024 Plans: Continue investigating minimally invasive testing methods and reduce dentification. Continue the development of a Point of Contamination (POC) diagnost infection within minutes and transition technology to Joint Program Exect Auclear Defense's (JPEO-CBRND) Advanced Differential Diagnostics (Appreces to determine personnel who are ideal candidates for troop moven Continue the development of a non-invasive diagnostic platform that can dresource optimization as well as quicker return of duty for a majority	tic platform, capable of pre-symptomatically diagnosir cutive Office for Chemical, Biological, Radiological an ADD) program. Pre-symptomatic evaluation will enab nents or basic training. an predict severity of disease which will enable logisti	d ble		
FY 2023 to FY 2024 Increase/Decrease Statement: Decrease due to change in program/project technical parameters.				
Title: 8) Chemical Diagnostics		-	1.914	1.69
Description: Provide innovative and integrated capabilities to the Warfig pectrum. Enhance force protection by investing in diagnostics for exponent protection by investing in diagnostics for exponent protection by the second protect protection by the second protection by the second protection by the second protect protection by the second protect protect protect protection by the second protect pr	sure to traditional and nontraditional CWAs, including	g		
FY 2023 Plans: Continue efforts that expand the capability of wearable devices from ar approved diagnostic platform that can detect a chemical threat and allow trategy for exposure to traditional/ nontraditional chemical agents.				
EY 2024 Plans: Continue efforts that expand the capability of wearable devices from an detect a chemical threat and allow a physician to diagnose and deter contraditional chemical agents.		1/		
Y 2023 to FY 2024 Increase/Decrease Statement:				
Decrease due to change in program/project technical parameters.				
<i>Title:</i> 9) Clinical Evaluation			1.914	0.84

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	I Defense Program	Date:	March 2023	
Appropriation/Budget Activity 0400 / 3	R-1 Program Element (Number/Name) PE 0603384BP <i>I Chemical and Biological</i> <i>Defense Program - Advanced Development</i>	Project (Number UN3 / Understand		
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
Description: Optimize the diagnostic development pathway by incorporating in informed prototype transition prior to advanced development. Investments in the through real world, austere environment testing. This area maintains access to exposed to diseases of interest that would affect the warfighter in battlefield set technologies and provide analytical testing, evaluation, and reach back support	his area allow e evaluation of diagnostic platfor o research sites that offer native populations ttings, and provides the ability to acquire novel			
 FY 2023 Plans: Continue to maintain the capability to access clinical samples for infectious disaround the world where diseases of concern are circulating. Initiate independent third-party testing - to establish clinical and performance through real world, austere environment testing and evaluation prior to transition 	parameters to evaluate diagnostic platforms			
 FY 2024 Plans: Continue to maintain the capability to access clinical samples for infectious disaround the world where diseases of concern are circulating. Continue independent third-party testing - to establish clinical and performance through real world, austere environment testing and evaluation prior to transition 	e parameters to evaluate diagnostic platforms			
FY 2023 to FY 2024 Increase/Decrease Statement: Decrease due to change in program/project technical parameters.				
Title: 10) Diagnostic Building Blocks		-	4.786	5.934
Description: Develop novel, state of the art capabilities that lay the foundation portfolio. This includes exploiting areas such as synthetic biology and chemistrutilization in the event of an outbreak of an unknown threat. Invest in efforts that and optimized test parameters through leveraging artificial intelligence (AI) and and develop assays for emerging threats in days instead of weeks.	ry to develop novel and rapid diagnostic tests f at lead to accelerated assay development time	or lines		
 FY 2023 Plans: Initiate field validation studies for diagnostics prototypes using synthetic binder standard diagnostic methods. Continue efforts to collect the baseline data required for future development of as a non-invasive sampling mechanism offers Warfighters little-to-no interruption for earlier diagnosis/indication of infection or chemical exposure. 	f a whole breath diagnostic platform use of bre	ath		

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	I Defense Program		Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 3	R-1 Program Element (Number/Name) PE 0603384BP <i>I Chemical and Biological</i> <i>Defense Program - Advanced Development</i>	-	t (Number/N Jnderstand	,	
B. Accomplishments/Planned Programs (\$ in Millions)			FY 2022	FY 2023	FY 2024
 Continue executing data transitions for the development of diagnostic assays development efforts. Complete a joint effort with CBDP Components to establish an assay develop DoD laboratories to be authorized assay developers, enabling the DoD to deve to quickly be functionalized for the fielded Next Generation Diagnostics System (MPDS) platform. 	ment and manufacturing process that would al lop assays against emerging threats and disea				
 FY 2024 Plans: -Continue field validation studies for diagnostics prototypes using synthetic bind gold standard diagnostic methods and integrate enzymes to create inexpensive burdens. -Continue efforts to collect the baseline data required for future development of breath as a non-invasive sampling mechanism offers warfighters little-to-no integrate efforts to identify and establish testing methods utilizing low to minimal sweat or interstitial fluid could significantly expand field-forward testing abilities collect and administer testing. 	e, on-demand, diagnostics with reduced logistic a whole breath diagnostic platform the use of erruption to mission activities and provides the lly invasive clinical matrices. Matrices like brea	ath,			
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to change in program/project technical parameters.					
<i>Title:</i> 11) Emerging Threats			-	2.828	3.391
Description: Push beyond the boundaries of the traditional threat list in the fiel Development of diagnostic systems that leverage novel approaches to character the classification of threat (e.g., bacterial vs viral) from an unknown sample. In actionable information, such as administering the appropriate medical counterm medic or primary care provider greatly improves turnaround time for soldier we	erize pathogen or host response and can ident vest in diagnostic tests that enable the delivery neasure (e.g. antibiotic, antiviral, vaccine), by a	of			
FY 2023 Plans: - Complete efforts to address challenges in small molecule toxin diagnosis at th validation of these prototypes for potential use as a threat agnostic capability to threats.					

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and		L	March 2023	
Appropriation/Budget Activity 0400 / 3	R-1 Program Element (Number/Name) PE 0603384BP <i>I Chemical and Biological</i> <i>Defense Program - Advanced Development</i>	Project (Numbe UN3 / Understan		
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
- Complete the development of a universal blood sample preparation improving the speed of sample preparation tools at low pathogen of challenges holding back diagnostics in point-of-care, outbreak, and	oncentrations (i.e. pre-symptomatic levels) is one of the bi			
 FY 2024 Plans: Initiate efforts to identify novel platforms that are capable of identify platforms will ideally enable the diagnosis of exposure to toxins as a capability in the hands of the warfighter. Begin preliminary research efforts to diagnose biological threats the changes in infected individuals. 	well as other biological threats, resulting in a broad-spectr			
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to change in program/project technical parameters.				
Title: 12) Emerging and Enhanced Biothreat Sensing		-	-	5.70
 FY 2024 Plans: Expand early warning through wastewater surveillance capabilitie unknown biological threats in Total Force populations. Initiate technology to deliver capabilities to detect any pathogen, in 				
FY 2023 to FY 2024 Increase/Decrease Statement: Additional investment to advance the overarching goals aligned wit Plan (NBS).	h the 2022 National Biodefense Strategy and Implementa	tion		
Title: 13) Distributed Chemical Reconnaissance		-	3.157	3.17
Description: Develop threat sensing and sampling payloads for maplatforms to enhance early warning and situational awareness of chreconnaissance and surveillance missions by providing low size, we that are rugged, rapid and accurate.	nemical threats. Sensor development will support dismour	nted		
FY 2023 Plans:Complete aerosol microsensor development.Development toward a deployable microsensor development pipe	line and enhance sensor integration efforts.			
FY 2024 Plans: - Continue development toward a deployable microsensor development	ment pipeline and enhance sensor integration efforts.			

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program		Date: N	Date: March 2023		
Appropriation/Budget Activity 0400 / 3	R-1 Program Element (Number/Name) PE 0603384BP <i>I Chemical and Biological</i> <i>Defense Program - Advanced Development</i>	Project (Number/Name) UN3 / Understand (ATD)			
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024	
- Initiate efforts to modernize capabilities to reduce false alarms and increase	e sensitivity and specificity.				
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.					
Title: 14) Expeditionary Analytical Toolkit (ExAnT) - Chemical Detection		-	14.757	17.269	
Description: Provide general and specialized forces with the ability to moder while enhancing detection capabilities for non-traditional, emerging, and mixed		s			
 FY 2023 Plans: Commence transition stand-off detector prototypes that identify and alert to Detector (PCAD) Program of Record. Continue development toward detection prototypes to address pharmaceuti Continue the development of sensor technologies against non-traditional the and reduce reliance on known threat libraries. 	cal based agent (PBA) and other emerging three	ats.			
FY 2024 Plans: - Transition stand-off detector prototypes that identify and alert to chemical ha - Continue development toward detection prototypes to address PBA and oth - Continue the development of sensor technologies against non-traditional the and reduce reliance on known threat libraries.	her emerging threats.	on			
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to change in program/project technical parameters.					
Title: 15) Unconventional Chemical Detection Modalities		-	1.485	2.443	
Description: Develop disruptive technologies to identify unknown or emergin that can operate in complex threat environments with high fidelity. This thrus Joint Force mission needs (e.g., expeditionary, perimeter defense, or unmanif	t area supports other thrust areas and as neede				
 FY 2023 Plans: Complete development and refinement of integrated photonics. Complete development and refinement of miniaturized Raman spectromete Complete development and refinement of machine learning algorithms for ir Initiate library-less detection efforts to move towards threat agnostic detection emerging chemical threats. 	ntegrating disparate sensor feeds.	ess			

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical	and Biological Defense Program	Date:	March 2023		
Appropriation/Budget Activity 0400 / 3	Adget Activity R-1 Program Element (Number/Name) Project (Number/Name) DE 0603384BP / Chemical and Biological UN3 / Understand (ATD) Defense Program - Advanced Development Defense Program - Advanced Development				
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024	
- Continue development of state of the art size and speed of detect Artificial Intelligence (AI)/Machine Learning (ML) to address the m		ols,			
 FY 2024 Plans: Continue pursuing advances in photonic integrated circuits by rebut keeping the selectivity and sensitivity of a traditional sensor. Incorporating early warning and threat mapping using ML/AI tool Continuing library-less detection to surmount current sustainment to be updated to detect emerging threats. Continue development in machine learning (ML) and artificial integrates. 	ls to aggregate and analyze sensor data in real-time. ht limitations of library-based or analyte-specific chemical ser	isor			
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to change in program/project technical parameters.					
Title: 16) Battlefield Readiness - Biodefense Improvement Progra	ım	-	-	4.23	
Description: Provide non-invasive disease screening capabilities enhance the warfighters ability to seek medical treatment at the end		,			
FY 2024 Plans: - Expand development of Wearable technologies to evaluate custor autonomic- response to biological warfare agents, both natural an					
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to change in program/project technical parameters.					
Title: 17) Diagnostic Building Blocks - Biodefense Improvement P	Program	-	1.500	1.34	
Description: Provide agile assay development capabilities aided of diagnostic assay design, addressing a key functional capability		асу			
<i>FY 2023 Plans:</i> - Expand the development of agile biological assays to reduce the emerging biological threats.	e design assay and increase assay quality to better respond	o			

xhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and I	Biological Defense Program	Date:	March 2023	
Appropriation/Budget Activity 400 / 3	R-1 Program Element (Number/Name) PE 0603384BP <i>I Chemical and Biological</i> <i>Defense Program - Advanced Development</i>	Project (Number UN3 / Understand	,	
8. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
Continue the development of agile biological assays to reduce the de emerging biological threats.	sign assay and increase assay quality to better respor	nd to		
FY 2023 to FY 2024 Increase/Decrease Statement: /linor change due to routine program adjustments.				
Title: 18) Emerging and Enhanced Biothreat Sensing - Biodefense Imp	provement Program	-	2.200	1.865
Description: Provide end users with a rapid assay capability (< 6 wee of the initial assay) that will be disruptive to current detection and diagreagents to rapidly respond to emerging biological threat.				
FY 2023 Plans: Accelerate assay development to provide rapid, agile, and scalable b piological threats and allow the warfighter to use a highly-specific assa riendly.				
FY 2024 Plans: Continue assay development to provide rapid, agile, and scalable bio hreats and allow the warfighter to use a highly-specific assay that is b		ogical		
FY 2023 to FY 2024 Increase/Decrease Statement: Decrease due to change in program/project technical parameters.				
Title: 19) Emerging Threats - Biodefense Improvement Program		-	1.000	3.170
Description: Expand on agnostic disease screening and sensing capa	abilities for emerging biological threats.			
FY 2023 Plans: Expand investments in agnostic sensing/screening capabilities for mu riendly and can be deployed in the field.	ultiple sample types and environments that are end use	er-		
FY 2024 Plans:				
Continue prototype development investments in agnostic sensing/scr environments that are end user-friendly and can be deployed in the fie				
FY 2023 to FY 2024 Increase/Decrease Statement: ncrease due to change in program/project technical parameters.				
Title: 20) Technical Surprise - Biodefense Improvement Program		-	3.000	0.500

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica		Date: N	larch 2023		
Appropriation/Budget Activity 0400 / 3	R-1 Program Element (Number/Name) PE 0603384BP <i>I Chemical and Biological</i> <i>Defense Program - Advanced Development</i>		ct (Number/Name) Understand (ATD)		
B. Accomplishments/Planned Programs (\$ in Millions)		F١	2022	FY 2023	FY 2024
Description: Technical Surprise assesses technological advancements for pot agent use and release. Technical Surprise includes horizon scanning to identifi technical assessments of emerging technological advancements (e.g. biotechn quantum computing). This program develops capabilities to evaluate and asses nature or magnitude of a threat agent. The technical surprise program will be a technologies that improve the ease of threat use and make threats more likely the limitations and barriers associated with synthetic biology and assess the im- assess former technology hurdles that have been lowered or overcome and as	by potential areas of concern as well as conduct sology, artificial intelligence, machine learning, ass technical enhancements that may alter the evaluating technologies and convergence of to survive being released. The program will identifications. And finally, these efforts will identifications.	entify y and			
 FY 2023 Plans: Identify and assess technological advancements that will impact the biological implications to biological defense capabilities. Use horizon scanning capability to provide situational awareness in assessing affect the threat space, while keeping abreast of changes in the nature of future Assessment of synthetic biological tools and other biotechnology development 	g technological growth and convergence that c				
FY 2024 Plans: - Complete the Threat Area Panel (TAP) efforts at US Army Medical Research Complete and augment horizon scanning capabilities, including identification of enhancing or altering the biological threat space, and use these to inform more	f knowledge gaps for emerging/future agents				
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project is entering completion and all activities will be closed.					
Title: 21) Distributed Biological Reconnaissance			-	1.598	1.741
Description: Develop threat sensing and sampling payloads for manned and uplatforms to enhance early warning and situational awareness of biological and support dismounted reconnaissance and surveillance missions by providing low collection systems that are rugged, rapid and accurate. Early indications from enhanced warning of threats.	l chemical threats. Sensor development will v size, weight, power and cost sensors or sens	sing/			
FY 2023 Plans: - Continue to develop innovative sensor solutions to increase situational threat - Continue to develop low-cost, low Size, Weight and Power (SWaP), and low-to chain, detection technologies to support of tactical and dismounted site assess	purden, with little to no dependence on supply	3 .			

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	I Defense Program	Date:	March 2023	
Appropriation/Budget Activity 0400 / 3		roject (Number/ N3 / Understand	,	
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
- Continue to enhance sensing capabilities for unmanned vehicles and its integ	ration into mobile platforms.			
 FY 2024 Plans: Continue to develop innovative sensor solutions and make technological impribiological threats. Continue to explore fundamental science and novel technologies to increase as specificity; low size, weight, and power (SWaP); low-burden; and reduced consistences. Continue developing enhanced sensing capabilities and sampling systems, to a linitiate the use of computational tools, like machine learning, into detector/ided due to environmental factors. 	ensing performance through enhanced speed a sumables and life-cycle costs of fielded biologica include unmanned vehicles and mobile platform	nd Is.		
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.				
Title: 22) Emerging and Enhanced Biothreat Sensing		-	2.069	3.453
Description: Establish robust capability to assess emerging and enhanced bio detecting emerging or enhanced biological threats. Quickly develop adaptable detection capabilities to provide a spectrum of improved detection assets for no omics data science or the combining multiple measurements to inform rational solutions. Synthetic biological concepts will be thoroughly evaluated and explor and refinement of laboratory methods.	, analyte-agnostic laboratory and field-forward ovel threats. This thrust area leverages multi- and rapid design and development of biodetecti	on		
 FY 2023 Plans: Continue development of detection and identification capabilities that discernidentify pathogens of unknown origin. Continue development of algorithms and laboratory workflows to identify threat Transition far-forward pathogen agnostic sensing toolkit to provide on-site threat Warfighter by using technologies that rely on little to no supply chain disposable Continue development of on-demand biological threat detection assays that prespond to emerging biological threats and provide only the assay needed for treagents needed by most current assay kits. FY 2024 Plans: Continue development of detection and identification capabilities that discerning the second secon	ats in unknown samples. eat identification while reducing the burden on thes. rovide the Warfighter with the ability to rapidly hreat identification and therefore reducing cost a			
identify pathogens of unknown origin.	· · · ·			

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical	and Biological Defense Program	Date:	March 2023			
Appropriation/Budget Activity 0400 / 3	R-1 Program Element (Number/Name) PE 0603384BP <i>I Chemical and Biological</i> <i>Defense Program - Advanced Development</i>	Project (Number/ UN3 / Understand				
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024		
 Continue development of detection algorithms, laboratory workflidentify threats in unknown samples Continue development of assays on demand biological threat derapidly respond to emerging biological threats and provide only threats and reagents needed by most current assay kits. 	etection assays that provide the Warfighter with the ability to					
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to change in program/project technical parameters.						
<i>Title:</i> 23) Unattended Perimeter Monitoring - Biological Detection			1.177	1.283		
Description: Establish a layered defense capability by developing enabling unattended monitoring for chemical and biological threat aerosol, solid, and liquid hazards and unencumber the Warfighter detect-to-warn capability at fixed or expeditionary sites will enhan as robust technologies can be miniaturized for portability and ope	ts. These technologies will provide early warning of vapor, by reducing logistics and operator burden. Providing a reli ce the overall protective posture of ground and maneuver for	able				
FY 2023 Plans: - Transition automated biological collection, detection and identific eliminating the need for laboratory personal to perform analysis Initiate efforts to modernize capabilities to reduce false alarms a		by				
FY 2024 Plans: - Continue efforts to modernize capabilities to reduce false alarms	s and increase sensitivity and specificity.					
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.						
Title: 24) Unconventional Biological Detection Modalities		-	0.871	-		
Description: Develop disruptive technologies to identify unknown that can operate in complex threat environments with high fidelity expeditionary, perimeter defense, or unmanned reconnaissance).	. This effort supports the Joint Force mission needs (e.g.,	ors				
FY 2023 Plans: - Complete development and refinement of integrated photonics. - Complete development and refinement of miniaturized Raman s - Complete development and refinement of machine learning algo						

PE 0603384BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program UNCLASSIFIED Page 21 of 69

Exhibit R-2A, RDT&E Project Just	tification: PB	2024 Chem	ical and Biol	ogical Defen	ise Program				Date: Ma	rch 2023	
Appropriation/Budget Activity 0400 / 3											
B. Accomplishments/Planned Pro	ograms (\$ in N	<u>/lillions)</u>						F	FY 2022	FY 2023	FY 2024
 Initiate library-less detection effort emerging biological threats. Continue development of state of Artificial Intelligence (AI)/Machine L 	the art size an	d speed of c	etection tecl	hnologies th	at include ac	dvances in co					
FY 2023 to FY 2024 Increase/Dec Decrease due to change in program											
				Accor	nplishment	s/Planned P	rograms Sub	ototals	-	68.415	83.82
C. Other Program Funding Summ	ary (\$ in Milli	<u>ons)</u>	FY 2024	FY 2024	FY 2024					Cost To	
Line Item	<u>FY 2022</u>	<u>FY 2023</u>	Base	000	Total	<u>FY 2025</u>	FY 2026	<u>FY 2027</u>		Complete	
UN4: Understand (ACD&P)	-	52.708	61.638	-	61.638	64.399	48.874	41.264	38.169	Continuing	Continuing
<u>Remarks</u>											
<u>D. Acquisition Strategy</u> N/A											

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program										Date: Marc	ch 2023	
Appropriation/Budget Activity 0400 / 3							Project (Number/Name) PT3 / Protect (ATD)					
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
PT3: Protect (ATD)	-	0.000	32.113	29.261	0.000	29.261	48.969	42.794	46.159	52.581	Continuing	Continuing
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

The Protect Advanced Technology Development (ATD) Project enhances mission performance while providing effective protection against current and emerging chemical and biological (CB) threats, enables Joint Force lethality by protecting Warfighters against adverse effects of CB hazards, and fields protection capabilities against engineered biological agents, opioids and other Pharmaceutical Based Agents (PBAs), and Fourth Generation Agents (FGAs). In FY 2023, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. PT3 efforts in FY 2022 remain in Projects CB3 and TM3. This restructuring provided standardization and alignment across CBDP research, development and acquisition efforts.

Thrust Areas included in this Project are:

- (1) Biological Warfare Defense Prophylaxis
- (2) Air Purification Enhancements
- (3) All-Hazards & Respiratory Protection
- (4) Dynamic Multifunctional Materials for Second Skin
- (5) Enhanced Survivability Coatings
- (6) Lightweight Protective Garments
- (7) Multifunctional Materials for Protection
- (8) Nerve Agent Prophylaxis/Pretreatments

Biological Warfare Defense Prophylaxis: Provides the Warfighter protection against biothreat agents through the pre-exposure administration of prophylactics against known bacterial, viral and toxin agents of interest and emerging infectious threats. Medical countermeasure (MCM) strategies against broader classes of biological agents will be pursued with emphasis on broad-spectrum protection based on mechanism of action. The manufacturing and formulation processes for platform technologies will be adapted to maximize flexibility, increase stability, shelf life, and expand storage conditions. Efforts will also be adapted to maximize delivery flexibility through modifying delivery routes, which will allow for dose and reagent sparing.

Air Purification Enhancements: Optimizes and extends filter life and reduces lifecycle costs while maintaining or enhancing protection against all chemical weapons agents and toxic industrial chemicals/materials. Improves integration of collective protection into developmental Service major combat platforms. Investigates existing filtration performance against emerging and non-traditional threats and identify and develop countermeasures. Efforts include additional investments in enhanced biodefense and pandemic preparedness.

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	Date: March 2023		
0400 / 3	, , , , , , , , , , , , , , , , , , ,	Project (N PT3 / Prote	umber/Name) ect (ATD)
	Belense i Togram - Auvanced Development		

All Hazards and Respiratory Protection: Develops next generation general purpose mask that unencumbers the warfighter, integrates with existing system technology, and closes capability gaps in current technologies. Supports special purpose units (e.g., special operations, Civil Support Teams, Explosive Ordnance Disposal) and modernization efforts to insert new, scalable protection technologies into current respirator programs of record that protect against the full spectrum of threats for the full range of military operations. Develops next generation antimicrobial respiratory protection. Efforts include additional investments in enhanced biodefense and pandemic preparedness.

Dynamic Multifunction Materials for Second Skin: Efforts support percutaneous protection and will utilize responsive technologies to provide chemical and biological protective suits that adapt to the environment by synthesizing scaled samples via roll-to-roll manufacture which exhibit materials properties that reduce thermal burden and integrate with current combat garments. These technologies include interpenetrating polymer networks that will change moisture permeability and molecular selectivity on demand, and membranes with higher moisture vapor transfer rates than existing fabrics.

Enhanced Survivability Coatings: Addresses materiel surface ease of decontamination and resistance to chemical agent penetration. Develops durable temporary coatings that resist chemical agent absorption and are quickly decontaminated in the field and allow the rapid regeneration of combat power.

Lightweight Protective Garments: Advances garment material and ensemble technologies with revolutionary capability improvements using integrated, low encumbrance garment designs and fabrication for thermal burden reduction. Incorporates state-of-the-art threat protection technologies and supporting test methodologies and methods that provide operationally relevant, comparable test data on garments. Improves testing methods for rapid, operationally-relevant, consistent garment performance evaluation. Develops next generation antimicrobial percutaneous protection to extend protective garment service life and reduce logistics and lifecycle costs. Efforts include additional investments in enhanced biodefense and pandemic preparedness.

Multifunctional Materials for Protection: Supports Protection and Hazard Mitigation Core Capability Areas. Combines basic and applied research to discover, develop, engineer, and integrate novel, reactive/catalytic materials into next generation CB defense systems. Engineers and scales material manufacturing to maximize sorption, reactivity, and service life while unencumbering the warfighter. Characterizes materials using state-of-the-art ambient pressure spectroscopies for integration into next generation filters and protective garments that reactively decontaminate chemical warfare agents.

Nerve Agent Prophylaxis/Pretreatments: Obtain the first prophylactic MCMs designed to prevent severe morbidity and mortality upon exposure to nerve agents without the need for additional individual physical protective equipment.

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2022	FY 2023	FY 2024
<i>Title:</i> 1) Biological Warfare Defense Prophylaxis	-	24.826	15.082
Description: The ultimate protection of the Warfighter is by pretreating the Warfighter to withstand any biological threat with no adverse side effects from the pretreatment. Such pretreatment would enable the Warfighter to work in a less restrictive environment, absent of any personal protective equipment allowing operation at peak performance. Investments support derisking of candidates for transition into advanced development and includes: platform and prototype candidate maturation, preclinical studies for lead candidates to allow initiation of clinical work, regulatory science to support clinical initiation, animal model			

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and	d Biological Defense Program		Date: N	/larch 2023		
Appropriation/Budget Activity 0400 / 3	R-1 Program Element (Number/Name) PE 0603384BP <i>I Chemical and Biological</i> <i>Defense Program - Advanced Development</i>	ological PT3 / Protect (ATD)				
B. Accomplishments/Planned Programs (\$ in Millions)		ſ	FY 2022	FY 2023	FY 2024	
development for Food and Drug Administration (FDA) animal rule lice advanced development once the Phase 1 clinical trial is complete.	ensure, and Phase 1 clinical trials. Candidates transitior	1 into				
 FY 2023 Plans: Bacterial: Complete Good Manufacturing Practices (GMP) manufacturing for Capsular Polysaccharide-bacterial virulence factor (CPS) conjugate - Complete manufacturing and nonclinical development of adjuvantee - Initiate toxicology studies of adjuvanted plague vaccine in support of - Continue non-clinical safety and efficacy studies of monoclonal anti- Continue layered defense studies for bacterial threats to test vaccine - Continue non-clinical safety and efficacy studies on a live attenuate Phase 1. Initiate manufacturing of anthrax CPS conjugate vaccine candidate Complete melioidosis human seroprevalence study in support of variables and efficiency of clinical Phase 1 for complete studies of phase 1 for complete studies of support of clinical Phase 1 for complete study in support of variables and efficiency studies of support of variables and efficiency studies of support of clinical phase 1 for complete study in support of variables and efficiency studies phase 1 for complete study in support of clinical phase	vaccine for advancement to clinical Phase 1. d plague vaccine for advancement to clinical Phase 1. of clinical Phase 1. libody cocktail against plague and Burkholderia. hes, antibody therapies and antibiotics in combination. ed plague vaccine candidate for advancement to clinical for advancement to clinical Phase 1. accine licensure.	olderia				
 Viral: Complete current Good Manufacturing Practices (cGMP) manufacter Phase 1 clinical trial as well as pivotal nonclinical studies. Continue cGMP manufacture of recombinant vesicular stomatitis Vistudies and upcoming Phase 1 clinical trial. Complete investigation into correlates of protection for Marburg viru. Continue correlates of protection studies for alphavirus vaccine ania. Continue evaluation and mitigation studies of Filovirus aerosol path Continue development of rVSV Marburg vaccine in animal models to upcoming Phase 1 clinical trial. Continued development of alphavirus animal models to support ania. Continue development of alphavirus animal models to support anial 	irus (rVSV) Marburg virus vaccine to support pivotal anin us survivors to support pivotal animal studies. mal models. nology. to support investigational new drug (IND) submission. e for Venezuelan Equine Encephalitis (VEE) Virus for mal rule licensure of alphavirus vaccines	•				
Broad Spectrum: - Continue development of the multivalent Nanolipoprotein (NLP) vac	ccine against multiple bacterial agents.					

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical a	and Biological Defense Program	Date:	March 2023	
Appropriation/Budget Activity 0400 / 3	R-1 Program Element (Number/Name) PE 0603384BP <i>I Chemical and Biological</i> <i>Defense Program - Advanced Development</i>	Project (Number/ PT3 / Protect (ATL		
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
 Continue non-clinical safety and efficacy studies with the broad s FY 2024 Plans: Bacterial: Initiate Phase 1 vaccine clinical trial in collaboration with Australi Continue building relationships in Madagascar to collect plague s emerging plague strains 	a for the Burkholderia OMV vaccine.			
Viral: - Initiate Phase 1 clinical trial for the VEE deoxyribonucleic acid (D - Continue preclinical development of Hydrovax pan-Alphavirus va - Continue preclinical development of mucosal SARS CoV2 vaccir - Complete Current Good Manufacturing Practices (cGMP) manuf virus vaccine and IND enabling studies to support pivotal animal s - Continue correlates of protection studies for viral vaccines. - Continue evaluation and mitigation studies of Filovirus aerosol pa - Continue development of rVSV Marburg vaccine in animal mode - Continued development of alphavirus animal models to support a - Continue assay qualification and validation for Marburg virus, an	accine he, expanding to multivalent coronavirus vaccine acture of Recombinant Vesicular Stomatitis Virus rVSV Ma tudies and upcoming Phase 1 clinical trial. athology. Is to support investigational new drug (IND) submission. animal rule licensure of alphavirus vaccines	rburg		
Broad Spectrum: - Continue layered defense studies for pathogen threats to test va broaden protection. - Continue development of the multivalent Nanolipoprotein vaccine - Continue preclincal development of universal cellular nanospong - Continue non-clinical safety and efficacy studies with the broad s - Initiate development of oral multivalent mRNA vaccine	e against multiple bacterial agents. je MCM to protect against multiple respiratory viruses.			
FY 2023 to FY 2024 Increase/Decrease Statement: Decrease due to change in program/project technical parameters.	All work associated with plague vaccines has been cancel	ed		
<i>Title:</i> 2) Air Purification Enhancements		-	-	0.11
Description: Existing Collective Protection (ColPro) systems have life. Efforts will focus on optimizing and extending filter life to redu				

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program				
Appropriation/Budget Activity 0400 / 3	R-1 Program Element (Number/Name) PE 0603384BP <i>I Chemical and Biological</i> <i>Defense Program - Advanced Development</i>	Project (Number/ PT3 / Protect (ATL	,	
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
FY 2024 Plans: - Transition improved, compact vehicle ColPro system filters to the M spectrum of threat protection and reduce production and replacement - Transition the Residual Life Indicator System to the Modernization life, reducing cost and logistics for facility and shipboard ColPro systems	nt costs. ColPro program of record to accurately predict remaining	filter		
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project funding transferred from another funding line. Project Protection thrust area to support transition of Residual Life Indicator Increase supports follow-up testing for transitioned technologies.		or		
Title: 3) All-Hazards & Respiratory Protection		-	1.345	1.912
Description: Efforts will improve chemical and biological agent proteintegrated research on respirator, seams, closures, and new manufa end-user jury input with frequent user operational evaluation; focus of	cturing techniques and materials; perform early surveys	for		
 FY 2023 Plans: Continue to evaluate and assess systems that provide CB respirate spectrum respiratory protection system. Transition operationally-relevant respirator fit testing system to Mode Transition specification for anti-fog lenses in respirators as a Grour Continue to design and test prototypes for a low-encumbrance, new 	dernization Individual Protection program of record. Ind Mask modification work order.	d, full		
FY 2024 Plans: - Transition a microcooling-garment system that extended the time for Protective Ensemble (TATPE) effort under the UIPE FoS GP program - Complete design challenge for next generation respiratory protection - Perform early user assessment of next generation prototype respiration unencumbering respirator that integrates with existing systems (e.g., profile filter designs.	m of record. on concepts. atory protection concepts in the form of a low-burden,	low		
FY 2023 to FY 2024 Increase/Decrease Statement:				
Increase due to change in program/project technical parameters.				
Title: 4) Dynamic Multifunction Materials for Second Skin		-	1.170	-

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica		Date: N	larch 2023		
Appropriation/Budget Activity 0400 / 3	R-1 Program Element (Number/Name) PE 0603384BP <i>I Chemical and Biological</i> <i>Defense Program - Advanced Development</i>	gical PT3 I Protect (ATD)			
B. Accomplishments/Planned Programs (\$ in Millions)			FY 2022	FY 2023	FY 2024
Description: This effort utilizes responsive technologies to provide CB protect synthesizing scaled samples via roll-to-roll manufacture which exhibit materials integrate with current combat garments.					
 FY 2023 Plans: Continue development and testing of protective garment materials that response Warfighter protection. Begin integration of responsive systems into protective suit paradigms for whether the systems into protective suit paradigms for systems into protective suit		ase			
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project funding transferred to another funding line. Dynamic Multifunc in FY23 and merges into the Lightweight Protection Garments, Enhanced Surv Protection thrust areas starting in FY24.					
<i>Title:</i> 5) Enhanced Survivability Coatings			-	0.416	0.629
Description: Efforts seek to produce enhanced coatings that increase chemical decontaminatability of military materiel to levels comparable to that of stainless absorption and be quickly decontaminated in field, to rapidly return materiel to	steel. Improved coatings will resist chemical	agent			
 FY 2023 Plans: Continue to characterize bio-inspired surface treatments for materiel coatings Evaluate and incorporate new or commercially-available appliques (to include coatings, novel coatings characterization, thin film overcoats, strippable coat, reCBRN Coatings, Coverings, and Protective Overlays. Advance thin repellent film coating systems from fundamental research to application. 	e chemical transport studies in current military eactive coat, and lock-down coats) in support of				
FY 2024 Plans: - Transition candidate temporary overcoats that are commercially-available, im on signature, and reduce logistics to the TTC (Tactical Temporary Coatings) pr - Continue to evaluate and demonstrate industry polymer coatings as potential coatings to decrease logistical burden of decontamination in support of the TTC - Conduct operational user assessments to validate temporary overcoats that in	ogram of record. temporary or permanent military equipment C program of record.				
FY 2023 to FY 2024 Increase/Decrease Statement:					

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	I Defense Program	Date	: March 2023		
Appropriation/Budget Activity 0400 / 3		Biological PT3 I Protect (ATD)			
B. Accomplishments/Planned Programs (\$ in Millions)		FY 202	2 FY 2023	FY 2024	
Program/project funding transferred from another funding line. Project funding to Materials for Second Skin thrust area which ends in FY23. Increase supports to TTC program of record in FY24.		e			
Title: 6) Lightweight Protective Garments				0.117	
Description: Efforts will advance garment material and ensemble technologies designs and fabrication for thermal burden reduction, state-of-the-art threat pro methodologies and methods that provide operationally relevant, comparable data	tection technologies, and supporting test				
FY 2024 Plans: - Manufacture scaled responsive/reactive prototype garments that adapt or rea thermal burden and integrate with current combat garments. - Test scaled responsive/reactive prototype garments using whole system test	-				
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project funding transferred from another funding line. Project funding to Second Skin thrust area which ended in FY23. Increase supports whole systematches.		als			
Title: 7) Multifunctional Materials for Protection			- 0.756	1.404	
Description: Efforts will discover, develop and integrate novel, reactive/catalyt with maximum sorption and reactivity. They will characterize materials using sta spectroscopies for eventual integration into next generation decontaminants, correactively decontaminate chemical warfare agents.	ate-of-the-art in operando and ambient pressure	9			
 FY 2023 Plans: Continue to engineer reactive/catalytic nano-structure materials from basic reactive air purification enhancement. Continue to integrate engineered reactive/catalytic nano-structure materials (or decontaminants, and textiles to assess materials in an operationally-relevant encoder and the structure materials to design reactive, regenerative protective thermal burden. 	derived from Applied Research efforts) into filter nvironment for personnel decontamination.				
FY 2024 Plans: - Generate prototype next generation reactive and regenerative protective garn thermal burden for whole system testing.	nent prototypes with longer service life and lowe	er			

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program			Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 3	R-1 Program Element (Number/Name) PE 0603384BP <i>I</i> Chemical and Biological Defense Program - Advanced Development		roject (Number/Name) T3 I Protect (ATD)		
B. Accomplishments/Planned Programs (\$ in Millions)		ſ	FY 2022	FY 2023	FY 2024
 Integrate responsive technologies to develop prototype protective suits that a low burden and high protection mode on demand in response to the presence protection. Integrate reactive materials into filters for enhanced threat spectrum protection. Scale materials manufacturing processes for cost-efficiency. Characterize materials using operationally-relevant test methods and conditionally-relevant test methods. 	of CB agents, offering proactive contamination on, extending service life and regenerative capa	l			
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project funding transferred from another funding line. Project funding Materials for Second Skin thrust area which ends in FY23. Increase supports of garments.		ve			
Title: 8) Air Purification Enhancements - Enhanced Biodefense (ENBD)			-	2.000	2.000
Description: This effort will focus on Improved Collective Protection (ColPro). driven by maintenance and limited service life. Efforts will focus on optimizing while maintaining or improving protection.					
FY 2023 Plans: - Develop low cost, continuous-operation collective protection engineering star enhancement of unprotected Department of Defense (DoD) facilities during pa - Demonstrate and validate concepts for layered protection to mitigate the biological applique and facility design features.	andemic or biological warfare agent release.	for			
 FY 2024 Plans: Generate validated experimental data that quantifies the range of biological is measurements. Use appropriate, validated experimental methodologies to characterize and confection risk and cost, and plan operationally-relevant testing. 					
Title: 9) All-Hazards & Respiratory Protection - Enhanced Biodefense (ENBD)			-	1.000	1.500
Description: Efforts will improve biological agent respiratory and ocular protect integrated research on respirator, seams, closures, and new manufacturing terend-user jury input with frequent user operational evaluation; focus on low bur protection against biological agents.	chniques and materials; perform early surveys	for			
FY 2023 Plans:					

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologic		Date: N	larch 2023		
Appropriation/Budget Activity 0400 / 3	R-1 Program Element (Number/Name) PE 0603384BP <i>I Chemical and Biological</i> <i>Defense Program - Advanced Development</i>	-	ct (Number/N Protect (ATD		
B. Accomplishments/Planned Programs (\$ in Millions)		ſ	FY 2022	FY 2023	FY 2024
- Develop low cost, low burden, antimicrobial respiratory and ocular for operat environment.	tions specifically in a biologically contaminated				
 FY 2024 Plans: Identify potential antimicrobial textiles and innovative designs for respirators laboratories, and academic performers. Evaluate textiles for bactericidal and bacteriostatic effects using standardized Scale manufacturing of candidate antimicrobial textiles for respirator prototype 	d test methods.	ense			
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project funding transferred from another funding line. Funding transference increase supports development and testing of antimicrobial respirator in FY24					
Title: 10) Lightweight Protective Garments - Enhanced Biodefense (ENBD)			-	0.600	0.500
Description: Efforts will advance garment material and ensemble technologie designs and fabrication for thermal burden reduction, state-of-the-art threat pr methodologies and methods that provide operationally relevant, comparable obiological threats.	otection technologies, and supporting test				
FY 2023 Plans: - Develop low cost, low burden, antimicrobial respiratory and ocular for operat environment.	tions specifically in a biologically contaminated				
FY 2024 Plans: - Partner with industry, Department of Defense laboratories, and academic pa evaluation Down select and evaluate textiles for bactericidal and bacteriostatic effects u	using standardized test methods.	for			
- Scale manufacturing of candidate antimicrobial textiles for prototype garmen	15.				
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project funding transferred to another funding line. Funding transferred	ed to All Hazards Respiratory Protection.				
Title: 11) Nerve Agent Prophylaxis/Pretreatments			-	-	6.000
Description: Develop pretreatments and prophylactics that counter chemical agents (OPNA), using targeted and innovative science and technology efforts route of administration, lower dose requirements, and reduced operational and	that will offer broad-spectrum protection, flexibl				

Exhibit R-2A, RDT&E Project Just	stification: PB	2024 Chemi	cal and Biol	ogical Defen	ise Program				Date: M	arch 2023	
Appropriation/Budget Activity 0400 / 3							PT3 / F	ect (Number/Name) I Protect (ATD)			
B. Accomplishments/Planned Pl countermeasures (MCM) will prote	• •	•	ss of our Wa	rfighters the	is maintainir	a force stre	arth and force		FY 2022	FY 2023	FY 2024
capability.		i enectivene:		ingners, inc			igth and lord	-			
FY 2024 Plans: - Continue to advance candidate b through current Good Manufacturing and PK studies.	ng Practice (cG	MP) product									
FY 2023 to FY 2024 Increase/Det Program/project funding transferre better alignment under budget acti	d from another		. FY 2024 fu	nding has be	een transferr	red from MT4	1 to Project M	IT3 for			
				Accon	nplishment	s/Planned P	rograms Sul	ototals	-	32.113	29.26
C. Other Program Funding Sum	nary (\$ in Milli	ions)	<u>FY 2024</u>	<u>FY 2024</u>	<u>FY 2024</u>					<u>Cost To</u>	<u>.</u>
Line Item	<u>FY 2022</u>	FY 2023	<u>Base</u>	<u>000</u>	<u>Total</u>	FY 2025	FY 2026	FY 2027			Total Cos
• PT4: Protect (ACD&P) <u>Remarks</u>	-	175.219	179.158	-	179.158	135.096	107.341	123.538	5 139.370	6 Continuing	Continuin
<u>D. Acquisition Strategy</u> N/A											

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program							Date: Marc	ch 2023				
Appropriation/Budget Activity 0400 / 3				PE 060338	am Elemen 34BP / Cher rogram - Ao	nical and B	iological	Project (N MT3 / Mitig		, , 		
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
MT3: Mitigate (ATD)	-	0.000	86.157	100.791	0.000	100.791	89.511	91.704	85.795	85.480	Continuing	Continuing
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

The Mitigate Advanced Technology Development (ATD) Project provides the Joint Force the ability to preserve combat power by mitigating exposure to chemical and biological (CB) hazards and restoring combat readiness of critical personnel and platforms. In FY 2023, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. MT3 efforts in FY 2022 remain in Projects CB3 and TM3. This restructuring provided standardization and alignment across CBDP research, development and acquisition efforts.

Thrust Areas included in this Project are:

- (1) Biological Warfare Defense Therapeutics
- (2) Discovery of Medical Countermeasures Against New and Emerging (DOMANE)
- (3) Chemical Reactive Ocular Wound and Dermal Therapeutics (CROWD)
- (4) Emerging and Pharmaceutical-based Agent Threats (EMPATH)
- (5) Reactivators of Acetylcholinesterase as Therapeutics (ReACT)
- (6) Enhanced Survivability Coatings
- (7) Equipment Decontamination
- (8) Multifunctional Materials for Protection
- (9) Personnel Decontamination
- (10) Wide Area Decontamination

Biological Warfare Defense Therapeutics: Develops broad-spectrum bacterial, toxin and viral therapeutics, and label expansion (repurposing) of medical countermeasures that are Food and Drug Administration (FDA) approved or in advanced stages of clinical development. These efforts are coordinated with Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA), and across the interagency and Department, to leverage public and force/defense health related investments made to minimize risk and speed approval of novel antibiotic countermeasures. Efforts include additional investments in enhanced biodefense and pandemic preparedness.

Discovery of Medical Countermeasures Against New and Emerging threats (DOMANE): Provides innovative and rapid medical countermeasures (MCMs) development capabilities that reduce developmental risks, cost and schedule associated with MCM fielding, and afford protection against and allow the Joint Force to rapidly respond to traditional, new and emerging biological warfare threat exposures to allow freedom of action. Efforts include additional investments in enhanced biodefense and pandemic preparedness.

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and	d Biological Defense Program		March 2023	
Appropriation/Budget Activity 0400 / 3	R-1 Program Element (Number/Name) PE 0603384BP / Chemical and Biologica Defense Program - Advanced Developm	MT3 / Mitigate (A7		
Chemically Reactive Ocular Wound and Dermal Therapeutics (CRC that has breached the skin. Collect the data that the Food and Drug		the Warfighter that car	treat a chemio	cal agent
Emerging and Pharmaceutical-based Agent Threats (EMPATH): As Activities focus on assessing current therapeutic drugs for protection				ducts.
Reactivators of Acetylcholinesterase (AChE) as Therapeutics (ReAC increase survival, reduce morbidity, and decrease neurological dam) reactivators, t	that
Enhanced Survivability Coatings: Addresses military equipment coa temporary coatings that resist chemical agent absorption and are qu				levelop
Equipment Decontamination: Develops decontaminant formulations decontamination with rapid unmasking; reduces logistic needs, enal improved realistic test methods. Efforts address the capability to de and pandemic preparedness.	bles rapid sorting of clean from dirty to return high-va	lue equipment to norma	al use, and dev	/elops
Multifunctional Materials for Protection: Discovers, develops and inte and reactivity, and characterize materials using state-of-the-art in op decontaminants that reactively decontaminate chemical warfare age	perando and ambient pressure spectroscopies, for ev			
Personnel Decontamination: Develops personnel decontaminants w to Warfighters for mass casualty decontamination, including possible				s burdens
Wide Area Decontamination: Addresses limited capabilities to rapid enable normal, unprotected operations. Efforts seek to improve con compatibility. Efforts support autonomous critical area biological dec preparedness.	tamination mitigation logistics/cost reduction, effectiv	eness, compatibility/sat	fety, and enviro	onmental
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
Title: 1) Biological Warfare Defense Therapeutics		-	29.439	29.703
<i>FY 2023 Plans:</i> Bacterial: - Continue efforts to identify and advance bacterial therapeutic cand Therapeutic candidates that are shown to be both safe and efficacio		nce		
PE 0603384BP: <i>Chemical and Biological Defense Program</i> Chemical and Biological Defense Program	UNCLASSIFIED Page 34 of 69 R-1 Lir	e #49	Vo	olume 4 - 96

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	Date: N	Aarch 2023		
Appropriation/Budget Activity 0400 / 3	- · · · · · · · · · · · · · · · · · · ·	Project (Number/ MT3 / <i>Mitigate (AT</i>	,	
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
 for additional nonclinical and clinical evaluation under Advanced Component D transition to an advanced developer. Continue to partner with interagency, international and industry partners to furtherapeutic candidates already in advanced development for public and force h. Continue to execute proof of concept efficacy studies for antibiotic therapy in treatments (layered medical defense). Advance layered combinations toward p models. 	ind nonclinical BW therapeutic efficacy studies nealth indications. combination with prophylaxis or complimentary			
Viral: - Continue efforts to identify and advance viral therapeutic candidates against r direct acting, broad-spectrum anti-virals and monoclonal antibodies. Therapeu and efficacious against BW threats will advance for additional nonclinical and c Development and Prototypes (PE 0603884BP) or transition to an advanced de - Continue proof of concept viral therapeutic efficacy studies for combinations of monoclonal antibody and host-directed therapeutics.	tic candidates that are shown to be both safe linical evaluation under Advanced Component veloper.			
Toxins: - Continue to evaluate efficacy of repurposed drug for treatment of botulinum n model.	eurotoxin (BoNT) A intoxication in NHP animal			
 FY 2024 Plans: Bacterial: Continue efforts to identify and advance bacterial therapeutic candidates, incle candidates that are shown to be both safe and efficacious against BW threats we evaluation or transition to other therapeutic efforts or an advanced developer. The advance to the Department of Health and Human Services, Biomedical Advance continued development. Continue to partner with interagency, international and industry partners to furtherapeutic candidates already in advanced development for public and force herapeutic continue to execute proof of concept efficacy studies for antibiotic therapy in treatments (layered medical defense). Advance layered combinations toward prodels. 	will advance for additional nonclinical and clinic Two broad-spectrum therapeutic candidates wil ced Research and Development Authority for and nonclinical BW therapeutic efficacy studies nealth indications. combination with prophylaxis or complimentary			
Viral:				

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical a	and Biological Defense Program	Date:	March 2023		
Appropriation/Budget Activity 0400 / 3	R-1 Program Element (Number/Name) PE 0603384BP <i>I Chemical and Biological</i> <i>Defense Program - Advanced Development</i>	MT3 / Mitigate (A7	Project (Number/Name) MT3 / Mitigate (ATD)		
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024	
 Continue efforts to identify and advance viral therapeutic candidata targeted and direct acting, broad-spectrum anti-virals and monocle both safe and efficacious against BW threats will advance for addit therapeutic efforts or an advanced developer. One broad-spectrum Executive Office for Chemical, Biological, Radiological and Nuclear development. Continue proof of concept viral therapeutic efficacy studies for comonoclonal antibody and host-directed therapeutics. 	onal antibodies. Therapeutic candidates that are shown to tional nonclinical and clinical evaluation or transition to oth n therapeutic candidate will advance to the Joint Program ar Defense Antiviral Oral Therapeutic Program for continue	be her			
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.					
Title: 2) Biological Warfare Defense Therapeutics - Enhanced Bio	defense (ENBD)	-	23.000	23.00	
Description: This effort focuses on Drug Repurposing; Micro phys Technology Host Response Studies. Activities include expediting a efficacy of approved drugs against biological threats (i.e., drug rep threats for U.S. Food & Drug Administration (FDA) approval; deve and development of therapeutic candidates in response to an eme target host response to disease caused by biological threats.	a response to emerging threats by assessing broad-spect purposing), advancing repurposed drugs against biological loping tools (e.g., small molecule libraries) to expedite disc	rum covery			
FY 2023 Plans: Initiate and accelerate projects to repurpose broad-spectrum dru Initiate and continue projects to create and sustain curated, sear and efficacy data for use in a response to emerging biological thre Initiate development of host-targeted technologies that can be used 	chable databases of molecules with toxicity, drug develop eats.				
 FY 2024 Plans: Continue to repurpose broad-spectrum drugs against viral, bacte Continue to create and sustain curated, searchable databases of use in a response to emerging biological threats. Continue to develop host-targeted technologies that can be used 	erial and toxin threats. f molecules with toxicity, drug development and efficacy d				
<i>Title:</i> 3) Biological Warfare Defense Therapeutics	••••				

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program				larch 2023		
Appropriation/Budget Activity 0400 / 3	R-1 Program Element (Number/Name) PE 0603384BP <i>I Chemical and Biological</i> <i>Defense Program - Advanced Development</i>		ect (Number/Name) 5 / Mitigate (ATD)			
B. Accomplishments/Planned Programs (\$ in Millions)		FY	2022	FY 2023	FY 2024	
Description: Funds biomedical research focused on the nonclinical and early of countermeasures against known and emerging viral, bacterial, and toxin biolog & Drug Administration (FDA) approved therapeutics are limited or lacking. BW effects of known and emerging viral, bacterial, and toxin biological warfare three disease. They are the last line of defense against BW threats and are critical to Biomedical research is focused on nonclinical development (e.g., animal mode early clinical evaluation of broad-spectrum therapeutic candidates that target viresponse (e.g., by modulating the immune system) and/or relieve BW diseases. Therapeutic candidates that are shown to be both safe and efficacious against and/or clinical evaluation under RDT&E budget activity 5, and can be accelerate during an outbreak. Clinical and nonclinical evaluation of novel small molecule molecules (isolated from natural sources), drug and drug/vaccine combinations approved by the FDA or in clinical development for other indications, are includ animal models in which to evaluate therapeutic candidates is also included. Printers and reduce costs.	ical warfare (BW) threats for which U.S. Food defense therapeutics mitigate and reverse the ats in symptomatic warfighters diagnosed with o returning symptomatic warfighters to service. I, and formulation/manufacturing studies) and ruses, bacteria or toxins directly, enhance the symptoms. BW threats will advance for further non-clinica ed for use against emerging infectious disease s (chemically synthesized), novel biologic c (aka layered defense), and repurposing of dru ed in this research. Refinement of appropriate	BW host I es ugs				
FY 2024 Plans: - Continue nonclinical and regulatory activities to transition broad spectrum anti Research and Development Authority (BARDA) Initiate clinical and/or nonclinical studies for broad-spectrum antiviral therapeu						
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project funding transferred from another funding line. FY 2024 funding alignment under budget activity 3.	has been transferred from Project PT4 for be	tter				
Title: 4) Discovery of Medical Countermeasures Against New and Emerging (D	OMANE)		-	3.403	7.469	
Description: This effort focuses on predicting pathogenesis of pathogens and machine learning (ML) to identify targets for both host and pathogen while condistructural models with AI to predict and recommend potential therapeutics. It su Toxicity forecasting using Multi-Organoid Systems (PATMOS) prototype, which assisted multi-organoid system capable of forecasting pathogenesis of viral three DOMANE thrusts like Medical Countermeasure Finder (MEDFIND) to prototype harnessing repurposed drugs and generate effective therapeutic intervention statements of the section of	ducting high throughput screens using new apports DOMANE thrusts like Pathogenesis an develops an advanced-artificial intelligence (A eats and toxicity of biotoxin threats. It supports a a flexible advanced Al-assisted system capa	id Al)				

hibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program			Date: N	larch 2023		
Appropriation/Budget Activity 0400 / 3	· · · · · · · · · · · · · · · · · · ·	Project (Number/Name) MT3 / Mitigate (ATD)				
B. Accomplishments/Planned Programs (\$ in Millions)			FY 2022	FY 2023	FY 2024	
FY 2023 Plans: - Continued development of prototype capability that forecasts pathogenicity or - Continued development of prototype capability for high-throughput screening identification.						
FY 2024 Plans: - Continue prototype development of PATMOS platform for high resolution fore interaction of new and emerging biological threats and providing initial safety da - Continue development of prototype development of ambient ionization mass system to rapidly characterize MCMs by collecting and analyzing large amount new MCMs.	ata on recommended medical countermeasure spectroscopy high-throughput screens (AIM-HI	TS)				
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to change in program/project technical parameters.						
Title: 5) Discovery of Medical Countermeasures Against New and Emerging (D	OOMANE) - Enhanced Biodefense (ENBD)		-	12.000	12.000	
Description: This effort focuses on predicting pathogenesis of pathogens and machine learning (ML) to identify targets for both host and pathogen while condistructural models with AI to predict and recommend potential therapeutics. It surfoxicity forecasting using Multi-Organoid Systems (PATMOS) prototype, which system capable of forecasting pathogenesis of viral threats and toxicity of biotor like Medical Countermeasure Finder (MEDFIND) to prototype a flexible advance repurposed drugs and generate effective therapeutic intervention strategies age	ducting high throughput screens using new upports DOMANE thrusts like Pathogenesis an develops an advanced- AI assisted multi-orga xin threats. It supports other DOMANE thrusts and AI-assisted system capable of harnessing	d				
FY 2023 Plans: - Prototype development PATMOS platform for high resolution forecasting of pa biological threat. - Prototype initiation for MEDFIND platform to identify repurposed drugs using a						
FY 2024 Plans: - Continue prototype development of PATMOS platform for high resolution fore that occurs during interaction of new and emerging biological threats. - Initiate 2nd PATMOS prototype to provide additional pathogenesis forecasting treatment.						

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	Date	: March 2023				
Appropriation/Budget Activity 0400 / 3	R-1 Program Element (Number/Name) PE 0603384BP <i>I</i> Chemical and Biological Defense Program - Advanced Development	•	roject (Number/Name) IT3 <i>I Mitigate (ATD)</i>			
B. Accomplishments/Planned Programs (\$ in Millions)		FY 202	FY 2023	FY 2024		
-Continued prototype development of ambient ionization mass spectroscopy h rapidly characterize MCMs and continued development of cryo-electron micros system to characterize MCMs at the atomic level combined with AI/ML to reco - Continue prototype development for MEDFIND platform to identify repurpose throughput screens and micro-electron diffraction to deliver crystal structures of host characterization leading to designing new MCMs.	scopy (cyro-em) prototype with high throughput mmend MCMS for new and emerging threats. In and new drugs using AI and ML using high					
Title: 6) Chemical Reactive Ocular Wound and Dermal Therapeutics (CROWE))		- 1.174	2.500		
Description: Focuses on therapeutic strategies to effectively treat Chemical V eyes, and large areas of intact skin. This effort involves the development of pr from those routes of exposure, to decrease the toxic load of agent and allow o	oducts capable of removing or neutralizing CW	'A				
 FY 2023 Plans: Submit investigational new drug (IND) submission to the FDA for organophosenzymes. Complete Good Laboratory Practice (GLP) pharmacokinetics, immunogenicit candidates in small animals. Complete enzyme current Good Manufacturing Practice (cGMP) manufacturing Complete formulation efforts. Complete enzyme non-cGMP manufacturing scale-up. 	ty and efficacy of catalytic scavenger enzyme le					
FY 2024 Plans: - Perform advanced preclinical studies to validate safety and efficacy in suppo	rt of clinical trials.					
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to change in program/project technical parameters.						
Title: 7) Emerging and Pharmaceutical-based Agent Threats (EMPATH)			- 1.463	4.361		
Description: Focus on therapeutic and proactive strategies to effectively mining to Pharmaceutical Based Agents (PBA). This will allow the warfighter to main battlefield scenario. This effort involves the evaluation U.S. Food & Drug Adm operational use, as well as generation of novel drug products to enhance level warfighter. Efforts in this area are designed to develop drug candidates that we identify previously licensed products for new uses in the treatment and pretreat	tain operational capacity in a chemically contest inistration (FDA) approved therapeutics for of protection and/or operational utility for the ill ultimately be submitted for FDA licensure or	ted				
FY 2023 Plans:						

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical ar	nd Biological Defense Program	Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 3		Project (Number/ MT3 / <i>Mitigate (AT</i>		
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
 Continue operational assessment of FDA approved drug products or unknown chemical exposure. Assess operational feasibility of employing FDA approved opioid a 				
<i>FY 2024 Plans:</i> - Continue cGMP production and non-GLP/GLP safety and/or effica - IND filing and initiation of a human bioavailability/bioequivalence s novel, multi-dose vialed formulation.				
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to fact of life change in the program/project.				
Title: 8) Reactivators of AChE as Therapeutics (ReACT)		-	3.618	8.20
Description: The Warfighter requires rapid acting MCMs to counter maintain force lethality. This effort involves the development of imp Efforts in this area are focused on formulation development and pre- submitted for FDA licensure or previously licensed products for new	roved therapies for acetylcholinesterase enzyme reactivati e-clinical studies for potential candidates that will ultimately	on.		
FY 2023 Plans: - Continue to advance pre-clinical development of lead therapeutic - Continue formulation efforts and scale up manufacturing for lead t - Initiate GLP toxicology and long-term stability studies for lead there	herapeutic candidates.			
FY 2024 Plans: - Continue to advance pre-clinical development of lead therapeutic - Complete IND-enabling studies on the current lead reactivator car - Continue development efforts in preparation for IND/phase 1 clinic	ndidates.			
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to change in program/project technical parameters. FY better alignment under budget activity 3.	Y 2024 funding has been transferred from Project MT4 for			
Title: 9) Enhanced Survivability Coatings		-	0.051	0.07
Description: Efforts seek to produce enhanced coatings that increat decontaminatability of military materiel to levels comparable to that		gent		

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	hibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program		Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 3	R-1 Program Element (Number/Name) PE 0603384BP <i>I Chemical and Biological</i> <i>Defense Program - Advanced Development</i>		c t (Number/N Mitigate (ATL		
B. Accomplishments/Planned Programs (\$ in Millions)		[FY 2022	FY 2023	FY 2024
 FY 2023 Plans: Continue to characterize bio-inspired surface treatments for equipment coating equipment coatings. Evaluate and incorporate new or commercially-available appliques (to include coatings, novel coatings characterization, thin film overcoats, strippable coat, reCBRN Coatings, Coverings, and Protective Overlays. Advance thin repellent film coating systems from fundamental research to application. 	chemical transport studies in current military eactive coat, and lock-down coats) in support o				
FY 2024 Plans: - Transition candidate temporary overcoats that are commercially-available, im on signature, and reduce logistics to the Tactical Temporary Coatings (TTC) pr - Continue to evaluate and demonstrate industry polymer coatings as potential coatings to decrease logistical burden of decontamination.	ogram of record.	npact			
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.					
Title: 10) Equipment Decontamination			-	0.951	0.454
Description: This effort seeks to develop decontaminant formulations and procontamination hazards; enable unit-level decontamination with rapid unmasking rapid sorting of clean from dirty to rapidly return high-value equipment to normal Successful efforts will result in improved efficacy, materials compatibility, flexible existing and emerging decontamination program requirements.	g; reduce logistic needs (need for water); enab al use; and develop improved realistic test met	hods.			
FY 2023 Plans: - Transition methodology for testing for effective decontamination of complex su Equipment Decontamination Systems (SEDS) or Tactical Contamination Mitiga - Finish development and demonstration of an autonomous decontamination pl operational decontamination.	tion Systems (TCMS) programs of record.				
FY 2024 Plans: - Demonstrate autonomous equipment decontamination platform to reduce troc decontamination Transition methodology for decontaminating chemically-contaminated sensitive		tional			

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Bi	ological Defense Program	Date: N	March 2023	
Appropriation/Budget Activity 0400 / 3		roject (Number/ IT3 / Mitigate (AT	,	
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
- Transition methodology for decontaminating bacterial spore-contamination	ated aircraft using hot, humid air.			
FY 2023 to FY 2024 Increase/Decrease Statement: Decrease due to transition of hot air decontamination technologies to Jo Service Equipment Decontamination Systems programs of record in ear				
Title: 11) Multifunctional Materials for Protection		-	0.189	0.117
Description: This effort will discover, develop and integrate novel, react with maximum sorption and reactivity, and characterize materials using spectroscopies, for eventual integration into next generation decontamination decontaminat	state-of-the-art in operando and ambient pressure	9		
FY 2023 Plans: - Develop and characterize novel reactive/catalytic materials that decon integrate materials into next generation decontaminants and coatings.	taminate chemical and biological (CB) threats and			
FY 2024 Plans: Integrate reactive materials into decontamination systems for enhance Continue ambient pressure characterization of reactive chemical decord Scale materials manufacturing processes for cost-efficiency and characterization 	ntamination mechanisms.	5.		
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.				
Title: 12) Personnel Decontamination		-	0.869	2.339
Description: This effort develops decontaminants for decontamination of constraints and determination of time, efficacy and logistics burdens to warfighter burden in the event of a chemical warfare agent (CWA) exposed decontamination process as well as possible substitutions for current approximation process as well as possible substitutions for current approximation process as well as possible substitutions for current approximation of the substitutions for current approximation process as well as possible substitutions for current approximation process as well approximate the substitutions for current approximation process as well approximate the substitutions for current approximation process as well approximate the substitutions for current approximation process as well approximate the substitutions for current	warfighters for mass casualty decontamination. Decrea sure by identifying S&T gaps in the mass personnel	se		
<i>FY 2023 Plans:</i> - Develop and use laboratory and animal models to assess physical rem Skin Decontamination Lotion (RSDL). - Continue to integrate new dry decontamination into a mitt form factor a procedure improvements. This includes investigation of Food and Drug technology as a medical device.	and determine S&T challenges within process and	3		
FY 2024 Plans:				

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	I Defense Program		Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 3	R-1 Program Element (Number/Name) PE 0603384BP <i>I Chemical and Biological</i> <i>Defense Program - Advanced Development</i>		Number/I tigate (ATI		
B. Accomplishments/Planned Programs (\$ in Millions)		F	Y 2022	FY 2023	FY 2024
- Prepare a medical device package for FDA consideration for a new personne sustainment risk of Reactive Skin Decontamination Lotion cold storage and she Decontamination Personnel Skin program of record.		I			
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to accelerated development effort.					
Title: 13) Wide Area Decontamination			-	-	0.585
Description: Develop processes and identify chemicals to decontaminate critic and mitigate contamination spread to enable normal, unprotected operations. E as potential wide area decontaminants and barriers to improve chemical wide a effectiveness in mitigating contamination; compatibility/safety, environmentally	Examine commercial bulk packaged chemicals area decontamination and improve logistics (i.e.				
FY 2024 Plans: -Optimize chemical wide area decontamination methods and processes for usin decontaminating critical infrastructure area surfaces for effectiveness, availabilit -Demonstrate chemical wide area decontamination methods, processes, and fe chemicals using operationally-relevant environments and simulants in support	ity, and sprayability/scalability. easibility for using commercially-available pack				
FY 2023 to FY 2024 Increase/Decrease Statement: Funding transferred from Equipment Decontamination thrust.					
Title: 14) Equipment Decontamination - Enhanced Biodefense (ENBD)			-	5.000	5.000
Description: This effort will focus on Improved Decontamination and Disinfecta to decontaminate personal equipment, weapons, vehicles, ships, and facilities; electronic equipment, interior spaces, and aircraft); and hazardous waste. Effort and procedures that reduce or eliminate residual contamination hazards; enable reduce logistic needs (need for water); enable rapid sorting of clean from dirty t use; and develop improved realistic test methods. Successful efforts will result flexibility, and reduced logistical burden compared to existing and emerging de	Sensitive equipment (weapon system optics, orts seek to develop decontaminant formulation e unit-level decontamination with rapid unmas to rapidly return high-value equipment to norma- in improved efficacy, materials compatibility,	is king;			
FY 2023 Plans: - Develop and demonstrate biological disinfection guidelines, procedures, and of Defense (DoD) facility and large-platform interiors, including development of plasma and ultraviolet germicidal irradiation.					

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologic	cal Defense Program	Date:	March 2023	
Appropriation/Budget Activity 0400 / 3	R-1 Program Element (Number/Name) PE 0603384BP / Chemical and Biologica Defense Program - Advanced Developme			
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
 Complete comparative laboratory study of Biosafety Level (BSL)-1 surrogate disinfection to support field demonstrations. Develop biological agent disclosure sprays for sensitive, specific biological c reduce logistics of decontamination. Explore solution concepts through resea functional prototype technologies in a phased approach for a biological agent Demonstrate a proof of concept demonstrating specific recognition and bind interest. 	contamination mapping on surfaces to guide arch, development, and demonstration of on disclosure spray.	and e or more		
FY 2024 Plans: - Complete and transition methods for field testing of surface decontamination surrogate to the Joint Biological Aircraft Decontamination Systems program of - Continue development of biological disinfection guidelines, procedures, and interiors, including directed energy decontamination approaches. - Optimize and verify laboratory methods for biological agent disclosure spray mapping on surfaces to guide and reduce logistics of decontamination.	f record. CONOPs, for DoD facility and large-platforr	n		
Title: 15) Wide Area Decontamination - Enhanced Biodefense (ENBD)		-	-	1.000
Description: This effort focuses on developing an autonomous decontaminat infrastructure (e.g., sea port or air base) and mitigate biological contamination Examines commercial packaged chemicals as potential wide area decontami area decontamination and improve logistics (i.e., effectiveness in mitigating co friendly; cost reduction).	n spread to enable normal, unprotected oper inants and barriers to improve biological wid	e		
FY 2024 Plans: Develop concept platform and required subsystems for autonomous wide area and feasibility and identify and optimize biological decontaminant formulations		esses,		
FY 2023 to FY 2024 Increase/Decrease Statement: Funding transferred from Equipment Decontamination - Enhanced Biodefense autonomous wide area decontamination project in FY24.	e thrust area. Increase supports biological			
	Accomplishments/Planned Programs S	Subtotals -	81.157	100.791
	FY 20	22 FY 2023		
Congressional Add: Broad Spectrum Small Molecule Anti-viral Development	t	- 5.000		

opropriation/Budget Activity 00 / 3				R-1 Pr	rogram Elen	nont (Numbe	or/Namo)	Draiget (N	lumbor/Na		
					03384BP / C	Chemical and		blogical MT3 / Mitigate (ATD)			
							FY 2022	FY 2023	7		
Y 2023 Plans: Viral: Enhance viral therapeutic develo oad-spectrum viral therapeutic on herapeutic candidates that are s dditional nonclinical and clinical of 503884BP) or transition to an ad	candidates agair hown to be both evaluation under	nst new and safe and ef r Advanced	existing biolo	ogical warfaı ainst BW thro Developmer	re (BW) viral eats will adv nt and Protot	threats. ance for ypes (PE					
				Cong	ressional A	dds Subtota	ls -	5.000)		
Other Program Funding Sum Line Item • MT4: Mitigate (ACD&P) emarks	mary (\$ in Milli <u>FY 2022</u> -	<u>ons)</u> <u>FY 2023</u> 17.302	<u>FY 2024</u> <u>Base</u> 28.785	<u>FY 2024</u> <u>OCO</u> -	<u>FY 2024</u> <u>Total</u> 28.785	<u>FY 2025</u> 20.885	<u>FY 2026</u> 15.433	<u>FY 2027</u> 13.369	<u>FY 2028</u> -	Cost To Complete Continuing	
<u>Acquisition Strategy</u> /A											

Exhibit R-2A, RDT&E Project Ju	ustification	: PB 2024 C	Chemical and	d Biologica	l Defense P	rogram				Date: Marc	ch 2023	
Appropriation/Budget ActivityR-1 Program Element (Number/Name)Project (Number/Name)400 / 3PE 0603384BP / Chemical and Biological Defense Program - Advanced DevelopmentEN3 / Enabling Investments			,)								
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
EN3: Enabling Investments (ATD)	-	0.000	39.540	43.196	0.000	43.196	43.198	44.449	44.449	44.449	Continuing	Continuing
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

The Enabling Investments Advanced Technology Development (ATD) Project focuses on early and continued involvement of the Warfighter in the technology development process and has implemented a user community engagement process to align science and technology (S&T) activities with operational needs and ensure functional design. This process begins with the identification of an innovative technology concept, continues through the assessment of the prototype, and ends at the operational and utility demonstrations to enhance transition to an advanced developer. Enabling efforts in this area support dedicated infrastructure capabilities, demonstrations, and overarching development support functions as portfolio enablers responding to emerging threats. In FY 2023, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. EN3 efforts in FY 2022 remain in Projects TM3 and TT3. This restructuring provided standardization and alignment across CBDP research, development and acquisition efforts.

Thrust Areas included in this Project are:

(1) Battlefield Readiness

(2) Diagnostic Building Blocks

(3) Emerging Threats

(4) Medical Countermeasures Initiative

(5) Advanced Technology Demonstration (ATD)

(6) Technology Concept

(7) User Assessment

Battlefield Readiness: Provides innovative capabilities to the warfighter that increase the speed of relevancy, enhance troop preparedness, aid with triage support, and provides diagnosis at lower roles of care. Develops field forward medical diagnostics to provide multiplexed detection of biological and toxin threats and leverages immunodiagnostics to identify specific targets using current or novel approaches to enable broader and more accurate diagnosis for a range of targets and across a wider window following exposure. Efforts include additional investments in Chem Bio Incident Preparedness and Response.

Diagnostic Building Blocks: Develops foundational capabilities for the entire diagnostics portfolio; invests in innovative, cutting-edge technologies to improve the development pipeline for diagnostics; and exploits areas in artificial intelligence synthetic biology and machine learning to develop novel and rapid diagnostic tests for utilization. Efforts accelerate assay development timelines and optimize test parameters by leveraging novel concepts and tools that readily allow a pivot to assay development for emerging threats. Efforts include additional investments in Chem Bio Incident Preparedness and Response.

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program	Date: M	larch 2023	
0400 / 3 PE 0603384BP / Chemical and Biological EN3 Defense Program - Advanced Development	ect (Number/N / Enabling Inve	estments (ATL	
Emerging Threats: Invests in diagnostic tests that enable the delivery of actionable information, such as administering the appropriate greatly advance efficacy rates and turnaround time for Warfighter wellness. Efforts focus on better preparing for surprise by development approaches to characterize pathogens or host response and can identify the classification of threat (e.g., bacterial vs viral) for include additional investments in Chem Bio Incident Preparedness and Response.	oping diagnosti	c systems that	at leverage
Medical Countermeasures Initiative: Advances medical capabilities to support CB Incident Preparedness and Response (CBIPR). capability development; novel encapsulation and delivery strategies that optimally tune the immune response to provide greater p laboratory sustainment for the Animal Model/Response Capability; genomics; and other medical countermeasure development the projects.	rotection from a	a vaccine as v	vell as
ATD: Execution of the ATD campaign plan across the Future Years Defense Program (FYDP) will close the identified gaps by con scenario based, threat relevant integrated capability demonstrations with Warfighters employing innovative, mature and optimized			ented,
Technology Concept: Validates technology requirements and scopes future S&T programs with the User community early in techn Results from these experiments shape operating concepts, doctrine, and materiel systems requirements for the future Joint Force technologies for subsequent portfolio investment decisions. Technology Concept outcomes explore new concepts of employment current operational paradigm. User Assessment: Execution of the User Assessments provide dynamic mission-based scenarios, exercises and field experiment expedite technology development as well as ensure transition and fielding success.	and informs th t for emerging o	e utility of em capabilities to	erging
B. Accomplishments/Planned Programs (\$ in Millions)			d can
	FY 2022	FY 2023	d can FY 2024
D: Accomprisements internet in ograms (# in winnens) Title: 1) Battlefield Readiness	FY 2022 -	FY 2023 5.094	FY 2024
			FY 2024
<i>Title:</i> 1) Battlefield Readiness <i>Description:</i> Provide innovative capabilities to the Warfighter that increase the speed of relevancy, enhance troop preparedness, aid with triage support, and provide diagnosis at lower roles of care. Develop field forward medical diagnostics that allow for multiplexed detection of biological and toxin threats. Leverage immunodiagnostics to identify specific targets using current or novel approaches to enable broader and more accurate diagnosis for a range of targets and across a wider window following			FY 2024
 <i>Title:</i> 1) Battlefield Readiness <i>Description:</i> Provide innovative capabilities to the Warfighter that increase the speed of relevancy, enhance troop preparedness, aid with triage support, and provide diagnosis at lower roles of care. Develop field forward medical diagnostics that allow for multiplexed detection of biological and toxin threats. Leverage immunodiagnostics to identify specific targets using current or novel approaches to enable broader and more accurate diagnosis for a range of targets and across a wider window following exposure. These funds support CB Incidence Preparedness Response (CBIPR). <i>FY 2023 Plans:</i> 			

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical	and Biological Defense Program	Date: N	Aarch 2023	
Appropriation/Budget Activity 0400 / 3	R-1 Program Element (Number/Name) PE 0603384BP <i>I Chemical and Biological</i> <i>Defense Program - Advanced Development</i>	Project (Number/ EN3 / Enabling Inv		D)
<u>B. Accomplishments/Planned Programs (\$ in Millions)</u>		FY 2022	FY 2023	FY 2024
Minor change due to routine program adjustments.				
Title: 2) Diagnostic Building Blocks		-	3.962	4.07
Description: Lays a foundation for the entire diagnostics portfolio biology and chemistry to develop novel and rapid diagnostic tests These funds support CB Incidence Preparedness Response (CBI	for utilization in the event of an outbreak of an unknown the			
<i>FY 2023 Plans:</i> - Continue novel efforts in Artificial Intelligence (AI) and ML for de CB agents to enable an agile response to emerging threats.	signing assays with high specificity against a broader range	of		
FY 2024 Plans: - Continue novel efforts utilizing AI and ML for designing assays v biological agents to enable an agile response to emerging threats		i		
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.				
Title: 3) Emerging Threats		-	2.264	2.91
Description: Advance the diagnosis of emerging and/or low previet technologies. Develop threat agnostic tests based on host biomar Characterize markers for antibiotic resistance or susceptibility to i Improve capabilities to identify diverse biological agents that are reapproaches. These funds support CB Incidence Preparedness Reference of the support CB Incidence Preparedness Preparednes	arkers that identify known or emerging bacterial or viral infect dentify challenging threats and inform treatment decisions. not well characterized using molecular or immunodiagnostic			
FY 2023 Plans: - Initiate efforts that establish multiple capabilities for Warfighters platforms that are capable of identifying broad classes of threat as		novel		
FY 2024 Plans: - Continue efforts that establish multiple capabilities for Warfighte novel platforms that are capable of identifying broad classes of th		g		
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to change in program/project technical parameters.				
<i>Title:</i> 4) Medical Countermeasures Initiative			19.928	22.26

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	I Defense Program		Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 3	R-1 Program Element (Number/Name) PE 0603384BP <i>I Chemical and Biological</i> <i>Defense Program - Advanced Development</i>		t (Number/I Enabling Inv	lame) estments (AT	D)
B. Accomplishments/Planned Programs (\$ in Millions)					FY 2024
Description: The Chem Bio Incident Preparedness and Response-Medical Co integrate advances in regulatory science, formulation and delivery technologies drug discovery and evaluation of platforms as enablers of the advanced develo These initiatives will lead to the establishment of multi-use platforms, novel forr during a CBRN response to accelerate medical product development and/or re development costs.	s and processes. Also will develop animal mod opment of CBDP medical countermeasure proc mulations and animal models that can be lever	lucts.			
 FY 2023 Plans: Complete preclinical studies for Marburg vesicular stomatitis vaccine (VSV) for Continue Burkholderia outer membrane vesicle (OMV) vaccine manufacturing Conduct good laboratory practice (GLP) toxicology on Burkholderia OMV vaccine Initiate good manufacturing practice (GMP) manufacturing of Francisella tular trial. Prepare for surprise by establishing drug discovery and evaluation platform caresponse. Continue to develop and advance animal models to accelerate medical counter respond to emerging biological threats. 	g to support Phase 1 clinical trial. cine prior to entry into Phase 1 clinical trial. rensis (FnIgID) vaccine to support Phase 1 clin apability that can be leveraged during a CBRN				
 FY 2024 Plans: Conduct evaluation of immune modulation strategies as stand alone, in layere Conduct test and evaluation of encapsulation technologies for vaccines that of specific host tissues and tune the immune response resulting in enhanced antig dose. Conduct test and evaluation of mucosal delivery methods for delivery for vaccives with the goal being vaccines with neutralizing efficacy against a respiratelivery has the ability to access unique compartments of immunity through introspecifically to the site of infection of a respiratory pathogen. Prepare for surprise by continuing to establish drug discovery and evaluation CBRN response. Continue to develop and advance animal models to accelerate medical counterespond to emerging biological threats. 	can co-deliver multiple antigens and adjuvants gen efficacy and immediate protection with a s cines that can fine-tune the immune response t ratory exposure to an emerging pathogen. Muc ranasal or oral delivery and target that immunit platform capability that can be leveraged durin	ingle cosal cy g a			

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	hemical and Biological Defense Program Date: March 2023			
Appropriation/Budget Activity 0400 / 3		roject (Numbe N3 / Enabling I	r/Name) nvestments (AT	D)
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
Increase due to change in program/project schedule.				
Title: 5) Advanced Technology Demonstration			- 6.043	5.943
Description: Advanced Technology Demonstrations (ATDs) are Joint Task For on warfighter operational needs that demonstrate and evaluate groupings of int Building on the Technology Concepts and User Assessments thrust areas con- feedback from the Warfighters during ATDs ensures that these technologies are be matured and potentially transitioned in a timely and effective manner to tran employment across the spectrum of Joint Force actions in a chemical, biologica Environment. ATD outcomes area designed to continue optimizing S&T solution can support prioritized operational needs, enhance transition of cutting edge C demonstrating operational utility.	tegrated technologies or prototype systems. ducted earlier in the technology maturation proc e operationally relevant, value added, and can sition partners for advanced development and al, radiological, and nuclear (CBRN) defense ons, demonstrate how maturing technologies	ess,		
FY 2023 Plans:				
 Plan and execute the first ATD under the Tenacious Dragon Campaign that we gather warfighter feedback on capabilities that enable the effective employment protection and mitigation capabilities across medical and non-medical portfolios operational impact of CBRN hazards. Leverage the Services' Future Operating Concepts into the scenario development -Demonstrate technologies from Defense Threat Reduction Agency (DTRA) Tedevelopment, maturation, and transition coordinated with other technologies, e Organization, Training, Materiel, Leadership and education, Personnel, Facilitie Research & Development (R&D) cycle. Expand warfighter participation to include a broad spectrum of warfighters from the scenario for the scenari	t and layering of CBRN awareness, understand s to provide rapid and effective reduction of the ment. echnology Divisions to accelerate and optimize to nhancing capability development and Doctrine, es and Policy (DOTMLPF-P) updates early in the	ng, neir		
 FY 2024 Plans: Continue Tenacious Dragon Campaign ATD. Demonstrate developmental technologies and gather warfighter feedback on and layering of CBRN awareness, understanding, protection and mitigation cap to provide rapid and effective reduction of the operational impact of CBRN haza Demonstrate novel technologies from Defense Threat Reduction Agency (DT optimize their development, maturation, and transition coordinated with other ter DOTMLPF-P updates early in the Research & Development (R&D) cycle. 	pabilities across medical and non-medical portfo ards. RA) Technology Divisions to accelerate and	lios		

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical a		L	Aarch 2023	
Appropriation/Budget Activity 0400 / 3	R-1 Program Element (Number/Name) PE 0603384BP <i>I Chemical and Biological</i> <i>Defense Program - Advanced Development</i>	Project (Number/ EN3 / Enabling Inv	,	D)
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
 Coordinate an active pathway for developmental technologies fro thrust areas to ATDs, where appropriate, to demonstrate feedback facilitate technology transitions. Continue the expansion of the service participation to include participation. 	c-based progress in increasingly complex environments and			
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.				
Title: 6) Technology Concept		-	0.300	1.496
Description: Initiatives prior to and during the development of S& requirements, explore utility including potential applications among stakeholders, including Combat Developers and Service represen Concepts, doctrine, and materiel systems requirements for the fut potential Warfighter utility of emerging technologies and technolog this area focus on Surveys, User Groups, Table Top Exercises (T to develop Use Cases, desired operational capabilities, key attribut utility of emerging technologies and concepts.	g the Services and scope future S&T programs with Warfigl tatives. Results from these experiments shape Operating ure Joint Force and inform technology developers about by concepts for subsequent portfolio investment. Activities TXs), and practical demonstration or User feedback worksh	in iops		
FY 2023 Plans: - Conduct 4-6 technology concept studies, workshops or Focus Gemitigation techniques. Additional technology concepts will be iden maturity, and application to Warfighter needs.		ry,		
FY 2024 Plans: - Explore select technology concepts from an operational perspect utility and application of technological approaches. These include threat diagnosis; improvements to sensitivity, specificity, and the lit therapeutic or medical countermeasure decisions and treatment; r protection guidelines and techniques; and coating concepts for po - Continue to conduct User Feedback Tents for Tech Concepts (C areas for improvement and/or employment of emerging technolog - Continue series of targeted questionnaires/surveys, facilitated fo operational capabilities, key attributes and concepts of employment	autonomous operations; enhanced biothreat detection; CB mit of detection for CB sensors; features of biosensors to in next generation respiratory or physical protection; collective rous surfaces. oncepts Tents) leveraging User community to identify pote- ies. cus groups, workshops and TTXs to define use cases, desi	nform		

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program										larch 2023		
Appropriation/Budget Activity 0400 / 3								EN3 / E	roject (Number/Name) N3 / Enabling Investments (ATD)			
B. Accomplishments/Planned P	rograms (\$ in I	<u>/lillions)</u>							FY 2022	FY 2023	FY 2024	
Operating Concepts and materiel Concept studies/experiments.	requirements. C	Concept Ten	t reports pro	vide tech rec	commendatio	ons for more	detailed Tec	h				
FY 2023 to FY 2024 Increase/De Increase due to change in program			ers.									
Title: 7) User Assessment									-	1.949	1.85	
fit, and function of maturing S&T p environment. The assessments s and partners. User assessments experiments that provide candid for limitations, vulnerabilities and tech FY 2023 Plans:	erve as baselin are characterize eedback focuse	es for future ed by TTXs, d on applica	ATD progra Early User A bility, utility a	ms, and driv Assessments and recomme	e S&T gap a s, Technical ended impro	nalysis for k demonstratio vements wh	ey customers ons and field ile exploring s	3				
- Continue the annual CB Operati	onal Analysis (C	BOA) event	i.									
FY 2024 Plans: - Continue the annual CBOA ever	nt.											
FY 2023 to FY 2024 Increase/De Minor change due to routine progr												
Accomplishments/Planned Programs Subtotals									-	39.540	43.19	
C. Other Program Funding Sum	<u>mary (\$ in Milli</u>	<u>ons)</u>	FY 2024	FY 2024	FY 2024					Cost To)	
Line Item	<u>FY 2022</u>	FY 2023	Base	000	Total	<u>FY 2025</u>	FY 2026	FY 2027		8 Complete		
• EN4: Enabling Investments (ACD&P)	-	6.781	47.272	-	47.272	51.579	9.792	9.840) 9.84	0 Continuing	continuing	
<u>Remarks</u>												
D. Acquisition Strategy												
N/A												

Exhibit R-2A, RDT&E Project Ju	stification	: PB 2024 C	chemical an	d Biologica	l Defense P	rogram				Date: Marc	ch 2023	
Appropriation/Budget Activity 0400 / 3					PE 060338	84BP I Cher	t (Number/ mical and Bi Ivanced De	ological	Project (N ET3 / Eme		,	
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
ET3: Emerging Threats (ATD)	-	0.000	0.000	10.000	0.000	10.000	10.000	10.000	10.000	10.000	Continuing	Continuing
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

Project ET3 aims to identify and develop scientific solutions, or to modernize capabilities, that allow for a more rapid response to emerging threats. This project supports the development of defense capabilities, collaborating across the DoD and specific interagency partners for doctrine, equipment, and training for the Warfighter and civilian population for defense against emerging threats. Additionally, this project supports advanced development of defensive science and technology capabilities aimed at proactive characterization of threats and potentially disruptive technologies.

Individual efforts in this Project include:

- Developing new science and technology capabilities that allow for the rapid characterization of emerging threats to support operational decision making and requirements setting. Support an integrated approach to developing new or enhanced countermeasures against emerging threats through innovative science and technology solutions for detection, protection, decontamination, and medical countermeasures (MCMs).

- Efforts supply test methodologies and supporting science to verify capabilities, develop protection and hazard mitigation options, expand hazard assessment tools, and develop MCMs against emerging threats.

Chemical and Biological Emerging Threat Innovation Fund challenge DoD Labs and innovation cells to deliver transformational technologies against emerging threats that enables the force to compete, deter, and win in strategic environments described in the National Defense Strategy.

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2022	FY 2023	FY 2024
Title: 1) Emerging Threat Innovation	-	-	10.000
Description: The Chemical and Biological Defense Emerging Threat Innovation Fund challenges DoD Labs and innovation cells to deliver transformational technologies against emerging threats that enables the force to compete, deter, and win in strategic environments described in the National Defense Strategy.			
<i>FY 2024 Plans:</i> Initiate enhanced capability to more rapidly characterize, and the development of medical countermeasures against, emerging chemical and biological threats through investment in high throughput technologies. Support development of challenges advancing concept and technology development.			
FY 2023 to FY 2024 Increase/Decrease Statement:			
FY 2023 to FY 2024 Increase/Decrease Statement:			

Exhibit R-2A, RDT&E Project Justif	ication: PB	2024 Chemi	ical and Biol	ogical Defen	se Program				Date: Ma	arch 2023	
Appropriation/Budget Activity 0400 / 3				PE 06	03384BP / C	nent (Numb Chemical and - Advanced I		ET3 / E	(Number/Na merging Thre	,	
B. Accomplishments/Planned Prog	rams (\$ in I	<u>//illions)</u>							FY 2022	FY 2023	FY 2024
FY24 provides funding to address fut	ure concepts	s and innova	tive technolo	ogy developr	ment.						
				Accon	nplishment	s/Planned P	rograms Sub	ototals	-	-	10.000
C. Other Program Funding Summa	ry (\$ in Milli	ons <u>)</u>									
			<u>FY 2024</u>	<u>FY 2024</u>	<u>FY 2024</u>					<u>Cost To</u>	
Line Item	<u>FY 2022</u>	<u>FY 2023</u>	Base	000	<u>Total</u>	<u>FY 2025</u>	FY 2026	FY 2027	FY 2028	<u>Complete</u>	Total Cost
 CA4: Contamination Avoidance (ACD&P) 	37.189	-	-	-	-	-	-	-	-	0.000	37.189
• DE4: Decontamination (ACD&P)	14.747	-	-	-	-	-	-	-	-	0.000	14.747
• IP4: Individual Protection (ACD&P)	4.748	-	-	-	-	-	-	-	-	0.000	4.748
• MT4: <i>Mitigate (ACD&P)</i>	-	17.302	28.785	-	28.785	20.885	15.433	13.369) –	Continuing	Continuing
• PT4: Protect (ACD&P)	-	175.219	179.158	-	179.158	135.096	107.341	123.538	139.376	-	Continuing
• UN4: Understand (ACD&P)	-	52.708	61.638	-	61.638	64.399	48.874	41.264	38.169	Continuing	Continuing
Demerike											

Remarks

D. Acquisition Strategy

N/A

Exhibit R-2A, RDT&E Project Ju	stification	: PB 2024 C	hemical an	d Biologica	l Defense P	rogram				Date: Mar	ch 2023		
Appropriation/Budget Activity 0400 / 3	0400/3				U					Project (Number/Name) CB3 <i>I Chemical Biological Defense (ATD)</i>			
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost	
CB3: Chemical Biological Defense (ATD)	-	28.484	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	28.484	
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-			

A. Mission Description and Budget Item Justification

Project CB3 develops technology advancements for joint service application in the areas of digital battlespace management technologies, protection/ hazard mitigation and detection. These activities will speed maturing of advanced technologies to reduce risk in system-oriented integration/demonstration efforts. After FY 2022, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. CB3 efforts in FY 2022 progress to Projects MT3, PT3, and UN3. This restructuring provides standardization and alignment across CBDP research, development and acquisition efforts.

Individual efforts in this Project include:

- Digital battlespace management focuses on situational awareness and threat agent applications, analytic applications platform for operational situational awareness, non-traditional detection sciences, tactical decision aids, and advanced computational methods.

- Protection/hazard mitigation works to provide technologies that protect from and reduce the impact of both chemical and biological threats and hazards to the Warfighter, weapons platforms, and structures.

- Detection strives to develop technologies for point and standoff detection and identification of both chemical and biological agents.

- Non-Traditional Agent (NTA) Defense includes chemical diagnostics, medical pretreatments, therapeutics, detection, and protection and hazard mitigation.

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2022	FY 2023	FY 2024
Title: 1) Distributed CB Reconnaissance	1.344	-	-
Description: Develop threat sensing and sampling payloads for manned and unmanned aerial system (UAS) and ground (UGS) platforms to enhance early warning and situational awareness of biological and chemical threats. Sensor development will support dismounted reconnaissance and surveillance missions by providing low size, weight, power and cost sensors or sensing/ collection systems that are rugged, rapid and accurate. Early indications from capabilities under CB Reconnaissance will allow for enhanced warning of threats.			
Title: 2) Enhanced/Emerging Biothreat Sensing	2.849	-	-
Description: Establish robust capability to assess emerging and enhanced biological threats to rapidly develop biosensors for detecting emerging or enhanced biological threats. Quickly develop adaptable, analyte-agnostic laboratory and field-forward detection capabilities to provide a spectrum of improved detection assets for novel threats. This thrust area leverages multiomics data science or the combining multiple measurements to inform rational and rapid design and development of biodetection			

I Defense Program		Date: N	larch 2023	
R-1 Program Element (Number/Name) PE 0603384BP <i>I Chemical and Biological</i> <i>Defense Program - Advanced Development</i>				nse (ATD)
	FY	2022	FY 2023	FY 2024
ited for the development of biosensing solution	IS			
		2.598	-	-
warfighter with modernized detection technolo emerging, and mixed chemical hazards.	gies			
		1.094	-	-
nnologies will provide early warning of vapor, ogistics and operator burden. Providing a relia				
		0.781	-	-
bes. These technologies focus on keeping the				
		4.848	-	-
nt Science & Technology Office (JSTO) will ex- ected human biomarkers. Current predictive m patients with comorbidities. Improving on the al and biological agent / agent proxy exposure ing indicators of respiratory infection, determining This capability will enable early implementation mus potentially reducing transmission, morbidit	pand le s. ng on y,			
	R-1 Program Element (Number/Name) PE 0603384BP / Chemical and Biological Defense Program - Advanced Development ited for the development of biosensing solution warfighter with modernized detection technologies emerging, and mixed chemical hazards. enting automated and integrated technologies mologies will provide early warning of vapor, ogistics and operator burden. Providing a relia protective posture of ground and maneuver for nment. or development by pulling technologies develop es. These technologies focus on keeping the P detectors that will protect the general forces , alert, and responds to deliberate releases and the Science & Technology Office (JSTO) will ex- tected human biomarkers. Current predictive m patients with comorbidities. Improving on the al and biological agent / agent proxy exposure ig indicators of respiratory infection, determinin This capability will enable early implementation bus potentially reducing transmission, morbidit	R-1 Program Element (Number/Name) Project (Nu PE 0603384BP / Chemical and Biological CB3 / Chemical Defense Program - Advanced Development FY 2 ited for the development of biosensing solutions FY 2 warfighter with modernized detection technologies emerging, and mixed chemical hazards. enting automated and integrated technologies nologies will provide early warning of vapor, ogistics and operator burden. Providing a reliable protective posture of ground and maneuver forces nment. or development by pulling technologies developed bes. These technologies focus on keeping the P detectors that will protect the general forces and nt Science & Technology Office (JSTO) will expand	R-1 Program Element (Number/Name) PE 0603384BP / Chemical and Biological Defense Program - Advanced Development Project (Number/N CB3 / Chemical Biological Defense Program - Advanced Development ited for the development of biosensing solutions FY 2022 ited for the development of biosensing solutions 2.598 warfighter with modernized detection technologies emerging, and mixed chemical hazards. 1.094 enting automated and integrated technologies nologies will provide early warning of vapor, ogistics and operator burden. Providing a reliable protective posture of ground and maneuver forces nment. 0.781 or development by pulling technologies developed bes. These technologies focus on keeping the P detectors that will protect the general forces and nt Science & Technology Office (JSTO) will expand cted human biomarkers. Current predictive m patients with comorbidities. Improving on the al and biological agent / agent proxy exposures. g indicators of respiratory infection, determining This capability will enable early implementation hus potentially reducing transmission, morbidity,	R-1 Program Element (Number/Name) Project (Number/Name) PE 0603384BP / Chemical and Biological Defense Program - Advanced Development CB3 / Chemical Biological Defention CB3 / Chemical Biological Defention FY 2022 FY 2023 ited for the development of biosensing solutions FY 2022 FY 2023 warfighter with modernized detection technologies emerging, and mixed chemical hazards. 2.598 - enting automated and integrated technologies inologies will provide early warning of vapor, ogistics and operator burden. Providing a reliable protective posture of ground and maneuver forces ment. 0.781 - or development by pulling technologies developed bes. These technologies focus on keeping the P detectors that will protect the general forces and nt Science & Technology Office (JSTO) will expand cted human biomarkers. Current predictive m patients with comorbidities. Improving on the al and biological agent / agent proxy exposures. Ig indicators of respiratory infection, determining This capability will enable early implementation hus potentially reducing transmission, morbidity, 4.848

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	al Defense Program	Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 3		roject (Number/I B3 / Chemical Bi		nse (ATD)
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
Title: 7) CBRN Decision Aids		1.400	-	-
Description: In order to unencumber the warfighter at the tactical edge, contin on End User Devices (EUDs) in both connected and disconnected operations. reducing the burden experienced by the warfighter, while providing accurate, a focus will be put on developing a Contamination Avoidance Decision Aid to infe plan routes around CB hazards.	Capabilities will focus on utilizing automation, ctionable information. During this time period, a	nd		
Another area of focus will be the development of Autonomous Asset Guidance other capabilities developed under the CBRN Decision Aids portfolio to optimiz burden incurred by the warfighter in order to operate them. This capability will Autonomous Assets to improve and refine other CBRN Decision Aids.	e the use of Autonomous Assets and reduce the			
Title: 8) CBRN Situational Awareness		4.264	-	-
Description: To enhance CB Situational Awareness, JSTO will expand the typ assessment capabilities to include fixed-wing and rotary-wing drones of interest and swarms to be modeled.		5		
Virtual Reality (VR) and Augmented Reality (AR) technologies will be leverage rehearsal capabilities that will be integrated into systems widely used by the Jo developed to implement, visualize and account for hazard source terms and pl models. Augmented Reality applications will also be explored for tactical use to the battlefield.	bint Force. Virtual training environments will be umes generated by transport and dispersion (T&			
JSTO will modernize hazard modeling capabilities by adopting a modular fram control systems. JSTO will further enhance hazard modeling by creating a sea and improve urban T&D modeling to support operations in urban and mixed er New state-of-the-art computational fluid dynamics modeling techniques and th be leveraged to increase both speed and accuracy.	amless indoor- to-outdoor T&D modeling capabil avironments.	ty		
JSTO will develop CB health effect modeling software and analytic tools to sup against chemical and biological agents. Epidemiological models will be develo impacts from exposure to, and spread of, infectious biological threat agents to leverage Threat Agent Science (TAS) data to enhance capabilities for modelin	ped that quantify and visualize mission operatio DoD relevant populations. Additionally, JSTO w	nal		

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and B	Biological Defense Program	Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 3	R-1 Program Element (Number/Name) PE 0603384BP <i>I Chemical and Biological</i> <i>Defense Program - Advanced Development</i>	Project (Number/N CB3 / Chemical Bio		nse (ATD)
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
exposures to traditional and non-traditional CB agents. This will provid accounting for human health effects.	e the warfighter with more accurate casualty estimate	3		
Title: 9) Air Purification Enhancements		0.287	-	-
Description: This effort supports the Expeditionary Collective Protection driven by maintenance and limited service life. Science & Technology reduce lifecycle costs while maintaining or improving protection.				
Title: 10) All-Hazards & Respiratory Protection		0.814	-	-
Description: This effort supports the Respiratory and Ocular Protection protection while maintaining warfighter capability through integrated resperform early surveys for end-user jury input; frequent user operational Breathing Apparatus.	search on respirator, seams, closures, and new mater	als;		
Title: 11) Dynamic Multifunction Materials for Second Skin		1.313	-	
Description: This effort supports the Percutaneous Protection. Efforts protective suits that adapt to the environment by synthesizing scaled sa properties that reduce thermal burden and integrate with current comba	amples via roll-to-roll manufacture which exhibit mater	als		
<i>Title:</i> 12) Enhanced Survivability Coatings		0.345	-	-
Description: This effort supports the Materiel Contamination Mitigation logistically intensive to decontaminate. Efforts within this thrust seek to warfare agent survivability and decontaminability of military equipment coatings will resist chemical agent absorption and be quickly decontaminate operations level.	p produce enhanced coatings that increase chemical to levels comparable to that of stainless steel. Improv	ed		
Title: 13) Equipment Decontamination		0.649	-	
Description: This effort supports the Materiel Contamination Mitigation personal equipment, weapons, vehicles, ships, and facilities; Sensitive interior spaces, and aircraft); and hazardous waste. Efforts within this the procedures that reduce or eliminate residual contamination hazards; er reduce logistic needs (need for water); enable rapid sorting of clean from the sense of	equipment (weapon system optics, electronic equipment thrust seek to develop decontaminant formulations an nable unit-level decontamination with rapid unmasking	ent, d		

Exhibit R-2A, RDT&E Project Justi	fication: PB	2024 Chem	ical and Biol	ogical Defen	nse Program				Date: M	arch 2023	
Appropriation/Budget Activity 0400 / 3				PE 06	03384BP / 0	ment (Numb Chemical and - Advanced		CB3 /	ct (Number/N Chemical Bio		se (ATD)
B. Accomplishments/Planned Prog	grams (\$ in I	<u> Millions)</u>						ſ	FY 2022	FY 2023	FY 2024
use; and develop improved realistic f flexibility, and reduced logistical burc								3			
Title: 14) Lightweight Protective Gar	ments								0.144	-	-
Description: This effort supports the with new capabilities using integrated protection technologies, and support test garments.	d garment de	signs and fa	brication for	thermal bur	den reductio	n, state-of-th	e-art threat	J. J			
Title: 15) Multifunctional Materials for	or Protection								1.040	-	-
Description: This effort supports the Protection, Materiel Contamination M integrate novel, reactive/catalytic ma characterize materials using state-of generation decontaminants, coatings	Aitigation, and Iterials and so -the-art in op	d Personnel cale material erando and	Contaminati I manufactur ambient pres	on Mitigatior ing with max ssure spectre	n. Efforts wi kimum sorpti oscopies, fo	ll discover, d on and react r eventual int	evelop and ivity, and ægration into	next			
Title: 16) Personnel Decontaminatio	n								4.714	-	-
Description: This effort supports the decontamination of unbroken skin will logistics burdens to warfighters for m Warfare Agent (CWA) exposure by id well as possible substitutions for current statement.	ith lower lifec nass casualty dentifying sci	ycle costs and decontamin ence and tee	nd storage c ation. Decre chnology gaj	onstraints ar ease Warfigl ps in the ma	nd determina hter burden i ss personne	ation of time, n the event o	efficacy and of a Chemica	l			
				Accor	nplishment	s/Planned P	rograms Su	btotals	28.484	-	-
C. Other Program Funding Summa	ary (\$ in Milli	<u>ons)</u>	FY 2024	FY 2024	FY 2024					Cost To	
Line Item • CA4: Contamination Avoidance (ACD&P)	<u>FY 2022</u> 37.189	<u>FY 2023</u> -	Base	<u>0C0</u>	<u>Total</u>	<u>FY 2025</u> -	<u>FY 2026</u> -	<u>FY 202</u>	<u>27 FY 2028</u> 	<u>Complete</u> 0.000	
• DE4: Decontamination (ACD&P) • MT4: Mitigate (ACD&P)	14.747 -	17.302	- 28.785	-	- 28.785	- 20.885	- 15.433	13.36	 69 -	0.000 Continuing	14.747 Continuing

Exhibit R-2A, RDT&E Project Just	tification: PB	2024 Chemi	ical and Biolo	ogical Defen	se Program				Date: Ma	rch 2023	
Appropriation/Budget Activity				R-1 Pi	ogram Eler	nent (Numb	er/Name)	Project (N	Number/Na	ime)	
0400/3						Chemical and	•		emical Biolo	ogical Defen	se (ATD)
				Defen	se Program	- Advanced	Development				
C. Other Program Funding Summ	ary (\$ in Milli	ons <u>)</u>									
			<u>FY 2024</u>	<u>FY 2024</u>	<u>FY 2024</u>					Cost To	
Line Item	<u>FY 2022</u>	FY 2023	Base	000	<u>Total</u>	<u>FY 2025</u>	FY 2026	<u>FY 2027</u>	<u>FY 2028</u>	<u>Complete</u>	Total Cost
 TT4: Technology 	0.740	-	-	-	-	-	-	-	-	0.000	0.740
Transition (ACD&P)											
UN4: Understand (ACD&P)	-	52.708	61.638	-	61.638	64.399	48.874	41.264	38.169	Continuing	Continuing
<u>Remarks</u>											

D. Acquisition Strategy

N/A

Exhibit R-2A, RDT&E Project Ju	stification	: PB 2024 C	Chemical and	d Biologica	Defense P	rogram				Date: Marc	ch 2023	
Appropriation/Budget Activity 0400 / 3					PE 060338	am Elemen 34BP / Cher rogram - Ac	nical and B	iological	Project (N NT3 / Non-		ne) Agents Defe	ense (ATD)
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
NT3: Non-Traditional Agents Defense (ATD)	-	10.843	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	10.843
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

Project NT3 develops future capabilities against emerging and novel threats and verifies current capabilities against Non-Traditional Agents (NTAs). This project focuses on demonstrating fast and agile scientific responses to enhance or develop capabilities that address emerging threats. This project is a comprehensive and focused effort for developing NTA defense capabilities, coordinated with specific interagency partners for doctrine, equipment, and training for the Warfighter and civilian population for defense against NTAs. This project supports advanced technology development of NTA defense science and technology initiatives and transitioning to advance development. After FY 2022, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. NT3 efforts in FY 2022 progress to Project UN3. This restructuring provides standardization and alignment across CBDP research, development and acquisition efforts.

Individual efforts in this Project include:

- Support an integrated approach to develop new or enhanced countermeasures against novel and emerging threats through innovative science and technology (S&T) solutions for detection, protection, decontamination and medical countermeasures (MCMs).

- Efforts supply test methodologies and supporting science to verify capabilities, develop protection and hazard mitigation options, expand hazard assessment tools, and develop MCMs against NTAs.

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2022	FY 2023	FY 2024
Title: 1) Distributed CB Reconnaissance	2.407	-	-
Description: Develop threat sensing and sampling payloads for manned and unmanned aerial system (UAS) and ground (UGS) platforms to enhance early warning and situational awareness of chemical threats. Sensor development will support dismounted reconnaissance and surveillance missions by providing low size, weight, power and cost sensors or sensing/collection systems that are rugged, rapid and accurate.			
<i>Title:</i> 2) Expeditionary Analytical Toolkit (ExAnT) <i>Description:</i> Provide general and specialized forces with the ability to modernize detection technologies for traditional threats while enhancing detection capabilities for non-traditional, emerging, and mixed chemical hazards.	6.613	-	-
Title: 3) Unconventional Detection Modalities	1.823	-	

Exhibit R-2A, RDT&E Project Justif	ication: PB	2024 Chem	ical and Biol	ogical Defen	ise Program				Date: Ma	arch 2023	
Appropriation/Budget Activity 0400 / 3								Project (Number/Name) NT3 / Non-Traditional Agents Defensent			
B. Accomplishments/Planned Prog	<u>rams (\$ in I</u>	<u>Millions)</u>							FY 2022	FY 2023	FY 2024
Description: Develop disruptive tech that can operate in complex threat en Joint Force mission needs (e.g., expe	vironments	with high fide	elity. This th	rust area su	pports other	thrust areas					
				Accon	nplishment	s/Planned P	rograms Sub	ototals	10.843	-	
C. Other Program Funding Summa	ry (\$ in Milli	<u>ons)</u>									
			<u>FY 2024</u>	<u>FY 2024</u>	<u>FY 2024</u>					<u>Cost To</u>	
Line Item	FY 2022	FY 2023	<u>Base</u>	000	Total	FY 2025	FY 2026	FY 2027	7 <u>FY 2028</u>	Complete	Total Cost
 CA4: Contamination Avoidance (ACD&P) 	37.189	-	-	-	-	-	-	-	-	0.000	37.189
• DE4: Decontamination (ACD&P)	14.747	-	-	-	-	-	-	-	-	0.000	14.747
IP4: Individual Protection (ACD&P)	4.748	-	-	-	-	-	-	-	-	0.000	4.748
• MT4: <i>Mitigate (ACD&P)</i>	-	17.302	28.785	-	28.785	20.885	15.433	13.369) -	Continuing	Continuing
• PT4: Protect (ACD&P)	-	175.219	179.158	-	179.158	135.096	107.341	123.538	3 139.376	•	Continuin
• UN4: Understand (ACD&P)	-	52.708	61.638	-	61.638	64.399	48.874	41.264		Continuing	
Remarks										C	

D. Acquisition Strategy

N/A

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program											Date: March 2023		
Appropriation/Budget Activity 0400 / 3										t (Number/Name) Techbase Medical Defense (ATD)			
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost	
TM3: Techbase Medical Defense (ATD)	-	144.779	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	144.779	
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-			

A. Mission Description and Budget Item Justification

Project TM3 supports preclinical and early phase clinical development of vaccines, therapeutic drugs, and diagnostic capabilities to provide safe and effective medical defense against validated biological threat agents or emerging infectious disease biothreats including bacteria, toxins, and viruses. After FY 2022, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. TM3 efforts in FY 2022 progress to Projects EN3, MT3, PT3, and UN3. This restructuring provides standardization and alignment across CBDP research, development and acquisition efforts.

Individual efforts in this project include:

- Innovative biotechnology approaches to advance medical systems designed to rapidly identify, diagnose, prevent, and treat disease due to exposure to biological threat agents will be evaluated.

- Rapid development of medical countermeasure solutions is a crucial modernization strategy to avoid technological surprise against an expanding and sophisticated biological weapons of mass destruction (WMD) threat. Techbase Medical Defense (ATD), therefore, supports the Discovery of Medical Countermeasures Against New and Emerging (DOMANE) threat thrust, which is designed to develop technologies that support understanding, mitigating, and protecting against new and emerging biological threats to include viral, bacterial, and biotoxins.

- Supports the advanced development of medical countermeasures to include prophylaxes, pretreatments, antidotes and therapeutic drugs against new and emerging biological threats. Demonstration of safety and toxicity data through adaptive trials for repurposed U.S. Food & Drug Administration (FDA) approved drugs, novel broad-spectrum drugs and drug combinations supporting submitting Investigational New Drug (IND) processes or Emergency Use Authorizations (EUA). Additionally, this effort supports development of technologies that protect, mitigate and understand new and emerging threats by forecasting pathogenesis and toxicity, structural determinations utilizing high throughput systems to identify both host and pathogen targets using advanced Artificial Intelligence (AI) and a curated repository of high-resolution 3D macromolecular structures to generate drug candidates.

- Leverage lessons learned to shorten future emergency response timelines, mitigate impacts of biological threat outbreaks, and create interim capabilities to protect the warfighter. Leveraging interagency, industry, and academia partnership to build the warfighter's bio-armor to protect against biological threat families. Develop alternative vaccine platform technologies and manage awards utilizing go/no-go checkpoints along the development pathway.

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2022	FY 2023	FY 2024
Title: 1) Battlefield Readiness - Chemical and Biological Incidence Preparedness and Response (CBIPR)	4.400	-	-

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	al Defense Program	Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 3		oject (Number/I 13 / Techbase M	,	se (ATD)
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
Description: Provide innovative capabilities to the Warfighter that increase the aid with triage support, and provide diagnosis at lower roles of care. Develop a multiplexed detection of biological and toxin threats. Leverage immunodiagno novel approaches to enable broader and more accurate diagnosis for a range exposure.	ield forward medical diagnostics that allow for stics to identify specific targets using current or	s,		
Title: 2) Diagnostic Building Blocks - Chemical and Biological Incidence Prepa	redness and Response (CBIPR)	2.751	-	-
Description: The Diagnostic Building Blocks thrust area lays a foundation for such as machine learning (ML), synthetic biology and chemistry to develop nor event of an outbreak of an unknown threat.				
Title: 3) Emerging Threats - Chemical and Biological Incidence Preparedness	and Response (CBIPR)	3.851	-	-
Description: Advance the diagnosis of emerging and/or low prevalence but hi technologies. Develop threat agnostic tests based on host biomarkers that ide Characterize markers for antibiotic resistance or susceptibility to identify challe Improve capabilities to identify diverse biological agents that are not well chara approaches.	ntify known or emerging bacterial or viral infection nging threats and inform treatment decisions.	IS.		
Title: 4) Medical Countermeasures Initiative		21.593	-	-
Description: The Chemical Biological Incident Preparedness and Response-N will integrate advances in regulatory science and flexible manufacturing technol and drug discovery and evaluation platforms as enablers of the advanced developments. These initiatives will lead to the establishment of multi-use platforms a CBRN response to accelerate medical product development and/or regulator costs.	ologies and processes; and develop animal mode elopment of CBDP medical countermeasure and animal models that can be leveraged during	S		
Title: 5) Medical Countermeasures Initiative - Validated Nucleic Acid Vaccine	Construction	7.430	-	-
Description: Prototype pan-viral medical countermeasure for the protection age effort will leverage DOD and other interagency partners to develop MCMs for p with existing innovative commercial molecular and synthetic biology technolog	protection against a panel of transmissible viruses			
<i>Title:</i> 6) Battlefield Readiness		9.437	-	-

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical an			larch 2023	
Appropriation/Budget Activity 0400 / 3		oject (Number/I 13 / Techbase M		se (ATD)
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
Description: Develop platforms to prepare the Warfighter with rapid healthy and ready for movement. Platforms developed with affinity-to the pathogen may leverage immunodiagnostics to identify specific approaches. This will enable broader and more accurate diagnosis exposure. Investments in this area will provide capabilities to the W preparedness, aid with triage support, and provide diagnosis at lower preparedness.	based identification of either pathogen or host response c targets using antibodies, or explore other innovative for a range of targets and across a wider window following arfighter that increase the speed of relevancy, enhance troo	5		
<i>Title:</i> 7) Chemical Diagnostics		5.371	-	
Description: Provide innovative and integrated capabilities to the W spectrum. Enhance force protection by investing in diagnostics for e pharmaceutical based agents. Coordinate with the Intelligence Con capabilities to meet the need.	exposure to traditional and nontraditional CWAs, including			
<i>Title:</i> 8) Clinical Evaluation		4.871	-	
Description: Optimize the diagnostic development pathway by inco- informed prototype transition prior to advanced development. Inves through real world, austere environment testing. This area maintain exposed to diseases of interest that would affect the Warfighter in b acquire novel technologies and provide analytical testing, evaluation	tments in this area allow evaluation of diagnostic platforms s access to research sites that offer native populations attlefield settings, and provides the ability to			
<i>Title:</i> 9) Diagnostic Building Blocks		6.456	-	
Description: Develop novel, state of the art capabilities that lay the portfolio. This includes exploiting areas such as synthetic biology at utilization in the event of an outbreak of an unknown threat. Invest i and optimized test parameters through leveraging artificial intelligen and develop assays for emerging threats in days instead of weeks.	nd chemistry to develop novel and rapid diagnostic tests for n efforts that lead to accelerated assay development timeline	es		
<i>Title:</i> 10) Emerging Threats		3.134	-	
Description: Push beyond the boundaries of the traditional threat libevelopment of diagnostic systems that leverage novel approaches the classification of threat (e.g., bacterial vs viral) from an unknown	to characterize pathogen or host response and can identify			

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biolo	ogical Defense Program	Date: N	1arch 2023	
Appropriation/Budget Activity 0400 / 3	R-1 Program Element (Number/Name) PE 0603384BP / Chemical and Biological Defense Program - Advanced Development	Project (Number/N TM3 / Techbase M		se (ATD)
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
actionable information, such as administering the appropriate medical cour medic or primary care provider greatly improves turnaround time for soldie		1		
Title: 11) Bacterial/Viral/Toxin/Broad Spectrum Prophylaxis		30.411	-	-
Description: The ultimate protection of the warfighter is by pretreating the no adverse side effects from the pretreatment. Such pretreatment would e environment, absent of any personal protective equipment allowing operat Element supports de-risking of candidates for transition into advanced dev development, pre-clinical studies for lead candidates to allow initiation of c initiation, animal model development for U.S. Food & Drug Administration Candidates transition into advanced development once the Phase 1 clinical	enable the warfighter to work in a less restrictive ion at peak performance. Investments in this Progreelopment and includes: manufacturing process linical work, regulatory science to support clinical (FDA) animal rule licensure, and Phase 1 clinical tr			
Title: 12) Internal COVID - VSV SARS CoV-2 vaccine		5.100	-	-
Description: Provide the warfighter with protection against Coronavirus D SARS-CoV-2 VSV vaccine.	isease 2019 (COVID-19) through the development	of a		
<i>Title:</i> 13) Bacterial Therapeutics		13.886	-	-
Description: Identify, optimize and evaluate potential therapeutic compou	nds effective against bacterial threat agents.			
<i>Title:</i> 14) Toxin Therapeutics		0.250	-	-
Description: Discover and develop therapeutic countermeasures to protect	ct the warfighter against biotoxin threats.			
<i>Title:</i> 15) Viral Therapeutics		13.887	-	-
Description: Identify, optimize and evaluate potential therapeutic candidate	tes effective against designated viral threat agents.			
Title: 16) Nerve Agent Prophylaxis/Pretreatments		3.352	-	-
Description: Develop pretreatments and prophylactics that counter non-tr threats to protect the lives and effectiveness of our Warfighters, thus main prophylactics will rapidly detoxify a broad spectrum of compounds of intere	taining force strength and force capability. Success	ful		
Title: 17) Pharmaceutical Based Agents (PBAs)		4.065	-	-
Description: Focuses on therapeutic and proactive strategies to effectivel to Pharmaceutical Based Agents (PBAs). This will allow the Warfighter to				

Appropriation/Budget Activity 0400 / 3 B. Accomplishments/Planned Progr battlefield scenario. This effort involve novel drug products to enhance level to develop drug candidates that will ul previously licensed products for new u	es the evalu	<u>/illions)</u>		PE 060	rogram Elen 03384BP / C se Program	hemical and			t (Number/Na Techbase Med		e (ATD)
battlefield scenario. This effort involve novel drug products to enhance level to develop drug candidates that will ul	es the evalu	<u>/lillions)</u>					-				
novel drug products to enhance level o to develop drug candidates that will ul									FY 2022	FY 2023	FY 2024
·······	timately be	n and/or opei submitted fo	rational utility r Food and I	y for the War Drug Adminis	rfighter. Effo stration (FDA	orts in this ar A) licensure o	ea are design				
Title: 18) Reactivators of AChE as Th	erapeutics ((ReACT)							4.534	-	-
Description: The warfighter requires exposure to Nerve Agents (NAs) and a acetylcholinesterase enzyme reactival potential candidates that will ultimately products for new uses in the treatmen	maintain for tion. Efforts y be submitt	ce lethality. in this area ted for U.S. F	This effort ir are focused ood and Dr	nvolves the d	development ion developr	of improved nent and pre	therapies for -clinical studie				
				Accon	nplishments	s/Planned P	rograms Sub	totals	144.779	-	-
C. Other Program Funding Summar	y (\$ in Milli	<u>ons)</u>									
			FY 2024	FY 2024	FY 2024					Cost To	
Line Item	FY 2022	FY 2023	Base	000	<u>Total</u>	FY 2025	<u>FY 2026</u>	FY 202			-
• EN3: Enabling Investments (ATD)	-	39.540	43.196	-	43.196	43.198	44.449	44.449		Continuing	
 EN4: Enabling Investments (ACD&P) 	-	6.781	47.272	-	47.272	51.579	9.792	9.840	9.840	Continuing	Continuin
• MB4: Medical Biological Defense (ACD&P)	46.791	-	-	-	-	-	-	-	-	0.000	46.79
• MT3: Mitigate (ATD)	-	86.157	100.791	-	100.791	89.511	91.704	85.79	5 85.480	Continuing	Continuin
PT3: Protect (ATD)	-	32.113	29.261	-	29.261	48.969	42.794	46.159	9 52.581	Continuing	Continuin
PT4: Protect (ACD&P)	-	175.219	179.158	-	179.158	135.096	107.341	123.53	3 139.376	Continuing	Continuin
• UN3: Understand (ATD)	-	68.415	83.825	-	83.825	81.392	87.384	73.51	5 71.015	Continuing	Continuin
Remarks											
D. Acquisition Strategy											
<u>si / loquioilion oliulogy</u>											
N/A											

Exhibit R-2A, RDT&E Project Ju	stification	: PB 2024 C	chemical and	d Biological	Defense P	rogram				Date: Marc	ch 2023	
Appropriation/Budget Activity 0400 / 3					R-1 Program Element (Number/Name) PE 0603384BP / Chemical and Biological Defense Program - Advanced Development				Project (Number/Name) TT3 / Technology Transition (ATD)			
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
TT3: Technology Transition (ATD)	-	7.589	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	7.589
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

Project TT3 validates high-risk/high-payoff technologies, concepts-of-operations, and a Joint Combat Developer concept development and experimentation process to significantly improve Warfighter capabilities in preparation for transition of mature chemical and biological (CB) defense technologies to advanced development programs. This project addresses the three primary chemical and biological defense thrust areas of Assess, Protect, and Mitigate with an emphasis on Integrated Early Warning (IEW) and Integrated Layered Defense (ILD). IEW is conducted through a coordinated program approach focused on layering chemical and biological detection technologies and integrating CB threat indicators, providing a combination of awareness and understanding that facilitates effective decision making so the force can continue military operations and achieve mission success in a CBRN environment. The ILD achieves solutions for capability gaps across medical and non-medical commodity areas to enable warfighter survival and rapid recovery in a CBRN environment. After FY 2022, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. TT3 efforts in FY 2022 progress to Project EN3. This restructuring provides standardization and alignment across CBDP research, development and acquisition efforts.

Individual efforts in this Project include:

Programs that offer the opportunity to identify and efficiently mature emerging technologies, reduce risks, and finalize engineering and integration efforts.
 Programs that seek to demonstrate the potential for enhanced military operational capability and/or cost effectiveness. Upon conclusion of the technical and operational demonstrations, the user or sponsor provides a determination of the military utility and operational impact of the technology and capability demonstrated. Successfully demonstrated technologies with proven military utility can remain in place for future extended user evaluations, accepted into the advanced stages of the formal acquisition process, proceed directly into limited or full- scale production or be returned to the technical base for further development.

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2022	FY 2023	FY 2024
Title: 1) Advanced Technology Demonstration	4.640	-	-
Description: Advanced Technology Demonstrations (ATDs) facilitate Warfighters and other operational stakeholders' participation in field demonstrations that evaluate integrated technologies or prototype systems with demonstrated technical performance in high fidelity and realistic operating environments. Building on the technology concepts and user assessments thrust areas conducted earlier in the technology maturation process, feedback from the Warfighters during ATDs ensures that these technologies are operationally relevant, value added, and can be matured and potentially transitioned in a timely and effective manner to S&T Managers or transition partners for advanced development and employment across the spectrum of Joint Force actions in a CBRN Defense Environment. In some cases, ATD residuals are left with ATD operating units for extended user			

Exhibit R-2A, RDT&E Project Ju	stification: PB	2024 Chem	cal and Biol	ogical Defen	se Program				Date: Ma	arch 2023	
Appropriation/Budget Activity 0400 / 3				PE 06	03384BP / 0	nent (Numb Chemical and - Advanced		TT3 / Te	(Number/N chnology Tr	ame) ansition (ATL))
B. Accomplishments/Planned P	rograms (\$ in N	<u>Aillions)</u>							FY 2022	FY 2023	FY 2024
evaluations which provides addition transition of cutting edge CBRN to Tactics and Procedures.								nics,			
Title: 2) Technology Concept									1.296	-	-
Description: Initiatives to validate including Combat Developers and and materiel systems requiremen of emerging technologies and tec User Groups, Table Top Exercise desired operational capabilities, k technologies.	d Service represents ts for the future hnology concept s (TTXs), and p	entatives. R Joint Force a ts for subsec ractical dem	esults from t and inform te quent portfoli onstration or	these experi echnology de io investmen User feedba	ments shape evelopers ab it. Activities ack worksho	e Operating (out potential in this area f ops to develo	Concepts, do Warfighter u ocus on Surv p Use Cases	tility ⁄eys,			
Title: 3) User Assessment									1.653	-	-
Description: User Assessments fit, and function of maturing S&T p environment. The assessments of S&T gap analysis for key customed Technical demonstrations and fie improvements while exploring system non-attributional environment.	prototypes and te serve as baseline ers and partners ld experiments t	echnologies es for future . User asse hat provide o	; and as app Advanced T ssments are candid feedb	ropriate, ass echnology D characterize ack focused	ess them wi bemonstratic ed by TTXs, on applicab	thin a simula on (ATD) prog Early User A pility, utility ar	ited operation grams, and d Assessments, nd recommen	nal rive ided			
				Accon	nplishment	s/Planned P	rograms Sul	ototals	7.589	-	-
C. Other Program Funding Sum <u>Line Item</u> • TT4: Technology Transition (ACD&P) <u>Remarks</u> <u>D. Acquisition Strategy</u> N/A	mary (\$ in Milli <u>FY 2022</u> 0.740	ons) FY 2023 -	<u>FY 2024</u> <u>Base</u> -	FY 2024 OCO -	<u>FY 2024</u> <u>Total</u> -	<u>FY 2025</u> -	<u>FY 2026</u> -	FY 2027	FY 2028 -	Cost To Complete 0.000	
DE 0602294DD: Chamical and Di		Due sure us									

PE 0603384BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program

THIS PAGE INTENTIONALLY LEFT BLANK

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item	Exhibit R-2, RDT&E Budget Item Justification: PB 2024 Chemical and Biological Defense Program											
Appropriation/Budget Activity 0400: Research, Development, Te Advanced Component Developme				A 4:	R-1 Progra PE 060388		•	fense Progi	gram - Dem/Val			
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
Total Program Element	0.000	133.902	252.010	316.853	0.000	316.853	271.959	181.440	188.011	187.385	Continuing	Continuing
UN4: Understand (ACD&P)	-	0.000	52.708	61.638	0.000	61.638	64.399	48.874	41.264	38.169	Continuing	Continuing
PT4: Protect (ACD&P)	-	0.000	175.219	179.158	0.000	179.158	135.096	107.341	123.538	139.376	Continuing	Continuing
MT4: Mitigate (ACD&P)	-	0.000	17.302	28.785	0.000	28.785	20.885	15.433	13.369	0.000	Continuing	Continuing
EN4: Enabling Investments (ACD&P)	-	0.000	6.781	47.272	0.000	47.272	51.579	9.792	9.840	9.840	Continuing	Continuing
CA4: Contamination Avoidance (ACD&P)	-	37.189	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	37.189
DE4: Decontamination (ACD&P)	-	14.747	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	14.747
IP4: Individual Protection (ACD&P)	-	4.748	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	4.748
MB4: <i>Medical Biological Defense</i> (ACD&P)	-	46.791	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	46.791
TM4: Techbase Medical Defense (ACD&P)	-	29.687	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	29.687
TT4: Technology Transition (ACD&P)	-	0.740	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.740

A. Mission Description and Budget Item Justification

This program element (PE) resources Advanced Component Development and Prototypes across the Understand, Protect, Mitigate, and Enabling Investments portfolios. Program efforts validate high-risk/high-payoff technologies and their respective concepts of operations for significant improvement to Warfighter capabilities in preparation for the transition of mature technologies to advanced development programs requiring chemical and biological (CB) defense technologies. Chemical Biological Defense Program (CBDP) investments provide an integrated, layered capability to enable Countering Weapons of Mass Destruction (CWMD) missions ranging from combat operations to Department of Defense (DoD) support to domestic incident prevention and response. The Projects in this PE support component and subsystem maturity prior to integration in major, complex systems and may involve risk reduction initiatives and include technology demonstrations. This effort facilitates transitions of Integrated Early Warning and Integrated Layered Defense products. FY24 funding accelerates characterization and situational awareness of emerging biothreats and accelerates delivery of improved protection from and mitigation of biothreats, including rapid repurposing of available therapeutics and development of new vaccines.

Individual Projects include:

PE 0603884BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program

Exhibit R-2, RDT&E Budget Item Justification: PB 2024 Chemical and Biolo	gical Defense Program	Date: March 2023
Appropriation/Budget Activity	R-1 Program Element (Number/Name)	
0400: Research, Development, Test & Evaluation, Defense-Wide I BA 4:	PE 0603884BP I Chemical and Biological De	fense Program - Dem/Val
Advanced Component Development & Prototypes (ACD&P)		

- Understand (UN4): Maintain effort in distinguishing between bacterial, viral, and toxin diagnostics. Update detector libraries for relevant detection and identification systems. Continue efforts to integrate detection capabilities into Service combat platforms. Develop detection and diagnostic technologies with compatibility to receive and transmit sensor data on Service networks. Identify Service concepts for Integrated Early Warning (IEW) and maintain cyber compliance of fielded Chemical Biological Radiological and Nuclear (CBRN) information systems.

- Protect (PT4): Continued efforts to unencumber the warfighter by delivering improved personal protection capabilities that incorporate inherent survivability into Service equipment and platforms and which offer protection against the diverse threat agents that near-peer adversaries are developing. Develop capability for next-generation individual protective equipment. In collaboration with Biomedical Advanced Research and Development Authority (BARDA), develops and tests monoclonal antibody medical countermeasures through Phase 1 clinical trials as an accelerated antibodies program. Develops a robust computational toolset/prototype database intended to decrease product development risk throughout the drug development life cycle, accelerate candidate development, and enable preemptive preparedness and rapid response. Leveraging the Advanced Development Manufacturing Network, delivers the ability to rapidly develop Medical Countermeasures (MCMs) against emerging or known chemical/biological threats by establishing mature platform technologies that allow for rapid response. Develops plague monoclonal antibody-based medical countermeasure prototype through Phase 1 clinical testing. Continues work to deliver prototype nucleic acid-based vaccines for three CBRN and two potential pandemic threats through non-clinical and human Phase I clinical trials.

- Mitigate (MT4): Sustain efforts in antiviral therapeutics. Develop capabilities to incorporate the use of in silico and Machine Learning/Artificial Intelligence technologies for drug discovery and development. Increase efforts regarding platform technologies. Development of repurposing pharmaceuticals that enable a rapid response capability to combat emerging threats. Supports the development of robot decontamination platform systems. Completes prototype development for a sprayable slurry Science & Technology (S&T) transition to decontaminate hardened and sensitive equipment, such as weapon system optics, electronic equipment and spot decontamination on vehicles. Continues prototype development for S&T transitions for tactical temporary coatings that mitigate the effects of a CBRN attack by protecting assets from the effects of chemical warfare agents.

- Enabling Investments (EN4): Development of efforts to evaluate integrated technologies or prototype systems in high fidelity and realistic operating environment, including system-specific efforts that help expedite technology transition from the laboratory to operational use. Increase efforts to improve integration of collective protection into Service major combat platforms.

- Contamination Avoidance (CA4), Decontamination (DE4), Individual Protection (IP4), Medical Biological Defense (MB4), Techbase Medical Defense (TM4) and Technology Transition (TT4) are no longer active FY24 Projects due to budget restructuring.

The projects in this PE support the advanced component technology development phase of the DoD acquisition system and are therefore correctly placed in Budget Activity 4.

ide / BA 4:	R-1 Program Element (Number/Name) PE 0603884BP / Chemical and Biological Defense Program - Dem/Val						
FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total			
133.945	291.364	261.239	-	26	1.239		
133.902	252.010	316.853	-	316.853			
-0.043	-39.354	55.614	-	5	5.614		
-	-						
-	-39.354						
-	-						
-	-						
-	-						
3.700	-						
-3.742	-						
-0.001	-	55.614	-	5	5.614		
les General Red	luctions)			FY 2022	FY 202		
ermeasures agai	inst novel entities ((DOMANE)	-	4.500			
	Co	ongressional Add Subto	tals for Project: TM4	4.500			
		Congressional Add 1	otals for all Projects	4.500			
	133.945 133.902 -0.043 - - - - - 3.700 -3.742 -0.001 les General Rec	133.945 291.364 133.902 252.010 -0.043 -39.354 - - les General Reducti	133.945 291.364 261.239 133.902 252.010 316.853 -0.043 -39.354 55.614 - - - - -39.354 - - - - <	133.945 291.364 261.239 - 133.902 252.010 316.853 - -0.043 -39.354 55.614 - - - - <t< td=""><td>133.945 291.364 261.239 - 26 133.902 252.010 316.853 - 31 -0.043 -39.354 55.614 - 5 - - - - 5 - - - - 5 - - - - 5 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -</td></t<>	133.945 291.364 261.239 - 26 133.902 252.010 316.853 - 31 -0.043 -39.354 55.614 - 5 - - - - 5 - - - - 5 - - - - 5 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -		

FY 2023 (-\$39.354 Million): Congressional Directed Reductions.

FY 2024 (\$55.614 Million): Increase for medical countermeasure manufacturing optimization (+\$38.100 Million), Departmental inflation rate adjustments (+\$1.266 Million); and Compact Vapor Chemical Agent Detector activities in support of MS B, Antiviral Oral Therapeutic natural history study, Reactivating Nerve Agent Treatment System animal model development, and additional enhanced biodefense priority efforts (+\$16.248 Million).

Schedule: N/A

l	UNCLASSIFIED	
Exhibit R-2, RDT&E Budget Item Justification: PB 2024 Chemical and Bi	iological Defense Program	Date: March 2023
Appropriation/Budget Activity 0400: Research, Development, Test & Evaluation, Defense-Wide I BA 4: Advanced Component Development & Prototypes (ACD&P)	R-1 Program Element (Number/Nam PE 0603884BP / Chemical and Biolog	
Technical: Provides for critical new start programs Advanced Differe TX), Botulinum Toxin Treatment program (BOT Tx), Consolidated Ne Monitoring Sensor Suite (PM2S), and the Reactivating Nerve Agent	erve Agent Treatment System (CNATS), C	

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program										Date: Marc	e: March 2023	
Appropriation/Budget Activity 0400 / 4					PE 060388	am Element (Number/Name) B4BP / Chemical and Biological rogram - Dem/Val						
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
UN4: Understand (ACD&P)	-	0.000	52.708	61.638	0.000	61.638	64.399	48.874	41.264	38.169	Continuing	Continuing
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

The Understand Advanced Component Development and Prototypes (ACD&P) Project provides the Joint Force the ability to continually receive information about the Chemical Biological Radiological and Nuclear (CBRN) situation at a desired time and place by detecting, identifying, and quantifying CBRN hazards in air, water, or on land, and on personnel, equipment or facilities. Efforts also develop a clear understanding of the current and predicted CBRN situation; collect, query, and assimilate information from sensors in real time to inform decisions and provide impacts of CBRN hazards. In FY 2023, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. UN4 efforts in FY 2022 remain in Project CA4. This restructuring provided standardization and alignment across CBDP research, development and acquisition efforts.

Efforts included in this Project are:

(1) Advanced Differential Diagnostics (ADD)

(2) Advanced Emerging Threat Defense (AET DEFENSE)

(3) Biological Defense Improvement Program (BDIP)

(4) Non-Targeted Sequencing Identification System (NSIS)

(5) Physiological Monitoring Sensor Suite (PM2S)

(6) Colorimetric Indicator (C-IND)

(7) CBRN Support to Command and Control (CSC2)

(8) Compact Vapor Chemical Agent Detector (CVCAD)

(9) Proximate Chemical Agent Detector (PCAD)

(10) Surveillance and Pathogen Characterization-Enhanced Biodefense (SPCHAR-ENBD)

The Advanced Differential Diagnostics (ADD) is a new start program in FY24 and will determine if an individual has likely been infected and the nature of that infection, during early stages of illness for unknown threats, including biological warfare agents and emerging infectious diseases. ADD will provide timely feedback for disease prevention in operational environments, by quickly identifying warfighters who may have contracted illness. ADD will utilize funding to initiate Technology Maturation and Risk Reduction activities, including the development and assessment of selected candidate prototypes.

The Advanced Emerging Threat Defense (AET DEFENSE) program continues to address the highest priority CBRN gaps and supports the CBDP Strategic Line of Effort to meet current and emerging threats by anticipating CB hazards and identifying capabilities to counter emerging and future threats. The AET DEFENSE program collaborates with the Joint Services, interagency, and international partners to align RDT&E resources to determine readiness against emerging threats, to include Non-Traditional Agents (NTAs), such as Novichoks and Pharmaceutical-Based Agents (PBA) (e.g. synthetic opioids), emerging biological threats, toxins and other

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program Date: March 2023						
0400/4	R-1 Program Element (Number/Name) PE 0603884BP <i>I Chemical and Biological</i> <i>Defense Program - Dem/Val</i>		umber/Name) erstand (ACD&P)			

advanced and emerging threats as they are identified across the entire CBDP enterprise portfolio. In FY24, AET Defense activities continue to focus on demonstrating and evaluating technologies to assess performance against emerging threats.

The Biological Defense Improvement Program (BDIP) will enhance the set of biodefense capabilities to significantly improve its ability to rapidly understand, prevent, prepare for, respond to, and recover from a vast array of future biological threats. BDIP will support the Department of Defense (DoD) CBDP mission with rapid prototyping capabilities to understand, and protect against threats. BDIP will address joint and service gaps and priorities related to biodefense, and will develop and execute a biodefense strategy. It considers the Biological Warfare threat and vulnerabilities to give biodefense the agility and speed necessary to provide relevant, effective, affordable, and sustainable capabilities that can be ubiquitously deployed on the battlefield against current, emerging and future biological threat. The DoD with academia, industry and other interagency departments will partner to gain opportunities to accelerate technology, adopt surge capacity and advance consumable and alternative solution across the entire Biodefense portfolio. BDIP transitions efforts to the Non-Targeted Sequencing Identification System (NSIS), Wearable All Hazard Remote Monitoring Program (WARP), Far Forward Biological Sequencing (FFBS), and the Physiological Monitoring Sensor Suite (PM2S) programs in FY24.

The Non-Targeted Sequencing Identification System (NSIS) provides a commercially available, rapid biological sequencing capability with the potential to identify an unlimited number of biological warfare agents (BWA), including emerging, engineered, or enhanced organisms on or near the objective. This reduces unknown identification time from days to hours, enabling decision support to all Command echelons (tactical, operational, strategic) at the speed of need. The NSIS itself is a small, portable device (about the size of tablet) that weighs approximately 5 lbs. It comes equipped with consumables (flow cells) that are small, electronic chips for processing the biological sample. Early testing will include operational demonstrations and user touchpoints with the National Guard Bureau to develop the necessary procedures for processing low- and high-density samples. Unlike traditional identification techniques in the field, NSIS identifies anomalies in Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA) and translates the data on a small computing device, enabling fast and effective mitigation and protection for the force. This capability can determine whether the enemy is using synthetic biology for the purpose of thwarting traditional medical countermeasures or current detection/identification devices. FY24 funding will be used for initial test articles, initial verification and validation of current commercial off-the-shelf (COTS) solutions, and nominal program support costs.

The Physiological Monitoring Sensor Suite (PM2S) is a new start program in FY24 that transitions out of the BDIP effort. It will develop CBRN exposure software algorithms that analyze physiological data collected from wearable sensors. These algorithms will provide commanders with actionable information to maximize warfighter readiness, performance, and enhance resiliency before, during, and after CBRN operations. Capabilities developed will integrate with the Chemical and Biological Wearables - Enhanced Biodefense (CB WEARABLES-ENBD) solution set to enable the Joint force to conduct force-wide monitoring to detect the presence or predict initial onset of CBRN threats under an integrated layered defense approach.

The Colorimetric Indicator (C-IND) is a new start program in FY24 and will provide the General Forces with low-cost, easy to use, higher confidence liquid, solid and vapor hazard detection capabilities for traditional and emerging (e.g. PBAs, NTAs in various states of matter) chemical hazards. The intent of the C-IND program is to provide improved hazard detection and classification performance with reduced false alarm rate, and potential for integration onto unmanned platforms. The C-IND was submitted as a new start pending new requirements to be developed. The C-IND program will provide a significantly better M256 Vapor Card that will address emerging and traditional threats (e.g. PBAs, NTAs in various states of matter) as well as drastically improve the usability/training burden that is associated with current Vapor Card

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical ar	nd Biological Defense Program	Date: N	larch 2023		
Appropriation/Budget Activity 0400 / 4	R-1 Program Element (Number/Name) PE 0603884BP <i>I Chemical and Biological</i> <i>Defense Program - Dem/Val</i>	Project (Number/I UN4 / Understand	derstand (ACD&P)		
as the recognized chemical unmasking tool. In FY24, C-IND will in maturation risk reduction (TMRR) testing activities.	itiate and conduct table top exercises to inform stakehold	er's of requirements	and fund tecl	hnology	
The CBRN Support to Command and Control (CSC2) is the overar CBRN and non-CBRN sensors to achieve needed situational awar Service Computing Environments. CSC2 will establish Service and architecture and deployment environments. FY24 consolidates Mo the currently deployed legacy CBRN information systems and sync continue software developmental testing and start operational testin Capability Releases (MVCR).	eness and understanding to accomplish CBRN integrated Joint All Domain Command and Control (JADC2) compa odernization CBRN Information Systems (MOD CBRN IS) chronization for the sunset of legacy capabilities with the o	I layered defense, in tible CBRN Concept with CSC2 for conti deployment of CSC2	terdependent t of Employme nuous engine . In FY24, CS	with ent (COE) ering of C2 will	
The Compact Vapor Chemical Agent Detector (CVCAD) is designed autonomously, monitor and alert general and specialized units to a mission. The small form factor (less than 2 lbs.) is amenable to bot action and other force protection decisions. In FY24, the CVCAD w	n unsafe environment without further burdening the warfind hear the marfing hear and unmanned aerial or ground system oper	phters payload or interations to enable time	erfering with t		
The Proximate Chemical Agent Detector (PCAD) will be a handhele The technology will provide detection and location of chemical agen a handheld non-contact prototype for trace chemical detection on w Agency Joint Science and Technology Office, and conducts develop	nts on various surfaces and under a variety of environme various surfaces, supports transition of developed prototy	ntal conditions. FY2	24 funding de	velops	
The technology will provide detection and location of chemical age a handheld non-contact prototype for trace chemical detection on v	nts on various surfaces and under a variety of environme various surfaces, supports transition of developed prototy opmental testing of breadboard prototypes. Tense (SPCHAR-ENBD) will utilize Pathogenicity Studies s. Results from these studies will be utilized to identify tar	ntal conditions. FY2 bes from the Defense to investigate develo	24 funding de e Threat Redu opment of dise	velops uction ease of	
The technology will provide detection and location of chemical age a handheld non-contact prototype for trace chemical detection on v Agency Joint Science and Technology Office, and conducts develo The Surveillance and Pathogen Characterization-Enhanced Biodef CBRN threat agents and verify usefulness of these disease models development, testing, and identify groups of CBRN threat agents th	nts on various surfaces and under a variety of environme various surfaces, supports transition of developed prototy opmental testing of breadboard prototypes. Tense (SPCHAR-ENBD) will utilize Pathogenicity Studies s. Results from these studies will be utilized to identify tar	ntal conditions. FY2 bes from the Defense to investigate develo	24 funding de e Threat Redu opment of dise	velops uction ease of	
The technology will provide detection and location of chemical age a handheld non-contact prototype for trace chemical detection on v Agency Joint Science and Technology Office, and conducts develo The Surveillance and Pathogen Characterization-Enhanced Biodef CBRN threat agents and verify usefulness of these disease models development, testing, and identify groups of CBRN threat agents th	nts on various surfaces and under a variety of environme various surfaces, supports transition of developed prototy opmental testing of breadboard prototypes. Tense (SPCHAR-ENBD) will utilize Pathogenicity Studies s. Results from these studies will be utilized to identify tar	ntal conditions. FY2 bes from the Defense to investigate develo gets for MCM (Medic	24 funding de e Threat Redu opment of dise cal Counterme	velops uction ease of easures)	
The technology will provide detection and location of chemical ager a handheld non-contact prototype for trace chemical detection on v Agency Joint Science and Technology Office, and conducts develo The Surveillance and Pathogen Characterization-Enhanced Biodef CBRN threat agents and verify usefulness of these disease models development, testing, and identify groups of CBRN threat agents th B. Accomplishments/Planned Programs (\$ in Millions)	nts on various surfaces and under a variety of environme various surfaces, supports transition of developed prototy opmental testing of breadboard prototypes. Tense (SPCHAR-ENBD) will utilize Pathogenicity Studies s. Results from these studies will be utilized to identify tar	ntal conditions. FY2 bes from the Defense to investigate develo gets for MCM (Medic	24 funding de e Threat Redu opment of dise cal Counterme	velops uction ease of easures) FY 2024	
The technology will provide detection and location of chemical ages a handheld non-contact prototype for trace chemical detection on v Agency Joint Science and Technology Office, and conducts develo The Surveillance and Pathogen Characterization-Enhanced Biodef CBRN threat agents and verify usefulness of these disease models development, testing, and identify groups of CBRN threat agents th B. Accomplishments/Planned Programs (\$ in Millions) <i>Title:</i> 1) ADD	nts on various surfaces and under a variety of environme various surfaces, supports transition of developed prototy opmental testing of breadboard prototypes. Tense (SPCHAR-ENBD) will utilize Pathogenicity Studies s. Results from these studies will be utilized to identify tar nat can be treated by broad-spectrum MCMs.	ntal conditions. FY2 bes from the Defense to investigate develo gets for MCM (Medic	24 funding de e Threat Redu opment of dise cal Counterme	velops uction ease of easures) FY 2024	

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	al Defense Program		Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 4	-	ct (Number/I Understand	,		
B. Accomplishments/Planned Programs (\$ in Millions)		[FY 2022	FY 2023	FY 2024
Program/project is new start effort in FY 2024.					
Title: 2) AET DEFENSE			-	2.792	6.629
Description: AET Defense activities will focus on demonstrating and evaluating emerging threats.	ng technologies to assess performance against				
FY 2023 Plans: Continue efforts to address emerging biological threats and Pharmaceutical Bahazard data management tools to incorporate emerging threat information. Provide and decontamination capabilities against new requirements and inform rapid firsupport Joint Service and interagency tactics, techniques, and procedures (TT solutions. Monitor market surveys and assessments of technologies for rapid firmitigate emerging threat gaps as threats are identified.	oduce additional data to better assess detectio elding decisions. Conduct table top exercises P) development and gaps analysis for materiel	n to			
FY 2024 Plans: Continue efforts to address emerging biological threats and Pharmaceutical Ba and assessment of ability to detect and mitigate three additional threat classes management tools to incorporate emerging threat information. Produce addition capabilities against new requirements and inform rapid fielding decisions. Con threat materials to support Joint Service and interagency tactics, techniques, a analysis for materiel solutions. Monitor market surveys and assessments of te mitigate defensive capability gaps as emerging threats are identified.	b. Update spectral libraries and hazard data bonal data to better assess detection and defense induct three table top exercises on three addition and procedures (TTP) development and gap				
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to significant increase in quantity of emerging threats being asserdue to a more thorough understanding of all defensive capabilities, not just ser DEFENSE program.					
Title: 3) BDIP			-	2.398	-
Description: Product Development, Program Management, Test and Evaluation	on and Support.				
FY 2023 Plans: Initiate market research and conduct a requirements table top exercise in orde request for white papers for prototyping plan#1 and Other Transactional Agree FY 2023 to FY 2024 Increase/Decrease Statement:		and			

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical a	R-1 Program Element (Number/Name)		March 2023	
Appropriation/Budget Activity 0400 / 4	Project (Number/ UN4 / Understand			
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
Program/project funding transferred to another funding line. BDIP f System (NSIS), Wearable All Hazard Remote Monitoring Program Physiological Monitoring Sensor Suite (PM2S) programs in FY24.				
Title: 4) NSIS		-	-	0.65
Description: Test and Evaluation, Product Purchase, and Program	n Management Support.			
FY 2024 Plans: Conduct initial verification and validation of commercial-off-the-she Technologies MinION Mk1C genomic sequencing devices, and as US Marine Corps. Continue user feedback trials with the National labor, office management, and administrative processes to include budgeting and programming, milestone and schedule tracking.	sess military utility for the National Guard Bureau, US Nav Guard Bureau Civil Support Teams. Funds will pay for pro	/y, and ogram		
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project funding transferred from another funding line. Pro	gram/project funding transferred from BDIP.			
<i>Title:</i> 5) PM2S		-	-	1.20
Description: This effort will develop algorithms to detect chemical	and biological threats.			
FY 2024 Plans: PM2S will develop and conduct software hardening on chemical ar enable capabilities to be deployed on a number of service-sponsor		to		
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project is new start effort in FY 2024.				
Title: 6) C-IND		-	-	1.04
Description: Program Development				
FY 2024 Plans: Initiate and conduct table top exercises to inform stakeholder's of r (TMRR) testing activities.	equirements and fund technology maturation risk reduction	on		
			1	

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemica	I and Biological Defense Program R-1 Program Element (Number/Name)		Aarch 2023		
Appropriation/Budget Activity 0400 / 4		ect (Number/Name) I Understand (ACD&P)			
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024	
Program/project is new start effort in FY 2024.					
<i>Title:</i> 7) CSC2		-	18.168		
Description: Automated Warning, Reporting, Analysis and Decis (COE) Convergence.	sion Support Tools. Service Common Operating Environme	nt			
FY 2023 Plans: Advanced development of next generation warning and reporting Integration of Non CBRN Data source into decision support tools Common Operating Environments and Computing Environments investments in artificial intelligence and machine learning applica systems engineering.	s. Initial convergence of CBRN information onto Service s (CoEs/CEs) and associated Cyber security requirements.				
FY 2023 to FY 2024 Increase/Decrease Statement: Effort consolidated to single effort "CSC2 Execution Phase of So Development, Integration, and Delivery" in FY24.	oftware Acquisition pathway, and Continuous Software				
Title: 8) CSC2		-	2.800		
Description: Program Management and Support					
FY 2023 Plans: Continue Program office management and administration proces justification, budgeting and programming, milestone and schedul		9			
FY 2023 to FY 2024 Increase/Decrease Statement: Effort consolidated to single effort "CSC2 Execution Phase of So Development, Integration, and Delivery" in FY24.	oftware Acquisition pathway, and Continuous Software				
Title: 9) CSC2		-	12.380		
Description: Product Development, Integration and Sensor Mar	nagement				
FY 2023 Plans: Continue integration of Chemical Biological Radiological and Num management system to include data visualization, analysis and r network.		e			
FY 2023 to FY 2024 Increase/Decrease Statement:					

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Chemical and Biological Chemical and Biological Chemical Chemic		Date: March 2023			
Appropriation/Budget Activity 0400 / 4	Project (I UN4 / Uni		,		
B. Accomplishments/Planned Programs (\$ in Millions)	F	Y 2022	FY 2023	FY 2024	
Effort consolidated to single effort "CSC2 Execution Phase of Software Ac Development, Integration, and Delivery" in FY24.	quisition pathway, and Continuous Software				
Title: 10) CSC2			-	-	28.039
Description: CSC2 Execution Phase of Software Acquisition pathway, an Delivery	d Continuous Software Development, Integration, a	and			
FY 2024 Plans: Continue to develop CBRN applications to support: CBRN hazard warning modeling: and Decision Support Tools. Continue the development of a Clebetween CBRN sensors, CBRN applications, and Service computing envir Development, Security, Operations (DevSecOps) leveraging existing DoD testing and operational testing in support of verifying the iterative, agile soft (MVCR).	oud-Native Software architecture for the interopera ronments. Start a software development pipeline us DevSecOps infrastructure. Continue cybersecurity	ing /			
FY 2023 to FY 2024 Increase/Decrease Statement: Effort consolidated to single effort "CSC2 Execution Phase of Software Ac Development, Integration, and Delivery" in FY24.	quisition pathway, and Continuous Software				
Title: 11) CVCAD			-	13.252	3.600
Description: Prototype Advanced Development, Testing & Program Mana	agement				
<i>FY 2023 Plans:</i> Continue and complete advanced development on prototype systems, confor initiation of engineering development. CVCAD will brief Acquisition Stedecision and prepare for next milestone, Milestone B. Activities will include program office management and administration processes to include programming, milestone and schedule tracking.	eering Panel (ASP) in 2QFY23 to inform milestone e milestone documentation, developmental testing	and			
FY 2024 Plans: Finalization of system design to complete Milestone B. Activities will include program office management and administration processes to include programming, milestone and schedule tracking.					
FY 2023 to FY 2024 Increase/Decrease Statement:					

Exhibit R-2A, RDT&E Project Ju	stification: PB	2024 Chem	ical and Biol	ogical Defen	se Program				Date: N	larch 2023		
Appropriation/Budget Activity 0400 / 4									ect (Number/Name) I Understand (ACD&P)			
B. Accomplishments/Planned P		•							FY 2022	FY 2023	FY 2024	
Decrease due to fact of life chang	e in the program	n/project.										
<i>Title:</i> 12) PCAD									-	0.918	8.48	
Description: Product Developme	nt, Test and Eva	aluation, and	d Program M	anagement.								
FY 2023 Plans: Evaluate prototype development Reduction Agency (DTRA), and c		•••	,,,,		•		Defense Thre	eat				
FY 2024 Plans: Transition breadboard prototypes Reduction phase. Conduct advar include development testing with activities to transition technologies	nced developme troops to suppor	ntal testing or the sting of the store of th	of prototypes B plan in FY	s to execute 25. Continu	an early use e program n	r feedback a	issessment t	o				
FY 2023 to FY 2024 Increase/De Increase supports technology ma technology readiness level asses	turation risk redu	uction activit					ackground te	esting,				
Title: 13) SPCHAR-ENBD									-	-	2.00	
Description: Pathogenicity Studie	es.											
FY 2024 Plans: Initiate studies to investigate CBR	N threat pathog	enesis and/	or pathogeni	city models.								
FY 2023 to FY 2024 Increase/De Additional investment in enhance			preparednes									
				Accor	nplishment	s/Planned P	rograms Su	btotals	-	52.708	61.63	
C. Other Program Funding Sum	<u>mary (\$ in Milli</u>	ons <u>)</u>										
Line Item	FY 2022	FY 2023	<u>FY 2024</u> <u>Base</u>	<u>FY 2024</u> <u>OCO</u>	<u>FY 2024</u> <u>Total</u>	FY 2025	FY 2026	FY 202	7 EV 202	<u>Cost To</u> 8 <u>Complete</u>		
	37.189	<u>- 1 2025</u>	<u>Dase</u> -	-	<u>- 10tai</u>	-	-	<u>1 1 202</u>	<u> </u>	0.000		
 CA4: Contamination 												
 CA4: Contamination Avoidance (ACD&P) CA5: Contamination 	84.967									0.000	84.96	

PE 0603884BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program									Date: Ma	rch 2023	
Appropriation/Budget Activity 0400 / 4						Number/Name) derstand (ACD&P)					
C. Other Program Funding Summa	ry (\$ in Milli	ons <u>)</u>		I				1			
			<u>FY 2024</u>	<u>FY 2024</u>	<u>FY 2024</u>					Cost To	
Line Item	FY 2022	FY 2023	Base	000	<u>Total</u>	<u>FY 2025</u>	FY 2026	FY 2027	<u>FY 2028</u>	Complete	Total Cost
UN5: Understand (SDD)	-	126.071	182.726	-	182.726	137.991	127.671	108.908	68.088	Continuing	Continuing
UN7: Understand (Op Sys Dev)	-	40.414	50.603	-	50.603	58.881	71.869	68.839	50.628	Continuing	Continuing
SA0024: Compact Vapor	-	-	-	-	-	-	0.585	8.200	22.144	Continuing	Continuing
Chemical Agent Detector (CVCAD)										_	-
• SA0050: CBRN	1.750	11.803	2.186	-	2.186	2.257	2.366	2.451	2.549	Continuing	Continuing
Support to C2 (CSC2)										-	-
SA0053: Bio Defense	-	-	-	-	-	-	3.917	17.356	31.850	Continuing	Continuing
Improvement Program (BDIP)										-	
SA0054: Advanced	-	-	-	-	-	-	-	-	4.261	Continuing	Continuing
Differential Diagnostics (ADD)										·	-
<u>Remarks</u>											

D. Acquisition Strategy

Advanced Differential Diagnostics

The Advanced Differential Diagnostic program will utilize Other Transaction Authorization (OTA) project agreements to identify and mature commercial prototypes deemed technologically viable, and evaluate them in as realistic an operational environment as possible. Successful candidate systems will transition to the Engineering and Manufacturing Development phase to be further developed under the OTA agreement, in order to satisfy military and U.S. Food & Drug Administration (FDA) regulatory requirements for subsequent production and fielding to the Services.

ADVANCED AND EMERGING THREAT DEFENSE (AET DEFENSE)

The AET Defense program will use a variety of acquisition approaches to survey, develop, assess, and rapidly field technologies to inform and fill advanced and emerging threat defense capability gaps. The program will utilize existing Multiple Award Indefinite Delivery Indefinite Quantify Task Order Contracts to provide technical support to studies and assessments of performance against emerging threats. For Program of Record (PoR) systems currently in development that will be assessed for performance against emerging threats will be modified to incorporate development engineering and test support for emerging threat capability. The AET Defense program will utilize OTAs for system development and prototyping activities and Government Agencies and Federally Funded Research and Development Centers to provide development, testing and technical support.

BIO DEFENSE IMPROVEMENT PROGRAM (BDIP)

UN	CLASSIFIED	
Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	I Defense Program	Date: March 2023
Appropriation/Budget Activity 0400 / 4	R-1 Program Element (Number/Name) PE 0603884BP / Chemical and Biological Defense Program - Dem/Val	Project (Number/Name) UN4 I Understand (ACD&P)
BDIP will provide and integrate prototypes in cyclic prototyping plan cycles bas acquisition process in order to keep pace with industry and the rapid advancen Middle Tier Acquisition (MTA) enabled by the Other Transactional Agreements the Services as well as laboratories and academia. Successful prototypes will production and eventual fielding across the services. Funding provides marker	nent of technologies. The BDIP strategy is to (OTA) contract vehicle. These prototypes w be evaluated for transition to the platforms a	utilize the rapid prototyping process in ill be demonstrated, evaluated and tested by nd Services for the next steps in acquisition,
Non-Targeted Sequencing Identification System		
The Non-targeted Sequencing Identification System (NSIS) program will utilize and Technology Office, as well as the Joint Project Manager Special Operation commercial off-the-shelf (COTS) solutions to determine the most appropriate s and conduct Developmental Testing with Joint Force end users to evaluate get	ns Forces Far-Forward Biological Sequencer sequencer for use in Joint Service operations.	(FFBS) to develop and assess sequencing
Physiological Monitoring Sensor Suite		
PM2S will follow a presumed software acquisition pathway to harden, test, and deployment across the Joint force. The program will leverage a variety of cont awards and Federally Funded Research and Development Centers.		
Colorimetric Indicator		
The Colorimetric Indicator (C-IND) program will work with the Defense Threat I technologies from Science and Technology to Acquisition. The program will w potential capabilities.		

CBRN SUPPORT TO C2 (CSC2)

CSC2 is executed through the Software Acquisition Pathway, leveraging existing Information Technology Box requirements and Capability Needs Statements (CNS) furnished through the Services and Combatant Commands. CSC2 is executing a modular contracting approach, where the use of Other Transaction Authorities (OTAs), and indefinite delivery/indefinite quantity (IDIQ) will be used to meet agile software objectives of continuous development, integration, delivery, and engineering. CSC2 will establish a Service and Joint All-Domain Command and Control (JADC2) compatible CBRN Common Operating Environment (COE) architecture and leverage existing enterprise Develop Security Operations (DevSecOps) efforts to facilitate continuous and iterative delivery of capability to the Joint Force through the development of a unified software solution.

COMPACT VAPOR CHEMICAL AGENT DETECTOR (CVCAD)

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	Date: March 2023	
0400/4	R-1 Program Element (Number/Name) PE 0603884BP <i>I Chemical and Biological</i> <i>Defense Program - Dem/Val</i>	 umber/Name) erstand (ACD&P)

The CVCAD program will use the Combating Weapons of Mass Destruction Other Transaction Authority (CWMD OTA) contract vehicle to transition four technologies from Science & Technology (S&T) into the program of record. This streamlined acquisition approach is broken into four phases; Phase I S&T advanced development, Phase II technology transition maturation evaluation, Phase III competitive prototyping down select and Engineering decision. CVCAD will brief Acquisition Steering Panel (ASP) in 2QFY23 to inform milestone decision and prepare for next milestone, Milestone B or Middle Tier Acquisition (MTA). Phase IV will execute Production and Development for low rate initial production (LRIP) systems. CVCAD will procure full rate production (FRP) items through a follow-on Federal Acquisition Regulation based contract.

PROXIMATE CHEMICAL AGENT DETECTOR (PCAD)

PCAD will leverage the existing S&T CWMD OTA contract in FY24 to procure prototypes for Technology Maturation Risk Reduction (TMRR) phase. This streamlined approach will use one contracting mechanism to transition technology from S&T to acquisition and allow follow-on acquisitions up through Low Rate Initial Production. PCAD will procure full rate production (FRP) items through a follow-on Federal Acquisition Regulation based contract.

SURVEILLANCE AND PATHOGEN CHARACTERIZATION-ENHANCED BIODEFENSE (SPCHAR-ENBD)

SPCHAR ENBD is an investment program that will leverage interagency partners and existing contracts to investigate disease progression and measure biomarkers of selected CBRN threat agents to inform medical defense against biological warfare threats. The tailored acquisition pathway will allow flexibility to counter new an emerging biothreats.

Exhibit R-3, RDT&E Project Cost Analysis: PB 2024 Chemical and Biologic Appropriation/Budget Activity 0400 / 4						PE 060		umber/Na al and Biol /al	Date: March 2023 Project (Number/Name) UN4 / Understand (ACD&P)						
Product Development (\$ in Millions) FY 2022					2022	FY 2023		FY 2024 Base		FY 2024 OCO		FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
ADD - HW C - Product Management	Various	Various : N/A	-	0.000		0.000		1.938	Dec 2023	-		1.938	Continuing	Continuing	0.000
ADD - HW C - Product Development	C/CPFF	TBD : N/A	-	0.000		0.000		6.950	Mar 2024	-		6.950	Continuing	Continuing	0.000
AET DEFENSE - HW C - Emerging threat detection/ decontamination/protection capability prototyping	MIPR	Various : N/A	-	0.000		0.444	Feb 2023	0.888	Jan 2024	-		0.888	Continuing	Continuing	0.000
AET DEFENSE - HW C - Detection/Decon/ Protection	MIPR	Various : N/A	-	0.000		0.900	May 2023	0.750	Feb 2024	-		0.750	Continuing	Continuing	0.000
AET DEFENSE - SW C - Hazard awareness tool updates	MIPR	Various : N/A	-	0.000		0.500	Apr 2023	0.000		-		0.000	0.000	0.500	0.000
AET DEFENSE - HW C - Emerging Threat Detection	C/CPFF	Johns Hopkins University - Applied Physics Laboratory : Laurel, MD	-	0.000		0.000		0.600	Apr 2024	-		0.600	Continuing	Continuing	0.000
BDIP - HW C - Tabletop Exercise - User Feedback Support	MIPR	Various : N/A	-	0.000		0.368	Oct 2022	0.000		-		0.000	0.000	0.368	0.000
BDIP - HW C - Surveillance and Pathogen Characterization (Genomic Sequencing)	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	-	0.000		1.709	Oct 2022	0.000		-		0.000	0.000	1.709	0.000
NSIS - HW C - COTS Oxford Nanopore MinION Genomic Sequencers and Flow Cells	MIPR	TBD : N/A	-	0.000		0.000		0.215	Dec 2023	-		0.215	Continuing	Continuing	0.000

Exhibit R-3, RDT&E Project Cost Analysis: PB 2024 Chemical and Biologic Appropriation/Budget Activity 0400 / 4						R-1 Program Element (Number/Name) PE 0603884BP / Chemical and Biological Defense Program - Dem/Val						Date: March 2023 Project (Number/Name) UN4 I Understand (ACD&P)					
Product Development (\$ in Millions) FY 2022					FY 2022 FY 2023		FY 2024 Base			2024 CO							
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract		
PM2S - SW C - Physiological Algorithm Development	Various	Various : N/A	-	0.000		0.000		1.000	Dec 2023	-		1.000	Continuing	Continuing	0.000		
C-IND - HW S - Initial Product Planning	Various	Various : N/A	-	0.000		0.000		0.664	Nov 2023	-		0.664	Continuing	Continuing	0.000		
CSC2 - SW S - Government Product Development Team Labor	MIPR	Various : N/A	-	0.000		1.963	Oct 2022	2.028	Dec 2023	-		2.028	Continuing	Continuing	0.000		
CSC2 - SW S - Operational Capability	C/CPAF	Various : N/A	-	0.000		19.816	Oct 2022	11.869	Dec 2023	-		11.869	Continuing	Continuing	0.000		
CSC2 - HW S - Contractor Product Development Team Labor	MIPR	JPEO Chem, Bio, Rad, and Nuc Defense (JPEO- CBRND) : Aberdeen Proving Ground, MD	-	0.000		0.491	Oct 2022	1.846	Dec 2023	-		1.846	Continuing	Continuing	0.000		
CSC2 - SW S - Service CoE and CE Convergence	MIPR	Various : N/A	-	0.000		4.540	Oct 2022	1.200	Dec 2023	-		1.200	Continuing	Continuing	0.000		
CVCAD - HW S - Advanced Prototype Development	C/FFP	Advanced Technologies International : Summerville, SC	-	0.000		6.420	Apr 2023	1.620	Jan 2024	-		1.620	Continuing	Continuing	0.000		
PCAD - HW S - Government Team Labor	Various	Various : N/A	-	0.000		0.000		0.581	Nov 2023	-		0.581	Continuing	Continuing	0.000		
PCAD - HW S - Advanced Prototype Development	C/FFP	Advanced Technologies International : Summerville, SC	-	0.000		0.000		4.808	Nov 2023	-		4.808	Continuing	Continuing	0.000		
SPCHAR-ENBD - Pathogenicity Studies	Various	Various : N/A	-	0.000		0.000		1.678	Dec 2023	-		1.678	Continuing	Continuing	0.000		
SPCHAR-ENBD - Direct Product Support	Various	Various : N/A	-	0.000		0.000		0.147	Dec 2023	-		0.147	Continuing	Continuing	0.000		
		Subtotal	-	0.000		37.151		38.782		-		38.782	Continuing	Continuing	N/A		

Exhibit R-3, RDT&E	•	-	2024 Che	mical and	Biologic		· · ·						March 2	J23	
Appropriation/Budget Activity 0400 / 4								Chemica	umber/Na al and Biol /al	Project (Number/Name) UN4 / Understand (ACD&P)					
Support (\$ in Millions)					FY 2022		FY 2023		FY 2024 Base		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
AET DEFENSE - ES C - Engineering support to evaluating, assessing, and designing capabilities	MIPR	Various : N/A	-	0.000		0.000		0.465	Jan 2024	-		0.465	Continuing	Continuing	0.00
NSIS - ES C - OGA Matrix Labor	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	-	0.000		0.000		0.108	Dec 2023	-		0.108	Continuing	Continuing	0.000
C-IND - Program Support Costs	Various	Various : N/A	-	0.000		0.000		0.075	Nov 2023	-		0.075	Continuing	Continuing	0.00
CSC2 - ES C - Contractor Support	C/CPFF	TBD : N/A,	-	0.000		0.885	Oct 2022	0.768	Nov 2023	-		0.768	Continuing	Continuing	0.00
CSC2 - ES C - Support	MIPR	TBD : N/A,	-	0.000		0.775	Feb 2023	4.551	Mar 2024	-		4.551	Continuing	Continuing	0.00
CVCAD - ES S - OGA Support	MIPR	Various : N/A	-	0.000		2.476	Apr 2023	1.000	Jan 2024	-		1.000	Continuing	Continuing	0.00
PCAD - ES S - OGA Support	MIPR	Various : N/A	-	0.000		0.485	Apr 2023	0.750	Nov 2023	-		0.750	Continuing	Continuing	0.00
	-	Subtotal	-	0.000		4.621		7.717		-		7.717	Continuing	Continuing	N/A
Test and Evaluation (\$ in Millions)			FY 2	2022	FY 2023		FY 2024 Base		FY 2024 OCO		FY 2024 Total				
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
AET DEFENSE - DTE C - Technology Assessments	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center	-	0.000		0.517	Feb 2023	1.750	Jan 2024	-		1.750	Continuing	Continuing	0.000

Appropriation/Budge 0400 / 4	t Activity	/				PE 060		Chemica	l umber/Na al and Biol /al			(Numbei Inderstan		>)	
Test and Evaluation ((\$ in Milli	ons)		FY 2	022	FY 2	2023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
		(CBC) : Aberdeen Proving Ground, MD													
AET DEFENSE - DTE C - Technology Assessments	MIPR	Various : N/A	-	0.000		0.000		0.651	Mar 2024	-		0.651	Continuing	Continuing	0.000
AET DEFENSE - DTE C - Technology Assessments	C/CPFF	Johns Hopkins University - Applied Physics Laboratory : Laurel, MD	-	0.000		0.000		0.650	Apr 2024	-		0.650	Continuing	Continuing	0.000
NSIS - DTE C - Tactics, Techniques & Procedures	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	-	0.000		0.000		0.265	Dec 2023	-		0.265	Continuing	Continuing	0.000
C-IND - DTE S - Initial Test Fixture	Various	Various : N/A	-	0.000		0.000		0.200	Nov 2023	-		0.200	Continuing	Continuing	0.000
CSC2 - OTE S - Technical/ Operational Demo	MIPR	TBD : N/A,	-	0.000		2.548	Feb 2023	2.801	Dec 2023	-		2.801	Continuing	Continuing	0.000
CVCAD - DTE S - MIL STD/Surety Testing	MIPR	Various : N/A	-	0.000		1.981	Aug 2023	0.620	Jan 2024	-		0.620	Continuing	Continuing	0.000
CVCAD - DTE S - Vapor Testing	MIPR	MRIGlobal : Kansas City, MO	-	0.000		0.700	Apr 2023	0.000		-		0.000	0.000	0.700	0.000
PCAD - DTE S - Technology Readiness Evaluation	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	-	0.000		0.348	Apr 2023	1.500	Nov 2023	-		1.500	Continuing	Continuing	0.000
		Subtotal	-	0.000		6.094		8.437		-		8.437	Continuing	Continuing	N/A

PE 0603884BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program

Exhibit R-3, RDT&E F	Project C	ost Analysis: PB 2	024 Che	mical and	l Biologic	al Defens	e Prograr	n				Date:	March 20	023	
Appropriation/Budge 0400 / 4	t Activity	/				PE 060		Chemica	l umber/N a al and Biol /al			: (Numbe i Inderstan		>)	
Management Service	es (\$ in M	illions)		FY 2	2022	FY 2	2023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
ADD - PM/MS S - Management Services	Various	Various : N/A	-	0.000		0.000		1.099	Dec 2023	-		1.099		Continuing	0.000
AET DEFENSE - PM/MS S - IPT Support/Program Management	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	-	0.000		0.431	Dec 2022	0.875	Dec 2023	-		0.875	Continuing	Continuing	0.000
BDIP - PM/MS S - Program Management Support	MIPR	Various : N/A	-	0.000		0.321	Oct 2022	0.000		-		0.000	0.000	0.321	0.000
NSIS - PM/MS S - Program Management Support	MIPR	Various : N/A	-	0.000		0.000		0.065	Dec 2023	-		0.065	Continuing	Continuing	0.000
PM2S - PM/MS C - Management for Algorithm Development	MIPR	Various : N/A	-	0.000		0.000		0.200	Nov 2023	-		0.200	Continuing	Continuing	0.000
C-IND - PM/MS C - Program Management Support	Various	Various : N/A	-	0.000		0.000		0.104	Nov 2023	-		0.104	Continuing	Continuing	0.000
CSC2 - PM/MS C - Program Management Support	MIPR	Various : N/A	-	0.000		2.330	Oct 2022	2.976	Nov 2023	-		2.976	Continuing	Continuing	0.000
CVCAD - PM/MS S - Program Management Support	MIPR	Various : N/A	-	0.000		1.675	Feb 2023	0.360	Jan 2024	-		0.360	Continuing	Continuing	0.000
PCAD - PM/MS S - Program Management	MIPR	Various : N/A	-	0.000		0.085	Mar 2023	0.848	Nov 2023	-		0.848	Continuing	Continuing	0.000
SPCHAR-ENBD - PM/MS SB - Management Support	Various	Various : N/A	-	0.000		0.000			Dec 2023	-				Continuing	
		Subtotal	-	0.000		4.842		6.702		-		6.702	Continuing	Continuing	N/A

PE 0603884BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program

Exhibit R-3, RDT&E Project Cost Analysis: PB 2	024 Che	mical and	Biologic	al Defense	e Progra	m				Date:	March 20)23	
Appropriation/Budget Activity 0400 / 4				PE 0603	3884BP	•	umber/Na al and Biolo /al		Project UN4 / UI	•	r/ Name) d (ACD&F	P)	
	Prior Years	FY	2022	FY 2	023	FY 2 Ba	2024 Ise	FY 2 OC		FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract
Project Cost Totals	-	0.000		52.708		61.638		-		61.638	Continuing	Continuing	N/A

Remarks

Exhibit R-4, RDT&E Schedule Profile: PB 2024 C	hen	nica	and	Bio	logic	cal C	Defei	nse	Prog	ram												Date	e: M	arch	202	3		
Appropriation/Budget Activity 0400 / 4								PE (Prog 0603 ense	884	BP /	Che	emi	cal a	and E									ame A <i>CD</i>				
			2022				2023				2024				2025	1		r	2026	1		-	2027			FY 20		
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
ADD - MDD-Materiel Development Decision											1																	
ADD - MS A-Milestone A																												
ADD - Technology Maturation and Risk Reduction (TMRR)																												
ADD - MS B-Milestone B																												
ADD - Engineering & Manufacturing Development (EMD)																												
AET DEFENSE - Technology Assessments/ Systems Engineering																												
BDIP - Tabletop Exercise - User Feedback Support						-															-							
BDIP - Surveillance and Pathogen Characterization (Genomic Sequencing)																												
NSIS - CDD Validation-Capability Development Document Validation - Requirements Documentation for Joint Force genomic sequencing capability																												
NSIS - MS B-Milestone B - Program Initiation at MS B																												
NSIS - DT&E-Developmental Test and Evaluation - National Guard Bureau testing on proficiency samples and tactics, techniques, and procedures development																												
PM2S - CDD Validation-Capability Development Document Validation																												
PM2S - Systems Engineering/Program Management																												
PM2S - Software Development & Integration																												

PE 0603884BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program UNCLASSIFIED Page 22 of 113

Exhibit R-4, RDT&E Schedule Profile: PB 2024 C	Che	mica	al ar	nd Bio	olog	ical I	Defe	nse	Prog	gran	n										D	ate	: Ma	rch 2	202	3		
Appropriation/Budget Activity 0400 / 4	_							PE (0603	3884		l Che	emi	cal a	mber and E				Proje UN4									
		_	20				202	-		-	2024	ŀ			2025				2026			Y 2	-			FY 2		
	1	2	2	3 4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3 4	4	1	2	3	4	1	2	3	4
C-IND - Pre-Milestone A							_																					
CSC2 - SWP Execution Phase Decision																												
CSC2 - Continuous Software DT/OT																												
CSC2 - MVP (CDP-1)																												
CSC2 - Service Common Operating Environment Integration																												
CSC2 - Cyber Security Compliance																												
CSC2 - CD-Capability Drop - MVCR Delivery 1 (CDP-1)																												
CSC2 - MVP (CDP-2)																												
CSC2 - Continuous Engineering & Software Updates																												
CSC2 - Operating System Architecture Updates																												
CSC2 - CD-Capability Drop - MVCR Delivery 2 (CDP-2)																												
CSC2 - Future MVPs																												
CSC2 - CD-Capability Drop - Future MVCR Deliveries																												
CVCAD - CDD Validation-Capability Development Document Validation																												
CVCAD - MS B-Milestone B																												
CVCAD - CDR-Critical Design Review																												
CVCAD - CDD Update																												
CVCAD - MS C-Milestone C																												
CVCAD - LRIP-Low Rate Initial Production																												
CVCAD - FRP-Full Rate Production Decision																												

PE 0603884BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program UNCLASSIFIED Page 23 of 113

R-1 Line #79

xhibit R-4, RDT&E Schedule Profile: PB 2024	Cher	nica	ıl an	nd E	Biolo	ogic	al D)efer	nse l	Prog	gram												Da	te: N	Лаг	rch 2	023	3		
Appropriation/Budget Activity 400 / 4									PE (0603	gra r 3884 e <i>Pro</i>	BP /	l Ch	emi	cal a	and					-	•				me) CD&	P)			
		FY	202	22			FY 2	2023	3		FY 2	2024	ŀ		FY	202	5		FY	202	5		FY	202	27		F	Y 2	028	
	1	2	3	; ,	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3		4	1	2	3	4
CVCAD - IOC-Initial Operational Capability				·																·						·				
CVCAD - FOC-Full Operational Capability																														
PCAD - MS C-Milestone C																														
PCAD - LRIP-Low Rate Initial Production																														
PCAD - Draft CDD																														
PCAD - MS A-Milestone A																														
PCAD - MS B-Milestone B																														
SPCHAR-ENBD - Pathogenicity Studies																														

ibit R-4A, RDT&E Schedule Details: PB 2024 Chemical and Biological Defense Pro	ogram		Date: Marc	h 2023
0/4 PE 0603	g ram Element (Numbe 884BP / Chemical and Program - Dem/Val		bject (Number/Nam 14 I Understand (ACI	,
Schedule D	etails			
	St	art	En	d
Events	Quarter	Year	Quarter	Year
ADD - MDD-Materiel Development Decision	2	2024	2	2024
ADD - MS A-Milestone A	2	2024	2	2024
ADD - Technology Maturation and Risk Reduction (TMRR)	2	2024	2	2026
ADD - MS B-Milestone B	2	2026	2	2026
ADD - Engineering & Manufacturing Development (EMD)	2	2026	4	2028
AET DEFENSE - Technology Assessments/Systems Engineering	1	2022	4	2028
BDIP - Tabletop Exercise - User Feedback Support	1	2024	4	2024
BDIP - Surveillance and Pathogen Characterization (Genomic Sequencing)	3	2023	4	2024
NSIS - CDD Validation-Capability Development Document Validation - Requirement Documentation for Joint Force genomic sequencing capability	s 4	2023	1	2024
NSIS - MS B-Milestone B - Program Initiation at MS B	1	2024	1	2024
NSIS - DT&E-Developmental Test and Evaluation - National Guard Bureau testing o proficiency samples and tactics, techniques, and procedures development	ⁱⁿ 2	2024	4	2024
PM2S - CDD Validation-Capability Development Document Validation	2	2023	2	2023
PM2S - Systems Engineering/Program Management	2	2024	4	2028
PM2S - Software Development & Integration	2	2024	4	2025
C-IND - Pre-Milestone A	1	2024	4	2024
CSC2 - SWP Execution Phase Decision	2	2023	2	2023
CSC2 - Continuous Software DT/OT	3	2023	4	2028
CSC2 - MVP (CDP-1)	4	2023	4	2023
CSC2 - Service Common Operating Environment Integration	1	2024	4	2028
CSC2 - Cyber Security Compliance	1	2024	4	2028
CSC2 - CD-Capability Drop - MVCR Delivery 1 (CDP-1)	4	2024	4	2025

PE 0603884BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program UNCLASSIFIED Page 25 of 113

propriation/Budget Activity 0 / 4	R-1 Program Elen PE 0603884BP / C Defense Program	chemical and		ect (Number/Nam I Understand (ACI	
		St	art	En	d
Events		Quarter	Year	Quarter	Year
CSC2 - MVP (CDP-2)		4	2024	4	2024
CSC2 - Continuous Engineering & Software Updates		1	2025	4	2028
CSC2 - Operating System Architecture Updates		1	2025	4	2028
CSC2 - CD-Capability Drop - MVCR Delivery 2 (CDP-2)		4	2025	4	2026
CSC2 - Future MVPs		2	2026	4	2028
CSC2 - CD-Capability Drop - Future MVCR Deliveries		4	2026	4	2028
CVCAD - CDD Validation-Capability Development Document Validation		3	2023	3	2023
CVCAD - MS B-Milestone B		4	2023	4	2023
CVCAD - CDR-Critical Design Review		3	2024	3	2024
CVCAD - CDD Update		3	2025	3	2025
CVCAD - MS C-Milestone C		4	2025	4	2025
CVCAD - LRIP-Low Rate Initial Production		4	2026	4	2026
CVCAD - FRP-Full Rate Production Decision		4	2027	4	2027
CVCAD - IOC-Initial Operational Capability		4	2028	4	2028
CVCAD - FOC-Full Operational Capability		4	2028	4	2028
PCAD - MS C-Milestone C		4	2027	4	2027
PCAD - LRIP-Low Rate Initial Production		4	2027	4	2028
PCAD - Draft CDD		2	2024	2	2024
PCAD - MS A-Milestone A		3	2024	3	2024
PCAD - MS B-Milestone B		1	2027	1	2027
SPCHAR-ENBD - Pathogenicity Studies		1	2023	2	2024

Exhibit R-2A, RDT&E Project Ju	ustification	: PB 2024 C	Chemical and	d Biologica	l Defense P	rogram				Date: Marc	ch 2023	
Appropriation/Budget Activity 0400 / 4					R-1 Progra PE 060388 <i>Defense P</i>	4BP / Cher	nical and B	,	Project (N PT4 / Prote		,	
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
PT4: Protect (ACD&P)	-	0.000	175.219	179.158	0.000	179.158	135.096	107.341	123.538	139.376	Continuing	Continuing
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

The Protect Advanced Component Development and Prototypes (ACD&P) Project provides the ability to shield the Joint Force from harm caused by Chemical Biological Radiological and Nuclear (CBRN) hazards by preventing or reducing individual and collective exposures, applying prophylaxis to prevent or mitigate negative physiological effects, and protecting critical equipment. In FY 2023, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. PT4 efforts in FY 2022 remain in Projects IP4, MB4, and TM4. This restructuring provided standardization and alignment across CBDP research, development and acquisition efforts.

Efforts included in this Project are:

- (1) Accelerated Antibodies-Enhanced Biodefense (AA-ENBD)
- (2) Biological Warfare Defense Prototype (BIOPROTO)
- (3) Generative Unconstrained Intelligent Drug Engineering-Enhanced Biodefense (GUIDE-ENBD)
- (4) Medical Countermeasure Platform Technologies (MCMPT)
- (5) Plague Monoclonal Antibodies (PLG MAB)
- (6) Uniform Integrated Protective Ensemble Family of Systems Footwear (UIPE FoS Footwear)
- (7) Vaccine Acceleration by Modular Progression-Enhanced Biodefense (VAMP-ENBD)

The Accelerated Antibodies - Enhanced Biodefense (AA-ENBD) will develop prophylactic and therapeutic monoclonal antibody (mAb) Medical Countermeasure (MCM) against a broad range of biological threats. Funded in FY22 as COVID Therapies Monoclonal Antibodies (COVID TX MAB), this is a continuation which will target the discovery, identification and small scale manufacture of mAbs with sufficient material to support non-clinical and clinical testing. Sufficient doses will be produced and maintained for potential use in emergency response situations. AA-ENBD was formerly known as Monoclonal Antibodies Therapeutics-Enhanced Biodefense (MAB TX-ENBD).

The Biological Warfare Defense Prototype (BIOPROTO) supports early-phase clinical development and supporting non-clinical safety, tolerability and toxicity data for candidate vaccines and therapeutic drugs prior to transition to System Development & Demonstration. This work provides safe and effective medical defense against validated biological threat agents and emerging infectious disease biothreats including bacteria, toxins, and viruses. This work also involves the evaluation of Food and Drug Administration (FDA) approved therapeutics for operational use, as well as generation of novel drug products and formulations, to enhance level of protection and/ or operational utility for the Warfighter. This effort reduces programmatic risk of failure in the advanced development phase.

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	al Defense Program	Date: March 2023
Appropriation/Budget Activity 0400 / 4	R-1 Program Element (Number/Name) PE 0603884BP <i>I Chemical and Biological</i> <i>Defense Program - Dem/Val</i>	Project (Number/Name) PT4 I Protect (ACD&P)
The Generative Unconstrained Intelligent Drug Engineering - Enhanced Biode to decrease product development risk throughout the medical countermeasure preparedness and rapid response. GUIDE impacts the discovery and design drugs through a multi-faceted optimization process capturing critical quality att (PK/PI). Furthermore, GUIDE incorporates computational approaches to man interagency, academia and industry partners and is integrated to the Acceleration develop a fully integrated computational approach to accelerating medical cou	e development life cycle, accelerate candidate of biologics products (e.g., monoclonal antibo ributes of safety, efficacy, manufacturability a ufacturing controls and preclinical/clinical test ted Antibodies and RNA vaccine (VAMP) pro	e development, and enable preemptive idies and vaccines) and small molecule and pharmacokinetics/pharmacodynamics ting. GUIDE is a collaboration between the
The Medical Countermeasure Platform Technologies (MCMPT) program streat known and emerging biological threats by establishing mature platform techno establishing enabling technologies and prepositioning platform systems within network using standardized discovery, design, manufacturing, and testing pro- deliver an enduring capability from which future candidates can be manufactur	logies that allow for rapid response and by re the Department of Defense (DoD)'s Advance cesses to reduce the medical countermeasure	educing developmental risks. MCMPT is ed Development Manufacturing (ADM)
The Plague Monoclonal Antibodies (PLG MAB) program was transitioned in F (ADAMANT), PLG MAB will provide a pre-exposure monoclonal antibody prod route of administration. This capability is complementary to plague therapeutic continues monoclonal antibody discovery and half-life extensions to produce p	luct to protect the Warfighter from aerosolized cs and will provide a continuum of protection	plague and is intended for intramuscular
The Uniform Integrated Protective Ensemble Family of Systems Footwear (UII vapor, dust, particulate, or sporulated toxic material, chemical and biological w Protection Ensemble (UIPE). In FY24 UIPE FoS Footwear will initiate prototyp testing to inform initial down select of alternatives, conduct limited early user to Milestone B 2QFY25.	varfare agents and radiological fallout particle be development to evaluate up to ten footwea	s when worn as part of the Uniform Individua ir alternatives, conduct chemical agent swate

The Vaccine Acceleration by Modular Progression - Enhanced Biodefense (VAMP-ENBD) will leverage lessons learned to shorten future emergency response timelines, mitigate impacts of biological threat outbreaks, and create interim capabilities to protect the Warfighter. Leveraging interagency, industry, and academia partnership, VAMP will continue to build the Warfighter's bio-armor to protect against biological threat families. VAMP will continue to develop alternative vaccine platform technologies and manage awards utilizing go/no-go checkpoints along the development pathway.

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2022	FY 2023	FY 2024
Title: 1) AA-ENBD	-	59.000	67.664
Description: This effort will focus on Accelerated Antibody Development and Production. Target the discovery, identification and small scale manufacture of monoclonal antibodies (mAbs) for 2 additional prototypes, with sufficient material to support non-clinical and clinical testing.			

PE 0603884BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	al Defense Program		Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 4	R-1 Program Element (Number/Name) PE 0603884BP <i>I Chemical and Biological</i> <i>Defense Program - Dem/Val</i>	-	ct (Number/I Protect (ACD	,	
B. Accomplishments/Planned Programs (\$ in Millions)			FY 2022	FY 2023	FY 2024
FY 2023 Plans: Initiate Nonclinical Investigational New Drug (IND) enabling testing for the first	2 prototypes.				
FY 2024 Plans: Initiate phase 1 clinical studies for the first 2 mAb products and complete large doses to transfer into the Rapid Access to Products In Development (RAPID) pmanufacturing scale up and nonclinical testing for mAb product #3. Initiate mA Exercise.	program for the first 2 mAb products. Initiate				
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.					
Title: 2) BIOPROTO			-	2.573	-
Description: BIOPROTO supports early-phase clinical development and support data for candidate vaccines and therapeutic drugs prior to transition to System provides safe and effective medical defense against validated biological threat including bacteria, toxins, and viruses. This work also involves the evaluation therapeutics for operational use, as well as generation of novel drug products a and/or operational utility for the Warfighter. This effort reduces programmatic the section of the warfighter.	Development & Demonstration. This work agents and emerging infectious disease bioth of Food and Drug Administration (FDA)-appro and formulations, to enhance level of protection	reats ved n			
 FY 2023 Plans: Complete human melioidosis clinical trial and continue Non-Human Primate (spectrum antibacterial candidate. Ready candidate for transition to Biomedica (BARDA). Complete testing of broad spectrum antiviral in endemic Lassa fever disease 	Advanced Research and Development Author	-			
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project funding transferred to another funding line. FY 2024 funding h alignment under budget activity 3.	nas been transferred to Project PT3 for better				
Title: 3) GUIDE-ENBD			-	55.000	49.633
Description: This effort will focus on Generative Unconstrained Intelligent Dru fully integrated computational approach to accelerating medical countermeasu		а			
FY 2023 Plans:					

PE 0603884BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Bio	ological Defense Program	Date: N	Aarch 2023	
Appropriation/Budget Activity 0400 / 4	R-1 Program Element (Number/Name) PE 0603884BP <i>I Chemical and Biological</i> <i>Defense Program - Dem/Val</i>	Project (Number/ PT4 / Protect (ACL		
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
Develop and implement a fully integrated computational approach to acc improving computational predictions of antibody-antigen interactions and to address manufacturing-related properties to include a panel of manufa selected candidates do not have known issues such as anti-drug antibody starting vaccine design modeling and technologies	d affinity (strength of interaction), incorporating the ab acturing tools, expanding the safety models to ensure			
FY 2024 Plans: Execute medical countermeasure design campaigns to discover prototypplanning, coding, building, and testing of up to 17 new and existing digitates of computational MCM discovery efforts and rapid response capability; Countermeasure will be transferred to Accelerated Antibodies program for the second	al tools and algorithms to increase speed and accurac Conduct Live Fire Exercise against an unknown targe			
FY 2023 to FY 2024 Increase/Decrease Statement: Decrease due to transition from development of computational tools to re-	efinement of those computational tools.			
Title: 4) MCMPT		-	4.794	1.20
Description: Manufacturing				
FY 2023 Plans: Initiate Digital Twin program to develop Artificial Intelligence models for reducing human intervention and control inputs.	manufacturing process controls to improve efficiency	by		
FY 2024 Plans: Continue refining Digital Twin Artificial Intelligence models for manufacturincrease process efficiency.	iring process controls to reduce human interventions	and		
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments. Effort concludes in F	Y24.			
Title: 5) MCMPT		-	5.774	5.07
Description: Rapid Response				
FY 2023 Plans: Initiate Pandemic Prevention Platform (P3) transfer from Defense Advandisease-agnostic antibody platform which will be further developed by the				
FY 2024 Plans:				

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chen		_	Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 4	R-1 Program Element (Number/Name) PE 0603884BP <i>I Chemical and Biological</i> <i>Defense Program - Dem/Val</i>		t (Number/I Protect (ACL	,	
B. Accomplishments/Planned Programs (\$ in Millions)			FY 2022	FY 2023	FY 2024
	lity to discover/optimize antigens against known and emerging t ograms for monoclonal and vaccine countermeasures and store)) program.				
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.					
Title: 6) MCMPT			-	-	4.200
Description: Nucleic Acid					
exposure countermeasure against chemical/biological threat manufacturing capability. This capability eliminates outsourc GUIDE to test and evaluate more candidates real time.	eic Acid (DNA) or Ribonucleic Acid (RNA) based medical both the onset of protection and duration of protection for a pre- s. Initiate transition of DARPA Nucleic Acid on Demand (NOW) ing of lengthy prototype manufacturing to allow programs such a				
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to change in program/project technical parame	ters.				
Title: 7) PLG MAB			-	13.078	14.700
Description: Manufacturing, Non-Clinical and Clinical Devel	opment				
antibodies (mAbs) . These efforts initiate Half-Life Extension	nt for Phase 1 Study. Continue in the discovery of Plague monod to extend half-life candidate mAbs to meet service requirement assay support to manufacturing and Phase 1 study, and Condu on-human primates using aerosol challenge.	s.			
material to Rapid Access to Products in Development (RAPI	inical study and delivery of 5-10K doses of Phase 2 compliant D) program for an Interim Fielding Capability. Complete Non-Hu I animal model toxicology studies and initiate Phase 1 clinical st				

Exhibit R-2A, RDT&E Project Jus	tification: PB	2024 Chem	cal and Biolo	ogical Defens	se Program				Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 4				PE 060		n ent (Numb Chemical and - Dem/Val		-	t (Number/ Protect (ACL	,	
B. Accomplishments/Planned Pr Increase due to start of phase 1 stu			cale manufa	cturing					FY 2022	FY 2023	FY 2024
<i>Title:</i> 8) UIPE FoS Footwear	and rainp t	ip of large s		sturnig.							2.38
Description: Development of the l	JIPE EoS Eoot	wear System	n								2.00
FY 2024 Plans: Initiate prototype Other Transaction testing to inform initial down select alternatives and generate document	n Authority (OT of alternatives	A) to evalua , conduct lim	te up to ten t iited early us								
FY 2023 to FY 2024 Increase/Dec UIPE FoS Footwear is a new effort			Systems sta	rting in FY24							
Title: 9) VAMP-ENBD									-	35.000	34.29
Description: Focus on Vaccine Admanufacturing processes and inter Defense Innovation Unit (DIU)] to s FY 2023 Plans:	agency partne support develop	rs [e.g., Bion oment of vac	nedical Adva cine(s) agaii	inced Resear nst priority th	rch and Dev	elopment A					
Continue vaccine development to p		() 0	. ,								
Continue vaccine development to p FY 2024 Plans: Continue development and manufa efforts in animals and human clinic		cine candida	tes against n	nultiple viral l	biothreats. (Continue tes	and evaluat	ion			
FY 2024 Plans: Continue development and manufa	al trials. crease Statem	ent:	tes against n	nultiple viral l	biothreats. (Continue tes	and evaluat	ion			
FY 2024 Plans: Continue development and manufa efforts in animals and human clinic FY 2023 to FY 2024 Increase/Dec	al trials. crease Statem	ent:	tes against n				and evaluat			175.219	179.15
FY 2024 Plans: Continue development and manufa efforts in animals and human clinic FY 2023 to FY 2024 Increase/Dec	al trials. c rease Statem am adjustments	ent: 5.		Accom	nplishment				-	ΙΙ	
FY 2024 Plans: Continue development and manufa efforts in animals and human clinic FY 2023 to FY 2024 Increase/Dec Minor change due to routine progra	al trials. c rease Statem am adjustments	ent: 5.	tes against n <u>FY 2024</u> <u>Base</u> -						- 7 FY 202	175.219 <u>Cost To</u> <u>8</u> <u>Complete</u> 0.000	

PE 0603884BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program

Exhibit R-2A, RDT&E Project Justi	fication: PB	2024 Chemi	cal and Biolo	ogical Defen	se Program				Date: March 2023
Appropriation/Budget Activity 0400 / 4				PE 06	-	nent (Numb Chemical and - Dem/Val	,		Number/Name) tect (ACD&P)
C. Other Program Funding Summa	ry (\$ in Milli	ons <u>)</u>		I					
			<u>FY 2024</u>	FY 2024	FY 2024				<u>Cost To</u>
Line Item	<u>FY 2022</u>	FY 2023	Base	000	Total	FY 2025	FY 2026	FY 2027	FY 2028 Complete Total Cost
 MT4: Mitigate (ACD&P) 	-	17.302	28.785	-	28.785	20.885	15.433	13.369	- Continuing Continuing
• PT2: Protect (Applied Research)	-	58.091	55.057	-	55.057	56.153	57.817	61.452	61.452 Continuing Continuing
• PT5: Protect (SDD)	-	87.923	97.975	-	97.975	69.858	66.259	52.871	67.776 Continuing Continuing

Remarks

D. Acquisition Strategy

ACCELERATED ANTIBODIES-ENHANCED BIODEFENSE (AA-ENBD)

AA-ENBD, in collaboration with interagency partners at Biomedical Advanced Research and Development Authority (BARDA) & Defense Advanced Research Projects Agency (DARPA), will address multiple high-priority threats by developing antibody solutions and advancing them through Phase 1 clinical trials by 2028. Additionally, all necessary studies will be completed to enable advanced development, as desired. AA-ENBD will provide a stockpile of 5-10K doses that will remain on a stability program as a potential rapid response capability for deployment. Furthermore, a commercial manufacturing process will be leveraged and developed that can be rapidly implemented for a larger response if needed. The intention is to work each candidate to the appropriate regulatory level (e.g., through Phase 1) within a codified timeframe (e.g., 2 years) from initiation. These efforts will leverage the Other Transactions Authority (OTA) through the medical OTA consortium. AA-ENBD was formerly known as Monoclonal Antibodies Therapeutics-Enhanced Biodefense (MAB TX-ENBD).

GENERATIVE UNCONSTRAINED INTELLIGENT DRUG ENGINEERING-ENHANCED BIODEFENSE (GUIDE-ENBD)

GUIDE computational tools, to include artificial intelligence and machine learning, are tailored specifically to Warfighter threats and needs through a preemptive approach that broadly addresses a diverse and dynamic threat space. GUIDE's intelligent drug design enables medical countermeasures (MCM) candidates to be developed across a wider aperture of threat space thereby reducing early development time. MCM candidates, particularly in the case of high priority threats, can be advanced preemptively. The GUIDE program offers a revolutionary approach to addressing unanticipated endemic and engineered threats through rapid retargeting and optimization. GUIDE is a collaboration between the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (CBRND) (JPEO-CBRND), Defense Advanced Research Projects Agency (DARPA), and the Department of Energy (DOE). The GUIDE program is utilizing Interagency Agreements (IAA) with the DOE National Labs as well as a Other Transaction Authority (OTA) agreement for high throughput testing.

MCM PLATFORM TECHNOLOGIES (MCMPT)

The goal of the MCMPT is to rapidly counter a broad-spectrum of threat agents using standardized discovery, design, manufacturing, and testing processes to reduce the MCM development risks. Efforts will focus on transitioning S&T programs from other DoD agencies, such as the Defense Threat Reduction Agency (DTRA)-Joint Science and Technology Office (JSTO) or DARPA, and establishing advanced platform technologies within the Department of Defense (DoD)'s Advanced Development Manufacturing (ADM) network and evaluating that capability through nonclinical and clinical testing. A subset of these technologies, such as the DARPA Pandemic

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	I Defense Program	Date: March 2023
0400 / 4	R-1 Program Element (Number/Name) PE 0603884BP <i>I Chemical and Biological</i> <i>Defense Program - Dem/Val</i>	Project (Number/Name) PT4 / Protect (ACD&P)

Prevention Platform (P3), will be adapted to deliver a rapid response capability to novel and emerging threats. Once established, future programs will be able to leverage these platforms for the development of future medical countermeasures. It is anticipated that these efforts will leverage the Other Transactions Authority (OTA) through the medical OTA consortium, or Army Contracting Command-Edgewood.

PLAGUE MONOCLONAL ANTIBODIES (PLG MAB)

The Plague Monoclonal Antibodies (PLG MAB) program was initiated by the Medical Countermeasure Platform Technologies (MCMPT) program and continued using the Accelerated Antibodies contracting methodology Medical CBRN Defense Consortium Other Transaction Agreement (MCDC OTA). The program's Milestone Development Decision (MDD) was approved 26 OCT 2022. The program is now a Major Defense Acquisition Program (MDAP) and anticipates a Milestone (MS) B Decision point in 2025. Prior to MS B the program will conduct the necessary nonclinical and clinical testing and large-scale manufacturing needed to advance into the Engineering and Manufacturing Development Phase.

Uniform Integrated Protective Ensemble Family of Systems Footwear

The Uniform Integrated Protective Ensemble Family of Systems (UIPE FoS) Footwear program will use Other Transaction Authority for prototype production. The program will develop and assess multiple prototypes with an emphasis on a balance between cost, protection, schedule, risk and interoperability. Early user testing will include comparison to legacy boots as well as laboratory testing with boots that are contaminated, followed by operational and developmental test efforts in realistic operational environments. Using a gated test approach, the program will select multiple candidates at Milestone (MS) B using Cost As an Independent Variable (CAIV) to trade risk, requirements, and schedule to achieve the maximum value at a fixed cost. Rather than choose the top performance candidates, the program will select a low cost candidate that meets Key Performance Parameters (KPP) and high performance candidates constrained by maximum target costs. Results of prototyping will inform developmental and operational testing, followed by a down select prior to Critical Design Review (CDR) and production initiation at MS C using a Federal Acquisition Regulation (FAR) based production contract.

VACCINE ACCELERATION BY MODULAR PROGRESSION-ENHANCED BIODEFENSE (VAMP-ENBD)

The Vaccine Acceleration by Modular Progression (VAMP) program is an investment program that leverages lessons learned, industrial leaders, established manufacturing processes, and interagency partners (including Biomedical Advanced Research and Development Authority (BARDA), Defense Innovation Unit (DIU)) to develop prototype vaccine candidates utilizing matured platforms from established commercial manufacturing that target biothreats while utilizing a modular approach to ensure flexibility. These prototype vaccines (including, but not limited to, Messenger Ribonucleic Acid (mRNA) vaccines) will use a tailored acquisition pathway and will create a strategic reserve to counter the biothreats against the Warfighter and shorten the development time when an emergency occurs. Data generated from these efforts may be used to support an interim fielding capability (U.S. Food & Drug Administration (FDA) pre-Emergency Use Authorizations (EUA)/EUA and Expanded Access protocols) that could achieve FDA licensure as appropriate. These efforts will leverage the Other Transactions Authority (OTA) through the Medical CBRN Defense consortium, Broad Agency Announcements, and Commercial Solutions Opening. Data on VAMP products will be captured within Rapid Acquisition of Products in Development (RAPID) defense system to aid in identification of MCMs to counter threats.

Exhibit R-3, RDT&E F	Project C	ost Analysis: PB 2	2024 Che	mical and	Biologica	al Defens	e Prograr	n				Date:	March 20	023	
Appropriation/Budge 0400 / 4	et Activity	/				PE 060		Chemica	l umber/Na al and Biol /al			rotect (AC			
Product Developmen	nt (\$ in Mi	illions)		FY 2	022	FY 2	2023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
AA-ENBD - Development	Various	Various : N/A	-	0.000		53.690	Dec 2022	62.544	Dec 2023	-		62.544	Continuing	Continuing	0.000
GUIDE-ENBD - Development	Various	Various : N/A	-	0.000		50.050	Dec 2022	45.713	Dec 2023	-		45.713	Continuing	Continuing	0.000
MCMPT - HW S - Rapid Response	C/CPFF	TBD : N/A	-	0.000		4.282	Dec 2022	4.782	Dec 2023	-		4.782	Continuing	Continuing	0.000
MCMPT - HW S - P3/ Nucleic Acid	C/CPFF	TBD : N/A,	-	0.000		5.247	Dec 2022	3.930	Dec 2023	-		3.930	Continuing	Continuing	0.000
MCMPT - HW S - Manufacturing	C/CPFF	TBD : N/A	-	0.000		0.000		0.993		-		0.993	Continuing	Continuing	0.000
PLG MAB - HW S - Manufacturing, Non- Clinical and Clinical Development	Various	Various : N/A	-	0.000		11.970	Mar 2023	13.546	Dec 2023	-		13.546	Continuing	Continuing	0.000
UIPE FoS Footwear - HW S - Footwear Prototype	C/FFP	TBD : N/A	-	0.000		0.000		0.100	Jan 2024	-		0.100	Continuing	Continuing	0.000
VAMP-ENBD - Vaccine - Development	Various	Various : N/A	-	0.000		29.925	Dec 2022	28.254	Dec 2023	-		28.254	Continuing	Continuing	0.000
VAMP-ENBD - SBIR/STTR - Direct Program Support	Various	Various : N/A	-	0.000		0.000		2.745	Dec 2023	-		2.745	Continuing	Continuing	0.000
		Subtotal	-	0.000		155.164		162.607		-		162.607	Continuing	Continuing	N/A
Support (\$ in Millions	s)			FY 2	022	FY 2	2023		2024 Ise		2024 CO	FY 2024 Total]		
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
BIOPROTO - TD/D S	MIPR	Army Contracting Command : Picatinny, NJ	-	0.000		2.573	Oct 2022	0.000		-		0.000	0.000	2.573	0.000
UIPE FoS Footwear - ES S - Logistics/Engineering Support	Various	Various : N/A	-	0.000		0.000		0.358	Jan 2024	-		0.358	Continuing	Continuing	0.000
		Subtotal	-	0.000		2.573		0.358		-		0.358	Continuing	Continuing	N/A

PE 0603884BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program

Appropriation/Budge 0400 / 4	et Activity	1				PE 060		Chemica	lumber/N a al and Biol Val			: (Numbe Protect (AC			
Test and Evaluation	(\$ in Milli	ons)		FY 2	022	FY 2	2023		2024 ase		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
UIPE FoS Footwear - OTHT S - Swatch Testing (new/worn)	TBD	TBD : N/A	-	0.000		0.000		0.500	Apr 2024	-		0.500	Continuing	Continuing	0.000
UIPE FoS Footwear - OTHT S - Early User Testing	TBD	TBD : N/A	-	0.000		0.000		1.000	Jun 2024	-		1.000	Continuing	Continuing	0.000
UIPE FoS Footwear - OTHT S - Infrastructure	MIPR	TBD : N/A	-	0.000		0.000		0.282	Jan 2024	-		0.282	Continuing	Continuing	0.000
		Subtotal	-	0.000		0.000		1.782		-		1.782	Continuing	Continuing	N/A
Management Service	es (\$ in M	illions)		FY 2	022	FY 2	2023		2024 ase		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
AA-ENBD - Program Management	Various	Various : N/A	-	0.000			Dec 2022		Dec 2023	-			•	Continuing	
GUIDE-ENBD - Program Management	Various	Various : N/A	-	0.000		4.950	Dec 2022	3.920	Dec 2023	-		3.920	Continuing	Continuing	0.000
MCMPT - PM Support	Various	JPL CBRND Enabling Biotechnologies, JPEO-CBRND : Fort Detrick, MD	-	0.000		1.039	Dec 2022	0.771	Dec 2023	-		0.771	Continuing	Continuing	0.000
PLG MAB - PM/MS S - Program Management	Various	Various : N/A	-	0.000		1.108	Dec 2022	1.154	Dec 2023	-		1.154	Continuing	Continuing	0.000
UIPE FoS Footwear - PM/MS S - Management Services	Various	Various : N/A	-	0.000		0.000		0.146	Jan 2024	-		0.146	Continuing	Continuing	0.000
VAMP-ENBD - PM/MS S -	Various	Various : N/A	-	0.000		5.075	Dec 2022	3.300	Dec 2023	-		3.300	Continuing	Continuing	0.000
Management Support															

PE 0603884BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program

Exhibit R-3, RDT&E Project Cost Analysis: PB 2	024 Che	mical and Biologic	al Defense Progra	am		Date:	March 20	23			
Appropriation/Budget Activity R-1 Program Element (Number/Name) Project (Number/Name) 0400 / 4 PE 0603884BP / Chemical and Biological PT4 / Protect (ACD&P) Defense Program - Dem/Val Defense Program - Dem/Val PT4 / Protect (ACD&P)											
	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract		
Project Cost Totals	-	0.000	175.219	179.158	-	179.158	Continuing	Continuing	N/A		

Remarks

Exhibit R-4, RDT&E Schedule Profile: PB 2024 (Cher	nica	al an	d Bic	ologi	cal D	Defens	e Pro	gram	۱											Da	ate: N	/larc	h 20)23			
Appropriation/Budget Activity 0400 / 4							P	- 1 Pro E 060 efens	3884	BP /	Che	emi	cal a	and I								nber/l (ACL						
		_	202			-	2023		_	2024			FY	-	_		_	202	-			Y 202			_	202	-]
	1	2	3	4	1	2	3	4 1	2	3	4	1	2	3	4	1	2	3	4	1		2 3	4	1	2	3	4	
AA-ENBD - Discovery, identification and small scale manufacture of mAbs																												
BIOPROTO - CDD Validation-Capability Development Document Validation																												
GUIDE-ENBD - Integrated computational approach development																												
MCMPT - Rapid Response Design, Manufacturing, Testing																												
MCMPT - MCM Optimization Phase Design, Manufacturing, Testing																												-
MCMPT - Plague Nonclinical Studies																												
MCMPT - Plague Clinical Studies																												
MCMPT - Plague Manufacturing																												1
MCMPT - P3/Nucleic Acid]
PLG MAB - Non-clinical Studies-Non-clinical Studies																												
PLG MAB - Manufacturing Development																												1
PLG MAB - Phase 1-Phase 1 Clinical Trials																												
PLG MAB - MS B-Milestone B																												1
UIPE FoS Footwear - Prototype Development																												1
UIPE FoS Footwear - MS B-Milestone B																												
UIPE FoS Footwear - DT&E-Developmental Test and Evaluation																												-
UIPE FoS Footwear - Operational Assessment																												1
UIPE FoS Footwear - CDR-Critical Design Review																												

Exhibit R-4, RDT&E Schedule Profile: PB 2024 C	hen	nical	and	Bio	ologi	cal [Defe	nse l	Pro	gram	۱										l	Date	e: Ma	arch	20	23			
Appropriation/Budget Activity 0400 / 4								PE (060		BP /	Ch	emi	cal a	nber Ind B				Pro PT₄	•	rote				e)				
		FY	2022	2		FY	2023	3		FY 2	2024	l.		FY 2	2025			FY 2	2026	;		FY 2	2027	'		FY 2	2028	3	
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	
UIPE FoS Footwear - OT&E-Operational Test and Evaluation																													
UIPE FoS Footwear - MS C-Milestone C																													
VAMP-ENBD - Vaccine Development																													

hibit R-4A, RDT&E Schedule Details: PB 2024 Chemical and Biological De	efense Program		Date: Marc	h 2023
propriation/Budget Activity 00 / 4	R-1 Program Element (Numbe PE 0603884BP <i>I Chemical and</i> <i>Defense Program - Dem/Val</i>		Project (Number/Nam PT4 / Protect (ACD&P)	
Sch	nedule Details			
	SI	art	Er	nd
Events	Quarter	Year	Quarter	Year
AA-ENBD - Discovery, identification and small scale manufacture of mAbs	1	2023	4	2028
BIOPROTO - CDD Validation-Capability Development Document Validatio	n 1	2023	4	2023
GUIDE-ENBD - Integrated computational approach development	1	2024	4	2028
MCMPT - Rapid Response Design, Manufacturing, Testing	1	2022	4	2028
MCMPT - MCM Optimization Phase Design, Manufacturing, Testing	1	2022	4	2023
MCMPT - Plague Nonclinical Studies	1	2023	2	2024
MCMPT - Plague Clinical Studies	1	2024	2	2024
MCMPT - Plague Manufacturing	1	2022	1	2026
MCMPT - P3/Nucleic Acid	1	2024	4	2026
PLG MAB - Non-clinical Studies-Non-clinical Studies	1	2024	4	2024
PLG MAB - Manufacturing Development	2	2023	4	2026
PLG MAB - Phase 1-Phase 1 Clinical Trials	1	2025	4	2025
PLG MAB - MS B-Milestone B	1	2025	1	2025
UIPE FoS Footwear - Prototype Development	2	2024	3	2024
UIPE FoS Footwear - MS B-Milestone B	2	2025	2	2025
UIPE FoS Footwear - DT&E-Developmental Test and Evaluation	2	2025	1	2027
UIPE FoS Footwear - Operational Assessment	4	2025	4	2025
UIPE FoS Footwear - CDR-Critical Design Review	2	2026	2	2026
UIPE FoS Footwear - OT&E-Operational Test and Evaluation	3	2026	4	2026
UIPE FoS Footwear - MS C-Milestone C	2	2027	2	2027
VAMP-ENBD - Vaccine Development	1	2023	1	2028

Exhibit R-2A, RDT&E Project Ju	stification	: PB 2024 C	hemical an	d Biologica	l Defense P	rogram				Date: Marc	ch 2023	
Appropriation/Budget Activity 0400 / 4	400/4							Name) iological	Project (N MT4 / Mitig		,	
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
MT4: Mitigate (ACD&P)	-	0.000	17.302	28.785	0.000	28.785	20.885	15.433	13.369	0.000	Continuing	Continuing
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

The Mitigate Advanced Component Development and Prototypes (ACD&P) Project provides the Joint Force the ability to conduct decontamination and medical actions that enable the quick restoration of combat power; maintain/recover essential functions that are free from the effects of Chemical Biological Radiological and Nuclear (CBRN) hazards; and facilitate the return to pre-incident operational capability as soon as possible. In FY 2023, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. MT4 efforts in FY 2022 remain in Projects DE4 and TM4. This restructuring provided standardization and alignment across CBDP research, development and acquisition efforts.

Efforts included in this Project are:

- (1) Automated Decon System (ADS)
- (2) Antiviral Oral Therapeutic (AVO TX)
- (3) Biological Warfare Defense Prototype (BIOPROTO)
- (4) Botulinum Toxin Therapeutic (BOT TX)
- (5) Consolidated Nerve Agent Treatment System (CNATS)
- (6) Discovery of Medical Countermeasures Against New and Emerging Threats (DOMANE)
- (7) Reactivating Nerve Agent Treatment System (RNATS)
- (8) Service Equipment Decontamination System (SEDS)
- (9) Tactical Contamination Mitigation System (TCMS)

The Automated Decontamination System (ADS) is a new start program in FY24. ADS is a semi-autonomous supported capability that relies on precision detection capabilities, modernized decontaminants, and robotics to allow a chemical, biological, radiological and nuclear (CBRN) decontamination squad to provide platoon level thorough decontamination on critical mission equipment and infrastructure. In FY24 ADS will award a concept prototype contract, accept delivery of an initial concept prototype and conduct an Alternative Systems Review.

The Antiviral Oral Therapeutics (AVO TX) is a new start program in FY24. AVO TX will provide the Joint Force the ability to recover from exposure to biological hazards and quickly return to the fight. Efforts include development of Food and Drug Administration (FDA) approved Medical Countermeasure (MCM) to protect the lives and maintain the battle readiness of the Warfighter. AVO TX fulfills an existing gap for a MCM to treat exposure to alpha virus.

The Biological Warfare Defense Prototype (BIOPROTO) supports early-phase clinical development and supporting non-clinical safety, tolerability and toxicity data for candidate vaccines and therapeutic drugs prior to transition to System Development & Demonstration. This work provides safe and effective medical defense against

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and	d Biological Defense Program	Date: March 2023
Appropriation/Budget Activity 0400 / 4	R-1 Program Element (Number/Name) PE 0603884BP <i>I Chemical and Biological</i> <i>Defense Program - Dem/Val</i>	Project (Number/Name) MT4 / Mitigate (ACD&P)
validated biological threat agents and emerging infectious disease b Drug Administration (FDA) approved therapeutics for operational us or operational utility for the Warfighter. This effort reduces program	e, as well as generation of novel drug products and forr	nulations, to enhance level of protection and/
The Botulinum Toxin Therapeutic (BOT TX) is a new start program if for the warfighter to treat respiratory depression caused by botulinur be administered for BOT treatment in the field environment. This int	m toxin exposure. Botulinum toxin exposure is lethal an	nd there are no available therapeutics that ca
The Consolidated Nerve Agent Treatment System (CNATS) is a new anticholinergics, atropine and scopolamine, and a new broad-spectr Generation Agents (FGAs). Combining nerve agent treatments into	rum oxime. The proposed oxime will have efficacy again	st emerging threats including Fourth
The Discovery of Medical Countermeasures Against Novel Entities to identify medical countermeasures (MCMs), MCM targets, and dis organs-on-a-chip, high-throughput screening as well as novel imagin and therapeutic drugs through the use of adaptive clinical trials to prinfectious disease biothreats including bacteria, toxins, and viruses. validated prototypes and generating clinical and supporting non-clin prior to transition to System Development & Demonstration.	sease pathogenesis and toxicity using the combination of ng platforms. Additionally, MT4 supports early-phase of rovide safe and effective medical defense against valida This effort reduces programmatic risk of failure in the a	of Artificial Intelligence/Machine Learning, linical development of prophylaxis treatments ated biological threat agents and emerging advanced development phase by developing
The Reactivator Nerve Agent Treatment System (RNATS) is a new address emerging chemical threats and fourth generation agents (F nerve agent therapeutics.		
The Service Equipment Decontamination System (SEDS) program of Decontamination (CEDS), which will develop a capability for use by the number of personnel experiencing adverse health effects by reduce This capability is needed to sustain both the Joint and SOF by reduce align with the National Defense Strategy (NDS). SEDS and CEDS with the Strategy (NDS).	the Warfighter during the decontamination operations to lucing contamination on equipment, individual combat e cing logistical burdens in order to increase tactical agility	hat will provide a quantifiable reduction in quipment, and sensitive platform interiors. y and sustain a resilient force posture, and

align with the National Defense Strategy (NDS). SEDS and CEDS will provide contamination mitigation capabilities for critical equipment that have been exposed to chemical and biological contamination and achieve efficacy levels that allow unprotected post-decontamination exposures for long periods with less than negligible severity effects. In FY24, the Joint SEDS effort will continue through the Engineering and Manufacturing Development (EMD) phase with Developmental Testing (DT) and a Critical Design Review (CDR). FY23 is last year of BA4 funding, program is transitioning to EMD.

The Tactical Containment Mitigation System (TCMS) is a Contamination Mitigation concept and intends to address gaps related to the decontamination of critical equipment and vehicles and it will reduce the time and logistics associated with decontamination. TCMS will limit the spread and mitigate the effects of Chemical,

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologi	ical Defense Program	Date: N	March 2023	
Appropriation/Budget Activity 0400 / 4	R-1 Program Element (Number/Name) PE 0603884BP <i>I Chemical and Biological</i> <i>Defense Program - Dem/Val</i>	Project (Number/ MT4 / Mitigate (AC	D&P)	
Biological, and Radiological (CBR) contamination to allow warfighters to con environment. The Program's intent is to mitigate the risk to personnel and lin TCMS will greatly enhance or eliminate the need for subsequent decontamin combined with weathering, Mission Oriented Protective Posture (MOPP) lev being decontaminated and the agent. In FY24 the program will continue pro Manufacturing & Development (EMD) Phase. FY24 is last year of BA4 fundi	mit the potential spread of CBR contamination b nation to mitigate contamination on military equip els may be reduced without further decontamina ototype testing and complete technical reviews in	y minimizing contac oment. Following an ation, depending on a support of the Mile	t and transfer oplication of T the surface of stone B/Engir	hazards. CMS, r material neering
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
Title: 1) ADS - Prototype Development		-	-	1.500
Description: Development of Robotic Platform Systems				
FY 2024 Plans: Begin prototype development, conduct alternative systems review				
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project is new start effort in FY 2024.				
<i>Title:</i> 2) AVO TX - Non Clinical Study		-	-	3.740
Description: Non Clinical Studies				
<i>FY 2024 Plans:</i> Initiate Natural History Study (NHS).				
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project is new start effort in FY 2024.				
Title: 3) BIOPROTO		-	2.572	-
Description: Funds biomedical research focused on the nonclinical and earl countermeasures against known and emerging viral, bacterial, and toxin biol and Drug Administration (FDA)-approved therapeutics are limited or lacking. effects of known and emerging viral, bacterial, and toxin biological warfare the disease. They are the last line of defense against BW threats and are critical Biomedical research is focused on nonclinical development (e.g., animal more early clinical evaluation of broad-spectrum therapeutic candidates that target response (e.g., by modulating the immune system) and/or relieve BW disease. Therapeutic candidates that are shown to be both safe and efficacious again and/or clinical evaluation under RDT&E budget activity 5, and can be acceled	ogical warfare (BW) threats for which U.S. Food BW defense therapeutics mitigate and reverse areats in symptomatic warfighters diagnosed with It to returning symptomatic warfighters to service del, and formulation/manufacturing studies) and t viruses, bacteria or toxins directly, enhance the se symptoms. Inst BW threats will advance for further non-clinica	the n BW n host		

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and	Biological Defense Program	Date	: March 2023	
Appropriation/Budget Activity 0400 / 4	R-1 Program Element (Number/Name) PE 0603884BP <i>I Chemical and Biological</i> <i>Defense Program - Dem/Val</i>	Project (Numbe MT4 / <i>Mitigate (</i>		
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
during an outbreak. Clinical and nonclinical evaluation of novel small molecules (isolated from natural sources), drug and drug/vaccine con approved by the FDA or in clinical development for other indications, animal models in which to evaluate therapeutic candidates is also inc investments to accelerate development and reduce costs.	nbinations (aka layered defense), and repurposing of d are included in this research. Refinement of appropria	te		
FY 2023 Plans: - Continue nonclinical and regulatory activities to transition broad spe - Initiate clinical and/or nonclinical studies for broad-spectrum antibac				
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project funding transferred to another funding line. FY 2024 alignment under budget activity 3.	funding has been transferred to Project PT3 for better			
Title: 4) BOT TX				2.84
Description: Nonclinical Studies				
FY 2024 Plans: Initiate non-clinical study for Dose Determination following FDA anima	al rule guidance.			
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project is new start effort in FY 2024.				
Title: 5) BOT TX				5.00
Description: Manufacturing				
FY 2024 Plans: Initiate scale-up manufacturing for intermuscular injection product.				
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project is new start effort in FY 2024.				
Title: 6) CNATS - Acquisition Activities				2.38
Description: Acquisition Activities				
FY 2024 Plans: Initiate activities to support the Milestone Development Decision (MD	D) and Milestone B.			

PE 0603884BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program UNCLASSIFIED Page 44 of 113

DADOI / 4 Image: PC 0003884BP / Chemical and Biological Defense Program - Dem/Val MT4 / Mitigate (ACD&P) B. Accomplishments/Planned Programs (\$ in Millions) FY 2022 FY 2023 FY 2023 FY 2024 1. Perform Market Research and develop AoA study guidance and plan as required. 2. Perform Affordability Analysis to support the development of Program goals. 3. 3. 3. Perform Technology Readiness Assessment for potential candidate materiel solutions. FY 2023 FY 2024 FY 2024 Program/project is new start effort in FY 2024. Title: 7) CNATS - Pre Milestone B - - 1.500 Description: Technical Studies and Feasibility FY 2023 Increase/Decrease Statement: - - 1.500 Program/project is new start effort in FY 2024. FY 2024 Increase/Decrease Statement: - - 1.500 Program/project is new start effort in FY 2024. FY 2023 Increase/Decrease Statement: - - 1.038 - Program/project is new start effort in FY 2024. - 1.038 - - - 1.038 - - - 1.038 - - - 1.038 - - - - - - - - -	Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Bio	logical Defense Program	Date:	March 2023	
1. Perform Market Research and develop AG study guidance and plan as required. 2. Perform Market Research and development of Program goals. 3. Perform Technology Readiness Assessment for potential candidate material solutions. - PY 2024 Increase/Decrease Statement: - Program/project is new start effort in FY 2024. - Title: 7) (CNATS - Pre Milestone B - - Description: Technical Studies and Feasibility - - FY 2024 Plans: - - Assess feasibility of drug combination. - - 1.038 FY 2023 to FY 2024 Increase/Decrease Statement: - - 1.038 Frogram/project is new start effort in FY 2024. - 1.038 - FY 2023 Plans: - - 1.038 - Obscription: Prototype Development and Early-Phase Clinical Development - 1.038 - FY 2023 Plans: - - 1.038 - Obscription: Prototype Development of medical countermeasures to include prophylaxes, pretreatments, antidotes and therapeutic drugs against identified and emerging biological warfare threat agents. - 1.038 - Obscription: Instruct the advanced development of medical countermeasures that interfere with key pathogen	Appropriation/Budget Activity 0400 / 4	PE 0603884BP / Chemical and Biological			
Program/project is new start effort in FY 2024.Image: constraint of the start of the	 Perform Affordability Analysis to support the development of Program 9 Perform Technology Readiness Assessment for potential candidate matrix 	goals.	FY 2022	FY 2023	FY 2024
Description: Technical Studies and Feasibility Image: Comparison of the co					
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project is new start effort in FY 2024. Title: 8) DOMANE - Description: Prototype Development and Early-Phase Clinical Development FY 2023 Plans: - - Supports the advanced development of medical countermeasures to include prophylaxes, pretreatments, antidotes and therapeutic drugs against identified and emerging biological warfare threat agents. - - Demonstration of human safety and tolerability prior to entry of candidate prophylaxes and therapeutics into advanced development of prototypes for high-resolution forecasting of pathogenesis or toxicity that occurs during host interaction of a biological threat with its host. - - Continued development of adaptive clinical trial platforms for drug re-purposing efforts. - - Development of prototypes for precision predictions of medical countermeasures that interfere with key pathogenesis or toxicity events and restore homeostasis coupled with artificial intelligence/machine learning (AI/ML). - Initiate development of prototype for accurate prediction of targets on the biological threat and within the host that result in the necessary engagements to produce pathogenesis or toxicity using AI/ML. FY 2023 to FY 2024 Increase/Decrease Statement: Program/project terminated in FY 2024. The impact will be a slow-down in the development of platform prototypes for high throughput screening as well as AI development for predicting MCMs for new and emerging pathogens.	<i>Description:</i> Technical Studies and Feasibility <i>FY 2024 Plans:</i>		-	-	1.500
Description: Prototype Development and Early-Phase Clinical Development FY 2023 Plans: - Supports the advanced development of medical countermeasures to include prophylaxes, pretreatments, antidotes and therapeutic drugs against identified and emerging biological warfare threat agents. - Demonstration of human safety and tolerability prior to entry of candidate prophylaxes and therapeutics into advanced development of prototypes for high-resolution forecasting of pathogenesis or toxicity that occurs during host interaction of a biological threat with its host. - Continued development of adaptive clinical trial platforms for drug re-purposing efforts. - Development of prototypes for precision predictions of medical countermeasures that interfere with key pathogenesis or toxicity events and restore homeostasis coupled with artificial intelligence/machine learning (AI/ML). - Initiate development to prototype for accurate prediction of targets on the biological threat and within the host that result in the necessary engagements to prototype state prediction of targets on the biological threat and within the host that result in the necessary logacerease Statement: Program/project terminated in FY 2024. The impact will be a slow-down in the development of platform prototypes for high throughput screening as well as AI development for predicting MCMs for new and emerging pathogens.	FY 2023 to FY 2024 Increase/Decrease Statement:				
 FY 2023 Plans: Supports the advanced development of medical countermeasures to include prophylaxes, pretreatments, antidotes and therapeutic drugs against identified and emerging biological warfare threat agents. Demonstration of human safety and tolerability prior to entry of candidate prophylaxes and therapeutics into advanced development using adaptive clinical trials. Continued development of prototypes for high-resolution forecasting of pathogenesis or toxicity that occurs during host interaction of a biological threat with its host. Continued development of adaptive clinical trial platforms for drug re-purposing efforts. Development of prototypes for precision predictions of medical countermeasures that interfere with key pathogenesis or toxicity events and restore homeostasis coupled with artificial intelligence/machine learning (Al/ML). Initiate development of prototype for accurate prediction of targets on the biological threat and within the host that result in the necessary engagements to produces pathogenesis or toxicity using Al/ML. FY 2023 to FY 2024 Increase/Decrease Statement: Program/project terminated in FY 2024. The impact will be a slow-down in the development of platform prototypes for high throughput screening as well as Al development for predicting MCMs for new and emerging pathogens. 	<i>Title:</i> 8) DOMANE		-	1.038	-
	 FY 2023 Plans: Supports the advanced development of medical countermeasures to ind therapeutic drugs against identified and emerging biological warfare threat - Demonstration of human safety and tolerability prior to entry of candidat development using adaptive clinical trials. Continued development of prototypes for high-resolution forecasting of pinteraction of a biological threat with its host. Continued development of adaptive clinical trial platforms for drug re-pute - Development of prototypes for precision predictions of medical counterre events and restore homeostasis coupled with artificial intelligence/machine - Initiate development of prototype for accurate prediction of targets on the necessary engagements to produces pathogenesis or toxicity using Al/MI FY 2023 to FY 2024 Increase/Decrease Statement: Program/project terminated in FY 2024. The impact will be a slow-down in the sub-down in the su	clude prophylaxes, pretreatments, antidotes and at agents. te prophylaxes and therapeutics into advanced pathogenesis or toxicity that occurs during host prosing efforts. measures that interfere with key pathogenesis or to ne learning (AI/ML). te biological threat and within the host that result in L.			
	<i>Title:</i> 9) RNATS	new and emerging pathogens.	-		5.270

PE 0603884BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and	d Biological Defense Program	Date:	March 2023						
Appropriation/Budget Activity 0400 / 4	R-1 Program Element (Number/Name) PE 0603884BP <i>I Chemical and Biological</i> <i>Defense Program - Dem/Val</i>		ject (Number/Name) 4 / <i>Mitigate (ACD&P)</i>						
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024					
Description: Reactivating Nerve Agent Treatment System (RNATS)									
FY 2024 Plans: Initiate development of broad spectrum oxime for FDA approval. Initiate development. Initiate API procurement and compounding development		model							
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project is new start effort in FY 2024.									
Title: 10) SEDS		-	9.515	-					
Description: Milestone (MS) B support and Prototype Development									
FY 2023 Plans: Integrate system components into full prototype system(s). Complet (DT) and Joint Service Early Developmental Testing (EDT). Conduct Preliminary Design Review (PDR) for Other Services, and Todocumentation and conduct MS B Decision Reviews.		-							
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project transitioned to Engineering and Manufacturing Deve	elopment Phase.								
Title: 11) TCMS		-	4.177	6.54					
Description: Milestone (MS) A support and Prototype Development									
<i>FY 2023 Plans:</i> Complete Milestone A and award a prototyping Other Transaction A Review (SRR) and Test Readiness Review (TRR) of the prototypes Conduct a Business Case Analysis (BCA) for the program sustainme	to be tested. Begin prototype testing and update prototy								
FY 2024 Plans: Continue iterative prototype testing and complete technical reviews a Engineering Manufacturing & Development (EMD) Phase.	and documentation in support of the Milestone (MS) B/								
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to change in program/project technical parameters. Inc	rease of funding to complete TMRR phase.								
	Accomplishments/Planned Programs Sul	-4-4-1-	17.302	28.78					

PE 0603884BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program UNCLASSIFIED Page 46 of 113

Exhibit R-2A, RDT&E Project Justi	fication: PB	2024 Chemi	cal and Biol	ogical Defen	se Program				Date: Ma	rch 2023	
Appropriation/Budget Activity 0400 / 4				PE 06	r ogram Ele r 03884BP / C se <i>Program</i>	Chemical and			Number/Na igate (ACD	,	
C. Other Program Funding Summa	ry (\$ in Milli	ons <u>)</u>									
			<u>FY 2024</u>	<u>FY 2024</u>	<u>FY 2024</u>					Cost To	
Line Item	FY 2022	FY 2023	Base	000	<u>Total</u>	<u>FY 2025</u>	FY 2026	FY 2027	<u>FY 2028</u>	<u>Complete</u>	Total Cost
• DE4: Decontamination (ACD&P)	14.747	-	-	-	-	-	-	-	-	0.000	14.747
• MT3: Mitigate (ATD)	-	86.157	100.791	-	100.791	89.511	91.704	85.795	85.480	Continuing	Continuing
• MT5: Mitigate (SDD)	-	74.225	88.441	-	88.441	92.279	91.431	87.773	93.250	Continuing	Continuing
 PT4: Protect (ACD&P) 	-	175.219	179.158	-	179.158	135.096	107.341	123.538	139.376	Continuing	Continuing
• TM4: Techbase Medical	29.687	-	-	-	-	-	-	-	-	0.000	29.687
Defense (ACD&P) • PHM007: Service Equipment Decontamination System (SEDS)	-	-	-	-	-	14.028	22.531	24.920	13.050	Continuing	Continuing
PHM042: Tactical Contamination Mitigation System (TCMS)	-	-	-	-	-	-	1.250	5.072	5.000	Continuing	Continuing
• PHM045: Botulinum Therapeutic (BOT TX)	-	-	-	-	-	-	-	-	54.485	Continuing	Continuing

Remarks

D. Acquisition Strategy

Automated Decontamination System

The Automated Decontamination System (ADS) acquisition approach will focus on the integration of hardware and software components to deliver a capability that performs decontamination procedures autonomously. It will use developmental, government off the shelf (GOTS), and commercial off the shelf (COTS) products using a system of systems approach and prototyping. The program will conduct developmental, operational, and integration testing to understand how an autonomous decontamination system will be employed, operated, and supported considering the current military operational framework.

Antiviral Oral Therapeutic

The Antiviral Oral Therapeutic Program (AVO TX) program acquisition strategy supports the development through the Engineering, Manufacturing and Development (EMD) phase for a Federal and Drug Administration (FDA) approved oral broad spectrum antiviral therapeutic for the Warfighter. Initial drug product will be developed targeting Encephalitic Virus Disease (VEEV), with potential for other indications as a broad spectrum oral antiviral. The operational concept is to provide an oral broad-spectrum therapeutic Medical Countermeasures (MCM) to the Joint Force following a "trigger event" relating to a virus exposure (e.g., a credible intelligence report of use or potential use, a positive outcome of an environmental sample analysis, or a clinical specimen diagnostic test). This is a transition from Science and Technology (S&T). This program will leverage safety and large scale manufacturing from COVID.

Botulinum Toxin Therapeutic

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	I Defense Program		Date: March 2023
0400 / 4	R-1 Program Element (Number/Name) PE 0603884BP <i>I Chemical and Biological</i> <i>Defense Program - Dem/Val</i>	•	umber/Name) gate (ACD&P)

The Botulinum Toxin Therapeutic (BOT TX) program will transition from the Joint Science and Technology Office for Chemical and Biological Defense (JSTO-CBD) to JPEO CBRND. In the BOT TX acquisition strategy, the continued advanced activities will be performed through the Medical CBRN Defense Consortium (MCDC)/Other Transaction Agreement (OTA) supporting the development through the Engineering, Manufacturing and Development (EMD) phase for a Food and Drug Administration (FDA) approved treatment for the Warfighter to against respiratory depression caused by botulinum toxin exposure. BOT TX is part of the layered defense against BONT covering both treatment (BOT TX) and pre-exposure prophylaxis (BOT MAB). The product will produce an intermuscular injection capability that is based on an oral drug that is already approved for human use by the FDA.

Consolidated Nerve Agent Treatment System

In the CNATS acquisition strategy, a contractor will sponsor and conduct activities to achieve Food and Drug Administration (FDA) approval. The government will leverage data obtained under a Small Business and Innovation Research (SBIR) project. The government contemplates utilizing an Other Transaction Authority (OTA) agreement. Upon FDA approval, a follow-on procurement contract will acquire quantities of product to meet Full Operational Capability (FOC). Sustainment will be the responsibility of the Defense Logistics Agency Troop Support. Post marketing commitments and requirements are anticipated as a result of the FDA approval and will be the responsibility of the contractor and the government.

Reactivating Nerve Agent Treatment System

The Reactivator Nerve Agent Treatment System (RNATS) acquisition strategy will leverage prior investments in prior oxime developments by Canada and the United Kingdom. A contractor shall be responsible for conducting activities associated with drug development to obtain U.S. Food and Drug Administration (FDA) approval via a government Other Transaction Authority (OTA) agreement. The contractor shall sponsor the drug. Upon FDA approval, a follow-on procurement contract will acquire quantities of product to meet Full Operational Capability (FOC). Subsequent purchases for product sustainment will be made by the Defense Logistics Agency Troop Support. Post marketing commitments and requirements are anticipated as a result of the FDA approval and will be the responsibility of the contractor and the government.

SERVICE EQUIPMENT DECONTAMINATION SYSTEM (SEDS)

The Joint Service Equipment Decontamination System (SEDS) and Special Operations Forces (SOF) Critical Equipment Decontamination System (CEDS) program will utilize the Countering Weapons of Mass Destruction Other Transaction Authority (CWMD OTA) to design and develop state of the art equipment using competitive and iterative prototyping. The program will test prototypes against live chemical warfare agents and biological warfare agents, conduct reliability, availability, and maintainability testing, conduct regular user evaluations to identify human system integration issues, and will conduct testing to ensure the system meets military standards. The program will use the Request for Prototype Proposals (RPP), under the CWMD OTA, followed by awards of Prototype Agreement. In FY24, the Program will conduct MS B activities for Special Operation Forces (SOF) and Other Services, conclude Engineering, Manufacturing and Development (EMD) testing, conduct operational testing and limited user evaluations, and conduct a Critical Design Review (CDR) for SOF.

Appropriation/Budget ActivityR-1 Program Element (Number/Name)Project (Number/Name)0400 / 4PE 0603884BP / Chemical and Biological Defense Program - Dem/ValMT4 / Mitigate (ACD&P)	Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	I Defense Program	Date: March 2023
		PE 0603884BP / Chemical and Biological	 ,

TACTICAL CONTAMINATION MITIGATION SYSTEM (TCMS)

The Tactical Containment Mitigation System (TCMS) program will develop the equipment, processes and procedures for contamination mitigation related to post-incident operations in a Chemical Biological Radiological and Nuclear (CBRN) contaminated environment. The acquisition strategy includes market research through both Requests for Information (RFIs) and a call for White Papers through an Other Transaction Authority (OTA) contracting approach. Data collected will inform a Milestone A decision in FY23. The OTA vehicle will also be used to request prototypes, which will undergo technology demonstrations and Early Field testing, followed by an analysis to determine the most suitable candidate. Results of Prototyping will inform Milestone B and Request for Proposals (RFPs) followed by developmental and operational testing and Milestone C/Full Rate Production Approval.

Appropriation/Budge 0400 / 4	t Activity	,				PE 060	•	Chemica	l umber/Na al and Biol /al	,		: (Number <i>Nitigate (A</i>	,		
Product Developmen	nt (\$ in Mi	illions)		FY 2	2022	FY 2	2023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
ADS - HW C - Prototype Modification	TBD	TBD : N/A	-	0.000		0.000		0.356	Jan 2024	-		0.356	Continuing	Continuing	0.000
BIOPROTO - Clinical/Non- clinical studies for Broad Spectrum antibacterial/ antiviral candidates	MIPR	U.S. Army Contracting Command (ACC- NJ) : Picatinny, NJ	-	0.000		2.572	Oct 2022	0.000		-		0.000	0.000	2.572	0.000
BOT TX - Nonclinical/ Manufacturing	Various	Various : N/A	-	0.000		0.000		6.590	Dec 2023	-		6.590	Continuing	Continuing	0.000
CNATS - Acq Activities/ Pre M/S B	Various	Various : N/A	-	0.000		0.000		2.925	Mar 2024	-		2.925	Continuing	Continuing	0.000
CNATS - Product Management	Various	JPM CBRN Medical, JPEO-CBRND : Fort Detrick, MD	-	0.000		0.000		0.535	Nov 2023	-		0.535	Continuing	Continuing	0.000
DOMANE	MIPR	U.S. Army Contracting Command (ACC- NJ) : Picatinny, NJ	-	0.000		1.038	Oct 2022	0.000		-		0.000	0.000	1.038	0.000
RNATS - HW C - Development	Various	JPM CBRN Medical, JPEO-CBRND : Fort Detrick, MD	-	0.000		0.000		4.208	Jun 2024	-		4.208	Continuing	Continuing	0.000
RNATS - Product Development	Various	JPM CBRN Medical, JPEO-CBRND : Fort Detrick, MD	-	0.000		0.000		0.482	Jan 2024	-		0.482	Continuing	Continuing	0.000
SEDS - HW S - Product Development	SS/FFP	TBD : N/A	-	0.000		4.366	Nov 2022	0.000		-		0.000	0.000	4.366	0.000
TCMS - HW S - Product Development	C/FFP	TBD : N/A	-	0.000		1.256	Nov 2022	1.800	Jan 2024	-		1.800	Continuing	Continuing	0.000
		Subtotal	-	0.000		9.232		16.896		-		16.896	Continuing	Continuing	N/A

Exhibit R-3, RDT&E F	Project C	ost Analysis: PB 2	2024 Che	mical and	Biologic	al Defens	e Prograr	n				Date:	March 20	023	
Appropriation/Budge 0400 / 4	t Activity	/				PE 060		Chemica	lumber/N al and Biol Val			: (Numbe <i>Aitigate (A</i>	,		
Support (\$ in Millions	port (\$ in Millions) Contract Method & Type Performing Activity & Location - Engineering Support MIPR TBD : N/A S - ILS S - Logistics, neering and IPT ort MIPR Various : N/A S - ES S - Logistics, neering and IPT ort MIPR Various : N/A S - ES S - Logistics, neering and IPT ort MIPR Various : N/A S - ES S - Logistics, neering and IPT ort MIPR Various : N/A S - ES S - Logistics, neering and IPT MIPR Various : N/A S - ES S - Logistics, neering and IPT MIPR Performing Activity & Location S - DTE C - Prototype m Testing MIPR TBD : N/A S - OTHT S - T&E IPR Planning Various N/A S - OTHT S - T&E IPR Planning MIPR Various : N/A S - OTHT S - T&E IPR Planning MIPR Various : N/A S - OTHT S - T&E IPR Test ing MIPR Various : N/A Subtotal		FY 2	022	FY 2023			2024 ase		2024 CO	FY 2024 Total]			
Cost Category Item	Method		Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
ADS - Engineering Support	MIPR	TBD : N/A	-	0.000		0.000		0.225	Nov 2023	-		0.225	Continuing	Continuing	0.000
SEDS - ILS S - Logistics, Engineering and IPT Support	MIPR	Various : N/A	-	0.000		2.098	Nov 2022	0.000		-		0.000	0.000	2.098	0.000
TCMS - ES S - Logistics, Engineering and IPT Support	MIPR	Various : N/A	-	0.000		0.684	Nov 2022	0.981	Nov 2023	-		0.981	Continuing	Continuing	0.000
	1	Subtotal	-	0.000		2.782		1.206		-		1.206	Continuing	Continuing	N/A
Test and Evaluation ((\$ in Milli	ons)		FY 2	:022	FY 2	2023		2024 ase		2024 CO	FY 2024 Total]		
Cost Category Item	Method		Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
ADS - DTE C - Prototype System Testing	MIPR	TBD : N/A	-	0.000		0.000		0.827	Nov 2023	-		0.827	Continuing	Continuing	0.000
AVO TX - Non Clinical Studies	Various	Various : N/A	-	0.000		0.000		2.940	Dec 2023	-		2.940	Continuing	Continuing	0.000
SEDS - OTHT S - T&E IPR Test Planning	MIPR	Various : N/A	-	0.000		2.280	Nov 2022	0.000		-		0.000	0.000	2.280	0.000
TCMS - OTHT S - Prototype T&E IPR Test Planning	MIPR	Various : N/A	-	0.000		1.732	Jan 2023	3.358	Nov 2023	-		3.358	Continuing	Continuing	0.000
		Subtotal	-	0.000		4.012		7.125		-		7.125	Continuing	Continuing	N/A
Management Service				FY 2	022	FY 2	2023		2024 ase		2024 CO	FY 2024 Total]		
Cost Category Item		Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
ADS - PM/MS C - Program Management	MIPR	TBD : N/A	-	0.000		0.000			Nov 2023	-			Continuing		
AVO TX - Management Support	Various	Various : N/A	-	0.000		0.000		0.800	Dec 2023	-		0.800	Continuing	Continuing	0.000

PE 0603884BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program

Exhibit R-3, RDT&E	•				Diologio	1	•			、	.		March 20		
Appropriation/Budge 0400 / 4	et Activity	/				PE 060	-	Chemica	umber/Na al and Biol /al		-	t (Numbe i <i>Aitigate (A</i>			
Management Service	es (\$ in M	illions)		FY 2	2022	FY 2	2023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
BOT TX - Various	Various	Various : N/A	-	0.000		0.000		1.257	Dec 2023	-		1.257	Continuing	Continuing	0.000
CNATS - Management Services	Various	JPM CBRN Medical, JPEO-CBRND : Fort Detrick, MD	-	0.000		0.000		0.428	Nov 2023	-		0.428	Continuing	Continuing	0.000
RNATS - Management Support	Various	JPM CBRN Medical, JPEO-CBRND : Fort Detrick, MD	-	0.000		0.000		0.580	Dec 2023	-		0.580	Continuing	Continuing	0.000
SEDS - PM/MS S - Program Management Support	MIPR	Various : N/A	-	0.000		0.771	Nov 2022	0.000		-		0.000	0.000	0.771	0.000
TCMS - PM/MS S - Program Management Support	C/FFP	TBD : N/A	-	0.000		0.505	Nov 2022	0.401	Jan 2024	-		0.401	Continuing	Continuing	0.000
		Subtotal	-	0.000		1.276		3.558		-		3.558	Continuing	Continuing	N/A
			Prior Years	FY 2	2022	FY	2023		2024 Ise		2024 CO	FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract
		Project Cost Totals	-	0.000		17.302		28.785		-		28.785	Continuing	Continuing	N/A

Remarks

hibit R-4, RDT&E Schedule Profile: PB 2024 C	hen	nical a	and E	Biolo	gica	al De	efense	e Prog	gram											I	Date	: Ma	arch	202	3		
propriation/Budget Activity 00 / 4							PE	1 Pro 5 0603 efense	3884	BP /	Che	mic	al a				1			•	mbe ate (A						
		FY 20	022		F	FY 20	023		FY 2	024			FY 2	2025			FY 2	2026			FY 2	027			FY 20	028	
	1	2	3	4	1	2	3 4	l 1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
ADS - Initial Concept Prototype																											
ADS - MDD-Materiel Development Decision																											
ADS - DT&E-Developmental Test and Evaluation - Prototyping Demonstration									ĺ																		
ADS - MS A-Milestone A																											
ADS - MS B-Milestone B																											
ADS - MS C-Milestone C																											
AVO TX - Non-clinical Studies-Non-clinical Studies - Natural History, efficacy, dose ranging and pivotal studies																											
BIOPROTO - CDD Validation-Capability Development Document Validation																											
BOT TX - Non-clinical Studies-Non-clinical Studies																											
BOT TX - Manufacturing Scale-up																											
CNATS - Pre Milestone B																											
CNATS - Acquisition activities																											
CNATS - MDD-Materiel Development Decision																											
CNATS - MS B-Milestone B																											
CNATS - MS C-Milestone C																											
CNATS - FDA Approval-Food and Drug Administration Approval																											
RNATS - DT&E-Developmental Test and Evaluation - Initiate natural history studies																											
RNATS - MS B-Milestone B																											

Exhibit R-4, RDT&E Schedule Profile: PB 2024 C	he	mic	al ai	nd B	Biolo	ogic	al D	Defe	nse	Pro	gra	am													Dat	e: M	arch	20 ו	23		
Appropriation/Budget Activity 0400 / 4		R-1 Program Element (Number/Name)														Project (Number/Name) MT4 / Mitigate (ACD&P)															
		F١	í 20	22			FY 2	202	3		F	Y 20)24		I	FY	202	5		FY	20	26			FY	2027	7		FY	202	8
	1	1	2 3	3 4	4	1	2	3	4	1		2	3	4	1	2	3	4	1	2	2	3	4	1	2	3	4	1	2	3	4
SEDS - Prototype Agreement Award (SOF and Other Services)																															
SEDS - CDD Validation-Capability Development Document Validation - Other Services																															
SEDS - Early Developmental Testing (Other Services)																															
SEDS - MS B-Milestone B - Other Services		_																													
SEDS - DT&E-Developmental Test and Evaluation - Other Services																															
SEDS - MS C-Milestone C - Other Services		_																													
SEDS - FRP-Full Rate Production Decision - Other Services																															
SEDS - DT&E-Developmental Test and Evaluation - SOF																															
SEDS - RFP-Development Request for Proposal Release Decision - SOF and Other Services																															
SEDS - MS B-Milestone B - SOF																															
SEDS - MS C-Milestone C - SOF																															
SEDS - IOC-Initial Operational Capability - SOF																															
SEDS - FOC-Full Operational Capability - SOF																															
TCMS - Market Research																															
TCMS - RFP-Development Request for Proposal Release Decision																															
TCMS - Prototype Contract Award																															
TCMS - Life Cycle Sustainment Plan (LCSP)																															

PE 0603884BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program UNCLASSIFIED Page 54 of 113

xhibit R-4, RDT&E Schedule Profile: PB 2024 C	her	nica	al a	nd I	Biol	ogi	cal	Defe	ens	se Pi	rog	Iram	l												Da	te: N	larc	ch 2	202	3		
ppropriation/Budget Activity 400 / 4	0/4								R-1 Program Element (Number/Name) PE 0603884BP <i>I Chemical and Biological</i> <i>Defense Program - Dem/Val</i>									Project (Number/Name) MT4 / Mitigate (ACD&P)														
		FY	[′] 20	22			FY	202	23			FY 2	2024	Ļ		FY	20	25		F	Y 20	026			FY	202	7		F	FY 2	028	3
	1	2	2 3	3	4	1	2	3	3	4	1	2	3	4	1	2	3	3 4	1	1	2	3	4	1	2	3	4	L	1	2	3	4
TCMS - System Readiness Review (SRR)																																
TCMS - Test and Evaluation Master Plan (TEMP)																																
TCMS - Test Readiness Review (TRR)																																
TCMS - Simplified Acquisition Management Plan (SAMP)																																_
TCMS - MS A-Milestone A		_																														_
TCMS - Prototype Testing																																-
TCMS - Acquisition Program Baseline (APB)																																
TCMS - CDD Validation-Capability Development Document Validation																																
TCMS - MS B-Milestone B																																
TCMS - DT&E-Developmental Test and Evaluation - Developmental Test & Evaluation																																
TCMS - System Verification Review/Production Readiness Review																																
TCMS - MS C-Milestone C																																-
TCMS - FRP-Full Rate Production Decision																																

nibit R-4A, RDT&E Schedule Details: PB 2024 Chemical and Biological Defense	e Program		Date: Marc	h 2023
0/4 PE 0	Program Element (Numbe)603884BP / Chemical and ense Program - Dem/Val		Project (Number/Nam MT4 / Mitigate (ACD&F	,
Schedu	le Details			
	St	art	En	ıd
Events	Quarter	Year	Quarter	Year
ADS - Initial Concept Prototype	1	2024	3	2027
ADS - MDD-Materiel Development Decision	2	2024	2	2024
ADS - DT&E-Developmental Test and Evaluation - Prototyping Demonstration	3	2024	3	2026
ADS - MS A-Milestone A	4	2025	4	2025
ADS - MS B-Milestone B	3	2026	3	2026
ADS - MS C-Milestone C	4	2028	4	2028
AVO TX - Non-clinical Studies-Non-clinical Studies - Natural History, efficacy, de ranging and pivotal studies	ose 1	2025	2	2025
BIOPROTO - CDD Validation-Capability Development Document Validation	1	2023	4	2023
BOT TX - Non-clinical Studies-Non-clinical Studies	1	2025	4	2025
BOT TX - Manufacturing Scale-up	1	2025	4	2025
CNATS - Pre Milestone B	1	2024	4	2024
CNATS - Acquisition activities	1	2025	1	2026
CNATS - MDD-Materiel Development Decision	2	2025	2	2025
CNATS - MS B-Milestone B	1	2027	1	2027
CNATS - MS C-Milestone C	4	2028	4	2028
CNATS - FDA Approval-Food and Drug Administration Approval	4	2028	4	2028
RNATS - DT&E-Developmental Test and Evaluation - Initiate natural history stu	dies 3	2024	3	2025
RNATS - MS B-Milestone B	3	2025	3	2025
SEDS - Prototype Agreement Award (SOF and Other Services)	4	2022	4	2022
SEDS - CDD Validation-Capability Development Document Validation - Other S	ervices 1	2023	2	2023
SEDS - Early Developmental Testing (Other Services)	1	2023	3	2023

0/4 PE	1 Program Element (Numb 0603884BP / Chemical and fense Program - Dem/Val		Date: Marc oject (Number/Nam 74 / Mitigate (ACD&F	ie)
· · · · · · · · · · · · · · · · · · ·	S	Start	Er	nd
Events	Quarter	Year	Quarter	Year
SEDS - MS B-Milestone B - Other Services	4	2023	4	2023
SEDS - DT&E-Developmental Test and Evaluation - Other Services	1	2024	3	2025
SEDS - MS C-Milestone C - Other Services	3	2026	3	2026
SEDS - FRP-Full Rate Production Decision - Other Services	4	2027	4	2027
SEDS - DT&E-Developmental Test and Evaluation - SOF	3	2022	4	2023
SEDS - RFP-Development Request for Proposal Release Decision - SOF and Services	Other 4	2022	4	2022
SEDS - MS B-Milestone B - SOF	3	2023	3	2023
SEDS - MS C-Milestone C - SOF	4	2024	4	2024
SEDS - IOC-Initial Operational Capability - SOF	2	2026	2	2026
SEDS - FOC-Full Operational Capability - SOF	4	2028	4	2028
TCMS - Market Research	1	2022	3	2022
TCMS - RFP-Development Request for Proposal Release Decision	3	2022	3	2022
TCMS - Prototype Contract Award	4	2022	4	2022
TCMS - Life Cycle Sustainment Plan (LCSP)	2	2023	2	2023
TCMS - System Readiness Review (SRR)	2	2023	2	2023
TCMS - Test and Evaluation Master Plan (TEMP)	2	2023	2	2023
TCMS - Test Readiness Review (TRR)	3	2023	3	2023
TCMS - Simplified Acquisition Management Plan (SAMP)	3	2023	3	2023
TCMS - MS A-Milestone A	3	2023	3	2023
TCMS - Prototype Testing	1	2024	2	2024
TCMS - Acquisition Program Baseline (APB)	3	2024	3	2024
TCMS - CDD Validation-Capability Development Document Validation	2	2025	2	2025
TCMS - MS B-Milestone B	2	2025	2	2025
TCMS - DT&E-Developmental Test and Evaluation - Developmental Test & Ev	valuation 3	2025	3	2026
TCMS - System Verification Review/Production Readiness Review	3	2026	3	2026

Exhibit R-4A, RDT&E Schedule Details: PB 2024 Chemical and Biological	Defense Program	1			Date: Marc	ch 2023		
Appropriation/Budget Activity 0400 / 4		Element (Numbe P I Chemical and I ram - Dem/Val	,	Project (Number/Name) MT4 / Mitigate (ACD&P)				
	·	St	art		E	nd		
Events		Quarter	Year		Quarter	Year		
TCMS - MS C-Milestone C		4	2026		4	2026		
TCMS - FRP-Full Rate Production Decision		4	2027		4	2027		

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program												
Appropriation/Budget Activity 0400 / 4	PE 060388	am Elemen 34BP / Chen rogram - De	nical and Bi		Project (Number/Name) EN4 / Enabling Investments (ACD&P)							
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
EN4: Enabling Investments (ACD&P)	-	0.000	6.781	47.272	0.000	47.272	51.579	9.792	9.840	9.840	Continuing	Continuing
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

The Enabling Investments Advanced Component Development and Prototypes (ACD&P) Project maintains the Department of Defense (DoD) advanced development manufacturing facility to rapidly develop, manufacture, and approve medical countermeasures. Enabling efforts in this area support dedicated infrastructure capabilities, demonstrations, and overarching development support functions as portfolio enablers responding to emerging threats. Priority access to the facility provides an on demand manufacturing capability not only for the DoD but for the entire United States Government enterprise. In FY 2023, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. EN4 efforts in FY 2022 remain in Project MB4. This restructuring provided standardization and alignment across CBDP research, development and acquisition efforts.

Efforts included in this Project are:

(1) Chem Bio Incident Preparedness and Response - Advanced Development and Manufacturing (CBIPR-ADM)(2) Medical Countermeasures Manufacturing Optimization (MCM MFRO)

The CBIPR-ADM ensures prioritization to domestic biopharmaceutical manufacturing capacities, capabilities, and infrastructure (e.g. the DoD-ADM Facility and other strategic partners) that are operationally ready to rapidly develop and manufacture medical countermeasures (MCMs) against current and emerging chemical and biological threats including pandemic response. Prioritization is achieved by establishing and enhancing proven biopharmaceutical manufacturing platform technologies and infrastructure at these facilities. Thus, these facilities will have the capability to accelerate development of MCMs at all stages of development, enhance preparedness for existing threats, and rapidly respond to emerging threats as part of a medical integrated layered defense. MCMs that benefit from these efforts include: Vaccines for Viral Agents, Vaccines for Bacterial Agents and Toxins, monoclonal antibodies, antibody fragments and conjugates for therapeutic and prophylactic use across all agent classes. Funds to support prioritization and operational readiness were previously provided via individual product development and manufacturing funding lines. The Department is now providing dedicated funds. The CBIPR-ADM return on investment is an increased level of preparedness and responsiveness. In FY24, the CBIPR-ADM program continues to establish and enhance new manufacturing platform technologies and infrastructure that will enable the development of MCMs against chemical and biological threats.

The MCM MFRO postures the DoD to rapidly respond to biological incidents by leveraging partners across Industrial Base, Chemical and Biological Defense Program, and Defense Health Program to reduce time required to onshore materials critical to the rapid production of medical countermeasures. Furthermore, MCM MFRO will increase the use of computational tools and manufacturing controls to optimize development of MCMs for accelerated delivery to the Warfighter. In FY24, MCM MFRO will increase usage of computational tools and manufacturing controls, initiate optimization of cell productivity, initiate development of starting materials and conduct a process efficiency study.

PE 0603884BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biolog	gical Defense Program		Date: N	arch 2023	
Appropriation/Budget Activity 0400 / 4	R-1 Program Element (Number/Name) PE 0603884BP <i>I Chemical and Biological</i> <i>Defense Program - Dem/Val</i>		t (Number/N Enabling Inve	lame) estments (AC	D&P)
B. Accomplishments/Planned Programs (\$ in Millions)			FY 2022	FY 2023	FY 2024
Title: 1) CBIPR-ADM			-	6.781	9.172
Description: Establish proven enabling manufacturing technologies at the Building.	Department of Defense (DoD) ADM Capability				
FY 2023 Plans: Continue technology transfer and enhancement of manufacturing technologies (MCM) development against biological threats. Manufacturing technologies the Joint Science & Technology Office for Chemical Biological Defense (JS (WRAIR), the Biomedical Advanced Research and Development Authority and other external sources and targets of opportunity from industry.	s can come from any government sources (includ TO-CBD), the Walter Reed Army Institute of Rese	ing earch			
FY 2024 Plans: Continue activities to technology-transfer and establish new manufacturing development and manufacturing of medical countermeasures (MCMs) at th approach ensures that the DoD's efforts are not limited to a single facility. N government sources (including JSTO, WRAIR, BARDA, etc. when mature e and targets of opportunity from industry.	e DoD-ADM Facility and strategic partners. This New manufacturing technologies can come from a				
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.					
Title: 2) MCM MFRO			-	-	27.000
Description: Biologics Optimization					
FY 2024 Plans: Initiate optimization of computational tools and manufacturing tools to reduct countermeasures through optimization of cell productivity and control, in ord stability.	•				
FY 2023 to FY 2024 Increase/Decrease Statement: Additional investment to advance the overarching goals aligned with the 20 Plan (NBS).	22 National Biodefense Strategy and Implementa	tion			
Title: 3) MCM MFRO			-	-	10.800
Description: Small Molecule Synthesis					

PE 0603884BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program

Exhibit R-2A, RDT&E Project Justifi	ication: PB	2024 Chem	ical and Biol	ogical Defen	se Program				Date: M	arch 2023	
Appropriation/Budget Activity 0400 / 4				PE 06	rogram Eler 03884BP / 0 se Program	chemical and			(Number/N Enabling Inve	a me) estments (AC	CD&P)
B. Accomplishments/Planned Prog	<u>rams (\$ in I</u>	<u>Millions)</u>							FY 2022	FY 2023	FY 2024
FY 2024 Plans: Initiate development of critical reagen sourcing of starting materials and critic								bid			
FY 2023 to FY 2024 Increase/Decrea Additional investment to advance the Plan (NBS).			ed with the 2	022 Nationa	l Biodefense	Strategy an	d Implement	ation			
Title: 4) MCM MFRO									-	-	0.300
Description: Process Improvement/C	Quality										
FY 2024 Plans: Initiate quality release process efficier	ncy study to	reduce dela	ys in the ma	nufacturing	batch releas	e process.					
FY 2023 to FY 2024 Increase/Decrea Additional investment to advance the Plan (NBS).			ed with the 2	022 Nationa	l Biodefense	Strategy an	d Implement	ation			
				Accor	nplishment	s/Planned P	rograms Su	btotals	-	6.781	47.272
C. Other Program Funding Summar	ry (\$ in Milli	ions)									
			<u>FY 2024</u>	<u>FY 2024</u>	FY 2024					Cost To	-
Line Item • EN5: Enabling Investments (SDD) Remarks	<u>FY 2022</u> -	FY 2023 13.392	<u>Base</u> 13.835	<u>000</u> -	<u>Total</u> 13.835	<u>FY 2025</u> 13.884	<u>FY 2026</u> 14.179	<u>FY 2027</u> 14.197		 <u>Complete</u> Continuinç 	
D. Acquisition Strategy CHEM BIO INCIDENT PREPAREDN	IESS AND F	RESPONSE	- (CBIPR-AD	DM)							
CBIPR-ADM establishes new capabil infrastructure improvements that will e operational readiness so that it can co ADM will implement a facility-agnostic	enable new ontinue to b c approach	additional m e an endurin for tech trans	edical count og domestic l sferring and	ermeasure (MCM manufa enhancing n	MCM) produ acturing cap	ct developm ability that pr	ent. This line ovides the D ologies and ir	e ensures oD with p	the DOD AD)M is in a sta s. In FY24 (ite of CBIPR-
manufacturing of MCMs against chen	nical/biologi	cal threats.	This approa	ch ensures t	hat these eff	orts are not	imited to a si		ty in order to	o provide rap	

xhibit R-2A, RDT&E Project Justification: PB 2024 C		Date: March 2023
Appropriation/Budget Activity 400 / 4	R-1 Program Element (Number/Name) PE 0603884BP / Chemical and Biological Defense Program - Dem/Val	Project (Number/Name) EN4 I Enabling Investments (ACD&P)
o known and unknown threats. New manufacturing tech for BA4 funding) and other external sources and targets	nnologies can come from any government sources (including JSTC of opportunity from industry.), WRAIR, BARDA, etc. when mature enoug
Medical Countermeasures Manufacturing Optimization		
API) and key starting materials (KSMs)) critical to produ	nd buy down risks to manufacturing by prioritizing onshoring of key ice DoD-unique enhanced biodefense medical countermeasure ne ce the risk associated with cost per dose and time to field, as well	eds. Additionally, increased use of

Exhibit R-3, RDT&E	Project C	ost Analysis: PB 2	024 Che	mical and	l Biologic	al Defens	e Progran	n				Date:	March 20)23	
Appropriation/Budge 0400 / 4	et Activity	/				PE 060	-	Chemica	lumber/N a al and Biol Val	Project (Number/Name) EN4 / Enabling Investments (ACD&P)					
Product Developmen	nt (\$ in M	illions)		FY 2	2022	FY 2	2023		2024 ase		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
CBIPR-ADM - Capability Establishment (Establish "Cell Free" Manufacturing Platform)	C/CPFF	Ology : Alachua, FL	-	0.000		6.473	Dec 2022	8.830	Dec 2023	-		8.830	Continuing	Continuing	0.000
CBIPR-ADM - Product Management Support	C/CPFF	Various : N/A	-	0.000		0.308	Dec 2022	0.342	Jan 2024	-		0.342	Continuing	Continuing	0.000
MCM MFRO - Development	Various	TBD : N/A	-	0.000		0.000		35.052	Dec 2024	-		35.052	Continuing	Continuing	0.000
		Subtotal	-	0.000		6.781		44.224		-		44.224	Continuing	Continuing	N/A
Management Service	es (\$ in M	lillions)		FY 2	2022	FY 2	2023		2024 ase		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
MCM MFRO - Program Management	Various	Various : N/A	-	0.000		0.000		3.048	Dec 2024	-		3.048	Continuing	Continuing	0.000
	-	Subtotal	-	0.000		0.000		3.048		-		3.048	Continuing	Continuing	N/A
			Prior Years	FY 2	2022	FY 2	2023		2024 ase		2024 CO	FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract
		Project Cost Totals	-	0.000		6.781		47.272		-		47.272	Continuing	Continuing	N/A

Remarks

Exhibit R-4, RDT&E Schedule Profile: PB 2024 C	hemical and Biological Defe	ense Program	Date: March 2023
Appropriation/Budget Activity 0400 / 4		R-1 Program Element (Number/Name) PE 0603884BP <i>I Chemical and Biological</i> <i>Defense Program - Dem/Val</i>	Project (Number/Name) EN4 / Enabling Investments (ACD&P)
	FY 2022 FY 2022 1 2 3 4 1 2 3		Y 2026 FY 2027 FY 2028 2 3 4 1 2 3 4
CBIPR-ADM - MCM Enabling Manufacturing Technologies			
CBIPR-ADM - MCM Development and Manufacturing Support (Infrastructure)			
MCM MFRO - Biologics Molecular Optimization			
MCM MFRO - Small molecule synthesis and scale up			
MCM MFRO - Process Efficiency Study			

khibit R-4A, RDT&E Schedule Details: PB 2024 Chemical and Biological Defense Prog	ram		Date: Ma	rch 2023		
PE 060388	am Element (Numbe 34BP / Chemical and rogram - Dem/Val	,	Project (Number/Name) EN4 <i>I Enabling Investments (ACD&P)</i>			
Schedule De	tails					
	St	art		End		
Events	Quarter	Year	Quarter	Year		
CBIPR-ADM - MCM Enabling Manufacturing Technologies	1	2022	4	2028		
CBIPR-ADM - MCM Development and Manufacturing Support (Infrastructure)	1	2022	4	2028		
MCM MFRO - Biologics Molecular Optimization	1	2024	4	2028		
0		2024	•	2020		
MCM MFRO - Small molecule synthesis and scale up	1	2024	4	2028		

Exhibit R-2A, RDT&E Project Ju	Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program												
Appropriation/Budget Activity 0400 / 4	PE 060388	am Elemen 34BP / Cher rogram - De	nical and B		Project (Number/Name) CA4 I Contamination Avoidance (ACD&P)								
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost	
CA4: Contamination Avoidance (ACD&P)	-	37.189	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	37.189	
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-			

A. Mission Description and Budget Item Justification

The Contamination Avoidance Advanced Component Development and Prototypes (ACD&P) Project supports reconnaissance, detection, identification, and hazard prediction equipment, hardware, and software. After FY 2022, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. CA4 efforts in FY 2022 progress to Project UN4. This restructuring provides standardization and alignment across CBDP research, development and acquisition efforts.

Efforts included in this Project are:

(1) Advanced Emerging Threat Defense (AET DEFENSE) ** Progresses to UN4 in FY2023**,

(2) CBRN Support to Command and Control (CSC2) **Progresses to UN4 in FY2023**, and

(3) Compact Vapor Chemical Agent Detector (CVCAD) ** Progresses to UN4 in FY2023**

The AET DEFENSE program continues to address the highest priority CBRN gaps and supports the Chemical Biological Defense Program (CBDP) Strategic Line of Effort to meet current and emerging threats by anticipating CB hazards and developing capabilities to counter emerging and future threats. The AET Defense program collaborates with the Joint Services, interagency, and international partners to align RDT&E resources to determine readiness against emerging threats, to include NTAs, such as Novichoks and Pharmaceutical-Based Agents (PBA) (e.g. synthetic opioids), emerging biological threats, and other advanced and emerging threats as they are identified across the entire CBDP enterprise portfolio.

CSC2 is the overarching System of Systems (SoS) that provides for the interoperability and integration of CBRN and Non CBRN sensors to achieve needed situational awareness and understanding to accomplish CBRN integrated layered defense, interdependent with Service and Mission Partner Common Operating Environments and Computing Environments (CoE/CE). This is not achievable in current Command and Control constructs. CSC2 addresses this objective by establishing a Service and Joint All Domain Command and Control (JADC2) compatible CBRN CoE architecture and deployment environments.

This consolidates CSC2 with Modernization CBRN Information Systems (MOD CBRN IS) in order to gain efficiencies of managing funding and programmatic efforts under one line. Additionally, it allows the consolidation of continuous engineering for the currently deployed legacy CBRN information systems (Joint Effects Model (JEM)/Joint Warning and Reporting Network (JWARN), CBRN Information System (CBRN IS)). This maintains the stopgap capability for CBRN warning, reporting, and effects modeling while setting conditions for the sun setting of the legacy capabilities replaced by CSC2 capabilities beginning in FY27. The approach to consolidate simplifies software BA7 management under one line (like the BA7 in other CBDP commodity areas) and synchronizes the sunset of legacy JEM and JWARN capabilities as replacement capabilities are deployed through CSC2.

Exhibit N-2A, NDT&E TTOJECT JUST	ification: PB	2024 Chem	ical and Biol	ogical Defen	ise Program				Date: M	larch 2023	
Appropriation/Budget Activity 0400 / 4				PE 06	rogram Eler 03884BP / 0 se Program	Chemical and			ct (Number/N Contaminatio	,	(ACD&P)
CVCAD is designed to be an unobtr units to an unsafe environment with amenable to both man-worn and un FY24 after milestone B decisions co engineering manufacturing and deve	out further bui manned aeria ompeting proto	rdening the I or ground otypes will u	warfighters p system oper ndergo dowr	bayload or in ations to ena selects bas	iterfering wit able timely p sed on perfo	n the primary ersonnel pro rmance and	v mission. Th tective action	e small f n and oth	orm factor (le	ess than 2 lbs	.) is ons. In
B. Accomplishments/Planned Prog	grams (\$ in N	<u>/lillions)</u>						ſ	FY 2022	FY 2023	FY 2024
Title: 1) AET DEFENSE									10.074	-	-
Description: Program Management assess performance against advance				Testing to de	emonstrate a	and evaluate	technologies	s to			
Title: 2) CSC2									4.400	-	-
Description: Automated Warning, F (COE) and CoE Convergence.	Reporting , An	alysis and d	lecision supp	ort tools. So	ervice Comn	non Operatin	g Environme	ent			
Title: 3) CSC2									2.321	-	-
Description: Program Management	t and Support										
Title: 4) CSC2									14.174	-	-
Description: Product Development,	, Integration a	nd Sensor N	/lanagement								
Title: 5) CVCAD									6.220	-	-
Description: Prototype Advanced D	evelopment,	Testing & P	rogram Mana	agement							
				Accor	nplishment	s/Planned P	rograms Su	btotals	37.189	-	-
C. Other Program Funding Summa	ary (\$ in Milli	ons)									
			<u>FY 2024</u>	<u>FY 2024</u>	<u>FY 2024</u>					<u>Cost To</u>	
I :	FY 2022	<u>FY 2023</u>	Base	000	<u>Total</u>	<u>FY 2025</u>	<u>FY 2026</u>	<u>FY 202</u>	27 FY 202		
Line Item	Q/ 067	-	-	-	-	-	-	-		0.000	84.96
CA5: Contamination	84.967										
	04.907	52.708	61.638	_	61.638	64.399	48.874	41.26	34 38 16	9 Continuing	Continuir

PE 0603884BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program UNCLASSIFIED Page 67 of 113

R-1 Line #79

Exhibit R-2A, RDT&E Project Justif	ication: PB	2024 Chemi	cal and Biolo	ogical Defen	se Program				Date: Ma	rch 2023	
Appropriation/Budget Activity 0400 / 4				PE 06		nent (Numb Chemical and - Dem/Val			Number/Na	m e) Avoidance	(ACD&P)
C. Other Program Funding Summar	ry (\$ in Milli	<u>ons)</u>									
			<u>FY 2024</u>	<u>FY 2024</u>	<u>FY 2024</u>					<u>Cost To</u>	
Line Item	<u>FY 2022</u>	<u>FY 2023</u>	Base	000	<u>Total</u>	<u>FY 2025</u>	FY 2026	FY 2027	<u>FY 2028</u>	<u>Complete</u>	Total Cost
• SA0005: CBRN Sensor Integration On Robotic Platforms (CSIRP)	3.461	2.099	-	-	-	-	-	-	-	0.000	6.063
SA0050: CBRN Support to C2 (CSC2)	1.750	11.803	2.186	-	2.186	2.257	2.366	2.451	2.549	Continuing	Continuing

<u>Remarks</u>

D. Acquisition Strategy

ADVANCED AND EMERGING THREAT DEFENSE (AET DEFENSE)

The AET DEFENSE program will use a variety of acquisition approaches to survey, develop, assess, and rapidly field technologies to inform and fill advanced and emerging threat gaps. The program will utilize an existing Multiple Award Indefinite Delivery Indefinite Quantify Task Order Contract to provide technical support to studies and assessments of performance against emerging threats. For Program of Record (PoR) systems currently in development that will be assessed for performance against emerging threats, those PoR's existing contracts will be modified to incorporate development engineering and test support for emerging threat capability. The AET DEFENSE program will utilize OTAs for system development and prototyping activities and Government Agencies and Federally Funded Research and Development Centers to provide development, testing and technical support.

CBRN SUPPORT TO C2 (CSC2)

CSC2 focuses on technology maturation, demonstration, integration and transitioning early warning capability sets to fielded Chemical Biological Defense Program (CBDP) programs of record to combat emerging and potentially urgent threats within Joint All Domain Operations. Contracting strategy includes the use of Other Transaction Authority Research & Development and prototyping. Annual development cycles and capability drops are requested and validated by all Department of Defense (DoD) Services in the Assistant Secretary of Defense (NCB/CB) Integrated Early Warning (IEW) Campaign Plan as well as approved capability development packages designated through the Joint Requirements Office and prioritized based on National Defense Strategy and National Military Strategy goals. Current strategy also collaborates with multi-agency partners to obtain synergy and interoperability across the areas of sensor data analytics, integrated early warning, and protect to warn/protect to treat capabilities. Efforts within CSC2 are driven by Service Chemical Biological Radiological and Nuclear (CBRN) capability gaps that are identified on an annual basis and evaluated by CBDP stakeholders; possible solutions and applicable technologies within the CBDP will be experimented, integrated, networked, and deployed through the software acquisition pathway.

COMPACT VAPOR CHEMICAL AGENT DETECTOR (CVCAD)

The CVCAD program will use the Combating Weapons of Mass Destruction Other Transaction Authority (CWMD OTA) contract vehicle to transition four technologies from Science & Technology (S&T) into the program of record. This streamlined acquisition approach is broken into four phases uses one contracting mechanism to

hibit R-2A, RDT&E Project Justification: PB 2024 C	nemical and Biological Defense Program	Date: March 2023
propriation/Budget Activity 00 / 4	R-1 Program Element (Number/Name) PE 0603884BP / Chemical and Biologica Defense Program - Dem/Val	CA4 I Contamination Avoidance (ACD&P,
	ase I S&T advanced development, Phase II technology transition e IV will execute Production and Development for low rate initia	

Exhibit R-3, RDT&E P	-		024 Che	mical and	d Biologica	1			L / b l		Ductors		March 20	23	
Appropriation/Budge 0400 / 4	t Activity					PE 060	3884BP /		umber/N al and Bio /al			: (Numbe i Contamina	r/ Name) tion Avoia	lance (A0	CD&P)
Product Developmen	it (\$ in Mi	illions)		FY	2022	FY 2	023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
AET DEFENSE - HW C - Emerging threat detection/ decontamination/protection capability prototyping	Various	Various : N/A	-	1.436	Dec 2021	0.000		0.000		-		0.000	0.000	1.436	0.000
AET DEFENSE - SW C - Spectral library enhancements	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	-	2.021	Nov 2021	0.000		0.000		-		0.000	0.000	2.021	0.000
AET DEFENSE - SW C - Hazard awareness tool updates	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	-	1.376	Dec 2021	0.000		0.000		-		0.000	0.000	1.376	0.000
AET DEFENSE - SW C - Physiological Monitoring Architecture	MIPR	Various : N/A	-	2.190	Aug 2022	0.000		0.000		-		0.000	0.000	2.190	0.000
CSC2 - HW C - Contractor Product Development Team Labor	MIPR	JPEO Chem, Bio, Rad, and Nuc Defense (JPEO- CBRND) : Aberdeen Proving Ground, MD	-	0.500	Feb 2022	0.000		0.000		-		0.000	0.000	0.500	0.000
CSC2 - HW C - Operational Capability	C/CPAF	Various : N/A	-	12.074	Feb 2022	0.000		0.000		-		0.000	0.000	12.074	0.000
CSC2 - HW - C Government Product Development Team Labor	MIPR	Various : N/A	-	2.500	Oct 2021	0.000		0.000		-		0.000	0.000	2.500	0.000
CVCAD - HW S - Government Team Labor	Various	Various : N/A	0.581	0.690	Nov 2021	0.000		0.000		-		0.000	0.000	1.271	0.000

PE 0603884BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program

Exhibit R-3, RDT&E F	Project C	ost Analysis: PB 2	2024 Chei	mical and	d Biologica	al Defens	e Prograr	n				Date:	March 20	23	
Appropriation/Budge 0400 / 4	et Activity	/				PE 060	3884BP /		l umber/N al and Bio Val		-	: (Numbe i Contamina	r/Name) ation Avoid	lance (A	CD&P)
Product Developmen	nt (\$ in M	illions)		FY 2	2022	FY 2	023		2024 ase		2024 CO	FY 2024 Total]		
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
CVCAD - HW S - Advanced Prototype Development	C/FFP	Advanced Technologies International : Summerville, SC	-	3.856	Oct 2021	0.000		0.000		-		0.000	0.000	3.856	0.000
	L	Subtotal	0.581	26.643		0.000		0.000		-		0.000	0.000	27.224	N/A
Support (\$ in Millions	S)			FY 2	2022	FY 2	023		2024 ase		2024 CO	FY 2024 Total]		<u>`</u>
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
CSC2 - ES C - Contractor Support	C/CPAF	TBD : N/A,	-	0.800	May 2022	0.000		0.000		-		0.000	0.000	0.800	0.000
CSC2 - ES C - Support	MIPR	TBD : N/A,	-	0.700	May 2022	0.000		0.000		-		0.000	0.000	0.700	0.000
CVCAD - ES S - Other Government Agency Developmental Support	MIPR	Various : N/A	-	0.600	Nov 2021	0.000		0.000		-		0.000	0.000	0.600	0.000
		Subtotal	-	2.100		0.000		0.000		-		0.000	0.000	2.100	N/A
Test and Evaluation	(\$ in Milli	ons)	 	EV	2022	FY 2	0022		2024 ase		2024 CO	FY 2024 Total]		
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
AET DEFENSE - DTE S - Technology Assessments	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	-	1.556	Dec 2021	0.000		0.000		-		0.000	0.000	1.556	0.000
CSC2 - DTE C - Technical/ Operational Demo	MIPR	JPEO Chem, Bio, Rad, and Nuc Defense (JPEO-	-	2.000	Jun 2022	0.000		0.000		-		0.000	0.000	2.000	0.000

PE 0603884BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program UNCLASSIFIED Page 71 of 113

Exhibit R-3, RDT&E	Project C	ost Analysis: PB 2	024 Cher	nical and	Biologica	al Defense	e Prograr	n				Date:	March 20	23	
Appropriation/Budge 0400 / 4	et Activity					PE 060	3884BP /		umber/N al and Bio /al			(Numbei Contamina		lance (AC	CD&P)
Test and Evaluation	(\$ in Milli	ons)	[FY2	2022	FY 2	023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
		CBRND) : Aberdeen Proving Ground, MD													
CVCAD - DTE S - Chemical Surety Testing	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	-	0.440	Aug 2022	0.000		0.000		-		0.000	0.000	0.440	0.000
CVCAD - DTE S - MIL- STD Testing	MIPR	Aberdeen Test Center (ATC) : Aberdeen Proving Ground, MD	-	0.080	Jun 2022	0.000		0.000		-		0.000	0.000	0.080	0.000
		Subtotal	-	4.076		0.000		0.000		-		0.000	0.000	4.076	N/A
Management Service	es (\$ in M	illions)	ſ	FY 2	2022	FY 2	023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
AET DEFENSE - PM/MS S - IPT Support/Program Management	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	-	1.495	Dec 2021	0.000		0.000		-		0.000	0.000	1.495	0.000
CSC2 - PM/MS C - Program Management Support	MIPR	Various : N/A	-	2.321	Oct 2021	0.000		0.000		-		0.000	0.000	2.321	0.000
CVCAD - PM/MS S - Program Management Support	MIPR	Various : N/A	0.080	0.554	Nov 2021	0.000		0.000		-		0.000	0.000	0.634	0.000

PE 0603884BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program

Exhibit R-3, RDT&E	Project C	ost Analysis: PB 2	024 Cher	mical and	d Biologic	al Defens	e Prograr	n				Date:	March 20	23	
Appropriation/Budg 0400 / 4	et Activity	/				PE 060	3884BP /	e ment (N Chemica n - Dem/V	al and Bio	,	-	(Numbe Contamina	r/Name) tion Avoid	ance (A	CD&P)
Management Servic	es (\$ in M	illions)		FY 2	2022	FY 2	2023	FY 2 Ba	-		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
		Subtotal	0.080	4.370		0.000		0.000		-		0.000	0.000	4.450	N//
			Prior Years	FY 2	2022	FY 2	2023	FY 2 Ba			2024 CO	FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract
		Project Cost Totals	0.661	37.189		0.000		0.000		-		0.000	0.000	37.850	N/A

xhibit R-4, RDT&E Schedule Profile: PB 2024 C	her	nica	l anc	l Bio	logio	cal [Defe	ense	Prog	gram	l											Dat	te: M	arch	202	23		
Appropriation/Budget Activity 400 / 4								PE	0603	3884		Ch	emi	cal a	nber and E I								oer/N inatio			nce	(AC	CD&P)
		FY	2022	2		FY	202	3		-	2024				2025	5		FY	2026	6			2027			FY 2	028	}
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
AET DEFENSE - Technology Assessments/ Systems Engineering																												
CSC2 - SWP Execution Phase Decision																												
CSC2 - Continuous Software DT/OT																												
CSC2 - MVP (CDP-1)																												
CSC2 - Service Common Operating Environment Integration																												
CSC2 - Cyber Security Compliance																												
CSC2 - CD-Capability Drop - MVCR Delivery 1 (CDP-1)																	I											
CSC2 - MVP (CDP-2)																												
CSC2 - Continuous Engineering & Software Updates																												
CSC2 - Operating System Architecture Updates																												
CSC2 - CD-Capability Drop - MVCR Delivery 2 (CDP-2)																												
CSC2 - Future MVPs																												
CSC2 - CD-Capability Drop - Future MVCR Deliveries																												
CVCAD - CDD Validation-Capability Development Document Validation																												
CVCAD - MS B-Milestone B																												
CVCAD - CDR-Critical Design Review																												
CVCAD - CDD Update																												
CVCAD - MS C-Milestone C																												

PE 0603884BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program UNCLASSIFIED Page 74 of 113

Exhibit R-4, RDT&E Schedule Profile: PB 2024 C	Che	mic	cal	and	l Bic	olog	gica	al E	Defe	ense	Pro	ogr	ram													Da	ite:	Mar	ch	202	23			
Appropriation/Budget Activity 0400 / 4										PE	060	038	884	BP /		em	ical	and	oer/N d Bio			1			•			r/Na Ition			ance	e (A	CD)&F
		F	Y 2	022	2		F	Y:	202	3		F	FY 2	2024	Ļ		F١	(20	25			FY 2	202	6		F١	1 20	27			FY	202	28	
	1	1	2	3	4	•	1	2	3	4	1		2	3	4	1	2	2	3	4	1	2	3	4	1		2	3	4	1	2	3	4	4
CVCAD - LRIP-Low Rate Initial Production									·		·									·												·		
CVCAD - FRP-Full Rate Production Decision																																	_	
CVCAD - IOC-Initial Operational Capability																																		
CVCAD - FOC-Full Operational Capability																																		

xhibit R-4A, RDT&E Schedule Details: PB 2024 Chemical and Biological	Defense Program		Date: Mar	ch 2023
Appropriation/Budget Activity 400 / 4	R-1 Program Element (Numb PE 0603884BP / Chemical and Defense Program - Dem/Val		Project (Number/Nai CA4 / Contamination	
S	chedule Details			
	S	start	E	ind
Events	Quarter	Year	Quarter	Year
AET DEFENSE - Technology Assessments/Systems Engineering	1	2022	4	2028
CSC2 - SWP Execution Phase Decision	2	2023	2	2023
CSC2 - Continuous Software DT/OT	3	2023	4	2028
CSC2 - MVP (CDP-1)	4	2023	4	2023
CSC2 - Service Common Operating Environment Integration	1	2024	4	2028
CSC2 - Cyber Security Compliance	1	2024	4	2028
CSC2 - CD-Capability Drop - MVCR Delivery 1 (CDP-1)	4	2024	4	2025
CSC2 - MVP (CDP-2)	4	2024	4	2024
CSC2 - Continuous Engineering & Software Updates	1	2025	4	2028
CSC2 - Operating System Architecture Updates	1	2025	4	2028
CSC2 - CD-Capability Drop - MVCR Delivery 2 (CDP-2)	4	2025	4	2026
CSC2 - Future MVPs	2	2026	4	2028
CSC2 - CD-Capability Drop - Future MVCR Deliveries	4	2026	4	2028
CVCAD - CDD Validation-Capability Development Document Validation	3	2023	3	2023
CVCAD - MS B-Milestone B	4	2023	4	2023
CVCAD - CDR-Critical Design Review	3	2024	3	2024
CVCAD - CDD Update	3	2025	3	2025
CVCAD - MS C-Milestone C	4	2025	4	2025
CVCAD - LRIP-Low Rate Initial Production	4	2026	4	2026
CVCAD - FRP-Full Rate Production Decision	4	2027	4	2027
CVCAD - IOC-Initial Operational Capability	4	2028	4	2028
CVCAD - FOC-Full Operational Capability	4	2028	4	2028

PE 0603884BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program UNCLASSIFIED Page 76 of 113

Exhibit R-2A, RDT&E Project Ju	stification	: PB 2024 C	hemical an	d Biologica	l Defense P	rogram				Date: Marc	ch 2023	
Appropriation/Budget Activity 0400 / 4					PE 060388	a m Elemen 34BP / Chen rogram - De	nical and Bi		Project (N DE4 / Deco		,	
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
DE4: Decontamination (ACD&P)	-	14.747	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	14.747
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

This project supports the development of Contamination Mitigation (ConMit) systems that reduce operational impact and logistics burden, reduce sustainment costs, increase safety, and minimize environmental effects associated with decontamination and contamination mitigation operations. These efforts align with Chemical, Biological, and Nuclear the National Defense Strategy by prioritizing preparedness for war and sustaining Joint Force military advantage and resilient force posture. After FY 2022, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. DE4 efforts in FY 2022 progress to Project MT4. This restructuring provides standardization and alignment across CBDP research, development and acquisition efforts.

Efforts included in this Project are:

(1) Chemical, Biological, Radiological, and Nuclear (CBRN) Covers, Coatings and Protective Overlays (C3PO),

(2) Service Equipment Decontamination System (SEDS) **Progresses to MT4 in FY2023**,

(3) Tactical Contamination Mitigation System (TCMS) **Progresses to MT4 in FY2023**, and

(4) Wide Area Decontamination System (WADS)

The Chemical Biological Coverings Coatings and Protective Overlays (C3PO) program, uses a Family of Systems approach to provide contamination mitigation capability to critical equipment and assets prior to a Chemical, Biological, Radiological and Nuclear (CBRN) attack. This mitigates the effects and amount of CBRN contamination exposure allowing the Joint Force to be better prepared for war, maintain a resilient force posture, and remain lethal. These capabilities include CBRN protective covers, coatings, paints, and other preventative measures. In FY23 and beyond, the Chemical Biological Defense Program (CBDP) terminated the program for higher priorities. All programmatic documentation will be archived and the Joint Requirements Office will archive the Draft Capability Development Document.

The Service Equipment Decontamination System (SEDS) program consists of two efforts, Joint SEDS and Special Operations Forces (SOF) Critical Equipment Decontamination (CEDS), the program will develop a capability for use by the Warfighter during the decontamination operations that will provide a quantifiable reduction in the number of personnel experiencing adverse health effects by reducing contamination on equipment, individual combat equipment, and sensitive platform interiors. This capability is needed to sustain both the Joint and SOF by reducing logistical burdens in order to increase tactical agility and sustain a resilient force posture, and align with the National Defense Strategy (NDS). SEDS and CEDS will provide contamination mitigation capabilities for critical equipment that have been exposed to chemical and biological contamination and achieve efficacy levels that allow unprotected post-decontamination exposures for long periods with less than negligible severity effects. In FY24, the Joint SEDS effort will continue through the Engineering and Manufacturing Development (EMD) phase with Developmental Testing (DT) and a Critical Design Review (CDR). FY23 is last year of BA4 funding, program is transitioning to EMD.

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical ar	nd Biological Defense Program	Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 4	R-1 Program Element (Number/Name) PE 0603884BP <i>I Chemical and Biological</i> <i>Defense Program - Dem/Val</i>	Project (Number/NDE4 / Decontamina	,	P)
Tactical Containment Mitigation System (TCMS) is a Contamination and vehicles and it will reduce the time and logistics associated wit and Radiological (CBR) contamination to allow warfighters to contin The Program's intent is to mitigate the risk to personnel and limit th greatly enhance or eliminate the need for subsequent decontamina with weathering, Mission Oriented Protective Posture (MOPP) leve decontaminated and the agent. In FY24 the program will continue Development (EMD) Phase. TCMS was a new start in FY22 and F The Wide Area Decontamination System (WADS), a new start prog warfare agents on various types of terrain and exterior of fixed site Terrain, Fix Site and Anti-access/Anti-denial decontamination opera Apparatus (PDDA) system is an Army lead program that consists o	h decontamination. TCMS will limit the spread and mitigation the their mission for an extended period of time in a high e potential spread of CBR contamination by minimizing con- tion to mitigate contamination on military equipment. Foll Is may be reduced without further decontamination, depen- prototype testing and complete technical reviews in suppor Y24 is the last year of BA4 funding as the program transition facilities. The WADS will be employed to conduct Airport ations. The WADS will be a replacement for the M12. Th	ate the effects of Che threat, CBR contam ontact and transfer h lowing application of nding on the surface ort of the MS B/Engi tions to the EMD Ph illities against chemic of Debarkation, Sea the M12A1, Power Dr	emical, Biolog inated enviro nazards. TCM TCMS, com or material b neering Manu ase. cal and biolog aport of Deba iven Deconta ter heater wit	gical, nment. MS will bined being ufacturing of gical urkation, amination h a spray
bar mounted to the system for terrain decontamination. The WADS and beyond, the Chemical Biological Defense Program (CBDP) rec	S will use the principles of the PDDA to further enhance te duced the program for higher priorities. All programmatic	documentation will b		
bar mounted to the system for terrain decontamination. The WADS and beyond, the Chemical Biological Defense Program (CBDP) rec Requirements Office will enter the Draft Capability Development Do	S will use the principles of the PDDA to further enhance te duced the program for higher priorities. All programmatic	documentation will b		nd the Joir
bar mounted to the system for terrain decontamination. The WADS and beyond, the Chemical Biological Defense Program (CBDP) rec Requirements Office will enter the Draft Capability Development Do B. Accomplishments/Planned Programs (\$ in Millions)	S will use the principles of the PDDA to further enhance te duced the program for higher priorities. All programmatic	documentation will t t tool for Archiving.	be archived a	nd the Joir
bar mounted to the system for terrain decontamination. The WADS and beyond, the Chemical Biological Defense Program (CBDP) red Requirements Office will enter the Draft Capability Development Do B. Accomplishments/Planned Programs (\$ in Millions) Title: 1) C3PO	S will use the principles of the PDDA to further enhance te duced the program for higher priorities. All programmatic	documentation will k t tool for Archiving. FY 2022	be archived a	
bar mounted to the system for terrain decontamination. The WADS and beyond, the Chemical Biological Defense Program (CBDP) red Requirements Office will enter the Draft Capability Development Do B. Accomplishments/Planned Programs (\$ in Millions) Title: 1) C3PO Description: Prototype Development Title: 2) SEDS - JOINT	S will use the principles of the PDDA to further enhance te duced the program for higher priorities. All programmatic	documentation will k t tool for Archiving. FY 2022	be archived a	nd the Joir
bar mounted to the system for terrain decontamination. The WADS and beyond, the Chemical Biological Defense Program (CBDP) rec Requirements Office will enter the Draft Capability Development Do B. Accomplishments/Planned Programs (\$ in Millions) Title: 1) C3PO Description: Prototype Development Title: 2) SEDS - JOINT	S will use the principles of the PDDA to further enhance te duced the program for higher priorities. All programmatic ocument in the Knowledge Management/Decision Suppor	documentation will t t tool for Archiving. FY 2022 2.893	be archived a	nd the Joir
bar mounted to the system for terrain decontamination. The WADS and beyond, the Chemical Biological Defense Program (CBDP) red Requirements Office will enter the Draft Capability Development Do B. Accomplishments/Planned Programs (\$ in Millions) Title: 1) C3PO Description: Prototype Development Title: 2) SEDS - JOINT Description: Milestone (MS) B support and Prototype Development	S will use the principles of the PDDA to further enhance te duced the program for higher priorities. All programmatic ocument in the Knowledge Management/Decision Suppor	documentation will t t tool for Archiving. FY 2022 2.893	be archived a	nd the Joir
bar mounted to the system for terrain decontamination. The WADS and beyond, the Chemical Biological Defense Program (CBDP) red Requirements Office will enter the Draft Capability Development Do B. Accomplishments/Planned Programs (\$ in Millions) Title: 1) C3PO Description: Prototype Development Title: 2) SEDS - JOINT Description: Milestone (MS) B support and Prototype Development Title: 3) SEDS - SOF	S will use the principles of the PDDA to further enhance te duced the program for higher priorities. All programmatic ocument in the Knowledge Management/Decision Suppor	documentation will b t tool for Archiving. FY 2022 2.893 4.339	be archived a	nd the Joir
bar mounted to the system for terrain decontamination. The WADS and beyond, the Chemical Biological Defense Program (CBDP) red Requirements Office will enter the Draft Capability Development Do B. Accomplishments/Planned Programs (\$ in Millions) Title: 1) C3PO Description: Prototype Development Title: 2) SEDS - JOINT Description: Milestone (MS) B support and Prototype Development Title: 3) SEDS - SOF Description: Milestone (MS) B Support and Prototype Development	S will use the principles of the PDDA to further enhance te duced the program for higher priorities. All programmatic ocument in the Knowledge Management/Decision Suppor	documentation will b t tool for Archiving. FY 2022 2.893 4.339	be archived a	nd the Joir
bar mounted to the system for terrain decontamination. The WADS and beyond, the Chemical Biological Defense Program (CBDP) red Requirements Office will enter the Draft Capability Development Do B. Accomplishments/Planned Programs (\$ in Millions) Title: 1) C3PO Description: Prototype Development Title: 2) SEDS - JOINT Description: Milestone (MS) B support and Prototype Developmen Title: 3) SEDS - SOF Description: Milestone (MS) B Support and Prototype Developmen Title: 4) TCMS	S will use the principles of the PDDA to further enhance te duced the program for higher priorities. All programmatic ocument in the Knowledge Management/Decision Suppor	documentation will b t tool for Archiving. FY 2022 2.893 4.339 4.485	be archived a	nd the Joir
bar mounted to the system for terrain decontamination. The WADS and beyond, the Chemical Biological Defense Program (CBDP) red Requirements Office will enter the Draft Capability Development Do B. Accomplishments/Planned Programs (\$ in Millions) Title: 1) C3PO Description: Prototype Development	S will use the principles of the PDDA to further enhance te duced the program for higher priorities. All programmatic ocument in the Knowledge Management/Decision Suppor	documentation will b t tool for Archiving. FY 2022 2.893 4.339 4.485	be archived a	nd the Joir
bar mounted to the system for terrain decontamination. The WADS and beyond, the Chemical Biological Defense Program (CBDP) red Requirements Office will enter the Draft Capability Development Do B. Accomplishments/Planned Programs (\$ in Millions) Title: 1) C3PO Description: Prototype Development Title: 2) SEDS - JOINT Description: Milestone (MS) B support and Prototype Developmen Title: 3) SEDS - SOF Description: Milestone (MS) B Support and Prototype Developmen Title: 4) TCMS Description: Milestone (MS) A support and Prototype Developmen	S will use the principles of the PDDA to further enhance te duced the program for higher priorities. All programmatic ocument in the Knowledge Management/Decision Suppor	documentation will b t tool for Archiving. FY 2022 2.893 4.339 4.485 2.354	be archived a	nd the Joir

PE 0603884BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program

Exhibit R-2A, RDT&E Project Justi	fication: PB	2024 Chem	ical and Biolo	ogical Defen	se Program				Date: Ma	rch 2023	
Appropriation/Budget Activity 0400 / 4				PE 06	ogram Elen 03884BP / C se Program	Chemical and	,		Number/Na contaminati	i me) on (ACD&P,)
C. Other Program Funding Summa	ry (\$ in Milli	ons)									
			<u>FY 2024</u>	<u>FY 2024</u>	<u>FY 2024</u>					<u>Cost To</u>	
Line Item	<u>FY 2022</u>	FY 2023	Base	000	<u>Total</u>	FY 2025	FY 2026	FY 2027	FY 2028	Complete	Total Cost
DE5: Decontamination (SDD)	7.485	-	-	-	-	-	-	-	-	0.000	7.485
MT4: Mitigate (ACD&P)	-	17.302	28.785	-	28.785	20.885	15.433	13.369	-	Continuing	Continuing
• MT5: Mitigate (SDD)	-	74.225	88.441	-	88.441	92.279	91.431	87.773	93.250	Continuing	Continuing
PHM007: Service Equipment	-	-	-	-	-	14.028	22.531	24.920	13.050	Continuing	Continuing
Decontamination System (SEDS)										-	-
• PHM042: Tactical Contamination	-	-	-	-	-	-	1.250	5.072	5.000	Continuing	Continuing
Mitigation System (TCMS)										C	C
Remarks											

D. Acquisition Strategy

CBRN COVERS COATINGS AND PROTECTIVE OVERLAYS (C3PO)

The Chemical Biological Coverings Coatings and Protective Overlays (C3PO) program acquisition approach involves testing fielded material against live chemical warfare agents and biological warfare agents. The C3PO program will evaluate Government and Commercial Off the Shelf options to reduce development costs. The program will test Government and Commercial Off the Shelf options against live chemical warfare agents and biological warfare agents, conduct regular user evaluations to identify human system integration issues, and will conduct testing to ensure the system meets military standards. The C3PO program funding ends in FY22 and all program contract, test, and acquisition documentation will be archived and the Joint Requirements Office will archive the Draft Capability Development Document.

SERVICE EQUIPMENT DECONTAMINATION SYSTEM (SEDS)

The Joint Service Equipment Decontamination System (SEDS) and Special Operations Forces (SOF) Critical Equipment Decontamination System (CEDS) program will utilize the Countering Weapons of Mass Destruction Other Transaction Authority (CWMD OTA) to design and develop state of the art equipment using competitive and iterative prototyping. The program will test prototypes against live chemical warfare agents and biological warfare agents, conduct reliability, availability, and maintainability testing, conduct regular user evaluations to identify human system integration issues, and will conduct testing to ensure the system meets military standards. The program will use the Request for Prototype Proposals (RPP), under the CWMD OTA, followed by Prototype Agreement awards. Milestone B approval is planned in FY23 for the United States Special Operations Command (SOCOM) and Joint Service variant. During the FY24-28 FYDP the SOCOM CEDS effort is planning to achieve a successful Milestone C decision and enter Full Rate Production, leading to an initial operational capability and reaching full operational capability by FY28.

TACTICAL CONTAMINATION MITIGATION SYSTEM (TCMS)

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	I Defense Program	Date: March 2023
0400 / 4	R-1 Program Element (Number/Name) PE 0603884BP <i>I Chemical and Biological</i> <i>Defense Program - Dem/Val</i>	 lumber/Name) ontamination (ACD&P)

The Tactical Containment Mitigation System (TCMS) program will develop the equipment, processes and procedures for contamination mitigation related to post-incident operations in a Chemical Biological Radiological and Nuclear (CBRN) contaminated environment. The acquisition strategy includes market research through both Requests for Information (RFIs) and a call for White Papers through an Other Transaction Authority (OTA) contracting approach. Data collected will inform a Milestone A decision in FY23. The OTA vehicle will also be used to request prototypes, which will undergo technology demonstrations and Early Field testing, followed by an analysis to determine the most suitable candidate. Results of Prototyping will inform Milestone B and Request for Proposals (RFPs) followed by developmental and operational testing and Milestone C/Full Rate Production Approval.

WIDE AREA DECONTAMINATION SYSTEM (WADS)

The Wide Area Decontamination System (WADS) program will develop the equipment, processes and procedures for contamination mitigation of various types of terrain and the exterior of Department of Defense (DoD) fixed site facilities contaminated by chemical, biological, and radiological agents. The acquisition strategy includes market research through both Requests for Information (RFIs) and a call for White Papers through an Other Transaction Authority (OTA) contracting approach. The OTA vehicle will also be used to request prototypes, which will undergo technology demonstrations and Early Field testing, followed by an analysis to determine the most suitable candidate. The WADS program funding ends in FY22 and all program contract, test, and acquisition documentation will be archived and the Joint Requirements Office will enter the Draft Capability Development Document into Knowledge Management/Decision Support tool for archiving.

Appropriation/Budge 0400 / 4	et Activity	y				PE 0603	3884BP /		umber/N al and Bio /al			(Number Decontami	r/ Name) nation (AC	CD&P)	
Product Developmen	nt (\$ in M	illions)	ſ	FY	2022	FY 2	023	FY 2 Ba	2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
C3PO - HW S - Advanced Product Development	Various	Various : N/A	0.203	0.208	Nov 2021	0.000		0.000		-		0.000	0.000	0.411	0.000
SEDS - HW S - SEDS - Product Development	SS/FFP	TBD : N/A	-	0.896	Aug 2022	0.000		0.000		-		0.000	0.000	0.896	0.000
SEDS - CEDS	C/FFP	Various : N/A	-	0.992	Aug 2022	0.000		0.000		-		0.000	0.000	0.992	0.000
TCMS - HW S - Product Development	C/FFP	TBD : N/A	-	0.784	Sep 2022	0.000		0.000		-		0.000	0.000	0.784	0.000
WADS - HW C - Autonomous Contamination Mitigation Prototype	C/FFP	TBD : N/A	-	0.676	Sep 2022	0.000		0.000		-		0.000	0.000	0.676	0.000
	1	Subtotal	0.203	3.556		0.000		0.000		-		0.000	0.000	3.759	N/A
Support (\$ in Millions	s)		 	FY	2022	FY 2	023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
C3PO - ILS S - Logistics, Engineering and IPT Support	MIPR	Various : N/A	0.525	0.434	Nov 2021	0.000		0.000		-		0.000	0.000	0.959	0.000
SEDS - ES S - SEDS - Logistics, Engineering and IPT Support	MIPR	Various : N/A	0.066	0.651	Oct 2021	0.000		0.000		-		0.000	0.000	0.717	0.000
SEDS - CEDS	MIPR	Various : N/A	-	0.852	Nov 2021	0.000		0.000		-		0.000	0.000	0.852	0.000
TCMS - ES S - Logistics, Engineering and IPT Support	MIPR	Various : N/A	-	0.353	Jun 2022	0.000		0.000		-		0.000	0.000	0.353	0.000
		Subtotal	0.591	2.290		0.000		0.000		-		0.000	0.000	2.881	N/A

Appropriation/Budge 0400 / 4	t Activity	,				PE 060	3884BP /	e ment (N Chemica n - Dem/V	l and Bio			(Number Decontami	r/ Name) nation (AC	CD&P)	
Test and Evaluation ((\$ in Milli	ons)	ſ	FY 2	2022	FY 2	023	FY 2 Ba	-	FY 2 OC		FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
C3PO - OTHT S - Other S - Developmental Testing and Test Planning Support	MIPR	Various : N/A	0.784	2.035	Dec 2021	0.000		0.000		-		0.000	0.000	2.819	0.000
SEDS - OTHT S - SEDS - T&E IPR Test Planning	MIPR	Various : N/A	0.562	2.459	Nov 2021	0.000		0.000		-		0.000	0.000	3.021	0.000
SEDS - CEDS	MIPR	Various : N/A	-	2.316	Sep 2022	0.000		0.000		-		0.000	0.000	2.316	0.000
TCMS - OTHT S - Prototype T&E IPR Test Planning	MIPR	Various : N/A	-	1.041	Jun 2022	0.000		0.000		-		0.000	0.000	1.041	0.000
		Subtotal	1.346	7.851		0.000		0.000		-		0.000	0.000	9.197	N/A
Management Service	• T	illions)		FY	2022	FY 2	023	FY 2 Ba		FY 2 OC		FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
C3PO - PM/MS S - PM/MS S- Program Management Support	MIPR	Various : N/A	0.131	0.216	Nov 2021	0.000		0.000		-		0.000	0.000	0.347	0.000
SEDS - PM/MS S - SEDS - Program Management Support	MIPR	Various : N/A	0.251	0.324	Jan 2022	0.000		0.000		-		0.000	0.000	0.575	0.000
SEDS - CEDS	MIPR	Various : N/A	-	0.334	Nov 2021	0.000		0.000		-		0.000	0.000	0.334	0.000
TCMS - PM/MS S - Program Management Support	Various	TBD : N/A	-	0.176	May 2022	0.000		0.000		-		0.000	0.000	0.176	0.000
		Subtotal	0.382	1.050		0.000		0.000		-		0.000	0.000	1.432	N/A
			Prior Years	FY	2022	FY 2	023	FY 2 Ba		FY 2 OC		FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract
		Project Cost Totals	2.522	14.747		0.000		0.000		-		0.000	0.000	17.269	N/A

PE 0603884BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program

whibit R-4, RDT&E Schedule Profile: PB 2024 C	Cher	nical	and	Biol	ogic	al D	efen	ise F	Prog	ram													Da	te: N	Marc	:h 2	023			
opropriation/Budget Activity 00 / 4							F	PE 0	603	g ram 884E <i>Prog</i>	3P /	Che	emi	cal a	and									ber/ Imin			CD	&P)		
		FY	2022			FY 2	2023			FY 2	024			FY	202	5		F	Y 20)26			FY	202	27		F	Y 20	28	
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	I	2	3	4	1	2	3	4	1	1	2	3	4
C3PO - Proof of Concept Demonstration and Testing																														
C3PO - Government and Commercial Off the Shelf Options Testing																														
C3PO - Prepare Programmatic Acquisition Documentation for Archive																														
C3PO - Prepare final program report																														
SEDS - Prototype Agreement Award (SOF and Other Services)																														
SEDS - CDD Validation-Capability Development Document Validation - Other Services																														
SEDS - Early Developmental Testing (Other Services)				l																		-								
SEDS - MS B-Milestone B - Other Services																														
SEDS - DT&E-Developmental Test and Evaluation - Other Services																														
SEDS - MS C-Milestone C - Other Services																														
SEDS - FRP-Full Rate Production Decision - Other Services																														
SEDS - DT&E-Developmental Test and Evaluation - SOF																														
SEDS - RFP-Development Request for Proposal Release Decision - SOF and Other Services																														
SEDS - MS B-Milestone B - SOF																														
SEDS - MS C-Milestone C - SOF																														
																														_

PE 0603884BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program UNCLASSIFIED Page 83 of 113

R-1 Line #79

Exhibit R-4, RDT&E Schedule Profile: PB 2024 C	her	nical	and	Biol	ogic	al D	efer	ise F	rogi	ram												Dat	e: M	arch	20	23		
Appropriation/Budget Activity 0400 / 4							F	PE 0	603	884E	3P /	men Cher 1 - De	nic	al a									oer/N mina			D&P)	
		FY 2	2022			FY 2	023		F	FY 2	024		I	FY 2	2025			FY 2	2026			FY	2027			FY 2	028	
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
SEDS - IOC-Initial Operational Capability - SOF																			I									
SEDS - FOC-Full Operational Capability - SOF																												
TCMS - Market Research																												
TCMS - RFP-Development Request for Proposal Release Decision																												
TCMS - Prototype Contract Award																												
TCMS - Life Cycle Sustainment Plan (LCSP)]																							
TCMS - System Readiness Review (SRR)																												
TCMS - Test and Evaluation Master Plan (TEMP)																												
TCMS - Test Readiness Review (TRR)																												
TCMS - Simplified Acquisition Management Plan (SAMP)																						_						
TCMS - MS A-Milestone A																												
TCMS - Prototype Testing																												
TCMS - Acquisition Program Baseline (APB)																												
TCMS - CDD Validation-Capability Development Document Validation																												
TCMS - MS B-Milestone B																												
TCMS - DT&E-Developmental Test and Evaluation - Developmental Test & Evaluation																												
TCMS - System Verification Review/Production Readiness Review																												
TCMS - MS C-Milestone C																												
TCMS - FRP-Full Rate Production Decision																												
WADS - Market Research																												

PE 0603884BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program UNCLASSIFIED Page 84 of 113

Exhibit R-4, RDT&E Schedule Profile: PB 2024	Che	mica	l and	l Bio	logi	cal D	Defer	nse	Prog	gram	۱											Date	e: M	arch	202	23		
Appropriation/Budget Activity 0400 / 4								PE (0603	3884		Che	əmic	cal a	n ber / nd Bi				Pro DE4		•					D&	P)	
		FY	2022	2		FY 2	2023			FY	2024			FY 2	2025			FY 2	2026			FY 2	2027	,		FY	2028	B
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
WADS - Prototype Development																												
WADS - Prepare Programmatic Acquisition Documentation for Archive									-																			_

hibit R-4A, RDT&E Schedule Details: PB 2024 Chemical and Biological Defense	Program		Date: Marcl	า 2023
D0/4 PE 06	rogram Element (Number 03884BP / Chemical and L se Program - Dem/Val		Project (Number/Nam DE4 / Decontamination	,
Schedule	e Details			
	Sta	art	En	d
Events	Quarter	Year	Quarter	Year
C3PO - Proof of Concept Demonstration and Testing	1	2022	1	2023
C3PO - Government and Commercial Off the Shelf Options Testing	1	2022	1	2023
C3PO - Prepare Programmatic Acquisition Documentation for Archive	4	2022	1	2023
C3PO - Prepare final program report	1	2023	2	2023
SEDS - Prototype Agreement Award (SOF and Other Services)	4	2022	4	2022
SEDS - CDD Validation-Capability Development Document Validation - Other Se	rvices 1	2023	2	2023
SEDS - Early Developmental Testing (Other Services)	1	2023	3	2023
SEDS - MS B-Milestone B - Other Services	4	2023	4	2023
SEDS - DT&E-Developmental Test and Evaluation - Other Services	1	2024	3	2025
SEDS - MS C-Milestone C - Other Services	3	2026	3	2026
SEDS - FRP-Full Rate Production Decision - Other Services	4	2027	4	2027
SEDS - DT&E-Developmental Test and Evaluation - SOF	3	2022	4	2023
SEDS - RFP-Development Request for Proposal Release Decision - SOF and Ot Services	her 4	2022	4	2022
SEDS - MS B-Milestone B - SOF	3	2023	3	2023
SEDS - MS C-Milestone C - SOF	4	2024	4	2024
SEDS - IOC-Initial Operational Capability - SOF	2	2026	2	2026
SEDS - FOC-Full Operational Capability - SOF	4	2028	4	2028
TCMS - Market Research	1	2022	3	2022
TCMS - RFP-Development Request for Proposal Release Decision	3	2022	3	2022
TCMS - Prototype Contract Award	4	2022	4	2022
TCMS - Life Cycle Sustainment Plan (LCSP)	2	2023	2	2023

00/4 PE	Program Element (Numbe 0603884BP / Chemical and ense Program - Dem/Val		Project (Number/Nam DE4 <i>I Decontamination</i>	
	St	art	Er	ıd
Events	Quarter	Year	Quarter	Year
TCMS - System Readiness Review (SRR)	2	2023	2	2023
TCMS - Test and Evaluation Master Plan (TEMP)	2	2023	2	2023
TCMS - Test Readiness Review (TRR)	3	2023	3	2023
TCMS - Simplified Acquisition Management Plan (SAMP)	3	2023	3	2023
TCMS - MS A-Milestone A	3	2023	3	2023
TCMS - Prototype Testing	1	2024	2	2024
TCMS - Acquisition Program Baseline (APB)	3	2024	3	2024
TCMS - CDD Validation-Capability Development Document Validation	2	2025	2	2025
TCMS - MS B-Milestone B	2	2025	2	2025
TCMS - DT&E-Developmental Test and Evaluation - Developmental Test & Eva	aluation 3	2025	3	2026
TCMS - System Verification Review/Production Readiness Review	3	2026	3	2026
TCMS - MS C-Milestone C	4	2026	4	2026
TCMS - FRP-Full Rate Production Decision	4	2027	4	2027
WADS - Market Research	3	2022	3	2022
WADS - Prototype Development	3	2022	3	2023
WADS - Prepare Programmatic Acquisition Documentation for Archive	4	2022	1	2023

Exhibit R-2A, RDT&E Project Ju	stification	: PB 2024 C	hemical an	d Biologica	l Defense P	rogram				Date: Marc	ch 2023	
Appropriation/Budget Activity 0400 / 4					PE 060388	am Elemen 34BP / Cher rogram - De	nical and Bi	,	Project (N IP4 / Indivi		ne) tion (ACD&F	?)
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
IP4: Individual Protection (ACD&P)	-	4.748	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	4.748
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

This project includes the development of next generation individual protective ensembles (e.g., suits, boots, and gloves) that enable the Joint Forces to survive and continue the mission in Chemical, Biological, and Radiological (CBR) contaminated environments. After FY 2022, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. IP4 efforts in FY 2022 progress to Project PT4. This restructuring provides standardization and alignment across CBDP research, development and acquisition efforts.

Efforts included in this Project are:

(1) UIPE FoS Gloves **Progresses to PT5 in FY2023**

Uniform Integrated Protective Ensemble (UIPE) Family of Systems (FoS) Gloves provides percutaneous protection to the Warfighter against traditional and nontraditional Chemical, Biological, Radiological and Nuclear (CBRN) threats. UIPE FoS Gloves provides improved comfort, tactility and dexterity, and for some mission profiles advanced features such as touch screen and flame resistance. In FY22, UIPE FoS Gloves will finalize UIPE FoS Glove prototype development and testing for multiple mission profiles (General Purpose, Aviation Light and Aviation Heavy Variants) and conduct Developmental Testing (DT) events on mature prototypes. FY22 is the last year of BA4 funding.

B. Accomplishments/Planned Prog	grams (\$ in N	<u>/lillions)</u>							FY 2022	FY 2023	FY 2024
Title: 1) UIPE FOS GLOVES									4.748	-	-
Description: Development of the Ne	ext Generatio	n Protective	Glove								
				Accon	nplishments	s/Planned P	rograms Su	btotals	4.748	-	-
C. Other Program Funding Summa	ry (\$ in Milli	ons <u>)</u>									
			<u>FY 2024</u>	<u>FY 2024</u>	<u>FY 2024</u>					Cost To	<u>)</u>
Line Item	FY 2022	FY 2023	Base	000	<u>Total</u>	<u>FY 2025</u>	<u>FY 2026</u>	FY 202	7 FY 2028	<u>Complete</u>	Total Cost
IP5: Individual Protection (SDD)	18.690	-	-	-	-	-	-	-	-	0.000	40.000
							66.259		1 67.776	6 Continuing	18.690

PE 0603884BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program

Exhibit R-2A, RDT&E Project Just	ification: PB	2024 Chemi	cal and Biol	ogical Defen	se Program				Date: Ma	rch 2023	
Appropriation/Budget Activity 0400 / 4				PE 06	-	n <mark>ent (Numb</mark> Chemical and - Dem/Val			Number/Na vidual Prote	a me) ection (ACD&	≩Ρ)
C. Other Program Funding Summ	ary (\$ in Milli	ons <u>)</u>									
			<u>FY 2024</u>	<u>FY 2024</u>	<u>FY 2024</u>					<u>Cost To</u>	
Line Item	FY 2022	FY 2023	Base	000	<u>Total</u>	<u>FY 2025</u>	<u>FY 2026</u>	<u>FY 2027</u>	<u>FY 2028</u>	Complete	Total Cost
PHM032: Uniform Integrated	-	-	4.978	-	4.978	6.215	7.974	8.328	8.926	Continuing	Continuing
Protective Ensemble FOS											
Gloves (UIPE FOS GLOVES)											
<u>Remarks</u>											
D. Acquisition Strategy											
UNIFORM INTEGRATED PROTEC	TIVE ENSEM	IBLE FOS G	LOVES (UIF	PE FOS GLO	OVES)						
Uniform Integrated Protective Ense a call for White Papers through an 0											

a call for White Papers through an Other Transaction Authority (OTA) contracting approach. Eight white papers were deemed acceptable and will be pursued through a Mid-Tier Acquisition Rapid Prototyping strategy. Candidate technologies will undergo Early User Tests/Wear events and material and system level testing to identify available capabilities as well as Analytical framework analyses to determine the most suitable solution(s) per mission profile.

Exhibit R-3, RDT&E Project Cost Analysis: PB 2024 Chemical and Biologic Appropriation/Budget Activity 0400 / 4							•						Date: March 2023				
							R-1 Program Element (Number/Name) PE 0603884BP <i>I Chemical and Biological</i> <i>Defense Program - Dem/Val</i>					Project (Number/Name) IP4 I Individual Protection (ACD&P)					
Product Development (\$ in Millions)				FY 2022		FY 2023		FY 2024 Base		FY 2024 OCO		FY 2024 Total					
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract		
UIPE FOS GLOVES - HW C - Prototype Development	C/CPFF	ATI Solutions, Inc. : Tysons Corner, VA	0.100	0.033	Jan 2022	0.000		0.000		-		0.000	0.000	0.133	0.000		
		Subtotal	0.100	0.033		0.000		0.000		-		0.000	0.000	0.133	N/A		
Support (\$ in Millions)				FY 2022		FY 2023		FY 2024 Base		FY 2024 OCO		FY 2024 Total					
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract		
UIPE FOS GLOVES - ES S - Engineering and Technical IPT Support / SME Support	MIPR	Various : N/A	0.113	0.712	Nov 2021	0.000		0.000		-		0.000	0.000	0.825	0.000		
		Subtotal	0.113	0.712		0.000		0.000		-		0.000	0.000	0.825	N/A		
Test and Evaluation (\$ in Millions)				FY 2	FY 2022		FY 2023		FY 2024 Base		FY 2024 OCO						
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract		
UIPE FOS GLOVES - DTE C - Prototype Testing & Test Support	MIPR	Various : N/A	0.241	3.648	Nov 2021	0.000		0.000		-		0.000	0.000	3.889	0.000		
		Subtotal	0.241	3.648		0.000		0.000		-		0.000	0.000	3.889	N/A		
Management Services (\$ in Millions)				FY 2022		FY 2023		FY 2024 Base		FY 2024 OCO		FY 2024 Total					
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract		
UIPE FOS GLOVES - PM/MS C - Program Management Support	Various	Various : N/A	0.040	0.355	Nov 2021	0.000		0.000		-		0.000	0.000	0.395	0.000		
		Subtotal	0.040	0.355		0.000		0.000		-		0.000	0.000	0.395	N/A		

PE 0603884BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program

Exhibit R-3, RDT&E Project Cost Analysis: PB 2	024 Cher	mical and B	iological Defens	e Program		Date	e: March 20)23	
Appropriation/Budget Activity 0400 / 4			PE 060	o gram Element (N 3884BP / Chemica e Program - Dem/	al and Biological	Project (Numb IP4 / Individual		(ACD&P)	
	Prior Years	FY 202	2 FY 2			2024 FY 2024 CO Total	4 Cost To Complete	Total Cost	Target Value of Contract
Project Cost Totals	0.494	4.748	0.000	0.000	-	0.00	0.000	5.242	N/A

Remarks

Exhibit R-4, RDT&E Schedule Profile: PB 2024 C	Che	mica	al ar	nd B	iolo	gica	al C)efer	nse	Pro	gra	m												D	ate	: Ma	arch	n 20	23		
Appropriation/Budget Activity)400 / 4									PE (060	388	am El 84BP rogra	I Ch	em	ical	and				1			•			er/Na Prote			'ACI	0&P)	
		FY	202	22		F	Y 2	2023	\$		FY	2024	1		FY	202	25			FY	202	6		F	Y 2	027			FY	2028	3
	1	2	: 3	3 4	4	1	2	3	4	1	2	3	4	1	2	3	6	4	1	2	3	4	1		2	3	4	1	2	3	4
UIPE FOS GLOVES - Early User, material and system level testing															_							_							_		
UIPE FOS GLOVES - Mid-Tier Acquisition Rapid Prototype Initiation																															
UIPE FOS GLOVES - Mid-Tier Acquisition DT/ OT																															
UIPE FOS GLOVES - Analytical Framework Analysis																															
UIPE FOS GLOVES - Mid-Tier Acquisition IPR																															
UIPE FOS GLOVES - Mid-Tier Acquisition Decision Point																															
UIPE FOS GLOVES - Mid-Tier Acquisition Rapid Fielding OR/Milestone C																															

Exhibit R-4A, RDT&E Schedule Details: PB 2024 Chemical and Biological D	efense Program			Date	e: March 2023
Appropriation/Budget Activity 0400 / 4	R-1 Program Ele PE 0603884BP / Defense Program	Chemical and	,	Project (Numbe IP4 / Individual I	er/Name) Protection (ACD&P)
Sci	hedule Details				
		St	art		End
Events		Quarter	Year	Quarte	er Year
UIPE FOS GLOVES - Early User, material and system level testing		1	2022	2	2024
UIPE FOS GLOVES - Mid-Tier Acquisition Rapid Prototype Initiation		1	2022	1	2023
UIPE FOS GLOVES - Mid-Tier Acquisition DT/OT		2	2022	3	2024
UIPE FOS GLOVES - Analytical Framework Analysis		3	2022	4	2022
UIPE FOS GLOVES - Mid-Tier Acquisition IPR		3	2023	3	2023
UIPE FOS GLOVES - Mid-Tier Acquisition Decision Point		3	2024	3	2024
UIPE FOS GLOVES - Mid-Tier Acquisition Rapid Fielding OR/Milestone C	;	4	2024	4	2024

Exhibit R-2A, RDT&E Project Ju	stification	: PB 2024 C	hemical an	d Biologica	l Defense P	rogram				Date: Mare	ch 2023	
Appropriation/Budget Activity 0400 / 4					PE 060388	am Elemen 34BP / Cher rogram - De	nical and Bi		Project (N MB4 / Mea		n e) cal Defense ((ACD&P)
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
MB4: <i>Medical Biological Defense</i> (ACD&P)	-	46.791	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	46.791
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

This project includes Medical Countermeasure platform technologies, Medical Countermeasures (vaccines and therapeutics), development of reagents, assays, diagnostic equipment, biosurveillance and supporting efforts. After FY 2022, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. MB4 efforts in FY 2022 progress to Projects EN4 and PT4. This restructuring provides standardization and alignment across CBDP research, development and acquisition efforts.

Efforts included in this Project are:

(1) COVID Therapies Monoclonal Antibodies (COVID TX MAB) ** Progresses to PT4 in FY2023**,

(2) Validated Nucleic Acid Vaccine Construction (COVID VAC) ** Progresses to PT4 in FY2023**,

(3) Chem Bio Incident Preparedness and Response - Advanced Development and Manufacturing (CBIPR - ADM) ** Progresses to EN4 in FY2023**, and

(4) Medical Countermeasure Platform Technologies (MCMPT) ** Progresses to PT4 in FY2023**

The COVID TX MAB program will leverage lessons learned from the COVID response to rapidly discover, manufacture, and clinically evaluate new monoclonal antibodies to deliver short term capabilities against long standing biological threats. Monoclonal antibodies are a proven technology and first line of defense for many biological threats. In FY22, COVID TX MAB will target the discovery, identification and small scale manufacture of monoclonal antibodies (mAbs), with sufficient material to support non-clinical and clinical testing. In FY23 COVID TX MAB transitions to the Accelerated Antibodies-Enhanced Biodefense (AA-ENBD) program.

COVID VAC will leverage lessons learned from the Coronavirus Disease 2019 (COVID-19) response to shorten future emergency response timelines, mitigate impacts of biological threat outbreaks, and create interim capabilities to protect the warfighter. In FY 2022, COVID VAC will leverage interagency, industry, and academia partnerships to develop nucleic acid vaccines. COVID VAC will transition to Vaccine Acceleration by Modular Progression (VAMP) in FY 2023 where VAMP will continue to build the Warfighter's bio-armor to protect against biological threats. In addition to nucleic acid vaccines, VAMP will develop alternative vaccine platform technologies and manage awards utilizing go/no-go checkpoints along the development pathway.

The CBIPR-ADM program ensures prioritization to domestic biopharmaceutical manufacturing capacities, capabilities, and infrastructure (e.g. the DoD-ADM Facility and other strategic partners) that are operationally ready to rapidly develop and manufacture medical countermeasures (MCMs) against current and emerging chemical and biological threats including pandemic response. Prioritization is achieved by establishing and enhancing proven biopharmaceutical manufacturing platform technologies and infrastructure at these facilities. Thus, these facilities will have the capability to accelerate development of MCMs at all stages of development, enhance preparedness for existing threats, and rapidly respond to emerging threats as part of a medical integrated layered defense. MCMs that benefit from these

Exhibit R-2A, RDT&E Project Justi	fication: PB	2024 Chemi	ical and Biol	ogical Defen	ise Program				Date: M	arch 2023	
Appropriation/Budget Activity 0400 / 4				PE 06	rogram Elei 03884BP / 0 se Program	Chemical and			t (Number/N Medical Biolo		e (ACD&P)
efforts include: Vaccines for Viral Ag prophylactic use across all agent cla manufacturing funding lines. The De responsiveness. In FY24, the CBIPI development of MCMs against chem	sses. Funds epartment is r R-ADM progr	to support p now providir am continue	prioritization ng dedicated es to establis	and operatic funds. The	onal readine: CBIPR-ADN	ss were prev I return on ir	iously providenvestment is a	ed via inc an increa	lividual produ sed level of p	ict developm preparednes	ent and s and
The MCMPT program streamlines an mature platform technologies that all platform systems within the Departm and testing processes to reduce the manufactured.	ow for rapid i ent of Defens	response an se (DoD)'s A	nd by reducin Advanced De	ng developm evelopment l	ental risks. I Vanufacturir	/ICMPT is es g (ADM) net	stablishing en work using s	abling te tandardiz	chnologies a ed discovery	nd prepositic , design, ma	ning nufacturing,
B. Accomplishments/Planned Prog	rams (\$ in N	<u>lillions)</u>							FY 2022	FY 2023	FY 2024
Title: 1) COVID TX MAB									10.276	-	-
Description: Rapid Monoclonal Anti	ody Develop	oment									
Title: 2) COVID VAC									9.776	-	-
Description: Validated Nucleic Acid	Vaccine Con	struction De	evelopment								
Title: 3) CBIPR-ADM									8.105	-	-
Description: Establish proven enabl Building.	ing manufact	uring techno	ologies at the	e Departmen	nt of Defense	(DoD) ADN	l Capability				
Title: 4) MCMPT									18.634	-	-
Description: Advanced Developmen	it and Manufa	acturing of A	ntibody Tec	hnology (AD	AMANT)						
				Accor	nplishment	s/Planned P	rograms Su	btotals	46.791	-	-
C. Other Program Funding Summa	rv (\$ in Millio	ons)									
	- -		<u>FY 2024</u>	<u>FY 2024</u>	<u>FY 2024</u>					Cost To	-
Line Item • EN4: Enabling	<u>FY 2022</u>	<u>FY 2023</u> 6.781	<u>Base</u> 47.272	<u>000</u>	<u>Total</u> 47.272	<u>FY 2025</u> 51.579	<u>FY 2026</u> 9.792	<u>FY 202</u> 9.84		<u>Complete</u> Continuing	
Investments (ACD&P)	-	0.701	41.Z1Z	-	41.ZIZ	51.579	9.192	9.04	J 9.04		Continuin
• EN5: Enabling Investments (SDD)	-	13.392	13.835	-	13.835	13.884	14.179	14.19	7 14.26	Continuing	Continuin
PE 0603884BP: Chemical and Biolog	ical Defense	Program		UNCLAS	SIFIED					Vo	ume 4 - 227

Chemical and Biological Defense Program

Page 95 of 113

R-1 Line #79

Exhibit R-2A, RDT&E Project Jus	stification: PB	2024 Chemi	ical and Biol	ogical Defen	se Program				Date: Ma	rch 2023	
Appropriation/Budget Activity					rogram Eler	•			Number/Na	,	
0400 / 4					03884BP / C se Program		d Biological	MB4 / Me	dical Biolog	gical Defens	e (ACD&P)
C. Other Program Funding Sumn	nary (\$ in Milli	ons <u>)</u>									
			FY 2024	<u>FY 2024</u>	<u>FY 2024</u>					<u>Cost To</u>	
Line Item	<u>FY 2022</u>	FY 2023	Base	000	<u>Total</u>	<u>FY 2025</u>	FY 2026	FY 2027	<u>FY 2028</u>	Complete	Total Cost
 MB5: Medical Biological 	138.156	-	-	-	-	-	-	-	-	0.000	138.156
Defense (SDD)											
PT4: Protect (ACD&P)	-	175.219	179.158	-	179.158	135.096	107.341	123.538	139.376	Continuing	Continuing
UN5: Understand (SDD)	-	126.071	182.726	-	182.726	137.991	127.671	108.908	68.088	Continuing	Continuing
SA0043: Next Gen Diag	-	-	1.881	-	1.881	9.579	10.982	11.898	11.861	Continuing	Continuing
2 Chemical Diagnostics										-	-
(NGDS 2 CHEM DX)											
Remarks											

D. Acquisition Strategy

COVID THERAPIES MONOCLONAL ANTIBODIES (COVID TX MAB)

COVID TX MAB will leverage industry capabilities, in the interest of speed, in order to establish capabilities that can be technology transferred to the DoD ADM for longer term use and scale up as necessary.

COVID VACCINE (COVID VAC)

The COVID VAC program is an investment master list (IML) program that leverages lessons learned from the COVID-19 response to develop vaccines that target biothreats while utilizing a modular approach to ensure flexibility. These prototype vaccines will use a tailored acquisition pathway and will create a strategic reserve to counter the biothreats against the Warfighter.

CHEM BIO INCIDENT PREPAREDNESS AND RESPONSE - (CBIPR-ADM)

By establishing new capabilities at the DoD-ADM Facility and other strategic partners, the CBIPR-ADM line ensures that the DoD will have priority access to critical technologies and infrastructure that are operationally ready to support the rapid development and manufacture of MCMs. This approach ensures that the DoD's efforts are not limited to a single facility. In FY24, the CBIPR-ADM line will continue to establish, enhance, and optimize new manufacturing platform technologies and infrastructure to support the production of MCMs. These new manufacturing technologies can come from any government sources (including the Joint Science & Technology Office for Chemical Biological Defense (JSTO-CBD), the Walter Reed Army Institute of Research (WRAIR), and the Biomedical Advanced Research and Development Authority (BARDA), etc. when mature enough for BA4 funding) and/or other external sources and targets of opportunity from industry.

MCM PLATFORM TECHNOLOGIES (MCMPT)

xhibit R-2A, RDT&E Project Justification: PB 2024 Chemical	l and Biological Defense Program	Date: March 2023
ppropriation/Budget Activity 400 / 4	R-1 Program Element (Number/Name) PE 0603884BP / Chemical and Biological Defense Program - Dem/Val	Project (Number/Name) MB4 I Medical Biological Defense (ACD&P
The goal of the MCMPT is to rapidly counter a broad-spectrum on the MCM development risks. Efforts will focus on transitioning S Science and Technology Office (JSTO) or Defense Advanced Re Department of Defense (DoD)'s Advanced Development Manufa of these technologies, such as the DARPA Pandemic Preventior Once established, future programs will be able to leverage these everage the Other Transactions Authority (OTA) through the me	Defense Program - Dem/Val of threat agents using standardized discovery, design, manu &T programs from other DoD agencies, such as Defense T esearch Projects Agency (DARPA), and establishing advar acturing (ADM) network and evaluating that capability throug n Platform (P3), will be adapted to deliver a rapid response e platforms for the development of future medical counterme	ufacturing, and testing processes to reduce Threat Reduction Agency (DTRA)-Joint need platform technologies within the gh nonclinical and clinical testing. A subset capability to novel and emerging threats. easures. It is anticipated that these efforts wil

Appropriation/Budge 0400 / 4	Project C t Activity	1				PE 0603	3884BP /	ement (N Chemica n - Dem/V	l and Biol			(Number Iedical Bio	r/ Name) plogical D	efense (A	4 <i>CD&P)</i>
Product Developmen	it (\$ in Mi	illions)		FY 2	2022	FY 2	023	FY 2 Ba	-		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
COVID TX MAB - Accelerated Antibody Development	C/CPFF	Various : N/A	-	9.329	Apr 2022	0.000		0.000		-		0.000	0.000	9.329	0.000
COVID VAC - Vaccine - Development	Various	Various : N/A	-	7.608	Aug 2022	0.000		0.000		-		0.000	0.000	7.608	0.000
COVID VAC - Direct Program Support	Various	Various : N/A	-	1.536	Nov 2022	0.000		0.000		-		0.000	0.000	1.536	0.000
CBIPR-ADM - Enabling Manufacturing Technologies	C/CPFF	Ology : Alachua, FL	13.804	7.756	Mar 2022	0.000		0.000		-		0.000	0.000	21.560	0.000
MCMPT - HW S - ADAMANT PLAGUE MCM Development	C/CPFF	Various : N/A	36.115	17.527	Apr 2022	0.000		0.000		-		0.000	0.000	53.642	0.000
		Subtotal	49.919	43.756		0.000		0.000		-		0.000	0.000	93.675	N/A
Management Service	s (\$ in M	illions)	ſ	FY 2	2022	FY 2	023	FY 2 Ba			2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
COVID TX MAB - Program Management Support	Various	JPL CBRND Enabling Biotechnologies, JPEO-CBRND : Fort Detrick, MD	-	0.947	Dec 2021	0.000		0.000		-		0.000	0.000	0.947	0.000
COVID VAC - PM/MS C - Indirect Management Support	Various	Various : N/A	-	0.632	Nov 2021	0.000		0.000		-		0.000	0.000	0.632	0.000
CBIPR-ADM - Program Management Support	Various	JPL CBRND Enabling Biotechnologies, JPEO-CBRND : Fort Detrick, MD	1.480	0.349	Feb 2022	0.000		0.000		-		0.000	0.000	1.829	0.000

Exhibit R-3, RDT&E	Project C	ost Analysis: PB 2	024 Cher	mical and	d Biologica	al Defens	e Prograi	n				Date:	March 20	23	
Appropriation/Budg 0400 / 4	et Activity	/				PE 0603	3884BP /	•	l umber/N al and Bio /al			: (Numbe i /ledical Bi	r/ Name) ological D	efense (/	ACD&P)
Management Servic	es (\$ in M	illions)	ſ	FY	2022	FY 2	023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
MCMPT - Program Management Support	Various	JPL CBRND Enabling Biotechnologies, JPEO-CBRND : Fort Detrick, MD	4.149	1.107	Dec 2021	0.000		0.000		-		0.000	0.000	5.256	0.000
		Subtotal	5.629	3.035		0.000		0.000		-		0.000	0.000	8.664	N/A
			Prior Years	FY	2022	FY 2	023		2024 Ise		2024 CO	FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract
		Project Cost Totals	55.548	46.791		0.000		0.000		-		0.000	0.000	102.339	N/A

Remarks

Exhibit R-4, RDT&E Schedule Profile: PB 2024 C	hen	nical	and	l Bio	logi	ical [Defe	ense	Pro	gra	n											Da	te: M	arch	202	23			
Appropriation/Budget Activity)400 / 4								PE	060	388	i m El 4BP <i>i</i> rograi	I Che	əmi	cal a	and					-	•		oer/N Biolo			efens	se (A	CD&F	?)
		FY	2022	2		FY	202	3		FY	2024	L		FY	202	5		FY	202	6		FY	2027	7		FY	2028		
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	
COVID TX MAB - Accelerated Antibody Development																													
CBIPR-ADM - MCM Enabling Manufacturing Technologies																													
CBIPR-ADM - MCM Development and Manufacturing Support (Infrastructure)																													
MCMPT - Rapid Response Design, Manufacturing, Testing																													
MCMPT - MCM Optimization Phase Design, Manufacturing, Testing																													
MCMPT - Plague Nonclinical Studies																													
MCMPT - Plague Clinical Studies																													
MCMPT - Plague Manufacturing																													
MCMPT - P3/Nucleic Acid																													

Exhibit R-4A, RDT&E Schedule Details: PB 2024 Chemical and Biological	Defense Program	1		D	ate: Marc	ch 2023
Appropriation/Budget Activity 0400 / 4	PE 0603884B	Element (Numbe P I Chemical and ram - Dem/Val	,	Project (Nun MB4 / Medica		ne) cal Defense (ACD&P)
S	Schedule Detail	S				
		St	art		E	nd
Events		Quarter	Year	Qua	arter	Year
COVID TX MAB - Accelerated Antibody Development		1	2022		4	2022
CBIPR-ADM - MCM Enabling Manufacturing Technologies		1	2022		4	2028
CBIPR-ADM - MCM Development and Manufacturing Support (Infrastru	icture)	1	2022		4	2028
MCMPT - Rapid Response Design, Manufacturing, Testing		1	2022		4	2028
MCMPT - MCM Optimization Phase Design, Manufacturing, Testing		1	2022		4	2023
MCMPT - Plague Nonclinical Studies		1	2023		2	2024
MCMPT - Plague Clinical Studies		1	2024		2	2024
MCMPT - Plague Manufacturing		1	2022		1	2026
MCMPT - P3/Nucleic Acid		1	2024		4	2026

Exhibit R-2A, RDT&E Project Ju	stification	: PB 2024 C	hemical an	d Biologica	l Defense P	rogram				Date: Mare	ch 2023	
Appropriation/Budget Activity 0400 / 4					PE 060388	a m Elemen 34BP / Chen rogram - De	nical and Bi		Project (N TM4 / Tech		n e) cal Defense (ACD&P)
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
TM4: Techbase Medical Defense (ACD&P)	-	29.687	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	29.687
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

Project TM4 supports early-phase clinical development of vaccines and therapeutic drugs to provide safe and effective medical defense against validated biological threat agents and emerging infectious disease biothreats including bacteria, toxins, and viruses. This effort reduces programmatic risk of failure in the advanced development phase by generating clinical and supporting non-clinical safety, tolerability and toxicity data for candidate vaccines and therapeutic drugs prior to transition to System Development & Demonstration. After FY 2022, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. TM4 efforts in FY 2022 progress to Projects MT4 and PT4. This restructuring provides standardization and alignment across CBDP research, development and acquisition efforts.

Individual efforts in this project include:

(1) Tech Base Medical - Transitional Medical Technology Initiative (TBMD TMTI), and

(2) Tech Base Medical Defense - Chem CM (TBMDC CHEM CM)

- Supports the advanced development of medical countermeasures to include prophylaxes, pretreatments, antidotes and therapeutic drugs against identified and emerging biological warfare threat agents.

- Demonstration of human safety and tolerability prior to entry of candidate vaccines and therapeutics into advanced development, supporting the preparation of technical data packages that conform to the Food and Drug Administration (FDA) Investigational New Drug (IND) processes, Department of Defense (DoD) acquisition regulations, and the oversight of early phase clinical trials in accordance with FDA guidelines.

- In addition, this project supports innovative biotechnology approaches to advance medical systems designed to rapidly identify, diagnose, prevent, and treat emerging biological threats whether naturally occurring or engineered.

- Focuses on therapeutic and prophylactic strategies to effectively minimize injuries resulting from exposure to Chemical Weapons Agents. This effort involves the evaluation FDA approved therapeutics for operational use, as well as generation of novel drug products and formulations to enhance level of protection and/ or operational utility for the Warfighter. Efforts in this area are designed to develop drug candidates that will ultimately be submitted for FDA licensure or to identify previously licensed products for new uses in the treatment and pretreatment against chemical warfare injury.

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2022	FY 2023	FY 2024
Title: 1) TBMD TMTI - DOMANE/LIMIT (Layered Integrated Medical Countermeasure Intervention Technologies)	9.000	-	_

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biolo	ogical Defense Program	Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 4	R-1 Program Element (Number/Name) PE 0603884BP <i>I Chemical and Biological</i> <i>Defense Program - Dem/Val</i>	Project (Number/ TM4 / Techbase M	,	se (ACD&P)
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
Description: Initiated platform biotechnologies, capabilities, processes and Investments will develop a rapid drug discovery and development engine to & emerging Biological Warfare (BW) threats by providing BW MCMs. Imm Therapeutics Programs to respond and treat the Joint Force against BW th	o enable the joint force to rapidly respond to new ediate alignment with Biological Prophylaxis and			
Title: 2) TBMD TMTI - Biological Warfare Defense Therapeutics		7.239	-	-
Description: Biological Warfare (BW) defense therapeutics mitigate and rebacterial, and toxin biological warfare threats in symptomatic warfighters dis focused on nonclinical and early clinical development of therapeutic courbacterial, and toxin BW threats for which Food and Drug Administration (Fl spectrum therapeutic candidates that are shown to be both safe and efficate evaluation and can be accelerated for use against emerging infectious distantiant models in which to evaluate therapeutic candidates is also included investments to accelerate development and reduce costs.	iagnosed with BW disease. Biomedical research ntermeasures against known and emerging viral, DA)-approved therapeutics are limited or lacking. B cious against BW threats will advance for further cl eases during an outbreak. Refinement of appropria	inical te		
Title: 3) TBMD TMTI - Bacterial/Viral/Toxin/Broad Spectrum Prophylaxis		7.238	-	-
Description: The ultimate protection of the Warfighter is by pretreating the no adverse side effects from the pretreatment. Such pretreatment would environment, absent of any personal protective equipment allowing operate Element supports GMP manufacturing of candidates for clinical testing, tox trials and Phase 1 clinical trials just prior to transition to advanced developed.	enable the Warfighter to work in a less restrictive ion at peak performance. Investments in this Progra kicology studies necessary for entry into Phase 1 cl			
Title: 4) TBMDC CHEM CM - PBA Medical Countermeasures		1.710	-	-
Description: Focuses on therapeutic and prophylactic strategies to effective exposure to Pharmaceutical Based Agents (PBA). This will allow the Warf contested battlefield scenario. This effort involves the evaluation FDA app generation of novel drug products and formulations to enhance level of proceedings of the the evaluation of t	ighter to maintain operational capacity in a chemica roved therapeutics for operational use, as well as otection and/or operational utility for the Warfighter. Itely be submitted for Food and Drug Administration			
	Accomplishments/Planned Programs Sub	otals 25.187	_	-
	· · · · · · · · · · · · · · · · · · ·		I	1

Exhibit R-2A, RDT&E Project Just	ification: PB	2024 Chemi	cal and Biol	ogical Defen	se Program				Date: Ma	arch 2023	
Appropriation/Budget Activity 0400 / 4				PE 06		nent (Numbe Chemical and - Dem/Val			Number/Na hbase Med	ame) dical Defense	e (ACD&P)
							FY 2022	FY 2023	7		
Congressional Add: Development	of medical co	untermeasu	res against r	novel entities			4.500	- 1	_		
countermeasures (MCMs). Investm the joint force to rapidly respond to Immediate alignment with Biologica Force against BW threats. - Enhance high-throughput screenin rapid target and drug identification, drugs. In cases where no existing of Nations approved drug inventory. - Additional investments will be made	new & emergi I Prophylaxis a ng technologie with an empha drug solution c le in microphy	ng BW threa and Therape s and advan asis on reput an be identi siological or	ts by providi outics Progra nced artificial rposing Food fied, new dru gan-on-a-ch	intelligence and Drug A igs will be id	I warfare (B) nd and treat /machine lea Administratio entified to fil esis forecast	W) MCMs. the Joint arning tools fo n approved I gaps in the	r				
address mechanisms of action, safe	ety, efficacy to	enhance dr	ug developm	•		dds Subtota	ls 4.500) _	-		
C. Other Program Funding Summ	on (¢ in Milli	ono)									
C. Other Frogram Funding Summ		0115)	FY 2024	FY 2024	FY 2024					Cost To	
Line Item	FY 2022	FY 2023	Base	000	Total	FY 2025	FY 2026	FY 2027	<u>FY 2028</u>	Complete	Total Cos
 MT4: Mitigate (ACD&P) 	-	17.302	28.785	-	28.785	20.885	15.433	13.369	-	Continuing	
 PT4: Protect (ACD&P) TM2: Techbase Medical Defense (Applied Research) 	- 107.608	175.219 -	179.158 -	-	179.158 -	135.096 -	107.341 -	123.538 -	139.376 -	Continuing 0.000	Continuino 107.608
<u>Remarks</u>											
D. Acquisition Strategy TECH BASE MEDICAL TRANSITIO	ONAL MED TE	ECHNOLOG	Y INTIATIVE	E (TBMD TM	ITI)						
Supports early-phase clinical devel to System Development & Demons disease biothreats including bacter operational use, as well as generat	tration. This v a, toxins, and	vork provide viruses. Th	s safe and e is work also	ffective med involves the	ical defense evaluation of	against valid of Food and D	ated biologic Drug Adminis	al threat ag tration (FD/	ents and e A)-approve	merging infe d therapeutic	ctious s for

reduces programmatic risk of failure in the advanced development phase.

Exhibit R-3, RDT&E F	•		024 Che	mical and	d Biologica		•				1		March 20	23	
Appropriation/Budge 0400 / 4	t Activity					PE 0603	8884BP /	ement (N Chemica n - Dem/V	l and Bio		-	e (Numbe i Techbase	r/ Name) Medical De	efense (/	4 <i>CD&P)</i>
Test and Evaluation ((\$ in Milli	ons)		FY	2022	FY 2	023	FY 2 Ba			2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
TBMD TMTI - DTE C - Viral Prophylaxis	C/CPFF	Advanced Technologies International : Summerville, SC	-	7.239	Oct 2021	0.000		0.000		-		0.000	0.000	7.239	0.000
TBMD TMTI - DTE C - DOMANE/LIMIT (Layered Integrated Medical Countermeasure Intervention Technologies)	C/CPFF	Advanced Technologies International : Summerville, SC	-	9.000	Oct 2021	0.000		0.000		-		0.000	0.000	9.000	0.000
TBMD TMTI - DTE C - Bacterial Therapeutics	C/CPFF	Advanced Technologies International : Summerville, SC	-	7.238	Oct 2021	0.000		0.000		_		0.000	0.000	7.238	0.000
TBMDC CHEM CM - DTE C - PBA Medical Countermeasures	MIPR	TBD : N/A	-	1.710	Oct 2021	0.000		0.000		-		0.000	0.000	1.710	0.000
CONG - DTE C - DOMANE	C/CPFF	Advanced Technologies International : Summerville, SC	-	4.500	Oct 2022	0.000		0.000		-		0.000	0.000	4.500	0.000
		Subtotal	-	29.687		0.000		0.000		-		0.000	0.000	29.687	N/A
			Prior Years	FY	2022	FY 2	023	FY 2 Ba	-		2024 CO	FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract
		Project Cost Totals	-	29.687		0.000		0.000		-		0.000	0.000	29.687	N/A

Remarks

Exhibit R-4, RDT&E Schedule Profile: PB 2024	Chen	nical	and	Bio	logi	cal D)efer	nse	Prog	gran	n											Date	e: Ma	arch	202	23		
Appropriation/Budget Activity 0400 / 4								PE (0603	3884		I Ch	emi	cal a	nbeı and E						•		er/N e <i>Me</i>			fens	e (A	CD&P)
		FY	2022	2		FY 2	2023	3		FY	2024	4		FY	2025	5		FY	2026	5		FY 2	2027	,		FY 2	028	
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
TBMD TMTI - Biological Therapeutics																												
TBMD TMTI - DOMANE/LIMIT (Layered Integrated Medical Countermeasure Intervention Technologies																												
TBMD TMTI - Viral Prophylaxis																												
TBMD TMTI - Biological Warfare Defense Therapeutics																												

Exhibit R-4A, RDT&E Schedule Details: PB 2024 Chemical and Biological De	efense Program			Date: M	arch 2023
Appropriation/Budget Activity 0400 / 4	-	Element (Numbe ? I Chemical and am - Dem/Val	,	Project (Number/N TM4 / Techbase Me	lame) edical Defense (ACD&P)
Sch	nedule Details	6			
	[St	art		End
Events		Quarter	Year	Quarter	Year
TBMD TMTI - Biological Therapeutics		1	2023	4	2027
TBMD TMTI - DOMANE/LIMIT (Layered Integrated Medical Countermeasu Intervention Technologies	ure	1	2023	4	2026
TBMD TMTI - Viral Prophylaxis		1	2023	4	2027
TBMD TMTI - Biological Warfare Defense Therapeutics		1	2024	4	2027

Appropriation/Budget Activity				a biologice	al Defense F	Togram				Dute. Mit	arch 2023	
0400/4					PE 060388	am Elemen 34BP / Chei Program - De	mical and B		-	Number/Na chnology Tr	a me) ansition (AC	D&P)
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	7 FY 2028	Cost To Complete	
TT4: Technology Transition (ACD&P)	-	0.740	0.000	0.000	0.000	0.000	0.000	0.000	0.00	0.00	0.00	0 0.74
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-			
biological (CB) defense technolog while soliciting end-user determine technologies with proven military proceed directly into limited or full	ation of the utility can e	military util ither be left	ity and ope in place for	rational imp · extended	bact of the te user evalua	echnology a tions, accep	ind capabilition ted into ad	ty demonstr	ated. Suc	cessfully de	emonstrated	
B. Accomplishments/Planned Pl	rograms (§	in Million	s <u>)</u>						F	Y 2022	FY 2023	FY 2024
Title: 1) TECHTRAN - Advanced	Technology	/ Demonstra	ation							0.740	-	-
			ina odao (`	nomical Dia	Jagiaal Dad	ialagiaal an	d Nuclear ((200			
Description: ATDs enable the effet & Technology (S&T) Technologies mission oriented demonstration. F added, and can be matured and tr	to the Wa eedback f	rfighter by p rom the Wa	providing the rfighters en	em an oppo sures that t	ortunity to er	ngage with toologies are	hese new to operational	echnologies	in a			
& Technology (S&T) Technologies mission oriented demonstration.	to the Wa eedback f	rfighter by p rom the Wa	providing the rfighters en	em an oppo sures that t	ortunity to en these techno o end users	ngage with toologies are	hese new to operational ment.	echnologies y relevant,	in a value	0.740	-	
& Technology (S&T) Technologies mission oriented demonstration. F added, and can be matured and tr	to the Wa Feedback f ansitioned	rfighter by p rom the Wa in a timely a	providing the rfighters en and effectiv	em an oppo sures that t e manner to	ortunity to en these techno o end users Accomplis	ngage with t ologies are for employi shments/Pl	hese new to operational ment.	echnologies y relevant,	in a value	0.740	-	
& Technology (S&T) Technologies mission oriented demonstration. F added, and can be matured and tr C. Other Program Funding Sum	to the Wa Feedback f ansitioned mary (\$ in	rfighter by p rom the Wa in a timely a <u>Millions)</u>	providing the rfighters en and effectiv	em an oppo sures that t e manner to 2024 FY	Accomplis	ngage with t blogies are for employe shments/PI	these new t operational ment. anned Prog	echnologies y relevant, [,] grams Sub	in a value totals	I	- <u>Cost To</u> Complete	
& Technology (S&T) Technologies mission oriented demonstration.	to the Wa Feedback f ansitioned mary (\$ in FY 20	rfighter by p rom the Wa in a timely a <u>Millions)</u>	providing the rfighters en and effectiv	em an oppo sures that t e manner to	ortunity to en these techno o end users Accomplis	ngage with to blogies are for employe shments/PI	these new t operational ment. anned Prog	echnologies y relevant, [,] grams Sub	in a value	I	- Cost To Complete 0.000	Total Cos
& Technology (S&T) Technologies mission oriented demonstration. F added, and can be matured and tr C. Other Program Funding Sum Line Item • TT3: Technology Transition (ATD	to the Wa Feedback f ansitioned mary (\$ in FY 20) 7.5	rfighter by p rom the Wa in a timely a <u>Millions)</u> 222 FY 2 589	providing the rfighters en and effectiv	em an oppo sures that t e manner to 2024 FY	Accomplis	ngage with to blogies are for employe shments/PI	these new t operational ment. anned Prog	echnologies y relevant, [,] grams Sub	in a value totals	I	Complete	Total Co
& Technology (S&T) Technologies mission oriented demonstration. F added, and can be matured and tr <u>C. Other Program Funding Sumu</u> <u>Line Item</u> • TT3: <i>Technology Transition (ATD</i> <u>Remarks</u> <u>D. Acquisition Strategy</u>	to the Wa Feedback fr ansitioned mary (\$ in FY 20) 7.5 (TECHTR/ ations (ATE d transition	rfighter by p rom the Wa in a timely a Millions) Millions Millions) Millions) Millions) Millions	providing the rfighters en and effective <u>FY 2</u> 023 <u>E</u> nature and r nal prototyp	em an oppo sures that t e manner to 2024 FY Base - naturing ter bes for prace	Accomplis	ngage with to ologies are for employe shments/Pi <u>(2024</u> <u>Total</u> F	hese new to operational ment. anned Prog Y 2025	echnologies y relevant, ' grams Sub FY 2026 - - ary problems er Project T	s in a value totals FY 2027 - s. ATDs e T4 are to	FY 2028 - emphasize t provide a pr	Complete 0.000 echnology ir ototype cap	Total Cos 7.58

xhibit R-2A, RDT&E Project Justification: PB 2024 Chemical	and Biological Defense Program	Date: March 2023
ppropriation/Budget Activity 400 / 4	R-1 Program Element (Number/Name) PE 0603884BP / Chemical and Biological Defense Program - Dem/Val	Project (Number/Name) TT4 / Technology Transition (ACD&P)
al military exercises and at a scale sufficient to fully assess mil boratories and DoD Federally Funded Research Development th the Economy Act in order to conduct operational evaluation TD efforts. Upon completion of efforts under this project, opera ssessment outcomes will be transitioned to Service stakeholder	Centers (FFRDCs) through the Military Interdepartmental F of technology solutions for Integrated Early Warning (IEW) ational prototypes of Technology Readiness Level (TRL) 6 c	Purchase Request (MIPR) in accordance and Integrated Layered Defense (ILD) or TRL 7 with documented operational utility

Exhibit R-3, RDT&E F			024 Cher	nical and	BIOIOGICa	1							March 20	23	
Appropriation/Budge 0400 / 4	t Activity	/				PE 060	3884BP /	ement (N Chemica n - Dem/V	l and Bio			: (Numbei echnology	r/ Name) Transition	n (ACD&	P)
Support (\$ in Millions	6)			FY 2	2022	FY 2	023	FY 2 Ba			2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contrac
TECHTRAN - IEW and ILD Transition	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	0.232	0.174	Jan 2022	0.000		0.000		-		0.000	0.000	0.406	0.00
		Subtotal	0.232	0.174		0.000		0.000		-		0.000	0.000	0.406	N//
Test and Evaluation ((\$ in Milli	ons)		FY 2	2022	FY 2	023	FY 2 Ba			2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contrac
TECHTRAN - IEW and ILD Transition	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	0.823	0.491	Jan 2022	0.000		0.000		-		0.000	0.000	1.314	0.00
	L	Subtotal	0.823	0.491		0.000		0.000		-		0.000	0.000	1.314	N//
Management Service	es (\$ in M	illions)		FY 2	2022	FY 2	023	FY 2 Ba	-		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contrac
TECHTRAN - PM/MS S - IEW and ILD Transition	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center	0.050		Jan 2022	0.000		0.000		-		0.000	0.000	0.125	0.00

PE 0603884BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program

Volume 4 - 242

Exhibit R-3, RDT&E	Project C	ost Analysis: PB 2	2024 Chei	mical and	d Biologic	al Defens	e Prograi	m				Date:	March 20	23	
Appropriation/Budg 0400 / 4	et Activity	1				PE 060	3884BP /	ement (N ' Chemica m - Dem/\	al and Bio		-	(Numbe echnology	r/Name) / Transitio	n (ACD&	P)
Management Servic	es (\$ in M	illions)		FY	2022	FY 2	2023		2024 Ise		2024 CO	FY 2024 Total]		
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
		(CBC) : Aberdeen Proving Ground, MD													
-		Subtotal	0.050	0.075		0.000		0.000		-		0.000	0.000	0.125	N/A
			Prior Years	FY	2022	FY 2	2023		2024 Ise		2024 CO	FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract
		Project Cost Totals	1.105	0.740		0.000		0.000		-		0.000	0.000	1.845	N/A

Remarks

xhibit R-4, RDT&E Schedule Profile: PB 20	024 Chemical and Biological D	efense Pro	gram					D	ate: M	arch	2023		
ppropriation/Budget Activity 400 / 4		PE 060	o gram Eleme 3884BP / Ch e Program - I	emica	al and Biolo	ne) gical			umber/Name) nology Transition (ACD&P)				
	FY 2022 FY 2	023	FY 2024	F	Y 2025	FY	2026	F	Y 2027	7	FY	2028	
[1 2 3 4 1 2	3 4 1	2 3 4	1	2 3 4	1 2	3 4	1	2 3	4	1 2	2 3	4
TECHTRAN - TECHTRAN - ITR ATD													

		·			
xhibit R-4A, RDT&E Schedule Details: PB 2024 Chemical ar	nd Biological Defense Program			Date: March	า 2023
ppropriation/Budget Activity 400 / 4		Element (Number ? I Chemical and B am - Dem/Val		Project (Number/Nam TT4 / Technology Trans	
	Schedule Details	5			
		Sta	rt	En	d
Events		Quarter	Year	Quarter	Year
TECHTRAN - TECHTRAN - ITR ATD		1	2022	1	2024

THIS PAGE INTENTIONALLY LEFT BLANK

UNCLASSIFIED

Volume 4 - 246

Exhibit R-2, RDT&E Budget Item Justification: PB 2024 Chemical and Biological Defense Program						Date: March 2023						
Appropriation/Budget Activity 0400: Research, Development, Test & Evaluation, Defense-Wide I BA 5: System Development & Demonstration (SDD)				A 5:		am Element 4BP / Chen			fense Progi	ram - EMD		
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
Total Program Element	0.000	291.122	301.611	382.977	0.000	382.977	314.012	299.540	263.749	243.375	Continuing	Continuing
UN5: Understand (SDD)	-	0.000	126.071	182.726	0.000	182.726	137.991	127.671	108.908	68.088	Continuing	Continuing
PT5: Protect (SDD)	-	0.000	87.923	97.975	0.000	97.975	69.858	66.259	52.871	67.776	Continuing	Continuing
MT5: Mitigate (SDD)	-	0.000	74.225	88.441	0.000	88.441	92.279	91.431	87.773	93.250	Continuing	Continuing
EN5: Enabling Investments (SDD)	-	0.000	13.392	13.835	0.000	13.835	13.884	14.179	14.197	14.261	Continuing	Continuing
CA5: Contamination Avoidance (SDD)	-	84.967	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	84.967
CO5: Collective Protection (SDD)	-	2.888	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	2.888
DE5: Decontamination (SDD)	-	7.485	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	7.485
IP5: Individual Protection (SDD)	-	18.690	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	18.690
MB5: Medical Biological Defense (SDD)	-	138.156	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	138.156
MC5: Medical Chemical Defense (SDD)	-	38.936	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	38.936

A. Mission Description and Budget Item Justification

This program element (PE) resources System Development & Demonstration across the Understand, Protect, Mitigate, and Enabling Investments portfolios. The Chemical Biological Defense Programs (CBDP) investments provide an integrated, layered capability to enable Countering Weapons of Mass Destruction (CWMD) missions ranging from combat operations to Department of Defense (DoD) support to domestic incident prevention and response. The projects in this PE support the development, build, and test of products to verify that all operational and derived requirements have been met and to support production or deployment decisions. The activities include mature system development, integration, and demonstration to support Milestone C decisions, and conducting operational tests and evaluation of production representative articles. FY24 funding accelerates characterization and situational awareness of emerging biothreats and accelerates delivery of improved protection from and mitigation of biothreats, including rapid repurposing of available therapeutics and development of new vaccines.

Individual Projects include:

Exhibit R-2, RDT&E Budget Item Justification: PB 2024 Chemical and Biol	logical Defense Program	Date: March 2023
Appropriation/Budget Activity 0400: Research, Development, Test & Evaluation, Defense-Wide I BA 5: System Development & Demonstration (SDD)	R-1 Program Element (Number/Na PE 0604384BP <i>I Chemical and Biol</i>	logical Defense Program - EMD
- Understand (UN5): Provides the Joint Force the ability to detect and identify timeliness and confidence of information for decision-makers. Supports free analyzing, and warning of chemical and biological (CB) hazards.		
- Protect (PT5): Provides the Joint Force the ability to prevent the effects of e biological, and radiological (CBR) liquid, vapor, and aerosol hazards through psychological, and logistical burdens to the Warfighter. Medical countermeas manufacturing process and validation of that process, nonclinical studies, der Focuses on platform-based approaches to accelerate the development of pro Warfare Agents (BWAs), toxins, non-traditional and emerging chemical threa License Application (BLA) to the U.S. Food & Drug Administration (FDA) for p	next-generation prototypes of masks, sure efforts conducted during this phase monstration of manufacturing consister ophylactic medical countermeasures the ts with minimal doses. The results of the	filters, and ensembles to reduce physiological, se include the development of a large-scale ncy, and expanded clinical human safety studies. nat rapidly and durably protect against Biological
- Mitigate (MT5): Preserves combat power by mitigating exposure to CB haza lethality by providing capabilities for Warfighters to rapidly respond to and mit biological agents, opioids and other Pharmaceutical-Based Agents, and Four	tigate the adverse effects of CB hazard	
- Enabling Investments (EN5): Provides fundamental knowledge and technol Dedicated funding for this Project supports National and Departmental incide		
- Contamination Avoidance (CA5), Collective Protection (CO5), Decontamina Chemical Defense (MC5) are no longer active FY24 Projects due to budget re-		Medical Biological Defense (MB5) and Medical
Middle Tier Acquisition programs:		
The total cost of the Rapid Opioid Countermeasure System (ROCS) Middle T of prototype units (CBDP BLIN Protection & Hazard Mitigation). The ROCS is The total cost of the Forward Area Mobility Spray System (FAMS-S) Middle T procurement of prototype units (CBDP BLIN Protection & Hazard Mitigation). The total cost of the Uniform Integrated Protective Ensemble Family of Syste including RDT&E (Projects IP4 and PT5) and procurement of prototype units funded across the Future Years Defense Program.	s fully funded across the Future Years Fier of Acquisition effort is \$34.141 mill The FAMS-S program is fully funded a ms Gloves (UIPE FOS GLOVES) Midd	Defense Program. ion, including RDT&E (Projects DE5 and MT5) and across the Future Years Defense Program. dle Tier of Acquisition effort is \$49.483 million,
The projects in this PE support the engineering and manufacturing developm correctly placed in Budget Activity 5.	nent phase of the Department of Defen	se (DoD) acquisition system and are, therefore,

Exhibit R-2, RDT&E Budget Item Justification: PB 2024 C	ogical Defense Pro	gram	Date	: March 2023		
Appropriation/Budget Activity 0400: Research, Development, Test & Evaluation, Defense-Wide I BA 5: System Development & Demonstration (SDD)		R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological Defense Program - EMD</i>				
3. Program Change Summary (\$ in Millions)	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	
Previous President's Budget	299.848	312.148	276.205	-	276.205	
Current President's Budget	291.122	301.611	382.977	-	382.977	
Total Adjustments	-8.726	-10.537	106.772	-	106.772	
 Congressional General Reductions 	-	-				
 Congressional Directed Reductions 	-	-10.537				
 Congressional Rescissions 	-	-				
 Congressional Adds 	-	-				
 Congressional Directed Transfers 	-	-				
Reprogrammings	-2.237	-				
SBIR/STTR Transfer	-6.488	-				
 Other Adjustments 	-0.001	-	106.772	-	106.772	

Change Summary Explanation

Funding: FY 2022 (-\$2.237 Million): Below threshold reprogramming to Advanced Component Development & Prototypes, Budget Activity 4 for Advanced Emerging Threat Defense efforts, and reprogrammed prior year execution balances to RDT&E Management Support, Budget Activity 6 in support of the Departments higher priorities.

FY 2022 (-\$6.488 Million): Transfer of funding to support Small Business Innovative Research/Small Business Technology Transfer efforts.

FY 2023 (-\$10.537 Million): Congressional Directed Reductions.

FY 2024 (+\$106.772 Million): Increase provides for biological defense improvement efforts, Next Generation Diagnostic System Increment 2 Man Portable Diagnostic System continued development and testing, Alternate Autoinjector Manufacturer Capability design development and prototype evaluations, complete engineering and manufacturing development (EMD) activities for the Multi-Phase Chemical Agent Detector, Aerosol Vapor Chemical Agent Detector activities in support of a Full Rate Production decision, Botulinum Monoclonal Antibodies manufacturing and clinical studies, initiating efforts within the Understand, Protect and Mitigate portfolios, and Departmental inflation rate adjustments (+\$1.687 Million).

Schedule: N/A

Technical: Provides for critical new start programs Advanced System for Protection and Integrated Reduction of Encumbrances - Enhanced Biodefense (ASPIRE-ENBD), Collective Protection CONEX Enhanced Biodefense (COL PRO CONEX-ENBD), Portable Patient Transport System-Enhanced Biodefense (PPTS-ENBD), and Shipboard Isolation System (SIS).

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program									Date: March 2023			
Appropriation/Budget Activity 0400 / 5				R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> <i>Defense Program - EMD</i>				Project (Number/Name) UN5 / Understand (SDD)				
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
UN5: Understand (SDD)	-	0.000	126.071	182.726	0.000	182.726	137.991	127.671	108.908	68.088	Continuing	Continuing
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

The Understand System Development & Demonstration (SDD) Project provides the Joint Force the ability to continually receive information about the Chemical, Biological, Radiological and Nuclear (CBRN) situation at a desired time and place by detecting, identifying, and quantifying CBRN hazards in air, water, or on land, and on personnel, equipment or facilities. These efforts support the ability to conduct early warning (informing protective posture) and employment of rapid detection, identification, and analysis tools needed to address emerging biological threats. Efforts also keep the Joint Force ahead of emerging chemical threats with portable, reduced size, weight, and power, cost detectors to protect general and specialized forces and to enhance operations on the battlefield by providing early warning and field analytics. Medical diagnostic activities develop U.S. Food & Drug Administration (FDA) approved products for the warfighter at the point of care to inform farforward medical and protection decisions. In FY 2023, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. UN5 efforts in FY 2022 remain in Project CA5, IP5, and MB5. This restructuring provided standardization and alignment across CBDP research, development and acquisition efforts.

Efforts included in this Project are:

- (1) Advanced Emerging Threat Defense (AET DEFENSE)
- (2) Aerosol & Vapor Chemical Agent Detector (AVCAD)
- (3) Chemical and Biological Wearables Enhanced Biodefense (CB Wearables ENBD)
- (4) Chemical Biological Radiological and Nuclear (CBRN) Sensor Integration on Robotics Platforms (CSIRP)
- (5) Compact Vapor Chemical Agent Detector (CVCAD)
- (6) Defense Biological Products Assurance Program (DBPAP)
- (7) Defense Biological Products Assurance Program-Enhanced Biodefense (DBPAP-ENBD)
- (8) Far Forward Biological Sequencing (FFBS)
- (9) Wearable All Hazard Remote Monitoring Program (WARP)
- (10) Joint Biological Tactical Detection System (JBTDS)
- (11) Mobile Field Kit (MFK)
- (12) Multi-Phase Chemical Agent Detector (MPCAD)
- (13) Nuclear Biological Chemical Reconnaissance Vehicle Sensor Suite Upgrade (NBCRV SSU)
- (14) Next Generation Diagnostic System Increment 2 Chemical Diagnostic (NGDS 2 CHEMDX)
- (15) NGDS 2 Man Portable Diagnostic System (NGDS 2 MPDS)
- (16) Surveillance and Pathogen Characterization Enhanced Biodefense (SPCHAR-ENBD)
- (17) Special Purpose Unit Rapid Capability Development and Deployment (SPU RCDD)

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	Date: March 2023		
0400/5	R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> <i>Defense Program - EMD</i>		umber/Name) erstand (SDD)

The Advanced Emerging Threat Defense (AET DEFENSE) program continues to address the highest priority CBRN gaps and supports the Chemical Biological Defense Program (CBDP) Strategic Line of Effort to meet current and emerging threats by anticipating CB hazards and developing capabilities to counter emerging and future threats. The AET DEFENSE program collaborates with the Joint Services, interagency, and international partners to align RDT&E resources to determine readiness against emerging threats, to include Non-Traditional Agents (NTAs), such as Novichoks and Pharmaceutical-Based Agents (PBA) (e.g. synthetic opioids), emerging biological threats, toxins, and other advanced and emerging threats as they are identified across the entire CBDP enterprise portfolio. In FY24, AET DEFENSE continues to broaden data set for emerging biological threats and PBAs to better assess detection and decontamination capabilities.

AVCAD is a man portable system to detect aerosol and vapor chemical agents. AVCAD fills critical gaps in current Joint Force chemical sensor capabilities, in the areas of liquid, solid and dusty aerosol Chemical Warfare Agent detection, and detection of specific advanced threats/Non-Traditional Agents. The AVCAD will also detect low-level off-gassing, or residual vapors, to prevent/mitigate health effects associated with low concentration exposures, and perform remote alarm warning and reporting. AVCAD will support chemical and biological defense missions, including monitoring, collective protection, base defense, decontamination, unmasking, and reconnaissance. AVCAD will be integrated on the Nuclear Biological Chemical Reconnaissance Vehicle (NBCRV) Stryker. AVCAD also has a fixed site variant that will be integrated onto ships. In FY24, AVCAD will execute and complete production and deployment testing.

CB Wearables-ENBD will continue to develop an integrated physiological monitoring capability that leverages artificial intelligence and machine learning (AI/ML) analytics to detect and alert anomalies that may indicate exposure to biological warfare agents (BWA) or other emerging threats. This will enable the Services to conduct force-wide monitoring to detect the presence or initial onset of CBRN threats and human physiological stressors before an operator's mission performance degrades, a communicable disease spreads, or an individual becomes a casualty. This provides the Government the ability to understand, address and provide solutions against emerging threats encountered under many operational scenarios, which could deter maneuver and ability to project force. CB Wearables-ENBD will continue to directly interface and integrate with existing Joint Force computing environments and directly supports the strategic goals of the CBDP's Enhanced Biodefense effort.

CSIRP is a prototyping and fielding effort that will focus on repackaging and integrating of modular CBRN sensor and common interface solutions to enhance Unmanned Aircraft Systems (UAS), Unmanned Surface Vessels (USV) and Unmanned Ground Vehicles (UGV) to provide situational awareness across the echelons of command in order to enable freedom of maneuver and action on the battlefield. An integrated CSIRP capability will exploit advances in artificial intelligence, machine learning and autonomy, sensing and communication capabilities that enable timely and accurate detection, warning and reporting of CBRN hazards. This reduces risk at tactical and operational echelons in mounted and dismounted configurations. CSIRP gives the Joint Force an opportunity to enhance capabilities and maintain operational advantage in a lethal and sophisticated operating environment. In FY24, CSIRP will integrate standoff detection and provide upgrades to CBRN autonomy, mapping and obstacle avoidance for denied global positioning system (GPS) operations on UASs.

The Compact Vapor Chemical Agent Detector (CVCAD) is designed to be an unobtrusive, low-profile chemical detection capability that will continuously, and autonomously, monitor and alert general and specialized units to an unsafe environment without further burdening the warfighters payload or interfering with the primary mission. The small form factor (less than 2 lbs.) is amenable to both man-worn and unmanned aerial or ground system operations to enable timely personnel protective

xhibit R-2A, RDT&E Project Justification: PB 2024 Chemical	and Biological Defense Program	Date: March 2023
Appropriation/Budget Activity 400 / 5	R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> <i>Defense Program - EMD</i>	Project (Number/Name) UN5 I Understand (SDD)
action and other force protection decisions. FY24 funding conduc program management support.	cts engineering manufacturing and development of system	s after Milestone B decision and provides
The Defense Biological Product Assurance Program (DBPAP) se and reagents that meet the requirements of the warfighter and Jo and predict effective medical countermeasure solutions that are c (OSCAR), where multiple government agencies and customers ca support optimization and expansion of biological threat agents ref	int biological defense systems. DBPAP pursues an array ritical to preparedness. The DBPAP enables an Ordering an place orders, track order status, and monitor ordering h	of analytical tools to verify assay performand System for Critical Assays and Reagents istory. In FY24 DBPAP will continue to
The Defense Biological Product Assurance Program - Enhanced through enhancements to biological threat agent reference mater increased repository of collected biothreat genomic information, a pandemics. In FY24 DBPAP-ENBD continues to support expande increased sequencing capabilities, expanding on analytical tools, biothreats and toxins against emerging diseases and potential pa	ials, analytical tools portfolios, increased sequencing capa and additional biorepository of targeted biothreats and toxin ed enhancements to biological threat agent reference mate additional repository of collected biothreat genomic inform	bilities, expanded analytical tool capabilities against emerging diseases and potential erials, and analytical tools portfolios,
Far Forward Biological Sequencing (FFBS) system is a rapid han (BWAs) to include emerging or engineered biological weapon thre Operations Task Forces (SOTFs) the detect-to-inform capability v t will save lives. The system includes sampling equipment, const interface. When used together, this system will allow for the ident warfare experts with detailed sequencing information. This system weeks to hours, significantly increasing the situational awareness real-time tactical decision-making. FY24 funds will focus on the d Document.	eats on or near the objective. It will provide far-forward Sp with a reduction in timeline from weeks to hours, increasing umables, a sequencing device, and a back-end bioinforma ification and documentation of emerging or engineered BV n will provide near-real time identification of BWAs, to decr of biological threats to SOF forces operating in a far-forwa	ecial Operations Forces (SOF) and Special g tactical flexibility and fighting strength, and tics library with an intuitive front-facing user VAs with the ability to reach back to biologica rease the tactical decision timeline from ard environment and enabling Commanders
Wearable All-hazard Remote-monitoring Project (WARP) is a fam operational environment, disposition of warfighters, and equipmen mission. This network of sensors may be accessed by multiple ec force and more timely and accurate situational awareness.	nt status in order to optimize actions on the objective and f	acilitate reconstruction of the force post-
JBTDS is the first tactical lightweight, low-cost biological surveilla components are man-portable, battery operable and easy to emp awareness to protect and preserve the forces and can archive a s providing a theater-wide array capable of biological detection, ide	loy by any military user. JBTDS provides notification of a sample for follow up analysis. When networked, JBTDS at	hazard and enhances battle-space ugments existing biological detection systen

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical	and Biological Defense Program	Date: March 2023
Appropriation/Budget Activity 1400 / 5	R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> <i>Defense Program - EMD</i>	Project (Number/Name) UN5 I Understand (SDD)
surface sampling capability which interfaces with the JBTDS ider support the low rate initial production (LRIP).	ntifier to support sensitive site exploitation missions. In FY2	24, JBTDS will continue activities required to
MFK effort is the modernization, development, and continuous er Awareness & Understanding capability for the Homeland Defens Guard CBRN Response Enterprise (CRE) Information Managem real-time visualization and mapping of CBRN threats, personnel modernization, development and continuous engineering require capability.	e Mission. MFK is a suite of software applications, platform ent System (NG-CIMS) operationally deployed in support o location and health, and other sensor data to support the H	is, and architecture residing on the National of Title 32 missions. MFK provides the NGB lomeland mission. FY24 funds will begin the
MPCAD is a two-man portable system that will conduct near real in a presumptively contaminated area. The MPCAD results will s decontamination, and treatment measures. The Army and Marin substantiate presumptive detector results. The Air Force will em missions by monitoring the environment at airbases after a chem levels through analysis of samples from collectors deployed at th information will support commander decisions to determine Missi MPCAD will complete the vapor LRIP testing and plan to conduct	support the Commander's tactical and operational decisions the Corps will employ MPCAD in Dismounted Reconnaissant ploy the MPCAD to support Post-Event Reconnaissance in thical release. The Air Force will continuously monitor conta the contamination site and brought back to the analyzer for its ion Oriented Protective Posture (MOPP) levels and eventual	s regarding maneuver, protection, ice and Site Assessment missions to support of Reconnaissance and Surveillan minated areas for chronic health effects dentification and quantification. This
Nuclear Biological Chemical Reconnaissance Vehicle Sensor Su Biological Radiological and Nuclear (CBRN) reconnaissance and & facilitate proactive risk-based decisions, to ensure freedom of a an Acquisition Category (ACAT) II modification work order (MWC maneuverability of the force, and standoff distance from the threa	d surveillance. The NBCRV SSU will answer the commande action and maintain maneuver momentum in Large Scale C D) effort to modernize the current NBCRV Sensor Suite to ir	er's priority intelligence requirements Combat Operations. NBCRV SSU is ncrease maintainability, reliability,
NGDS 2 ChemDx program will provide a rapid, hand-held, point- of possible Nerve Agent exposure in individuals. NGDS 2 Chem healthcare. NGDS 2 ChemDx test results are to be used to aid in FY24, NGDS 2 ChemDx continues Engineering & Manufacturing clinical trials.	Dx will be employed by the Army, Air Force, Navy, Marines n the diagnosis and treatment of individuals suspected of h	and SOCOM at multiple echelons of aving exposure to chemical nerve agents.
The NGDS 2 MPDS program will provide a simple-to-use, portab diagnosis of infectious diseases and biological warfare agents. T and command situational awareness, and; mitigate the effects of hardware, software and assay design, including planning for Initia	The MPDS will enable earlier patient diagnosis, improve de exposure to unknown infectious disease and biological age	cision support for treatment, evacuation ents. In FY24, NGDS 2 MPDS concludes

A non no ministica na (Develope 4. A patients)	chibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program				
Appropriation/Budget Activity 0400 / 5	R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> <i>Defense Program - EMD</i>	-	roject (Number/Name) N5 / Understand (SDD)		
SPCHAR-ENBD (contact tracing) integrates innovative and emerg Wearables-ENBD. This effort will leverage on-going COVID-19 in Needs Statement (JEONS) JS-0003. It will include person-worn d strategic goals of the Chemical Biological Defense Program's (CB	vestments in contact tracing stemming from the joint servic ligital proximity tools for logging close contacts with the infe	ce response to Joint	Emergent Op	perational	
SPU RCDD facilitates Joint Special Operations Command (JSOC) This includes select elements from across the Special Operations Force enabling units such as the 20th Chemical, Biological, Radio Defense Program (CBDP) by creating a portfolio of operationally-r capability needs of the geographic combatant commanders. These focused conduct of combat evaluations and mission-oriented oper existing Commercial-Off-The-Shelf (COTS) and Government-Off-T new challenges supported by "buy-try-decide-acquire" acquisition unmanned aerial and ground platform sensor integration, develop Biological ensembles that have gone through requirements validat SOF equipment to counter emerging threats. In FY24, SPU RCDI capabilities into production for the SOF user to close near-term JS	Force (SOF) Enterprise such as CBRN Assessment Resp logical, Nuclear and Explosives Command. SPU RCDD me elevant CB capabilities that can be quickly transitioned in se objectives are met by the early transitioning of promising rational assessments to assess technological and mission The-Shelf (GOTS) products along with novel redesign appr strategies. SPU RCDD initiates efforts such as respiratory ment of enhanced and augmented reality systems, and mo tion and continues product enhancement development and D will continue prototype development and test and evaluation	oonse Teams (CART nitigates risk across response to the artic g science and techn suitability; and the a roaches to optimize y breathing systems odernization of prote d technology upgrad tion activities to trar	s) and other of the Chemical culated, emergologies (S&T) ctive leveragin existing soluti , biological ide ctive Chemica es on current sition critical (Joint Biological gent ; the ng of ons to entification, al and y fielded CBRND	
3. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023		
<i>Title:</i> 1) AET DEFENSE		-	1.248	FY 2024	
Description: This effort will focus on Expand capabilities of Defen Program Management, Product Development, Support, and Testin		s		FY 2024 2.69	
Technology Readiness Level (TRL) 6 or higher in order to rapidly f					
Technology Readiness Level (TRL) 6 or higher in order to rapidly f FY 2023 Plans: Continue efforts to leverage expanded requirements to broaden da Based Agents (PBAs). Produce additional data to better assess d requirements and inform rapid fielding decisions. Conduct field ex techniques, and procedures (TTP) development and gap analysis the Engineering and Manufacturing Development (EMD) phase of after fielding.	Tield solutions to combat emerging threats. ata set for emerging biological threats and Pharmaceutical etection and decontamination capabilities against new ercises to support Joint Service and interagency tactics, for materiel solutions. Assess potential upgrades to system	ms in			

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical a	and Biological Defense Program	Date:	March 2023		
Appropriation/Budget Activity 0400 / 5		Project (Number/Name) UN5 / Understand (SDD)			
B. Accomplishments/Planned Programs (\$ in Millions) Produce additional data to better assess detection and defensive of decisions. Produce new data to understand decontamination capa exercises to support Joint Service and interagency tactics, techniq materiel solutions. Assess potential upgrades to systems in the Er acquisitions to add emerging threat defensive capability prior to or <i>FY 2023 to FY 2024 Increase/Decrease Statement:</i>	bilities against multiple emerging threat materials. Conduc ues, and procedures (TTP) development and gap analysis igineering and Manufacturing Development (EMD) phase of	t for	FY 2023	FY 2024	
Increase due to significant increase in quantity of emerging threats due to a more thorough understanding of all defensive capabilities DEFENSE program.					
 <i>Title:</i> 2) AVCAD <i>Description:</i> Product Development, Testing, Support Cost, Progra <i>FY 2023 Plans:</i> Complete Low Rate Initial Production (LRIP) contract activities and support the Full Rate Production decision. Continue Systems Eng development and materiel release. Complete Multi-Service Opera Production decision. <i>FY 2024 Plans:</i> Executing and completing product development and testing. Prep classification / material release (TCMR). Continue Systems Engine 	d Pharmaceutical Based Agents (PBA) algorithm developm ineering and other Integrated Product Teams (IPTs) for pri- tional Test and Evaluation (MOT&E) in support of a Full Ra aring for Full Rate Production (FRP) to include type	oduct ate	12.972	11.290	
release. Complete Multi-Service Operational Test and Evaluation Continue Program management and administration processes to i justification, budgeting and programming, milestone and schedule for logistics and test evaluation results in support of a Full Rate Pro <i>FY 2023 to FY 2024 Increase/Decrease Statement:</i> Program/project transitioned to Production and Deployment Phase starting in FY24.	(MOT&E) in support of a Full Rate Production decision. nclude but not limited to program oversight, resource tracking. Continue Other Government Agency (OGA) Sup oduction decision.	port			
<i>Title:</i> 3) AVCAD <i>Description:</i> Support Costs/Program Management <i>FY 2023 Plans:</i>		-	3.972	-	

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	al Defense Program		Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 5	R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> <i>Defense Program - EMD</i>	Project (N UN5 / Und			
B. Accomplishments/Planned Programs (\$ in Millions)		F	(2022	FY 2023	FY 2024
Continue Program management and administration processes to include but no justification, budgeting and programming, milestone and schedule tracking. Co evaluation results in support of a Full Rate Production decision.					
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.					
Title: 4) CB WEARABLES-ENBD			-	38.700	39.201
Description: This effort will develop and field wearable sensor capabilities and	architectures for use across the joint services	S.			
FY 2023 Plans: Develops, tests, and evaluates a series of interfaces that connect a family of w networks and architectures operating within all phases of multi-domain operation algorithmic tools used to monitor and predict joint Warfighter exposure to emer	ons. Conducts advanced development on				
FY 2024 Plans: Continues to develop, test, and evaluate a series of interfaces that connect a fa combat networks and architectures operating within all phases of multi-domain on algorithmic tools used to monitor and predict joint warfighter exposure to emarchitectures and standards to support integrating existing Government and inc	operations. Conducts advanced developmer nerging threats and CBRN hazards. Develops				
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments. Additional investment in en	hanced biodefense and pandemic preparedne	ess.			
Title: 5) CSIRP			-	12.730	18.505
Description: Product Development, Program Management, Test and Evaluation	on and Support.				
<i>FY 2023 Plans:</i> Continue chemical sensor integration on an Unmanned Air Systems (UAS) to se Reconnaissance Vehicles Sensor Suite Upgrade (NBCRV SSU) program, as p of demonstrations and test events for additional Service end users. Continue p processes to include, but not limited to, program oversight, resource justification schedule tracking. Continue evaluation of capability and development of Conc	part of Prototype Plan #2. Continue coordinati program office management and administratio on, budgeting and programming, milestone and	n			
FY 2024 Plans: Completion of chemical sensor integration on an Unmanned Air Systems (UAS Reconnaissance Vehicle Sensor Suite Upgrade (NBCRV SSU) program and in		6			

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologi	ical Defense Program	Date: N	/larch 2023	
Appropriation/Budget Activity 0400 / 5	ation/Budget Activity R-1 Program Element (Number/Name) Proje PE 0604384BP / Chemical and Biological UN5 / Defense Program - EMD UN5 /			
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
(USV). Initiate repacking and integration of standoff detection, cross platform mapping in denied GBS operations for UASs, as part of the Development Ob demonstrations and test events for additional Service end users. Continue p processes to include, but not limited to, program oversight, resource justifical schedule tracking. Continue evaluation of capability and development of Co	ojective Strategy #2. Continue coordination of program office management and administration tion, budgeting and programming, milestone and			
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to fact of life change in the program/project. Increase in FY24 r Development Objectives Strategy #2.	reflects new service objectives identified in			
Title: 6) CVCAD		-	3.606	16.834
Description: Engineering, Manufacturing and Product Development, and Pr	ogram Management Support			
FY 2023 Plans: Initiate award Phase III engineering and development tasks following Milesto	one decision and programmatic activities.			
FY 2024 Plans: Conduct Engineering and Development tasks to include military standard enconduct a soldier touch point to assess and measure system performance and administration processes to include but not limited to program oversight, milestone and schedule tracking.	nd assess risk. Continue Program management	ng,		
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to ramp up of engineering and manufacturing development test	ting and operational testing.			
Title: 7) DBPAP		-	8.163	8.31
Description: Development				
<i>FY 2023 Plans:</i> Continue development/expansion of biological threat agents reference mater development of assays and nucleic acid based genomic assays to support fi Assurance/Quality Control (QA/QC) testing to encompass the transition and maintain yearly accreditation audits such as ISO 9001, 17025, and Guide 34 maintain the quality managed systems. Continue development of prototypes Collection. Supports establishment of a Common Reference Repository - a s	elded and developmental systems. Continue Qu fielding of biological detection assays. Continue certifications. Continue quality actions through s/information for strains contained in Unified Cult	to but to ure		

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and	Date:	Date: March 2023				
Appropriation/Budget Activity 0400 / 5		Project (Number/Name) JN5 / Understand (SDD)				
B. Accomplishments/Planned Programs (\$ in Millions) articles and vital information for biological defense, effective verificat technologies, all at a decreased cost for the individual organizations.		FY 2022	FY 2023	FY 2024		
<i>FY 2024 Plans:</i> Continue development/expansion of biological threat agents reference development of assays and nucleic acid based genomic assays to su Assurance/Quality Control (QA/QC) testing to encompass the transit maintain yearly accreditation audits such as ISO 9001, 17025, and C maintain the quality managed systems. Continue development of pr Collection. Supports establishment of a Common Reference Reposi articles and vital information for biological defense, effective verificat technologies, all at a decreased cost for the individual organizations.	upport fielded and developmental systems. Continue Q tion and fielding of biological detection assays. Continue Guide 34 certifications. Continue quality actions through rototypes/information for strains contained in Unified Cul- itory - a single source for well-characterized, traceable to tion of proficiency testing, improved acquisition of emerg	e to out to ture est				
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.						
<i>Title:</i> 8) DBPAP-ENBD <i>Description:</i> Development		-	2.600	1.900		
FY 2023 Plans: Expansion of site locations for increased sequencing capabilities to rexchange critical data (sequence information) collected at these site Expanding the repository of collected biothreat genomic information center in order to support analytics from the field. Enable exchange of data by creating data compression/decompress Expansion of biorepository of targeted biothreats and toxins strategic Maintain information storage capabilities on DoD Accredited sites.	s. (One Site Per Year through FY28). to a government access controlled, cloud-based informa sion capabilities prior to storage and retrieval on GARDIC	ation C.				
<i>FY 2024 Plans:</i> Continue expansion of site locations for increased sequencing capal biothreats, and exchange critical data (sequence information) collect Continue expanding the repository of collected biothreat genomic inf information center to support analytics from the field. Maintain exchange of data by creating data compression/decompress Continue expansion of biorepository of targeted biothreats and toxins pandemics.	ted at these sites. (One Site per Year through FY28). formation to a government access controlled, cloud-base ssion capabilities prior to storage and retrieval on GARD					

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical	and Biological Defense Program		Date: March 2023				
Appropriation/Budget Activity 0400 / 5	R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> <i>Defense Program - EMD</i>						
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024			
Maintain information storage capabilities on DoD Accredited sites	i.						
FY 2023 to FY 2024 Increase/Decrease Statement: Decrease due to change in program/project technical parameters	. Reduced infrastructure costs in FY24.						
Title: 9) FFBS		-	-	2.48			
Description: Prototype Development							
FY 2024 Plans: Prototype development and testing effort will focus on the develop requirements of decreasing sample to answer time, increasing the bioinformatics data and software and database development.							
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project funding transferred from another funding line. Pro Program (BDIP) starting in FY24.	ogram funding transferred from Biological Defense Improve	ment					
<i>Title:</i> 10) WARP		-	-	2.10			
Description: Prototype Development: this effort will initiate, proto off-the-shelf and Government off-the-shelf (COTS/GOTS), agains (USSOCOM) requirements.		ercial					
FY 2024 Plans: Execute integration of commercial off-the-shelf and Government of tool that is viewable on a customer-specific Team Awareness Kit		on					
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project funding transferred from another funding line. W/ Improvement Program (BDIP) subdivision.	ARP is a byproduct of the required Biological Defense						
Title: 11) WARP		-	-	1.10			
Description: Test & Evaluation: this effort will test and evaluate withe WARP kits. The exit criteria will be a technology readiness level Special Operations Command (USSOCOM) requirements.							
FY 2024 Plans:							

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical a	and Biological Defense Program	Date: N	/larch 2023			
Appropriation/Budget Activity 0400 / 5		Project (Number/Name) UN5 I Understand (SDD)				
B. Accomplishments/Planned Programs (\$ in Millions)	FY 2022	FY 2023	FY 2024			
Execute test and evaluation on the software and communication p Awareness Kit (TAK) device(s).	rotocol for the integrated CBRN sensors and the Team					
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project funding transferred from another funding line. WA Improvement Program (BDIP) subdivision.	RP is a byproduct of the required Biological Defense					
Title: 12) JBTDS		-	2.596	7.892		
Description: Test & Evaluation (T&E)						
FY 2023 Plans: Conduct Low Rate Initial Production T&E activities.						
FY 2024 Plans: Complete Low Rate Initial Production T&E activities.						
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to fact of life change in the program/project. Increase Production (FRP) in FY25.	e funds completion of T&E activities to support Full Rate					
<i>Title:</i> 13) MFK		-	-	6.300		
Description: Modernization, Development and Continuous Engin	eering					
FY 2024 Plans: Begin the modernization, development and continuous engineerin cyber security. Effort also includes updates to the software based						
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project is new start effort in FY 2024.						
Title: 14) MPCAD		-	2.103	8.265		
Description: Product Development, Testing & Program Managen	nent					
FY 2023 Plans: Complete two Low Rate Initial Procurement (LRIP) contracts, Gov systems engineering and Integrated Product Team (IPT) Support. (OGA) support of development and testing of MPCAD systems inc	Complete operational testing, Other Government Agency	am,				

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological I	Defense Program		Date: March 2023					
0400/5	R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> Defense Program - EMD	-	ct (Number/N Understand	,				
B. Accomplishments/Planned Programs (\$ in Millions)		Γ	FY 2022	FY 2023	FY 2024			
reports. No additional LRIP test articles will be items purchased in FY23. Compl Government system engineering, program/financial management, costing, perso								
FY 2024 Plans: Complete Vapor Low Rate Initial Procurement (LRIP) product and development (efforts including Government system engineering, program/financial management		ent						
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to change in program/project schedule. Increase in FY24 funding re FY22 EMD vapor testing experienced performance challenges and lower trials th end of EMD vapor testing to 3QFY23 and LRIP vapor testing to occur in FY24. In LRIP vapor testing based on experience during EMD testing.	roughput then originally estimated. This put	shed						
Title: 15) NBCRV SSU			-	16.916	21.629			
Description: Product Development, Program Management, Test and Evaluation	and Support.							
FY 2023 Plans: Continue government strategic planning, systems engineering, logistics, training, integration, and system level developmental testing.	test and evaluation, technical support,							
<i>FY 2024 Plans:</i> Continue government strategic planning, systems engineering, logistics, training, integration, and developmental testing. Complete Limited User Test for Capabilit integrated sensor suite prototype development, and maturation of CS2.2, and init program office management and administration processes to include but not limit budgeting and programming, milestone and schedule tracking. Continue program office management and administration processes.	ty Set 2.1 (CS2.1). Complete CBRN sensor tiate CS2.2 developmental testing. Continue							
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to change in program/project schedule. Increase due to refined CS2 within Test and Evaluation Master Plan (TEMP) approved on 7 March 2022, and development in CS2.2 configuration prior to beginning test activities in FY24.		•						
Title: 16) NGDS 2 CHEMDX			-	5.288	7.808			
Description: Engineering and Manufacturing Development.								
FY 2023 Plans:								

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and	nd Biological Defense Program	Date: March 2023				
Appropriation/Budget Activity 0400 / 5	R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> <i>Defense Program - EMD</i>	Project (Number/Name) UN5 / Understand (SDD)				
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024		
Continue engineering and manufacturing development, initiate development	elopmental testing.					
FY 2024 Plans: Continue Engineering Development, conduct Development Testing	and Operational User Evaluations, begin clinical trials.					
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to change in program/project schedule.						
Title: 17) NGDS 2 MPDS		-	6.914	19.359		
Description: Engineering and Manufacturing Development.						
FY 2023 Plans: Continues hardware and software development based on new mate material solution leveraging work accomplished based on previous configurations. Plans for two clinical trial starts.						
FY 2024 Plans: Continue hardware, software, assay development; instrument deve	lopmental testing, and analytical testing/ two clinical trials					
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to fact of life change in the program/project.						
Title: 18) SPCHAR-ENBD		-	1.400	-		
Description: This effort will focus on Innovative Contact Tracing.						
FY 2023 Plans: Integrates innovative and emerging contact tracing capabilities ster (JEONS) JS-0003 response into the pre-symptomatic exposure we		nent				
FY 2023 to FY 2024 Increase/Decrease Statement: Efforts will wind down by end of fiscal year FY23, with no additional	resources required in FY24.					
Title: 19) SPU RCDD		-	6.863	7.050		
Description: Advanced Development: this line includes Product De Support to mature technology across multiple commodity areas to r		and				
FY 2023 Plans:						

xhibit R-2A, RDT&E Project Justi	tication: PB	2024 Chemi	cal and Biolo	-					Date: March 2023				
Appropriation/Budget Activity 9400 / 5				PE 06		nent (Numb Chemical and - EMD		Project (Number/Name) JN5 I Understand (SDD)					
B. Accomplishments/Planned Prog	grams (\$ in I	<u>/lillions)</u>						Γ	FY 2022	FY 2023	FY 2024		
Continue developing, prototyping, an and emerging threats and opportunit Ground Vehicle (UGV) and Unmanne (JSOC) capability gaps.	ties. Continue	e developing	Special Ope	erations Con	nmand (SOC	COM) specifi	c Unmanned						
FY 2024 Plans: Continue developing, prototyping, an and emerging threats and opportunit close Joint Special Operations Comr	ties. Continue	e developing	prototype s										
FY 2023 to FY 2024 Increase/Decre Minor change due to routine program													
				Accon	nplishments	s/Planned P	rograms Sub	totals	-	126.071	182.72		
C. Other Program Funding Summa	ary (\$ in Milli	ons <u>)</u>											
			FY 2024	FY 2024	FY 2024					Cost To			
Line Item	FY 2022	<u>FY 2023</u>	<u>Base</u>	000	<u>Total</u>	<u>FY 2025</u>	<u>FY 2026</u>	<u>FY 202</u>	<u>7 FY 2028</u>	<u>Complete</u>			
 CA4: Contamination Avoidance (ACD&P) 	37.189	-	-	-	-	-	-	-	-	0.000	37.1		
 CA5: Contamination Avoidance (SDD) 	84.967	-	-	-	-	-	-	-	-	0.000	84.9		
• IP5: Individual Protection (SDD)	18.690	-	-	-	-	-	-	-	_	0.000	18.69		
• IP7: Individual Protection (Op Sys Dev)	11.659	-	-	-	-	-	-	-	-	0.000	11.6		
• MB4: Medical Biological Defense (ACD&P)	46.791	-	-	-	-	-	-	-	-	0.000	46.79		
• MB5: <i>Medical Biological</i> Defense (SDD)	138.156	-	-	-	-	-	-	-	-	0.000	138.1		
	-	52.708	61.638	-	61.638	64.399	48.874	41.26	4 38 169	Continuing	Continui		
• UN4 [·] Understand (ACD&P)		40.414	50.603	-	50.603	58.881	71.869	68.83		Continuing			
• UN4: Understand (ACD&P) • UN7: Understand (Op Sys Dev)	-	40414				00.001				Containing	Continui		

Exhibit R-2A, RDT&E Project Justif Appropriation/Budget Activity 0400 / 5		2024 Chemi	ical and Biol	R-1 Pr PE 060	se Program ogram Eler 04384BP / C se Program	Date: March 2023 Project (Number/Name) UN5 / Understand (SDD)					
C. Other Program Funding Summa	ry (\$ in Milli	ons <u>)</u>									
			FY 2024	FY 2024	<u>FY 2024</u>					Cost To	
Line Item	<u>FY 2022</u>	<u>FY 2023</u>	Base	000	<u>Total</u>	<u>FY 2025</u>	<u>FY 2026</u>	<u>FY 2027</u>		Complete	
 MX0001: Joint Bio Tactical 	17.060	-	7.025	-	7.025	22.238	17.385	44.150	44.150	Continuing	Continuir
Detection System (JBTDS)											
 PHM018: SPU Rapid 	10.834	9.914	49.455	-	49.455	20.689	20.180	24.216	26.638	Continuing	Continuir
Capability Development											
And Demo (SPU RCDD)											
• SA0005: CBRN Sensor Integration	3.461	2.099	-	-	-	-	-	-	-	0.000	6.06
On Robotic Platforms (CSIRP)											
 SA0015: Aerosol Vapor 	-	-	2.458	-	2.458	43.262	55.762	66.237	43.029	Continuing	Continuir
Chemical Agent Detector (AVCAD)											
 SA0017: Multiphase Chemical 	6.502	4.014	13.561	-	13.561	21.852	36.758	37.261	0.829	Continuing	Continuir
Agent Detector (MPCAD)											
 SA0024: Compact Vapor 	-	-	-	-	-	-	0.585	8.200	22.144	Continuing	Continuir
Chemical Agent Detector (CVCAD)											
 SA0043: Next Gen Diag 	-	-	1.881	-	1.881	9.579	10.982	11.898	11.861	Continuing	Continuir
2 Chemical Diagnostics											
(NGDS 2 CHEM DX)											
 SA0044: Next Gen Diag 	0.336	-	-	-	-	7.949	7.291	4.752	2.290	Continuing	Continuir
2 Man Portable Diagnostic											
System (NGDS 2 MPDS)											
SA0055: Wearable	-	-	-	-	-	17.500	-	-	-	Continuing	Continuir
All Hazard Remote											
Monitoring Program (WARP)											
SA0056: Nuclear Biological	-	-	16.795	-	16.795	-	15.525	15.561	16.222	Continuing	Continuir
Chemical Reconnaissance										-	
Vehicle Sensor Suite											
Upgrade (NBCRV SSU)											

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical ar	nd Biological Defense Program	Date: March 2023
Appropriation/Budget Activity 0400 / 5	R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> <i>Defense Program - EMD</i>	Project (Number/Name) UN5 / Understand (SDD)
The AET DEFENSE program will use a variety of acquisition appro emerging threat defensive capability gaps. The program will utilize technical support to studies and assessments of performance again assessed for performance against emerging threats, those PoR's e emerging threat capability. The AET DEFENSE program will utilize and Government Agencies and Federally Funded Research and De	existing Multiple Award Indefinite Delivery Indefinite Quants emerging threat. For Program of Record (PoR) systems is contracts will be modified to incorporate development of the Transaction Authority (OTA) agreements for systems of the transaction Authority (OTA) agreements for systems of the transaction Authority (OTA) agreement for	antify Task Order Contracts to provide oms currently in development that will be nent engineering and test support for em development and prototyping activities
AEROSOL VAPOR CHEMICAL AGENT DETECTOR (AVCAD)		
The AVCAD program is conducting full Engineering & Manufacturir to award the low rate initial production (LRIP) as an existing option production options are also available.		
CHEMICAL AND BIOLOGICAL WEARABLES-ENHANCED BIODE	FENSE (CB WEARABLES-ENBD)	
CB Wearables-ENBD will leverage a presumed hybrid acquisition s developed under the PM2S program, as well as middle tier of acqu on service-sponsored networks and weapons platforms.		
CBRN SENSOR INTEGRATION ON ROBOTIC PLATFORMS (CS	IRP)	
CSIRP is a streamlined and tailored acquisition effort to rapidly pro- unmanned CBRN payload prototypes in cyclic prototyping plan cyc in order to keep pace with industry and the rapid advancement of te Transactional Agreements (OTA) contract vehicle. Upon award, th selected (air and/or ground) platforms. These prototypes will be de prototypes will be transitioned to the platforms and services for the integration, demonstrations, testing, development of interface contr residual capabilities and final configurations to Program of Record (les based on service requirements. The prototyping plan echnologies. The CSIRP strategy is to utilize the rapid p e awardees will have two to three years to produce proto emonstrated, evaluated and tested by the Services as we next steps in acquisition, production and eventual fieldin of documentation, and operational assessments of proto	ns will use a streamlined acquisition process rototyping process enabled by the Other otype sensors that are integrated onto servic ell as laboratories and academia. Successfu g across the services. BA5 funding provide
COMPACT VAPOR CHEMICAL AGENT DETECTOR (CVCAD)		
The CVCAD program will use the Combating Weapons of Mass De from Science & Technology (S&T) into the program of record. This Phase II technology transition maturation evaluation, Phase III com	streamlined acquisition approach is broken into four pha	ases; Phase I S&T advanced development,

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense ProgramDate: March 2023									
Appropriation/Budget Activity	R-1 Program Element (Number/Name)	Project (Number/Name)							
0400 / 5	PE 0604384BP / Chemical and Biological	UN5 I Understand (SDD)							
	Defense Program - EMD								
Development for low rate initial production (LRIP) systems CVCAD will	Il procure full rate production (FRP) items through a	follow-on Federal Acquisition Regulation							

Development for low rate initial production (LRIP) systems. CVCAD will procure full rate production (FRP) items through a follow-on Federal Acquisition Regulation based contract.

DEFENSE BIOLOGICAL PRODUCTS ASSURANCE PROGRAM (DBPAP)

DBPAP utilizes best buying principles and acquisition rigor for alignment to requirements to perform an "enabling" function for certain programs of record (e.g., Analytical Lab System (ALS), Common Analytical Lab System (CALS), Next Generation Diagnostic System (NGDS)) and other enterprise partners. The DBPAP uses better buying power to consolidate requirements for "commodity-like" biological detection products. The DBPAP coordinates closely with the Joint, Science and Technology Office to enhance the DBPAP reference material holdings in the Unified Culture Collection (UCC); improve antibodies and expand the portfolio of DBPAP immunoassays and reagents; and develop new molecular assays. The DBPAP uses a mix of competitive commercial contracts and funding of government laboratories to produce high quality assays and reagents.

DEFENSE BIOLOGICAL PRODUCTS ASSURANCE PROGRAM-ENHANCED BIODEFENSE (DBPAP-ENBD)

The DBPAP-ENBD provides increased capabilities above baseline abilities by utilizing best buying principles and acquisition rigor for alignment to requirements to perform an "enabling" function for certain programs of record (e.g., ALS, CALS, NGDS) and other enterprise partners. The DBPAP-ENBD uses better buying power to consolidate requirements for "commodity-like" biological detection products. The DBPAP-ENBD coordinates closely with the Joint, Science and Technology Office to enhance the DBPAP-ENBD reference material holdings in the Unified Culture Collection (UCC); improve antibodies and expand the portfolio of DBPAP-ENBD immunoassays and reagents; and develop new molecular assays. The DBPAP-ENBD uses a mix of competitive commercial contracts and funding of government laboratories to produce high quality assays and reagents.

Far Forward Biological Sequencing

Anticipate Assistant Secretary of the Army for Acquisition, Logistics, & Technology approval of the FFBS acquisition strategy by 1st Quarter FY23. The FFBS Prototype development was conducted via iterative process of early user feedback and assessments, and laboratory testing with biological agents. FFBS is a bio-sequencing Commercial Off-The-Shelf (COTS) system that is integrated into a stand-alone military-hardened hand-held system that added battery life, reduced size and weight and provided a bioinformatics database on the system (vice COTS product that uses a laptop). Sample preparation procedures developed for Special Operations Forces (SOF) users' skill set and refined library preparation to reduce data output timeline from weeks to hours. FFBS will seek a competitive production award in FY25 to meet Initial Operational Capability (IOC) in 4QFY26 and Full Operational Capability (FOC) in 4QFY27.

Wearable All Hazard Remote Monitoring Program

Wearable All Hazard Remote Monitoring Program (WARP) will leverage other Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) developmental efforts that integrate CBRN sensors and COTS physiological monitoring devices into a common network infrastructure for

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	Date: March 2023		
0400 / 5	R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> <i>Defense Program - EMD</i>		umber/Name) erstand (SDD)

display on Tactical Assault Kit devices in order to capitalize on previous development. This will be accomplished through Multiple Award Indefinite Delivery Indefinite Quantify Task Order and Government Agencies for prototype development, test and evaluation, and technical support.

JOINT BIO TACTICAL DETECTION SYSTEM (JBTDS)

The JBTDS program utilizes a streamlined acquisition strategy leveraging a contract with Chemring Sensors and Electronic Systems (CSES). The contract includes options for Low Rate Initial Production (LRIP) and Full Rate Production (FRP). The JBTDS is moving towards a MS C decision in third quarter FY23, utilizing the current contract to award both the LRIP and FRP options. To support the National Guard requirement, the Joint Handheld Biological Identifier (JHBI) will award congruently with the JBTDS LRIP and FRP options. The JBTDS program uses an agile acquisition strategy which leverages current technologies, recognizing up front the need for potential technology insertion to provide more cost effective capabilities.

Mobile Field Kit

Development of MFK will transition from the Defense Threat Reduction Agency (DTRA) by coordinating a Joint Development plan that addresses current technical and acquisition shortfalls and limitations. MFK will manage the continuous engineering process in support of National Guard Bureau operations by assuming control of the requirements generation process and incrementally modernizing the software architecture. Additional work includes modernizing the MFK architecture to make it interoperable with the Joint architecture, and assessing and validating cyber security. The long-term strategy is to align MFK with the CBRN Support to C2 (CSC2) program, provide a capability to CSC2 in order to support the Homeland Defense Mission, and finally manage MFK as an application that supports CSC2. This strategy will be executed without impacting the current operational relevancy of MFK.

MULTI-PHASE CHEMICAL AGENT DETECTOR (MPCAD)

The MPCAD is using a streamlined acquisition strategy. The MPCAD contract(s) are utilizing the Countering Weapons of Mass Destruction (CWMD) Other Transaction Authority (OTA) for EMD and LRIP items. The MPCAD will procure production items through a follow-on Federal Acquisition Regulation based contract. The program will develop and validate the systems during EMD and LRIP utilizing two contractors to increase competition and minimize production price.

Nuclear Biological Chemical Reconnaissance Vehicle Sensor Suite Upgrade

Nuclear Biological Chemical Reconnaissance Vehicle Sensor Suite Upgrade (NBCRV SSU) is an upgrade for the Stryker NBCRV. The Army Requirements Oversight Council (AROC) Review Board (ARB) decided on 1 FEB 2022 to continue a Modification Work Order (MWO) pathway for Capability Set 2.1 (CS2.1) (initial SSU capability) as a bridge to CS2.2 (full SSU capability). The NBCRV SSU program received prototype CS2.1 systems via Other Transaction Authority (OTA) in March 2022, and will continue testing through October 2023, to inform a Conditional Materiel Release Decision in FY24. An In Progress Review (IPR) will be held starting in FY23 to execute an MWO for CS2.1 production and fielding, starting in FY24. The NBCRV SSU program will receive prototype CS2.2 systems via another OTA in August 2024, followed by testing in FY24 through early FY26 to inform the CS2.2 MWO Full Materiel Release Decision in FY26.

	UNCLASSIFIED	
xhibit R-2A, RDT&E Project Justification: PB 2024 Chemical	and Biological Defense Program	Date: March 2023
ppropriation/Budget Activity 400 / 5	R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> <i>Defense Program - EMD</i>	Project (Number/Name) UN5 / Understand (SDD)
IEXT GEN DIAG 2 CHEMICAL DIAGNOSTICS (NGDS 2 CHEM	MDX)	
IGDS 2 ChemDx is using an Other Transactions Authority (OTA echnology to develop a capability for the diagnosis of nerve age nd pre-developmental testing. ChemDx will use Department of Clinical trials will inform approval of the ChemDx system by the U	ent exposure in individuals. The OTA agreement holder is of Defense (DoD) test agencies to conduct Development Test	conducting system development, clinical trials
IEXT GEN DIAG 2 MAN PORTABLE DIAGNOSTIC SYSTEM (1	NGDS 2 MPDS)	
IGDS 2 MPDS is currently in engineering and manufacturing de f nontraditional Defense contractor offerings. MPDS will use the evelopmental testing (pre-DT) instrument testing. MPDS will be Defense (DoD) agencies to conduct Developmental Testing (DT)	e agreement holder to develop the system and assays, con e using DoD clinical trial sites to support the agreement hole	duct the clinical trials, and for pre- der. MPDS will be using Department of
URVEILLANCE AND PATHOGEN CHARACTERIZATION-ENH	HANCED BIODEFENSE (SPCHAR-ENBD)	
PCHAR-ENBD (contact tracing) sunsets at the end of FY23 and	d will integrate all capabilities into the CB-Wearables ENBD).
PU RAPID CAPABILITY DEVELOPMENT AND DEPLOYMENT	T (SPU RCDD)	
The SPU RCDD overall acquisition strategy allows for rapid proto shelf (GOTS) systems against mission critical capabilities to enh ems to identify materiel that requires modernization and incorpor ontracting vehicles such as Multiple Award Indefinite Delivery In Juthority (CWMD OTA) for the development of prototype test as and technical support.	nance mission success. The SPU RCDD will use technical prate operationally-relevant system developments. This wil indefinite Quantify Task Order and the Countering Weapons	and functional evaluations of currently fielded I be accomplished through competitive of Mass Destruction Other Transaction

Appropriation/Budge 0400 / 5	ppropriation/Budget Activity 400 / 5								R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> <i>Defense Program - EMD</i>						Project (Number/Name) UN5 / Understand (SDD)					
Product Developmen	nt (\$ in Mi	llions)		FY 2	022	FY 2	2023		2024 ase		2024 CO	FY 2024 Total								
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract					
AET DEFENSE - HW C - Protection Capability Prototyping	Various	Various : N/A	-	0.000		0.197	Feb 2023	0.280	Jan 2024	-		0.280	Continuing	Continuing	0.00					
AET DEFENSE - HW S - System Prototyping and Modification	Various	Various : N/A	-	0.000		0.197	Feb 2023	0.000		-		0.000	0.000	0.197	0.00					
AET DEFENSE - HW S - Emerging threat detection/ decontamination/protection capability engineering development	Various	Various : N/A	-	0.000		0.197	Jan 2023	0.000		-		0.000	0.000	0.197	0.00					
AET DEFENSE - HW C - Emerging Threat Detection	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	-	0.000		0.000		0.964	Mar 2024	-		0.964	Continuing	Continuing	0.000					
AVCAD - Government Product Development Team Labor	MIPR	Various : N/A	-	0.000		2.200	Nov 2022	1.850	Feb 2024	-		1.850	Continuing	Continuing	0.00					
AVCAD - HW S - P&D Contract	C/CPIF	Smiths Detection : Edgewood, MD	-	0.000		6.019	Nov 2022	0.000		-		0.000	0.000	6.019	0.00					
AVCAD - SW C - Pharmaceutical Based Agent (PBA) Development	C/CPIF	TBD : N/A	-	0.000		0.600	Nov 2022	0.000		-		0.000	0.000	0.600	0.00					
CB WEARABLES-ENBD - SW C - Software Interface Development	C/CPFF	Various : N/A	-	0.000		10.460	Jan 2023	13.430	Jan 2024	-		13.430	Continuing	Continuing	0.00					
CB WEARABLES- ENBD - HW C - Platform Development	C/CPFF	Various : N/A	-	0.000		19.816	Jan 2023	14.410	Jan 2024	-		14.410	Continuing	Continuing	0.00					

Exhibit R-3, RDT&E P	Project C	ost Analysis: PB 2	024 Che	mical and	Biologic	al Defens	e Progran	n				Date:	March 20)23			
Appropriation/Budge 0400 / 5	t Activity	1				R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> <i>Defense Program - EMD</i>						Project (Number/Name) UN5 / Understand (SDD)					
Product Developmen	it (\$ in Mi	illions)		FY 2	022	FY	2023		2024 ase		2024 CO	FY 2024 Total					
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract		
CSIRP - HW C - Government Product Development Team Labor	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	-	0.000		1.900	Nov 2022	1.900	Nov 2023	-		1.900	Continuing	Continuing	0.000		
CSIRP - HW C - Contractor Product Development Team Labor	C/FFP	Various : N/A	-	0.000		0.500	Feb 2023	0.540	Feb 2024	-		0.540	Continuing	Continuing	0.000		
CSIRP - HW C - Chem Sensor Design	Various	Various : N/A	-	0.000		1.300	Nov 2022	1.600	Nov 2023	-		1.600	Continuing	Continuing	0.000		
CSIRP - HW C - UAS Manufacturing and Design	MIPR	Various : N/A	-	0.000		3.000	Nov 2022	5.500	Nov 2023	-		5.500	Continuing	Continuing	0.000		
CSIRP - SW C - UAS and Sensor Manufacturing and Design	C/CPFF	T2S Solutions (T2S, LLC) : Belcamp, MD	-	0.000		1.468	Nov 2022	0.000		-		0.000	0.000	1.468	0.000		
CSIRP - HW C - Sensor Integration	C/FFP	FLIR Systems, Inc. : Elkridge, MD	-	0.000		0.000		2.500	Nov 2023	-		2.500	Continuing	Continuing	0.000		
CSIRP - SW C - Sensor Integration	C/CPFF	Charles Stark Draper Laboratories, Inc. : Cambridge, MA	-	0.000		1.000	Nov 2022	1.400	Nov 2023	-		1.400	Continuing	Continuing	0.000		
CVCAD - HW S - CWMD OTA Phase 3 Task Awards	MIPR	Advanced Technologies International : Summerville, SC	-	0.000		3.572	Jun 2023	9.200	May 2024	-		9.200	Continuing	Continuing	0.000		
DBPAP - HW C - Development of Select Biological Threat Agent Reference Materials and Assays	MIPR	Various : N/A	-	0.000		3.618	Mar 2023	4.869	Feb 2024	-		4.869	Continuing	Continuing	0.000		
DBPAP-ENBD - HW C - Targeted Acquisition of Reference Materials	MIPR	Various : N/A	-	0.000		2.600	Feb 2023	1.900	Feb 2024	-		1.900	Continuing	Continuing	0.000		

PE 0604384BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program UNCLASSIFIED Page 24 of 158

Appropriation/Budge 0400 / 5	t Activity	,				PE 060		Chemica	umber/Na Il and Biol			(Number Inderstand			
Product Developmen	it (\$ in Mi	llions)		FY 2	2022	FY 2	023	FY 2 Ba	-		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Augmenting Capabilities (TARMAC) initiative															
FFBS - HW S - Hardware - prototype refinement and maturation	Various	Various : N/A	-	0.000		0.000		1.363	Apr 2024	-		1.363	Continuing	Continuing	0.000
WARP - HW C - Prototype Development	Various	Various : N/A	-	0.000		0.000		2.100	Dec 2023	-		2.100	Continuing	Continuing	0.000
JBTDS - Government Product Development Team Labor	MIPR	Various : N/A	-	0.000		0.442	Jan 2023	0.829	Jan 2024	-		0.829	Continuing	Continuing	0.000
MFK - SW S - Modernization	C/CPFF	Various : N/A	-	0.000		0.000		3.000	Oct 2023	-		3.000	Continuing	Continuing	0.000
MFK - SW S - Cyber Security Sustainment	MIPR	TBD : N/A	-	0.000		0.000		0.620	Mar 2024	-		0.620	Continuing	Continuing	0.000
MFK - SW S - CSC2 Interoperability	C/CPFF	Various : N/A	-	0.000		0.000		0.389	Mar 2024	-		0.389	Continuing	Continuing	0.000
MPCAD - HW S - EMD Contract	C/CPFF	FLIR Systems, Inc. : West Lafayette, IN	-	0.000		0.750	Nov 2022	1.035	Nov 2023	-		1.035	Continuing	Continuing	0.000
MPCAD - HW S - EMD Contract	C/CPFF	Signature Science : Austin, TX	-	0.000		0.639	Nov 2022	1.035	Nov 2023	-		1.035	Continuing	Continuing	0.000
MPCAD - PM/MS S - Government Team Labor	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	-	0.000		0.200	Nov 2022	1.804	Nov 2023	-		1.804	Continuing	Continuing	0.000
MPCAD - HW C - Contract Support	C/FFP	Various : N/A	-	0.000		0.000		0.161	Feb 2024	-		0.161	Continuing	Continuing	0.000
NBCRV SSU - HW C - Virtual Trainer	Various	Various : N/A	-	0.000		1.419	Nov 2022	0.000		-		0.000	0.000	1.419	0.000

Exhibit R-3, RDT&E F		-	024 Che	mical and	Biologic		•						March 20	023	
Appropriation/Budge 0400 / 5	t Activity					PE 060		Chemica	umber/Na al and Biol			(Numbe Inderstan			
Product Developmen	nt (\$ in Mi	illions)		FY 2	022	FY :	2023		2024 Ise		2024 CO	FY 2024 Total]		
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
NBCRV SSU - HW C - Government Product Development Team Labor	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	-	0.000		2.535	Nov 2022	0.000		-		0.000	0.000	2.535	0.000
NBCRV SSU - HW C - Contractor Team Labor	C/FFP	Various : N/A	-	0.000		0.549	Feb 2023	0.000		-		0.000	0.000	0.549	0.000
NBCRV SSU - SW C - Integration	C/FFP	FLIR Systems Inc. : Elkridge, MD	-	0.000		2.223	Nov 2022	7.418	Nov 2023	-		7.418	Continuing	Continuing	0.000
NGDS 2 CHEMDX - HW C - Product Development	C/CPFF	MRIGlobal : Kansas City, MO	-	0.000		2.657	Feb 2023	3.895	Dec 2023	-		3.895	Continuing	Continuing	0.000
NGDS 2 CHEMDX - HW C - Product Management	Various	Various : N/A	-	0.000		1.954	Dec 2022	2.304	Dec 2023	-		2.304	Continuing	Continuing	0.000
NGDS 2 MPDS - HW C - Product Development	C/CPFF	Cepheid : Sunnyvale, CA	-	0.000		3.162	Mar 2023	11.870	Dec 2023	-		11.870	Continuing	Continuing	0.000
NGDS 2 MPDS - HW C - Product Management	Various	Various : N/A	-	0.000		2.370	Dec 2022	3.930	Dec 2023	-		3.930	Continuing	Continuing	0.000
SPCHAR-ENBD - SW C - JEONS JS 0003 Integration	C/CPFF	Various : N/A	-	0.000		1.000	Jan 2023	0.000		-		0.000	0.000	1.000	0.000
SPU RCDD - HW C - Prototype Procurement	Various	Various : N/A	-	0.000		4.802	Dec 2022	4.156	Dec 2023	-		4.156	Continuing	Continuing	, 0.000
		Subtotal	-	0.000		83.346		106.252		-		106.252	Continuing	Continuing	N/A
Support (\$ in Millions	5)			FY 2	022	FY	2023		2024 Ise		2024 CO	FY 2024 Total]		
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
AVCAD - ES C - OGAs	MIPR	Various : N/A	-	0.000		3.017	Nov 2022	2.907	Nov 2023	-		2.907	Continuing	Continuing	0.000

PE 0604384BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program

Exhibit R-3, RDT&E P Appropriation/Budge 0400 / 5	-		2024 Che	mical and	BIOIOGIC	R-1 Pro PE 060	ogram Ele	ement (N Chemica	lumber/Na al and Biol	,		Inderstan	,)23	
Support (\$ in Millions	\$)			FY 2	2022	FY 2	2023		2024 ase		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
CB WEARABLES- ENBD - ES S - Systems Engineering Support Services	MIPR	Various : N/A	-	0.000		4.023	Jan 2023	5.200	Dec 2023	-		5.200	Continuing	Continuing	0.000
CSIRP - ES C - Engineering Support	Various	Various : N/A	-	0.000		0.390	Nov 2022	0.395	Nov 2023	-		0.395	Continuing	Continuing	0.000
CVCAD - OGA Support and Analysis	Various	Various : N/A	-	0.000		0.000		3.000	Feb 2024	-		3.000	Continuing	Continuing	0.000
DBPAP - Select Biological Threat Agent Reference Material Support	MIPR	Various : N/A	-	0.000		1.683	Mar 2023	1.714	Feb 2024	-		1.714	Continuing	Continuing	0.000
DBPAP - Select Biological Threat Agent Reference Material Regulatory/Quality Assurance (QA) Support	MIPR	Edgewood Chemical Biological Center (ECBC) : Aberdeen Proving Ground, MD	-	0.000		1.699	Mar 2023	1.730	Feb 2024	-		1.730	Continuing	Continuing	0.000
FFBS - ES S - System engineering and design support	Various	Various : N/A	-	0.000		0.000		0.212	Nov 2023	-		0.212	Continuing	Continuing	0.000
JBTDS - Contract and Product Support	MIPR	Various : N/A	-	0.000		0.546	Nov 2022	0.000		-		0.000	0.000	0.546	0.000
MFK - ES S - Program Support	TBD	Various : N/A	-	0.000		0.000		0.550	Oct 2023	-		0.550	Continuing	Continuing	0.000
NBCRV SSU - ES C - Stryker NBCRV Maintenance	C/FFP	General Dynamics Land Systems : Detroit, MI	-	0.000		4.043	Nov 2022	0.900	Nov 2023	-		0.900	Continuing	Continuing	0.000
NBCRV SSU - ILS C - Logistic Support	C/FFP	TBD : N/A	-	0.000		0.250	Nov 2022	0.000		-		0.000	0.000	0.250	0.000
NBCRV SSU - ES C - Contract and Product Support	Various	Various : N/A	-	0.000		1.350	Nov 2022	0.000		-		0.000	0.000	1.350	0.000
SPU RCDD - Engineering Support	Various	Various : N/A	-	0.000		0.626	Dec 2022	0.669	Dec 2023	-		0.669	Continuing	Continuing	0.000
		Subtotal	-	0.000		17.627		17.277		-		17.277	Continuing	Continuing	N/A

PE 0604384BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program

Exhibit R-3, RDT&E P Appropriation/Budge 0400 / 5	•		024 Che	mical and	Biologica	R-1 Pro PE 060	e Progran ogram Ele 4384BP / e Progran	ement (N Chemica				Date: (Number Inderstan	,)23	
Test and Evaluation (\$ in Milli	ons)		FY 2	2022		2023	FY 2	2024 Ise		2024 CO	FY 2024 Total]		
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
AET DEFENSE - DTE C - Technology Assessments	MIPR	Various : N/A	-	0.000		0.284	Feb 2023	0.300	Mar 2024	-		0.300	Continuing	Continuing	0.000
AET DEFENSE - DTE S - Technology Assessments	Various	Various : N/A	-	0.000		0.284	Dec 2022	0.000		-		0.000	0.000	0.284	0.000
AET DEFENSE - DTE C - Technology Assessments	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	-	0.000		0.000		0.906	Mar 2024	-		0.906	Continuing	Continuing	0.000
AVCAD - OTE C - DT/OT Test Activities	MIPR	Various : N/A	-	0.000		3.300	Nov 2022	5.374	Jun 2024	-		5.374	Continuing	Continuing	0.000
CB WEARABLES-ENBD - DTE S - System DT&E	MIPR	Various : N/A	-	0.000		0.725	Jan 2023	1.475	Jan 2024	-		1.475	Continuing	Continuing	0.000
CSIRP - DTE C - Testing and Evaluation	Various	Various : N/A	-	0.000		1.500	Nov 2022	1.530	Nov 2023	-		1.530	Continuing	Continuing	0.000
CSIRP - DTE C - JHU Applied Physics Lab	MIPR	Johns Hopkins University - Applied Physics Lab : Laurel, MD	-	0.000		0.400	Nov 2022	0.660	Jan 2024	-		0.660	Continuing	Continuing	0.000
CVCAD - DTE S - Developmental Test Activities	MIPR	Various : N/A	-	0.000		0.000		2.834	May 2024	-		2.834	Continuing	Continuing	0.000
FFBS - DTE S - T&E for prototype refinement and maturation	Various	Various : N/A	-	0.000		0.000		0.665	Apr 2024	-		0.665	Continuing	Continuing	0.000
WARP - DTE C - Prototype Testing	Various	Various : N/A	-	0.000		0.000		1.100	Dec 2023	-		1.100	Continuing	Continuing	0.000
JBTDS - Operational Assessment	MIPR	Various : N/A	-	0.000		0.000		3.000	Feb 2024	-		3.000	Continuing	Continuing	0.000
JBTDS - DT/OT Test Activities	MIPR	Various : N/A	-	0.000		1.439	Nov 2022	3.125	Feb 2024	-		3.125	Continuing	Continuing	0.000

PE 0604384BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program UNCLASSIFIED Page 28 of 158

R-1 Line #132

Appropriation/Budge 0400 / 5	et Activity					PE 060	o gram Ele 4384BP / e <i>Program</i>	Chemica			-	(Number Inderstand			
Test and Evaluation	(\$ in Milli	ons)		FY 2	022	FY 2	2023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
MFK - DTE S - Integration and Interoperability T&E	MIPR	Various : N/A	-	0.000		0.000		1.200	Oct 2023	-		1.200	Continuing	Continuing	0.000
MPCAD - DTE C - Program Management Evaluation for Solid/Liquid Vapor Testing	MIPR	West Desert Test Center : Dugway, UT	-	0.000		0.150	Nov 2022	0.000		-		0.000	0.000	0.150	0.000
MPCAD - DTE C - DT/OT Chemical Chamber Event	MIPR	West Desert Test Center : Dugway, UT	-	0.000		0.164	Nov 2022	1.000	Dec 2023	-		1.000	Continuing	Continuing	0.000
MPCAD - OTE S - Multi- Service Test	MIPR	Operational Test Command (OTC) : Fort Hood, TX	-	0.000		0.000		0.838	Nov 2023	-		0.838	Continuing	Continuing	0.000
MPCAD - DTE C - CVI, Program Support, OGA Support, CBRCS, Non- Chemical testing	MIPR	Various : N/A	-	0.000		0.000		1.607	Dec 2023	-		1.607	Continuing	Continuing	0.000
NBCRV SSU - DTE C - Test and Evaluation	Various	TBD : N/A	-	0.000		2.855	Nov 2022	0.000		-		0.000	0.000	2.855	0.000
NBCRV SSU - DTE C - Component Level Developmental Testing	MIPR	West Desert Test Center : Dugway, UT	-	0.000		0.000		1.200	Nov 2023	-		1.200	Continuing	Continuing	0.000
NBCRV SSU - DTE C - Component Level Developmental Testing	C/FFP	MRIGlobal : Kansas City, MO	-	0.000		0.000		1.800	Nov 2023	-		1.800	Continuing	Continuing	0.000
NBCRV SSU - DTE C - System Level Testing Developmental Testing	MIPR	Aberdeen Test Center (ATC) : Aberdeen Proving Ground, MD	-	0.000		0.000		7.000	Nov 2023	-		7.000	Continuing	Continuing	0.000
NGDS 2 CHEMDX - DTE S - Testing	MIPR	Various : N/A	-	0.000		0.200	Apr 2023	0.750	Dec 2023	-		0.750	Continuing	Continuing	0.000
NGDS 2 MPDS - OTHT C - Analytical/Clinical Testing	MIPR	U.S. Army Medical Research and Development Command	-	0.000		0.733	May 2023	1.430	Dec 2023	-		1.430	Continuing	Continuing	0.000

Appropriation/Budg 0400 / 5	et Activity					PE 060		Chemica	lumber/Na al and Biol			: (Numbe i Inderstand			
Test and Evaluation	(\$ in Milli	ons)		FY 2	022	FY 2	2023		2024 ase		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location (USAMRDC) : Fort	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
		Detrick, MD													
SPU RCDD - DTE C - Testing and Evaluation	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	-	0.000		0.449	Dec 2022	1.249	Dec 2023	-		1.249	Continuing	Continuing	0.000
	!	Subtotal	-	0.000		12.483		39.043		-		39.043	Continuing	Continuing	N/A
Management Servic	es (\$ in M	illions)		FY 2	022	FY 2	2023		2024 ase		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
AET DEFENSE - PM/MS S - IPT Support/Program Management	MIPR	JPEO Chem, Bio, Rad, and Nuc Defense (JPEO- CBRND) : Aberdeen Proving Ground, MD	-	0.000		0.089	Dec 2022	0.242	Dec 2023	-		0.242	Continuing	Continuing	0.000
AVCAD - PM/MS S - Program Management	MIPR	Various : N/A	-	0.000		1.808	Nov 2022	1.159	Nov 2023	-		1.159	Continuing	Continuing	0.000
CB WEARABLES-ENBD - PM/MS C - Program Management	MIPR	Various : N/A	-	0.000		3.676	Jan 2023	4.686	Dec 2023	-		4.686	Continuing	Continuing	0.000
CSIRP - PM/MS C - PM/MS S Program Management Support	Various	Various : N/A	-	0.000		1.272	Jan 2023	2.480	Jan 2024	-		2.480	Continuing	Continuing	0.000
CVCAD - PM/MS C - Program Management Support	MIPR	Various : N/A	-	0.000		0.034	Dec 2022	1.800	Oct 2023	-		1.800	Continuing	Continuing	0.000

PE 0604384BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program

Exhibit R-3, RDT&E P	Project C	ost Analysis: PB 2	2024 Cher	nical and	Biologic	al Defens	e Prograr	n				Date:	March 20)23	
Appropriation/Budge 0400 / 5	t Activity	/				PE 060	-	Chemica	umber/Na al and Biol		-	(Number Inderstand			
Management Service	s (\$ in M	illions)		FY 2	2022	FY 2	2023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
DBPAP - PM/MS C - Product Management Contractor Support	SS/FFP	Various : N/A	-	0.000		1.163	Mar 2023	0.000		-		0.000	0.000	1.163	0.000
FFBS - PM/MS C - Program management	Various	Various : N/A	-	0.000		0.000		0.248	Nov 2023	-		0.248	Continuing	Continuing	0.000
JBTDS - Program Management	MIPR	Various : N/A	-	0.000		0.169	Mar 2023	0.938	Jan 2024	-		0.938	Continuing	Continuing	0.000
MFK - PM/MS S - Program Management Office Support	MIPR	TBD : N/A	-	0.000		0.000		0.541	Oct 2023	-		0.541	Continuing	Continuing	0.000
MPCAD - PM/MS S - Program Management Support	MIPR	Various : N/A	-	0.000		0.200	Nov 2022	0.785	Nov 2023	-		0.785	Continuing	Continuing	0.000
NBCRV SSU - PM/MS C - Program Management Support	Various	Various : N/A	-	0.000		1.692	Jan 2023	3.311	Jan 2024	-		3.311	Continuing	Continuing	0.000
NGDS 2 CHEMDX - PM/ MS S - Management Services	Various	Various : N/A	-	0.000		0.477	Dec 2022	0.859	Dec 2023	-		0.859	Continuing	Continuing	0.000
NGDS 2 MPDS - PM/MS S - Management Services	Various	Various : N/A	-	0.000		0.649	Dec 2022	2.129	Dec 2023	-		2.129	Continuing	Continuing	0.000
SPCHAR-ENBD - PM/MS C - Program Management	MIPR	Various : N/A	-	0.000		0.400	Jan 2023	0.000		-		0.000	0.000	0.400	0.000
SPU RCDD - PM/MS C - Program Management Support	Various	Various : N/A	-	0.000		0.986	Dec 2022	0.976	Dec 2023	-		0.976	Continuing	Continuing	0.000
		Subtotal	-	0.000		12.615		20.154		-		20.154	Continuing	Continuing	N/A
			Prior Years	FY	2022	FY 2	2023		2024 Ise		2024 CO	FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract
		Project Cost Totals	-	0.000		126.071		182.726		-		182.726	Continuing	Continuing	N/A

Remarks

PE 0604384BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program

Exhibit R-4, RDT&E Schedule Profile: PB 2024 (Che	nica	and	d Bio	logi	cal D	Defe	nse l	Prog	ram												Date	e: Ma	arch	202	3		
Appropriation/Budget Activity 0400 / 5								R-1 PE (Defe	0604	384	BP /	Che	emi	cal a								imbe ersta						
		FY	-	_			202:				2024			_	2025			-	2026	1		FY 2	-			FY 2		\$
AET DEFENSE - Technology Assessments/ Systems Engineering	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
AVCAD - EMD Contract																												
AVCAD - MS C-Milestone C																												
AVCAD - LRIP-Low Rate Initial Production																												
AVCAD - FRP-Full Rate Production Decision																												
AVCAD - IOC-Initial Operational Capability																												
CB WEARABLES-ENBD - Capability Development Document (CDD)																												
CB WEARABLES-ENBD - Software Development & Integration																												
CSIRP - Test and Evaluation of Prototypes - Development Objectives Strategy #1																												
CSIRP - Transition Decision - Development Objectives Strategy #1																												
CSIRP - OTA Award and Execution for Development Objectives Strategy #2																												
CSIRP - Test and Evaluation of Prototypes - Development Objectives Strategy #2																												
CSIRP - Transition Decision - Development Objectives Strategy #2																												
CSIRP - OTA Award and Execution for Development Objectives Strategy #3																												
CSIRP - Test and Evaluation of Prototypes - Development Objectives Strategy #3																												1
CVCAD - CDD Validation-Capability Development Document Validation																												

PE 0604384BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program UNCLASSIFIED Page 32 of 158

Exhibit R-4, RDT&E Schedule Profile: PB 2024 C	Cher	nica	l and	Biol	ogica	al De	fense	e Pro	gra	am									C	ate	e: Ma	rch 2	202	3		
Appropriation/Budget Activity 0400 / 5							PE	060	43	r am El 84BP <i>I</i> Prograr	Chen	nica							(Nui Inder							
		FY	2022		F	Y 20)23		F	Y 2024		F	Y 202	5		FY 2	2026		F	Y 2	2027			FY 20)28	
	1	2	3	4	1	2	3 4	1		2 3	4 1	1	2 3	4	1	2	3	4	1	2	3	4	1	2	3	4
CVCAD - MS B-Milestone B																										
CVCAD - CDR-Critical Design Review																										
CVCAD - CDD Update																										
CVCAD - MS C-Milestone C																										
CVCAD - LRIP-Low Rate Initial Production										,																
CVCAD - FRP-Full Rate Production Decision																										
CVCAD - IOC-Initial Operational Capability																										
CVCAD - FOC-Full Operational Capability																										
DBPAP - Acquire and Distribute Quality Select Biological Reference Materials and Assays while Storing and Analyzing Related Data																										
DBPAP-ENBD - Expansion of Site Locations for Sequencing Capabilities																										
DBPAP-ENBD - Expanding the Repository of Collected Biothreat Genomic Information																										
DBPAP-ENBD - Data Compression/ Decompression Capabilities																										
DBPAP-ENBD - Expansion of Biorepository				l																						
DBPAP-ENBD - Maintain Information Storage Capabilities																										
FFBS - CDD Validation-Capability Development Document Validation																										
FFBS - PDR-Preliminary Design Review																										
FFBS - OT&E-Operational Test and Evaluation																										
FFBS - CDR-Critical Design Review																										
FFBS - BD-Build Decision																										
FFBS - FDD-Full Deployment Decision																										
L	_																									

PE 0604384BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program UNCLASSIFIED Page 33 of 158

R-1 Line #132

Exhibit R-4, RDT&E Schedule Profile: PB 2024 C	Cher	nica	al and	d Bio	ologio	cal D	Defe	nse F	Prog	ram											Date	e: M	arch	202	23		
Appropriation/Budget Activity 0400 / 5								PE 0	604	384E	Elen BP / C gram	Cher	nica					Pro UN				er/N					
		FY	202	2		FY 2	2023	3		FY 20	024		F	Y 20	25		FY	2026			FY 2	2027			FY 20	28	
	1	2	3	4	1	2	3	4	1	2	3 4	4	1	2	3 4	1	2	3	4	1	2	3	4	1	2	3	4
FFBS - IOC-Initial Operational Capability																											
FFBS - FOC-Full Operational Capability																											
WARP - Prototype Development																											
WARP - Prototype T&E																											
WARP - Procurement & Fielding																											
JBTDS - MS C-Milestone C																											
JBTDS - LRIP Contract Award																											
JBTDS - PVT																											
JBTDS - MOT&E																											
JBTDS - FRP-Full Rate Production Decision																											
JBTDS - FRP Award																											
JBTDS - IOC-Initial Operational Capability																											
MFK - MFK User Definition workshop 1																											
MFK - CD-Capability Drop - Capability release																											
MFK - MFK User Definition workshop 2																											
MFK - CD-Capability Drop - Capability release 2																											
MFK - MFK User Definition workshop 3																											
MFK - CD-Capability Drop - Capability release 3																											
MFK - MFK User Definition workshop 4																											
MFK - CD-Capability Drop - Capability release																											
MPCAD - DT&E-Developmental Test and Evaluation - EMD Contract/LRIP contract																											

Exhibit R-4, RDT&E Schedule Profile: PB 2024 C	he	mic	al a	nd B	iolc	ogica	al De	efens	e Pr	rog	ram	l											Da	te: I	Mar	ch 2	202	3		
Appropriation/Budget Activity 400 / 5								P	E 06	604	384	n El BP / ograr	Che	emi	cal a						ojec N5 /	•								
		F١	′ 20	22		F	Y 20	023		F	FY 2	2024			FY	202	5		FY	202	6		FY	202	27		F	Y 2	028	
	1	2	2	3 4	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	3	4 [·]	1	2	3	4
MPCAD - MS C-Milestone C - Liquid / Solid MS C																														
MPCAD - LRIP-Low Rate Initial Production																														
MPCAD - MS C-Milestone C - Vapor / Quant MS C																														
MPCAD - FRP-Full Rate Production Decision																														
MPCAD - IOC-Initial Operational Capability																														
MPCAD - FOC-Full Operational Capability																														
NBCRV SSU - Component Test & System Level Test 1																														
NBCRV SSU - Modification Work Order IPR																														
NBCRV SSU - Design and Fabrication Phase 3 (CS2.2)																														
NBCRV SSU - Limited User Test (LUT)																														
NBCRV SSU - Design and Fabrication Phase 2 (CS2.1)																														
NBCRV SSU - Initial Operational Test and Evaluation (IOT&E)																														
NBCRV SSU - FRP-Full Rate Production Decision																														
NGDS 2 CHEMDX - MS B-Milestone B																														
NGDS 2 CHEMDX - EMD																														
NGDS 2 CHEMDX - MS C-Milestone C																														
NGDS 2 MPDS - EMD																														
NGDS 2 MPDS - MS C-Milestone C - LRIP																														
NGDS 2 MPDS - FRP-Full Rate Production Decision																														

PE 0604384BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program UNCLASSIFIED Page 35 of 158

R-1 Line #132

Exhibit R-4, RDT&E Schedule Profile: PB 2024	Che	mica	al an	nd B	iolog	gica	l Defe	ense	e Pro	gram	۱											Date	e: Ma	arch	202	23		
Appropriation/Budget Activity 0400 / 5								PE	1 Pro E 060 efens	4384	1BP	I Ch	emi	cal a						-	•		er/Na nd (S					
		FY	202	22		F	Y 202	23		FY 2	202	4		FY 2	2025	5		FY 2	2026			FY 2	2027			FY 2	2028	
	1	2	2 3	; 4	l 1	1	2 3	4	1 1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
SPCHAR-ENBD - Pathogenicity Studies									÷																			
SPU RCDD - Modernize CBRN Materiel																												
SPU RCDD - Develop Modular Self Contained Breathing Apparatus (MSCBA)																												
SPU RCDD - Develop Enhanced Warfighter Augmented Training (EWAT)																												
SPU RCDD - Prototype Novel CBRN Equipment																												
SPU RCDD - Develop Low Temperature Plasma Mass Spectrometer (LTPMS)																												
SPU RCDD - Develop Optimized CBRN Hydration System (OCHS)																												
SPU RCDD - Develop Assault Respirator																												
SPU RCDD - Develop USSOCOM-specific UGV/UAS Sensor Integration																												

0/5 PE	1 Program Element (Numbe 5 0604384BP <i>I Chemical and</i> 5 ofense Program - EMD			
Sched	lule Details			
	St	art	Er	nd
Events	Quarter	Year	Quarter	Year
AET DEFENSE - Technology Assessments/Systems Engineering	1	2022	4	2028
AVCAD - EMD Contract	1	2022	2	2023
AVCAD - MS C-Milestone C	2	2023	2	2023
AVCAD - LRIP-Low Rate Initial Production	2	2023	1	2026
AVCAD - FRP-Full Rate Production Decision	1	2026	1	2026
AVCAD - IOC-Initial Operational Capability	2	2026	2	2026
CB WEARABLES-ENBD - Capability Development Document (CDD)	2	2022	2	2023
CB WEARABLES-ENBD - Software Development & Integration	2	2023	1	2026
CSIRP - Test and Evaluation of Prototypes - Development Objectives Strateg	y #1 1	2022	2	2023
CSIRP - Transition Decision - Development Objectives Strategy #1	3	2023	3	2023
CSIRP - OTA Award and Execution for Development Objectives Strategy #2	3	2023	3	2024
CSIRP - Test and Evaluation of Prototypes - Development Objectives Strateg	y #2 3	2023	3	2025
CSIRP - Transition Decision - Development Objectives Strategy #2	3	2025	3	2025
CSIRP - OTA Award and Execution for Development Objectives Strategy #3	3	2025	3	2028
CSIRP - Test and Evaluation of Prototypes -Development Objectives Strategy	<i>י</i> #3 4	2025	3	2028
CVCAD - CDD Validation-Capability Development Document Validation	3	2023	3	2023
CVCAD - MS B-Milestone B	4	2023	4	2023
CVCAD - CDR-Critical Design Review	3	2024	3	2024
CVCAD - CDD Update	3	2025	3	2025
CVCAD - MS C-Milestone C	4	2025	4	2025
CVCAD - LRIP-Low Rate Initial Production	4	2026	4	2026
CVCAD - FRP-Full Rate Production Decision	4	2027	4	2027

)/5					Date: March 2023 Project (Number/Name) UN5 / Understand (SDD)		
		Sta	art		En	d	
Events	0	Quarter	Year	Qua	rter	Year	
CVCAD - IOC-Initial Operational Capability		4	2028	4		2028	
CVCAD - FOC-Full Operational Capability		4	2028	4		2028	
DBPAP - Acquire and Distribute Quality Select Biological Reference Materia Assays while Storing and Analyzing Related Data	als and	1	2022	4		2028	
DBPAP-ENBD - Expansion of Site Locations for Sequencing Capabilities		1	2023	4		2028	
DBPAP-ENBD - Expanding the Repository of Collected Biothreat Genomic I	nformation	1	2023	4		2028	
DBPAP-ENBD - Data Compression/Decompression Capabilities		1	2023	4		2028	
DBPAP-ENBD - Expansion of Biorepository		1	2023	4		2028	
DBPAP-ENBD - Maintain Information Storage Capabilities		1	2023	4		2028	
FFBS - CDD Validation-Capability Development Document Validation		3	2022	3		2022	
FFBS - PDR-Preliminary Design Review		3	2024	3		2024	
FFBS - OT&E-Operational Test and Evaluation		2	2025	2		2025	
FFBS - CDR-Critical Design Review		3	2025	3		2025	
FFBS - BD-Build Decision		4	2025	4		2025	
FFBS - FDD-Full Deployment Decision		4	2025	4		2025	
FFBS - IOC-Initial Operational Capability		4	2026	4		2026	
FFBS - FOC-Full Operational Capability		4	2027	4		2027	
WARP - Prototype Development		1	2024	3		2024	
WARP - Prototype T&E		3	2024	1		2025	
WARP - Procurement & Fielding		1	2025	4		2026	
JBTDS - MS C-Milestone C		3	2023	3		2023	
JBTDS - LRIP Contract Award		4	2023	4		2023	
JBTDS - PVT		3	2024	3		2024	
JBTDS - MOT&E		4	2024	4		2024	
JBTDS - FRP-Full Rate Production Decision		4	2025	4		2025	
JBTDS - FRP Award		4	2025	4		2025	

PE 0604384BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program UNCLASSIFIED Page 38 of 158

0/5 P	-1 Program Element (Num E 0604384BP / Chemical an efense Program - EMD		Project (Number/Nam UN5 / Understand (SD	
		Start	Er	nd
Events	Quarter	Year	Quarter	Year
JBTDS - IOC-Initial Operational Capability	2	2028	2	2028
MFK - MFK User Definition workshop 1	2	2024	2	2024
MFK - CD-Capability Drop - Capability release 1	1	2026	1	2026
MFK - MFK User Definition workshop 2	2	2025	2	2025
MFK - CD-Capability Drop - Capability release 2	1	2027	1	2027
MFK - MFK User Definition workshop 3	2	2026	2	2026
MFK - CD-Capability Drop - Capability release 3	1	2028	1	2028
MFK - MFK User Definition workshop 4	2	2027	2	2027
MFK - CD-Capability Drop - Capability release 4	1	2029	1	2029
MPCAD - DT&E-Developmental Test and Evaluation - EMD Contract/LRIP co	ontract 1	2022	3	2024
MPCAD - MS C-Milestone C - Liquid / Solid MS C	3	2023	3	2023
MPCAD - LRIP-Low Rate Initial Production	3	2023	3	2024
MPCAD - MS C-Milestone C - Vapor / Quant MS C	2	2024	2	2024
MPCAD - FRP-Full Rate Production Decision	4	2024	4	2024
MPCAD - IOC-Initial Operational Capability	4	2027	4	2027
MPCAD - FOC-Full Operational Capability	4	2028	4	2028
NBCRV SSU - Component Test & System Level Test 1	1	2022	1	2024
NBCRV SSU - Modification Work Order IPR	3	2023	3	2024
NBCRV SSU - Design and Fabrication Phase 3 (CS2.2)	1	2024	1	2025
NBCRV SSU - Limited User Test (LUT)	4	2023	1	2024
NBCRV SSU - Design and Fabrication Phase 2 (CS2.1)	1	2022	2	2022
NBCRV SSU - Initial Operational Test and Evaluation (IOT&E)	1	2026	2	2026
NBCRV SSU - FRP-Full Rate Production Decision	3	2026	3	2026
NGDS 2 CHEMDX - MS B-Milestone B	1	2022	1	2022
NGDS 2 CHEMDX - EMD	1	2023	2	2025

hibit R-4A, RDT&E Schedule Details: PB 2024 Chemical and Biological Def	ense Program		Date: N	larch 2023
00/5 F	R-1 Program Element (Numbe PE 0604384BP <i>I Chemical and</i> Defense Program - EMD	,	Project (Number/I UN5 / Understand	-
	S	tart		End
Events	Quarter	Year	Quarter	Year
NGDS 2 CHEMDX - MS C-Milestone C	2	2025	2	2025
NGDS 2 MPDS - EMD	1	2022	1	2026
NGDS 2 MPDS - MS C-Milestone C - LRIP	2	2025	2	2025
NGDS 2 MPDS - FRP-Full Rate Production Decision	2	2026	2	2026
SPCHAR-ENBD - Pathogenicity Studies	1	2023	2	2024
SPU RCDD - Modernize CBRN Materiel	1	2022	4	2027
SPU RCDD - Develop Modular Self Contained Breathing Apparatus (MSCB	A) 1	2022	4	2024
SPU RCDD - Develop Enhanced Warfighter Augmented Training (EWAT)	1	2022	4	2024
SPU RCDD - Prototype Novel CBRN Equipment	1	2022	4	2027
SPU RCDD - Develop Low Temperature Plasma Mass Spectrometer (LTPM	1S) 1	2022	4	2024
SPU RCDD - Develop Optimized CBRN Hydration System (OCHS)	1	2022	2	2023
SPU RCDD - Develop Assault Respirator	1	2022	4	2023
SPU RCDD - Develop USSOCOM-specific UGV/UAS Sensor Integration	1	2022	4	2023

Exhibit R-2A, RDT&E Project Ju	stification	: PB 2024 C	Chemical an	d Biologica	l Defense P	rogram				Date: Marc	ch 2023	
Appropriation/Budget Activity 0400 / 5			. ,				Project (Number/Name) PT5 / Protect (SDD)					
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
PT5: Protect (SDD)	-	0.000	87.923	97.975	0.000	97.975	69.858	66.259	52.871	67.776	Continuing	Continuing
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

The Protect System Development & Demonstration (SDD) Project enhances mission performance and provides effective protection against current and emerging threats by rapidly developing and fielding modernized protection capabilities. Developmental efforts focus on advances in materials and systems engineering to enhance protective properties against a broader array of hazards, while reducing Countering Weapons of Mass Destruction (CWMD) operational challenges and logistical burdens. Developmental efforts focus on advanced medical countermeasures that provide safe and effective medical defenses against biological agents (bacteria, toxins, and viruses), emerging infectious diseases, and chemical agents. In FY 2023, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. PT5 efforts in FY 2022 remain in Projects IP5 and MB5. This restructuring provided standardization and alignment across CBDP research, development and acquisition efforts.

Efforts included in this Project are:

- (1) Advanced System for Protection and Integrated Reduction of Encumbrances (ASPIRE)
- (2) ASPIRE-Enhanced Biodefense (ASPIRE-ENBD)
- (3) Botulinum Monoclonal Antibodies (BOT MAB)
- (4) Collective Protection Conex-Enhanced Biodefense (COL PRO CONEX-ENBD)
- (5) Portable Biocontainment Patient Transport System-Enhanced Biodefense (PPTS-ENBD)
- (6) Shipboard Isolation System (SIS)
- (7) Uniform Integrated Protection Ensemble Family of Systems Air (UIPE FOS AIR)
- (8) UIPE FOS General Purpose (UIPE FOS GP)
- (9) UIPE FOS Gloves (UIPE FOS GLOVES)
- (10) Special Immunizations Program (VAC SIP)
- (11) Rapid Access to Products in Development (RAPID)

The Advanced System for Protection and Integrated Reduction of Encumbrances (ASPIRE) program allows near normal operations in a CBRN environment by minimizing or eliminating physical and psychological burden and increasing Warfighter lethality. The ASPIRE program will provide respiratory and ocular protection against CBRN threats. Multiple weapons system sights and enabling equipment are taking away space on the warfighter required to make existing protective masks work. Without this program we will be five to ten years late to need as this trend continues. The program will provide the capability to incorporate upgrades into the current ground masks to improve the suit hood/mask interface with Uniform Integrated Protective Ensemble Family of Systems General Purpose (UIPE FoS GP). In addition, this program, in conjunction with work by Joint Science and Technology Office (JSTO), will lay out the strategy and path forward required to minimize the burden to the warfighter while still providing respiratory and ocular protection against chemical, biological, radiological and nuclear agents. In FY24 the program will

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemica	Date: March 2023	
Appropriation/Budget Activity 0400 / 5	R-1 Program Element (Number/Name) PE 0604384BP / Chemical and Biological Defense Program - EMD	Project (Number/Name) PT5 / Protect (SDD)
initiate optimization of the current ground mask systems to addre improvements into current ground masks for down selection and	1 11	d evaluation of suit hood/mask interface
Advanced System for Protection and Integrated Reduction of Er		ew start program in FY24, supports
unencumbering warfighters and revolutionizing respiratory and c protection from biological, toxic industrial chemicals, and other e new and emerging equipment. ASPIRE-ENBD will unencumber	ocular protection against Chemical, Biological, Radiological a merging threats. ASPIRE-ENBD provides a revolutionary n	and Nuclear (CBRN) threats, including new capability to address interface issues wit

new and emerging equipment. ASPIRE-ENBD will unencumber the warfighter while still providing respiratory and ocular protection against biological agents, provide durable and extended wear capability, and incorporate anti-microbial materials to develop a reusable respirator. The solution will be optimized to minimize impact on the wearer's performance to continue lethality in Biological environment by reducing burden, improving filtration capability, utilizing powered and supplied air systems as required, and integrate with existing and future equipment that cannot be integrated with current mask systems. ASPIRE-ENBD will provide a revolutionized capability to the Services for the next generation of respiratory and ocular protection. The ASPIRE-ENBD effort will develop half masks/bio-masks that are low-burden, provide protection against bio threats, and are designed as a reusable system with modularity and/or scalability for additional ocular protection. In FY24, the ASPIRE-ENBD program will initiate bio mask prototype development and evaluation.

The Botulinum Monoclonal Antibodies (BOT MAB) program will develop and deliver Food and Drug Administration (FDA) approved Botulinum Monoclonal Antibodies to the warfighter. The BOT MAB will be a monoclonal antibody cocktail that protects warfighter against exposure to botulinum toxins A and B, which is the most lethal toxin known to man. Defense against this toxin is a known gap in defense to the warfighter. This product will do large scale Good Manufacturing Practices (GMP) in the DoD Advanced Development Manufacturing (ADM) facility. This is a transition from Science and Technology (S&T).

Collective Protection CONEX Enhanced Biodefense (COL PRO CONEX-ENBD), a new start program in FY24, will provide a negative pressure shelter system for medical treatment of biologically contaminated patients in an Army field hospital environment. The Bio-Containment Shelter provides an isolation area to treat infectious personnel while preventing spread of the infection to other personnel. It is a modification of a standard two-side expandable International Standards Organization (ISO) shelter that integrates negative pressure containment systems that can be deployed with existing Army field hospitals to provide an isolation capability to Army field hospitals. In FY25, COL PRO CONEX will complete concept design, system planning and conduct an initial concept demonstration.

Portable Patient Transport System-Enhanced Biodefense (PPTS-ENBD), a new start program in FY24, is a patient transport system that enables safe transport of asymptomatic, symptomatic, or infected patients while ensuring that the medical attending personnel and platform crew members are protected from exposure. In FY25, PPTS ENBD will Begin system test and evaluation and develop logistics products.

Shipboard Isolation System (SIS) program is a new start in FY24, and will develop a kitted system that provides U.S. Navy ships the capability to setup an area to effectively isolate patients infected (or suspected of infection) with biological organisms or infectious disease. The SIS also allows medical staff to safely monitor and treat patients, and when necessary, provides a capability to safely evacuate patients off the ship. As a result, the spread of infectious disease among the crew will be minimized and the impact to mission readiness will be reduced significantly. Centers for Disease Control and Prevention (CDC) and DoD requirements for isolation and quarantine will be incorporated into the design of the SIS. In FY24, SIS will begin system planning and prototype development.

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical a	and Biological Defense Program	Date: N	/larch 2023	
Appropriation/Budget Activity 0400 / 5	R-1 Program Element (Number/Name) PE 0604384BP / Chemical and Biological Defense Program - EMD	Project (Number/ PT5 / Protect (SDL	,	
The Uniform Integrated Protection Ensemble (UIPE) Family of Systraditional and non-traditional Chemical, Biological, Radiological, I conditions by reducing thermal burden and bulk, while increasing two variants. The UIPE FoS Air Chemical, Biological, Radiological ejection fixed wing platforms and the Two Piece Undergarment (2 ejection seat (rotary wing) and non-ejection (fixed wing) platforms conduct integration testing on 40+ USAF, USN, and USMC platfor transitioning to production.	Nuclear (CBRN) threats. UIPE FoS Air will improve aircre mobility and resulting in an increase operational effective al Layer (CBRL) to address the specific requirements of th 2PUG) to address the remaining USAF and United States s. In FY23, UIPE FoS Air will finalize Engineering, Manufa	ew performance and s ness. The UIPE FoS ne United States Air F Navy / United States acturing and Develop	survivability un Air is compo- orce (USAF) Marine Corps mental (EMD)	nder CBRN sed of tactical/ tactical/ testing an
The Uniform Integrated Protective Ensemble Family of Systems G protection from operationally relevant traditional, non-traditional, a threats likely to be encountered during joint force operations. The requirements such as emerging threats, aerosol protection, and fl duty uniform replacement that has an aerosol liner, is flame resist FY24, program will conduct a Multi Service Operational Test and transitioning to Production.	and advanced Chemical, Biological, Radiological and Nuc legacy chemical biological garment is nearing the end of lame resistance. The UIPE FoS GP is a two-piece lightwe tant, and does not reduce Warfighter effectiveness in the a	lear (CBRN)/Toxic In its service life and do ight (compared to the areas of mobility and	dustrial Mater les not meet u legacy syste thermal burde	ial (TIM) updated m) en. In
Uniform Integrated Protective Ensemble (UIPE) Family of System against traditional and non-traditional Chemical, Biological, Radio dexterity and for certain mission profiles enhanced touch screen a (MTA) approach. In FY24, the UIPE FoS Gloves program will cor Purpose, Aviation Heavy and Aviation Light). Conduct operationa	ological and Nuclear (CBRN) threats. UIPE FoS Gloves w and flame resistant capability. The UIPE FoS Gloves will nduct developmental testing and complete prototype deve	ill provide improved o be developed using a	omfort, tactilit Middle Tier A	y and Acquisition
The Special Immunizations Program (VAC SIP) restructures to the updates, and executes the Investigational New Drugs (INDs) of se protection to individuals that are at high risk of exposure to CBRN storage and to conduct the periodic potency and stability testing o	elected prophylaxis, treatments and diagnostics developm I agents. DoD has the mission to maintain IND vaccines i	nent products which p in Good Manufacturin	orovide additic g Practice (G	nal
RAPID (Rapid Access to Products in Development) an FY24 restr being developed to differential states of readiness by storing and retargeting, or continued development as a Program of Record. R	maintaining data packages and doses of countermeasure	es to enable Interim F	ielding Capab	ility (IFC),
development and how quickly/costly it will be to achieve IFC.				
development and how quickly/costly it will be to achieve IFC. B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024

PE 0604384BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program		Date: March 2023				
Appropriation/Budget Activity 0400 / 5	Project (Number/ PT5 / Protect (SD					
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024		
Description: Development of Advanced System for Protection and the warfighter respiratory and ocular protection against CBRN three	•	vide				
FY 2024 Plans: Initiate optimization of the current ground mask systems to address evaluation of suit hood/mask interface improvements into current g		ıd				
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project funding transferred from another funding line. Prog	gram is a continuation of the ASPIRE - ENBD program.					
Title: 2) ASPIRE-ENBD		-	-	1.600		
Description: This effort will focus on Low Burden Half Mask						
FY 2024 Plans: Initiate bio mask/half-mask prototype development and evaluation f	for down selection and refinement.					
FY 2023 to FY 2024 Increase/Decrease Statement: Additional investment in enhanced biodefense and pandemic prepa	aredness.					
Title: 3) BOT MAB		-	36.504	16.528		
Description: Manufacturing						
FY 2023 Plans: Continue large scale Good Manufacturing Practices (GMP) and exe	ecute product/process characterization and validation req	uired.				
FY 2024 Plans: Complete large scale GMP manufacturing and initiate Process Qua	alification runs for final drug product.					
FY 2023 to FY 2024 Increase/Decrease Statement: Decrease due to change in program/project technical parameters. I manufacturing in FY24 and scale of Process Qualification runs redu						
Title: 4) BOT MAB		-	27.000	48.000		
Description: Clinical and Nonclinical Studies						
FY 2023 Plans:						

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemic	R-1 Program Element (Number/Name)		March 2023	
Appropriation/Budget Activity 0400 / 5	Project (Numbe PT5 / Protect (Sl			
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
Obtain results from the Phase 2 clinical trial and along with the continue manufacturing for Process Performance Qualification Capability (IOC).				
FY 2024 Plans: Complete large scale Good Manufacturing Practices (GMP) m product.	anufacturing and initiate Process Qualification runs for final dr	ug		
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to change in program/project technical paramete number of clinical site locations to meet required enrollment ar studies.				
Title: 5) COL PRO CONEX-ENBD		-	· _	4.60
Description: Prototype, test and evaluate ground based biocc	ontainment isolation systems.			
FY 2024 Plans: Complete concept design, system planning and conduct an ini	tial concept demonstration.			
FY 2023 to FY 2024 Increase/Decrease Statement: Additional investment in enhanced biodefense and pandemic p	preparedness.			
Title: 6) PPTS-ENBD		-	· _	5.30
Description: Prototype, test and evaluate Aircraft Transportation	ble biocontainment isolation systems			
FY 2024 Plans: Begin system test and evaluation and develop logistics produc	sts.			
FY 2023 to FY 2024 Increase/Decrease Statement: Additional investment in enhanced biodefense and pandemic p	preparedness.			
Title: 7) SIS		-	· _	0.97
Description: Resource the development and test and evaluat	ion of shipboard portable infectious disease isolation kits			

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical	and Biological Defense Program		Date: March 2023	
Appropriation/Budget Activity 0400 / 5				
B. Accomplishments/Planned Programs (\$ in Millions)		FY	2022 FY 2023	FY 2024
Begin system planning and award Countering Weapons of Mass Contract.	Destruction Other Transaction Authority (CWMD OTA) Pro	totype		
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project is new start effort in FY 2024.				
Title: 8) UIPE FOS AIR			- 5.132	- 2
Description: Test and Integration of the 2 Piece Undergarment (2PUG)			
FY 2023 Plans: Finalize EMD testing and conduct integration testing on 40+ USA final flight clearance.	F, USN, and USMC platforms for airworthiness, safe to fly	and		
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project transitioned to Production and Deployment Phas production.	e. FY23 is last year of BA5 funding, program is transitionin	g to		
Title: 9) UIPE FOS GP			- 9.640	0 7.05
Description: Development of the next generation protective ense	embles.			
FY 2023 Plans: Conduct System Verification Review, complete MOT&E, award p (PVT).	roduction contract, and conduct Production Verification Tes	sting		
FY 2024 Plans: Conduct Multi Service Operational Test and Evaluation (MOT&E)	and evaluate program cost reduction material alternatives.			
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project transitioned to Production and Deployment Phas	e.			
Title: 10) UIPE FOS GLOVES			- 2.699	3.85
Description: Development of the Next Generation Protective Glo	ove			
FY 2023 Plans:				

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biolog	gical Defense Program	Date: N	larch 2023		
Appropriation/Budget Activity 0400 / 5		Project (Number/ PT5 / Protect (SDL	ect (Number/Name) I Protect (SDD)		
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024	
Continue to conduct prototype development on multiple prototypes for multi Heavy and Aviation Light). Conduct testing such as tactility, dexterity, chen interoperability will be conducted as well as analytical framework analysis a	nical protection, flame resistance, wear trials, and				
FY 2024 Plans: Conduct developmental testing, complete prototype development on multip and Aviation Light) and conduct operational testing on prototypes for the mu		<i>r</i> y			
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to accelerated development effort. Funding increase supports development efforts.	Middle Tier Acquisition strategy research and				
Title: 11) VAC SIP		-	6.948	-	
Description: Storage, Distribution, Potency Testing					
FY 2023 Plans: Continue storage, distribution, potency testing, and biosurety compliance ad Program closure.	ctivities in support of the Special Immunization				
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project funding transferred to another funding line. FY 2024 funding	g moves to RAPID Project PT5.				
Title: 12) RAPID		-	-	5.28	
Description: Storage, Testing					
<i>FY 2024 Plans:</i> Initiate RAPID storage and stability testing by leveraging existing Accelerate Vaccine Acceleration by Modular Progression-Enhanced Biodefense (VAM Intelligent Drug Engineering-Enhanced Biodefense (GUIDE-ENBD) program build a RAPID database that will be the interface for Department of Defense and availability of medical countermeasures in development.	P-ENBD), RAIDR, and Generative Unconstrained n data packages and prototype doses; Design and	us			
FY 2023 to FY 2024 Increase/Decrease Statement:					
Program/project funding transferred from another funding line. VAC SIP transferred from another funding line.	-				
	Accomplishments/Planned Programs Subto	tals -	87.923	97.97	

Example FY 2024 FY 2025 FY 2026 FY 2026 <t< th=""><th></th><th>(Number/Na otect (SDD)</th><th>ime)</th><th></th></t<>		(Number/Na otect (SDD)	ime)	
Line Item FY 2022 FY 2023 Base OCO Total FY 2025 FY 2020 • IP4: Individual Protection (ACD&P) 4.748 - <th></th> <th></th> <th></th> <th></th>				
Line Item FY 2022 FY 2023 Base OCO Total FY 2025 FY 2020 • IP4: Individual Protection (ACD&P) 4.748 - <th></th> <th></th> <th></th> <th></th>				
• IP4: Individual Protection (ACD&P) 4.748			Cost To	
• IP5: Individual Protection (SDD) 18.690	<u>6 FY 2027</u>	<u>FY 2028</u>	<u>Complete</u>	Total Cos
• MB5: Medical Biological 138.156	-	-	0.000	4.74
Defense (SDD)	-	-	0.000	18.69
	-	-	0.000	138.15
DT4: Protoot (ACD8D) 175 210 170 159 170 159 125 006 107 24				
• PT4: Protect (ACD&P) - 175.219 179.158 - 179.158 135.096 107.34	1 123.538	139.376	Continuing	Continuin
• JP1111: Joint Expeditionary 22.719 30.737 3.000 3.750	- C	-	Continuing	Continuin
Collective Protection (JECP)				
• PHM032: Uniform Integrated 4.978 - 4.978 6.215 7.974	4 8.328	8.926	Continuing	Continuin
Protective Ensemble FOS				
Gloves (UIPE FOS GLOVES)				
• PHM033: Uniform Integrated 4.456 30.145 55.100 - 55.100 111.350 111.783	3 112.106	113.401	Continuing	Continuin
Protective Ensemble General				
Purpose (UIPE FOS GP)				
• PHM034: Uniform Integrated 47.798 23.407 25.794 - 25.794 26.195 26.403	3 17.586	0.492	Continuing	Continuin
Protection Ensemble				
FOS Air (UIPE FOS AIR)				
• PHM039: Botulinum Monoclonal 33.60	1 -	-	Continuing	Continuin
Antibodies (BOT MAB)				
PHM044: Uniform Integrated	6.354	10.954	Continuing	Continuin
Protective Ensemble FOS				
Footwear (UIPE FOS FOOTWEAR)				

Remarks

D. Acquisition Strategy

ADVANCED SYSTEM FOR PROTECTION AND INTEGRATED REDUCTION OF ENCUMBRANCES (ASPIRE)

Efforts for the suit hood/mask interface improvements into current ground masks will be accomplished through the Countering Weapons of Mass Destruction Other Transaction Authority (CWMD OTA) and current Joint Service General Purpose Mask (JSGPM) M53A1 contract. Efforts for the ASPIRE next generation respirator will be accomplished by awarding an agreement through the CWMD OTA to procure multiple prototypes for further development and evaluation to select down to a final solution.

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	I Defense Program	Date: March 2023
Appropriation/Budget Activity 0400 / 5	R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> <i>Defense Program - EMD</i>	Project (Number/Name) PT5 / Protect (SDD)
ADVANCED SYSTEM FOR PROTECTION AND INTEGRATED REDUCTION	OF ENCUMBRANCES-ENHANCED BIODEF	ENSE (ASPIRE-ENBD)
Efforts will be accomplished by awarding an agreement through the Countering multiple prototypes for evaluation and further refinement.	g Weapons of Mass Destruction Other Transac	ction Authority (CWMD OTA) to develop
BOTULINUM MONOCLONAL ANTIBODIES (BOT MAB)		
The Botulinum Monoclonal Antibodies (BOT MAB) program acquisition strateg Manufacturing and Development (EMD) phase against the Botulinum Neuro To or progression of botulism disease, following exposure to BoNT serotypes A ar Food and Drug Administration (FDA) approval under the Animal Rule.	oxin (BoNT). This Medical Countermeasure (I	MCM) will prevent and reduce the incidence
COLLECTIVE PROTECTION CONEX-ENHANCED BIODEFENSE (COL PRO	CONEX-ENBD)	
Resource prototype system design and development through the Countering V Prototypes will undergo evaluation and further refinement to optimize performa		on Agreement (CWMD OTA) contract.
PORTABLE PATIENT TRANSPORT SYSTEM-ENHANCED BIODEFENSE (P	PTS-ENBD)	
Resource prototype system design and development through the Countering V Leverage lessons learned from previous efforts to optimize performance and n		Fransactional Authority (OTA) contract.
Shipboard Isolation System		
The SIS program will utilize the Countering Weapons of Mass Destruction (CW to meet the shipboard isolation requirements. Once a final prototype design is package (TDP) and logistics package will be developed. The program will culr concentration areas on both CONUS and OCONUS locations.	selected and successfully completes testing a	nd user evaluations, a technical data
UNIFORM INTEGRATED PROTECTION ENSEMBLE FOS AIR (UIPE FOS A	IR)	
The Uniform Integrated Protection Ensemble (UIPE) Family of Systems (FoS) capitalizes on work accomplished by the United States Air Force (USAF) Integ FoS Air will utilize a Milestone A-C acquisition strategy that will accelerate field	rated Aircrew Ensemble (IAE) and UIPE FoS (General Purpose (GP) programs. The UIPE
L		

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biolog	cal Defense Program	Date: March 2023
Appropriation/Budget Activity	R-1 Program Element (Number/Name)	Project (Number/Name)
0400/5	PE 0604384BP / Chemical and Biological	PT5 / Protect (SDD)
	Defense Program - EMD	
Innovation Research (SBIR) Phase III contract to procure UIPE Air CBRL. T	he UIPE FoS Air 2PUG is a government owned	I design and as an item on the Federal
Procurement List, will be produced by Source America and Ready One Indu	stries.	
UNIFORM INTEGRATED PROTECTIVE ENSEMBLE GENERAL PURPOSI	E (UIPE FOS GP)	
The Uniform Integrated Protective Ensemble Family of Systems General Pu designed prototypes produced in conjunction with an Industry Partner to acc chemical testing resulted in three government designed candidates being do burden and provide improved form, fit, function, and integration with the curr stakeholder guidance, and a risk analysis led to the selection of two variants Developmental/Operational Testing. UIPE FoS GP will be executing multiple completion of UIPE evaluation (effectiveness, suitability and survivability) pr pricing (labor and material) with an initial production ramp up; and Mitigates	uire prototypes for early user testing. Warfighter own selected in 3QFY20. These three candidate ent Warfighter kits compared to legacy systems b. During 3QFY22, one variant will be selected to awards in the next 3 years, where production for to award of a high ceiling production contract	er feedback, trade space analysis, and es are designed to minimize operational s. Additional testing, review of the results, o enter the Operational Assessment and occurring before the milestone to allow for t. This will allow the vendor to better estima
UNIFORM INTEGRATED PROTECTIVE ENSEMBLE FOS GLOVES (UIPE	FOS GLOVES)	
The Uniform Integrated Protective Ensemble (UIPE) Family of Systems (Fos and a call for White Papers through an Other Transaction Authority (OTA) co	, , ,	÷

and a call for White Papers through an Other Transaction Authority (OTA) contracting approach. Eight white papers were deemed acceptable and will be pursued through a Middle Tier Acquisition Rapid Prototyping strategy. Candidate technologies will undergo Early User Tests/Wear events and material and system level testing to identify available capabilities as well as Analytical framework analyses to determine the most suitable solution(s) per mission profile.

SPECIAL IMMUNIZATION PROGRAM (VAC SIP)

The SIP program manages the continual storage, testing, compliance, and distribution activities associated with Investigational New Drugs (INDs) for legacy prophylactic medical countermeasures, as well as the recent Bot and Plague vaccine candidates. Additionally, the SIP maintains interagency agreements with US Army Medical Research and Development Command to support testing and compliance requirements. This Department of Defense program supports the Federal interagency with this effort, as well as academic and industry partners.

Rapid Access to Products in Development

RAPID (Rapid Access to Products in Development) will leverage existing Chemical Biological Defense Program (CBDP) advanced development programs within the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) to build a repository of medical countermeasures at tiered development stages, in order to establish a rapid response capability by providing access to products still in development and provide prototype Medical Countermeasures (MCMs) for transition to Programs of Record.

Appropriation/Budge 0400 / 5	t Activity	1				PE 060	•	Chemica	umber/Na al and Biolo	,	-	(Number rotect (SE			
Product Developmer	nt (\$ in Mi	illions)		FY 2	2022	FY	2023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
ASPIRE - HW S - Hood/ Mask Interface Prototype Development	C/FFP	ATI Solutions, Inc. : Tysons Corner, VA	-	0.000		0.000		2.708	Jan 2024	-		2.708	Continuing	Continuing	0.000
ASPIRE-ENBD - HW C - Bio half-mask Prototype Development	Various	Various : N/A	-	0.000		0.000		0.700	Dec 2023	-		0.700	Continuing	Continuing	0.000
BOT MAB - SW C - BOT MONO	C/CPFF	Resilience Government Services, Inc. : Alachua, Florida	-	0.000		59.164	Dec 2022	54.011	Dec 2023	-		54.011	Continuing	Continuing	0.000
COL PRO CONEX-ENBD - HW S - Concept Design	Various	TBD : N/A,	-	0.000		0.000	Dec 2022	2.187	Nov 2023	-		2.187	Continuing	Continuing	0.000
PPTS-ENBD - HW S - Prototyping Contract	TBD	TBD : N/A	-	0.000		0.000	Dec 2022	2.461	Jan 2024	-		2.461	Continuing	Continuing	0.000
SIS - HW S - Develop Requirements and Specifications, Develop Shipboard Isolation System Concepts	TBD	TBD : N/A	-	0.000		0.000		0.481	Dec 2023	-		0.481	Continuing	Continuing	0.000
UIPE FOS AIR - HW C - Prototype Development (2PUG)	Various	Various : N/A	-	0.000		0.330	Nov 2022	0.000		-		0.000	0.000	0.330	0.000
UIPE FOS GP - HW C - Prototype Development	MIPR	TBD : N/A	-	0.000		0.839	Nov 2022	1.750	Nov 2023	-		1.750	Continuing	Continuing	0.000
UIPE FOS GLOVES - HW C - Prototype Manufacturing, Demonstration and Down- select	MIPR	Various : N/A	-	0.000		0.562	Nov 2022	0.400	Nov 2023	-		0.400	Continuing	Continuing	0.000
	<u>.</u>	Subtotal	-	0.000		60.895		64.698		-	1	64.698	Continuing	Continuing	N/A

Exhibit R-3, RDT&E F Appropriation/Budge 0400 / 5	-					R-1 Pro PE 060	ogram Ele 4384BP / e Program	e ment (N Chemica			-	rotect (SD			
Support (\$ in Million	s)			FY 2	022	FY	2023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
ASPIRE - ES C - Engineering Support	Various	Various : N/A	-	0.000		0.000		0.716	Nov 2023	-		0.716	Continuing	Continuing	
ASPIRE-ENBD - ES S - Engineering and Technical Support	Various	Various : N/A	-	0.000		0.000		0.240	Nov 2023	-		0.240	Continuing	Continuing	0.000
BOT MAB - PM/MS C - BOT MONO	Various	JPEO Chem, Bio, Rad, and Nuc Defense (JPEO- CBRND) : Aberdeen Proving Ground, MD	-	0.000		4.340	Dec 2022	4.517	Dec 2023	-		4.517	Continuing	Continuing	0.000
BOT MAB - PM/MS C - BOT MONO	Various	JPL CBRND Enabling Biotechnologies, JPEO-CBRND : Fort Detrick, MD	-	0.000		0.000		6.000	Dec 2023	_		6.000	Continuing	Continuing	0.000
COL PRO CONEX-ENBD - ES S - Engineering, Logistics, Technical, IPT Support	MIPR	Various : N/A	-	0.000		0.000	Dec 2022	0.956	Nov 2023	-		0.956	Continuing	Continuing	0.000
PPTS-ENBD - ES S - Engineering, Logistics, Technical, IPT Support	MIPR	Various : N/A	-	0.000		0.000	Dec 2022	1.962	Nov 2023	-		1.962	Continuing	Continuing	0.000
SIS - ES S - Engineering, Logistics, Technical, IPT Support	TBD	TBD : N/A	-	0.000		0.000		0.150	Dec 2023	-		0.150	Continuing	Continuing	0.000
UIPE FOS AIR - ES C - Engineering and IPT Support	Various	Various : N/A	-	0.000		1.821	Nov 2022	0.000		-		0.000	0.000	1.821	0.000
UIPE FOS GP - ILS C - Integrated Log Support- System	Various	Various : N/A	-	0.000		0.608	Nov 2022	0.442	Nov 2023	-		0.442	Continuing	Continuing	0.000
UIPE FOS GP - ES C - Engineering & Technical	Various	Various : N/A	-	0.000		2.477	Nov 2022	0.610	Nov 2023	-		0.610	Continuing	Continuing	0.000

Exhibit R-3, RDT&E F	Project C	ost Analysis: PB 2	2024 Che	mical and	l Biologic	al Defens	e Progran	n				Date:	March 20	023	
Appropriation/Budge 0400 / 5	et Activity	/				PE 060		Chemica	umber/Na al and Biol			(Number rotect (SE			
Support (\$ in Million	s)			FY 2	2022	FY 2	2023		2024 Ise		2024 CO	FY 2024 Total]		
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
IPT Support / SME Support															
UIPE FOS GLOVES - ES C - Engineering, Logistics, Technical, IPT Support	MIPR	Various : N/A	-	0.000		0.812	Nov 2022	0.578	Nov 2023	-		0.578	Continuing	Continuing	0.000
		Subtotal	-	0.000		10.058		16.171		-		16.171	Continuing	Continuing	N/A
Test and Evaluation	(\$ in Milli	ions)		FY 2	2022	FY 2	2023		2024 Ise		2024 CO	FY 2024 Total]		
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
ASPIRE - OTHT C - Prototype Evaluation	Various	Various : N/A	-	0.000		0.000		1.157	Nov 2023	-		1.157	Continuing	Continuing	0.000
ASPIRE-ENBD - OTHT C - Prototype Evaluation	Various	Various : N/A	-	0.000		0.000		0.562	Dec 2023	-		0.562	Continuing	Continuing	0.000
COL PRO CONEX-ENBD - DTE C - T&E Support	MIPR	Various : N/A	-	0.000		0.000	Dec 2022	1.175	Nov 2023	-		1.175	Continuing	Continuing	0.000
PPTS-ENBD - DTE S - T&E Support	MIPR	Various : N/A	-	0.000		0.000	Dec 2022	0.552	Nov 2023	-		0.552	Continuing	Continuing	0.000
SIS - DTE S - Develop T&E strategy, Provide T&E Inputs to Contract Documentation	TBD	TBD : N/A	-	0.000		0.000		0.285	Dec 2023	-		0.285	Continuing	Continuing	0.000
UIPE FOS AIR - DTE C - System Level Testing	Various	Various : N/A	-	0.000		2.587	Nov 2022	0.000		-		0.000	0.000	2.587	0.000
UIPE FOS GP - DTE C - DT/OT	Various	Various : N/A	-	0.000		5.022	Nov 2022	3.993	Nov 2023	-		3.993	Continuing	Continuing	0.000
UIPE FOS GLOVES - DTE C - Early User Testing, Developmental Testing	MIPR	Various : N/A	-	0.000		1.153	Nov 2022	2.642	Nov 2023	-		2.642	Continuing	Continuing	0.000
VAC SIP - OTHT C - Storage and Distribution of Vaccines	SS/FP	Fisher BioServices : Rockville, MD	-	0.000		1.365	Mar 2023	0.000		-		0.000	0.000	1.365	0.000

PE 0604384BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program

Exhibit R-3, RDT&E F	Project Co	ost Analysis: PB 2	024 Che	mical and	l Biologic		0					Date:	March 20	023	
Appropriation/Budge 0400 / 5	et Activity	,				PE 060		Chemica	lumber/Na al and Biol			: (Numbe i Protect (SE	,		
Test and Evaluation	(\$ in Milli	ons)		FY 2	2022	FY	2023		2024 ase		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
VAC SIP - OTHT C - Potency Testing of Vaccines	MIPR	US Army Medical Research Institute of Infectious Disease (USAMRIID) : Fort Detrick, MD	-	0.000		1.196	Mar 2023	0.000		-		0.000	0.000	1.196	0.000
VAC SIP - OTHT C - Potency Testing of Vaccines	C/CPFF	Battelle Memorial Institute : Columbus, OH	-	0.000		1.642	Jan 2023	0.000		-		0.000	0.000	1.642	0.000
VAC SIP - OTHT C - BOT & PLG Stability	C/CPFF	TBD : N/A	-	0.000		2.080	Jan 2023	0.000		-		0.000	0.000	2.080	0.000
RAPID - OTHT C	TBD	Various : N/A	-	0.000		0.000		4.927	Dec 2023	-		4.927	Continuing	Continuing	0.000
	L.	Subtotal	-	0.000		15.045		15.293		-		15.293	Continuing	Continuing	N/A
Management Service	es (\$ in M	illions)		FY 2	2022	FY 2	2023		2024 ase		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
ASPIRE - PM/MS S - Management Support Services	Various	Various : N/A	-	0.000		0.000		0.195	Nov 2023	-		0.195	Continuing	Continuing	0.000
ASPIRE-ENBD - PM/MS C - Program Management Support	Various	Various : N/A	-	0.000		0.000		0.098	Dec 2023	-		0.098	Continuing	Continuing	0.000
COL PRO CONEX-ENBD - PM/MS S - Program Management	MIPR	Various : N/A	-	0.000		0.000	Dec 2022	0.282	Nov 2023	-		0.282	Continuing	Continuing	0.000
PPTS-ENBD - PM/MS S - Program Management	MIPR	Various : N/A	-	0.000		0.000	Dec 2022	0.325	Nov 2023	-		0.325	Continuing	Continuing	0.000
SIS - PM/MS S - Program Management Support	Various	Various : N/A	-	0.000		0.000		0.060	Dec 2023	-		0.060	Continuing	Continuing	0.000
UIPE FOS AIR - PM/MS C - Program Management Services	MIPR	Various : N/A	-	0.000		0.394	Nov 2022	0.000		-		0.000	0.000	0.394	0.000

PE 0604384BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program

Exhibit R-3, RDT&E	Project C	ost Analysis: PB 2	024 Che	mical and	I Biologic	al Defens	e Progran	n				Date:	March 20)23	
Appropriation/Budg 0400 / 5	et Activity	1				PE 060	-	Chemica	lumber/Na al and Biol			t (Numbe Protect (SL			
Management Servic	es (\$ in M	illions)		FY 2	2022	FY	2023		2024 ase		2024 CO	FY 2024 Total]		
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
UIPE FOS GP - SBIR/ STTR - Program Management Support	Various	Various : N/A	-	0.000		0.694	Nov 2022	0.257	Nov 2023	-		0.257	Continuing	Continuing	0.000
UIPE FOS GLOVES - PM/MS C - Program Management Support	Various	Various : N/A	-	0.000		0.172	Dec 2022	0.236	Nov 2023	-		0.236	Continuing	Continuing	0.000
VAC SIP - PM Support	Various	JPL CBRND Enabling Biotechnologies, JPEO-CBRND : Fort Detrick, MD	-	0.000		0.665	Jan 2023	0.000		-		0.000	0.000	0.665	0.000
RAPID - PM/MS C	C/CPFF	Various : N/A	-	0.000		0.000		0.360	Dec 2023	-		0.360	Continuing	Continuing	0.000
		Subtotal	-	0.000		1.925		1.813		-		1.813	Continuing	Continuing	N/A
			Prior Years	FY 2	2022	FY	2023		2024 ase		2024 CO	FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract
		Project Cost Totals	-	0.000		87.923		97.975		-		97.975	Continuing	Continuing	N/A

Remarks

Exhibit R-4, RDT&E Schedule Profile: PB 2024 C	he	mic	al ar	nd E	Biolo	ogic	cal D	Defe	nse	Prog	grar	n												D	ate:	Ма	arch	202	23		
Appropriation/Budget Activity 0400 / 5									PE	0604	138	m E 4BP ogra	I Cł	nemi	ical										nbei t (SE)			
		F`	(20	22			FY	202:	3		FY	2024	4		FY	20	25			FY	202	6		F	Y 20	27			FY 2	028	5
	1		2 :	3	4	1	2	3	4	1	2	3	4	1	2	: 3	3	4	1	2	3	4	1		2	3	4	1	2	3	4
ASPIRE - Suit Hood/Mask Interface Prototype Development																															
ASPIRE - Suit Hood/Mask Interface Prototype Testing and Evaluation																															
ASPIRE - Next Generation Respirator new material development																															
ASPIRE - Suit Hood/Mask Interface Production																															
ASPIRE-ENBD - Prototype Development																															
ASPIRE-ENBD - Prototype Testing and Evaluation																															
BOT MAB - Platform Development																															
BOT MAB - Clinical and Nonclinical																															
BOT MAB - Manufacturing																															
BOT MAB - MS B-Milestone B																															
BOT MAB - MS C-Milestone C																															
BOT MAB - Biologics License Application (BLA) Submission																															
COL PRO CONEX-ENBD - Concept Design and System Planning																															
COL PRO CONEX-ENBD - Initial Concept Demonstration																															
COL PRO CONEX-ENBD - Iterative Prototyping																															
COL PRO CONEX-ENBD - ILS Development																															
COL PRO CONEX-ENBD - Training Development																															

Exhibit R-4, RDT&E Schedule Profile: PB 2024 C	Che	mic	al a	nd E	liolo	ogica	al D	efen	ise F	Prog	Iram	ı											Da	te: N	/larc	h 20)23	3		
Appropriation/Budget Activity 0400 / 5	-							F	PE 0)604	384	BP /		mi	(Num ical al D									oer/l SDL		ıe)				
		F	Y 20	22		F	Y 2	023			FY 2	2024			FY 2	2025			FY	2020	6		FY	202	7		F	Y 20	28	
	1		2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1		2	3	4
PPTS-ENBD - Concept Development and System Planning																														
PPTS-ENBD - CWMD OTA Contract Award																														
PPTS-ENBD - User Demonstrations																														
PPTS-ENBD - MOT&E																														
PPTS-ENBD - Logistics Demonstration																														
PPTS-ENBD - Technical Design Package Complete																														
PPTS-ENBD - Logistics/Sustainment Package Complete																														
PPTS-ENBD - Final Prototype Purchase Contract																														
SIS - RDP-Requirements Definition Package - Requirements Definition																														
SIS - Concept Development and System Planning																														
SIS - CWMD OTA Contract Award																														
SIS - Initial Prototype Fabrication and Delivery																														
SIS - Initial Prototype Testing																														
SIS - Modified Prototype Fabrication and Delivery																														
SIS - Modified Prototype Testing and User Demo																														
SIS - Final Prototype Fabrication and Delivery																														
SIS - Final Prototype MOT&E and Logistics Demo																														
SIS - Technical Data Package and Logistics Package																														

PE 0604384BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program

Exhibit R-4, RDT&E Schedule Profile: PB 2024	Che	mica	l and	Biolo	ogica	al D	efer	nse F	Prog	grar	n											Date	e: Ma	arch	2023		
Appropriation/Budget Activity 0400 / 5								PE ()604	438	i m El 4BP <i>i</i> rograi	I Ch	emi	cal a									er/Na SDD))		
			2022			Y 2				_	2024				2025	1		_	2026				2027			2028	_
QIO - Oustan Estriction and Delivery	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1 2	3	4
SIS - System Fabrication and Delivery UIPE FOS AIR - Aircraft Integration Testing																				_							
UIPE FOS AIR - Swatch and System Level Testing																											
UIPE FOS AIR - Fixed Wing Ejection Aircraft Integration Testing																											
UIPE FOS AIR - Fixed Wing Non-Ejection Aircraft Testing																											
UIPE FOS AIR - Rotary Wing Aircraft Integration Testing																											
UIPE FOS AIR - Prototype Development (2PUG)																											
UIPE FOS AIR - IOC-Initial Operational Capability - CBRL																											
UIPE FOS AIR - Human Factors Testing																											
UIPE FOS AIR - Safe to Fly Certification																											
UIPE FOS AIR - FOC-Full Operational Capability - CBRL													-								•						
UIPE FOS AIR - Developmental/Operational Testing (DT/OT)																											
UIPE FOS AIR - Safe-to-Fly and Airworthiness Testing																											
UIPE FOS AIR - Capability Development Document (CDD) Update													-							-	•						
UIPE FOS AIR - FRP-Full Rate Production Decision - 2PUG																											
UIPE FOS AIR - IOC-Initial Operational Capability - 2PUG																											

PE 0604384BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program UNCLASSIFIED Page 58 of 158

R-1 Line #132

Exhibit R-4, RDT&E Schedule Profile: PB 2024 (Che	mica	and	Biol	ogic	al D	efen	se Pi	rogi	ram												Date	e: Ma	arch	20	23		
Appropriation/Budget Activity 0400 / 5							F	PE 06	604	gram 384B <i>Prog</i>	Ρ/	Chen	nic	al ai					Proj PT5						e)			
		FY	2022			FY 2	023		F	FY 20	24		F	FY 2	2025		F	Y 2	2026			FY 2	2027			FY	202	B
UIPE FOS AIR - FOC-Full Operational Capability - 2PUG	1	2	3	4	1	2	3	4	1	2	3	4 ⁻	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
UIPE FOS GP - TATPE Technical Testing			<u> </u>																									
UIPE FOS GP - MS C-Milestone C - TATPE UIPE FOS GP - TATPE Production Contract Award																												
UIPE FOS GP - FRP-Full Rate Production Decision - TATPE																												
UIPE FOS GP - IOC-Initial Operational Capability - TATPE																												
UIPE FOS GP - FOC-Full Operational Capability - TATPE																												
UIPE FOS GP - DT/OT																												
UIPE FOS GP - CDR-Critical Design Review																												
UIPE FOS GP - Production Initiation Contract																												
UIPE FOS GP - Operational Assessment																												
UIPE FOS GP - Manufacturing Readiness Assessment (MRA)																												
UIPE FOS GP - Joint Independent Logistics Assessment (JILA)																												
UIPE FOS GP - MS C-Milestone C																												
UIPE FOS GP - Capability Development Document (CDD) Update (if needed)																												
UIPE FOS GP - Production Contract Award																												
UIPE FOS GP - OT&E-Operational Test and Evaluation																												
UIPE FOS GP - FRP-Full Rate Production Decision																Į												

PE 0604384BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program UNCLASSIFIED Page 59 of 158

R-1 Line #132

xhibit R-4, RDT&E Schedule Profile: PB 2024 C	he	mic	al a	nd	Biolo	ogic	al D)efei	nse	Pro	gram	ı												Dat	e: M	arch	20	23		
Appropriation/Budget Activity 400 / 5									PE (0604	o gra i 4384 e Pro	BP	I Ch	emi	cal a										oer/N SDD,		e)			
		F	(20	22			FY 2	2023	3		FY :	2024	1		FY	20	25		F	Y 20)26			FY	2027	,		FY	202	3
	1		2	3	4	1	2	3	4	1	2	3	4	1	2		3 4	1	1	2	3	4	1	2	3	4	1	2	3	4
UIPE FOS GP - IOC-Initial Operational Capability																														
UIPE FOS GLOVES - Early User, material and system level testing																														
UIPE FOS GLOVES - Mid-Tier Acquisition Rapid Prototype Initiation																														
UIPE FOS GLOVES - Mid-Tier Acquisition DT/ OT																														
UIPE FOS GLOVES - Analytical Framework Analysis																														
UIPE FOS GLOVES - Mid-Tier Acquisition IPR																														
UIPE FOS GLOVES - Mid-Tier Acquisition Decision Point																														
UIPE FOS GLOVES - Mid-Tier Acquisition Rapid Fielding OR/Milestone C																														
VAC SIP - Storage, distribution, potency testing, biosurety compliance activities																														
RAPID - DT&E-Developmental Test and Evaluation - Storage and stability testing																														

hibit R-4A, RDT&E Schedule Details: PB 2024 Chemical and Biological I propriation/Budget Activity 0 / 5	R-1 Program Element (Number PE 0604384BP / Chemical and Defense Program - EMD	Date: March 2023 Project (Number/Name) PT5 / Protect (SDD)		
S	chedule Details			
	Si	tart	E	nd
Events	Quarter	Year	Quarter	Year
ASPIRE - Suit Hood/Mask Interface Prototype Development	1	2025	4	2025
ASPIRE - Suit Hood/Mask Interface Prototype Testing and Evaluation	1	2025	3	2027
ASPIRE - Next Generation Respirator new material development	1	2027	4	2028
ASPIRE - Suit Hood/Mask Interface Production	3	2027	4	2028
ASPIRE-ENBD - Prototype Development	1	2024	3	2026
ASPIRE-ENBD - Prototype Testing and Evaluation	4	2024	4	2026
BOT MAB - Platform Development	1	2022	4	2025
BOT MAB - Clinical and Nonclinical	1	2022	3	2025
BOT MAB - Manufacturing	1	2022	4	2025
BOT MAB - MS B-Milestone B	2	2022	2	2022
BOT MAB - MS C-Milestone C	2	2023	2	2023
BOT MAB - Biologics License Application (BLA) Submission	4	2025	4	2025
COL PRO CONEX-ENBD - Concept Design and System Planning	2	2024	4	2024
COL PRO CONEX-ENBD - Initial Concept Demonstration	4	2024	4	2024
COL PRO CONEX-ENBD - Iterative Prototyping	4	2024	3	2026
COL PRO CONEX-ENBD - ILS Development	3	2025	4	2026
COL PRO CONEX-ENBD - Training Development	3	2025	4	2026
PPTS-ENBD - Concept Development and System Planning	1	2025	4	2025
PPTS-ENBD - CWMD OTA Contract Award	4	2024	4	2024
PPTS-ENBD - User Demonstrations	3	2025	4	2025
PPTS-ENBD - MOT&E	4	2026	4	2026
PPTS-ENBD - Logistics Demonstration	4	2026	4	2026

PE 0604384BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program

oropriation/Budget Activity 0 / 5	R-1 Program Element (I PE 0604384BP <i>I Chemic</i> <i>Defense Program - EMD</i>	al and Biological	Project (Number/Na PT5 / Protect (SDD)	me)
		Start	E	Ind
Events	Quart	er Year	Quarter	Year
PPTS-ENBD - Technical Design Package Complete	3	2027	3	2027
PPTS-ENBD - Logistics/Sustainment Package Complete	3	2027	4	2027
PPTS-ENBD - Final Prototype Purchase Contract	4	2027	4	2027
SIS - RDP-Requirements Definition Package - Requirements Definition	1	2024	2	2024
SIS - Concept Development and System Planning	2	2024	4	2024
SIS - CWMD OTA Contract Award	4	2024	1	2026
SIS - Initial Prototype Fabrication and Delivery	2	2025	3	2025
SIS - Initial Prototype Testing	4	2025	4	2025
SIS - Modified Prototype Fabrication and Delivery	1	2026	2	2026
SIS - Modified Prototype Testing and User Demo	3	2026	4	2026
SIS - Final Prototype Fabrication and Delivery	1	2027	2	2027
SIS - Final Prototype MOT&E and Logistics Demo	3	2027	3	2027
SIS - Technical Data Package and Logistics Package	2	2027	4	2027
SIS - System Fabrication and Delivery	1	2028	4	2028
UIPE FOS AIR - Aircraft Integration Testing	1	2022	2	2022
UIPE FOS AIR - Swatch and System Level Testing	1	2022	4	2022
UIPE FOS AIR - Fixed Wing Ejection Aircraft Integration Testing	1	2022	4	2023
UIPE FOS AIR - Fixed Wing Non-Ejection Aircraft Testing	1	2022	4	2023
UIPE FOS AIR - Rotary Wing Aircraft Integration Testing	1	2022	4	2023
UIPE FOS AIR - Prototype Development (2PUG)	1	2022	4	2022
UIPE FOS AIR - IOC-Initial Operational Capability - CBRL	2	2022	2	2022
UIPE FOS AIR - Human Factors Testing	3	2022	3	2022
UIPE FOS AIR - Safe to Fly Certification	4	2022	4	2023
UIPE FOS AIR - FOC-Full Operational Capability - CBRL	4	2022	4	2022
UIPE FOS AIR - Developmental/Operational Testing (DT/OT)	1	2022	4	2022

D/5	R-1 Program Element (Numb PE 0604384BP / Chemical and Defense Program - EMD		Project (Number/Nan PT5 / Protect (SDD)	ne)
		Start	E	nd
Events	Quarter	Year	Quarter	Year
UIPE FOS AIR - Safe-to-Fly and Airworthiness Testing	1	2023	4	2023
UIPE FOS AIR - Capability Development Document (CDD) Update	2	2023	2	2023
UIPE FOS AIR - FRP-Full Rate Production Decision - 2PUG	2	2023	2	2023
UIPE FOS AIR - IOC-Initial Operational Capability - 2PUG	2	2024	2	2024
UIPE FOS AIR - FOC-Full Operational Capability - 2PUG	4	2028	4	2028
UIPE FOS GP - TATPE Technical Testing	1	2022	2	2022
UIPE FOS GP - MS C-Milestone C - TATPE	3	2022	3	2022
UIPE FOS GP - TATPE Production Contract Award	4	2022	4	2022
UIPE FOS GP - FRP-Full Rate Production Decision - TATPE	4	2022	4	2022
UIPE FOS GP - IOC-Initial Operational Capability - TATPE	2	2024	2	2024
UIPE FOS GP - FOC-Full Operational Capability - TATPE	3	2025	3	2025
UIPE FOS GP - DT/OT	2	2022	3	2023
UIPE FOS GP - CDR-Critical Design Review	3	2022	3	2022
UIPE FOS GP - Production Initiation Contract	2	2023	2	2023
UIPE FOS GP - Operational Assessment	1	2024	1	2024
UIPE FOS GP - Manufacturing Readiness Assessment (MRA)	2	2023	2	2023
UIPE FOS GP - Joint Independent Logistics Assessment (JILA)	3	2023	4	2023
UIPE FOS GP - MS C-Milestone C	4	2023	4	2023
UIPE FOS GP - Capability Development Document (CDD) Update (if neede	d) 4	2023	4	2023
UIPE FOS GP - Production Contract Award	1	2025	1	2025
UIPE FOS GP - OT&E-Operational Test and Evaluation	2	2024	2	2024
UIPE FOS GP - FRP-Full Rate Production Decision	1	2026	1	2026
UIPE FOS GP - IOC-Initial Operational Capability	4	2028	4	2028
UIPE FOS GLOVES - Early User, material and system level testing	1	2022	2	2024
UIPE FOS GLOVES - Mid-Tier Acquisition Rapid Prototype Initiation	1	2022	1	2023

hibit R-4A, RDT&E Schedule Details: PB 2024 Chemical and Biol	Date: Marc	ch 2023				
100 / 5 PE 0604384		n Element (Numbe BP <i>I Chemical and I</i> gram - EMD	,	Project (Number/Name) PT5 / Protect (SDD)		
	·	St	art		E	nd
Events	Quarter	Year	(Quarter	Year	
UIPE FOS GLOVES - Mid-Tier Acquisition DT/OT		2	2022		3	2024
UIPE FOS GLOVES - Analytical Framework Analysis		3	2022		4	2022
UIPE FOS GLOVES - Mid-Tier Acquisition IPR		3	2023		3	2023
UIPE FOS GLOVES - Mid-Tier Acquisition Decision Point	UIPE FOS GLOVES - Mid-Tier Acquisition Decision Point				3	2024
UIPE FOS GLOVES - Mid-Tier Acquisition Rapid Fielding OR/Mile	4	2024		4	2024	
VAC SIP - Storage, distribution, potency testing, biosurety complia	ance activities	1	2022		4	2023
RAPID - DT&E-Developmental Test and Evaluation - Storage and stability testing		1	2024		4	2028

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program												
Appropriation/Budget Activity 0400 / 5					R-1 Program Element (Number/Name) PE 0604384BP / Chemical and Biological Defense Program - EMD				Project (Number/Name) MT5 / Mitigate (SDD)			
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
MT5: Mitigate (SDD)	-	0.000	74.225	88.441	0.000	88.441	92.279	91.431	87.773	93.250	Continuing	Continuing
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

The Mitigate System Development & Demonstration (SDD) Project provides the Joint Force the ability to recover from exposure to chemical and biological hazards and quickly return to the fight. Efforts include development of U.S. Food & Drug Administration (FDA) approved medical countermeasures (MCMs) to protect the lives and maintain the battle readiness of the warfighter. Efforts also provide safe, effective MCMs to enable Warfighter recovery and return to duty after exposure to chemical threat agents, and reduce logistics needs of decontamination methods with operationally-relevant test methods and allows personnel to reduce Mission-Oriented Protective Posture (MOPP) levels as rapidly as possible. Activities in this project realize considerable efficiencies through cost sharing agreements. In FY 2023, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. MT5 efforts in FY 2022 remain in Projects DE5, MB5, and MC5. This restructuring provided standardization and alignment across CBDP research, development and acquisition efforts.

Efforts included in this Project are:

- (1) Alternative Autoinjector Manufacturer Capability (AUTOINJ)
- (2) Antiviral Therapeutics Program (AV TX)
- (3) Countering Emerging Threats Rapid Acquisition and Investigation of Drugs for Repurposing (CET RAIDR)
- (4) Countering Emerging Threats Rapid Acquisition and Investigation of Drugs for Repurposing-Enhanced Biodefense (CET RAIDR-ENBD)
- (5) Decontamination Family of Systems Contamination Indicator Decontamination Assurance System (DFoS CIDAS BLISTER)
- (6) Forward Area Mobility Spray System (FAMS-S)
- (7) Improved Nerve Agent Treatment System Centrally Acting (INATS CA)
- (8) Service Equipment Decontamination System (SEDS)

The AUTOINJ effort provides for FDA approved alternative source(s) for autoinjectors that deliver DoD nerve agent antidote and treatment capabilities to the warfighter; thereby mitigating capability fielding and operational readiness risks. This program augments legacy autoinjectors, antidote treatment nerve agent autoinjector (ATNAA), 2-PAM, and Convulsant Antidote for Nerve Agents (CANA) by providing alternative commercial sources which includes Dual Drug Delivery Device (D4), the Atropine Auto-Injector, and an anticonvulsant autoinjector. In FY24, AUTOINJ will submit New Drug Application packages to the FDA for D4 and Alternative-Diazepam, initiate activities for a wet-dry atropine autoinjector that provides an extended shelf-life compared to the fielded FDA approved Atropine Auto-Injector.

The Anti-viral Therapeutics (AV TX) program will develop and deliver a Food and Drug Administration (FDA) approved antiviral therapeutics for the warfighter. Based on the current gap in defense to the Warfighter, the initial therapeutic candidate is a treatment against the Marburg virus. Developed broad spectrum antiviral therapeutics will be employed after suspected or confirmed exposure to the relevant threat agents and AV TX Medical Countermeasures (MCM) will ameliorate the effect of threat agents to the warfighter. In the event of a natural occurring outbreak, antiviral therapeutics can be provided to ensure freedom of operation.

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical	I and Biological Defense Program	Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 5	R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> <i>Defense Program - EMD</i>	Project (Number/I MT5 / Mitigate (SD	,	
The Countering Emerging Threats Rapid Acquisition and Investig countermeasures towards known, potential, and emerging threat RAIDR will leverage lessons learned to repurpose U.S. Food & I countermeasures to CBRN threat symptoms. CET RAIDR will e studies to repurpose as a CBRN Medical Countermeasure. Stud threats. Efforts include additional investments in enhanced biode	ats, bridging the gap from when a threat is identified until targ Drug Administration (FDA) approved therapeutics to reduce evaluate FDA-approved and/or late stage products through r dies will generate safety and efficacy data to support the use	geted countermeasur risk to the Warfighte nonclinical Non-Huma	es are availat r by providing an Primate (N	ole. CET medical HP)
The Decontamination Family of Systems (DFoS) Contamination agents, two separate threat scenarios that require different mate Defense Strategy. In FY24, the program will conduct a Manufac and complete Operational Testing in support of Full Rate Product	eriel solutions, modernizing a key capability to help build a m cturing Readiness Assessment (MRA) and a Physical Config	nore lethal force, as o guration Audit (PCA)	outlined in the with Prime Co	National ontractor
The FAMS-S will provide Special Operations Forces (SOF) and variants: man-portable, small vehicle-mounted, and large vehicle vehicles and support equipment to a level that is clean enough for maximize tactical flexibility and fighting strength while minimizing CB operations. FAMS-S is a Middle Tier Acquisition (MTA) prog	e-mounted systems to rapidly decontaminate chemical and for re-use during missions without the need for donning CB p g the logistical burden and the cost of conducting Countering	biological (CB) agent personal protective e	ts from the ext quipment. Th	terior of is will
The INATS CA program will develop the centrally-acting antichol nerve agents. When added to currently fielded nerve agent trea at definitive care, and in an autoinjector for use in the field. In F ¹ environmental testing for the autoinjector, and begin manufactur PL115-92 will occur during nonclinical testing and autoinjector de	atments, scopolamine will improve overall medical outcomes Y24, INATS CA will continue nonclinical work to refine the e re of current Good Manufacturing Practice (cGMP) registrati	and will be available fficacious dose, com	in both a vial	for use al and
The Joint Service Equipment Decontamination System (SEDS) a hardware intended to decontaminate military equipment in opera capability is needed to sustain the both the Joint and Special Op force posture, and align with the National Defense Strategy (NDS been exposed to chemical and biological contamination and ach than negligible severity effects. In FY24, the Joint SEDS effort w (CDR).	ational environments, including personal effects and weapor berations Forces by reducing logistical burdens in order to in S). SEDS and CEDS will provide contamination mitigation on hieve efficacy levels that allow unprotected post-decontamin	ns, to pre-contaminat icrease tactical agility capabilities for critica ation exposures for l	ion conditions / and sustain a l equipment th ong periods w	a This a resilient nat have rith less
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical a	nd Biological Defense Program		March 2023		
Appropriation/Budget Activity 0400 / 5		roject (Number/Name) IT5 <i>I Mitigate (SDD)</i>			
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024	
Description: Reconstituting Autoinjector Development (RAD-A)					
FY 2023 Plans: Initiate development of a Wet/Dry atropine autoinjector.					
FY 2024 Plans: Initiate formulation and device development with two performers whethods for atropine. Initiate human factors evaluation of the atrop production of atropine. Initiate equipment purchases and certification standards.	ine autoinjector. Initiate technology transfer and batch				
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to change in program/project technical parameters. F transferred to Wet/Dry atropine autoinjector to fund additional perfo					
Title: 2) AUTOINJ - Dual Drug Delivery Device (D4)		-	0.656	0.77	
Description: Food and Drug Administration (FDA) Coordination					
FY 2023 Plans: Submit FDA application for D4 and ALT- Diazepam.					
FY 2024 Plans: Continue FDA submission of FDA application for Dual Drug Deliver	ry Device (D4) & ALT-Diazepam.				
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to change in program/project schedule. Schedule mo	ved to right due to additional development activities in FY2	22.			
Title: 3) AV TX		-	10.506	-	
Description: Enabling Technologies					
FY 2023 Plans: Complete efficacy studies and prepare Food and Drug Administrati	on (FDA) approval package.				
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project is entering completion and all activities will be clos	ed.				
Title: 4) CET RAIDR		_	7.871	13.70	

PE 0604384BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program

Appropriation/Budget Activity 0400 / 5 B. Accomplishments/Planned Programs (\$ in Millions)	R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> <i>Defense Program - EMD</i>					
B. Accomplishments/Planned Programs (\$ in Millions)			Project (Number/Name) MT5 / <i>Mitigate (SDD)</i>			
		FY 2022	FY 2023	FY 2024		
Description: Advanced Development						
FY 2023 Plans: Continue advanced development of up to two (2) FDA-approved and/or late-staindications	age products for repurposing against CBRN					
FY 2024 Plans: Continue nonclinical studies to evaluate up to two (2) FDA-approved and/or late Medical Countermeasure. Studies will generate safety and efficacy data to sup symptoms.		RN				
FY 2023 to FY 2024 Increase/Decrease Statement: Additional investment in enhanced biodefense and pandemic preparedness. In non-clinical studies to generate additional safety and efficacy data to support d		er				
Title: 5) CET RAIDR-ENBD		-	8.500	8.500		
Description: Advanced Development						
FY 2023 Plans: Initiate nonclinical studies to evaluate FDA-approved and/or late-stage product: Countermeasure. Studies will generate safety and efficacy data to support the threat.		N				
FY 2024 Plans: Continue Non-human primate (NHP) studies to evaluate FDA-approved therap Countermeasure. These studies will generate data to support potential expanse						
Title: 6) DFoS CIDAS BLISTER		-	3.681	2.500		
Description: Blister Indicator Kits and Large Scale Applicators (LSA)						
FY 2023 Plans: Award contract option with prime contractor to acquire 200 SSA Blister Kits and testing. Conduct System Verification Review (SVR), Production Readiness Re (MRA) and Logistics Demonstration. Award Low-Rate Initial Production (LRIP) SSA-B kits and 30 LSKB kits in support of Operational Test planned for 4QFY2	view (PRR), Manufacturing Readiness Assess option for production representative kits for 2	sment				
FY 2024 Plans:						

PE 0604384BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical an	d Biological Defense Program	Date: N	/larch 2023		
Appropriation/Budget Activity 0400 / 5	Project (Number/ MT5 / Mitigate (SD	ect (Number/Name) I Mitigate (SDD)			
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024	
Conduct a Manufacturing Readiness Assessment (MRA) and a Phy complete Operational Testing (OT) in support of Full Rate Production		d			
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project transitioned to Production and Deployment Phase. Production.	FY24 is last year of BA5 funding, program is transitioning	g to			
Title: 7) FAMS-S		-	2.967	-	
Description: Small and large variant prototype refinement and clos	e out of remaining DT/OT activities.				
FY 2023 Plans: Complete engineering and manufacturability development for the m operational testing for the vehicle-mounted prototypes to include ch systems engineering and integration with vehicle platforms, and operation with vehicle platforms.	emical and biological decontamination level assessment,				
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project transitioned to Production and Deployment Phase.					
Title: 8) INATS CA - Clinical		-	5.101	4.572	
Description: Clinical Testing to support FDA approval					
FY 2023 Plans: Complete drug/drug interaction clinical safety study.					
FY 2024 Plans: Initiate Bioavailability/Bioequivalent (BA/BE) clinical trial with autoinj	ector.				
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.					
Title: 9) INATS CA - Manufacturing		-	14.815	6.019	
Description: Manufacture drug product and device development					
FY 2023 Plans: Continue Auto-Injector Development and manufacturing activities of	the drug product and autoinjector device				

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and	nd Biological Defense Program	Date:	March 2023	
Appropriation/Budget Activity 0400 / 5	0	Project (Number/ AT5 / Mitigate (SL	,	
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
Initiate manufacture of GMP registration lots. Initiate stability studie	es.			
FY 2024 Plans: Continuing manufacturing of registration lots, and stability studies.				
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments. Decrease due t	o ramping down manufacturing activities.			
Title: 10) INATS CA - Non-Clinical		-	3.063	5.65
Description: Non-Clinical				
FY 2023 Plans: Continuing Non-Clinical Animal Studies.				
Continuing Pivotal Animal Efficacy Studies.				
FY 2024 Plans: Continuing Non-Clinical Studies.				
Continue Pivotal Animal and Efficacy Studies.				
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to change in program/project schedule. Increase due	to bulk of studies occurring in FY24.			
Title: 11) SEDS		-	2.995	11.02
Description: Engineering, Manufacturing and Development (EMD)	activities and Product Development			
FY 2023 Plans: Conduct MS B activities for Special Operation Forces (SOF) and O Conduct Preliminary Design Review (PDR) for SOF. Prepare for C		5.		
FY 2024 Plans: Continue through the Joint SEDS Engineering, Manufacturing and and post MS B activities. Conduct a CDR and complete EMD phase		-)		
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project funding transferred from another funding line.				
	Accomplishments/Planned Programs Subto	- tals	74.225	88.44

PE 0604384BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program UNCLASSIFIED Page 70 of 158

Exhibit R-2A, RDT&E Project Just	ification: PB	2024 Chem	ical and Biolo	ogical Defen	se Program				Date: Ma	rch 2023	
Appropriation/Budget Activity 1400 / 5							Number/Na igate (SDD)				
C. Other Program Funding Summa	ary (\$ in Milli	<u>ons)</u>									
			<u>FY 2024</u>	<u>FY 2024</u>	<u>FY 2024</u>					Cost To	
Line Item	FY 2022	FY 2023	Base	000	<u>Total</u>	<u>FY 2025</u>	<u>FY 2026</u>	<u>FY 2027</u>	<u>FY 2028</u>	Complete	Total Cos
 DE5: Decontamination (SDD) 	7.485	-	-	-	-	-	-	-	-	0.000	7.485
MB5: Medical Biological	138.156	-	-	-	-	-	-	-	-	0.000	138.15
Defense (SDD)											
 MC5: Medical Chemical 	38.936	-	-	-	-	-	-	-	-	0.000	38.93
Defense (SDD)											
 MC7: Medical Chemical 	1.013	-	-	-	-	-	-	-	-	0.000	1.01
Defense (Op Sys Dev)											
 MT4: Mitigate (ACD&P) 	-	17.302	28.785	-	28.785	20.885	15.433	13.369	-	Continuing	Continuin
 MT7: Mitigate (Op Sys Dev) 	-	5.098	3.074	-	3.074	1.987	1.819	1.845	1.862	Continuing	Continuing
 JD0050: Decontamination 	7.797	4.795	6.062	-	6.062	8.673	8.820	16.518	5.996	Continuing	Continuing
Family Of Systems (DFoS)											
 PHM007: Service Equipment 	-	-	-	-	-	14.028	22.531	24.920	13.050	Continuing	Continuing
Decontamination System (SEDS)											
 PHM025: Forward Air Mobility 	-	4.607	4.824	-	4.824	4.724	4.724	4.724	4.889	Continuing	Continuing
Spray System (FAMS-S)											
PHM040: Improved	-	-	-	-	-	-	-	6.511	33.883	Continuing	Continuing
Nerve Agent Treatment											
Centrally Acting (INATS CA)											
<u>Remarks</u>											

D. Acquisition Strategy

ALTERNATE AUTOINJECTOR MANUFACTURER CAPABILITY (AUTOINJ)

The AUTOINJ will identify an alternative source(s) to develop and provide required Food and Drug Administration (FDA)-approved autoinjector-delivered nerve agent antidote and treatment capabilities to the DoD. The AUTOINJ effort leverages novel technologies and industrial base expansion in order to develop the autoinjector products. AUTOINJ uses contracts and Other Transactional Agreements (OTAs) in which the performer shall be responsible for conducting development and testing activities consistent with current FDA regulations. The contractor shall sponsor the combination product to the FDA and hold all approvals and/or licenses. Upon FDA approval, purchases for product sustainment will be made by the Defense Logistics Agency.

ANTI-VIRAL THERAPEUTICS (AV TX)

PE 0604384BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	Date: March 2023	
0400/5	R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> <i>Defense Program - EMD</i>	Project (Number/Name) MT5 / Mitigate (SDD)

The Antiviral Therapeutics (AV TX) program acquisition strategy supports the development of therapeutics against Marburg virus bio-warfare threats. The overall regulatory approach of the program remains to pursue development for FDA approval und the Animal Rule. The acquisition strategy is for the Marburg indication and will leverage collected safety data and large-scale manufacturing from the COVID efforts. This product was transitioned from Science and Technology (S&T).

COUNTERING EMERGING THREATS RAPID ACQUISITION AND INVESTIGATION OF DRUGS FOR REPURPOSING (CET RAIDR)

CET RAIDR: Countering Emerging Threats - Rapid Acquisition and Investigation of Drugs for Repurposing (CET RAIDR) is an investment program that leverages lessons learned and established manufacturing and safety databases to conduct studies to evaluate U.S. Food & Drug Administration (FDA) approved and late-stage development therapeutics against CBRN threats. Data generated from these efforts will be used to provide a solution to protect the Warfighter against CBRN threats that do not have any identified medical countermeasures. CET RAIDR utilizes multiple contracting and management strategies through existing service laboratory Interagency Agreements (IAAs), Cooperative Research and Development Agreements (CRADAs), flexible contracts, Broad Agency Announcements, and Other Transaction Authority (OTA) agreements.

COUNTERING EMERGING THREATS RAPID ACQUISITION AND INVESTIGATION OF DRUGS FOR REPURPOSING-ENHANCED BIODEFENSE (CET RAIDR-ENBD)

The Countering Emerging Threats - Rapid Acquisition and Investigation of Drugs for Repurposing Enhanced Biodefense (CET RAIDR ENBD) program will leverage lessons learned to conduct NHP studies to evaluate FDA-approved therapeutics against CBRN threats. Data generated from these efforts will be utilized to support potential expansion of use against CBRN symptoms. CET RAIDR ENBD utilizes multiple contracting and management strategies through existing service laboratory IAAs, Cooperative Research and Development Agreements (CRADAs), flexible contracts, Broad Agency Announcements, and Other Transaction Authority (OTA) agreements.

DFoS CONTAMINATION INDICATOR DECON ASSURANCE SPRAY BLISTER (DFoS CIDAS BLISTER)

The DFoS CIDAS Blister program will follow an evolutionary acquisition strategy. The program office coordinated with Science and Technology efforts to identify blister technologies that met Service requirements. After further development, a sole-source performance based indefinite delivery indefinite quantity contract was awarded to develop blister indicator and small scale applicator systems with options for production. The program will leverage the contract to procure blister indicator kits and conduct test and evaluation events for the Engineering and Manufacturing Development (EMD) phase in preparation of Milestone C/Full Rate Production (FRP).

FORWARD AREA MOBILITY SPRAY SYSTEM (FAMS-S)

The FAMS-S will be developed using Middle Tier Acquisition (MTA) to advance decontamination technology and capability for Special Operations Forces (SOF) and Special Operations Task Forces (SOTF) application to tactical and strategic platforms in accordance with MTA authorities and regulations and the Capability Development Document (CDD). FAMS-S will reduce technological risk by reviewing existing materials and technologies as well as designs, configurations, and test data from mature legacy and commercial decontamination systems. The program will utilize the CWMD Other Transaction Authority (OTA) agreement to competitively

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical	and Biological Defense Program	Date: March 2023
Appropriation/Budget Activity 0400 / 5	R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> <i>Defense Program - EMD</i>	Project (Number/Name) MT5 / Mitigate (SDD)
award projects to three vendors for the man-portable and three v perform technical evaluations, undergo developmental and opera preparation for the man-portable variant production decision in F	ational testing, and early user assessments to inform the fir	
IMPROVED NERVE AGENT TREATMENT CENTRALLY ACTIN	G (INATS CA)	
The Improved Nerve Agent Treatment System Centrally Acting (I countermeasure (MCM) treatments. Addition of scopolamine to e	, , , , , , , , , , , , , , , , , , ,	

countermeasure (MCM) treatments. Addition of scopolamine to existing treatments for nerve agent exposure increases survival of casualties compared to treatment without scopolamine. The contractors shall be the sponsor and conduct drug development activities to achieve Food and Drug Administration (FDA) approval of both a vialed product, and the drug-device combination product. Upon U.S. Food & Drug Administration (FDA) approval, a follow-on procurement contract will allow the contractor to manufacture and deliver sufficient quantities of the autoinjector to meet Full Operational Capability (FOC). Product sustainment will the responsibility of Defense Logistics Agency Troop Support. Post marketing commitments and requirements are anticipated as a result of FDA approval and will be the responsibility of the contractor and the government.

SERVICE EQUIPMENT DECONTAMINATION SYSTEM (SEDS)

The Joint Services Equipment Decontamination System (SEDS) and SOCOM Critical Equipment Decontamination System (CEDS) program will utilize the Countering Weapons of Mass Destruction Other Transaction Authority (CWMD OTA) to design and develop state of the art equipment using competitive and iterative prototyping. The program will test prototypes against live chemical warfare agents and biological warfare agents, conduct reliability, availability, and maintainability testing, conduct regular user evaluations to identify human system integration issues, and will conduct testing to ensure the system meets military standards. The program will use the Request for Prototype Proposals (RPP), under the CWMD OTA, followed by awards of Prototype Agreement.

In FY24, the Program will conduct MS B activities for Joint Services/SEDS and Special Operation Forces (SOF) CEDS will conclude Engineering, Manufacturing and Development (EMD) testing, conduct operational testing and limited user evaluations, and conduct a Critical Design Review (CDR) for SOF.

Exhibit R-3, RDT&E F	Project C	ost Analysis: PB 2	2024 Cher	mical and	l Biologica	al Defens	e Progran	n				Date:	March 20	023	
Appropriation/Budge 0400 / 5	t Activity	/				PE 060		Chemica	umber/Na al and Biol		-	t (Numbe i Mitigate (S			
Product Developmen	nt (\$ in M	illions)		FY 2	2022	FY 2	2023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
AUTOINJ - HW C - RAD-A	C/CPFF	TBD : N/A	-	0.000		10.558	Mar 2023	30.372	Dec 2023	-		30.372	Continuing	Continuing	0.000
AUTOINJ - HW C - Program Management Labor	Various	JPM CBRN Medical, JPEO-CBRND : Fort Detrick, MD	-	0.000		1.119	Dec 2022	1.670	Nov 2023	-		1.670	Continuing	Continuing	0.000
AUTOINJ - HW C - Program Management	C/CPFF	JPM CBRN Medical, JPEO-CBRND : Fort Detrick, MD	-	0.000		1.347	Dec 2022	2.011	Nov 2023	-		2.011	Continuing	Continuing	0.000
AV TX - Nonclinical Trials - OTA	C/FP	Gilead Sciences : San Francisco, CA	-	0.000		10.506	Dec 2022	0.000		-		0.000	0.000	10.506	0.000
CET RAIDR - Direct Product Support	Various	Various : N/A	-	0.000		0.000		1.254	Dec 2023	-		1.254	Continuing	Continuing	0.000
CET RAIDR-ENBD - Nonclinical Studies	Various	Various : N/A	-	0.000		7.268	Dec 2022	6.787	Dec 2023	-		6.787	Continuing	Continuing	0.000
CET RAIDR-ENBD - Direct Program Support	Various	Various : N/A	-	0.000		0.000		0.778	Dec 2023	-		0.778	Continuing	Continuing	0.000
DFoS CIDAS BLISTER - HW S - Small and Large Scale Applicators/Kits	SS/ Various	FLIR Systems, Inc. : Stillwater, OK	-	0.000		1.280	Jan 2023	0.000		-		0.000	0.000	1.280	0.000
FAMS-S - HW S - System Development and Prototype Refinement	C/CPIF	ATI Solutions, Inc. : Tysons Corner, VA	-	0.000		1.500	May 2023	0.000		-		0.000	0.000	1.500	0.000
INATS CA - HW C - Program Management Labor	Allot	JPM CBRN Medical, JPEO-CBRND : Fort Detrick, MD	-	0.000		0.000		1.234	Nov 2023	-		1.234	Continuing	Continuing	0.000
INATS CA - HW C - Clinical	C/CPFF	Battelle Memorial Institute : Columbus, OH	-	0.000		2.143	Dec 2022	3.531	Dec 2023	-		3.531	Continuing	Continuing	0.000
INATS CA - HW C - Non- Clinical	C/CPFF	Battelle Memorial Institute : Columbus, OH	-	0.000		3.904	Nov 2022	4.290	Dec 2023	-		4.290	Continuing	Continuing	0.000
INATS CA - HW C - Manufacturing	C/FFP	Aktivax : Boulder, CO	-	0.000		11.008	Dec 2022	3.915	Dec 2023	-		3.915	Continuing	Continuing	0.000

PE 0604384BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program

Exhibit R-3, RDT&E	Project C	ost Analysis: PB 2	2024 Che	mical and	Biologica	al Defens	e Progran	n			_	Date:	March 20	023	
Appropriation/Budge 0400 / 5	et Activity	1				PE 060		Chemica	umber/Na al and Biol			t (Numbe i Mitigate (S	,		
Product Developmer	nt (\$ in Mi	illions)		FY 2	022	FY 2	2023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
SEDS - HW S - SEDS - Prototypes	C/FFP	ATI Solutions, Inc. : Tysons Corner, VA	-	0.000		1.450	May 2023	3.453	Nov 2023	-		3.453	Continuing	Continuing	0.000
SEDS - HW S - CEDS	MIPR	Various : N/A	-	0.000		0.000		1.712	Jan 2024	-		1.712	Continuing	Continuing	0.000
		Subtotal	-	0.000		52.083		61.007		-		61.007	Continuing	Continuing	N/A
Support (\$ in Million	s)			FY 2	022	FY 2	2023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
DFoS CIDAS BLISTER - TD/D S - IPT and Technical Support	MIPR	Various : N/A	-	0.000		0.656	Nov 2022	0.375	Nov 2023	-		0.375	Continuing	Continuing	0.000
FAMS-S - ES S - Systems Engineer/Technical SME Support	MIPR	Various : N/A	-	0.000		0.750	Dec 2022	0.000		-		0.000	0.000	0.750	0.000
SEDS - ILS S - SEDS - Logistics, Engineering and IPT Support	MIPR	Various : N/A	-	0.000		0.900	Mar 2023	0.836	Nov 2023	-		0.836	Continuing	Continuing	0.000
SEDS - ILS S - CEDS	MIPR	Various : N/A	-	0.000		0.000		0.210	Nov 2023	-		0.210	Continuing	Continuing	0.000
		Subtotal	-	0.000		2.306		1.421		-		1.421	Continuing	Continuing	N/A
Test and Evaluation	(\$ in Milli	ons)		FY 2	022	FY 2	2023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
CET RAIDR - DTE C - Continuing Repurposing Efforts	Various	Various : N/A	-	0.000		6.964	Dec 2022	10.942	Dec 2023	-		10.942	Continuing	Continuing	0.000
DFoS CIDAS BLISTER - OTHT S - OTHT S - DT/ OT	MIPR	Various : N/A	-	0.000		1.462	Nov 2022	1.972	Nov 2023	-		1.972	Continuing	Continuing	0.000

PE 0604384BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program

Exhibit R-3, RDT&E P	Project C	ost Analysis: PB 2	024 Che	mical and	Biologic	al Defens	e Program	n				Date:	March 20	023	
Appropriation/Budge 0400 / 5	t Activity	1				PE 060	ogram Ele 4384BP / e Progran	Chemica			-	t (Numbe Mitigate (S			
Test and Evaluation (\$ in Milli	ons)		FY 2	2022	FY	2023		2024 ase		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
FAMS-S - DTE SB - Decon Solution Analysis	Various	TBD : N/A	-	0.000		0.288	Jan 2023	0.000		-		0.000	0.000	0.288	0.000
SEDS - OTHT S - SEDS - T&E IPR Test Planning	MIPR	Various : N/A	-	0.000		0.425	Mar 2023	0.944	Nov 2023	-		0.944	Continuing	Continuing	0.000
SEDS - OTHT S - CEDS T&E	MIPR	Various : N/A	-	0.000		0.000		3.177	Jan 2024	-		3.177	Continuing	Continuing	0.000
		Subtotal	-	0.000		9.139		17.035		-		17.035	Continuing	Continuing	N/A
Management Service	s (\$ in M	illions)		FY 2	2022	FY	2023		2024 ase		2024 CO	FY 2024 Total]		
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
AUTOINJ - PM/MS C - Management Services	Various	Various : N/A	-	0.000		1.702	Dec 2022	2.417	Nov 2023	-		2.417	Continuing	Continuing	0.000
CET RAIDR - PM/MS S - Indirect Management Support	Various	Various : N/A	-	0.000		0.907	Dec 2022	1.507	Dec 2023	-		1.507	Continuing	Continuing	0.000
CET RAIDR-ENBD - PM/MS S - Indirect Management Support	Various	Various : N/A	-	0.000		1.232	Dec 2022	0.935	Dec 2023	-		0.935	Continuing	Continuing	0.000
DFoS CIDAS BLISTER - PM/MS S - Program Management Support	MIPR	Various : N/A	-	0.000		0.283	Nov 2022	0.153	Nov 2023	-		0.153	Continuing	Continuing	0.000
FAMS-S - PM/MS S - Indirect Program Management	MIPR	Various : N/A	-	0.000		0.429	Dec 2022	0.000		-		0.000	0.000	0.429	0.000
INATS CA - PM/MS C - Management Services Labor	Various	JPEO Chem, Bio, Rad, and Nuc Defense (JPEO- CBRND) : Aberdeen Proving Ground, MD	-	0.000		4.595	Dec 2022	1.787	Nov 2023	-		1.787	Continuing	Continuing	0.000
INATS CA - PM/MS C - Management Services	Various	JPEO Chem, Bio, Rad, and Nuc	-	0.000		1.329	Dec 2022	1.486	Nov 2023	-		1.486	Continuing	Continuing	0.000

PE 0604384BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program

Exhibit R-3, RDT&E I	Project C	ost Analysis: PB 2	024 Che	mical and	Biologic	al Defens	e Progran	n				Date:	March 20)23	
Appropriation/Budge 0400 / 5	et Activity	,				PE 060	-	Chemica	umber/Na al and Biol	,	-	: (Numbe i <i>litigate (</i> S			
Management Service	es (\$ in M	illions)		FY 2	2022	FY 2	2023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
		Defense (JPEO- CBRND) : Aberdeen Proving Ground, MD													
SEDS - PM/MS C - SEDS - PM/MS S - Program Management Support	MIPR	Various : N/A	-	0.000		0.220	Mar 2023	0.341	Nov 2023	-		0.341	Continuing	Continuing	0.000
SEDS - PM/MS C - CEDS	MIPR	Various : N/A	-	0.000		0.000		0.352	Nov 2023	-		0.352	Continuing	Continuing	0.000
		Subtotal	-	0.000		10.697		8.978		-		8.978	Continuing	Continuing	N/A
			Prior Years	FY 2	2022	FY 2	2023		2024 Ise		2024 CO	FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract
		Project Cost Totals	-	0.000		74.225		88.441		-		88.441	Continuing	Continuing	N/A

Remarks

Exhibit R-4, RDT&E Schedule Profile: PB 2024 (Cher	nica	and	Bio	logic	cal D	Defe	nse	Prog	gram	ו											Date	e: Ma	arch	202	3		
Appropriation/Budget Activity 0400 / 5								PE		1384	BP /	l Che	emi	ical a	nber and E						•		er/N ′SDE		e)			
		-	2022			-	202	_		r	2024	1		-	2025	1		1	202	1		-	2027			FY 20		
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
AUTOINJ - Development																												
AUTOINJ - Manufacturing																												
AUTOINJ - Prototyping and Testing	_													_														
AUTOINJ - Dual Drug Delivery Device (D4)		_																										
AUTOINJ - Government Testing																												
AUTOINJ - RAD - A																												
AV TX - sNDA (Marburg)	_															-												
AV TX - Natural History Study (Marburg)																												
AV TX - Animal Efficacy Studies (Marburg)																												
CET RAIDR - Advance Development Efforts to Repurpose FDA Approved Products																												
CET RAIDR-ENBD - Advance Development Efforts to Repurpose FDA Approved Products																												
DFoS CIDAS BLISTER - Sustainment Cost Reduction Plan (SCRP)																												
DFoS CIDAS BLISTER - DT&E-Developmental Test and Evaluation - Phase 1	I																											
DFoS CIDAS BLISTER - System Verification Review (SVR)/Production Readiness Review																												
DFoS CIDAS BLISTER - Functional Configuration Audit (FCA)																												
DFoS CIDAS BLISTER - DT&E-Developmental Test and Evaluation - Phase 2	I																											
DFoS CIDAS BLISTER - OT&E-Operational Test and Evaluation - CIDAS Blister										l																		
DFoS CIDAS BLISTER - Manufacturing Readiness Assessment																												

PE 0604384BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program UNCLASSIFIED Page 78 of 158

R-1 Line #132

xhibit R-4, RDT&E Schedule Profile: PB 2024 C	Cher	nica	l and	d Bio	logi	cal D	Defe	nse F	Prog	gram											D	ate	: Ma	arch 2	202	3		
ppropriation/Budget Activity 400 / 5								PE 0	604	gram 1384E 9 <i>Prog</i>	BP /	Chen	nica						r oje 1T5 /)			
		_	202	_			2023			FY 20				Y 20				′ 20					027			FY 2		8
DFoS CIDAS BLISTER - Physical Configuration Audit	1	2	3	4	1	2	3	4	1	2	3	4 ⁻	1	2	3 4	/	1 2	2 :	3 4	1	1 1	2	3	4	1	2	3	4
DFoS CIDAS BLISTER - MS C-Milestone C																												
DFoS CIDAS BLISTER - FRP-Full Rate Production Decision																												
DFoS CIDAS BLISTER - IOC-Initial Operational Capability																												
DFoS CIDAS BLISTER - FOC-Full Operational Capability - CIDAS Blister																												
FAMS-S - PDR-Preliminary Design Review - Man-Portable Variant																												
FAMS-S - CDR-Critical Design Review - Man- Portable Variant																												
FAMS-S - MTA Outcome Decision Memorandum-Middle Tier Acquisition Outcome Decision Memorandum - Man-Portable Variant																												
FAMS-S - OT&E-Operational Test and Evaluation - Man-Portable Variant																												
FAMS-S - PDR-Preliminary Design Review - Small/Large Variants																												
FAMS-S - OT&E-Operational Test and Evaluation - Small/Large Variants																												
FAMS-S - CDR-Critical Design Review - Small/ Large Variants																									-			
FAMS-S - MTA Outcome Decision Memorandum-Middle Tier Acquisition Outcome Decision Memorandum - Small/Large Variants	!																											
FAMS-S - IOC-Initial Operational Capability - All Variants																												

PE 0604384BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program UNCLASSIFIED Page 79 of 158

khibit R-4, RDT&E Schedule Profile: PB 2024 C	Che	mica	al ar	nd Bi	ologi	cal	Defe	ense	e Pro	gra	am												[Date	e: M	arch	20 ו	23		
opropriation/Budget Activity 100 / 5								PE	060	43	r am I 84BF Progr	P/(Cherr	nica											er/N SDL		e)			
			20			_	202	_			Y 202			F	FY 2		5		_	20					2027	•			202	28
FAMS-S - FOC-Full Operational Capability - All Variants	1	2	2 (3 4	1	2	3	4	1		2 3	3	4 1		2	3	4	1	2		3	4	1	2	3	4	1	2	3	4
INATS CA - MS B-Milestone B																														
INATS CA - Clinical Trials																														
INATS CA - Manufacturing/Auto-Injector	_																													
INATS CA - Non-Clinical Studies	_																													
INATS CA - NDA Submission-New Drug Application Submission																														
INATS CA - FDA Approval-Food and Drug Administration Approval																														
INATS CA - SNAPP Modernization - BA7																														
INATS CA - PB Extended Release Tablet Development - BA7																														
SEDS - Prototype Agreement Award (SOF and Other Services)	I																													
SEDS - CDD Validation-Capability Development Document Validation - Other Services																														
SEDS - Early Developmental Testing (Other Services)																														
SEDS - MS B-Milestone B - Other Services																														
SEDS - DT&E-Developmental Test and Evaluation - Other Services																														
SEDS - MS C-Milestone C - Other Services																														
SEDS - FRP-Full Rate Production Decision - Other Services																														
SEDS - DT&E-Developmental Test and Evaluation - SOF																														

PE 0604384BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program UNCLASSIFIED Page 80 of 158

xhibit R-4, RDT&E Schedule Profile: PB 2024 C	her	nica	l and	l Bio	ologi	cal [Defer	nse	Prog	gram	۱											Da	te: M	arcl	h 20	23		
ppropriation/Budget Activity 400 / 5								ΡE	0604	4384		I Ch	nemi	cal a	nbei and E						•		ber/N (SDI		e)			
		FY	2022	2		FY	2023	3		FY :	2024	ŀ		FY	2025	5		FY	2026	5		FY	2027	7		FY	2028	8
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
SEDS - RFP-Development Request for Proposal Release Decision - SOF and Other Services						1	1		L								1	1		<u> </u>						-		_
SEDS - MS B-Milestone B - SOF																												
SEDS - MS C-Milestone C - SOF																												
SEDS - IOC-Initial Operational Capability - SOF																												_
SEDS - FOC-Full Operational Capability - SOF																												

Exhibit R-4A, RDT&E Schedule Details: PB 2024 Chemical and Biological De	fense Program			Da	ate: March	n 2023
Appropriation/Budget Activity 0400 / 5	R-1 Program Elem PE 0604384BP / Ch Defense Program -	nemical and		Project (Num MT5 / Mitigate		e)
Sch	edule Details					
		St	art		En	d
Events		Quarter	Year	Qua	rter	Year
AUTOINJ - Development		1	2022		1	2023
AUTOINJ - Manufacturing		1	2022		1	2023
AUTOINJ - Prototyping and Testing		1	2022		2	2023
AUTOINJ - Dual Drug Delivery Device (D4)		1	2022		1	2025
AUTOINJ - Government Testing		1	2022	:	2	2022
AUTOINJ - RAD - A		2	2023		4	2027
AV TX - sNDA (Marburg)		4	2023		2	2024
AV TX - Natural History Study (Marburg)		1	2022		1	2023
AV TX - Animal Efficacy Studies (Marburg)		1	2022		1	2023
CET RAIDR - Advance Development Efforts to Repurpose FDA Approved	Products	1	2023		1	2028
CET RAIDR-ENBD - Advance Development Efforts to Repurpose FDA App Products	proved	1	2024		4	2028
DFoS CIDAS BLISTER - Sustainment Cost Reduction Plan (SCRP)		1	2022	;	3	2022
DFoS CIDAS BLISTER - DT&E-Developmental Test and Evaluation - Phase	se 1	2	2022		1	2022
DFoS CIDAS BLISTER - System Verification Review (SVR)/Production Re Review	adiness	3	2023	:	3	2023
DFoS CIDAS BLISTER - Functional Configuration Audit (FCA)		4	2023		4	2023
DFoS CIDAS BLISTER - DT&E-Developmental Test and Evaluation - Phase	se 2	1	2024		1	2025
DFoS CIDAS BLISTER - OT&E-Operational Test and Evaluation - CIDAS I	Blister	1	2024		1	2024
DFoS CIDAS BLISTER - Manufacturing Readiness Assessment		1	2024		1	2024
DFoS CIDAS BLISTER - Physical Configuration Audit		2	2024		2	2024
DFoS CIDAS BLISTER - MS C-Milestone C		4	2024		1	2024
DFoS CIDAS BLISTER - FRP-Full Rate Production Decision		4	2024		4	2024

/5 PE (Program Element (Numb 0604384BP / Chemical an ense Program - EMD		Project (Number/Nam MT5 / Mitigate (SDD)	ne)
		Start	Er	nd
Events	Quarter	Year	Quarter	Year
DFoS CIDAS BLISTER - IOC-Initial Operational Capability	2	2027	2	2027
DFoS CIDAS BLISTER - FOC-Full Operational Capability - CIDAS Blister	2	2028	2	2028
FAMS-S - PDR-Preliminary Design Review - Man-Portable Variant	3	2022	3	2022
FAMS-S - CDR-Critical Design Review - Man-Portable Variant	2	2023	2	2023
FAMS-S - MTA Outcome Decision Memorandum-Middle Tier Acquisition Outco Decision Memorandum - Man-Portable Variant	me 3	2023	3	2023
FAMS-S - OT&E-Operational Test and Evaluation - Man-Portable Variant	2	2023	2	2023
FAMS-S - PDR-Preliminary Design Review - Small/Large Variants	4	2022	4	2022
FAMS-S - OT&E-Operational Test and Evaluation - Small/Large Variants	2	2024	2	2024
FAMS-S - CDR-Critical Design Review - Small/Large Variants	3	2024	3	2024
FAMS-S - MTA Outcome Decision Memorandum-Middle Tier Acquisition Outco Decision Memorandum - Small/Large Variants	me 3	2024	3	2024
FAMS-S - IOC-Initial Operational Capability - All Variants	3	2024	2	2026
FAMS-S - FOC-Full Operational Capability - All Variants	4	2028	4	2028
INATS CA - MS B-Milestone B	2	2022	2	2022
INATS CA - Clinical Trials	1	2022	4	2024
INATS CA - Manufacturing/Auto-Injector	1	2022	2	2025
INATS CA - Non-Clinical Studies	1	2022	2	2025
INATS CA - NDA Submission-New Drug Application Submission	1	2026	3	2026
INATS CA - FDA Approval-Food and Drug Administration Approval	3	2026	1	2028
INATS CA - SNAPP Modernization - BA7	1	2022	4	2025
INATS CA - PB Extended Release Tablet Development - BA7	1	2023	1	2026
SEDS - Prototype Agreement Award (SOF and Other Services)	4	2022	4	2022
SEDS - CDD Validation-Capability Development Document Validation - Other S	Services 1	2023	2	2023
SEDS - Early Developmental Testing (Other Services)	1	2023	3	2023
SEDS - MS B-Milestone B - Other Services	4	2023	4	2023

nibit R-4A, RDT&E Schedule Details: PB 2024 Chemical and Biological De	efense Program	1		Date: I	March 2023
propriation/Budget Activity 00 / 5		Element (Numbe P I Chemical and ram - EMD	,	Project (Number/ MT5 / Mitigate (SL	,
		St	art		End
Events		Quarter	Year	Quarter	Year
SEDS - DT&E-Developmental Test and Evaluation - Other Services		1	2024	3	2025
SEDS - MS C-Milestone C - Other Services		3	2026	3	2026
SEDS - FRP-Full Rate Production Decision - Other Services		4	2027	4	2027
SEDS - DT&E-Developmental Test and Evaluation - SOF		3	2022	4	2023
SEDS - RFP-Development Request for Proposal Release Decision - SOF Services	and Other	4	2022	4	2022
SEDS - MS B-Milestone B - SOF		3	2023	3	2023
SEDS - MS C-Milestone C - SOF		4	2024	4	2024
SEDS - IOC-Initial Operational Capability - SOF		2	2026	2	2026
SEDS - FOC-Full Operational Capability - SOF		4	2028	4	2028

Exhibit R-2A, RDT&E Project J	ustification	n: PB 2024 C	Chemical an	d Biologica	l Defense P	rogram				Date: Marc	ch 2023	
Appropriation/Budget Activity 0400 / 5				PE 060438	am Elemen 34BP / Cher rogram - EN	(Number/Name) nabling Investments (SDD)						
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
EN5: Enabling Investments (SDD)	-	0.000	13.392	13.835	0.000	13.835	13.884	14.179	14.197	14.261	Continuing	Continuing
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

The Enabling Investments System Development & Demonstration (SDD) Project provides the capability to rapidly develop, manufacture, and approve medical countermeasures through sustaining the Department of Defense advanced development manufacturing facility. Enabling efforts in this area support dedicated infrastructure capabilities, demonstrations, and overarching development support functions as portfolio enablers responding to emerging threats. Additional efforts facilitate incorporation of chemical and biological (CB) survivability equipment into Service major acquisition programs. In FY 2023, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. EN5 efforts in FY 2022 remain in Projects DE5 and MB5. This restructuring provided standardization and alignment across CBDP research, development and acquisition efforts.

Efforts included in this Project are:

(1) Chem Bio Incident Preparedness and Response - Advanced Development and Manufacturing (CBIPR-ADM)(2) Major Defense Acquisition Program (MDAP)

The CBIPR-ADM ensures prioritization to domestic biopharmaceutical manufacturing capacities, capabilities, and infrastructure (e.g. the DoD-ADM Facility and other strategic partners) that are operationally ready to rapidly develop and manufacture medical countermeasures (MCMs) against current and emerging chemical and biological threats including pandemic response. Prioritization is achieved by establishing and enhancing proven biopharmaceutical manufacturing platform technologies and infrastructure at these facilities. Thus, these facilities will have the capability to accelerate development of MCMs at all stages of development, enhance preparedness for existing threats, and rapidly respond to emerging threats as part of a medical integrated layered defense. MCMs that benefit from these efforts include: Vaccines for Viral Agents, Vaccines for Bacterial Agents and Toxins, monoclonal antibodies, antibody fragments and conjugates for therapeutic and prophylactic use across all agent classes. Funds to support prioritization and operational readiness were previously provided via individual product development and manufacturing funding lines. The Department is now providing dedicated funds. The CBIPR-ADM return on investment is an increased level of preparedness and responsiveness. In FY24, the CBIPR-ADM program continues to establish and enhance new manufacturing platform technologies and infrastructure that will enable the development of MCMs against chemical and biological threats.

The MDAP Chemical Biological Radiological and Nuclear (CBRN) Survivability Initiative ensures weapon system programs at all Acquisition Category (ACAT) levels, as well as non-DoD agency programs such as those at the Department of Homeland Security (DHS), meet their CBRN defense requirements. This effort facilitates and coordinates the research, development, test and evaluation, procurement, delivery, and life cycle sustainment of affordable CBRN defense materiel solutions for each program's documented CBRN requirements.

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical a	nd Biological Defense Program	Date:	March 2023			
Appropriation/Budget Activity 0400 / 5		Project (Number/Name) EN5 / Enabling Investments (SDD)				
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024		
Title: 1) CBIPR-ADM		-	10.974	11.46		
Description: ADM Infrastructure						
FY 2023 Plans: Continue activities to maintain the Department of Defense (DoD) A Countermeasure (MCM) development and manufacturing.	DM's capabilities in a state of readiness to support Medic	al				
FY 2024 Plans: Continue activities to enhance and optimize known manufacturing other strategic partner facilities in a state of operational readiness t countermeasure (MCMs). This approach ensures that the DoD's efforts and the state of	o support the development and manufacture of medical					
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.						
Title: 2) MDAP		-	2.418	2.37		
Description: CBRN Survivability Support						
FY 2023 Plans: Continue to ensure CBRN survivability requirements are met for M execution plans. Attend meetings to address integration needs and subject matter expertise in the execution of CBRN survivability requand assist in document preparation for milestones and programs recoptionally Manned Fighting Vehicle, Robotic Combat Vehicle, Future Aircraft, Synthetic Training Environment, Precision Navigation and survivability system integration in preparation for various program a production reviews.	d present CBRN system and hardware options. Provide uirements for both materiel and non-material solutions. R eviews. Conduct CBRN survivability compliance reviews f ire Long Range Assault Aircraft, Future Attack Reconnais Timing, multiple Soldier Lethality programs, and other CB	eview or sance				
FY 2024 Plans: Provide subject matter expertise in the execution of CBRN survival Review and assist in document preparation for milestones and progreviews for Optionally Manned Fighting Vehicle, Robotic Combat V Reconnaissance Aircraft, Synthetic Training Environment, Precisio	grams reviews. Conduct CBRN survivability compliance /ehicle, Future Long Range Assault Aircraft, Future Attack					

Exhibit R-2A, RDT&E Project Just	tification: PB	2024 Chem	ical and Biol	ogical Defen	se Program				Date: Ma	arch 2023			
Appropriation/Budget Activity 0400 / 5									oject (Number/Name) 15 I Enabling Investments (SDD)				
B. Accomplishments/Planned Pro	grams (\$ in N	<u>Millions)</u>						[FY 2022	FY 2023	FY 2024		
and other CBRN survivability system rate initial production reviews. <i>FY 2023 to FY 2024 Increase/Decr</i> Minor change due to routine program	rease Statem	ent:	n for various	program ac	quisition mile	estones, des	ign reviews a	nd low					
				Accon	nplishment	s/Planned P	rograms Sul	ototals	-	13.392	13.835		
C. Other Program Funding Summ	ary (\$ in Milli	ons <u>)</u>	EV 2024	EV 2024	EV 2024					Coot To			
Line Item	<u>FY 2022</u>	FY 2023	<u>FY 2024</u> <u>Base</u>	<u>FY 2024</u> <u>OCO</u>	<u>FY 2024</u> <u>Total</u>	<u>FY 2025</u>	<u>FY 2026</u>	FY 202	27 <u>FY 2028</u>	<u>Cost To</u> Complete	Total Cos		
 DE5: Decontamination (SDD) 	7.485	-	-	-	-	-	-			0.000	7.48		
• EN4: Enabling Investments (ACD&P)	-	6.781	47.272	-	47.272	51.579	9.792	9.84	9.840	Continuing	Continuing		
MB4: Medical Biological Defense (ACD&P)	46.791	-	-	-	-	-	-			0.000	46.79		
• MB5: Medical Biological Defense (SDD)	138.156	-	-	-	-	-	-			0.000	138.156		
Remarks													

D. Acquisition Strategy

CHEM BIO INCIDENT PREPAREDNESS AND RESPONSE - (CBIPR-ADM)

By establishing new capabilities at the DoD-ADM Facility and other strategic partners, the CBIPR-ADM line ensures that the DoD will have priority access to critical technologies and infrastructure that are operationally ready to support the rapid development and manufacture of MCMs. This approach ensures that the DoD's efforts are not limited to a single facility. In FY24, the CBIPR-ADM line will continue to establish, enhance, and optimize new manufacturing platform technologies and infrastructure to support the production of MCMs. These new manufacturing technologies can come from any government sources (including Joint Science & Technology Office for Chemical Biological Defense (JSTO-CBD), the Walter Reed Army Institute of Research (WRAIR), the Biomedical Advanced Research and Development Authority (BARDA), etc. when mature enough for BA4 funding) and/or other external sources and targets of opportunity from industry.

MAJOR DEFENSE ACQUISITION PROGRAM (MDAP)

MDAP effort provides CBRN capability requirements integration support to Major Defense Acquisition Programs, Services, and Program Executive Offices. Crosswalk requirements with program execution plans, introduce new/existing materiel solutions, develop common integrated CBRN solutions, support Modernization and Readiness efforts.

PE 0604384BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program

Exhibit R-3, RDT&E I	Project C	ost Analysis: PB 2	024 Che	mical and	l Biologic	al Defens	e Progran	n				Date:	March 20	023	
Appropriation/Budge 0400 / 5	et Activity	/				PE 060		Chemica	lumber/Na al and Biol			(Number Inabling Ir		ts (SDD)	
Product Developme	nt (\$ in M	illions)		FY 2	2022	FY 2	2023		2024 ase		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
CBIPR-ADM - Capability Optimization (Vero Cell Platform, BSAT Surrogate Platform)	C/CPFF	Ology : Alachua, FL	-	0.000		9.944	Dec 2022	10.763	Dec 2023	-		10.763	Continuing	Continuing	0.00
		Subtotal	-	0.000		9.944		10.763		-		10.763	Continuing	Continuing	N//
Support (\$ in Million	s)			FY 2	2022	FY 2	2023		2024 ase		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
MDAP - TD/D SB - IPT and Technical Support	MIPR	Various : N/A	-	0.000		2.081	Nov 2022	0.921	Jan 2024	-		0.921	•	Continuing	0.00
		Subtotal	-	0.000		2.081		0.921		-		0.921	Continuing	Continuing	N/A
Test and Evaluation	(\$ in Milli	ions)		FY 2	2022	FY 2	2023		2024 ase		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
MDAP - Robotic Sensors Testing	MIPR	Various : N/A	-	0.000		0.000		0.900	Mar 2024	-		0.900	Continuing	Continuing	0.00
		Subtotal	-	0.000		0.000		0.900		-		0.900	Continuing	Continuing	N/#
Management Service	es (\$ in M	illions)		FY 2	2022	FY	2023		2024 ase		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
CBIPR-ADM - PM/MS C - Program Management Support (SETA)	Various	JPL CBRND Enabling Biotechnologies, JPEO-CBRND : Fort Detrick, MD	-	0.000		1.030	Dec 2022	0.702	Dec 2023	-		0.702	Continuing	Continuing	0.00

PE 0604384BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program

Exhibit R-3, RDT&E	Project C	ost Analysis: PB 2	2024 Che	mical and	l Biologic	al Defens	e Progran	า				Date:	March 2	023	
Appropriation/Budg 0400 / 5	et Activity	PE 060	o gram Ele 4384BP / e <i>Program</i>	Chemica	t (Numbe Enabling Ir		ts (SDD)								
Management Servic	es (\$ in M	illions)		FY 2	2022	FY 2	2023		2024 ase		2024 CO	FY 2024 Total]		
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
MDAP - PM/MS S - Program Management Support	MIPR	Various : N/A	-	0.000		0.337	Nov 2022	0.549	Nov 2023	-		0.549	Continuing	continuing	0.000
		Subtotal	-	0.000		1.367		1.251		-		1.251	Continuing	Continuing	N/A
			Prior Years	FY 2	2022	FY 2	2023		2024 ase		2024 CO	FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract
		Project Cost Totals	-	0.000		13.392		13.835		-		13.835	Continuing	Continuing	N/A

Remarks

Exhibit R-4, RDT&E Schedule Profile: PB 2024	Cher	nical a	and B	olo	gical	Defe	ense	Prog	gram									Dat	e: M	arch	202	23	
Appropriation/Budget Activity 0400 / 5							PE	0604	gram I 1384BF e <i>Progr</i>	' I Ch	emi	cal ar				ojec N5 / L	•				,	: (SDE))
		FY 2	022		FY	202	3		FY 202	24		FY 2	025	F١	(202	26		FY	2027	7		FY 20	28
	1	2	3 4	ŀ	1 2	3	4	1	2 3	4	1	2	3 4	1 2	2 3	4	1	2	3	4	1	2	3 4
CBIPR-ADM - MCM Enabling Manufacturing Technologies																							
CBIPR-ADM - MCM Development and Manufacturing Support (Infrastructure)																							
MDAP - Engage with services to develop relationships for CBRN requirements																							

Exhibit R-4A, RDT&E Schedule Details: PB 2024 Chemical and Biological De	fense Program		Da	ate: March	2023						
ppropriation/Budget ActivityR-1 Program Element (Number/Name)Project (Number/Name)400 / 5PE 0604384BP / Chemical and Biological Defense Program - EMDEN5 / Enabling Investments											
Sch	edule Details	Start		End							
Events	Quarter	Year	Qua	arter	Year						
CBIPR-ADM - MCM Enabling Manufacturing Technologies	1	2022	4	4	2028						
CBIPR-ADM - MCM Development and Manufacturing Support (Infrastructu	re) 1	2022	4	4	2028						
MDAP - Engage with services to develop relationships for CBRN requirem	ents 1	2022	4	4	2028						

Exhibit R-2A, RDT&E Project Ju	stification	: PB 2024 C	hemical an	d Biologica	l Defense P	rogram				Date: Marc	ch 2023	
Appropriation/Budget Activity 0400 / 5		PE 060438	a m Elemen 34BP / Chen rogram - EN	(Number/Name) ontamination Avoidance (SDD)								
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
CA5: Contamination Avoidance (SDD)	-	84.967	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	84.967
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

This project supports Engineering and Manufacturing Development (EMD) and Low Rate Initial Production (LRIP) of an array of reconnaissance, detection and identification equipment, and warning systems. After FY 2022, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. CA5 efforts in FY 2022 progress to Project UN5. This restructuring provides standardization and alignment across CBDP research, development and acquisition efforts.

Efforts included in this Project are:

(1) Advanced Emerging Threat Defense (AET DEFENSE) ** Progresses to UN5 in FY2023**,

(2) Aerosol & Vapor Chemical Agent Detector (AVCAD) ** Progresses to UN5 in FY2023**,

(3) Multi-Phase Chemical Agent Detector (MPCAD) ** Progresses to UN5 in FY2023**,

(4) Chemical Biological Radiological and Nuclear (CBRN) Sensor Integration on Robotics Platforms (CSIRP) ** Progresses to UN5 in FY2023**,

(5) Joint Biological Tactical Detection System (JBTDS) ** Progresses to UN5 in FY2023**,

(6) Nuclear Biological Chemical Reconnaissance Vehicle Sensor Suite Upgrade (NBCRV SSU) ** Progresses to UN5 in FY2023**, and

(7) Reactive Chemistry Orthogonal Surface and Environmental Threat Ticket Array (ROSETTA)

The AET DEFENSE program continues to address the highest priority CBRN gaps and supports the Chemical Biological Defense Program (CBDP) Strategic Line of Effort to meet current and emerging threats by anticipating chemical and biological (CB) hazards and developing capabilities to counter emerging and future threats. The AET Defense program collaborates with the Joint Services, interagency, and international partners to align RDT&E resources to determine readiness against emerging threats, to include Non-Traditional Agents (NTAs), such as Novichoks and Pharmaceutical-Based Agents (PBA) (e.g. synthetic opioids), emerging biological threats, and other advanced and emerging threats as they are identified across the entire CBDP enterprise portfolio.

AVCAD is a man portable system to detect aerosol and vapor chemical agents. AVCAD fills critical gaps in current Joint Force chemical sensor capabilities, in the areas of liquid, solid and dusty aerosol Chemical Warfare Agent detection, and detection of specific advanced threats/Non-Traditional Agents. The AVCAD will also detect low-level off-gassing, or residual vapors, to prevent/mitigate health effects associated with low concentration exposures, and perform remote alarm warning and reporting. AVCAD will support chemical and biological defense missions, including monitoring, collective protection, base defense, decontamination, unmasking, reconnaissance, and shipboard and aviation platform chemical detection. In FY24, AVCAD will execute and complete production and deployment testing.

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and	nd Biological Defense Program	Date: March 2023
Appropriation/Budget Activity 0400 / 5	R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> <i>Defense Program - EMD</i>	Project (Number/Name) CA5 / Contamination Avoidance (SDD)
The MPCAD is a two-person portable system that will conduct near operator in a presumptively contaminated area. The MPCAD result decontamination, and treatment measures. The Army and Marine substantiate presumptive detector results. The Air Force will employ missions by monitoring the environment at airbases after a chemic levels through analysis of samples from collectors deployed at the information will support commander decisions to determine Mission	Its will support the Commander's tactical and operationa Corps will employ MPCAD in Dismounted Reconnaissan by the MPCAD to support Post-Event Reconnaissance in al release. The Air Force will continuously monitor conta contamination site and brought back to the analyzer for	I decisions regarding maneuver, protection, nce and Site Assessment missions to n support of Reconnaissance and Surveilland aminated areas for chronic health effects identification and quantification. This
CSIRP is a prototyping and fielding effort that will focus on repacka Aircraft Systems (UAS), Unmanned Surface Vessels (USV) and Ur in order to enable freedom of maneuver and action on the battlefiel and autonomy, sensing and communication capabilities that enable maneuver forces and individual Warfighter in mounted and dismou standoff detection and provide upgrades to CBRN autonomy, map	nmanned Ground Vehicles (UGV) to provide situational a ld. An integrated CSIRP capability will exploit advances a timely and accurate detection, warning and reporting o nted operations at the tactical and operational levels. Ur	awareness across the echelons of command in artificial intelligence, machine learning f CBRN hazards. CSIRP reduces risk to the nder Project UN5, in FY24 CSIRP will integra
JBTDS is the first tactical lightweight, low-cost biological surveilland components are man-portable, battery operable and easy to emplo awareness to protect and preserve the forces and can archive a sa providing a theater-wide array capable of biological detection, iden surface sampling capability which interfaces with the JBTDS identities support the low rate initial production (LRIP) decision.	by by any military user. JBTDS provides notification of a ample for follow up analysis. When networked, JBTDS a tification and warning to support time sensitive force pro	hazard and enhances battle-space sugments existing biological detection system tection decisions. The JBTDS provides
Nuclear Biological Chemical Reconnaissance Vehicle Sensor Suite Biological Radiological and Nuclear (CBRN) reconnaissance and s & facilitate proactive risk-based decisions, to ensure freedom of ac an Acquisition Category (ACAT) II modification work order (MWO) maneuverability of the force, and standoff distance from the threat,	urveillance. The NBCRV SSU will answer the command tion and maintain maneuver momentum in Large Scale effort to modernize the current NBCRV Sensor Suite to	er's priority intelligence requirements Combat Operations. NBCRV SSU is increase maintainability, reliability,
The ROSETTA is a modernization effort to provide a higher confide timely decisions for the general forces. These decisions will reduce chemical threats. ROSETTA is based on colorimetric technologies addition, the ROSETTA tickets will provide improved hazard detect reduced detection time especially for compounds of interest (Chem and Toxic Industrial Chemicals (TICs)), and potential for integration	e casualties and improve the combat effectiveness of tro and will be eye-readable and ease the Warfighter from tion performance with reduced false alarm rate, potential nical Warfare Agents (CWA), Pharmaceutical Based Age	pops engaged in conflicts involving the use of current training and operational burden. In I for increased number of chemicals detected ents (PBAs), Non-Traditional Agents (NTAs),

discontinues after FY23.

Exhibit R-2A, RDT&E Project Justification: PB 2024 Ch	nemical and Biological Defense Program	Date: M	larch 2023	
Appropriation/Budget Activity 0400 / 5	R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> <i>Defense Program - EMD</i>	Project (Number/N CA5 / Contamination		(SDD)
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
Title: 1) AET DEFENSE		2.567	-	-
Description: Program Management, Product Developme be TRL 6 or higher in order to rapidly field solutions to cor	nt, Support, and Testing of technologies that have been demonstrat nbat emerging threats.	ted to		
Title: 2) AVCAD		12.640	-	-
Description: Product Development/Testing				
Title: 3) AVCAD		3.685	-	
Description: Support Costs/Program Management				
Title: 4) MPCAD - Product Development		7.010	-	
Description: Product Development				
<i>Title:</i> 5) MPCAD - Testing		4.804	-	
Description: Testing				
Title: 6) MPCAD - Program Support		1.159	-	-
Description: Program Management Support				
Title: 7) CSIRP		15.653	-	-
Description: Product Development, Program Manageme	nt, Test and Evaluation and Support.			
Title: 8) JBTDS		2.146	-	
Description: Test & Evaluation				
Title: 9) JBTDS		7.544	-	
Description: EMD Contract & Program Management				
Title: 10) NBCRV SSU		27.551	-	
Description: CBRN Sensor Development and Integration				
Title: 11) ROSETTA - M8		0.208	-	

PE 0604384BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program UNCLASSIFIED Page 94 of 158

Exhibit R-2A, RDT&E Project Justi	fication: PB	2024 Chemi	ical and Biol	ogical Defen	se Program				Date: Ma	arch 2023	
Appropriation/Budget Activity 0400 / 5	PE 06	-	nent (Numb Chemical and - EMD		Project (Number/Name) CA5 / Contamination Avoidance (Sl						
B. Accomplishments/Planned Prog	grams (\$ in N	<u>/lillions)</u>						F	Y 2022	FY 2023	FY 2024
Description: Product Development &	& Technical A	Assessment	of the M256	A2 Kit.							
				Accon	nplishment	s/Planned P	rograms Su	btotals	84.967	-	-
C. Other Program Funding Summa	ry (\$ in Milli	ons <u>)</u>									
			<u>FY 2024</u>	<u>FY 2024</u>	<u>FY 2024</u>					<u>Cost To</u>	
Line Item	<u>FY 2022</u>	<u>FY 2023</u>	Base	000	<u>Total</u>	<u>FY 2025</u>	FY 2026	<u>FY 2027</u>	<u>FY 2028</u>	<u>Complete</u>	Total Cos
 CA4: Contamination 	37.189	-	-	-	-	-	-	-	-	0.000	37.18
Avoidance (ACD&P)											
 CA7: Contamination 	12.244	-	-	-	-	-	-	-	-	0.000	12.24
Avoidance (Op Sys Dev)											
 UN5: Understand (SDD) 	-	126.071	182.726	-	182.726	137.991	127.671	108.908		Continuing	
 UN7: Understand (Op Sys Dev) 	-	40.414	50.603	-	50.603	58.881	71.869	68.839	50.628	Continuing	Continuing
MC0100: Joint NBC	-	-	-	-	-	-	-	-	-	0.000	0.00
Reconnaissance System (JNBCRS)											
MX0001: Joint Bio Tactical	17.060	-	7.025	-	7.025	22.238	17.385	44.150	44.150	Continuing	Continuing
Detection System (JBTDS)											
• SA0005: CBRN Sensor Integration	3.461	2.099	-	-	-	-	-	-	-	0.000	6.06
On Robotic Platforms (CSIRP)											
SA0015: Aerosol Vapor	-	-	2.458	-	2.458	43.262	55.762	66.237	43.029	Continuing	Continuing
Chemical Agent Detector (AVCAD)											
SA0017: Multiphase Chemical	6.502	4.014	13.561	-	13.561	21.852	36.758	37.261	0.829	Continuing	Continuing
Agent Detector (MPCAD)											

<u>Remarks</u>

D. Acquisition Strategy

ADVANCED AND EMERGING THREAT DEFENSE (AET DEFENSE)

The AET DEFENSE program will use a variety of acquisition approaches to survey, develop, assess, and rapidly field technologies to inform and fill advanced and emerging threat gaps. The program will utilize an existing Multiple Award Indefinite Delivery Indefinite Quantify Task Order Contract to provide technical support to studies and assessments of performance against emerging threats. For Program of Record (PoR) systems currently in development that will be assessed for performance against emerging threats will be modified to incorporate development engineering and test support for emerging threat

PE 0604384BP: Chemical and Biological Defense Program ... Chemical and Biological Defense Program

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical a	nd Biological Defense Program	Date: March 2023
Appropriation/Budget Activity 0400 / 5	R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> <i>Defense Program - EMD</i>	Project (Number/Name) CA5 / Contamination Avoidance (SDD)
capability. The AET DEFENSE program will utilize Other Transac Agencies and Federally Funded Research and Development Cent		
AEROSOL VAPOR CHEMICAL AGENT DETECTOR (AVCAD)		
Aerosol & Vapor Chemical Agent Detector (AVCAD) awarded two AVCAD program is conducting full EMD Record Testing in suppor forward with LRIP option award.		
MULTI-PHASE CHEMICAL AGENT DETECTOR (MPCAD)		
The Multi-Phase Chemical Agent Detector (MPCAD) (formerly NG Weapons of Mass Destruction (CWMD) Other Transaction Authori on Federal Acquisition Regulation based contract. The program w competition and minimize production price.	ity (OTA) for EMD and LRIP items. The MPCAD will proc	cure production items through a follow-
CBRN SENSOR INTEGRATION ON ROBOTIC PLATFORMS (CS	SIRP)	
CSIRP is a streamlined and tailored acquisition effort to rapidly pro unmanned CBRN payload prototypes in cyclic prototyping plan cyclic in order to keep pace with industry and the rapid advancement of the Transactional Agreements (OTA) contract vehicle. Upon award, the selected (air and/or ground) platforms. These prototypes will be d prototypes will be transitioned to the platforms and services for the integration, demonstrations, testing, development of interface cont residual capabilities and final configurations to Program of Record	cles based on service requirements. The prototyping plat technologies. The CSIRP strategy is to utilize the rapid p he awardees will have two to three years to produce proto emonstrated, evaluated and tested by the Services as we e next steps in acquisition, production and eventual fieldin trol documentation, and operational assessments of proto	ns will use a streamlined acquisition process prototyping process enabled by the Other otype sensors that are integrated onto servi ell as laboratories and academia. Success ng across the services. BA5 funding provide
JOINT BIO TACTICAL DETECTION SYSTEM (JBTDS)		
The JBTDS program utilizes a streamlined acquisition strategy lev options for Low Rate Initial Production (LRIP) and Full Rate Produ the current contract to award both the LRIP and FRP options. To congruently with the JBDTS LRIP and FRP options. The JBTDS p the need for potential technology insertion to provide more cost eff	ction (FRP). The JBTDS is moving towards a Milestone support the National Guard requirement, the Joint Handh program uses an agile acquisition strategy which leverage	C decision in third quarter FY23, utilizing eld Biological Identifier (JHBI) will award

	nd Biological Defense Program	Date: March 2023
ppropriation/Budget Activity 400 / 5	R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> <i>Defense Program - EMD</i>	Project (Number/Name) CA5 / Contamination Avoidance (SDD)
luclear Biological Chemical Reconnaissance Vehicle Sensor Suite	Upgrade	
luclear Biological Chemical Reconnaissance Vehicle Sensor Suite luclear Biological Chemical Reconnaissance Vehicle Sensor Suite council (AROC) Review Board (ARB) decided on 1 FEB 2022 to co apability) as a bridge to CS2.2 (full SSU capability). The NBCRV 2022, and will continue testing through October 2023, to inform a C n FY23 to execute an MWO for CS2.1 production and fielding, star august 2024, followed by testing in FY24 through early FY26 to infor REACTIVE CHEMISTRY ORTHOGONAL SURFACE AND ENVIRC ROSETTA will use a streamlined approach to rapidly field multiple of ehicles including Countering Weapons of Mass Destruction (CWM 18 component to the M256 kit and will support the acquisition of a agents and Toxic Industrial Chemicals.	e Upgrade (NBCRV SSU) is an upgrade for the Stryker N ontinue a Modification Work Order (MWO) pathway for C SSU program received prototype CS2.1 systems via Oth conditional Materiel Release Decision in FY24. An In Pro- ting in FY24. The NBCRV SSU program will receive pro- form the CS2.2 MWO Full Materiel Release Decision in F ONMENTAL THREAT TICKET ARRAY (ROSETTA) components of the modernization of the M256A2 kit. The ID) Other Transactional Authority (OTA). The ROSETTA	apability Set 2.1 (CS2.1) (initial SSU ler Transaction Authority (OTA) in March ogress Review (IPR) will be held starting ototype CS2.2 systems via another OTA in Y26. ese efforts will utilize multiple contract A funding will complete the acquisition of th

Exhibit R-3, RDT&E F	Project C	ost Analysis: PB 2	2024 Cher	nical and	d Biologica	al Defense	e Prograr	n				Date:	March 20	23	
Appropriation/Budge 0400 / 5	et Activity	/				PE 0604		ement (N Chemica n - EMD				: (Numbe i Contamina	r/ Name) tion Avoid	lance (SI))
Product Developmer	nt (\$ in M	illions)		FY	2022	FY 2	023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
AET DEFENSE - SW C - Prototyping and Modification	Various	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	-	0.931	Jan 2022	0.000		0.000		-		0.000	0.000	0.931	0.000
AET DEFENSE - HW S - System Prototyping and Modification	Various	Various : N/A	-	0.369	Dec 2021	0.000		0.000		-		0.000	0.197	0.566	0.000
AVCAD - Government Product Development Team Labor	MIPR	Various : N/A	4.520	2.001	May 2022	0.000		0.000		-		0.000	0.000	6.521	0.000
AVCAD - HW S - EMD Contract- Smiths Detection	C/CPIF	Smiths Detection : Edgewood, MD	20.975	8.193	Nov 2021	0.000		0.000		-		0.000	0.000	29.168	0.000
MPCAD - HW S - EMD Contract	C/CPFF	FLIR Systems, Inc. : West Lafayette, IN	22.520	2.475	Dec 2021	0.000		0.000		-		0.000	0.000	24.995	0.000
MPCAD - HW C - Contractor Product Development Team Labor	C/FFP	Kalman & Company Inc. : Virginia Beach, VA	0.408	0.385	Dec 2021	0.000		0.000		-		0.000	0.000	0.793	0.000
MPCAD - PM/MS S - Government Product Development Team Labor	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	5.962	1.932	Nov 2021	0.000		0.000		-		0.000	0.000	7.894	0.000
MPCAD - HW S - EMD Contract	C/CPFF	Signature Science : Austin, TX	32.314	2.218	Dec 2021	0.000		0.000		-		0.000	0.000	34.532	0.000
CSIRP - HW C - Contractor Product Development Labor	C/FFP	Various : N/A	0.318	0.558	Feb 2022	0.000		0.000		-		0.000	0.000	0.876	0.000

PE 0604384BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program

Exhibit R-3, RDT&E	Project C	ost Analysis: PB 2	2024 Cher	nical and	d Biologica	al Defense	e Prograr	n				Date:	March 20	23	
Appropriation/Budge 0400 / 5	et Activity	/				PE 0604		Chemica	lumber/N al and Bio			t (Numbe i Contamina		ance (SI	(סכ
Product Developmer	nt (\$ in M	illions)		FY	2022	FY 2	023		2024 ase		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
CSIRP - HW C - Development and Integration	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	0.679	1.493	Dec 2021	0.000		0.000		-		0.000	0.000	2.172	0.000
CSIRP - HW C - Government Product Development Team Labor	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	1.383	1.239	Dec 2021	0.000		0.000		-		0.000	0.000	2.622	0.000
CSIRP - SW C - Sensor Integration	C/CPFF	FLIR Systems Inc. : Elkridge, MD	-	2.976	Jun 2022	0.000		0.000		-		0.000	0.000	2.976	0.000
CSIRP - HW C - RN Sensor Prototype and Integration	C/FFP	Radiation Monitoring Devices, Inc : Boston, MA	0.615	0.030	May 2022	0.000		0.000		-		0.000	0.000	0.645	0.000
CSIRP - SW C - Sensor Integration	C/CPFF	Charles Stark Draper Laboratories, Inc. : Cambridge, MA	1.500	2.624	Nov 2021	0.000		0.000		-		0.000	0.000	4.124	0.000
CSIRP - HW C - Chemical Sensor Prototype and Integration	C/FFP	Intelligent Optical Systems (IOS) : Torrance, CA	0.485	0.239	Nov 2021	0.000		0.000		-		0.000	0.000	0.724	0.000
CSIRP - SW C - UAS and Sensor Manufacturing and Design	C/CPFF	T2S Solutions (T2S, LLC) : Belcamp, MD	1.687	1.600	Dec 2021	0.000		0.000		-		0.000	0.000	3.287	0.000
JBTDS - HW C - EMD Contract Award	C/CPIF	Chemring Detection Systems, Inc. : Charlotte, NC	37.021	3.898	Dec 2021	0.000		0.000		-		0.000	0.000	40.919	0.000
JBTDS - HW C - Program Team Labor	MIPR	Various : N/A	28.547	1.659	Nov 2021	0.000		0.000		-		0.000	0.000	30.206	0.000

PE 0604384BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program

Appropriation/Budge 0400 / 5	t Activity	/			l Biologica	R-1 Pro PE 0604	gram Ele	ement (N Chemica		,		: (Numbe i Contamina	r/ Name) tion Avoid	ance (SI	(סכ
Product Developmen	nt (\$ in M	illions)		FY	2022	FY 2	023	FY 2 Ba			2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
JBTDS - HW C - JHBI	C/CPFF	Biomeme : Philadelphia, PA	1.752	0.562	Mar 2022	0.000		0.000		-		0.000	0.000	2.314	0.000
NBCRV SSU - HW C - Government Product Development Team Labor	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	-	2.590	Dec 2021	0.000		0.000		-		0.000	0.000	2.590	0.000
NBCRV SSU - SW C - Integration	C/FFP	FLIR Systems Inc. : Elkridge, MD	-	2.830	Dec 2021	0.000		0.000		-		0.000	0.000	2.830	0.000
NBCRV SSU - HW C - Chemical Surface Detector Development	C/CPFF	FLIR Systems Inc. : Elkridge, MD	-	2.733	Jan 2022	0.000		0.000		-		0.000	0.000	2.733	0.000
NBCRV SSU - HW C - Contractor Team Labor	C/FFP	Various : N/A	-	0.896	Feb 2022	0.000		0.000		-		0.000	0.000	0.896	0.000
NBCRV SSU - SW C - Virtual Un-manned Platform Trainer	C/FFP	Various : N/A	-	0.898	Aug 2022	0.000		0.000		-		0.000	0.000	0.898	0.000
NBCRV SSU - HW C - cSDS On the Move	C/FFP	Various : N/A	-	2.774	Sep 2022	0.000		0.000		-		0.000	0.000	2.774	0.000
ROSETTA - HW C - Government Product Development Core Team Labor	MIPR	JPM CBRN Sensors, JPEO-CBRND : Aberdeen Proving Ground, MD	0.573	0.054	Nov 2022	0.000		0.000		-		0.000	0.000	0.627	0.000
		Subtotal	161.259	48.157		0.000		0.000		-		0.000	0.197	209.613	N/A

Exhibit R-3, RDT&E	Project C	ost Analysis: PB 2	024 Cher	nical and	d Biologica	al Defens	e Progra	m				Date:	March 20	23	
Appropriation/Budge 0400 / 5	et Activity	/				PE 060		ement (N I Chemica n - EMD				(Numbe Contamina	r/ Name) tion Avoia	lance (SI	(סכ
Support (\$ in Million	s)		ſ	FY	2022	FY 2	2023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
AVCAD - ES C - OGA support (IPTs)	MIPR	Various : N/A	2.132	2.011	May 2022	0.000		0.000		-		0.000	0.000	4.143	0.000
CSIRP - ES C - Engineering Support	Various	Various : N/A	1.421	0.981	Dec 2021	0.000		0.000		-		0.000	0.000	2.402	0.000
JBTDS - Engineering Support	MIPR	Various : N/A	1.602	0.414	Jun 2022	0.000		0.000		-		0.000	0.000	2.016	0.000
JBTDS - OTA/OGA Service Representation	MIPR	Various : N/A	14.749	0.678	Mar 2022	0.000		0.000		-		0.000	0.000	15.427	0.000
NBCRV SSU - ILS C - Logistic Support	C/FFP	Various : N/A	-	0.938	Feb 2022	0.000		0.000		-		0.000	0.000	0.938	0.000
NBCRV SSU - ES C - Engineering Support	MIPR	Various : N/A	-	1.020	Apr 2022	0.000		0.000		-		0.000	0.000	1.020	0.000
NBCRV SSU - Stryker NBCRV Maintenance	C/FFP	General Dynamics Land Systems : Detroit, MI	-	2.154	Mar 2022	0.000		0.000		-		0.000	0.000	2.154	0.000
NBCRV SSU - ES C - Contract and Product Support	Various	Various : N/A	-	0.313	Dec 2021	0.000		0.000		-		0.000	0.000	0.313	0.000
		Subtotal	19.904	8.509		0.000		0.000		-		0.000	0.000	28.413	N/A
Test and Evaluation	(\$ in Milli	ions)	ſ	FY	2022	FY 2	2023	FY 2 Ba	2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
AET DEFENSE - OTHT C - Product Demonstration Events for Users	MIPR	Various : N/A	-		Feb 2022	0.000		0.000		-		0.000	0.000	0.441	0.000
AET DEFENSE - DTE S - Technology Assessments	Various	Various : N/A	-	0.745	Dec 2021	0.000		0.000		-		0.000	0.000	0.745	0.000
AVCAD - OTE C - DT/ OT Chemical Chamber & Chemical Purchase for Chamber	MIPR	U.S. Army Combat Capabilities Development Command	5.833	2.092	Nov 2021	0.000		0.000		-		0.000	0.000	7.925	0.000

PE 0604384BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program UNCLASSIFIED Page 101 of 158

Exhibit R-3, RDT&E F Appropriation/Budge 0400 / 5		•	.024 01101			R-1 Pro PE 0604	gram Ele	ement (N Chemica	umber/Na al and Biol		-	(Number	March 20 / Name) tion Avoid		סכ)
Test and Evaluation	(\$ in Milli	ons)		FY	2022	FY 2	023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
		(DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD													
AVCAD - OTE C - DT/OT Test Activities	MIPR	Various : N/A	7.595	0.354	Jul 2022	0.000		0.000		-		0.000	0.000	7.949	0.00
MPCAD - DTE C - DT/OT Chemical Chamber Event	MIPR	West Desert Test Center : Dugway, UT	6.350	2.460	Jan 2022	0.000		0.000		-		0.000	0.000	8.810	0.00
MPCAD - DTE C - Various	MIPR	Various : N/A	3.312	1.887	Jan 2022	0.000		0.000		-		0.000	0.000	5.199	0.00
MPCAD - DTE C - Support	MIPR	Aberdeen Test Center (ATC) : Aberdeen Proving Ground, MD	2.264	0.457	Nov 2021	0.000		0.000		-		0.000	0.000	2.721	0.00
CSIRP - DTE C - JHU-APL	MIPR	Johns Hopkins University - Applied Physics Lab : Laurel, MD	0.400	1.367	May 2022	0.000		0.000		-		0.000	0.000	1.767	0.00
CSIRP - DTE C - Environmental Testing	Various	Various : N/A	0.574	1.177	Jun 2022	0.000		0.000		-		0.000	0.000	1.751	0.00
JBTDS - DTE SB - V&V of JBTDS Military Utility Model	Various	Institute for Defense Analysis (IDA) : Alexandria, VA	0.875	0.285	Mar 2022	0.000		0.000		-		0.000	0.000	1.160	0.000
JBTDS - DTE SB - ARCA Chamber and Record Test Support	C/FFP	Battelle Memorial Institute : Columbus, OH	1.564	0.380	Nov 2021	0.000		0.000		-		0.000	0.000	1.944	0.000
JBTDS - DTE SB - Identifier Live Agent Trials / Developmental Testing	MIPR	Various : N/A	9.265	1.401	Nov 2021	0.000		0.000		-		0.000	14.788	25.454	0.00
JBTDS - OTE S - Operational Assessment	MIPR	Various : N/A	1.799	0.080	Nov 2021	0.000		0.000		-		0.000	0.000	1.879	0.00
NBCRV SSU - DTE C - Test and Evaluation	Various	Various : N/A	-	2.869	Mar 2022	0.000		0.000		-		0.000	0.000	2.869	0.00

PE 0604384BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program

Exhibit R-3, RDT&E I	Project C	ost Analysis: PB 2	2024 Che	mical and	l Biologica	al Defens	e Prograr	m				Date:	March 20)23	
Appropriation/Budge 0400 / 5	et Activity	/				PE 060		' Chemica	umber/N al and Bio			(Number Contamina	r/ Name) tion Avoid	lance (SI	(סכ
Test and Evaluation	(\$ in Milli	ons)		FY 2	2022	FY 2	023	FY 2 Ba	2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
NBCRV SSU - DTE C - Component Level Testing	MIPR	Various : N/A	-	3.789	Jan 2022	0.000		0.000		-		0.000	0.000	3.789	0.000
NBCRV SSU - DTE S - System Level Testing	MIPR	Various : N/A	-	1.472	Feb 2022	0.000		0.000		-		0.000	0.000	1.472	0.000
		Subtotal	39.831	21.256		0.000		0.000		-		0.000	14.788	75.875	N/A
Management Service	es (\$ in M	illions)		FY	2022	FY 2	023	FY 2 Ba	2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
AET DEFENSE - PM/MS S - IPT Support/Program Management	MIPR	JPEO Chem, Bio, Rad, and Nuc Defense (JPEO- CBRND) : Aberdeen Proving Ground, MD	-	0.081	Dec 2021	0.000		0.000		-		0.000	0.000	0.081	0.000
AVCAD - PM/MS S - Management Services	MIPR	Various : N/A	6.312	1.674	Nov 2021	0.000		0.000		-		0.000	0.000	7.986	0.000
MPCAD - PM/MS S - Program Management Support	MIPR	Various : N/A	10.492	1.159	Dec 2021	0.000		0.000		-		0.000	0.000	11.651	0.000
CSIRP - PM/MS C - PM/MS S Program Management Support	Various	Various : N/A	1.262	1.369	Oct 2021	0.000		0.000		-		0.000	0.000	2.631	0.000
JBTDS - PM/MS S - Program Management Support	MIPR	Various : N/A	21.756	0.333	Nov 2021	0.000		0.000		-		0.000	0.000	22.089	0.000
NBCRV SSU - PM/MS C - Program Management Support	MIPR	Various : N/A	-	2.275	Oct 2021	0.000		0.000		-		0.000	0.000	2.275	0.000
ROSETTA - PM/MS S - Program Management Support	MIPR	Various : N/A	0.870	0.154	Oct 2021	0.000		0.000		-		0.000	0.000	1.024	0.000
		Subtotal	40.692	7.045		0.000		0.000		-		0.000	0.000	47.737	N/A

PE 0604384BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program UNCLASSIFIED Page 103 of 158

Exhibit R-3, RDT&E Project Cost Analysis: PB 2	2024 Cher	nical and	d Biologica	I Defense	e Progra	m			Date:	March 20	23	
Appropriation/Budget Activity 0400 / 5				PE 0604	4384BP	l ement (N I Chemic m - EMD		,	(Numbe Contamina	r/Name) ation Avoid	ance (SI	(סכ
	Prior Years	FY 2	2022	FY 2	023		2024 ase	FY 2 OC	 FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract
Project Cost Totals	261.686	84.967		0.000		0.000)	-	0.000	14.985	361.638	N/

Remarks

Exhibit R-4, RDT&E Schedule Profile: PB 2024 C	he	nica	l an	d Bi	olog	ical	Defe	ense	Prog	gram												Da	te: M	arch	202	23		
Appropriation/Budget Activity 0400 / 5								PE	0604	o grar 4384 e <i>Prc</i>	BP /	Ch	emic	cal a									ber/N inatio			ance	e (Sl	DD)
		FY		_			202				2024				2025	r			2026	1		_	2027	1		FY	1	_
AET DEFENSE - Technology Assessments/ Systems Engineering	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
AVCAD - EMD Contract																												
AVCAD - MS C-Milestone C																												
AVCAD - LRIP-Low Rate Initial Production																												
AVCAD - FRP-Full Rate Production Decision																												
AVCAD - IOC-Initial Operational Capability																												
MPCAD - DT&E-Developmental Test and Evaluation - EMD Contract/LRIP contract														-														
MPCAD - MS C-Milestone C - Liquid / Solid MS C																												
MPCAD - LRIP-Low Rate Initial Production																												
MPCAD - MS C-Milestone C - Vapor / Quant MS C																												
MPCAD - FRP-Full Rate Production Decision																												
MPCAD - IOC-Initial Operational Capability																												
MPCAD - FOC-Full Operational Capability																												
CSIRP - Test and Evaluation of Prototypes - Development Objectives Strategy #1																												
CSIRP - Transition Decision - Development Objectives Strategy #1																												
CSIRP - OTA Award and Execution for Development Objectives Strategy #2																												
CSIRP - Test and Evaluation of Prototypes - Development Objectives Strategy #2																												
CSIRP - Transition Decision - Development Objectives Strategy #2																												

PE 0604384BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program UNCLASSIFIED Page 105 of 158

R-1 Line #132

xhibit R-4, RDT&E Schedule Profile: PB 2024 C	Cher	nica	l and	l Bio	logic	al D	efen	se F	Prog	ram											I	Dat	e: M	larch	n 20	23		
ppropriation/Budget Activity 400 / 5							F	PE 0)604 ense	384 Pro	BP I gran	Che n - E	mi	cal a		r/Na ı Biolo			Pro CA5							ance	(SE	D)
			202	_	-		023				024			FY 2	1				2026				2027	7		FY 2		8
CSIRP - OTA Award and Execution for Development Objectives Strategy #3	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
CSIRP - Test and Evaluation of Prototypes - Development Objectives Strategy #3																												
JBTDS - MS C-Milestone C																												
JBTDS - LRIP Contract Award																												
JBTDS - PVT																												
JBTDS - MOT&E																												
JBTDS - FRP-Full Rate Production Decision																												
JBTDS - FRP Award																												
JBTDS - IOC-Initial Operational Capability																												
NBCRV SSU - Component Test & System Level Test 1																												
NBCRV SSU - Modification Work Order IPR																												-
NBCRV SSU - Design and Fabrication Phase 3 (CS2.2)																												
NBCRV SSU - Limited User Test (LUT)																												
NBCRV SSU - Design and Fabrication Phase 2 (CS2.1)																												
NBCRV SSU - Initial Operational Test and Evaluation (IOT&E)																												
NBCRV SSU - FRP-Full Rate Production Decision																												
ROSETTA - Testing & Demonstrations (M8)																												
ROSETTA - Engineering Design																												
ROSETTA - OTA Contract Award																												

PE 0604384BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program

hibit R-4A, RDT&E Schedule Details: PB 2024 Chemical and Biological Defense	se Program		C	Date: Marcl	า 2023
00/5 PE	Program Element (Numbe 0604384BP <i>I Chemical and</i> fense Program - EMD	,	Project (Nui CA5 / Conta		e) voidance (SDD)
Schedu	ule Details				
	St	art		En	d
Events	Quarter	Year	Qu	arter	Year
AET DEFENSE - Technology Assessments/Systems Engineering	1	2022		4	2028
AVCAD - EMD Contract	1	2022		2	2023
AVCAD - MS C-Milestone C	2	2023		2	2023
AVCAD - LRIP-Low Rate Initial Production	2	2023		1	2026
AVCAD - FRP-Full Rate Production Decision	1	2026		1	2026
AVCAD - IOC-Initial Operational Capability	2	2026		2	2026
MPCAD - DT&E-Developmental Test and Evaluation - EMD Contract/LRIP con	itract 1	2022		3	2024
MPCAD - MS C-Milestone C - Liquid / Solid MS C	3	2023		3	2023
MPCAD - LRIP-Low Rate Initial Production	3	2023		3	2024
MPCAD - MS C-Milestone C - Vapor / Quant MS C	2	2024		2	2024
MPCAD - FRP-Full Rate Production Decision	4	2024		4	2024
MPCAD - IOC-Initial Operational Capability	4	2027		4	2027
MPCAD - FOC-Full Operational Capability	4	2028		4	2028
CSIRP - Test and Evaluation of Prototypes - Development Objectives Strategy	#1 1	2022		2	2023
CSIRP - Transition Decision - Development Objectives Strategy #1	3	2023		3	2023
CSIRP - OTA Award and Execution for Development Objectives Strategy #2	3	2023		3	2024
CSIRP - Test and Evaluation of Prototypes - Development Objectives Strategy	#2 3	2023		3	2025
CSIRP - Transition Decision - Development Objectives Strategy #2	3	2025		3	2025
CSIRP - OTA Award and Execution for Development Objectives Strategy #3	3	2025		3	2028
CSIRP - Test and Evaluation of Prototypes -Development Objectives Strategy	#3 4	2025		3	2028
JBTDS - MS C-Milestone C	3	2023		3	2023
JBTDS - LRIP Contract Award	4	2023		4	2023

propriation/Budget Activity 00 / 5	Element (Numbe I Chemical and am - EMD		Project (Nun CA5 / Contar		e) voidance (SDD)
	St	art		En	d
Events	Quarter	Year	Qua	arter	Year
JBTDS - PVT	3	2024		3	2024
JBTDS - MOT&E	4	2024		4	2024
JBTDS - FRP-Full Rate Production Decision	4	2025		4	2025
JBTDS - FRP Award	4	2025		4	2025
JBTDS - IOC-Initial Operational Capability	2	2028		2	2028
NBCRV SSU - Component Test & System Level Test 1	1	2022		1	2024
NBCRV SSU - Modification Work Order IPR	3	2023		3	2024
NBCRV SSU - Design and Fabrication Phase 3 (CS2.2)	1	2024		1	2025
NBCRV SSU - Limited User Test (LUT)	4	2023		1	2024
NBCRV SSU - Design and Fabrication Phase 2 (CS2.1)	1	2022		2	2022
NBCRV SSU - Initial Operational Test and Evaluation (IOT&E)	1	2026		2	2026
NBCRV SSU - FRP-Full Rate Production Decision	3	2026		3	2026
ROSETTA - Testing & Demonstrations (M8)	1	2022		2	2022
ROSETTA - Engineering Design	4	2022		2	2023
ROSETTA - OTA Contract Award	3	2022		4	2027

Exhibit R-2A, RDT&E Project Ju	xhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program													
Appropriation/Budget Activity 0400 / 5					-	34BP I Cher	t (Number/ nical and B //D		Project (N CO5 / Colle		ne) ection (SDD)			
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost		
CO5: Collective Protection (SDD)	-	2.888	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	2.888		
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-				

A. Mission Description and Budget Item Justification

This project supports Engineering and Manufacturing Development and Low Rate Initial Production of Joint Service Chemical, Biological, and Radiological (CBR) Collective Protection (CP) systems that are smaller, lighter, less costly to produce and maintain, and more logistically supportable. CP systems provide spaces safe from the effects of CBR contamination enabling mission accomplishment in CBR environments.

Efforts included in this Project are:

(1) Joint Expeditionary Collective Protection (JECP) Family of Systems

The Joint Expeditionary Collective Protection (JECP) program provides the Joint Expeditionary Forces a collective protection capability that is lightweight, compact, modular, and affordable. JECP is a family of systems, developed in two phases that will allow the application of CP to transportable soft-side shelters, enclosed spaces of opportunity and in remote austere locations as a standalone resource. Phase 1 includes standalone CP systems and kits that provide existing host platforms and structures with Chemical Biological Radiological Nuclear (CBRN) protection. Phase 2 includes kits that provide CBRN protection to other host platforms and structures that were not explicitly designed in Phase 1. JECP will be capable of protecting personnel groups of varying size, unencumbered by Individual Protective Equipment (IPE), from the effects of CB agents, Toxic Industrial Materials (TIMs), radiological particles, heat, dust, and sand. The employment of JECP will reduce the need for personnel and equipment decontamination and is a strategic deterrence against state adversaries and non-state actors from using weapons of mass destruction. FY22 is the last year of BA5 funding for this program.

B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
Title: 1) JECP		2.888	-	-
Description: Phase 2 system Development and Demonstration Events				
	Accomplishments/Planned Programs Subtotals	2.888	-	-
C. Other Program Funding Summary (\$ in Millions)				
N/A				
Remarks				

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical a	5 PE 0604384BP / Chemical and Biological										
Appropriation/Budget Activity 0400 / 5	PE 0604384BP / Chemical and Biological	Project (Number/Name) CO5 / Collective Protection (SDD)									
D. Acquisition Strategy JOINT EXPEDITIONARY COLLECTIVE PROTECTION (JECP)	Defense Program - EMD										
JECP Family of Systems (FoS) (Phase 1 and Phase 2) involves m Production and Deployment Phases of the program. Having achie	eved a Full Rate Production (FRP) decision for Phase 1 S	Systems in December 2016, the program									
exercised Fixed Price Incentive (FPI) production options in FY17 & (IOC). A competitive build-to print follow-on production delivery or remaining production of Phase 1 Systems to meet Full Operational under a separate competitive delivery order awarded March 2019	der contract was awarded June 2019 to Production Produ I Capability (FOC). Phase 2 systems were developed as	ucts Manufacturing and will support the s engineering changes to the Phase 1 systems									

EXHIBIT R-3, RDI &E I	Project Co	ost Analysis : PB 2	2024 Cher	nical and	I Biologica	al Defense	e Prograr	n				Date:	March 20	23	
Appropriation/Budge 0400 / 5	et Activity	,				PE 0604		ement (Ni Chemica n - EMD				(Number Collective	r/ Name) Protection	(SDD)	
Product Developmer	nt (\$ in Mi	illions)		FY 2	2022	FY 2	023	FY 2 Bas	-		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
JECP - HW S - Phase 2 System Product Development/Phase 2 Prototype Manufacturing	C/Various		8.819		Nov 2021	0.000		0.000		-		0.000	0.000	9.673	0.000
		Subtotal	8.819	0.854		0.000		0.000		-		0.000	0.000	9.673	N/A
upport (\$ in Millions)				FY 2	2022	FY 2	023	FY 2 Bas			2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
JECP - DTE C - ES S/ILS S - Engineering, Logistics, Technical, IPT Support	MIPR	Various : N/A	6.451	1.119	Nov 2021	0.000		0.000		-		0.000	0.000	7.570	0.000
		Subtotal	6.451	1.119		0.000		0.000		-		0.000	0.000	7.570	N/A
		Castotai													
Test and Evaluation	(\$ in Milli		[FY 2	2022	FY 2	023	FY 2 Bas			2024 CO	FY 2024 Total			
	Contract Method	ONS) Performing	Prior Years		Award		Award	Ba	se Award	0	CO Award	Total	Cost To Complete	Total Cost	
Cost Category Item JECP - OTHT SB - Test & Evaluation IPT/OTE S - Operational Testing/DTE S - Phase 2 Developmental testing	Contract Method & Type	ons)	Prior Years 12.442	Cost		FY 2 Cost 0.000			se		co		Cost To Complete 0.000	Total Cost 13.142	Target Value of Contract

PE 0604384BP: Chemical and Biological Defense Program ... Chemical and Biological Defense Program

Exhibit R-3, RDT&E	Project C	ost Analysis: PB 2	024 Cher	nical and	d Biologica	al Defens	e Progran	n				Date:	March 20	23	
Appropriation/Budg 0400 / 5		PE 060		e ment (N Chemica n - EMD				t (Numbe Collective	r/ Name) Protection	(SDD)					
Management Services (\$ in Millions) FY 2022						FY 2	2023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
JECP - PM/MS S - Program Management Support	MIPR	Various : N/A	14.799	0.215	Nov 2021	0.000		0.000		-		0.000	0.000	15.014	0.000
		Subtotal	14.799	0.215		0.000		0.000		-		0.000	0.000	15.014	N/A
Prior Years			-	FY	2022	FY 2	2023		2024 Ise		2024 CO	FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract
	42.511	2.888		0.000		0.000		-		0.000	0.000	45.399	N/A		

Remarks

Exhibit R-4, RDT&E Schedule Profile: PB 2024 C	nibit R-4, RDT&E Schedule Profile: PB 2024 Chemical and Biological Defense Program																Dat	e: M	arch	120	23								
Appropriation/Budget Activity 0400 / 5								PE (0604	1384		Ch	emi	cal a	nber/ and B						•		er/N e Pro		,	(SD	D)		
		F١	1 20)22			FY	2023	3		FY	2024			FY	2025			FY 2	2026	;		FY	2027	,		FY	2028	}
	1		2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
JECP - FRP-Full Rate Production Decision - Phase 2							-																						
JECP - IOC-Initial Operational Capability - IOC																													
JECP - FOC-Full Operational Capability - FOC																													

Exhibit R-4A, RDT&E Schedule Details: PB 2024 Chemical and Bio	RDT&E Schedule Details: PB 2024 Chemical and Biological Defense Program /Budget Activity PE 0604384BP / Chemical and Biological Defense Program - EMD								
Appropriation/Budget Activity 0400 / 5	PE 0604384BP / Chemical and		Project (Number/Nai CO5 / Collective Prote	,					
	Schedule Details	tart	E	ind					
Events	Quarter	Year	Quarter	1					
Evoluto				Year					
JECP - FRP-Full Rate Production Decision - Phase 2	2	2022	2	Year 2022					
	2	2022 2023	2						

Exhibit R-2A, RDT&E Project Ju	ustification	: PB 2024 C	hemical an	d Biologica	l Defense P	rogram				Date: Marc	ch 2023	
Appropriation/Budget Activity 0400 / 5		-	34BP I Cher	i t (Number / mical and B MD	,	Project (N DE5 / Deco		,				
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
DE5: Decontamination (SDD)	-	7.485	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	7.485
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

This project supports the development of Contamination Mitigation (ConMit) systems utilizing solutions that remove and/or detoxify contaminated material without damaging combat equipment, platforms, personnel, or the environment, helping sustain a resilient force posture, one of the efforts outlined in the National Defense Strategy. ConMit systems provide a force restoration capability for units that become contaminated. Development efforts will provide systems that reduce operational impact and logistics burden, reduce sustainment costs, increase safety, and minimize environmental effects associated with decontamination and contamination mitigation operations. Experimentation and demonstration will be used in this phase to reduce risk and inform supporting materiel solutions, Concept of Operations and Tactics, Techniques & Procedures. After FY 2022, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. DE5 efforts in FY 2022 progress to Projects EN5 and MT5. This restructuring provides standardization and alignment across CBDP research, development and acquisition efforts.

Efforts included in this Project are:

(1) Decontamination Family of Systems (DFoS) Contamination Indicator Decontamination Assurance System (CIDAS) Blister **Progresses to MT5 in FY2023**,
 (2) Forward Area Mobility Spray - System (FAMS-S) **Progresses to MT5 in FY2023**, and
 (3) Major Defense Acquisition Program (MDAP) **Progresses to EN5 in FY2023**

The Decontamination Family of Systems Contamination Indicator Decontamination Assurance System (DFoS CIDAS) Blister program addresses traditional blister agents, two separate threat scenarios that require different materiel solutions, modernizing a key capability to help build a more lethal force, as outlined in the National Defense Strategy. In FY24, the program will conduct a Manufacturing Readiness Assessment (MRA) and a Physical Configuration Audit (PCA) with the Prime Contractor and complete Operational Testing in support of Full Rate Production (FRP)/Fielding Decision.

The FAMS-S will provide Special Operations Forces (SOF) and SOF Task Forces (SOTFs) with transportable, rapidly-deployable decontamination systems in three variants: man-portable, small vehicle-mounted, and large vehicle-mounted systems to rapidly decontaminate chemical and biological (CB) agents from the exterior of vehicles and support equipment to a level that is clean enough for re-use during missions without the need for donning CB personal protective equipment. This will maximize tactical flexibility and fighting strength while minimizing the logistical burden and the cost of conducting Countering Weapons of Mass Destruction (CWMD) and CB operations. FAMS-S is a Middle Tier Acquisition (MTA) program.

The MDAP Chemical Biological Radiological and Nuclear (CBRN) Survivability Initiative ensures weapon system programs at all Acquisition Category (ACAT) levels, as well as non-DoD agency programs such as those at the Department of Homeland Security (DHS), meet their CBRN defense requirements. In FY24, this effort continues

Exhibit R-2A, RDT&E Project Justi	fication: PB	2024 Chemi	ical and Biol	ogical Defen	se Program				Date: M	arch 2023	
Appropriation/Budget Activity 0400 / 5				PE 06	-	nent (Numb Chemical and - EMD	,	-	t (Number/N Decontamina	,	
to facilitate and coordinate the resea solutions for each program's docume				n, procureme	ent, delivery,	and life cycl	e sustainme	nt of affor	dable CBRN	defense mat	eriel
B. Accomplishments/Planned Prog	grams (\$ in I	<u>Millions)</u>						Γ	FY 2022	FY 2023	FY 2024
Title: 1) DFoS CIDAS BLISTER									2.564	-	-
Description: Blister Indicator Kits an	d Large Sca	le Applicator	s (LSA)								
Title: 2) FAMS-S									2.681	-	-
Description: Small and large variant	t prototype de	evelopment	and close ou	it of remainir	ng DT/OT ac	tivities will c	omplete.				
Title: 3) MDAP									2.240	-	-
Description: CBRN Survivability Sup	oport										
				Accon	nplishments	s/Planned P	rograms Su	btotals	7.485	-	-
C. Other Program Funding Summa	ry (\$ in Milli	ons <u>)</u>									
			<u>FY 2024</u>	<u>FY 2024</u>	<u>FY 2024</u>					Cost To	
Line Item	FY 2022	<u>FY 2023</u>	<u>Base</u>	000	<u>Total</u>	<u>FY 2025</u>	<u>FY 2026</u>	<u>FY 202</u>	7 FY 2028		
• DE4: Decontamination (ACD&P)	14.747	-	- 13.835	-	-	- 12 001	-	-	- 7 14 261	0.000 Continuing	14.74 Continuin
EN5: Enabling Investments (SDD) MT5: Mitigate (SDD)	-	13.392 74.225	88.441	-	13.835 88.441	13.884 92.279	14.179 91.431	14.19 87.77		Continuing Continuing	
• JD0050: Decontamination	- 7.797	4.795	6.062	-	6.062	92.279 8.673	8.820	16.51		6 Continuing	
Family Of Systems (DFoS)	1.191	ч. <i>13</i> 5	0.002	-	0.002	0.075	0.020	10.51	0 0.990	, continuing	Continuin
PHM025: Forward Air Mobility	-	4.607	4.824	-	4.824	4.724	4.724	4.72	4 4.889	Continuing	Continuir
Spray System (FAMS-S)											
Remarks											

D. Acquisition Strategy

DFoS CONTAMINATION INDICATOR DECON ASSURANCE SPRAY BLISTER (DFoS CIDAS BLISTER)

The Decontamination Family of Systems Contamination Indicator Detection Assurance System (DFoS CIDAS) Blister program will follow an evolutionary acquisition strategy. The program office coordinated with Science and Technology efforts to identify blister technologies that met Service requirements. After further development, in 4QFY19 a sole-source performance based indefinite delivery indefinite quantity contract was awarded to develop blister indicator and small scale applicator systems with options for production. The program will leverage the contract to procure blister indicator kits and conduct test and evaluation events for the Engineering & Manufacturing Development (EMD) phase in preparation of Milestone C/Full Rate Production (FRP).

	UNGLASSIFIED	
Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical	and Biological Defense Program	Date: March 2023
Appropriation/Budget Activity 0400 / 5	R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> <i>Defense Program - EMD</i>	Project (Number/Name) DE5 <i>I Decontamination (SDD)</i>
FORWARD AREA MOBILITY SPRAY SYSTEM (FAMS-S)		
The FAMS-S will be developed using Middle Tier Acquisition (MT and Special Operations Task Forces (SOTF) application to tactic Development Document (CDD). FAMS-S will reduce technologic data from mature legacy and commercial decontamination system award projects to three vendors for the man-portable and three v perform technical evaluations, undergo developmental and opera preparation for the man-portable variant production decision in F	cal and strategic platforms in accordance with MTA authorit cal risk by reviewing existing materials and technologies as ms. The program will utilize the CWMD Other Transaction vendors for the vehicle-mounted variants followed by a prote ational testing, and early user assessments to inform the fir	ies and regulations and the Capability well as designs, configurations, and test Authority (OTA) agreement to competitive otype down-select. The program will
MAJOR DEFENSE ACQUISITION PROGRAM (MDAP)		
The MDAP program will leverage JPEO-CBRN expertise and pro	oduct portfolios to provide non-CBD programs with CBRN S	Survivability and Force Protection capabiliti

Exhibit R-3, RDT&E F	Project C	ost Analysis: PB 2	024 Cher	nical and	d Biologica	al Defens	e Prograr	n			_	Date:	March 20	23	
Appropriation/Budge 0400 / 5	t Activity	1				PE 060		ement (N Chemica m - EMD				: (Numbe r Decontami	r/ Name) nation (SL	DD)	
Product Developmen	nt (\$ in M	illions)		FY 2	2022	FY 2	023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
DFoS CIDAS BLISTER - HW S - Small Scale / Large Scale Applicators/ Kits	SS/ Various	FLIR Systems, Inc. : Stillwater, OK	2.269	0.624	Nov 2021	0.000		0.000		-		0.000	0.000	2.893	0.000
FAMS-S - HW S - System Development and Prototype Refinement	C/CPIF	ATI Solutions, Inc. : Tysons Corner, VA	0.876	0.686	Jan 2022	0.000		0.000		-		0.000	0.000	1.562	0.000
	·	Subtotal	3.145	1.310		0.000		0.000		-		0.000	0.000	4.455	N/A
Support (\$ in Millions	Support (\$ in Millions)		ſ	FY	2022	FY 2	023	FY 2 Ba	2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
DFoS CIDAS BLISTER - ES S - IPT and Technical Support	MIPR	Various : N/A	0.980	0.385	Dec 2021	0.000		0.000		-		0.000	0.000	1.365	0.000
FAMS-S - ES S - Systems Engineer/Technical SME Support	MIPR	Various : N/A	0.272	0.686	Jan 2022	0.000		0.000		-		0.000	0.000	0.958	0.000
MDAP - TD/D SB - IPT and Technical Support	MIPR	Various : N/A	2.480	2.081	Nov 2021	0.000		0.000		-		0.000	0.000	4.561	0.000
		Subtotal	3.732	3.152		0.000		0.000		-		0.000	0.000	6.884	N/A
Test and Evaluation ((\$ in Milli	ons)	ſ	FY	2022	FY 2	023	FY 2 Ba	2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
DFoS CIDAS BLISTER - OTHT S - OTHT S - DT/ OT	MIPR	Various : N/A	1.003	1.363	Dec 2021	0.000		0.000		-		0.000	0.000	2.366	0.000
FAMS-S - DTE SB - Decon Solution Analysis	Various	TBD : N/A	0.100	1.042	Feb 2022	0.000		0.000		-		0.000	0.000	1.142	0.000

PE 0604384BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program

Exhibit R-3, RDT&E	Project C	ost Analysis: PB 2	024 Chei	mical and	Biologica	al Defens	e Prograr	n				Date:	March 20	23	
Appropriation/Budg 0400 / 5	et Activity	/				PE 060	-	e ment (N Chemica n - EMD			-	(Numbe Decontami	r/ Name) Ination (SL	(סכ	
Test and Evaluation	(\$ in Milli	ons)		FY 2	2022	FY 2	023	FY 2 Ba			2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
		Subtotal	1.103	2.405		0.000		0.000		-		0.000	0.000	3.508	N/A
Management Servic	anagement Services (\$ in Millions)				2022	FY 2	023	FY 2 Ba			2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
DFoS CIDAS BLISTER - PM/MS S - Program Management Support	MIPR	Various : N/A	0.369	0.192	Dec 2021	0.000		0.000		-		0.000	0.000	0.561	0.000
FAMS-S - PM/MS S - Program Management	MIPR	Various : N/A	0.016	0.267	Dec 2021	0.000		0.000		-		0.000	0.000	0.283	0.000
MDAP - PM/MS S - Program Management Support	MIPR	Various : N/A	0.488	0.159	Nov 2021	0.000		0.000		-		0.000	0.000	0.647	0.000
		Subtotal	0.873	0.618		0.000		0.000		-		0.000	0.000	1.491	N/A
	Prior Years	-	FY	2022	FY 2	023	FY 2 Ba			2024 CO	FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract	
		Project Cost Totals	8.853	7.485		0.000		0.000		-		0.000	0.000	16.338	N/A

Remarks

Exhibit R-4, RDT&E Schedule Profile: PB 2024 C	her	nical	and	Bio	logio	cal [Defe	nse	Prog	gram												Dat	te: M	arch	n 202	23		
Appropriation/Budget Activity 400 / 5								R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> <i>Defense Program - EMD</i>										Project (Number/Name) DE5 <i>I Decontamination (SDD)</i>										
			FY 2022				202	3		FY 2	Y 2024			FY 2025			FY		2026		FY 2027			,	FY 2			}
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
DFoS CIDAS BLISTER - Sustainment Cost Reduction Plan (SCRP)																												
DFoS CIDAS BLISTER - DT&E-Developmental Test and Evaluation - Phase 1																												
DFoS CIDAS BLISTER - System Verification Review (SVR)/Production Readiness Review																												
DFoS CIDAS BLISTER - Functional Configuration Audit (FCA)																												
DFoS CIDAS BLISTER - DT&E-Developmental Test and Evaluation - Phase 2																												
DFoS CIDAS BLISTER - OT&E-Operational Test and Evaluation - CIDAS Blister																												
DFoS CIDAS BLISTER - Manufacturing Readiness Assessment																												
DFoS CIDAS BLISTER - Physical Configuration Audit																												
DFoS CIDAS BLISTER - MS C-Milestone C																												
DFoS CIDAS BLISTER - FRP-Full Rate Production Decision										-																		
DFoS CIDAS BLISTER - IOC-Initial Operational Capability																												
DFoS CIDAS BLISTER - FOC-Full Operational Capability - CIDAS Blister																												
FAMS-S - PDR-Preliminary Design Review - Man-Portable Variant																												
FAMS-S - CDR-Critical Design Review - Man- Portable Variant																												

PE 0604384BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program UNCLASSIFIED Page 120 of 158

R-1 Line #132

Exhibit R-4, RDT&E Schedule Profile: PB 2024 C	he	nica	al a	nd E	Biolo	ogic	cal D	efe	nse	Prog	gran	n												Dat	te: N	larc	h 2	023	3		
Appropriation/Budget Activity 0400 / 5									ΡE	0604	4384	m El 4BP <i>i</i> ograi	I Ch	em	ical a					1					oer/l mina			SDD))		
		FY	20	22			FY 2	2023	3		FY	2024	ŀ		FY	20	25		F	- Y 2	2026	5		FY	202	7		F	Y 2	028	
FAMS-S - MTA Outcome Decision Memorandum-Middle Tier Acquisition Outcome Decision Memorandum - Man-Portable Variant	1	2	2	3	4	1	2	3	4	1	2	3	4	1	2		3 4	1	1	2	3	4	1	2	3	4	. •	1	2	3	4
FAMS-S - OT&E-Operational Test and Evaluation - Man-Portable Variant																															
FAMS-S - PDR-Preliminary Design Review - Small/Large Variants																															
FAMS-S - OT&E-Operational Test and Evaluation - Small/Large Variants																															
FAMS-S - CDR-Critical Design Review - Small/ Large Variants																															
FAMS-S - MTA Outcome Decision Memorandum-Middle Tier Acquisition Outcome Decision Memorandum - Small/Large Variants																															
FAMS-S - IOC-Initial Operational Capability - All Variants																															
FAMS-S - FOC-Full Operational Capability - All Variants																															
MDAP - Engage with services to develop relationships for CBRN requirements																															

0/5 PE	1 Program Element (Numbe 5 0604384BP <i>I Chemical and</i> 6 fense Program - EMD		Date: Marc Project (Number/Nam DE5 / Decontamination	ie)
Sched	lule Details			
	St	art	Er	nd
Events	Quarter	Year	Quarter	Year
DFoS CIDAS BLISTER - Sustainment Cost Reduction Plan (SCRP)	1	2022	3	2022
DFoS CIDAS BLISTER - DT&E-Developmental Test and Evaluation - Phase	1 2	2022	4	2022
DFoS CIDAS BLISTER - System Verification Review (SVR)/Production Read Review	iness 3	2023	3	2023
DFoS CIDAS BLISTER - Functional Configuration Audit (FCA)	4	2023	4	2023
DFoS CIDAS BLISTER - DT&E-Developmental Test and Evaluation - Phase 2	2 1	2024	1	2025
DFoS CIDAS BLISTER - OT&E-Operational Test and Evaluation - CIDAS Blis	ster 1	2024	1	2024
DFoS CIDAS BLISTER - Manufacturing Readiness Assessment	1	2024	1	2024
DFoS CIDAS BLISTER - Physical Configuration Audit	2	2024	2	2024
DFoS CIDAS BLISTER - MS C-Milestone C	4	2024	4	2024
DFoS CIDAS BLISTER - FRP-Full Rate Production Decision	4	2024	4	2024
DFoS CIDAS BLISTER - IOC-Initial Operational Capability	2	2027	2	2027
DFoS CIDAS BLISTER - FOC-Full Operational Capability - CIDAS Blister	2	2028	2	2028
FAMS-S - PDR-Preliminary Design Review - Man-Portable Variant	3	2022	3	2022
FAMS-S - CDR-Critical Design Review - Man-Portable Variant	2	2023	2	2023
FAMS-S - MTA Outcome Decision Memorandum-Middle Tier Acquisition Outo Decision Memorandum - Man-Portable Variant	come 3	2023	3	2023
FAMS-S - OT&E-Operational Test and Evaluation - Man-Portable Variant	2	2023	2	2023
FAMS-S - PDR-Preliminary Design Review - Small/Large Variants	4	2022	4	2022
FAMS-S - OT&E-Operational Test and Evaluation - Small/Large Variants	2	2024	2	2024
FAMS-S - CDR-Critical Design Review - Small/Large Variants	3	2024	3	2024
FAMS-S - MTA Outcome Decision Memorandum-Middle Tier Acquisition Outo Decision Memorandum - Small/Large Variants	come 3	2024	3	2024

hibit R-4A, RDT&E Schedule Details: PB 2024 Chemical and Biolo	gical Defense Prograr	n		Date: Marc	h 2023
propriation/Budget Activity 00 / 5		Belement (Number BP / Chemical and B gram - EMD		oject (Number/Nam 5 / Decontamination	,
		Sta	art	Er	nd
Events		Quarter	Year	Quarter	Year
FAMS-S - IOC-Initial Operational Capability - All Variants		3	2024	2	2026
FAMS-S - FOC-Full Operational Capability - All Variants		4	2028	4	2028
MDAP - Engage with services to develop relationships for CBRN re	equirements	1	2022	4	2028

Exhibit R-2A, RDT&E Project Ju	stification	: PB 2024 C	chemical an	d Biologica	l Defense P	rogram				Date: Marc	ch 2023	
Appropriation/Budget Activity 0400 / 5					R-1 Progra PE 060438 Defense P	4BP / Cher	nical and B		Project (N IP5 / Indivi			
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
IP5: Individual Protection (SDD)	-	18.690	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	18.690
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

This project provides Engineering & Manufacturing Development Phase and Low Rate Initial Production (EMD/LRIP) for individual protection equipment, with the goal of providing equipment that allows the individual Soldier, Sailor, Airman, or Marine to operate in a contaminated Nuclear, Biological and Chemical (NBC) environment with little or no degradation of his/her performance. After FY 2022, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. IP5 efforts in FY 2022 progress to Projects PT5 and UN5. This restructuring provides standardization and alignment across CBDP research, development and acquisition efforts.

Efforts included in this Project are:

(1) Joint Service Aircrew Mask for Strategic Aircraft (JSAM SA),

(2) Special Purpose Unit Rapid Capability Development and Deployment (SPU RCDD) - **Progresses to UN5 in FY2023**,

(3) UIPE FoS General Purpose (GP) - **Progresses to PT5 in FY2023**, and

(4) UIPE FoS Air - **Progresses to PT5 in FY2023**

Joint Service Aircrew Mask (JSAM) Strategic Aircraft (SA) will provide individual respiratory, ocular, and percutaneous protection of chemical and biological warfare agents, and select toxic industrial chemicals for United States Air Force (USAF), Aeromedical personnel, United States Navy (USN), United States Marine Corps (USMC), and United States Army (USA) strategic aircrew. The mask components will be optimized to minimize their impact on the wearer's performance to continue lethality in a chemical biological (CB) environment and maximize its ability to interface with aircrew protective clothing. JSAM SA will provide pressure breathing for altitude for aircraft that do not require pressure breathing for gravity. JSAM SA will integrate with aircraft subsystems which include aviation life support equipment, aircrew flight equipment, aircraft seating, portable aircrew systems, communications systems, and aircraft oxygen systems. FY22 is the last year of BA5 funding for this program as they approach FOC in FY25.

SPU RCDD facilitates Joint Special Operations Command (JSOC) rapid response requirements to near-term and emergent chemical-biological defensive capabilities. This includes select elements from across the Special Operations Force (SOF) Enterprise such as CBRN Assessment Response Teams (CARTs) and other Joint Force enabling units such as the 20th Chemical, Biological, Radiological, Nuclear and Explosives Command. SPU RCDD mitigates risk across the Chemical Biological Defense Program (CBDP) by creating a portfolio of operationally-relevant CB capabilities that can be quickly transitioned in response to the articulated, emergent capability needs of the geographic combatant commanders. These objectives are met by the early transitioning of promising science and technologies (S&T); the focused conduct of combat evaluations and mission-oriented operational assessments to assess technological and mission suitability; and the active leveraging of existing Commercial-Off-The-Shelf (COTS) and Government-Off-The-Shelf (GOTS) products along with novel redesign approaches to optimize existing solutions to new challenges supported by "buy-try-decide-acquire" acquisition strategies. SPU RCDD initiates efforts such as respiratory breathing systems, biological identification,

	Biological Defense Program	Date: M	larch 2023	
Appropriation/Budget Activity 0400 / 5	R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> <i>Defense Program - EMD</i>	Project (Number/N IP5 / Individual Prot	,)
unmanned aerial and ground platform sensor integration, developmer Biological ensembles that have gone through requirements validation SOF equipment to counter emerging threats.				
The Uniform Integrated Protective Ensemble Family of Systems Gene protection from operationally relevant traditional, non-traditional, and threats likely to be encountered during joint force operations. The lega requirements such as emerging threats, aerosol protection, and flame uniform replacement that has an aerosol liner, is flame resistant, and program will conduct a Multi Service Operational Test and Evaluation	advanced Chemical, Biological, Radiological and Nucle acy chemical biological garment is nearing the end of i e resistance. The UIPE FoS GP is a two-piece lightweig does not reduce Warfighter effectiveness in the areas	ear (CBRN)/Toxic Ind ts service life and doe ght (compared to the	lustrial Mater es not meet ι legacy syste	ial (TIM) updated m) duty
The Tactical All-Hazards Threat Protective Ensemble (TATPE) will propersonnel with increased protection against non-traditional and advar level of protection and performance not previously available together. align with the necessary operational requirements. The TATPE is a s (SCBA), M53 protective mask, and cooling and hydration systems. T	nced threat agents during CWMD crisis and response in TATPE will capitalize on the protection factor of commission system consisting of a protective garment that integrate	missions in a more at nercial Level A with o s with a Self-Contain	hletic fit coml design modifi ded Breathing	bining a cations to Apparatus
delivering a similar capability applied against the range of military ope Initial Production/Full Rate Production decision and expects to achiev	erations in all environments under all conditions. In FY	22, the TATPE obtair	ned a MS C L	ow Rate
delivering a similar capability applied against the range of military ope	erations in all environments under all conditions. In FY e an Initial Operations Capability (IOC) for SOF, EOD, FoS) Air program will provide the Warfighter percutaned lear (CBRN) threats. UIPE FoS Air will improve aircreating ing mobility and resulting in an increase operational eff , Radiological Layer (CBRL) to address the specific record ergarment (2PUG) to address the remaining USAF and	22, the TATPE obtair and Special Mission ous protection from o w performance and s fectiveness. The UIP quirements of the Uni I United States Navy	ned a MS C L Units within perationally r urvivability ur E FoS Air pro ted States Ai / United State	ow Rate SOCOM. elevant nder ogram r Force
delivering a similar capability applied against the range of military oper Initial Production/Full Rate Production decision and expects to achieve Uniform Integrated Protection Ensemble (UIPE) Family of Systems (F traditional and non-traditional Chemical, Biological, Radiological, Nuc CBRN conditions by reducing thermal burden and bulk, while increase is composed of two variants. The UIPE FoS Air Chemical, Biological, (USAF) tactical/ejection fixed wing platforms and the Two Piece Under Corps tactical/ejection seat (rotary wing) and non-ejection (fixed wing	erations in all environments under all conditions. In FY e an Initial Operations Capability (IOC) for SOF, EOD, FoS) Air program will provide the Warfighter percutaned lear (CBRN) threats. UIPE FoS Air will improve aircreating ing mobility and resulting in an increase operational eff , Radiological Layer (CBRL) to address the specific record ergarment (2PUG) to address the remaining USAF and	22, the TATPE obtair and Special Mission ous protection from o w performance and s fectiveness. The UIP quirements of the Uni I United States Navy	ned a MS C L Units within perationally r urvivability ur E FoS Air pro ted States Ai / United State	ow Rate SOCOM. elevant nder ogram r Force
delivering a similar capability applied against the range of military oper Initial Production/Full Rate Production decision and expects to achieve Uniform Integrated Protection Ensemble (UIPE) Family of Systems (F traditional and non-traditional Chemical, Biological, Radiological, Nuc CBRN conditions by reducing thermal burden and bulk, while increase is composed of two variants. The UIPE FoS Air Chemical, Biological, (USAF) tactical/ejection fixed wing platforms and the Two Piece Under Corps tactical/ejection seat (rotary wing) and non-ejection (fixed wing	erations in all environments under all conditions. In FY e an Initial Operations Capability (IOC) for SOF, EOD, FoS) Air program will provide the Warfighter percutaned lear (CBRN) threats. UIPE FoS Air will improve aircreating ing mobility and resulting in an increase operational eff , Radiological Layer (CBRL) to address the specific record ergarment (2PUG) to address the remaining USAF and	22, the TATPE obtair and Special Mission ous protection from o w performance and s fectiveness. The UIP quirements of the Uni I United States Navy is transitioning to pro	ned a MS C L Units within perationally r urvivability ur E FoS Air pro ted States Ai / United States duction.	ow Rate SOCOM. elevant nder ogram r Force es Marine
delivering a similar capability applied against the range of military oper Initial Production/Full Rate Production decision and expects to achiev Uniform Integrated Protection Ensemble (UIPE) Family of Systems (F traditional and non-traditional Chemical, Biological, Radiological, Nuc CBRN conditions by reducing thermal burden and bulk, while increasi is composed of two variants. The UIPE FoS Air Chemical, Biological, (USAF) tactical/ejection fixed wing platforms and the Two Piece Under Corps tactical/ejection seat (rotary wing) and non-ejection (fixed wing B. Accomplishments/Planned Programs (\$ in Millions) Title: 1) JSAM SA	erations in all environments under all conditions. In FY e an Initial Operations Capability (IOC) for SOF, EOD, FoS) Air program will provide the Warfighter percutaned lear (CBRN) threats. UIPE FoS Air will improve aircreating ing mobility and resulting in an increase operational eff , Radiological Layer (CBRL) to address the specific record ergarment (2PUG) to address the remaining USAF and	22, the TATPE obtair and Special Mission ous protection from o w performance and s fectiveness. The UIP quirements of the Uni I United States Navy is transitioning to pro	ned a MS C L Units within perationally r urvivability ur E FoS Air pro ted States Ai / United States duction.	ow Rate SOCOM. elevant nder ogram r Force es Marine
delivering a similar capability applied against the range of military oper Initial Production/Full Rate Production decision and expects to achiev Uniform Integrated Protection Ensemble (UIPE) Family of Systems (F traditional and non-traditional Chemical, Biological, Radiological, Nuc CBRN conditions by reducing thermal burden and bulk, while increasi is composed of two variants. The UIPE FoS Air Chemical, Biological, (USAF) tactical/ejection fixed wing platforms and the Two Piece Under Corps tactical/ejection seat (rotary wing) and non-ejection (fixed wing B. Accomplishments/Planned Programs (\$ in Millions)	erations in all environments under all conditions. In FY e an Initial Operations Capability (IOC) for SOF, EOD, FoS) Air program will provide the Warfighter percutaned lear (CBRN) threats. UIPE FoS Air will improve aircreating ing mobility and resulting in an increase operational eff , Radiological Layer (CBRL) to address the specific record ergarment (2PUG) to address the remaining USAF and	22, the TATPE obtair and Special Mission ous protection from o w performance and s fectiveness. The UIP quirements of the Uni I United States Navy is transitioning to pro	ned a MS C L Units within perationally r urvivability ur E FoS Air pro ted States Ai / United States duction.	ow Rate SOCOM. elevant nder ogram r Force es Marine
delivering a similar capability applied against the range of military oper Initial Production/Full Rate Production decision and expects to achiev Uniform Integrated Protection Ensemble (UIPE) Family of Systems (F traditional and non-traditional Chemical, Biological, Radiological, Nuc CBRN conditions by reducing thermal burden and bulk, while increase is composed of two variants. The UIPE FoS Air Chemical, Biological, (USAF) tactical/ejection fixed wing platforms and the Two Piece Under Corps tactical/ejection seat (rotary wing) and non-ejection (fixed wing B. Accomplishments/Planned Programs (\$ in Millions) Title: 1) JSAM SA Description: Completed Operational Testing and Evaluation (OT&E)	erations in all environments under all conditions. In FY re an Initial Operations Capability (IOC) for SOF, EOD, FoS) Air program will provide the Warfighter percutaned lear (CBRN) threats. UIPE FoS Air will improve aircreating mobility and resulting in an increase operational eff , Radiological Layer (CBRL) to address the specific record ergarment (2PUG) to address the remaining USAF and) platforms. FY23 is last year of BA5 funding, program attion, Management Services, and Support to mature	22, the TATPE obtair and Special Mission bus protection from o w performance and s fectiveness. The UIP quirements of the Uni I United States Navy is transitioning to pro FY 2022 1.005	ned a MS C L Units within perationally r urvivability ur E FoS Air pro ted States Ai / United States oduction. FY 2023	ow Rate SOCOM. elevant nder ogram r Force es Marine

PE 0604384BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program

Exhibit R-2A, RDT&E Project Justi Appropriation/Budget Activity 0400 / 5				R-1 P I PE 06	ogram Eler	nent (Numb Chemical and - EMD			ct (Number/Na ndividual Prote		
B. Accomplishments/Planned Prog	grams (\$ in N	<u>/lillions)</u>							FY 2022	FY 2023	FY 2024
Description: Development of the ne	xt generation	protective e	ensembles.								
<i>Title:</i> 4) UIPE FOS AIR									3.858	-	-
Description: Design, Test, and Integ	gration of the	Two Piece I	Jndergarme	nt (2PUG)							
				Accon	nplishment	s/Planned P	rograms Su	btotals	18.690	-	-
C. Other Program Funding Summa	-		<u>FY 2024</u>	<u>FY 2024</u>	<u>FY 2024</u>					Cost To	
<u>Line Item</u> • IP7: <i>Individual</i> Protection (Op Sys Dev)	<u>FY 2022</u> 11.659	<u>FY 2023</u> -	Base -	<u>000</u> -	<u>Total</u> -	<u>FY 2025</u> -	<u>FY 2026</u> -	<u>FY 202</u>	<u>27 FY 2028</u> 	<u>Complete</u> 0.000	<u>Total Cos</u> 11.65
• PT5: Protect (SDD)	-	87.923	97.975	-	97.975	69.858	66.259	52.87	71 67.776	Continuing	Continuin
• UN5: Understand (SDD)	-	126.071	182.726	-	182.726	137.991	127.671	108.90		Continuing	
• UN7: Understand (Op Sys Dev)	-	40.414	50.603	-	50.603	58.881	71.869	68.83		Continuing	
• JI0002: JS Aircrew Mask (JSAM)	29.744	20.823	-	-	-	-	-			0.000	105.07
• PHM018: SPU Rapid Capability Development And Demo (SPU RCDD)	10.834	9.914	49.455	-	49.455	20.689	20.180	24.21	16 26.638	Continuing	Continuin
• PHM032: Uniform Integrated Protective Ensemble FOS Gloves (UIPE FOS GLOVES)	-	-	4.978	-	4.978	6.215	7.974	8.32	28 8.926	Continuing	Continuin
PHM033: Uniform Integrated Protective Ensemble General Purpose (UIPE FOS GP)	4.456	30.145	55.100	-	55.100	111.350	111.783	112.10)6 113.401	Continuing	Continuin
• PHM034: Uniform Integrated Protection Ensemble FOS Air (UIPE FOS AIR)	47.798	23.407	25.794	-	25.794	26.195	26.403	17.58	36 0.492	Continuing	Continuin
Remarks											
D. Acquisition Strategy JOINT SERVICE AIRCREW MASK	STRATEGIC	AIRCRAFT	(JSAM SA)								
PE 0604384BP: Chemical and Biolog Chemical and Biological Defense Pro		Program		UNCLAS Page 126			R-1 Line #	¥132		Vol	ume 4 - 372

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	I Defense Program	Date: March 2023
0400 / 5	R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> <i>Defense Program - EMD</i>	 umber/Name) dual Protection (SDD)

The contract strategy consists of two sole-source contracts with Avon Protection Systems, the manufacturer of the fielded M53 mask. The first contract, which was awarded on 31 July 2013, covers all activities during the Engineering and Manufacturing Development (EMD) phase to include all LRIP builds. The second contract, which was awarded on 4 January 2019 to Avon Protection Systems, will cover the activities during the Production and Deployment (PD) phase including all Full Rate Production (FRP) builds for the Services.

SPU RAPID CAPABILITY DEVELOPMENT AND DEPLOYMENT (SPU RCDD)

The SPU RCDD overall acquisition strategy allows for rapid prototyping and testing of novel and modified COTS or GOTS systems against mission critical capabilities to enhance mission success. The SPU RCDD will use technical and functional evaluations of currently fielded items to identify materiel that requires modernization and incorporate operationally-relevant system developments. This will be accomplished through competitive contracting vehicles such as Multiple Award Indefinite Delivery Indefinite Quantify Task Order and the Countering Weapons of Mass Destruction Other Transaction Authority (CWMD OTA) for the development of prototype test assets. The SPU RCDD will use Government Agencies for prototype development, test and evaluation, and technical support.

UNIFORM INTEGRATED PROTECTIVE ENSEMBLE GENERAL PURPOSE (UIPE FOS GP)

The Uniform Integrated Protective Ensemble Family of Systems General Purpose (UIPE FoS GP) program used an Other Transaction Authority (OTA) and Government designed prototypes produced in conjunction with an Industry Partner to acquire prototypes for early user testing. Warfighter feedback, trade space analysis, and chemical testing resulted in three government designed candidates being down selected in 3QFY20. These three candidates are designed to minimize operational burden and provide improved form, fit, function, and integration with the current Warfighter kits compared to legacy systems. Additional testing, review of the results, stakeholder guidance, and a risk analysis led to the selection of two variants. During 3QFY22, one variant will be selected to enter the Operational Assessment and Developmental/Operational Testing. UIPE FoS GP will be executing multiple awards in the next 3 years, where production occurring before the milestone to allow for completion of UIPE evaluation (effectiveness, suitability and survivability) prior to award of a high ceiling production contract. This will allow the vendor to better estimate pricing (labor and material) with an initial production ramp up; and mitigates schedule risk for award of a high ceiling production contract.

TATPE completed all EMD activities with FY21 RDT&E and transitioned to procurement in FY22.

UNIFORM INTEGRATED PROTECTION ENSEMBLE FOS AIR (UIPE FOS AIR)

The Uniform Integrated Protection Ensemble (UIPE) Family of Systems (FoS) Air utilizes a streamlined acquisition strategy that identifies mature technology and capitalizes on work accomplished by the United States Air Force (USAF) Integrated Aircrew Ensemble (IAE) and UIPE FoS General Purpose programs. The UIPE FoS Air will utilize an Milestone A-C acquisition strategy that will accelerate fielding to the Warfighter. The contract strategy leverages the USAF IAE Small Business Innovation Research (SBIR) Phase III contract to procure UIPE FoS Air Chemical, Biological, Radiological Layer (CBRL). The UIPE FoS Air Two Piece Undergarment (2PUG) will be procured utilizing a Government design on a separate contract.

Appropriation/Budge 0400 / 5	et Activity	,				PE 0604		ement (N Chemica n - EMD				(Number dividual Pl	r/ Name) rotection (SDD)	
Product Developmer	nt (\$ in Mi	illions)	ſ	FY	2022	FY 2	023	FY 2 Ba	-		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
SPU RCDD - HW C - Assault Respirator	Various	Various : N/A	0.564	0.046	Nov 2021	0.000		0.000		-		0.000	0.000	0.610	0.000
SPU RCDD - HW C - Prototype Procurement	Various	Various : N/A	4.239	1.780	Dec 2021	0.000		0.000		-		0.000	0.000	6.019	0.000
SPU RCDD - HW S - Low Temperature Plasma Mass Spectrometer (LTPMS)	C/CPFF	Advanced Technologies International : Summerville, SC	-	0.821	Jan 2022	0.000		0.000		-		0.000	0.000	0.821	0.000
	1	Subtotal	4.803	2.647		0.000		0.000		-		0.000	0.000	7.450	N/A
Support (\$ in Million	s)		ſ	FY	2022	FY 2	023	FY 2 Ba	-		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
JSAM SA - TD/D S - Logistics, Engineering, and IPT Support	MIPR	Various : N/A	1.030	0.768	Nov 2021	0.000		0.000		-		0.000	0.000	1.798	0.000
SPU RCDD - ES C - Engineering Support	Various	Various : N/A	0.672	0.311	Dec 2021	0.000		0.000		-		0.000	0.000	0.983	0.000
UIPE FOS GP - ES C - Engineering & Technical IPT Support / SME Support	Various	Various : N/A	1.049	0.807	Nov 2021	0.000		0.000		-		0.000	0.000	1.856	0.000
UIPE FOS GP - ILS S - Integrated Log Support- System	Various	Various : N/A	-	0.595	Nov 2021	0.000		0.000		-		0.000	0.000	0.595	0.000
UIPE FOS AIR - ES S - Engineering and IPT Support	Various	Various : N/A	-	0.578	Nov 2021	0.000		0.000		-		0.000	0.000	0.578	0.000
		Subtotal	2.751	3.059		0.000		0.000		-		0.000	0.000	5.810	N/A

PE 0604384BP: Chemical and Biological Defense Program ... Chemical and Biological Defense Program

Exhibit R-3, RDT&E P	Project C	ost Analysis: PB 2	2024 Chei	mical and	d Biologica		•				-	Date:	March 20	23	
Appropriation/Budge 0400 / 5	et Activity					PE 0604	-	Chemica	umber/N al and Biol		-	(Number dividual P	r/ Name) rotection (SDD)	
Test and Evaluation	(\$ in Milli	ons)		FY	2022	FY 2	023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
JSAM SA - DTE S - DT/OT	MIPR	Various : N/A	4.197	0.167	Nov 2021	0.000		0.000		-		0.000	0.000	4.364	0.00
SPU RCDD - DTE C - Testing and Evaluation	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	0.218	0.753	Dec 2021	0.000		0.000		-		0.000	0.000	0.971	0.000
UIPE FOS GP - DTE C - DT/OT	Various	Various : N/A	2.816	7.247	Nov 2021	0.000		0.000		-		0.000	0.000	10.063	0.00
UIPE FOS AIR - DTE C - System Level Testing	Various	Various : N/A	3.043	2.991	Nov 2021	0.000		0.000		-		0.000	0.000	6.034	0.00
		Subtotal	10.274	11.158		0.000		0.000		-		0.000	0.000	21.432	N/#
Management Service	es (\$ in M	illions)		FY	2022	FY 2	023	FY 2 Ba	2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
JSAM SA - PM/MS S - Program Management Support	MIPR	Various : N/A	1.846	0.070	Nov 2021	0.000		0.000		-		0.000	0.000	1.916	0.00
SPU RCDD - PM/MS C - Program Management Support	Various	Various : N/A	0.979	0.767	Nov 2021	0.000		0.000		-		0.000	0.000	1.746	0.00
UIPE FOS GP - PM/MS C - Program Management Support	Various	Various : N/A	0.673	0.700	Nov 2021	0.000		0.000		-		0.000	0.000	1.373	0.00
UIPE FOS AIR - PM/MS C - Program Management Services	MIPR	Various : N/A	0.269	0.289	Nov 2021	0.000		0.000		-		0.000	0.000	0.558	0.00
															1

PE 0604384BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program

Exhibit R-3, RDT&E Project Cost Analysis: PB 2	024 Cher	mical and	Biologia	cal Defense	e Progra	am				Date:	March 20	23	
Appropriation/Budget Activity 0400 / 5		PE 0604	4384BP	lement (N I Chemica m - EMD		,	-	(Numbei lividual Pl	r/ Name) rotection (SDD)			
	Prior Years	FY	2022	FY 2	2023		2024 Ise	FY 2 OC		FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract
Project Cost Totals	21.595	18.690		0.000		0.000		-		0.000	0.000	40.285	N/A

Remarks

ppropriation/Budget Activity 400 / 5							F	PE 0	604	384	BP /		mic	Num al ar				I						ame ectio		DD))	
			(202			 Ý 20					2024			FY 2		-		·	2026	-		FY 2	,				2028	_
JSAM SA - OT&E-Operational Test and Evaluation - DT/OT (Capability, Integration, Airworthiness Certification)	1		2 3	3 4	- 1 ■	2 :	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
JSAM SA - FOC-Full Operational Capability																												
SPU RCDD - Modernize CBRN Materiel																												
SPU RCDD - Develop Modular Self Contained Breathing Apparatus (MSCBA)																												
SPU RCDD - Develop Enhanced Warfighter Augmented Training (EWAT)																												-
SPU RCDD - Prototype Novel CBRN Equipment																												
SPU RCDD - Develop Low Temperature Plasma Mass Spectrometer (LTPMS)																												-
SPU RCDD - Develop Optimized CBRN Hydration System (OCHS)																												
SPU RCDD - Develop Assault Respirator																												
SPU RCDD - Develop USSOCOM-specific UGV/UAS Sensor Integration																												-
UIPE FOS GP - TATPE Technical Testing																												-
UIPE FOS GP - MS C-Milestone C - TATPE		_																										-
UIPE FOS GP - TATPE Production Contract Award																												
UIPE FOS GP - FRP-Full Rate Production Decision - TATPE																												-
UIPE FOS GP - IOC-Initial Operational Capability - TATPE																												-

Exhibit R-4, RDT&E Schedule Profile: PB 2024 C	nemical	and Bio	logical	Defens	e Prog	jram							Dat	e: Marc	h 20	23	
Appropriation/Budget Activity 0400 / 5				P	E 0604	384BP		nical a	nber/Na and Biolo					er/Nan Protec		SDD)	
		2022		2023		FY 202			2025		′ 2026			2027		FY 202	-
	1 2	3 4	1 2	3	4 1	2 3	4 1	2	3 4	1 2	2 3	4	1 2	3 4	1	2 3	4
UIPE FOS GP - FOC-Full Operational Capability - TATPE																	
UIPE FOS GP - DT/OT																	
UIPE FOS GP - CDR-Critical Design Review																	
UIPE FOS GP - Production Initiation Contract																	
UIPE FOS GP - Operational Assessment																	
UIPE FOS GP - Manufacturing Readiness Assessment (MRA)																	
UIPE FOS GP - Joint Independent Logistics Assessment (JILA)																	
UIPE FOS GP - MS C-Milestone C																	
UIPE FOS GP - Capability Development Document (CDD) Update (if needed)																	
UIPE FOS GP - Production Contract Award																	
UIPE FOS GP - OT&E-Operational Test and Evaluation																	
UIPE FOS GP - FRP-Full Rate Production Decision																	
UIPE FOS GP - IOC-Initial Operational Capability																	
UIPE FOS AIR - Aircraft Integration Testing																	
UIPE FOS AIR - Swatch and System Level Testing																	
UIPE FOS AIR - Fixed Wing Ejection Aircraft Integration Testing																	
UIPE FOS AIR - Fixed Wing Non-Ejection Aircraft Testing																	

Exhibit R-4, RDT&E Schedule Profile: PB 2024 (Cher	nica	l and	d Bio	logic	al D	efen	ise Pi	rogi	ram												Date	e: M	arch	202	23		
Appropriation/Budget Activity 0400 / 5			R-1 Program Element (N PE 0604384BP / Chemic Defense Program - EMD								ical and Biological IP5 I II					oject (Number/Name) 5 I Individual Protection (SDD)												
	FY 2022			FY 2023		2023		F	FY 20)24			FY	2025	5				2026		FY 2027			FY 2028				
[1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
UIPE FOS AIR - Rotary Wing Aircraft Integration Testing																												
UIPE FOS AIR - Prototype Development (2PUG)																												
UIPE FOS AIR - IOC-Initial Operational Capability - CBRL																												
UIPE FOS AIR - Human Factors Testing																												
UIPE FOS AIR - Safe to Fly Certification																												
UIPE FOS AIR - FOC-Full Operational Capability - CBRL																												
UIPE FOS AIR - Developmental/Operational Testing (DT/OT)																												
UIPE FOS AIR - Safe-to-Fly and Airworthiness Testing																												
UIPE FOS AIR - Capability Development Document (CDD) Update																												
UIPE FOS AIR - FRP-Full Rate Production Decision - 2PUG																												
UIPE FOS AIR - IOC-Initial Operational Capability - 2PUG																												
UIPE FOS AIR - FOC-Full Operational Capability - 2PUG																												

Exhibit R-4A, RDT&E Schedule Details: PB 2024 Chemical and Biological De	Date: March 2023		
	R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> <i>Defense Program - EMD</i>	•	umber/Name) dual Protection (SDD)

Schedule Details

	Sta	art	End			
Events	Quarter	Year	Quarter	Year		
JSAM SA - OT&E-Operational Test and Evaluation - DT/OT (Capability, Integration, Airworthiness Certification)	1	2022	4	2022		
JSAM SA - FOC-Full Operational Capability	2	2025	2	2025		
SPU RCDD - Modernize CBRN Materiel	1	2022	4	2027		
SPU RCDD - Develop Modular Self Contained Breathing Apparatus (MSCBA)	1	2022	4	2024		
SPU RCDD - Develop Enhanced Warfighter Augmented Training (EWAT)	1	2022	4	2024		
SPU RCDD - Prototype Novel CBRN Equipment	1	2022	4	2027		
SPU RCDD - Develop Low Temperature Plasma Mass Spectrometer (LTPMS)	1	2022	4	2024		
SPU RCDD - Develop Optimized CBRN Hydration System (OCHS)	1	2022	2	2023		
SPU RCDD - Develop Assault Respirator	1	2022	4	2023		
SPU RCDD - Develop USSOCOM-specific UGV/UAS Sensor Integration	1	2022	4	2023		
UIPE FOS GP - TATPE Technical Testing	1	2022	2	2022		
UIPE FOS GP - MS C-Milestone C - TATPE	3	2022	3	2022		
UIPE FOS GP - TATPE Production Contract Award	4	2022	4	2022		
UIPE FOS GP - FRP-Full Rate Production Decision - TATPE	4	2022	4	2022		
UIPE FOS GP - IOC-Initial Operational Capability - TATPE	2	2024	2	2024		
UIPE FOS GP - FOC-Full Operational Capability - TATPE	3	2025	3	2025		
UIPE FOS GP - DT/OT	2	2022	3	2023		
UIPE FOS GP - CDR-Critical Design Review	3	2022	3	2022		
UIPE FOS GP - Production Initiation Contract	2	2023	2	2023		
UIPE FOS GP - Operational Assessment	1	2024	1	2024		
UIPE FOS GP - Manufacturing Readiness Assessment (MRA)	2	2023	2	2023		

15	R-1 Program Element (N PE 0604384BP <i>I Chemic</i> Defense Program - EMD		Project (Number/Name) IP5 / Individual Protection (SDD)			
		Start	E	nd		
Events	Quart	er Year	Quarter	Year		
UIPE FOS GP - Joint Independent Logistics Assessment (JILA)	3	2023	4	2023		
UIPE FOS GP - MS C-Milestone C	4	2023	4	2023		
UIPE FOS GP - Capability Development Document (CDD) Update (if neede	ed) 4	2023	4	2023		
UIPE FOS GP - Production Contract Award	1	2025	1	2025		
UIPE FOS GP - OT&E-Operational Test and Evaluation	2	2024	2	2024		
UIPE FOS GP - FRP-Full Rate Production Decision	1	2026	1	2026		
UIPE FOS GP - IOC-Initial Operational Capability	4	2028	4	2028		
UIPE FOS AIR - Aircraft Integration Testing	1	2022	2	2022		
UIPE FOS AIR - Swatch and System Level Testing	1	2022	4	2022		
UIPE FOS AIR - Fixed Wing Ejection Aircraft Integration Testing	1	2022	4	2023		
UIPE FOS AIR - Fixed Wing Non-Ejection Aircraft Testing	1	2022	4	2023		
UIPE FOS AIR - Rotary Wing Aircraft Integration Testing	1	2022	4	2023		
UIPE FOS AIR - Prototype Development (2PUG)	1	2022	4	2022		
UIPE FOS AIR - IOC-Initial Operational Capability - CBRL	2	2022	2	2022		
UIPE FOS AIR - Human Factors Testing	3	2022	3	2022		
UIPE FOS AIR - Safe to Fly Certification	4	2022	4	2023		
UIPE FOS AIR - FOC-Full Operational Capability - CBRL	4	2022	4	2022		
UIPE FOS AIR - Developmental/Operational Testing (DT/OT)	1	2022	4	2022		
UIPE FOS AIR - Safe-to-Fly and Airworthiness Testing	1	2023	4	2023		
UIPE FOS AIR - Capability Development Document (CDD) Update	2	2023	2	2023		
UIPE FOS AIR - FRP-Full Rate Production Decision - 2PUG	2	2023	2	2023		
UIPE FOS AIR - IOC-Initial Operational Capability - 2PUG	2	2024	2	2024		
UIPE FOS AIR - FOC-Full Operational Capability - 2PUG	4	2028	4	2028		

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program												Date: March 2023			
Appropriation/Budget Activity 0400 / 5		PE 060438	am Elemen 34BP / Chen rogram - EN	nical and Bi		Project (Number/Name) MB5 / Medical Biological Defense (SDD)									
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost			
MB5: Medical Biological Defense (SDD)	-	138.156	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	138.156			
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-					

A. Mission Description and Budget Item Justification

This Project supports Engineering and Manufacturing Development and Low Rate Initial Production (EMD/LRIP) of medical countermeasures, development of reagents, assays, diagnostic equipment, Biosurveillance and supporting efforts. After FY 2022, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. MB5 efforts in FY 2022 progress to Projects UN5, PT5, MT5 and EN5. This restructuring provides standardization and alignment across CBDP research, development and acquisition efforts.

Efforts included in this Project are:

- (1) Antiviral Therapeutics Program (AV TX) **Progresses to MT5 in FY2023**,
- (2) Botulinum Monoclonal Antibodies (BOT MAB) ** Progresses to PT5 in FY2023**,
- (3) Chem Bio Incident Preparedness and Response Advanced Development and Manufacturing (CBIPR ADM) ** Progresses to EN5 in FY2023**,
- (4) Countering Emerging Threats Rapid Acquisition and Investigation of Drugs for Repurposing (CET RAIDR) ** Progresses to MT5 in FY2023**,
- (5) Defense Biological Products Assurance Program (DBPAP) **Progresses to UN5 in FY2023**,
- (6) Next Generation Diagnostic System (NGDS) 2 Chemical Diagnostic (NGDS 2 CHEMDX) ** Progresses to UN5 in FY2023**,
- (7) Next Generation Diagnostic System (NGDS) 2 Man Portable Diagnostic System (NGDS 2 MPDS) ** Progresses to UN5 in FY2023**, and
- (8) Special Immunizations Program (VAC SIP) **Progresses to PT5 in FY2023**

The Antiviral Therapeutics (AV TX) program will develop and deliver U.S. Food & Drug Administration (FDA) approved antiviral therapeutics for the warfighter. Based on the current gap in defense to the warfighter, the initial therapeutic candidate is now for a treatment against the Marburg virus in lieu of Ebola Zaire to follow for approval of a PanFilo therapeutic. Other pathogens on the biological warfare threat lists, include viruses of interest from Filoviridae, Arenaviridae, Bunyaviridae, and Flaviviridae. Developed broad spectrum antiviral therapeutics will be employed after suspected or confirmed exposure to the relevant threat agents and AV TX Medical Countermeasures (MCMs) will ameliorate the effect of threat agents to the warfighter. In the event of a natural occurring outbreak, antiviral therapeutics can be provided to ensure freedom of operation.

The Botulinum Monoclonal Antibodies (BOT MAB) program will provide protection from Botulinum neurotoxin (BoNT) which is classified by the Centers for Disease Control and Prevention (CDC)as a category A threat, one that poses the highest risk to the public and national security. This Medical Countermeasure (MCM) will prevent (pre-exposure) and reduce the incidence or progression of botulism disease, following exposure to BoNT serotypes A/B. The drug product contains a total of six monoclonal antibodies, three for BoNT type A and three for BoNT type B, and the planned route of administration is Intra-Muscular (IM) injection.

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical a	nd Biological Defense Program	Date: March 2023				
Appropriation/Budget Activity 0400 / 5	R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> <i>Defense Program - EMD</i>	Project (Number/Name) MB5 / Medical Biological Defense (SDD)				
The CBIPR-ADM program ensures prioritization to domestic bioph and other strategic partners) that are operationally ready to rapidly and biological threats including pandemic response. Prioritization technologies and infrastructure at these facilities. Thus, these faci enhance preparedness for existing threats, and rapidly respond to efforts include: Vaccines for Viral Agents, Vaccines for Bacterial A prophylactic use across all agent classes. Funds to support priorit manufacturing funding lines. The Department is now providing de responsiveness. In FY24, the CBIPR-ADM program continues to e development of MCMs against chemical and biological threats.	v develop and manufacture medical countermeasures (M is achieved by establishing and enhancing proven bioph ilities will have the capability to accelerate development of emerging threats as part of a medical integrated layered gents and Toxins, monoclonal antibodies, antibody fragm tization and operational readiness were previously provid dicated funds. The CBIPR-ADM return on investment is	ICMs) against current and emerging chemical harmaceutical manufacturing platform of MCMs at all stages of development, d defense. MCMs that benefit from these ments and conjugates for therapeutic and ded via individual product development and an increased level of preparedness and				
The Countering Emerging Threats Rapid Acquisition and Investiga countermeasures towards known, potential, and emerging threats, available. CET RAIDR will leverage lessons learned in Coronaviru Repurposed Therapeutics (CR TX) to address repurposing of thera additional drugs candidates for repurposing.	, bridging the gap from when a threat is identified until tak s Aid, Relief, and Economic Security (CARES) Act funde	rgeted countermeasures such as vaccines and efforts under Coronavirus Disease (COVIE				
The Defense Biological Product Assurance Program (DBPAP) ser and reagents that meet the requirements of the warfighter and Join and predict effective medical countermeasure solutions that are cr (OSCAR), where multiple government agencies and customers ca support optimization and expansion of biological threat agents refe	nt biological defense systems. DBPAP pursues an array itical to preparedness. The DBPAP enables an Ordering In place orders, track order status, and monitor ordering	of analytical tools to verify assay performan System for Critical Assays and Reagents history. In FY24 DBPAP will continue to				
The NGDS 2 ChemDx program will provide a rapid, hand-held, po samples, an indicator of possible Nerve Agent exposure in individu multiple echelons of healthcare. NGDS 2 ChemDx test results are chemical nerve agents.	uals. NGDS 2 ChemDx will be employed by the Army, A	ir Force, Navy, Marines and SOCOM at				
The NGDS 2 MPDS program will provide a simple-to-use, portable diagnosis of infectious diseases and biological warfare agents. The command situational awareness, and mitigate the effects of exposed of the second structure	ne MPDS will enable earlier patient diagnosis, improve de	ecision support for treatment, evacuation and				
The SIP continually manages, updates, and executes the Investiga products which provide additional protection to individuals that are		•				

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical	I and Biological Defense Program	Date: N	larch 2023					
Appropriation/Budget Activity 0400 / 5	R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> <i>Defense Program - EMD</i>	Project (Number/Name) MB5 / <i>Medical Biological Defense (SDD)</i>						
Manufacturing Practice (GMP) storage and to conduct the period continues storage of product until destruction. VAC SIP restruct				3 SIP				
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024				
Title: 1) AV TX		14.152	-	-				
Description: Enabling Technologies								
Title: 2) BOT MAB		26.364	-	-				
Description: Clinical and Nonclinical Studies								
Title: 3) BOT MAB		33.000	-	-				
Description: Manufacturing								
Title: 4) CBIPR-ADM		10.131	-	-				
Description: ADM Infrastructure								
Title: 5) CET RAIDR		7.708	-	-				
Description: Advance Development								
Title: 6) CET RAIDR		11.500	-	-				
Description: Pandemic Preparedness								
Title: 7) DBPAP		7.588	-	-				
Description: Development								
Title: 8) NGDS 2 CHEMDX		2.693	-	-				
Description: Engineering & Manufacturing Development								
Title: 9) NGDS 2 CHEMDX		2.126	-	-				
Description: Product Management								
Title: 10) NGDS 2 MPDS		13.437	-					
Description: Product Development								

PE 0604384BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program

Exhibit R-2A, RDT&E Project Justi	fication: PB	2024 Chem	ical and Biol	ogical Defen	se Program				Date: Ma	arch 2023	
Appropriation/Budget Activity 0400 / 5				PE 06	r ogram Ele r 04384BP / C se <i>Program</i>	Chemical and	ct (Number/Name) I Medical Biological Defense (SDD)				
B. Accomplishments/Planned Prog	grams (\$ in N	<u>Millions)</u>						[FY 2022	FY 2023	FY 2024
Title: 11) NGDS 2 MPDS									2.974	-	-
Description: Program Management	and Support										
Title: 12) VAC SIP									6.483	-	-
Description: Storage, Distribution, F	otency Testi	ng									
				Accon	nplishment	s/Planned P	rograms Su	btotals	138.156	-	-
C. Other Program Funding Summa	ry (\$ in Milli	<u>ons)</u>	FY 2024	FY 2024	<u>FY 2024</u>					Cost To	
Line Item	FY 2022	FY 2023	Base	000	Total	<u>FY 2025</u>	FY 2026	FY 202	27 FY 2028	Complete	
• EN4: Enabling	-	6.781	47.272		47.272	51.579	9.792	9.84		Continuing	
Investments (ACD&P)										U	
• EN5: Enabling Investments (SDD)	-	13.392	13.835	-	13.835	13.884	14.179	14.19	97 14.261	Continuing	Continuin
• MT5: <i>Mitigate (SDD)</i>	-	74.225	88.441	-	88.441	92.279	91.431	87.77		Continuing	
PT4: Protect (ACD&P)	-	175.219	179.158	-	179.158	135.096	107.341	123.53	38 139.376	Continuing	Continuing
• PT5: Protect (SDD)	-	87.923	97.975	-	97.975	69.858	66.259	52.87	71 67.776	Continuing	Continuin
UN5: Understand (SDD)	-	126.071	182.726	-	182.726	137.991	127.671	108.90	68.088	Continuing	Continuing
JX0210: Defense Biological	2.760	2.736	2.736	-	2.736	2.736	2.736	2.73	36 2.736	Continuing	Continuin
Products Assurance											
Program (DBPAP)											
PHM039: Botulinum Monoclonal	-	-	-	-	-	-	33.601			Continuing	Continuin
Antibodies (BOT MAB)											
 SA0043: Next Gen Diag 	-	-	1.881	-	1.881	9.579	10.982	11.89	98 11.861	Continuing	Continuin
2 Chemical Diagnostics											
(NGDS 2 CHEM DX)											
 SA0044: Next Gen Diag 	0.336	-	-	-	-	7.949	7.291	4.75	52 2.290	Continuing	Continuin
2 Man Portable Diagnostic											
System (NGDS 2 MPDS)											
<u>Remarks</u>											
D. Acquisition Strategy											
ANTI-VIRAL THERAPEUTICS (AV 1	IX)										

PE 0604384BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	Date: March 2023	
	R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> <i>Defense Program - EMD</i>	Project (Number/Name) MB5 <i>I Medical Biological Defense (SDD)</i>

The Antiviral Therapeutics (AV TX) program acquisition strategy supports the development of therapeutics against Marburg virus bio-warfare threats. The overall regulatory approach of the program remains to pursue development for Food and Drug Administration (FDA) approval under the Animal Rule. The acquisition strategy is for the Marburg indication and will leverage collected safety data and large-scale manufacturing from the COVID efforts. This product was transitioned from Science and Technology (S&T).

BOTULINUM MONOCLONAL ANTIBODIES (BOT MAB)

The BOT MAB program was initiated by the Medical Countermeasure Platform Technologies (MCMPT). The regulatory approach of the program is to pursue development of products for U.S. Food & Drug Administration (FDA) approval. The program will conduct clinical and non-clinical studies to confirm duration of protection and on-set of protection. The performer will complete small model development and procure long lead items during the Technology Maturation and Risk Reduction (TMRR) phase in order to mitigate risk and accelerate the schedule activities for Biologics License Application (BLA) submission during the Product & Development (P&D) phase. The performer will continue large scale manufacturing during the Engineering and Manufacturing Development (EMD) phase in order to accelerate the schedule activities for the prophylactic indication.

CHEM BIO INCIDENT PREPAREDNESS AND RESPONSE - (CBIPR-ADM)

By establishing new capabilities at the DoD-ADM Facility and other strategic partners, the CBIPR-ADM line ensures that the DoD will have priority access to critical technologies and infrastructure that are operationally ready to support the rapid development and manufacture of Medical Countermeasures (MCMs). This approach ensures that the DoD's efforts are not limited to a single facility. In FY24, the CBIPR-ADM line will continue to establish, enhance, and optimize new manufacturing platform technologies and infrastructure to support the production of MCMs. These new manufacturing technologies can come from any government sources (including Joint Science & Technology Office for Chemical Biological Defense (JSTO-CBD), the Walter Reed Army Institute of Research (WRAIR), the Biomedical Advanced Research and Development Authority (BARDA), etc. when mature enough for BA4 funding) and/or other external sources and targets of opportunity from industry.

COUNTERING EMERGING THREATS RAPID ACQUISITION AND INVESTIGATION OF DRUGS FOR REPURPOSING (CET RAIDR)

The Countering Emerging Threats - Rapid Acquisition and Investigation of Drugs for Repurposing (CET RAIDR) program will leverage lessons learned from the COVID-19 response to conduct studies to evaluate U.S. Food & Drug Administration (FDA) approved and late-stage development products against CBRN threats. Data generated from these efforts will be used to support interim capabilities.

DEFENSE BIOLOGICAL PRODUCTS ASSURANCE PROGRAM (DBPAP)

DBPAP utilizes best buying principles and acquisition rigor for alignment to requirements to perform an "enabling" function for certain programs of record (e.g., Analytical Lab System (ALS), Common Analytical Lab System (CALS), Next Generation Diagnostic System (NGDS)) and other enterprise partners. The DBPAP uses better buying

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program Date: March 2023									
0400 / 5	PE 0604384BP I Chemical and Biological		umber/Name) ical Biological Defense (SDD)						
nower to consolidate requirements for "commedity like" biological detection pro	Defense Program - EMD								

power to consolidate requirements for "commodity-like" biological detection products. The DBPAP coordinates closely with the Joint, Science and Technology Office to enhance the DBPAP reference material holdings in the Unified Culture Collection (UCC); improve antibodies and expand the portfolio of DBPAP immunoassays and reagents; and develop new molecular assays. The DBPAP uses a mix of competitive commercial contracts and funding of government laboratories to produce high quality assays and reagents.

NEXT GEN DIAG 2 CHEMICAL DIAGNOSTICS (NGDS 2 CHEMDX)

NGDS Increment 2 ChemDx is using an Other Transactions Authority (OTA) agreement to take advantage of nontraditional Defense contractor offerings, leveraging commercial technology to develop a capability for the diagnosis of nerve agent exposure in individuals. The OTA agreement holder is conducting system development, clinical trials and pre-developmental testing. ChemDx will use Department of Defense (DoD) test agencies to conduct Development Testing and operational user evaluations. Clinical trials will inform approval of the ChemDx system by the U.S. Food and Drug Administration for Prescription Home Use.

NEXT GEN DIAG 2 MAN PORTABLE DIAGNOSTIC SYSTEM (NGDS 2 MPDS)

NGDS 2 MPDS is currently in engineering and manufacturing development (EMD). MPDS is using Other Transactions Authority (OTA) agreements to take advantage of nontraditional Defense contractor offerings, leveraging commercial technology for Warfighter use. MPDS will use the agreement holder to conduct system development, clinical trials and pre-developmental testing (pre-DT) instrument testing. MPDS will also be using DoD clinical trial sites to support the agreement holder. MPDS will be using Department of Defense (DoD) agencies to conduct DT, operational assessment (OA), and Initial Operational Test & Evaluation (IOT&E). For the Production/ Deployment Phase, the NGDS 2 MPDS will be using an existing COVID-established Indefinite Delivery/Indefinite Quantity (IDIQ) contract with the EMD performer to procure production systems, support, and assays.

SPECIAL IMMUNIZATION PROGRAM (VAC SIP)

The SIP program manages the continual storage, testing, compliance, and distribution activities associated with Investigational New Drugs (INDs) for legacy prophylactic medical countermeasures, as well as the recent Bot and Plague vaccine candidates. Additionally, the SIP maintains interagency agreements with US Army Medical Research and Development Command to support testing and compliance requirements. This Department of Defense program supports the Federal interagency with this effort, as well as academic and industry partners.

Exhibit R-3, RDT&E F	Project C	ost Analysis: PB 2	2024 Chei	mical and	d Biologica	al Defens	e Progra	m				Date:	March 20	23		
Appropriation/Budge 0400 / 5	t Activity	1				PE 060		Chemica	lumber/N al and Bio		Project (Number/Name) MB5 / Medical Biological Defense (SDD)					
Product Developmen	nt (\$ in Mi	illions)		FY	2022	FY 2023		FY 2024 Base			2024 CO	FY 2024 Total				
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract	
AV TX - Nonclinical Trials - OTA	C/FP	Gilead Sciences : San Francisco, CA	18.903	5.223	Nov 2021	0.000		0.000		-		0.000	0.000	24.126	0.000	
AV TX - Product Development	Various	Various : N/A	-	2.175	Jun 2022	0.000		0.000		-		0.000	0.000	2.175	0.000	
CBIPR-ADM - Infrastructure	C/CPFF	Ology Bioservices, Inc. : Alachua, FL	-	9.553	Mar 2022	0.000		0.000		-		0.000	0.000	9.553	0.000	
CET RAIDR - Direct Product Support	Various	Various : N/A	-	1.927	Nov 2021	0.000		0.000		-		0.000	0.000	1.927	0.000	
DBPAP - HW C - Development of Select Biological Threat Agent Reference Materials and Assays	MIPR	Various : N/A	6.761	1.698	Mar 2022	0.000		0.000		-		0.000	0.000	8.459	0.000	
NGDS 2 CHEMDX - HW C - Product Management	Various	Various : N/A	-	1.485	Jan 2022	0.000		0.000		-		0.000	0.000	1.485	0.000	
NGDS 2 CHEMDX - HW C - Product Development	C/CPFF	MRIGlobal : Kansas City, MO	1.849	2.860	Jan 2022	0.000		0.000		-		0.000	0.000	4.709	0.000	
NGDS 2 MPDS - HW C - Product Management	Various	Various : N/A	2.505	2.627	Nov 2021	0.000		0.000		-		0.000	0.000	5.132	0.000	
NGDS 2 MPDS - HW C - Man Portable Diagnostic System (MPDS)	C/CPFF	Cepheid : Sunnyvale, CA	21.112	10.942	Jan 2022	0.000		0.000		-		0.000	0.000	32.054	0.000	
		Subtotal	51.130	38.490		0.000		0.000		-		0.000	0.000	89.620	N/A	
Support (\$ in Millions	5)			FY	2022	FY 2	2023		2024 ase		2024 CO	FY 2024 Total				
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract	
AV TX - PM/MS - Sustainment	Various	US Army Medical Research Institute of Infectious Disease (USAMRIID) : Fort Detrick, MD	4.627	2.175	Dec 2022	0.000		0.000		-		0.000	0.000	6.802	0.000	

PE 0604384BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program

Exhibit R-3, RDT&E F	Project C	ost Analysis: PB 2	024 Chei	mical and	l Biologica	al Defens	e Progra	m				Date:	March 20	23	
Appropriation/Budge 0400 / 5	Appropriation/Budget Activity 0400 / 5								umber/N al and Bio	Project (Number/Name) MB5 / Medical Biological Defense (SDD)					
Support (\$ in Millions	s)		ſ	FY 2	2022	FY 2023		FY 2024 Base			2024 CO	FY 2024 Total]		
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
DBPAP - Select Biological Threat Agent Reference Material Support	MIPR	Various : N/A	6.807	1.732	Mar 2022	0.000		0.000		-		0.000	0.000	8.539	0.000
DBPAP - Select Biological Threat Agent Reference Material Regulatory/Quality Assurance (QA) Support	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	6.350	1.747	Mar 2022	0.000		0.000		-		0.000	0.000	8.097	0.000
NGDS 2 CHEMDX - ES C - Studies and Support	Various	Various : N/A	-	0.042	Mar 2022	0.000		0.000		-		0.000	0.000	0.042	0.000
NGDS 2 MPDS - ES C - Studies and Support	Various	Various : N/A	0.129	0.256	Jan 2022	0.000		0.000		-		0.000	0.000	0.385	0.000
		Subtotal	17.913	5.952		0.000		0.000		-		0.000	0.000	23.865	N/A
Test and Evaluation ((\$ in Milli	ons)		FY 2	2022	FY 2023		FY 2024 Base		FY 2024 OCO					
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
BOT MAB - DTE C - BOT MONO	C/CPFF	Resilience Government Services, Inc. : Alachua, Florida	14.437	50.799	Apr 2022	0.000		0.000		-		0.000	52.034	117.270	0.000
CET RAIDR - DTE C - Screening of Drugs for Repurposing	Various	Various : N/A	-	15.550	Dec 2021	0.000		0.000		-		0.000	0.000	15.550	0.000
NGDS 2 MPDS - OTHT S - Analytical/Clinical Testing	MIPR	US Army Medical Research and Development Command (USAMRDC) : Fort Detrick, MD	0.364	1.093	Feb 2022	0.000		0.000		-		0.000	0.000	1.457	0.000

PE 0604384BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program

Exhibit R-3, RDT&E P	Project C	ost Analysis: PB 2	2024 Cher	mical and	Biologica	al Defens	e Prograr	n			_	Date:	March 20	23	
Appropriation/Budge 0400 / 5	t Activity	1				PE 060		Chemica	umber/Nal and Bio			(Number Medical Bi		efense (S	SDD)
Test and Evaluation ((\$ in Milli	ons)		FY 2	2022	FY 2	023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
NGDS 2 MPDS - DTE S - System Test & Evaluation	MIPR	Various : N/A	1.454	0.067	Feb 2022	0.000		0.000		-		0.000	0.000	1.521	0.00
VAC SIP - OTHT C - Storage and Distribution of Vaccines	SS/FP	Fisher BioServices : Rockville, MD	3.154	0.593	Jan 2022	0.000		0.000		-		0.000	0.000	3.747	0.00
VAC SIP - OTHT C - Potency Testing of Vaccines	C/CPFF	Battelle Memorial Institute : Columbus, OH	1.112	4.210	Jan 2022	0.000		0.000		-		0.000	0.000	5.322	0.00
VAC SIP - OTHT C - Potency Testing of Vaccines	MIPR	US Army Medical Research Institute of Infectious Disease (USAMRIID) : Fort Detrick, MD	17.501	1.680	Jan 2022	0.000		0.000		-		0.000	0.000	19.181	0.00
		Subtotal	38.022	73.992		0.000		0.000		-		0.000	52.034	164.048	N//
Management Service	es (\$ in M	illions)	ſ	FY 2	2022	FY 2	023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
AV TX - PM/MS - SB - Program Management	Various	JPEO Chem, Bio, Rad, and Nuc Defense (JPEO- CBRND) : Aberdeen Proving Ground, MD	10.445	1.074	Dec 2021	0.000		0.000		-		0.000	0.000	11.519	0.00
AV TX - PM/MS - SB - Management Support (Biological Therapeutics)	Various	JPM CBRN Medical : Ft. Detrick, MD	3.287	3.505	Feb 2022	0.000		0.000		-		0.000	0.000	6.792	0.00
BOT MAB - Program Management Support	Various	JPM CBRN Medical, JPEO-CBRND : Fort Detrick, MD	4.338	4.060	Dec 2021	0.000		0.000		-		0.000	4.765	13.163	0.00
BOT MAB - CBRN Medical Support	Various	JPEO Chem, Bio, Rad, and Nuc Defense (JPEO-	1.700	4.505	Apr 2022	0.000		0.000		-		0.000	5.577	11.782	0.00

PE 0604384BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program

Exhibit R-3, RDT&E F Appropriation/Budge 0400 / 5	-	*				R-1 Pro PE 060	gram Ele	ement (N Chemica	umber/N al and Bio			(Number	March 20 r/ Name) ological D		SDD)
Management Service	es (\$ in M	illions)		FY	2022	FY 2	023	FY 2 Ba	2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
		CBRND) : Aberdeen Proving Ground, MD													
CBIPR-ADM - Program Management Support	Various	JPL CBRND Enabling Biotechnologies, JPEO-CBRND : Fort Detrick, MD	-	0.578	Feb 2022	0.000		0.000		-		0.000	0.000	0.578	0.000
CET RAIDR - PM/MS SB - Indirect Management Support	Various	Various : N/A	-	1.731	Nov 2021	0.000		0.000		-		0.000	0.000	1.731	0.000
DBPAP - PM/MS C - Product Management Contractor Support	SS/FFP	Various : N/A	3.907	0.975	Feb 2022	0.000		0.000		-		0.000	0.000	4.882	0.000
DBPAP - PM/MS C - Product Management Support	Various	Various : N/A	7.776	1.436	Jan 2022	0.000		0.000		-		0.000	0.000	9.212	0.000
NGDS 2 CHEMDX - PM/ MS S - Management Services	Various	Various : N/A	0.167	0.432	Nov 2021	0.000		0.000		-		0.000	0.000	0.599	0.000
NGDS 2 MPDS - PM/MS S - Management Services	Various	Various : N/A	5.040	1.426	Nov 2021	0.000		0.000		-		0.000	0.000	6.466	0.000
		Subtotal	36.660	19.722		0.000		0.000		-		0.000	10.342	66.724	N/A
			Prior Years	FY	2022	FY 2	023	FY 2 Ba	-		2024 CO	FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract
		Project Cost Totals	143.725	138.156		0.000		0.000		-		0.000	62.376	344.257	N/A

Remarks

xhibit R-4, RDT&E Schedule Profile: PB 2024 C	hem	nical	and	Bio	logic	cal D)efer	nse F	Progr	ram												Dat	e: M	arch	1 202	3		
ppropriation/Budget Activity 400 / 5								R-1 I PE 0 <i>Defe</i>	604	384E	3P /	Che	emic	al ai									er/N Biolc			fens	e (S	SDE
			2022			-	2023			FY 2					2025				2026			-	2027			FY 2		
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
AV TX - sNDA (Marburg)																								-				
AV TX - Natural History Study (Marburg)																												
AV TX - Animal Efficacy Studies (Marburg)																												
BOT MAB - Platform Development																												
BOT MAB - Clinical and Nonclinical																												
BOT MAB - Manufacturing																												
BOT MAB - MS B-Milestone B																												
BOT MAB - MS C-Milestone C																												
BOT MAB - Biologics License Application (BLA) Submission																												
CBIPR-ADM - MCM Enabling Manufacturing Technologies																												
CBIPR-ADM - MCM Development and Manufacturing Support (Infrastructure)																												
CET RAIDR - Advance Development Efforts to Repurpose FDA Approved Products																												
DBPAP - Acquire and Distribute Quality Select Biological Reference Materials and Assays while Storing and Analyzing Related Data																												
NGDS 2 CHEMDX - MS B-Milestone B																												
NGDS 2 CHEMDX - EMD																												
NGDS 2 CHEMDX - MS C-Milestone C																												
NGDS 2 MPDS - EMD																												
NGDS 2 MPDS - MS C-Milestone C - LRIP																												
NGDS 2 MPDS - FRP-Full Rate Production Decision																												

PE 0604384BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program UNCLASSIFIED Page 146 of 158

R-1 Line #132

chibit R-4, RDT&E Schedule Profile: PB 202	4 Chemical a	nd Bio	logical														arch		3		
propriation/Budget Activity 00 / 5				PE	0604	384BF	E <mark>lemer</mark> P I Chei am - El	mica	lumbe al and	r/Na Biolo	me) gical	F	Proje MB5 /	ct (N Me	lumb dical	er/N Biolo	ame ogical) I Def	fense	(SDI)
	FY 20	22	FY	2023		FY 20	24	F	Y 202	5	F	Y 20	026		FY	2027	,	F	Y 20	28	Τ
	1 2	3 4	1 2	3 4	1	2 3	3 4	1	2 3	4	1	2	3 4	1 1	2	3	4	1	2	3 4	
VAC SIP - Storage, distribution, potency testing, biosurety compliance activities																					
																			<u>.</u>		

Exhibit R-4A, RDT&E Schedule Details: PB 2024 Chemical and Biological Defense	se Program		Date: Marc	h 2023
0400/5 PE	Program Element (Numbe 0604384BP <i>I Chemical and</i> fense Program - EMD		Project (Number/Nam MB5 / Medical Biologic	,
Schedu	ule Details			
	St	art	E	nd
Events	Quarter	Year	Quarter	Year
AV TX - sNDA (Marburg)	4	2023	2	2024
AV TX - Natural History Study (Marburg)	1	2022	1	2023
AV TX - Animal Efficacy Studies (Marburg)	1	2022	4	2023
BOT MAB - Platform Development	1	2022	4	2025
BOT MAB - Clinical and Nonclinical	1	2022	3	2025
BOT MAB - Manufacturing	1	2022	4	2025
BOT MAB - MS B-Milestone B	2	2022	2	2022
BOT MAB - MS C-Milestone C	2	2023	2	2023
BOT MAB - Biologics License Application (BLA) Submission	4	2025	4	2025
CBIPR-ADM - MCM Enabling Manufacturing Technologies	1	2022	4	2028
CBIPR-ADM - MCM Development and Manufacturing Support (Infrastructure)	1	2022	4	2028
CET RAIDR - Advance Development Efforts to Repurpose FDA Approved Proc	ducts 1	2023	4	2028
DBPAP - Acquire and Distribute Quality Select Biological Reference Materials Assays while Storing and Analyzing Related Data	and 1	2022	4	2028
NGDS 2 CHEMDX - MS B-Milestone B	1	2022	1	2022
NGDS 2 CHEMDX - EMD	1	2023	2	2025
NGDS 2 CHEMDX - MS C-Milestone C	2	2025	2	2025
NGDS 2 MPDS - EMD	1	2022	1	2026
NGDS 2 MPDS - MS C-Milestone C - LRIP	2	2025	2	2025
NGDS 2 MPDS - FRP-Full Rate Production Decision	2	2026	2	2026
VAC SIP - Storage, distribution, potency testing, biosurety compliance activities	s 1	2022	4	2023

Exhibit R-2A, RDT&E Project Ju	stification	: PB 2024 C	Chemical and	d Biological	Defense P	rogram				Date: Marc	ch 2023	
Appropriation/Budget Activity 0400 / 5					PE 060438	am Elemen 34BP / Cher rogram - EN	nical and B		Project (N MC5 / Med		ne) cal Defense	(SDD)
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
MC5: <i>Medical Chemical Defense</i> (SDD)	-	38.936	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	38.936
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

This project supports efforts in the Engineering and Manufacturing Development (EMD) phase of the acquisition strategy for prophylactic, pre-treatment, and therapeutic drugs and diagnostic medical devices for the protection, treatment, detection, and medical management of chemical warfare agent exposures. This project provides for the research and development of safety studies, manufacturing scale-up, process validation, drug interaction, performance test, and submission of the Food and Drug Administration (FDA) drug licensure application(s). In FY2023, the CBDP RDT&E Projects have been restructured to align to the CBDP portfolio. MC5 efforts in FY2022 progress to the Mitigate (MT5) portfolio. This restructuring is intended to provide standardization and alignment across CBDP research, development and acquisition efforts.

Efforts included in this Project are:

(1) Advanced Anticonvulsant System (AAS),

(2) Alternative Autoinjector Manufacturer Capability (AUTOINJ) **Progresses to MT5 in FY2023**,

- (3) Improved Nerve Agent Treatment System Centrally Acting (INATS CA) ** Progresses to MT5 in FY2023**, and
- (4) Rapid Opioid Countermeasure System (ROCS)

The AAS program provides for midazolam in an autoinjector for treatment of nerve agent induced seizures. Midazolam, injected intramuscularly, will treat traditional nerve agent and non-traditional agent-induced seizures and prevent subsequent neurological damage. Midazolam is more water-soluble than diazepam (the currently fielded medication to control nerve agent-induced seizures) and terminates nerve agent-induced seizures more quickly than diazepam. AAS will not eliminate the need for other protective and therapeutic systems. FY22 is the last year of RDT&E funding and completes a Phase 1 clinical study from a new manufacturer and submits a New Drug Application (NDA).

The INATS CA program provides a centrally-acting anticholinergic agent to increase survivability and decrease morbidity after exposure to toxic nerve agent threats. Scopolamine was selected for development after an extensive analysis of alternatives and review of data by the Science and Technology community. Added to the currently fielded system, the INATS CA program will improve overall medical outcomes and will be utilized as both a vial for use at definitive care and a stand-alone auto-injector for use in the field. INATS CA continues autoinjector development and manufacturing activities of the drug product and autoinjector device, as well as continues non-clinical animal studies.

The ROCS program supports the discovery, characterization, development, and fielding of FDA-approved therapeutic Medical Countermeasures (MCMs) to protect the Joint Service warfighter against operational exposures to the opioid class of pharmaceutical-based agents (PBAs), a high priority. The ROCS program will

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical	and Biological Defense Program	Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 5	R-1 Program Element (Number/Name) PE 0604384BP <i>I Chemical and Biological</i> <i>Defense Program - EMD</i>	Project (Number/N MC5 / Medical Che	,	se (SDD)
develop a naloxone autoinjector as a rescue treatment that will control Tier Acquisition (MTA) approach. FY22 is the last year of RDT&E autoinjector device, and completes regulatory activities such as p	E funding and completes manufacturing activities, including	manufacturing of the		
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
Title: 1) AAS - NDA Submission		3.157	-	
Description: New Drug Application (NDA) Submission Activities				
Title: 2) AUTOINJ - Manufacturing		3.000	-	
Description: Manufacturing				
<i>Title:</i> 3) AUTOINJ - Prototyping and Testing		1.000	-	
Description: Prototyping and Testing				
Title: 4) AUTOINJ - Development		2.000	-	
Description: Development				
<i>Title:</i> 5) AUTOINJ - Government Testing		0.188	-	
Description: Government Testing				
Title: 6) AUTOINJ - FDA Coordination		1.093	-	
Description: FDA Coordination				
Title: 7) AUTOINJ - Reconstituted Drug Autoinjector		6.577	-	
Description: Reconstituted Drug Autoinjector Development for In	nproved Stability			
<i>Title:</i> 8) INATS CA - Clinical		0.400	-	
Description: Clinical				
Title: 9) INATS CA - Manufacturing		4.237	-	· · ·
Description: Manufacture drug product and device development				
Title: 10) INATS CA - Non-Clinical		8.659		

Exhibit R-2A, RDT&E Project Justi	ification: PB	2024 Chemi	cal and Biolo	ogical Defen	se Program				Date: Ma	arch 2023	
Appropriation/Budget Activity 0400 / 5				PE 060		n ent (Numb Chemical and - EMD		-	t (Number/Na Medical Cher	,	e (SDD)
B. Accomplishments/Planned Prog	grams (\$ in I	<u>/lillions)</u>							FY 2022	FY 2023	FY 2024
Description: Non-Clinical Testing to	support FDA	approval									
Title: 11) ROCS - Manufacturing									7.471	-	-
Description: Manufacturing											
Title: 12) ROCS - Regulatory									1.154	-	-
Description: FDA & Regulatory acti	vities										
				Accom	nplishments	/Planned P	rograms Su	btotals	38.936	-	-
C. Other Program Funding Summa	ary (\$ in Milli	ons)							·		
			FY 2024	FY 2024	<u>FY 2024</u>					Cost To	
Line Item	<u>FY 2022</u>	<u>FY 2023</u>	<u>Base</u>	000	Total	<u>FY 2025</u>	<u>FY 2026</u>	<u>FY 202</u>	<u>7 FY 2028</u>		
 MC7: Medical Chemical 	1.013	-	-	-	-	-	-	-	-	0.000	4 0 4
Defense (Op Sys Dev)										0.000	1.01
• MT5: Mitigate (SDD)	-	74.225	88.441	-	88.441	92.279	91.431	87.77		Continuing	Continuin
MT5: Mitigate (SDD) MT7: Mitigate (Op Sys Dev)	-	5.098	3.074	-	3.074	1.987	91.431 1.819	87.77 1.84		Continuing Continuing	Continuin Continuin
 MT5: Mitigate (SDD) MT7: Mitigate (Op Sys Dev) JM6677: Advanced 	- - 4.243			- - -						Continuing	Continuin Continuin
 MT5: Mitigate (SDD) MT7: Mitigate (Op Sys Dev) JM6677: Advanced Anticonvulsant System (AAS) 	4.243	5.098	3.074	-	3.074	1.987	1.819			Continuing Continuing Continuing	Continuin Continuin Continuin
 MT5: <i>Mitigate</i> (SDD) MT7: <i>Mitigate</i> (Op Sys Dev) JM6677: Advanced Anticonvulsant System (AAS) PHM015: Rapid Opioid 	-	5.098	3.074	-	3.074	1.987	1.819			Continuing Continuing	Continuin Continuin Continuin
 MT5: Mitigate (SDD) MT7: Mitigate (Op Sys Dev) JM6677: Advanced Anticonvulsant System (AAS) PHM015: Rapid Opioid Countermeasure System (ROCS) 	4.243	5.098	3.074	-	3.074	1.987	1.819	1.84 - -	5 1.862 - -	Continuing Continuing Continuing 0.000	Continuin Continuin 4.34
 MT5: Mitigate (SDD) MT7: Mitigate (Op Sys Dev) JM6677: Advanced Anticonvulsant System (AAS) PHM015: Rapid Opioid Countermeasure System (ROCS) PHM040: Improved 	4.243	5.098	3.074	-	3.074	1.987	1.819		5 1.862 - -	Continuing Continuing Continuing	Continuin Continuin Continuin 4.34
 MT5: Mitigate (SDD) MT7: Mitigate (Op Sys Dev) JM6677: Advanced Anticonvulsant System (AAS) PHM015: Rapid Opioid Countermeasure System (ROCS) PHM040: Improved Nerve Agent Treatment 	4.243	5.098	3.074	-	3.074	1.987	1.819	1.84 - -	5 1.862 - -	Continuing Continuing Continuing 0.000	Continuin Continuin Continuin 4.34
 MT5: Mitigate (SDD) MT7: Mitigate (Op Sys Dev) JM6677: Advanced Anticonvulsant System (AAS) PHM015: Rapid Opioid Countermeasure System (ROCS) PHM040: Improved 	4.243	5.098	3.074	-	3.074	1.987	1.819	1.84 - -	5 1.862 - -	Continuing Continuing Continuing 0.000	Continuin Continuin Continuin 4.34

ADVANCED ANTICONVULSANT SYSTEM (AAS)

The Advanced Anticonvulsant System (AAS), consists of Midazolam in an autoinjector for treatment of seizures, to include those caused by nerve agent. A contractor shall be responsible for conducting activities associated with drug development in a manner consistent with eventual approval by the Food and Drug Administration (FDA). The contractor shall sponsor the drug to the FDA and hold all approvals and/or licenses. The Contractor will need to initiate and complete studies that comply with new FDA requirements for manufacturing and quality for autoinjector products, ultimately leading to FDA approval. Upon FDA approval, sufficient quantities of

PE 0604384BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program UNCLASSIFIED Page 151 of 158

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical	and Biological Defense Program	Date: March 2023
Appropriation/Budget Activity 0400 / 5	R-1 Program Element (Number/Name) PE 0604384BP / Chemical and Biological Defense Program - EMD	Project (Number/Name) MC5 / Medical Chemical Defense (SDD)
product to meet Initial Operational Capability (IOC) and Full Oper Subsequent purchases for product sustainment will be made by result of the FDA approval and will be the responsibility of the co	he Defense Logistics Agency. Post marketing commitment	•
ALTERNATE AUTOINJECTOR MANUFACTURER CAPABILITY	(AUTOINJ)	
The AUTOINJ will identify an alternative source(s) to develop and antidote and treatment capabilities to the Department of Defense develop the autoinjector products. AUTOINJ uses contracts and development and testing activities consistent with current FDA re or licenses. Upon FDA approval, purchases for product sustain	(DoD). The AUTOINJ effort leverages novel technologies Other Transactional Agreements (OTAs) in which the per- gulations. The contractor shall sponsor the combination p	s and industrial base expansion in order to former shall be responsible for conducting
IMPROVED NERVE AGENT TREATMENT CENTRALLY ACTIN	G (INATS CA)	
In the Engineering and Manufacturing Development (EMD) phas is in accordance with Food and Drug Administration (FDA) regula		•

is in accordance with Food and Drug Administration (FDA) regulations. For scopolamine autoinjector development INATS CA uses contracts and Other Transactional Agreements (OTAs) in which the performer shall be responsible for conducting development and testing activities consistent with current FDA regulations. The contractor shall sponsor the combination product to the FDA and hold all approvals and/or licenses. Upon FDA approval, a follow-on procurement agreement will be used to procure initial operational capability (IOC) / full operational capability (FOC).

RAPID OPIOID COUNTERMEASURE SYSTEM (ROCS)

The ROCS program is a Joint Acquisition Category (ACAT) III Medical Countermeasure (MCM) Middle Tier Acquisition Program of Record (POR). ROCS utilized existing naloxone autoinjector capabilities identified from focused Market Research and developed an FDA approved product under Other Transaction Authority (OTA) agreement. The program is currently in the procurement phase and will transition to the Primary Pharmaceutical Vendor (PPV) program.

Exhibit R-3, RDT&E F	-		2024 Cher	nical and	d Biologica		-		()		Ducie		March 20	23	
Appropriation/Budge 0400 / 5	et Activity	/				PE 0604	•	Chemica	umber/N al and Bio	,		(Number Aedical Cl	r/ Name) hemical D	efense (S	SDD)
Product Developmer	nt (\$ in M	illions)		FY	2022	FY 2	023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
AAS - NDA Submission Activities	C/CPFF	RAFA Laboratories : N/A	3.345	2.221	Dec 2021	0.000		0.000		-		0.000	0.000	5.566	0.000
AAS - Product Management	C/CPFF	JPM CBRN Medical, JPEO-CBRND : Fort Detrick, MD	0.944	0.362	Nov 2021	0.000		0.000		-		0.000	0.000	1.306	0.000
AUTOINJ - Program Management	C/FFP	JPM CBRN Medical, JPEO-CBRND : Fort Detrick, MD	3.060	1.737	Nov 2021	0.000		0.000		-		0.000	0.000	4.797	0.000
AUTOINJ - HW C - Diazepam Autoinjector	C/CPFF	Emergent Biosolutions : Gaithersburg/ Rockville, MD	18.045	3.725	Nov 2021	0.000		0.000		-		0.000	0.000	21.770	0.000
AUTOINJ - HW C - Dual Drug Delivery Device (D4) Prototype	C/CPFF	Emergent Biosolutions : Gaithersburg/ Rockville, MD	1.785	0.300	Dec 2021	0.000		0.000		-		0.000	0.000	2.085	0.000
AUTOINJ - HW C - RAD-A	C/CPFF	Various : N/A	-	6.577	Nov 2022	0.000		0.000		-		0.000	0.000	6.577	0.000
INATS CA - Product Management	C/CPFF	JPM CBRN Medical, JPEO-CBRND : Fort Detrick, MD	2.602	1.674	Mar 2022	0.000		0.000		-		0.000	0.000	4.276	0.000
INATS CA - HW C - Clinical	C/CPFF	Battelle Memorial Institute : Columbus, OH	3.198	0.400	Apr 2022	0.000		0.000		-		0.000	0.000	3.598	0.000
INATS CA - HW C - Manufacturing	C/FFP	Aktivax : Boulder, CO	4.716	4.237	Dec 2021	0.000		0.000		-		0.000	0.000	8.953	0.000
INATS CA - HW C - Non- Clinical	C/CPFF	Battelle Memorial Institute : Columbus, OH	9.397	2.132	Nov 2021	0.000		0.000		-		0.000	0.000	11.529	0.000
ROCS - Product Management	Various	JPM CBRN Medical, JPEO-CBRND : Fort Detrick, MD	0.711	0.357	Feb 2022	0.000		0.000		-		0.000	0.000	1.068	0.000
ROCS - HW C - Manufacturing	C/CPFF	kaleo : Richmond, VA	8.026	4.798	Nov 2021	0.000		0.000		-		0.000	0.000	12.824	0.000

PE 0604384BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program

Exhibit R-3, RDT&E	Project C	ost Analysis: PB 2	024 Cher	nical and	Biologica	al Defens	e Prograr	n			_	Date:	March 20	23	
Appropriation/Budge 0400 / 5	et Activity	1				PE 060	-	ement (N Chemica n - EMD			-	(Number Aedical Cl	r/ Name) hemical D	efense (S	SDD)
Product Developme	nt (\$ in M	illions)		FY 2	2022	FY 2	023	FY 2 Ba	-		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
ROCS - HW C - Regulatory	C/CPFF	kaleo : Richmond, VA	-	1.154	Oct 2021	0.000		0.000		-		0.000	0.000	1.154	0.000
		Subtotal	55.829	29.674		0.000		0.000		-		0.000	0.000	85.503	N/A
Support (\$ in Million	s)			FY 2	2022	FY 2	023	FY 2 Ba			2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
		Subtotal	-	-		-		-		-		-	-	-	N/A
Management Service	es (\$ in M	illions)		FY	2022	FY 2	023	FY 2 Ba	-		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
AAS - Management Services	Various	JPEO Chem, Bio, Rad, and Nuc Defense (JPEO- CBRND) : Aberdeen Proving Ground, MD	0.389	0.574	Dec 2021	0.000		0.000		-		0.000	0.000	0.963	0.000
AUTOINJ - Management Services	Various	JPEO Chem, Bio, Rad, and Nuc Defense (JPEO- CBRND) : Aberdeen Proving Ground, MD	6.766	1.519	Dec 2021	0.000		0.000		-		0.000	0.000	8.285	0.000
INATS CA - Management Services	Various	JPM CBRN Medical, JPEO-CBRND : Fort Detrick, MD	4.322	1.061	Dec 2021	0.000		0.000		-		0.000	0.000	5.383	0.000
INATS CA - Management Services	Various	JPEO Chem, Bio, Rad, and Nuc Defense (JPEO- CBRND) : Aberdeen Proving Ground, MD	-	3.792	Dec 2021	0.000		0.000		-		0.000	0.000	3.792	0.000

PE 0604384BP: *Chemical and Biological Defense Program ...* Chemical and Biological Defense Program

Exhibit R-3, RDT&E	Project C	ost Analysis: PB 2	024 Chei	mical and	d Biologica	al Defens	e Prograi	n				Date:	March 20	23	
Appropriation/Budg 0400 / 5	et Activity	1				PE 060	-	e ment (N ' Chemica n - EMD				(Number Nedical Cl	r/ Name) hemical De	efense (S	SDD)
Management Servic	es (\$ in M	illions)		FY 2	2022	FY 2	2023	FY 2 Ba			2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
ROCS - Management Services	Various	JPEO Chem, Bio, Rad, and Nuc Defense (JPEO- CBRND) : Aberdeen Proving Ground, MD	2.627	1.163	Dec 2021	0.000		0.000		-		0.000	0.000	3.790	0.000
ROCS - Management Services	Various	JPM CBRN Medical, JPEO-CBRND : Fort Detrick, MD	-	1.153	Dec 2021	0.000		0.000		-		0.000	0.000	1.153	0.000
		Subtotal	14.104	9.262		0.000		0.000		-		0.000	0.000	23.366	N/A
			Prior Years	FY	2022	FY 2	2023	FY 2 Ba			2024 CO	FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract
		Project Cost Totals	69.933	38.936		0.000		0.000		-		0.000	0.000	108.869	N/A

Remarks

Exhibit R-4, RDT&E Schedule Profile: PB 2024 C	hem	nical	and	Bio	logic	al D)efer	nse F	Prog	Iram												Dat	e: M	arch	1 202	23		
Appropriation/Budget Activity 0400 / 5																	Project (Number/Name) MC5 / Medical Chemical Defense (SDL											
	FY 2022			FY 2023			3		FY 2	FY 2024			FY 2025			FY		2026		FY 2027			7		FY 2	Y 2028		
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
AAS - NDA Submission-New Drug Application Submission																												
AAS - FDA Approval-Food and Drug Administration Approval																												
AAS - RFP-Development Request for Proposal Release Decision																												
AAS - IOC-Initial Operational Capability																												
AAS - FOC-Full Operational Capability																												
AUTOINJ - Development																												
AUTOINJ - Manufacturing																												
AUTOINJ - Prototyping and Testing																												
AUTOINJ - Dual Drug Delivery Device (D4)																												
AUTOINJ - Government Testing																												
AUTOINJ - RAD - A																												
INATS CA - MS B-Milestone B																												
INATS CA - Clinical Trials																												
INATS CA - Manufacturing/Auto-Injector																												
INATS CA - Non-Clinical Studies																												
INATS CA - NDA Submission-New Drug Application Submission																												
INATS CA - FDA Approval-Food and Drug Administration Approval																												
INATS CA - SNAPP Modernization - BA7																												
INATS CA - PB Extended Release Tablet Development - BA7																					-							
ROCS - Manufacturing Activities																												

PE 0604384BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program UNCLASSIFIED Page 156 of 158

Exhibit R-4, RDT&E Schedule Profile: PB 2024	Chem	nical a	and Bio	ologi	ical De														te: №			23		
ppropriation/Budget Activity 400 / 5						PE	060	4384	n Eler BP / C gram	Chen	nical	and l	r/Na Biolo	me) gical		Proje MC5						fens	e (SL)D,
		FY 20	022		FY 2	023		FY 2	2024		FY	202	5	F	Y 2	026		FY	202	7		FY 2	2028	
	1	2	3 4	1	2	3 4	1	2	3	4 1	I 2	2 3	4	1	2	3	4	1 2	3	4	1	2	3	4
ROCS - FDA Approval-Food and Drug Administration Approval - FDA Approval & PMRs																								

hibit R-4A, RDT&E Schedule Details: PB 2024 Chemical and Biological Defense propriation/Budget Activity R-1 I	Program Element (Numbe	r/Namo)	Date: Marcl Project (Number/Nam	
0/5 PE 0	604384BP / Chemical and i nse Program - EMD		MC5 / Medical Chemica	,
Schedul	e Details			
	St	art	En	d
Events	Quarter	Year	Quarter	Year
AAS - NDA Submission-New Drug Application Submission	1	2022	3	2022
AAS - FDA Approval-Food and Drug Administration Approval	4	2022	4	2022
AAS - RFP-Development Request for Proposal Release Decision	1	2024	1	2024
AAS - IOC-Initial Operational Capability	4	2023	4	2023
AAS - FOC-Full Operational Capability	4	2025	4	2025
AUTOINJ - Development	1	2022	4	2023
AUTOINJ - Manufacturing	1	2022	4	2023
AUTOINJ - Prototyping and Testing	1	2022	2	2023
AUTOINJ - Dual Drug Delivery Device (D4)	1	2022	1	2025
AUTOINJ - Government Testing	1	2022	2	2022
AUTOINJ - RAD - A	2	2023	4	2027
INATS CA - MS B-Milestone B	2	2022	2	2022
INATS CA - Clinical Trials	1	2022	4	2024
INATS CA - Manufacturing/Auto-Injector	1	2022	2	2025
INATS CA - Non-Clinical Studies	1	2022	2	2025
INATS CA - NDA Submission-New Drug Application Submission	1	2026	3	2026
INATS CA - FDA Approval-Food and Drug Administration Approval	3	2026	1	2028
INATS CA - SNAPP Modernization - BA7	1	2022	4	2025
INATS CA - PB Extended Release Tablet Development - BA7	1	2023	1	2026
ROCS - Manufacturing Activities	1	2022	4	2022
ROCS - FDA Approval-Food and Drug Administration Approval - FDA Approval	& PMRs 1	2022	4	2022

PE 0604384BP: *Chemical and Biological Defense Program* ... Chemical and Biological Defense Program

Volume 4 - 404

Exhibit R-2, RDT&E Budget Item	n Justificat	ion: PB 202	24 Chemica	l and Biolog	gical Defens	e Program				Date: Marc	ch 2023	
Appropriation/Budget Activity 0400: Research, Development, Te RDT&E Management Support	est & Evalua	ation, Defen	se-Wide I B	A 6:	R-1 Progra PE 060538		•	ram				
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
Total Program Element	0.000	116.573	126.432	74.382	0.000	74.382	73.757	75.320	75.378	73.142	Continuing	Continuing
DW6: Major Range And Test Facility Base (Mgmt Support)	-	63.914	63.390	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	127.304
LS6: Laboratory Support (Mgmt Support)	-	8.659	10.187	10.290	0.000	10.290	10.290	10.290	10.290	10.290	Continuing	Continuing
MS6: Management Support (Mgmt Support)	-	41.950	52.855	64.092	0.000	64.092	63.467	65.030	65.088	62.852	Continuing	Continuing
DT6: Joint Doctrine And Training Support (Mgmt Support)	-	0.836	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.836
O49: Joint Concept Development (Mgmt Support)	-	1.214	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	1.214

A. Mission Description and Budget Item Justification

This program element (PE) resources to research, development, test, and evaluation (RDT&E) management support as a key enabler across the Understand, Protect, Mitigate, and Enabling Investments portfolios. Chemical Biological Defense Program (CBDP) investments provide an integrated, layered capability to enable combating weapons of mass destruction (CWMD) missions ranging from combat operations to Department of Defense (DoD) support to domestic incident prevention and response. The Projects in this PE support sustainment and modernization of laboratory infrastructure, test capabilities, studies and analyses, Joint doctrine and training, and program and financial management support. FY24 funding accelerates characterization and situational awareness of emerging biothreats and accelerates delivery of improved protection from and mitigation of biothreats, including rapid repurposing of available therapeutics and development of new vaccines.

Individual Projects include:

- Major Range and Test Facility Base (MRTFB) (DW6): Operating support to West Desert Test Center (WDTC) and BioTesting Division (Chemical Biological Center) for the required institutional test operating costs (e.g., institutional civilian and contractor labor; repair and maintenance of test instrumentation, equipment, and facilities; and replacement of test equipment). Beginning in FY24, Project DW6 will functionally transfer program and funding to the 2040 appropriation, PE 0605601A / Project WD1, West Desert Test Center.

- Laboratory Support (LS6): Operating support for sustainment and modernization efforts for surety laboratory infrastructure in order to maintain and enhance DoD infrastructure capabilities to counter an expanding threat space, exploit advances in technology, and develop and transition CB defense equipment and countermeasures to the Warfighter.

ppropriation/Budget Activity 400: Research, Development, Test & Evaluation, Defense-N 2DT&E Management Support	<i>Vide I</i> BA 6:		lement (Number/Name) I Chemical and Biologica			
Management Support (MS6): Management support for the Assistant Secretary of Defense for Nuclear, Chemical, and Biological Defense (DASD(CBD)).						
Joint Doctrine and Training Support (DT6) and Joint Conce	ept Development (O49) are no longe	er active FY24 Projects d	lue to budget restructu	ring.	
. Program Change Summary (\$ in Millions)	FY 2022	<u>FY 2023</u>	FY 2024 Base	FY 2024 OCO	<u>FY 2024</u>	Total
Previous President's Budget	115.503	124.475	125.966	-	12	5.966
Current President's Budget	116.573	126.432	74.382	-	7	4.382
Total Adjustments	1.070	1.957	-51.584	-	-5	1.584
 Congressional General Reductions 	-	-				
 Congressional Directed Reductions 	-	-2.243				
 Congressional Rescissions 	-	-				
Congressional Adds	-	4.200				
 Congressional Directed Transfers 	-	-				
Reprogrammings	6.362	-				
SBIR/STTR Transfer	-2.923	-				
Other Adjustments	-2.369	-	-51.584	-	-5	1.584
Congressional Add Details (\$ in Millions, and Inclu	udes General Red	luctions)			FY 2022	FY 2023
Project: DW6: Major Range And Test Facility Base (I	Mgmt Support)					
Congressional Add: Chemical/Biological Defense	Testing				5.000	4.20
		C	ongressional Add Subtol	als for Project: DW6	5.000	4.20
			Congressional Add 1	otals for all Projects	5.000	4.20
<u>Change Summary Explanation</u> Funding: FY 2022 (+\$5.000 Million): Congressional A FY 2022 (+\$6.362 Million): Below threshold reprogram Biological (NCB) high priority efforts and the Departm	mming increase fro	om prior year exe	•		•	emical, and

FY 2022 (-\$2.923 Million): Transfer of funding to support Small Business Innovative Research/Small Business Technology Transfer efforts.

FY 2022 (-\$2.369 Million): CBDP funding transferred to Nuclear, Chemical, and Biological (NCB) high priority efforts.

FY 2023 (-\$2.243 Million): Congressional Directed Reductions.

FY 2023 (+\$4.200 Million): Congressional Add for major range and test facility base management support.

Exhibit R-2, RDT&E Budget Item Justification: PB 2024 Chemical and Biolog	gical Defense Program	Date: March 2023
	R-1 Program Element (Number/Name)	
0400: Research, Development, Test & Evaluation, Defense-Wide / BA 6: RDT&E Management Support	PE 0605384BP I Chemical and Biological Defense Prog	ram

FY 2024 (-\$51.584 Million): Decrease due Project DW6 functional transfer of program and funding to the 2040 appropriation, PE 0605601A / Project WD1, West Desert Test Center (-\$63.028 Million); and additional adjustments to increase situational awareness of biodefense materiel readiness (+\$5.200 Million), Departmental inflation rate adjustments (+\$1.687 Million), and routine program adjustments to balance overall portfolio efforts (+\$4.557 Million).

Schedule: N/A

Technical: N/A

Exhibit R-2A, RDT&E Project Ju	ustification	: PB 2024 C	Chemical an	d Biologica	l Defense P	rogram				Date: Marc	ch 2023	
Appropriation/Budget Activity 0400 / 6					R-1 Progra PE 060538 <i>Defense P</i>	4BP / Cher	•	Number/Name) ajor Range And Test Facility Base upport)				
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
DW6: Major Range And Test Facility Base (Mgmt Support)	-	63.914	63.390	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	127.304
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

The Major Range and Test Facility Base (MRTFB) Research, Development, Test, and Evaluation (RDT&E) Management Support Project provides for the Dugway Proving Ground (DPG) MRTFB technical and operational capability for proving Department of Defense (DoD) Chemical and Biological (CB) and Non Traditional Agent (NTA) defense materiel, equipment, and systems from concept through production to include associated special operations Tactics, Techniques, and Procedures Development (TTPD) activities.

Efforts included in this Project are:

(1) Combat Capability Development Command (DEVCOM) Chemical and Biological Center BioTesting Division (BTD-CBC)(2) West Desert Test Center (WDTC)

Together WDTC and BTD-CBC are the reliance centers for all DoD CB defense testing and provide the United States' only combined range, chamber, toxic chemical lab, and bio-safety level 3 Biological Select Agent and Toxin (BSAT) aerosol test capability. WDTC and BTD-CBC use unique, state-of-the-art chemical and life-science test facilities and test chambers to perform CB defense testing of protective gear, decontamination systems, detectors, equipment, and non-materiel CB defense solutions while maintaining safety, security, and surety of chemical agents and biological pathogens. WDTC also provides surveyed and instrumented outdoor ranges and specialized structures for CB simulant agent dissemination in operationally threat-relevant environments and TTPD activities.

Beginning in FY24, the PE 0605384BP / Project DW6, MRTFB RDT&E Management Support will functionally transfer program and funding from appropriation 0400, to the 2040 appropriation, PE 0605601A / Project WD1, West Desert Test Center.

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2022	FY 2023	FY 2024
Title: 1) BTB TEST - MRTFB	7.609	7.641	-
Description: Funding maintains MRTFB test and evaluation (T&E) mission readiness at Bio Testing Division for biological surety laboratory operations, bio-safety risk management, and defensive T&E mission support activities. Lothar Salomon Life Sciences Test Facility (LSTF) and Baker complex contains biosafety level (BSL) 1, 2, and 3 laboratories for testing biological weapons detectors, individual protective clothing and equipment, decontamination systems, and material survivability in a bioweapon contaminated environment. LSTF is the sole DoD facility certified to challenge developmental defensive test equipment with			

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	al Defense Program		Date: M	larch 2023	
Appropriation/Budget Activity 0400 / 6	R-1 Program Element (Number/Name) PE 0605384BP <i>I Chemical and Biological</i> <i>Defense Program</i>	DW6	ct (Number/N Major Range t Support)	,	cility Base
B. Accomplishments/Planned Programs (\$ in Millions)		ſ	FY 2022	FY 2023	FY 2024
aerosolized biological warfare agents, including bacteria, viruses, and biological MRTFB activity's institutional and overhead T&E mission support activities not					
FY 2023 Plans: Continue T&E mission support activities (civilian labor, travel, training, communequipment acquisition, contract support, and purchased equipment maintenance mission readiness of biological developmental and operational T&E capability.		iin			
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project funding transferred to another funding line. In FY24, PE 06053 Support will realign from appropriation 0400 to the 2040 appropriation, PE 060					
<i>Title:</i> 2) DPG - WDTC, MRTFB Civilian Pay			26.882	27.715	-
Description: MRTFB Civilian Pay					
<i>FY 2023 Plans:</i> Funds will continue to support the overhead costs of civilian labor, with the bala to pay all costs directly attributable to the use of a test facility or resource for the Center (WDTC) will continue to provide a specially trained support staff to open	esting of a particular program. West Desert Te				
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project funding transferred to another funding line. In FY24, PE 06053 Support will realign from appropriation 0400 to the 2040 appropriation, PE 060					
Title: 3) DPG - WDTC, MRTFB Mission Support			12.431	12.588	-
Description: MRTFB Mission Support - Provides ongoing sustainment of exist at WDTC necessary for chemical laboratories, chemical/biological field and sin readiness, and staff functions not chargeable to a test customer. Supports and diagnostics, calibration, and certification, as well as routine life-cycle and user administrative, and analytical instrumentation components and systems. Support disposal of hazardous materials, transportation, postage, administrative supplie installation costs, temporary duty/training of civilian and contractor personnel, p communications.	nulant chamber, data science test mission nual service contracts for test equipment opera elated replacement of existing field, test related ports test facility maintenance, handling and es, tools, software, spare parts, mission unique	tions, d			
FY 2023 Plans:					

gical	DW6 / M (Mgmt S illity ng ement		Name) e And Test Fa FY 2023 11.246	FY 2024
d use- test faci oftware, ns, printir Manage	ility ng ement			FY 2024
d use- test faci oftware, ns, printir Manage	ng	11.992	11.246	
		11.992	11.246	
		11.992	11.246	
test fielc to test				
		58.914	59.190	
2022	FY 2023	3		
5.000	4.20	00		
5.000	4.20	00		
	to test Manage It Cente ns Subt 7 2022 5.000	test field to test Management t Center. ns Subtotals 7 2022 FY 202 5.000 4.20	test field to test Management tt Center. ns Subtotals 58.914 7 2022 FY 2023 5.000 4.200	test field to test Management tt Center. ns Subtotals 58.914 59.190 <u>7 2022 FY 2023</u> 5.000 4.200

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical	and Biological Defense Program	Date: March 2023
Appropriation/Budget Activity 400 / 6	R-1 Program Element (Number/Name) PE 0605384BP / Chemical and Biological Defense Program	Project (Number/Name) DW6 I Major Range And Test Facility Base (Mgmt Support)
C. Other Program Funding Summary (\$ in Millions)		
<u>Remarks</u>		
0. Acquisition Strategy		
N/A		

Exhibit R-2A, RDT&E Project Ju	stification	: PB 2024 C	Chemical an	d Biological	Defense P	rogram				Date: Marc	ch 2023	
Appropriation/Budget Activity 0400 / 6							t (Number/ mical and Bi		c t (Number/Name) Laboratory Support (Mgmt Support)			
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
LS6: Laboratory Support (Mgmt Support)	-	8.659	10.187	10.290	0.000	10.290	10.290	10.290	10.290	10.290	Continuing	Continuing
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

The Laboratory Support Research, Development, Test, and Evaluation (RDT&E) Management Support Project provides Department of Defense (DoD) laboratory infrastructure sustainment and modernization to upgrade key systems to current state-of-the-art capabilities. Ensures that the necessary surety operations can be conducted effectively and safely in support of the Chemical and Biological Defense Program (CBDP). As a force multiplier, this Project will provide more robust capabilities to the CBDP and ensure continuity of operations and environmental compliance.

Efforts included in this Project are:

(1) U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) Laboratory Infrastructure, and (2) U.S. Army Medical Research and Development Command (MRDC) Laboratory Infrastructure

DEVCOM Chemical Biological Center (CBC) laboratory infrastructure provides sustainment and modernization to research and develop CB defense capabilities that enable the Joint Force to fight and win in contested environments. CBC explores, assesses, and demonstrates operational utility of Integrated Early Warning and Integrated Layered Defense approaches that impact the Warfighter's ability to manage operational decisions while playing a critical role in modernizing the Army and DoD's Biodefense capabilities. CBC assesses and characterizes emerging threats in order to prevent use and avoid surprise in addition to exploring technology integration of CB defense capabilities into combat platforms thus unencumbering the Warfighter.

MRDC laboratory infrastructure provides for laboratory operations, facilities sustainment, and regulatory compliance for critical CB defense activities at the U.S. Army Medical Research Institute for Infectious Diseases (USAMRID) and the U.S. Army Medical Research Institute for Chemical Defense (USAMRICD) to counter an expanding threat space, exploit advances in technology, and develop and transition CB defense equipment and countermeasures to the Warfighter.

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2022	FY 2023	FY 2024
Title: 1) LABINF - Chemical Biological Center (CBC) Laboratory Infrastructure	7.399	8.850	8.849
Description: Provides the necessary sustainment and modernization needed at key tier 1 laboratories at DEVCOM CBC. Affords DEVCOM CBC the ability to provide innovative chemical, biological, radiological, nuclear and explosive (CBRNE) defense capabilities that enable the joint warfighter's dominance on the battlefield and interagency defense of the homeland.			
FY 2023 Plans:			

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical a	nd Biological Defense Program	Date: N	larch 2023	
Appropriation/Budget Activity 0400 / 6	Project (Number/ LS6 / Laboratory S		t Support)	
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
Continuation of the sustainment and modernization efforts that sup life-cycle engineering capabilities at DEVCOM CBC. Continue test decontamination capabilities as it relates to CB Protection systems of Chemical Weapons (OPCW) support mission to both the Warfigl SMARTMAN mask tests to protect both the Warfighter and First Re research. Perform testing, validation, and certification of product lo Defense (DoD) activated carbon products.	ting and characterization to inform detection, protection, and and concepts. Continue Organization for the Prohibition hter and Homeland Defense. Conduct carbon testing and esponders. Continue execution of Operational Toxicology			
FY 2024 Plans: Continues sustainment and modernization efforts that support cherr engineering capabilities at DEVCOM CBC. Supports permeation to permeable, semi-permeable, and non-permeable materials used to Acceptance testing as dictated by various military specifications. No chemical agent contaminated test articles that support both the wa	esting of military issued gloves, airline hoses, and other o support the warfighter. Supports First Article Production Aodernizes two steam baths used in the decontamination			
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.				
<i>Title:</i> 2) LABINF - Medical Research and Development Command	(MRDC) Laboratory Infrastructure	1.260	1.337	1.441
Description: U.S. Army Medical Research Institute for Infectious E Institute for Chemical Defense (USAMRICD) provides support to la sustainment, and regulatory compliance for critical chemical biolog	boratory infrastructure for laboratory operations, facilities	h		
<i>FY 2023 Plans:</i> Funds will continue to support laboratory infrastructure for laborator for critical chemical biological defense activities at USAMRIID and laboratory support operations, maintenance and repair of existing of compliance, chemical and biological safety, and/or research protect System (JWICS) access at USAMRICD for Top Secret (TS) and TS communication. The SCIF will assist with ensuring USAMRICD medefense mission.	USAMRICD. Activities supported include elements of capabilities, chemical agent security, quality systems ctions. Sustain Joint Worldwide Intelligence Communication S/Sensitive Compartmented Information (SCI) onsite	ons		
FY 2024 Plans: Continue support laboratory infrastructure for laboratory operations chemical and biological defense activities at USAMRIID and USAM operations, maintenance and repair of existing capabilities, chemic	IRICD. Support includes elements of laboratory support			

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical	and Biological Defense Program		Date: M	arch 2023	
Appropriation/Budget Activity 0400 / 6	R-1 Program Element (Number/Name) PE 0605384BP <i>I Chemical and Biological</i> <i>Defense Program</i>	Project (Number/Name) LS6 / Laboratory Support (Mgmt Sup			Support)
B. Accomplishments/Planned Programs (\$ in Millions)			2022	FY 2023	FY 2024
chemical and biological safety, key maintenance contracts, and/or USAMRICD for TS and TS/SCI onsite communication. The SCIF related to its chemical defense mission.					
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.					
	Accomplishments/Planned Programs Sul	ototals	8.659	10.187	10.29
N/A Remarks D. Acquisition Strategy N/A					

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program								Date: Marc	ch 2023			
Appropriation/Budget Activity 0400 / 6					-	am Elemen 34BP / Cher rogram	•	,	Project (N MS6 / Man		ne) upport (Mgn	nt Support)
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
MS6: Management Support (Mgmt Support)	-	41.950	52.855	64.092	0.000	64.092	63.467	65.030	65.088	62.852	Continuing	Continuing
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

The Management Support Research, Development, Test, and Evaluation (RDT&E) Project provides management support for the Department of Defense (DoD) Chemical and Biological Defense Program (CBDP). It includes program oversight and integration of overall non-Chemical Biological Radiological Nuclear (CBRN) Defense Equipment (non-CDE) and CBRN Defense Equipment (CDE) programs by the Assistant Secretary of Defense for Nuclear, Chemical, and Biological Defense Programs (ASD(NCB)) and defense programs through the Deputy Assistant Secretary of Defense for Chemical and Biological Defense (DASD(CBD)).

Efforts included in this Project are:

- (1) Biological Select Agent and Toxins (BSAT) Biorisk Program Office (BBPO),
- (2) Biodefense Materiel Readiness Common Operating Picture (BDMR COP),
- (3) Executive Agent Management (EA MGT),
- (4) Joint Acquisition CB Knowledge System Defense Business System (JACKS DBS),
- (5) Joint Concepts, Studies, and Analysis (JCSA),
- (6) Joint Requirements Office Management (JRO MGT),
- (7) Joint Test Infrastructure Working Group (JTIWG),
- (8) Office of the Secretary of Defense Management (OSD MGT),
- (9) Joint CBRN Defense Program Analysis and Integration Office Management (PAIO MGT), and
- (10) Workforce and Biosafety Enhanced Biodefense (WB-ENBD)

BSAT BBPO supports the DoD EA and EA Responsible Official (EARO) for BSAT Biosafety and Biosecurity Programs in their responsibilities for mission oversight, technical review, inspection, harmonization of biosafety and biosecurity protocols and procedures across DoD laboratories handling BSAT. Efforts also support the Scientific Gaps in Biorisk Research Program (SGBRP) to address gaps in scientific knowledge to facilitate validation of BSAT protocols and procedures. Closing these gaps will reduce the inherent risks associated with BSAT research in CBDP laboratories and supports research and development work on priority agents. Research projects, selected from an order of merit list are funded for one year.

The BDMR COP will increase situational awareness of biodefense readiness through a biodefense logistics common operating picture (COP) to ensure preparedness and enable a more rapid response to biological threats. The platform will enable the biodefense enterprise to monitor assets and acquisition programs to consolidate data streams into executive dashboards, working level planning tools to provide material readiness status, and provide supply chain visibility and illuminations. This situational awareness of required biodefense materiel capabilities, including medical and non-medical personal protective equipment, will also enable leaders to track

Exhibit N-2A, NDTRE Troject Justification. TD 2024 Chemica	I and Biological Defense Program	Date: March 2023
Appropriation/Budget Activity 0400 / 6	R-1 Program Element (Number/Name) PE 0605384BP / Chemical and Biological Defense Program	Project (Number/Name) MS6 I Management Support (Mgmt Suppo
and manage the necessary capabilities to protect the Total Force supply chain risk management, resiliency and security to across		ort will enable a holistic approach to addressing
EA MGT, as the DoD Executive Agent for the CBDP, is responsi requirements of the Military Departments and National Guard Bu Execution (PPBE) process for the CBDP enterprise.		•
JACKS DBS is a flexible, web-hosted CBRN data warehouse the comprehensive source of CBRN information. JACKS also support intelligence tools to provide the Joint Force with the ability to mir	orts the acquisition domain by utilizing cutting edge inform	
JCSA, through the Joint Requirements Office (JRO) for CBRN D foundational Joint Concepts development, studies, and analyses systems; coordinates WMD/CBRN threat information requirement	s to enable requirements and capabilities development of	
JRO MGT, through the Joint Requirements Office (JRO) for CBF representing the Services and Combatant Commands (CCMD) i in the medical and physical CBRN defense mission areas. Direct at the Joint and Service levels and provides technical and subject (CWMD), including during CCMD exercises.	n the requirements generation process for the development ctly supports the improvement of CBRN defense-related I	ent of Joint materiel and non-materiel solutions eadership development, education, and trainin
JTIWG, through the Chemical, Biological, Radiological and Nucl and oversight of test infrastructure and test technology requirem The JTIWG program supports T&E Early Involvement; test threa Services to include medical T&E efforts. The CBRND T&E Exec validated instrumentation and infrastructure to ensure the adequ The CBRND T&E Executive provides the T&E infrastructure inve Service Community to ensure that program needs are met. The the Warfighter.	ents to support Developmental Testing (DT) and Operation at planning; T&E studies; and T&E standards planning and cutive oversees the Enterprise processes to develop and acy of test for CBRND systems in alignment with acquising estment strategy and coordinates investment planning an	onal Testing (OT) of DoD CBRND systems. d development to support CBRND testing for al sustain standardized T&E methodologies and tion milestones and associated decision points. d T&E capabilities validation among the Joint
OSD MGT performs program reviews/assessments, provides pro management. OSD MGT also provides the CBDP Enterprise all	ogrammatic PPBE oversight/analysis, provides Congress	

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemica		Date: N	arch 2023		
Appropriation/Budget Activity 0400 / 6	R-1 Program Element (Number/Name) PE 0605384BP / Chemical and Biological Defense Program	Project (Number/Name) MS6 / Management Support (Mgmt S			
PAIO MGT conducts independent analysis and provides object to inform senior leader decision-making across the DoD and will processes support operational requirements, promote efficience WB-ENBD provides centralized DoD expertise, implements bio	hole of government partners. PAIO ensures CBRN defense p y and readiness, and meet national security objectives.	rograms mission are	eas, policies,	and	
property.	salety improvements, and adds protections for CDDF defense			lectual	
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024	
Title: 1) OSD BIOSAFETY		1.956	1.824	1.95	
Description: Biological Select Agent and Toxins (BSAT) Support	ort				
FY 2023 Plans: Continue to maintain the Joint Interagency Biorisk Program Sys laboratory site visits, participate and oversee laboratory inspect Panel (BSRP) meetings, Scientific Gaps in Biorisk Research Pr the biosafety and biosecurity across Department of Defense (D	ions, execute stakeholders meetings, Biorisk Scientific Review ogram (SGBRP) committees, contribute towards harmonization	N			
FY 2024 Plans: Continue to maintain the Joint Interagency Biorisk Program Sys laboratory site visits, participate and oversee laboratory inspect committees, contribute towards harmonization of the biosafety a	ions, execute stakeholders meetings, BSRP meetings, SGBR				
FY 2023 to FY 2024 Increase/Decrease Statement:					
Minor change due to routine program adjustments. Title: 2) BSAT RSRCH SPT		0.806	0.748	0.80	
		0.800	0.740	0.000	
Description: Scientific Gaps in Biorisk Research Program (SG	BRP) Support				
FY 2023 Plans: Select gap research projects based on a new order of merit list, Research Program (SGBRP) Charter.	, while remaining in accordance with the Scientific Gap Biorisk	x			
FY 2024 Plans:	while remaining in accordance with the Scientific Gap Biorisk	x			
Select gap research projects based on a new order of merit list, Research Program (SGBRP) Charter.	,				

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical a	and Biological Defense Program	Date: N	larch 2023			
Appropriation/Budget Activity 0400 / 6	R-1 Program Element (Number/Name) PE 0605384BP <i>I Chemical and Biological</i> <i>Defense Program</i>		oject (Number/Name) S6 / Management Support (Mgmt			
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024		
Minor change due to routine program adjustments.						
Title: 3) BDMR COP		-	-	5.20		
<i>Description:</i> Enables a logistic common operating picture (COP) management.	framework and platform for biodefense supply chain risk					
FY 2024 Plans: Initiate management support and activities for the execution of a lo materials to include both medical and non-medical personal protect a holistic view to ensure complete readiness across biological defe	ctive equipment. Supports multiple support contracts to en					
FY 2023 to FY 2024 Increase/Decrease Statement: Additional investment to advance the overarching goals aligned with Plan (NBS).	ith the 2022 National Biodefense Strategy and Implementa	tion				
Title: 4) EA MGT		0.940	0.872	1.024		
FY 2023 Plans: Funds will continue providing support to the DoD EA to conduct correquirements of the military departments for CB warfare defense p CBDP as codified in public law and DoDD 5160.05E.		or the				
FY 2024 Plans: Provide subject matter expertise and acquisition program manage and acquisition functions. Conduct reviews and assessments of c solutions for issues requiring EA decision, coordination, and integr	urrent CBRN strategy, guidance and plans to identify and i					
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to change in program/project schedule.						
Title: 5) JACKS DBS		3.128	3.246	3.65		
Description: Provided CBRN Enterprise Services and Support						
FY 2023 Plans: Funds will update and streamline the JACKS user interface with a will provide users with a better overall user experience and enable						

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and	Biological Defense Program	Da	te: March 2023			
Appropriation/Budget Activity 0400 / 6	R-1 Program Element (Number/Name) PE 0605384BP <i>I Chemical and Biological</i> <i>Defense Program</i>					
B. Accomplishments/Planned Programs (\$ in Millions) changes to the user interface will help improve data quality and integ	rity by making it easier to identify report, and correct da	FY 20	22 FY 2023	FY 2024		
to JACKS from external systems.	The by making it easier to identify, report, and correct da					
<i>FY 2024 Plans:</i> JACKS will begin developing and deploying data marts into the JACK compartmentalized areas. The JACKS data marts will enable JACKS curating authoritative Chemical Biological Defense Program data from	S users to quickly make informed business decisions by	,				
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.						
Title: 6) JCSA			- 1.320	0 1.320		
Funds will conduct the follow-on study/assessment to the FY20 CBR Initiate a Post-Integrated Early Warning Doctrine, Organization, Train Facilities (DOTMLPF-P) Change Recommendation Study/Assessment (Wound and Ocular Decontamination) Analysis of Alternatives. Plan support of CASSANDRA 24, the preeminent CBRN-focused Operation operational risk analyses to support CBDP leadership decisions.	ning, Materiel, Leadership and Education, Personnel, an nt. Sponsor the first Personal Contamination Mitigation and conduct all modelling and scenario development in	1				
FY 2024 Plans: Funds will be used to conduct studies/assessments and analysis in s development to meet milestone decisions in coordination with the DA additionally be used to plan and conduct CASSANDRA 24, the preen Lastly, funds will continue to support detailed operational risk analyse planning constructs.	SD(CBD) and CBDP Component organizations. Fundi ninent CBRN-focused Operational Risk Analysis exercise	se.				
Title: 7) JRO MGT		7	868 8.499	9 9.158		
FY 2023 Plans: Funds will continue to represent the Services and Combatant Comma for Joint materiel and non-materiel solutions in the medical and physi studies for the combating weapons of mass destruction (CWMD) / CE service doctrine development, including the preparation of various Jo Techniques and Procedures (MTTPs). Continue to support CBRN/C schools. Continue to support COCOM scenario development and co exercises. Continue to chair the CWMD Working Group to ensure sy	ical CBRN defense mission areas; conduct foundational BRN defense community; provide support to Joint and N bint publications which then inform Multi-service Tactics, WMD training efforts at various Joint Senior Leadership ontroller/evaluator training and provide expertise to CCM	/lulti- ID				

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	al Defense Program		Date: M	arch 2023	
Appropriation/Budget Activity 0400 / 6	R-1 Program Element (Number/Name) PE 0605384BP <i>I Chemical and Biological</i> <i>Defense Program</i>	-	(Number/N lanagement	lame) t Support (Mg	ymt Support)
B. Accomplishments/Planned Programs (\$ in Millions)			FY 2022	FY 2023	FY 2024
System (JCIDS) documents are appropriately vetted and staffed prior to being Board. Continue to chair the CBRN Support to Command and Control Sub-wo Capabilities Board (FCB) include the preparation and validation of Capability D	rking Group supporting the C4Cyber Function	al			
FY 2024 Plans: Funds will continue to represent the Services and Combatant Commands (CCI for Joint materiel and non-materiel solutions in the medical and physical CBRN studies for the combating weapons of mass destruction (CWMD) / CBRN defer service doctrine development, including the preparation of various Joint publica Techniques and Procedures (MTTPs). Continue to support CBRN/CWMD train schools. Continue to support CCMD scenario development and controller/eval exercises. Continue to chair the CWMD Working Group to ensure synchronize System (JCIDS) documents are appropriately vetted and staffed prior to being Board (P-FCB). Continue to chair the CBRN Support to Command and Control Functional Capabilities Board (FCB) include the preparation and validation of CPackages.	I defense mission areas; conduct foundational nee community; provide support to Joint and M ations which then inform Multi-service Tactics, ning efforts at various Joint Senior Leadership luator training and provide expertise to CCMD ed Joint Capabilities Integration and Developm brought to the Protection Functional Capabiliti of Sub-working Group supporting the C4Cyber	ent es			
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.					
Title: 8) JTIWG			5.664	5.831	6.286
FY 2023 Plans: Continue T&E Executive mission support to ensure credible testing; T&E Early support for CBDP systems; support the DOT&E for OSD T&E Oversight; support efforts to develop, refine, and/or streamline processes for identifying, assessing ensure timely support to acquisition programs. Continue mission to improve the execution; eliminate unnecessary redundancies in test infrastructure. Continue Evaluation Gaps in order to reduce cost/test schedule impacts to near-term proceeding processes to support more efficient and effective management and sustain	ort the NCB in infrastructure planning; continue g, and addressing gaps in T&E capabilities to le quality and reduce the costs of test planning e efforts to identify and mitigate critical Test an ograms. Continue to align and streamline polic	e and d cies			
FY 2024 Plans: Continue Test and Evaluation (T&E) Executive mission support to ensure cred Studies; evaluation and decision support for CBDP systems; support the Direc Oversight; support the NCB in infrastructure planning; continue efforts to devel identifying, assessing, and addressing gaps in T&E capabilities to ensure timel mission to improve the quality and reduce the costs of test planning and execu	tor of Operational T&E (DOT&E) for OSD T&E op, refine, and/or streamline processes for y support to acquisition programs. Continue				

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical a	nd Biological Defense Program	Date: I	March 2023	
Appropriation/Budget Activity 0400 / 6	R-1 Program Element (Number/Name) PE 0605384BP / Chemical and Biological Defense Program	Project (Number/ MS6 / Manageme		ımt Support
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
test infrastructure. Continue efforts to identify and mitigate critical impacts to near-term programs. Continue aligning and streamlining management and sustainment of test infrastructure and methodological stream in the stream of the strea	g policies and processes to support more efficient and effe	ective		
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.				
Title: 9) OSD MGT		13.698	15.565	18.001
FY 2023 Plans: Funds will continue performing program oversight/reviews/assessm and Congressional engagements. Funds Defense Finance and Ac to support financial management and audit functions for the CBDP statements; reconciliation of budgetary and proprietary accounts, p compliance; funds management and control; management of the M integration and coordination.	counting Service transactions and direct support. Continu Enterprise including all aspects of accounting; financial processing of commitments and obligations; financial acco			
FY 2024 Plans: Funds continue performing program reviews/assessments, providin oversight/analysis, and providing Congressional issue analysis and by the Defense Threat Reduction Agency (DTRA), such as funding CBDP Enterprise all aspects of accounting; financial statements; re of commitments and obligations; financial accounting compliance; Internal Control Program and financial systems integration and con	d support. Supporting financial management services pro- g distribution and execution reporting. Continue to provide econciliation of budgetary and proprietary accounts, proce funds management and control; management of the Mana	vided the ssing		
FY 2023 to FY 2024 Increase/Decrease Statement: Increased support for strategic high priority efforts.				
Title: 10) PAIO MGT		7.890	8.592	9.692
FY 2023 Plans: Funds will continue to analyze and evaluate CWMD defense plans projected threats, allied contributions, estimated costs, and resource programs for execution of approved strategies and policies. Promo and methods for analyzing CWMD defense planning and the allocation of the electron of	ce constraints. Review, analyze, and evaluate CWMD de ote improved analytical skills and competencies, tools, dat	ense a,		

	d Biological Defense Program	[Date: Ma	arch 2023	
Appropriation/Budget Activity 400 / 6	R-1 Program Element (Number/Name) PE 0605384BP <i>I Chemical and Biological</i> <i>Defense Program</i>	Project (Nu MS6 / Mana	gmt Support		
8. Accomplishments/Planned Programs (\$ in Millions)			2022	FY 2023	FY 2024
CWMD defense programs are presented accurately and completely. policies to ensure that CWMD defense programs can be implemented		rnative			
FY 2024 Plans: Funds will continue to analyze and evaluate CWMD defense plans, porojected threats, allied contributions, estimated costs, and resource programs for execution of approved strategies and policies. Promote and methods for analyzing CWMD defense planning and the allocation CWMD defense programs are presented accurately and completely.	e constraints. Review, analyze, and evaluate CWMD de the improved analytical skills and competencies, tools, dat ion of resources. Ensure that the costs/budget justificati . Provide independent analytic advice and evaluate alte	fense ta, on for			
FY 2023 to FY 2024 Increase/Decrease Statement: ncrease due to change in program/project technical parameters.					
Title: 11) WB-ENBD			-	6.358	7.00
Description: This effort will focus on Biodefense and Biosafety Expe Management (Biosecurity)	ertise & Technology Protection & Supply Chain Risk				
FY 2023 Plans: Supported CBDP biosafety and biosecurity (biorisk) priorities through esearch to close gaps in scientific knowledge to facilitate validation o manage and ensure DoD biorisk. Implementing an enduring capa he CBDP supply chain, its cybersecurity, protection of intellectual pr	of DoD biological agent procedures and protocols, and a ability to surveil, address threats, and mitigate risks relat	tools			
FY 2024 Plans: Support CBDP biosafety and biosecurity (biorisk) priorities through be esearch to close gaps in scientific knowledge to facilitate validation o manage and ensure DoD biorisk. Continue implementing an endu- elated to the CBDP supply chain, its cybersecurity, protection of inter-	of DoD biological agent procedures and protocols, and t uring capability to surveil, address threats, and mitigate				
FY 2023 to FY 2024 Increase/Decrease Statement: Minor change due to routine program adjustments.					
	Accomplishments/Planned Programs Sub	statala /	1.950	52.855	64.092

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical		Date: March 2023
Appropriation/Budget Activity 0400 / 6	R-1 Program Element (Number/Name) PE 0605384BP / Chemical and Biological Defense Program	Project (Number/Name) MS6 / Management Support (Mgmt Support
C. Other Program Funding Summary (\$ in Millions)	· · · · · · · · · · · · · · · · · · ·	
<u>Remarks</u>		
D. Acquisition Strategy		
N/A		

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program								Date: Marc	ch 2023			
Appropriation/Budget Activity 0400 / 6					R-1 Program Element (Number/Name)Project (Number/Name)PE 0605384BP / Chemical and BiologicalDT6 / Joint Doctrine And TiDefense Program(Mgmt Support)				,	Support		
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
DT6: Joint Doctrine And Training Support (Mgmt Support)	-	0.836	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.836
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

The Joint Doctrine and Training Support Research, Development, Test, and Evaluation (RDT&E) Management Support Project provides the Joint Requirements Office for Chemical, Biological, Radiological and Nuclear Defense (JRO-CBRND) Training and Leader Education program directly supporting the Chemical Biological Defense Program (CBDP). In FY2023, the CBDP RDT&E Projects have been restructured to align to the CBDP Portfolio. DT6 efforts in FY2022 progress to the Management Support (MS6) portfolio. This restructuring is intended to provide standardization and alignment across CBDP research, development and acquisition efforts.

Efforts included in this Project are:

(1) Joint Requirements Office Doctrine and Training (JRO DT) **Progresses to MS6 in FY2023**

JRO DT develops Joint Chemical, Biological, Radiological, and Nuclear (CBRN) defense capability requirements and the improvement of CBRN defense related education and training at the Joint and Service levels. This requirement provides technical and subject matter expert support in the areas of CBRN Defense (CBRND) and Countering Weapons of Mass Destruction (CWMD). Joint and Service training, leadership development, and education includes: (1) The CBDP Joint Senior Leader Course (JSLC) and (2) Assistance in correcting training and doctrine deficiencies covered in the lessons learned process, combat operations, capability development studies and Department of Defense Inspector General (DoDIG) and Government Accountability Office (GAO) reports. Provide contract support to the CBDP-directed Graduate Fellowship Program in CBRN/CWMD Studies.

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2022	FY 2023	FY 2024
Title: 1) JRO DT	0.836	-	-
Description: Supports Joint Doctrine, Training, Leader Development & Education.			
Accomplishments/Planned Programs Subtotals	0.836	-	-
C. Other Program Funding Summary (\$ in Millions)			
N/A			
Remarks			

xhibit R-2A, RDT&E Project Justification: PB 2024 (Chemical and Biological Defense Program	Date: March 2023
ppropriation/Budget Activity 400 / 6	R-1 Program Element (Number/Name) PE 0605384BP <i>I Chemical and Biological</i> <i>Defense Program</i>	Project (Number/Name) DT6 <i>I Joint Doctrine And Training Support</i> (Mgmt Support)
Acquisition Strategy		
I/A		

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program										Date: March 2023		
Appropriation/Budget Activity R-1 Program Element (Number/Name) Project (Number/N 0400 / 6 PE 0605384BP / Chemical and Biological 049 / Joint Concept Defense Program Support)						,	(Mgmt					
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
O49: Joint Concept Development (Mgmt Support)	-	1.214	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	1.214
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

The Joint Concept Development Research, Development, Test, and Evaluation (RDT&E) Management Support Project supports the Joint Requirements Office and the Chairman's Risk Assessment Process by producing, coordinating, & executing Chemical, Biological, Radiological, and Nuclear (CBRN) defense studies, experiments, analyses, and architecture, in order to develop future operational concepts and support the efficient and effective generation of CBRN requirements. In FY2023, the CBDP RDT&E Projects have been restructured to align to the CBDP Portfolio. O49 efforts in FY2022 progress to the Management Support (MS6) portfolio. This restructuring is intended to provide standardization and alignment across CBDP research, development and acquisition efforts.

Efforts included in this Project are:

(1) Joint Concepts, Studies, and Analyses (JCSA) **Progresses to MS6 in FY2023**

JCSA provides specific lines of effort to include: qualitatively characterizing emerging CBRN threats and operational risks to the Joint Force; conducting innovative approaches to deal with technical studies; analyzing Concepts of Operations (CONOPS) for employing and developing capabilities; and analyzing specific issues as part of program development.

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2022	FY 2023	FY 2024
Title: 1) JCSA	1.214	-	-
Description: Support to JCSA			
Accomplishments/Planned Programs Subtotals	1.214	-	-
C. Other Program Funding Summary (\$ in Millions)			
N/A			
Remarks			
D. Acquisition Strategy			
N/A			

Exhibit R-2, RDT&E Budget Iten	n Justificat	ion: PB 202	24 Chemica	I and Biolog	gical Defens	e Program				Date: Mar	ch 2023	
Appropriation/Budget Activity 0400: Research, Development, Te RDT&E Management Support	est & Evalua	ntion, Defen	se-Wide I E	A 6:	R-1 Progra PE 060550				Research - (Chemical E	iological De	f
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
Total Program Element	0.000	21.179	2.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	23.17
SB6: Small Business Innovative Research (Mgmt Support)	-	21.179	2.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	23.17
A. Mission Description and Bud	lget Item Ju	ustification										
chemical and biological detection individual soldiers and equipment	t.			ncludes ider FY 2022	ntification, m	-	id intelligend Y 2024 Ba s		nation avoic FY 2024 O(FY 2024 To	
3. Program Change Summary (<u>s)</u>							<u>FT 2024 O</u>	<u></u>		
Previous President's Budg Current President's Budge				0.000 21.179	0.00 2.00		0.0 0.0			-		000 000
Total Adjustments	÷l			21.179 21.179	2.00		0.0			-		000
Congressional G	eneral Ped	uctions		21.179	2.00	0	0.00	00		-	0.0	000
Congressional D				-								
Congressional R				_	_							
Congressional A				_	2.00	0						
Congressional D		nsfers		-		U C						
Reprogramming				-	-							
• SBIR/STTR Trar				21.179	-							
 Other Adjustmer 	nts			-	-		0.0	00		-	0.0	000
Congressional Add Detai	ils (\$ in Mill	ions, and I	ncludes G	eneral Red	uctions)					FY	2022	FY 2023
Project: SB6: Small Busin	ess Innovat	ive Resear	ch (Mgmt S	upport)								
Congressional Add: Int	fectious Dis	ease Diagn	ostics								-	2.00
·		-				Congre	ssional Add	Subtotals	for Project:	SB6	-	2.00
						Co	ongressiona	Add Totals	s for all Proj	ects	-	2.00
						Co	ongressiona	I Add Totals	s for all Proj	ects	-	2

xhibit R-2, RDT&E Budget Item Justification: PB 2024 Chemical and Bio	ological Defense Program	Date: March 2023
ppropriation/Budget Activity 400: Research, Development, Test & Evaluation, Defense-Wide I BA 6: DT&E Management Support	R-1 Program Element (Number/Name) PE 0605502BP <i>I Small Business Innovative Research</i> -	Chemical Biological Def
Change Summary Explanation Funding: FY2022 (+\$21.179 Million): Funding transferred and applied	d to Small Business Innovative Research program.	
FY2023 (+\$2.000 Million): Congressional Add for infectious disease	diagnostics.	
Schedule: N/A		
Technical: N/A		

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program										Date: March 2023		
Appropriation/Budget Activity R-1 Program Element (Number/Name) Project (Number/Name) 0400 / 6 PE 0605502BP / Small Business Innovative Research - Chemical Biological Def SB6 / Small (Mgmt Support							ll Business	ne) Innovative F	Research			
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
SB6: Small Business Innovative Research (Mgmt Support)	-	21.179	2.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	23.179
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

The Small Business Innovative Research (SBIR) Program is a Congressionally mandated program established to increase the participation of small business in federal research and development (R&D). Currently, each participating Government agency must reserve 3.2% of its extramural R&D for SBIR awards to competing small businesses. The goal of the SBIR Program is to invest in the innovative capabilities of the small business community to help meet Government R&D objectives while allowing small companies to develop technologies and products which they can then commercialize through sales back to the Government or in the private sector.

The Small Business Technology Transfer (STTR) Program like SBIR, is a Government-wide program, mandated by the Small Business Research and Development Enhancement Act of 1992, Public Law (PL) 102-564. STTR was established as a companion program to the SBIR Program and is executed in essentially the same manner; however, there are several distinct differences. The STTR Program provides a mechanism for participation by university, Federally-Funded Research and Development Centers (FFRDCs), and other non-profit research institutions. Specifically, the STTR Program is designed to provide an incentive for small companies and research at academic institutions and non-profit research and development institutions to work together to move emerging technical ideas from the laboratory to the marketplace to foster high-tech economic development and to advance U.S. economic competitiveness. Each STTR proposal must be submitted by a team which includes a small business (as the prime contractor for contracting purposes) and at least one research institution, which have entered into a Cooperative Research and Development Agreement for the purposes of the STTR effort. Furthermore, the project must be divided up such that the small business performs at least 40% of the work and the research institution(s) performs at least 30% of the work. The remainder of the work may be performed by either party or a third party. The budget is separate from the SBIR budget and is significantly smaller (0.45% of the extramural R&D budget vs. 3.2% for the SBIR Program).

The overall objective of the CBD SBIR/STTR program is to improve the transition or transfer of innovative CBD technologies between DoD components and the private sector for mutual benefit. The CBD program includes those technology efforts that maximize a strong defensive posture in a biological or chemical environment using passive and active means as deterrents. These technologies include chemical and biological detection; information assessment, which includes identification, modeling, and intelligence; contamination avoidance; and protection of both individual soldiers and equipment. The executive agent for the SBIR/STTR portion of the CBDP is the Army Research Office-Washington.

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2022	FY 2023	FY 2024
Title: 1) ZSBIR	21.179	0.000	0.000
Description: Small Business Innovative Research/Small Business Technology Transfer (SBIR/STTR)			
FY 2023 Plans:			

PE 0605502BP: *Small Business Innovative Research - Che...* Chemical and Biological Defense Program

	al and Biological Defense Program		Date:	March 2023	
Appropriation/Budget Activity 0400 / 6	R-1 Program Element (Number/Name) PE 0605502BP I Small Business Innovativ Research - Chemical Biological Def	Project (Number/Name) SB6 I Small Business Innovative (Mgmt Support)			
B. Accomplishments/Planned Programs (\$ in Millions)		ſ	FY 2022	FY 2023	FY 2024
 Sensor – Battlespace Environments (\$4.4 Million): Artificial Intel 3D Model Generation from Multiple Image Sources for Situation - Detection – Sensors (\$2.2 Million): Development and Testing of Properties of Aerosols. Individual Protection (\$4.4 Million): Non-Perfluoroalkyl and Nor Materials; Non-PFAS (Perfluoroalkyl or Polyfluoroalkyl Substance - Canine Protection (\$2.2 Million): Collapsible and Protective Po - Point Detection (\$3.3 Million): Millimeter Wave Imaging with Hi Rectifiers. 	al Awareness and Transport and Dispersion Modeling. of Contact-Free Methods for Classifying the Morphological n-Polyfluoroalkyl Substances (PFAS) Elastomeric Chemica ces) Liquid Repellant Coatings. rtable Canine Shelter.	Barrier			
FY 2024 Plans: - Medical Pretreatments (estimated funding, \$2.2 Million) - Medical Diagnostics (estimated funding, \$2.2 Million) - Medical Therapeutics – Biological Countermeasures (estimated - Medical Therapeutics – Chemical Countermeasures (estimated					
	Accomplishments/Planned Programs So	ıbtotals	21.179	0.000	0.00
	FY 202	2 FY 2	023		
Congressional Add: Infectious Disease Diagnostics		- 2	.000		
FY 2023 Plans: Conduct infectious disease diagnostics.					
	Congressional Adds Subtotals	- 2	.000		
<u>C. Other Program Funding Summary (\$ in Millions)</u> N/A <u>Remarks</u> D. Acquisition Strategy					

Exhibit R-2, RDT&E Budget Item Justification: PB 2024 Chemical and Biological Defense Program								Date: March 2023				
Appropriation/Budget Activity 0400: Research, Development, Test & Evaluation, Defense-Wide I BA 7: Operational Systems Development					R-1 Program Element (Number/Name) PE 0607384BP / Chemical and Biological Defense (Operational Systems Development)							
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
Total Program Element	0.000	55.359	65.588	80.495	0.000	80.495	83.683	89.178	84.877	66.102	Continuing	Continuing
UN7: Understand (Op Sys Dev)	-	0.000	40.414	50.603	0.000	50.603	58.881	71.869	68.839	50.628	Continuing	Continuing
PT7: Protect (Op Sys Dev)	-	0.000	20.076	26.818	0.000	26.818	22.815	15.490	14.193	13.612	Continuing	Continuing
MT7: Mitigate (Op Sys Dev)	-	0.000	5.098	3.074	0.000	3.074	1.987	1.819	1.845	1.862	Continuing	Continuing
CA7: Contamination Avoidance (Op Sys Dev)	-	12.244	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	12.244
CM7: Homeland Defense (Op Sys Dev)	-	1.463	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	1.463
C07: Collective Protection (Op Sys Dev)	-	9.645	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	9.645
DE7: <i>Decontamination (Op Sys Dev)</i>	-	1.020	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	1.020
IP7: Individual Protection (Op Sys Dev)	-	11.659	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	11.659
IS7: Information Systems (Op Sys Dev)	-	14.589	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	14.589
MB7: <i>Medical Biological Defense</i> (Op Sys Dev)	-	3.726	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	3.726
MC7: <i>Medical Chemical Defense</i> (Op Sys Dev)	-	1.013	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	1.013

A. Mission Description and Budget Item Justification

This program element (PE) resources Operational System Development across the Understand, Protect, and Mitigate portfolios. Chemical Biological Defense Program (CBDP) investments provide an integrated, layered capability to enable Countering Weapons of Mass Destruction (CWMD) missions ranging from combat operations to Department of Defense (DoD) support to domestic incident prevention and response. The Projects in this PE support the upgrade of systems that have been fielded or have received approval for full-rate production in order to maintain Joint Force readiness.

Individual Projects include:

PE 0607384BP: *Chemical and Biological Defense (Operati...* Chemical and Biological Defense Program

Exhibit R-2, RDT&E Budget Item Justification: PB 2024 Chemical and Biol	ogical Defense Prog	gram	Date:	Date: March 2023		
Appropriation/Budget Activity	R-1 Program Ele	ement (Number/Name)				
0400: Research, Development, Test & Evaluation, Defense-Wide I BA 7:			l Defense (Operational	Systems Development)		
Operational Systems Development		•				
- Understand (UN7): Technology refresh, modernization and continuous engi	neering of software	applications and information	ation systems to shape	and inform the		
battlespace against CBRN threats. Continued development and testing of CB	sensor equipment	to maintain system inter	operability with emergin	ng information technology		
and decrease size, weight, and power requirements to reduce the logistical b						
and associated capabilities (e.g., assays) that contribute to the layered medic				ed medical nerve agent		
treatment system that contribute to the layered medical defenses against che	mical warfare agen	t threats facing U.S. For	ces in the field.			
- Protect (PT7): Efforts to refresh technology of fielded individual and protective						
biological, and radiological (CBR) environment with little or no degradation of are smaller, lighter, less costly to produce and maintain, and more logistically						
contamination.	supportable, eriabl	ing mission accomplishi	nent in spaces sale no	In the effects of CBR		
- Mitigate (MT7): Technology refresh of fielded Contamination Mitigation (Cor	nMit) systems that w	/ill remove and/or detoxi	fv contaminated materi	al without damaging		
combat equipment, personnel, or the environment.	, -, -,		· · · · · · · · · · · · · · · · · · ·			
- Contamination Avoidance (CA7), Homeland Defense (CM7), Collective Prot	ection (C07), Decor	ntamination (DE7), Indiv	idual Protection (IP7), I	nformation Systems		
(IS7), Medical Biological Defense (MB7) and Medical Chemical Defense (MC	are no longer act	ive FY24 Projects due to	o budget restructuring.			
The projects in this PE support operational systems development necessary	to maintain operatio	nal effectiveness and ar	e, therefore, correctly p	blaced in Budget Activity		
7.						
B. Program Change Summary (\$ in Millions) FY 2022	<u>FY 2023</u>	FY 2024 Base	FY 2024 OCO	FY 2024 Total		
Previous President's Budget 58.261	68.030	55.189	-	55.189		
Current President's Budget 55.359	65.588	80.495	-	80.495		
Total Adjustments -2.902	-2.442	25.306	-	25.306		
Congressional General Reductions	-					
Congressional Directed Reductions	-2.442					
Congressional Rescissions	-					
Congressional Adds	-					
Congressional Directed Transfers	-					
Reprogrammings -1.937	-					
SBIR/STTR Transfer -0.965 Other Adjustments	-	25.206		25 206		
Other Adjustments -	-	25.306	-	25.306		
Change Summary Explanation						

Change Summary Explanation

Funding: FY 2022 (-\$1.937 Million): Below threshold reprogramming to System Development & Demonstration, Budget Activity 5 in support of sensor and detection efforts.

PE 0607384BP: *Chemical and Biological Defense (Operati...* Chemical and Biological Defense Program

Exhibit R-2, RDT&E Budget Item Justification: PB 2024 Chemical and Biolo	ogical Defense Program	Date: March 2023			
Appropriation/Budget Activity R-1 Program Element (Number/Name)					
0400: Research, Development, Test & Evaluation, Defense-Wide I BA 7:	PE 0607384BP / Chemical and Biological Defense (Operational Systems Developmen				
Operational Systems Development					
EV 2022 (\$0.965 Million): Transfer of funding to support Small Busines	se Innovative Research/Small Business Technology Trans	efer efforte			

FY 2022 (-\$0.965 Million): Transfer of funding to support Small Business Innovative Research/Small Business Technology Transfer efforts.

FY 2023 (-\$2.442 Million): Congressional Directed Reductions.

FY 2024 (+\$25.306 Million): Increase for Departmental inflation rate adjustments (+\$0.403 Million) and to address modernization, obsolescence and continuous engineering of collective protection systems, sensor equipment and information systems, and CBRN medical devices. These efforts will increase the readiness, sustainability, reliability, and affordability of these systems.

Schedule: N/A

Technical: N/A

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program								Date: March 2023				
Appropriation/Budget Activity 0400 / 7									Project (Number/Name) UN7 / Understand (Op Sys Dev)			
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
UN7: Understand (Op Sys Dev)	-	0.000	40.414	50.603	0.000	50.603	58.881	71.869	68.839	50.628	Continuing	Continuing
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

The Understand Operational System Development Project provides the Joint Force continued readiness of fielded sensor, information technology and medical diagnostic capabilities and provides size, weight and power improvements to reduce logistical burden on the Warfighter and Services. In FY 2023, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. UN7 efforts in FY 2022 remain in Projects CA7, CM7, IP7, IS7, and MB7. This restructuring provided standardization and alignment across CBDP research, development and acquisition efforts.

Efforts included in this Project are:

- (1) Modernization Chemical Biological Radiological Nuclear Information Systems (MOD CBRN IS),
- (2) CBRN Support to Command and Control (CSC2),
- (3) Enhanced Maritime Biological Detection (EMBD),
- (4) Reactive Chemistry Orthogonal Surface and Environmental Threat Ticket Array (ROSETTA),
- (5) Modernization Sensors (MOD SEN),
- (6) Modernization Medical (MOD MED),
- (7) Special Purpose Unit Rapid Capability Development and Deployment (SPU RCDD), and
- (8) Weapons of Mass Destruction Civil Support Team (WMD CST)

MOD CBRN IS combines CBRN IS (Cloud), Joint Effects Model (JEM), the Joint Warning and Reporting Network (JWARN), and the Software Support Activity within one portfolio. MOD CBRN IS provides for the continuous engineering and sustainment efforts to modernize capabilities and conduct Post Deployment Software Support (PDSS) to fielded CBRN software programs. Activities include: software code updates and modernization to correct deficiencies; compliance with system architectural changes to ensure interoperability; cybersecurity updates ensuring compliance with policies and standards; test and evaluation to identify possible cybersecurity vulnerabilities; configuration management; software redistribution, documentation, and training. In FY24, MOD CBRN IS funding will be consolidated under CBRN Support to Command and Control (CSC2).

Effort consolidates CBRN Support to Command and Control (CSC2) with MOD CBRN IS in order to gain efficiencies of managing funding and programmatic efforts under one line. Additionally, it allows the consolidation of continuous engineering for the currently deployed legacy CBRN information systems (Joint Effects Model (JEM)/Joint Warning and Reporting Network (JWARN), CBRN Information System (CBRN IS)). Effort encompasses the processes, procedures, people, material and information required to support and modernize fielded CBRN information systems and applications. Legacy capabilities and efforts will be transitioned to the CSC2 Capability set in the FY27-29 time frame, maintaining the stopgap capability for CBRN warning, reporting, and effects modeling while setting conditions for the sun

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and	d Biological Defense Program	Date: March 2023
Appropriation/Budget Activity 0400 / 7	R-1 Program Element (Number/Name) PE 0607384BP <i>I Chemical and Biological</i> <i>Defense (Operational Systems Developm</i> <i>nt)</i>	
setting of the legacy capabilities. The approach to consolidate simpli JWARN capabilities as replacement capabilities are deployed throug	•	ynchronizes the sunset of legacy JEM and
The EMBD program will undertake engineering efforts to combat Din line. The EMBD program will address major obsolescence problems EMBD hardware/software remains procurable, field upgradeable and efforts to resolve obsolescence of the flash memory in the Rapid Age (DT) of all new components.	s identified by the prime contractor that could affect a deckwards compatible with previously fielded units.	stable production line and to ensure new In FY24, EMBD will undertake engineering
ROSETTA is a modernization effort to provide the General Forces a warfare agents (CWAs) and non-traditional agents (NTAs). These h of common battlefield interferents at the tactical-level. ROSETTA is unmanned platforms especially micro-sized unmanned aerial sensor reduced false alarm rate, potential for increased number of chemical based agents (PBAs), NTAs and toxic industrial chemicals (TICs)), a sensors. ROSETTA funding discontinues after FY23, program deen	ighly-selective, multiplexed array tickets will enable a based on colorimetric technology and will be eye-rea rs. In addition, the ROSETTA tickets will provide imp ls detected, reduced detection time especially for cor and potential for integration onto unmanned platforms	accurate hazard identification in the presence adable and has potential for integration onto roved hazard detection performance with npounds of interest (CWAs, pharmaceutical
The MOD SEN program conducts technology refresh, modernization inform the battlespace against CBRN threats for the Analytical Labor Confirmatory Analytical Capability Set (FC ACS), CALS Theater Vali Enhanced Maritime Biological Detection (EMBD) programs. Continue equipment and functionality issues for the Services in order to mainta power requirements to reduce logistical burden of associated capabil CBRN DRS, CALS, ALS MOD, M8, and EMBD.	ratory System Modification (ALS MOD), Common An idation Integrated System (TV IS), CBRN Dismounte ed development and testing of CB sensor equipment ain system interoperability with emerging information	alytical Laboratory System (CALS) Field d Reconnaissance System (DRS), M8, and is planned to address obsolescence of critical technology and decrease size, weight and
The MOD MED program supports improvements to fielded systems devices, including FDA-approved autoinjectors and diagnostic equip continue annual cyber security updates and management of hardwa Diagnostic System Increment 1 (NGDS 1) replacement system to ma (DoD) sponsored regulatory activities for legacy autoinjectors and co	ment, in order to mitigate obsolescence and maintair re and software configurations for diagnostic system aintain the current Biological Warfare diagnostics cap	n fielded capabilities. In FY24, MOD MED will s; initiate development of a Next Generation
SPU RCDD facilitates Joint Special Operations Command (JSOC) ra This includes select elements from across the Special Operations For Force enabling units such as the 20th Chemical, Biological, Radiolog	orce (SOF) Enterprise such as CBRN Assessment R	esponse Teams (CARTs) and other Joint

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical ar	Date: N	Date: March 2023			
Appropriation/Budget Activity 0400 / 7		oject (Number/Name) I7 I Understand (Op Sys Dev)			
Defense Program (CBDP) by creating a portfolio of operationally-recapability needs of the geographic combatant commanders. These focused conduct of combat evaluations and mission-oriented operations are challenges supported by "buy-try-decide-acquire" acquisition summanned aerial and ground platform sensor integration, developm Biological ensembles that have gone through requirements validations SOF equipment to counter emerging threats. Weapons of Mass Destruction Civil Support Team (WMD CST) sup Shelf (COTS) and Government Off The Shelf (GOTS) analytical de the operational capabilities of the WMD CST. Program efforts suppling supported by the manufacturer. In FY24, the WMD C	e objectives are met by the early transitioning of promising ational assessments to assess technological and mission su he-Shelf (GOTS) products along with novel redesign appro- trategies. SPU RCDD initiates efforts such as respiratory nent of enhanced and augmented reality systems, and mod- on, and continues product enhancement development and oports the fielded system upgrade and ongoing assessment tection, protection, decontamination and sampling equipme- port upgrades of key components of the WMD CST Program	science and techn uitability; and the a aches to optimize breathing systems lernization of prote technology upgrad t and acquisition o ent for survey in or m that have becon	ologies (S&T) active leveragi existing soluti , biological ide active Chemica des on current f Commercial der to expand ne obsolete, o	; the ng of ons to entification, al and tly fielded Off The /enhance r are no	
to obtain or validate engineering data on the performance of the sy	stem.				
	stem.	FY 2022	FY 2023	FY 2024	
to obtain or validate engineering data on the performance of the sy	stem.	FY 2022	FY 2023 18.995	FY 2024	
to obtain or validate engineering data on the performance of the sy. B. Accomplishments/Planned Programs (\$ in Millions)	stem.	FY 2022 -		FY 2024 -	
to obtain or validate engineering data on the performance of the sys. B. Accomplishments/Planned Programs (\$ in Millions) <i>Title:</i> 1) MOD CBRN IS	nuous engineering efforts to modernize currently fielded porting Network (JWARN) and CBRN IS hosted on cloud a chitectures, operating systems, cyber security requirement o maintain interoperability, efficiency and functionality and testing on software updates and modernization efforts.	- nd s		FY 2024 -	
to obtain or validate engineering data on the performance of the system. B. Accomplishments/Planned Programs (\$ in Millions) Title: 1) MOD CBRN IS Description: CBRN Information Systems Modernization FY 2023 Plans: Perform management, preplanned product improvements and contric capabilities of the Joint Effects Model (JEM), Joint Warning and Ref Joint Service Command and Control (C2) systems. Update host arr and North Atlantic Treaty Organization (NATO) standards in order to compliance. Continue Government developmental and operational Provide program/financial management, costing, contracting, sched software redeployment and training to operational forces. FY 2023 to FY 2024 Increase/Decrease Statement: Program/project funding transferred to another funding line. In FY24	nuous engineering efforts to modernize currently fielded porting Network (JWARN) and CBRN IS hosted on cloud a chitectures, operating systems, cyber security requirement o maintain interoperability, efficiency and functionality and testing on software updates and modernization efforts. luling and acquisition oversight. Provide product support for	- nd s or		FY 2024	
to obtain or validate engineering data on the performance of the system. B. Accomplishments/Planned Programs (\$ in Millions) Title: 1) MOD CBRN IS Description: CBRN Information Systems Modernization FY 2023 Plans: Perform management, preplanned product improvements and contric capabilities of the Joint Effects Model (JEM), Joint Warning and Ref Joint Service Command and Control (C2) systems. Update host are and North Atlantic Treaty Organization (NATO) standards in order to compliance. Continue Government developmental and operational Provide program/financial management, costing, contracting, sched software redeployment and training to operational forces. FY 2023 to FY 2024 Increase/Decrease Statement:	nuous engineering efforts to modernize currently fielded porting Network (JWARN) and CBRN IS hosted on cloud a chitectures, operating systems, cyber security requirement o maintain interoperability, efficiency and functionality and testing on software updates and modernization efforts. luling and acquisition oversight. Provide product support for	- nd s or		FY 2024 - 20.48	

PE 0607384BP: *Chemical and Biological Defense (Operati...* Chemical and Biological Defense Program

xhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program			Date: March 2023				
Appropriation/Budget Activity 0400 / 7	priation/Budget Activity R-1 Program Element (Number/Name) F						
B. Accomplishments/Planned Programs (\$ in Millions)		FY	2022	FY 2023	FY 2024		
FY 2024 Plans: Continue engineering, integration, and delivery of the CSC2 capability s (MVCR). Continue post-production software support of the Legacy CBR deploy. This continued development will include updates to host archite and North Atlantic Treaty Organization (NATO) standards. Supports cor on software updates and modernization efforts. Provide program/finance acquisition oversight and product support for software redeployment and	IN information systems, until the CSC2 is available to ctures, operating systems, cyber security requiremen- ntinuous software developmental and operational tes- cial management, costing, contracting, scheduling an	ts ing					
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project funding transferred from another funding line. FY23 fur requires regular delivery of capabilities within one year of the execution deployed capabilities.	nding under MOD CBRN IS. Software acquisition path decision. Provide for continuous engineering of the	iway					
Title: 3) EMBD			-	1.748	-		
Description: Product Development, Test and Evaluation, and Manager	nent						
FY 2023 Plans: Continue obsolescence support to include production efforts, testing and	d verification efforts.						
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project funding transferred to another funding line. FY 24 fundious obsolescence needs.	ing is combined under MOD SEN Project UN7 to exe	cute					
Title: 4) ROSETTA			-	2.447	-		
Description: Product Development, Engineering Design & Testing							
FY 2023 Plans: Continue contract efforts and conduct contractor testing for down select							
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project terminated in FY 2024.							
Title: 5) MOD SEN			-	6.379	11.66		
Description: Sensors Modernization							

PE 0607384BP: *Chemical and Biological Defense (Operati...* Chemical and Biological Defense Program

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program			Date: March 2023				
ropriation/Budget Activity R-1 Program Element (Number/Name) Pro				Project (Number/Name) JN7 I Understand (Op Sys Dev)			
B. Accomplishments/Planned Programs (\$ in Millions)			FY 2022	FY 2023	FY 2024		
FY 2023 Plans: Complete evaluation of improved and integrated sensors and pers Reconnaissance System (DRS), identifying new electrochemilumin Analytical Laboratory System (CALS) and Analytical Laboratory Sy Chromatography Mass Spectrometry (LCMS) technology and assa	nescence (ECL) technology to refresh CBRN DRS, Comm ystem (ALS) Modification (MOD). Initiate evaluation of Liq						
FY 2024 Plans: Complete evaluation of prototyping efforts associated with the CBF Modernization Program (SMP), and the continued technical refrest System (CALS), Analytical Laboratory System (ALS) Modification ((EMBD). Plans include laboratory information systems and gas ch refreshment and communications updates for DRS, modernizing th 1960s, and software refreshments and electronics components ob	hment of CBRN DRS, Common Analytical Laboratory (MOD), M8, and Enhanced Maritime Biological Detection promatography mass spectrometer refreshments for CALS ne M8 to refresh the technology originally manufactured in	, suit					
FY 2023 to FY 2024 Increase/Decrease Statement: Program/project funding transferred from another funding line. In F ROSETTA (M8 MWO) and EMBD UN7 lines to execute those activ							
Title: 6) MOD MED - Diagnostic System Upgrades / Assay Develo	pment		-	5.354	3.024		
Description: Maintain system hardware and software configuratio	ns for fielded diagnostics.						
FY 2023 Plans: Annual cyber security updates and management of hardware and fielded systems.	software configurations, and develop additional assays for						
FY 2024 Plans: Continue annual cyber security updates and management of hardwassays for NGDS 1.	ware and software configurations, and develop additional						
FY 2023 to FY 2024 Increase/Decrease Statement: Decrease due to change in program/project schedule. Delay of MF	PDS Milestone C to FY25.						
Title: 7) MOD MED - Autoinjector Post Marketing Commitments an	nd Requirements (PMRs/PMCs)		-	0.527	1.906		
Description: Food and Drug Administration (FDA) required Post-M products.	Marketing Commitments and Requirements for combination	n					

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	I Defense Program	Date:	March 2023	
Appropriation/Budget Activity 0400 / 7	R-1 Program Element (Number/Name) PE 0607384BP <i>I Chemical and Biological</i> <i>Defense (Operational Systems Developme</i> <i>nt)</i>	Project (Number UN7 / Understan)
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
FY 2023 Plans: Office Regulatory Affairs (ORA) Support - regulatory activities for legacy autoin	jectors.			
FY 2024 Plans: Support Army, Office of the Surgeon General (OTSG) - Sponsored regulatory a Marketing Commitments.	activities for legacy autoinjectors. Initiate FDA	Post-		
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to change in program/project schedule. Due to the delays to Dual to Dec 2024.	Drug Delivery Device (D4) pushing FDA appr	oval		
Title: 8) MOD MED - NGDS 1 Tech Refresh		-	-	8.04
Description: NGDS 1 technology refresh				
FY 2024 Plans: Initiate developmental activities for system to maintain the Biological Warfare d	iagnostics capability currently provided by NG	DS 1.		
FY 2023 to FY 2024 Increase/Decrease Statement: New effort within MOD MED.				
Title: 9) SPU RCDD - System Modernization		-	1.463	1.83
Description: This line includes Product Development, Test and Evaluation, an across multiple commodity areas in order to rapidly field solutions in response to		logy		
FY 2023 Plans: Initiate product enhancement, development, and technology upgrades on currer conduct limited user evaluations and operational assessments, and provide proceed Self Contained Breathing Apparatus (M-SCBA) and Enhanced Warfighter Augr development, and technology upgrades, conduct limited user evaluation, and or management support.	ogram management support. Continue the Mo nented Training (EWAT) product enhancemen	dular t,		
FY 2024 Plans: Continue product enhancement, development, and technology upgrades on cu threats, conduct limited user evaluations and operational assessments, and pro		9		

PE 0607384BP: *Chemical and Biological Defense (Operati...* Chemical and Biological Defense Program

	stification: PB	2024 Chemi	cal and Biolo	ogical Defen	se Program				Date: Ma	arch 2023	
Appropriation/Budget Activity 0400 / 7				PE 06	07384BP / C	nent (Numb Chemical and nal Systems		UN7 I Un	Number/N derstand (ame) Op Sys Dev)	
B. Accomplishments/Planned Pr	<u>ograms (\$ in I</u>	<u> Millions)</u>						F	Y 2022	FY 2023	FY 2024
the MSCBA and EWAT product er operational assessments, and pro				ogy upgrades	s, conduct li	nited user e	valuation, an	d			
FY 2023 to FY 2024 Increase/De Minor change due to routine progr											
Title: 10) WMD CST									-	3.501	3.644
Description: System Upgrade and	d Support										
						perations. C					
engineering and integrated logistic and activation of the system). Initi testing. <i>FY 2024 Plans:</i> FY24 funding address capability g modification (MOD) process in coll	ate start of Pha	escence issue	ned aerial s	ntenance sup ensors (UAS identified by	oport, facilitie 3) testing and	es, personne d larger scal	el, training, te e Decon efflu	esting, Jent			
and activation of the system). Initi testing. FY 2024 Plans: FY24 funding address capability g modification (MOD) process in coll	ate start of Pha aps and obsole aboration with	escence issue the National	ned aerial s	ntenance sup ensors (UAS identified by	oport, facilitie 3) testing and	es, personne d larger scal	el, training, te e Decon efflu	esting, Jent			
and activation of the system). Initi testing. <i>FY 2024 Plans:</i> FY24 funding address capability g	ate start of Pha aps and obsole aboration with crease Statem	escence issue the National ent:	ned aerial s	ntenance sup ensors (UAS identified by	oport, facilitie 3) testing and	es, personne d larger scal	el, training, te e Decon efflu	esting, Jent			
and activation of the system). Initi testing. <i>FY 2024 Plans:</i> FY24 funding address capability g modification (MOD) process in coll <i>FY 2023 to FY 2024 Increase/Dec</i>	ate start of Pha aps and obsole aboration with crease Statem	escence issue the National ent:	ned aerial s	ntenance sup ensors (UAS identified by au.	oport, facilitie) testing and the comme	es, personne d larger scal rcial of the s	el, training, te e Decon efflu	esting, Juent	_	40.414	50.603
and activation of the system). Initi testing. <i>FY 2024 Plans:</i> FY24 funding address capability g modification (MOD) process in coll <i>FY 2023 to FY 2024 Increase/Dec</i>	ate start of Pha aps and obsole aboration with crease Statem am adjustments	escence issue the National ent: s.	ned aerial s es that were Guard Bure	ntenance sup ensors (UAS identified by au. Accon	oport, facilitie 5) testing and 7 the comme	es, personne d larger scal rcial of the s	el, training, te e Decon efflu helf (COTS)	esting, Juent	-		
and activation of the system). Initi testing. FY 2024 Plans: FY24 funding address capability g modification (MOD) process in coll FY 2023 to FY 2024 Increase/De Minor change due to routine progr	ate start of Pha aps and obsole aboration with crease Statem am adjustments	escence issue the National ent: s.	ned aerial s	ntenance sup ensors (UAS identified by au.	oport, facilitie) testing and the comme	es, personne d larger scal rcial of the s	el, training, te e Decon efflu helf (COTS)	esting, Juent	- FY 2028	40.414 <u>Cost To</u> <u>Complete</u>	<u>.</u>
and activation of the system). Initi testing. <i>FY 2024 Plans:</i> FY24 funding address capability g modification (MOD) process in coll <i>FY 2023 to FY 2024 Increase/De</i> Minor change due to routine progr C. Other Program Funding Summ	ate start of Pha aps and obsole aboration with crease Statem am adjustments mary (\$ in Milli	escence issue the National ent: s.	es that were Guard Bures <u>FY 2024</u>	identified by au. <u>Accon</u>	oport, facilitie b) testing and the comme nplishments <u>FY 2024</u>	es, personne d larger scal rcial of the s s/Planned P	el, training, te e Decon efflu helf (COTS)	esting, Jent	- FY 2028	<u>Cost To</u>	Total Cost
and activation of the system). Initi testing. FY 2024 Plans: FY24 funding address capability g modification (MOD) process in coll FY 2023 to FY 2024 Increase/Dec Minor change due to routine progr <u>C. Other Program Funding Summ</u> <u>Line Item</u> • CA5: Contamination	ate start of Pha aps and obsole aboration with crease Statem am adjustments nary (\$ in Milli FY 2022	escence issue the National ent: s.	es that were Guard Bures <u>FY 2024</u>	identified by au. <u>Accon</u>	oport, facilitie b) testing and the comme nplishments <u>FY 2024</u>	es, personne d larger scal rcial of the s s/Planned P	el, training, te e Decon efflu helf (COTS)	esting, Jent	 FY 2028 	Cost To Complete	Total Cost 84.967 12.244

Exhibit R-2A, RDT&E Project Justi	fication: PB	2024 Chem	ical and Biolo	ogical Defen	se Program				Date: Ma	rch 2023	
Appropriation/Budget Activity 0400 / 7				PE 06	07384BP / C	nent (Numb Chemical and nal Systems	•		Number/Na derstand (C	m e) Op Sys Dev)	
C. Other Program Funding Summa	ary (\$ in Milli	ions)									
			<u>FY 2024</u>	<u>FY 2024</u>	<u>FY 2024</u>					Cost To	
Line Item	FY 2022	FY 2023	Base	000	<u>Total</u>	FY 2025	FY 2026	FY 2027	<u>FY 2028</u>	Complete	Total Cos
• IP5: Individual Protection (SDD)	18.690	-	-	-	-	-	-	-	-	0.000	18.690
 IP7: Individual 	11.659	-	-	-	-	-	-	-	-	0.000	11.659
Protection (Op Sys Dev)											
 IS7: Information 	14.589	-	-	-	-	-	-	-	-	0.000	14.589
Systems (Op Sys Dev)											
 MB7: Medical Biological 	3.726	-	-	-	-	-	-	-	-	0.000	3.726
Defense (Op Sys Dev)											
 UN5: Understand (SDD) 	-	126.071	182.726	-	182.726	137.991	127.671	108.908	68.088	Continuing	Continuing
 JS0005: Common Analytical 	48.258	30.530	7.167	-	7.167	-	-	-	-	0.000	128.728
Laboratory System (CALS)											
 JS5230: Modernization 	0.611	0.656	-	-	-	-	-	-	-	0.000	1.267
CBRN Information											
Systems (MOD CBRN IS)											
• MC0101: CBRN	21.611	47.324	60.492	-	60.492	64.556	37.802	23.292	-	Continuing	Continuin
Dismounted Reconnaissance											
Systems (CBRN DRS)											
 PHM018: SPU Rapid 	10.834	9.914	49.455	-	49.455	20.689	20.180	24.216	26.638	Continuing	Continuin
Capability Development											
And Demo (SPU RCDD)											

Remarks

D. Acquisition Strategy

MODERNIZATION CBRN INFORMATION SYSTEMS (MOD CBRN IS)

MOD CBRN IS funding will be consolidated under CBRN Support to Command and Control (CSC2) starting in FY24 to gain program management efficiencies and to adequately sustain Joint Effects Model (JEM) and Joint Warning and Reporting Network (JWARN) capabilities until a CSC2 capability is available.

CBRN SUPPORT TO C2 (CSC2)

Effort combines the MOD CBRN IS effort with CSC2. The acquisition strategy utilizes a managed portfolio approach to align multiple capabilities in support of continuous engineering and modernization of CBRN Information Systems. This encompasses the continuous engineering to maintain, modernize, and conduct post production and

xhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Bic	ological Defense Program	Date: March 2023
Appropriation/Budget Activity 400 / 7	R-1 Program Element (Number/Name) PE 0607384BP <i>I</i> Chemical and Biological Defense (Operational Systems Developme nt)	Project (Number/Name) UN7 / Understand (Op Sys Dev)
deployment support to fielded CBRN software information systems and of CBRN IS effort to reduce cost and technical risk through the existing infravell as initiate the sun setting of the legacy capabilities associated with N	astructure and software platforms for integration and	
ENHANCED MARITIME BIOLOGICAL DETECTION (EMBD)		
The EMBD program uses a streamlined acquisition strategy utilizing a For Support in Production (OSIP) to resolve diminishing sources and obsoles by the prime contractor that could affect a stable production line and to e compatible with previously fielded units. The FY24 OSIP Option will under Aerosol Detector (RAAD), multiple circuit card electrical components and	scence issues. The FY24 OSIP Option will address ensure new EMBD hardware/software remains procu ertake engineering efforts to resolve obsolescence of	major obsolescence problems identified irable, field upgradeable and backwards of the flash memory in the Rapid Agent
REACTIVE CHEMISTRY ORTHOGONAL SURFACE AND ENVIRONME	ENTAL THREAT TICKET ARRAY (ROSETTA)	
ROSETTA will use a streamlined approach to rapidly field multiple comp that will transition from Science and Technology Efforts and/or commerci- vehicles including Countering Weapons of Mass Destruction (CWMD) Or Production/Procurement (JERDAP) in order to streamline the acquisition the M256 kit and will support the acquisition of a pharmaceutical based agent (PBA) ticket, the M256 vapor unmasking tool, and the other transitioned to TACOM for production.	ial off the shelf (COTS) products to the M256 kit. The ther Transactional Authority (OTA) and Joint Enterp of the products. The ROSETTA funding will complete the products.	nese efforts will utilize multiple contract rise- Research, Development, Acquisition, ete the acquisition of the M8 component to
MODERNIZATION SENSORS (MOD SEN)		
MOD SEN program uses a Commercial Off-The-Shelf (COTS)/Governm programs. This strategy employs an Non-developmental Item acquisition component to solve obsolescence and technology update needs. Current and EMBD modernization activities. The program maintains baseline can changes in requirements. This program modernizes the Joint Force to c assessment and exploitation capabilities require a system modernization	n concept to translate mission needs and emerging nt planned funding supports CALS TV-IS, FC-ACS, pabilities with obsolescence management, technolo combat advancing threats and current capability gap	technology capabilities into a fieldable ALS MOD, CBRN DRS, M8 Modification, gy insertions, and enhancements based or
MODERNIZATION MEDICAL (MOD MED)		

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and	Biological Defense Program	Date: March 2023
Appropriation/Budget Activity 0400 / 7	R-1 Program Element (Number/Name) PE 0607384BP <i>I Chemical and Biological</i> <i>Defense (Operational Systems Developme</i> <i>nt)</i>	Project (Number/Name) UN7 <i>I Understand (Op Sys Dev)</i>
MOD MED leverages an existing Indefinite Delivery/Indefinite Quantit 1) original equipment manufacturer for both hardware and software up address emerging biological threats and diseases.		
MOD MED will mitigate obsolescence of the NGDS 1, by awarding co replacement for the current commercial system, and maintain the exis MOD MED for AUTOINJ will ensure post-marketing commitments and and will be the responsibility of the performer and the government. Al shall be responsible for conducting post-approval FDA requirements.	sting Biological Warfare diagnostic capability. I requirements are anticipated as a result of the U.S. Fo	ood & Drug Administration (FDA) approval,
SPU RAPID CAPABILITY DEVELOPMENT AND DEPLOYMENT (SP	PU RCDD)	
The SPU RCDD overall acquisition strategy allows for rapid prototypir to enhance mission success. The SPU RCDD will use technical and and incorporate operationally-relevant system developments. This wi Delivery Indefinite Quantify Task Order and the Countering Weapons test assets. The SPU RCDD will use Government Agencies for proto-	functional evaluations of currently fielded items to iden II be accomplished through competitive contracting veh of Mass Destruction Other Transaction Authority (CWM	tify materiel that requires modernization nicles such as Multiple Award Indefinite //D OTA) for the development of prototype
WMD - CIVIL SUPPORT TEAMS (WMD CST)		
The Weapons of Mass Destruction Civil Support Team Program (WM commercial off the shelf (COTS)/government-off-the-shelf (GOTS) eq this is to address analytical equipment obsolescence.		

Exhibit R-3, RDT&E P	Project C	ost Analysis: PB 2	024 Che	mical and	l Biologic	al Defens	e Progran	n				Date:	March 20	023	
Appropriation/Budge 0400 / 7	t Activity	1				PE 060	7384BP /	Chemica	l umber/N a al and Biol stems Dev	ogical		(Numbe Inderstan		s Dev)	
Product Developmen	it (\$ in Mi	illions)		FY 2	2022	FY :	2023		2024 ase		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
MOD CBRN IS - SW S - Modernization	Various	Various : N/A	-	0.000		13.118	Dec 2022	0.000		-		0.000	0.000	13.118	0.000
CSC2 - Continuous Engineering CBRN-IS	TBD	Various : N/A	-	0.000		0.000		11.681	Dec 2023	-		11.681	Continuing	Continuing	0.000
CSC2 - Modernization CBRN Warning & Reporting	C/CPIF	Various : N/A	-	0.000		0.000		2.137	Jan 2024	-		2.137	Continuing	Continuing	0.000
EMBD - HW SB - Obsolescence Support in Production	C/CPIF	Various : N/A	-	0.000		1.059	Dec 2022	0.000		-		0.000	0.000	1.059	0.000
ROSETTA - HW C - Program and OGA Support	MIPR	Various : N/A	-	0.000		2.203	Apr 2023	0.000		-		0.000	0.000	2.203	0.000
MOD SEN - HW C - Government Team Labor	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	-	0.000		0.345	Nov 2022	0.992	Nov 2023	-		0.992	Continuing	Continuing	0.000
MOD MED - HW C - Product Management	Various	Various : N/A	-	0.000		1.756	Dec 2022	3.520	Dec 2023	-		3.520	Continuing	Continuing	0.000
MOD MED - HW C - Autoinjector ORA	MIPR	U.S. Army Medical Research and Development Command (USAMRDC) : Fort Detrick, MD	-	0.000		0.193	Nov 2022	0.794	Nov 2023	-		0.794	Continuing	Continuing	0.000
MOD MED - HW C - Autoinjector PMR/PMCs	C/CPFF	Kaleo : Richmond, VA	-	0.000		0.334	Sep 2023	0.000		-		0.000	0.000	0.334	0.000
MOD MED - HW C - Next Generation Diagnostic System 1 (NGDS 1)	C/CPFF	BioFire Dx : Salt Lake City, UT	-	0.000		3.029	Feb 2023	2.160	Dec 2023	-		2.160	Continuing	Continuing	0.000

PE 0607384BP: *Chemical and Biological Defense (Operati...* Chemical and Biological Defense Program

Volume 4 - 444

Exhibit R-3, RDT&E F	Project C	ost Analysis: PB 2	024 Che	mical and	Biologica	al Defens	e Progran	n				Date:	March 2	023	
Appropriation/Budge 0400 / 7	t Activity	1				PE 060	7384BP /	Chemica	l umber/N al al and Biol atems Dev	logical		: (Numbe Inderstan		s Dev)	
Product Developmer	nt (\$ in Mi	illions)		FY 2	2022	FY	2023		2024 ase		2024 CO	FY 2024 Total]		
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
MOD MED - HW C - NGDS 1 Tech Refresh	C/CPFF	TBD : N/A	-	0.000		0.000		4.792	Mar 2024	-		4.792	Continuing	Continuing	0.000
SPU RCDD - HW C - Prototype development	Various	Various : N/A	-	0.000		1.253	Dec 2022	1.613	Dec 2023	-		1.613	Continuing	Continuing	0.000
WMD CST - HW S - Team Labor	Various	Various : N/A	-	0.000		0.000		0.853	Nov 2023	-		0.853	Continuing	Continuing	0.000
		Subtotal	-	0.000		23.290		28.542		-		28.542	Continuing	Continuing	N/A
Support (\$ in Million	5)			FY 2	2022	FY	2023		2024 ase		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
MOD CBRN IS - ES S - milCloud	MIPR	Various : N/A	-	0.000		2.477	Dec 2022	0.000		-		0.000	0.000	2.477	0.000
CSC2 - CBRN-IS Platform Maintenance	MIPR	Various : N/A	-	0.000		0.000		3.763	Jan 2024	-		3.763	Continuing	Continuing	0.000
EMBD - ES S - Software Support	C/CPIF	Various : N/A	-	0.000		0.054	Dec 2022	0.000		-		0.000	0.000	0.054	0.000
MOD SEN - ES C - Science and Engineering Support	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	-	0.000		0.170	Nov 2022	0.000		-		0.000	0.000	0.170	0.000
MOD SEN - ES C - Obsolescent Management	Various	Various : N/A	-	0.000		0.784	Nov 2022	3.408	Nov 2023	-		3.408	Continuing	Continuing	0.000
WMD CST - ES C - Science & Engineering Support	MIPR	Naval Air Warfare Center (Aircraft Division) : Patuxent River, MD	-	0.000		0.120	Jan 2023	0.190	Nov 2023	-		0.190	Continuing	Continuing	0.000

PE 0607384BP: *Chemical and Biological Defense (Operati...* Chemical and Biological Defense Program

Volume 4 - 445

Appropriation/Budge 0400 / 7	t Activity	,				PE 060	7384BP /	Chemica	lumber/Na al and Biol stems Deve	ogical		(Number Inderstand		s Dev)	
Support (\$ in Millions	5)			FY 2	022	FY	2023		2024 ase		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
WMD CST - ES C - Government Product Development Team Labor	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	-	0.000		0.384	Feb 2023	0.190	Nov 2023	-		0.190	Continuing	Continuing	g 0.000
		Subtotal	-	0.000		3.989		7.551		-		7.551	Continuing	Continuing	N/A
Test and Evaluation ((\$ in Milli	ons)		FY 2	022	FY	2023		2024 ase		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
MOD CBRN IS - OTHT S - System Testing	MIPR	Various : N/A	-	0.000		1.500	Dec 2022	0.000		-		0.000	0.000	1.500	0.000
CSC2 - System update T&E	TBD	U.S. Navy Space and Naval Warfare (SPAWAR) Systems Center : San Diego, CA	-	0.000		0.000		0.952	Oct 2023	-		0.952	Continuing	Continuing	g 0.000
EMBD - Obsolescence Support in Production testing and verification	C/CPIF	Various : N/A	-	0.000		0.401	Dec 2022	0.000		-		0.000	0.000	0.401	0.000
MOD SEN - DTE C - Component Test and Evaluation	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	-	0.000		0.959	Nov 2022	0.750	Nov 2023	-		0.750	Continuing	Continuing	g 0.000

Exhibit R-3, RDT&E	-		2024 Che	mical and	Biologic						_		March 20	023	
Appropriation/Budge 0400 / 7	et Activity					PE 060	7384BP /	Chemica	lumber/Na al and Biol stems Dev	ogical		: (Numbe i Inderstan		s Dev)	
Test and Evaluation	(\$ in Milli	ons)		FY 2	2022	FY 2	2023		2024 ase		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
MOD SEN - DTE C - Information Assurance	Various	Various : N/A	-	0.000		0.247	Nov 2022	0.000		-		0.000	0.000	0.247	0.000
MOD SEN - DTE C - System Modernization	Various	Various : N/A	-	0.000		3.274	Nov 2022	4.953	Nov 2023	-		4.953	Continuing	Continuing	0.000
WMD CST - OTHT C - CBRN COTS Component	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	-	0.000		1.120	Feb 2023	1.680	Nov 2023	-		1.680	Continuing	Continuing	g 0.000
WMD CST - OTHT C - CBRN COTS Component	MIPR	Naval Air Warfare Center (Aircraft Division) : Patuxent River, MD	-	0.000		1.574	Jan 2023	0.367	Nov 2023	-		0.367	Continuing	Continuing	g 0.000
		Subtotal	-	0.000		9.075		8.702		-		8.702	Continuing	Continuing	N/A
Management Service	es (\$ in M	illions)		FY 2	2022	FY	2023		2024 ase		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
MOD CBRN IS - PM/MS S - Program Management Support	Various	Various : N/A	-	0.000		1.900	Dec 2022	0.000		-		0.000	0.000	1.900	0.000
CSC2 - Program Management Office Support	Various	Various : N/A	-	0.000		0.000		1.952	Oct 2023	-		1.952	Continuing	Continuing	g 0.000
EMBD - PM/MS S - Program Management	MIPR	Various : N/A	-	0.000		0.234	Dec 2022	0.000		-		0.000	0.000	0.234	0.000

Exhibit R-3, RDT&E	Project C	ost Analysis: PB 2	024 Chei	mical and	Biologic	al Defens	e Progran	n				Date:	March 20	023	
Appropriation/Budg 0400 / 7	et Activity	1				PE 060	7384BP /	Chemica	lumber/Na al and Biol stems Dev	ogical	-	t (Numbe i Inderstand		s Dev)	
Management Servic	es (\$ in M	illions)		FY	2022	FY 2	2023		2024 ase		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
ROSETTA - PM/MS S - Program Management Support	MIPR	Various : N/A	-	0.000		0.244	Jan 2023	0.000		-		0.000	0.000	0.244	0.000
MOD SEN - PM/MS C - Program Management Cost	Various	Various : N/A	-	0.000		0.000		1.563	Nov 2023	-		1.563	Continuing	Continuing	0.000
MOD SEN - PM/MS S - Program Management Support	Various	Various : N/A	-	0.000		0.600	Jan 2023	0.000		-		0.000	0.000	0.600	0.000
MOD MED - PM/MS C - Management Services	Various	Various : N/A	-	0.000		0.569	Dec 2022	1.707	Dec 2023	-		1.707	Continuing	Continuing	0.000
SPU RCDD - PM/MS C - Program Management Support	Various	Various : N/A	-	0.000		0.210	Dec 2022	0.222	Dec 2023	-		0.222	Continuing	Continuing	0.000
WMD CST - PM/MS S - Program Management Support	MIPR	Various : N/A	-	0.000		0.303	Dec 2022	0.364	Nov 2023	-		0.364	Continuing	Continuing	0.000
		Subtotal	-	0.000		4.060		5.808		-		5.808	Continuing	Continuing	N/A
			Prior Years	FY2	2022	FY 2	2023		2024 ase		2024 CO	FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract
		Project Cost Totals	-	0.000		40.414		50.603		-		50.603	Continuing	Continuing	N/A

Remarks

Exhibit R-4, RDT&E Schedule Profile: PB 2024 C	Che	nica	l and	d Bic	ologi	cal [Defer	nse l	Prog	gram												Da	te: M	arch	n 20)23			
Appropriation/Budget Activity 0400 / 7								PE (0607	7384	n Ele BP / berat	Che	emi	cal a	and	Biole	ogic	al					ber/N and (s De	ev)		
		FY	202	2		FY	2023	3		FY 2	2024			FY	202	5		FY	202	26		FY	2027	7		F۲	′ 20	28	
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	2 ;	3	4
MOD CBRN IS - Modernization									l																				
MOD CBRN IS - Continuous Engineering/SW Codes Updates																													
MOD CBRN IS - Cyber Security Compliance																													
MOD CBRN IS - Operating system architecture updates																													
MOD CBRN IS - Configuration Management and Test and Evaluation																													
MOD CBRN IS - Validation, Verification and Accreditation																													
CSC2 - SWP Execution Phase Decision																													
CSC2 - Continuous Software DT/OT																													
CSC2 - MVP (CDP-1)																													
CSC2 - Service Common Operating Environment Integration																													
CSC2 - Cyber Security Compliance																													
CSC2 - CD-Capability Drop - MVCR Delivery 1 (CDP-1)																													
CSC2 - MVP (CDP-2)																													
CSC2 - Continuous Engineering & Software Updates																													
CSC2 - Operating System Architecture Updates																													
CSC2 - CD-Capability Drop - MVCR Delivery 2 (CDP-2)																													
CSC2 - Future MVPs																													

PE 0607384BP: *Chemical and Biological Defense (Operati...* Chemical and Biological Defense Program

Exhibit R-4, RDT&E Schedule Profile: PB 2024 C	Cher	nica	and	Bio	logio	cal D	Defe	nse	Pro	grai	m											Date	e: Ma	arcl	h 202	23		
Appropriation/Budget Activity 0400 / 7								ΡE	060	738	4BP	lem I Ch ation	nemi	cal a	and	Biolo	ogic	al					er/Na nd (C			Dev)		
		FY	2022			FY 2	2023	3		FY	202	4		FY 2	202	5		FY	202	6		FY 2	2027			FY 2	2028	
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	2 3	4	1	2	3	4	1	2	3	4
CSC2 - CD-Capability Drop - Future MVCR Deliveries																												
EMBD - IOC-Initial Operational Capability																												
EMBD - FRP Production																												
EMBD - FOC-Full Operational Capability																												
ROSETTA - Testing & Demonstrations (M8)																												
ROSETTA - Engineering Design																												
ROSETTA - OTA Contract Award																												
MOD SEN - DT/OT for refreshed components and obsolescence management within MOD SEN																												
MOD MED - Diagnostic System Upgrades / Assay Development																												
MOD MED - NGDS 1 Tech Refresh																												
MOD MED - Autoinjector Post Marketing Commitments and Requirements (PMRs/ PMCs)																												
SPU RCDD - Modernize CBRN Materiel																												
SPU RCDD - Develop Modular Self Contained Breathing Apparatus (MSCBA)																												
SPU RCDD - Develop Enhanced Warfighter Augmented Training (EWAT)																												
SPU RCDD - Prototype Novel CBRN Equipment																												
SPU RCDD - Develop Low Temperature Plasma Mass Spectrometer (LTPMS)																												

Exhibit R-4, RDT&E Schedule Profile: PB 2024	Cher	nica	l anc	l Bio	logio	cal D	Defer	nse	Pro	grai	m											Dat	e: N	larch	ו 20	23		
Appropriation/Budget Activity 0400 / 7								PE (060	738	am E 34BP Opera	I Ch	emi	cal a	nd E	Biolo	ogica	a/			•		er/N and (Dev)	
		FY	2022	2		FY 2	2023	3		FY	202	4		FY 2	2025	5		FY	2026	6		FY	202	7		FY 2	202	8
	1	2	3	4	1	2	3	4	1	2	2 3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
SPU RCDD - Develop Optimized CBRN Hydration System (OCHS)				-														-	-				_ _	-	-	-		
SPU RCDD - Develop Assault Respirator																												
SPU RCDD - Develop USSOCOM-specific UGV/UAS Sensor Integration																												
WMD CST - Upgrade Fielded Systems																												

Exhibit R-4A, RDT&E Schedule Details: PB 2024 Chemical	and Biological Defense Program	Date: March 2023
Appropriation/Budget Activity 0400 / 7	R-1 Program Element (Number/Name) PE 0607384BP <i>I Chemical and Biological</i> <i>Defense (Operational Systems Developme</i> <i>nt)</i>	Project (Number/Name) UN7 I Understand (Op Sys Dev)

Schedule Details

	Sta	art	Er	nd
Events	Quarter	Year	Quarter	Year
MOD CBRN IS - Modernization	1	2022	4	2023
MOD CBRN IS - Continuous Engineering/SW Codes Updates	1	2022	4	2023
MOD CBRN IS - Cyber Security Compliance	1	2022	4	2023
MOD CBRN IS - Operating system architecture updates	1	2022	4	2023
MOD CBRN IS - Configuration Management and Test and Evaluation	1	2022	4	2023
MOD CBRN IS - Validation, Verification and Accreditation	1	2022	4	2023
CSC2 - SWP Execution Phase Decision	2	2023	2	2023
CSC2 - Continuous Software DT/OT	3	2023	4	2028
CSC2 - MVP (CDP-1)	4	2023	4	2023
CSC2 - Service Common Operating Environment Integration	1	2024	4	2028
CSC2 - Cyber Security Compliance	1	2024	4	2028
CSC2 - CD-Capability Drop - MVCR Delivery 1 (CDP-1)	4	2024	4	2025
CSC2 - MVP (CDP-2)	4	2024	4	2024
CSC2 - Continuous Engineering & Software Updates	1	2025	4	2028
CSC2 - Operating System Architecture Updates	1	2025	4	2028
CSC2 - CD-Capability Drop - MVCR Delivery 2 (CDP-2)	4	2025	4	2026
CSC2 - Future MVPs	2	2026	4	2028
CSC2 - CD-Capability Drop - Future MVCR Deliveries	4	2026	4	2028
EMBD - IOC-Initial Operational Capability	2	2023	2	2023
EMBD - FRP Production	1	2022	3	2027
EMBD - FOC-Full Operational Capability	4	2028	4	2028

PE 0607384BP: *Chemical and Biological Defense (Operati...* Chemical and Biological Defense Program

0/7 PE	1 Program Element (Numbe 0607384BP <i>I Chemical and</i> fense (Operational Systems I	, Biological	Date: Marcl Project (Number/Nam UN7 / Understand (Op	e)
	St	art	En	d
Events	Quarter	Year	Quarter	Year
ROSETTA - Testing & Demonstrations (M8)	1	2022	2	2022
ROSETTA - Engineering Design	4	2022	2	2023
ROSETTA - OTA Contract Award	3	2022	4	2027
MOD SEN - DT/OT for refreshed components and obsolescence management MOD SEN	t within 1	2023	4	2028
MOD MED - Diagnostic System Upgrades / Assay Development	1	2023	4	2028
MOD MED - NGDS 1 Tech Refresh	4	2023	4	2028
MOD MED - Autoinjector Post Marketing Commitments and Requirements (PM PMCs)	/IRs/ 1	2023	4	2028
SPU RCDD - Modernize CBRN Materiel	1	2022	4	2027
SPU RCDD - Develop Modular Self Contained Breathing Apparatus (MSCBA)	1	2022	4	2024
SPU RCDD - Develop Enhanced Warfighter Augmented Training (EWAT)	1	2022	4	2024
SPU RCDD - Prototype Novel CBRN Equipment	1	2022	4	2027
SPU RCDD - Develop Low Temperature Plasma Mass Spectrometer (LTPMS) 1	2022	4	2024
SPU RCDD - Develop Optimized CBRN Hydration System (OCHS)	1	2022	2	2023
SPU RCDD - Develop Assault Respirator	1	2022	4	2023
SPU RCDD - Develop USSOCOM-specific UGV/UAS Sensor Integration	1	2022	4	2023
WMD CST - Upgrade Fielded Systems	1	2022	4	2027

Exhibit R-2A, RDT&E Project Ju	stification	: PB 2024 C	hemical an	d Biologica	l Defense P	rogram				Date: Marc	ch 2023	
Appropriation/Budget Activity 0400 / 7					R-1 Progra PE 060738 <i>Defense (C</i> <i>nt)</i>		nical and B	iological	Project (N PT7 / Prote		,	
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
PT7: Protect (Op Sys Dev)	-	0.000	20.076	26.818	0.000	26.818	22.815	15.490	14.193	13.612	Continuing	Continuing
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

The Protect Operational System Development Project provides the Joint Force the continued readiness of fielded collective and individual protective capabilities and provides size, weight and power improvements to reduce logistical burden on the Warfighter and Services. In FY 2023, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. PT7 efforts in FY 2022 remain in Projects C07 and IP7. This restructuring provided standardization and alignment across CBDP research, development and acquisition efforts.

Efforts included in this Project are:

(1) Modernization Protection Collective Protection (MODPROT CP), and

(2) Modernization Protection Individual Protection (MODPROT IP)

Modernization Protection Collective Protection (MODPROT CP) addresses modernization and obsolescence across the DoD CP portfolio to increase readiness, sustainability, reliability, and affordability of these systems. The obsolescence of critical equipment, if not modernized, will continue to face significantly increased cost and long lead times making the equipment unaffordable and unprocurable to meet major weapon system program's requirements and schedules. MODPROT CP modernizes decades old collective protection equipment reducing costs, shortening lead times, and updating key components to extend service life and ensure affordable and procurable to warfighters. In FY24, MODPROT CP will continue M48A1 Filter Redesign, Collective Protection Modernization for Ships and Buildings, and begin shipboard system installation. Additionally, the program will continue Mobile Platform Filter Modernization to reduce logistics costs and continue conducting collective protection system filter surveillance testing to improve system sustainment.

Modernization Protection Individual Protection (MODPROT IP) addresses obsolescence issues with Individual Protective (IP) equipment and the need to modernize fielded IP with capabilities to meet or exceed the Services requirements. MODPROT IP will also conduct modernization efforts and reverse engineering of maintenance and repair procedures for the Joint Services Mask Leakage Tester (JSMLT). MODPROT IP will also provide mask and filter system upgrades and modernization of fielded protection systems to enhance respiratory and ocular protection resulting in an increased lethality of fighter aircraft by mitigating risk due to operationally unsuitable aircrew Chemical Biological Radiological Nuclear (CBRN) masks. Modernization efforts will include technical manual updates and a Logistics Demonstration for an updated, lightweight version of the Joint Protective Aircrew Ensemble (JPACE). Testing and analysis with aircraft will fully validate and refine new Tactics, Techniques and Procedures (TTPs) that allow aircrews to operate without restrictive CBRN protective equipment by determining time and techniques required to reduce cockpit hazards to acceptable levels by flushing with clean air. The impact of funding these programs will address modernization and obsolescence across the DoD IP portfolio to increase readiness, sustainability, reliability, and affordability of these systems. In FY24, MODPROT IP will continue modernization of the Joint Mask Leakage Tester (JSMLT), continue Fixed Wing Aircraft/Aircrew Personal Protective Equipment (PPE) optimization effort for multiple airframes, finalize Second

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical ar	nd Biological Defense Program	Date: N	/larch 2023	
Appropriation/Budget Activity 0400 / 7	R-1 Program Element (Number/Name) PE 0607384BP <i>I Chemical and Biological</i> <i>Defense (Operational Systems Developme</i> <i>nt)</i>	Project (Number/ PT7 / Protect (Op		
Generation Filter Engineering Change Proposal (ECP), initiate perf Chemical Biological Incident Response Force (CBIRF) Class 3 Mor Protective Equipment (CRE PPE) Unit Modernization. FY24 increa	dernization, and initiate Chemical Biological Radiological	and Nuclear Respon		
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
Title: 1) MODPROT CP		-	10.088	13.468
Description: Upgrades, improvements, and modernizations to field	led collective protection (CP) systems			
FY 2023 Plans: Continue redesign of M49 gas filters. Continue M48A1 Filter Redes and Buildings and complete system lab testing and system design collective protection system filter surveillance testing to improve system	packages for platform installation. Continue conducting	nips		
FY 2024 Plans: Continue M48A1 Filter Redesign. Continue Collective Protection (C system installation. Continue Mobile Platform Filter Modernization t surveillance testing to improve system sustainment.				
FY 2023 to FY 2024 Increase/Decrease Statement: Increase due to fact of life change in the program/project. The incre from the Shipboard ColPro Modernization project's effort to install p	e 1	ed		
Title: 2) MODPROT IP		-	9.988	13.350
Description: Upgrades, improvements, and modernizations to field	led individual protection (IP) systems			
FY 2023 Plans: Continue modernization of the Joint Mask Leakage Tester (JSMLT) for multiple airframes. Finalize Second Generation Filter Engineerin Prototype Developmental Testing (DT).				
FY 2024 Plans: Continue modernization of the Joint Mask Leakage Tester (JSMLT) Equipment (PPE) optimization effort for multiple airframes. Finalize				

Exhibit R-2A, RDT&E Project Jus	tification: PB	2024 Chemi	cal and Biol	ogical Defen	se Program				Date: Ma	arch 2023	
Appropriation/Budget Activity 0400 / 7				PE 06	r ogram Eler 07384BP / (se (Operatio	Chemical and	,		Number/N otect (Op S		
B. Accomplishments/Planned Pro	ograms (\$ in N	<u>Aillions)</u>						F	Y 2022	FY 2023	FY 2024
Biological Incident Response Force Response Enterprise Personal Pro	· /				Biological F	Radiological a	and Nuclear				
FY 2023 to FY 2024 Increase/Dec Increase due to change in program Modernization efforts.			ers. FY24 ind	crease of \$3	M for Persor	nal Protective	e Equipment				
				Accon	nplishment	s/Planned P	rograms Sul	btotals	-	20.076	26.818
C. Other Program Funding Summ	<u>nary (\$ in Milli</u>	<u>ons)</u>									
			<u>FY 2024</u>	<u>FY 2024</u>	FY 2024					Cost To	
Line Item	FY 2022	<u>FY 2023</u>	Base	000	<u>Total</u>	<u>FY 2025</u>	FY 2026	<u>FY 2027</u>	<u>FY 2028</u>		Total Cos
• IP7: Individual	11.659	-	-	-	-	-	-	-	-	0.000	11.659
Protection (Op Sys Dev)											
PHM036: Modernization	1.385	1.385	-	-	-	-	-	1.375	2.517	Continuing	Continuin
Protection Collective											
Protection (MODPROT CP)											
<u>Remarks</u>											
D. Association Stratemy											

D. Acquisition Strategy

MODERNIZATION PROTECTION COLLECTIVE PROTECTION (MODPROT CP)

Modernization Protection Collective Protection (MODPROT CP) leverages mature technology from contractor developed components to address and replace obsolete components of various fielded collective protection systems. Modernization efforts will also use items developed by the Government that have transitioned from lower to higher technology readiness levels that can be inserted into fielded systems. A combination of competitive and sole source contracts to various industry vendors and project orders to various Government activities will be used to adapt previously developed components to modernize systems. Robust component and system level testing to meet applicable military standards will validate both Government and contractor furnished improvements. The improvements will be added into the specific systems' updated Technical Data Packages (TDPs) to be used in Engineering Change Proposals (ECPs) and provided to the item managers.

MODERNIZATION PROTECTION INDIVIDUAL PROTECTION (MODPROT IP)

Modernization Protection Individual Protection (MODPROT IP) leverages mature technology from contractor developed components to address and replace obsolete components of various fielded individual protection systems. Modernization efforts will also use items developed by the Government that have transitioned from lower to higher technology readiness levels that can be inserted into fielded systems. A combination of competitive and sole source contracts to various industry vendors and

Exhibit R-2A, RDT&E Project Justification: PB 2024 Cl	hemical and Biological Defense Program	Date: March 2023
Appropriation/Budget Activity 0400 / 7	R-1 Program Element (Number/Nam PE 0607384BP <i>I</i> Chemical and Biolog Defense (Operational Systems Develo nt)	ical PT7 I Protect (Op Sys Dev)
	ed to adapt previously developed components to modernize ished improvements. The improvements will be added into th	

Exhibit R-3, RDT&E F	Project C	ost Analysis: PB 2	024 Che	mical and	l Biologica	al Defens	e Progran	า				Date:	March 20)23	
Appropriation/Budge 0400 / 7	et Activit <u>y</u>	y				PE 060	7384BP /	Chemica	umber/Na al and Biol tems Deve	ogical		: (Number rotect (Op)	
Product Developmer	nt (\$ in M	illions)		FY 2	2022	FY	2023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
MODPROT CP - HW C - Collective Protection Modernization for Ships	Various	Various : N/A	-	0.000		6.604	Nov 2022	8.604	Nov 2023	-		8.604	Continuing	Continuing	0.00
MODPROT CP - HW C - Filter Redesign & Modernization, Filter Life Extension Residual Life Indicator (RLI)	MIPR	Various : N/A	-	0.000		0.721	Nov 2022	1.167	Nov 2023	-		1.167	Continuing	Continuing	0.00
MODPROT IP - HW C - Filter Prototypes, JSMLT Modernization, and CBIRF & CRE Modernization	Various	Various : N/A	-	0.000		3.732	Dec 2022	4.576	Nov 2023	-		4.576	Continuing	Continuing	0.000
		Subtotal	-	0.000		11.057		14.347		-		14.347	Continuing	Continuing	N//
Support (\$ in Million	s)			FY 2	2022	FY	2023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
MODPROT CP - ES C - IPT, Technical, Engineering and Logistics Support	MIPR	Various : N/A	-	0.000			Nov 2022		Nov 2023	-			Continuing		
MODPROT IP - ES C - IPT, Engineering, Technical, Logistics	MIPR	Various : N/A	-	0.000		0.545	Dec 2022	1.318	Nov 2023	-		1.318	Continuing	Continuing	0.00
Support		Subtotal		0.000		1.094		2.970		-		2.070	Continuing	Continuina	N//

Exhibit R-3, RDT&E I	Project C	ost Analysis: PB 2	2024 Che	mical and	Biologica	al Defens	e Progran	n			_	Date:	March 20)23	
Appropriation/Budge 0400 / 7	et Activity	/				PE 060	7384BP /	Chemica	umber/Na al and Biol tems Deve	ogical		: (Numbe i rotect (Op)	
Test and Evaluation	(\$ in Milli	ions)		FY 2	022	FY 2	2023	FY 2 Ba	2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
MODPROT CP - DTE C - CP Modernization Testing	Various	Various : N/A	-	0.000		1.465	Oct 2022	1.219	Nov 2023	-		1.219	Continuing	Continuing	0.000
MODPROT IP - DTE C - Fixed Wing Aircraft/Aircrew PPE Optimization Effort	MIPR	Various : N/A	-	0.000		3.200	Dec 2022	3.497	Nov 2023	-		3.497	Continuing	Continuing	0.000
MODPROT IP - DTE C - Filter Prototype Testing	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	-	0.000		1.770	Dec 2022	3.141	Nov 2023	-		3.141	Continuing	Continuing	0.000
	_	Subtotal	-	0.000		6.435		7.857		-		7.857	Continuing	Continuing	N/A
Management Service	es (\$ in M	lillions)		FY 2	022	FY 2	2023		2024 Ise	FY 2 O	2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
MODPROT CP - PM/MS C - Program Management Support	MIPR	Various : N/A	-	0.000		0.749	Nov 2022	0.826	Nov 2023	-		0.826	Continuing	Continuing	0.000
MODPROT IP - PM/MS C - Program Management Support	MIPR	Various : N/A	-	0.000		0.741	Dec 2022	0.818	Nov 2023	-		0.818	Continuing	Continuing	0.000
		Subtotal	-	0.000		1.490		1.644		-		1.644	Continuing	Continuing	N/A
			Prior Years	FY 2	022	FY 2	2023		2024 Ise	FY 2 O	2024 CO	FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract
		Project Cost Totals	-	0.000		20.076		26.818		-		26.818	Continuina	Continuing	N/A

PE 0607384BP: *Chemical and Biological Defense (Operati...* Chemical and Biological Defense Program

Volume 4 - 459

Exhibit R-4, RDT&E Schedule Profile: PB 2024 C	her	nical	and	Biol	ogic	cal D	efer	nse F	Prog	gram												Dat	e: M	arch	n 20	23			
Appropriation/Budget Activity 0400 / 7								PE 0)607	9 gram 7384[9 (<i>Op</i>	3P /	Che	mi	cal a	nd B	liolo	, gica	1					oer/N Op S						
		FY	2022			FY 2	2023			FY 2	024			FY 2	2025			FY	2026	;		FY	2027	,		FY	202	8	7
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1
MODPROT CP - M93 GPFU Electro Magnetic Interference																													
MODPROT CP - Non Destructive (ND) Acceptance Leak Test CP Filters																													
MODPROT CP - Environmental M98 Guard Bed Testing																													
MODPROT CP - M49 Filter Modernization																													
MODPROT CP - Filter Prototype Design Analysis and Development																													
MODPROT CP - Collective Protection Training Development																													
MODPROT CP - M48A1 Filter Redesign																													
MODPROT CP - Collective Protection Modernization for Ships and Buildings																													
MODPROT CP - M14 Protective Entrance Modernization																													
MODPROT CP - Filter Prototype Laboratory Testing and Evaluation																													
MODPROT CP - Contaminated Filter Changeout Procedures																													
MODPROT CP - Filter Technical Design Package and Procurement of Filter Design Test Articles	:																												
MODPROT CP - Platform Interoperability Testing and Final Technical Design Package																													
MODPROT CP - Mobile Platform Filter Modernization																													

PE 0607384BP: *Chemical and Biological Defense (Operati...* Chemical and Biological Defense Program UNCLASSIFIED Page 30 of 91

R-1 Line #208

Volume 4 - 460

Exhibit R-4, RDT&E Schedule Profile: PB 2024 C	he	mica	l and	l Bio	logic	al D	efen	se Pro	gran	۱											Date	e: Ma	arch	202	3		
Appropriation/Budget Activity 0400 / 7							F	R-1 Pro PE 060 Defense nt)	7384	BP /	Che	əmi	cal a	nd B	iolo	, gica	Ι		-	•		er/Na Op Sy					
		FY	2022	2		FY 2	023		FY	2024			FY 2	2025			FY	2026	5		FY 2	2027		l	FY 2	028	
	1	2	3	4	1	2	3	4 1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
MODPROT CP - Filter Surveillance Testing																											
MODPROT IP - Second Generation Filter & NIOSH DT																											
MODPROT IP - JSMLT Modernization																											
MODPROT IP - LJPACE TM Updates & LOGDEMO																											
MODPROT IP - MALO Shelf Life Extension Testing																											
MODPROT IP - Fixed Wing Aircraft/Aircrew PPE Optimization Effort																											
MODPROT IP - Maximum Age Study for JB2GU nFR Glove																											
MODPROT IP - Second Generation Filter ECP																											
MODPROT IP - CBIRF Class 3 Modernization																											
MODPROT IP - CRE PPE Modernization																											
MODPROT IP - Third Generation Filter Prototype DT											[
MODPROT IP - Third Generation Filter Technology ECP																											

Exhibit R-4A, RDT&E Schedule Details: PB 2024 Chemical a	and Biological Defense Program	Date: March 2023
Appropriation/Budget Activity 0400 / 7	R-1 Program Element (Number/Name) PE 0607384BP / Chemical and Biological Defense (Operational Systems Developme nt)	Project (Number/Name) PT7 I Protect (Op Sys Dev)

Schedule Details

	Sta	art	Er	d
Events	Quarter	Year	Quarter	Year
MODPROT CP - M93 GPFU Electro Magnetic Interference	1	2022	4	2022
MODPROT CP - Non Destructive (ND) Acceptance Leak Test CP Filters	1	2022	4	2022
MODPROT CP - Environmental M98 Guard Bed Testing	1	2022	4	2022
MODPROT CP - M49 Filter Modernization	1	2022	4	2022
MODPROT CP - Filter Prototype Design Analysis and Development	1	2022	4	2022
MODPROT CP - Collective Protection Training Development	1	2022	4	2022
MODPROT CP - M48A1 Filter Redesign	1	2022	4	2025
MODPROT CP - Collective Protection Modernization for Ships and Buildings	1	2022	4	2026
MODPROT CP - M14 Protective Entrance Modernization	1	2022	4	2022
MODPROT CP - Filter Prototype Laboratory Testing and Evaluation	1	2023	2	2023
MODPROT CP - Contaminated Filter Changeout Procedures	3	2022	4	2023
MODPROT CP - Filter Technical Design Package and Procurement of Filter Design Test Articles	1	2023	4	2023
MODPROT CP - Platform Interoperability Testing and Final Technical Design Package	1	2024	4	2024
MODPROT CP - Mobile Platform Filter Modernization	1	2025	4	2025
MODPROT CP - Filter Surveillance Testing	1	2025	4	2028
MODPROT IP - Second Generation Filter & NIOSH DT	1	2022	4	2022
MODPROT IP - JSMLT Modernization	1	2022	4	2026
MODPROT IP - LJPACE TM Updates & LOGDEMO	1	2022	4	2022
MODPROT IP - MALO Shelf Life Extension Testing	1	2022	2	2022
MODPROT IP - Fixed Wing Aircraft/Aircrew PPE Optimization Effort	1	2023	4	2026
MODPROT IP - Maximum Age Study for JB2GU nFR Glove	2	2022	4	2022

PE 0607384BP: *Chemical and Biological Defense (Operati...* Chemical and Biological Defense Program

Volume 4 - 462

Exhibit R-4A, RDT&E Schedule Details: PB 2024 Chemical and Biologica	al Defense Program	1			Date: Marc	h 2023
Appropriation/Budget Activity 0400 / 7	PE 0607384B	Element (Numbe P I Chemical and rational Systems I	Biological	•	umber/Nam ect (Op Sys	
		St	art		Er	nd
Events		Quarter	Year	Q	uarter	Year
MODPROT IP - Second Generation Filter ECP		1	2023		2	2023
MODPROT IP - CBIRF Class 3 Modernization		2	2024		4	2024
MODPROT IP - CRE PPE Modernization		2	2024		4	2024
MODPROT IP - Third Generation Filter Prototype DT		1	2025		4	2025
MODPROT IP - Third Generation Filter Technology ECP		1	2026		2	2026

Exhibit R-2A, RDT&E Project Ju	ustification	: PB 2024 C	hemical an	d Biologica	l Defense P	rogram				Date: Marc	ch 2023	
Appropriation/Budget Activity 0400 / 7					PE 060738	84BP I Cher	t (Number/ nical and Bi Systems De	ological	Project (N MT7 / Mitig		,	
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
MT7: Mitigate (Op Sys Dev)	-	0.000	5.098	3.074	0.000	3.074	1.987	1.819	1.845	1.862	Continuing	Continuing
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

The Mitigate Operational System Development Project provides the Joint Force continued readiness of fielded personnel and materiel contamination mitigation and chemical agent therapeutic capabilities and provides size, weight and power improvements to reduce logistical burden on the Warfighter. In FY 2023, the Chemical Biological Defense Program (CBDP) RDT&E Projects were restructured to align with the CBDP portfolio construct. MT7 efforts in FY 2022 remain in Projects MC7 and DE7. This restructuring provided standardization and alignment across CBDP research, development and acquisition efforts.

Efforts included in this Project are:

(1) Improved Nerve Agent Treatment System Centrally Acting (INATS CA), and

(2) Modernization Protection Decontamination (MODPROT DE)

INATS CA includes modernization of Soman Nerve Agent Pretreatment Pyridostigmine (SNAPP; pyridostigmine bromide [PB] tablets). In FY24, INATS CA continues studies on the Food and Drug Administration (FDA)-approved SNAPP, a medical pretreatment against nerve agent poisoning to upgrade its joint service utility and ensure its continued safety and efficacy. Also in FY24, the INATS CA program will submit to the FDA for approval, documents supporting sustained release PB tablets in blister packs. These tablets will provide a single tablet per day dose alternative to the current SNAPP dosing regimen for the pretreatment against soman nerve agent poisoning.

Modernization Protection Decontamination (MODPROT DE) addresses modernization and obsolescence across the DoD DE portfolio to increase readiness, sustainability, reliability, and affordability of these systems. Beginning with the obsolescence and technical data concerns, beginning with the M26 Joint Services Transportable Decontamination System-Small Scale (JSTDS-SS) through validation and verification of Technical Manual (TM) changes as well as technical data for spare and repair parts; the M12A1 Power Driven Decontamination Apparatus (PDDA) by updating technical references and performing the necessary validation and verification before publishing an updated TM. In FY24, MODPROT DE will complete the M12 Pressure Accumulator Project, continue M26 modernization efforts to extend service life and sustainment support to include Technical Manual updates with verification and validation, and initiate and complete the M295 and M100 Performance Characterization Project.

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2022	FY 2023	FY 2024
Title: 1) INATS CA - SNAPP	-	0.346	0.506

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical	and Biological Defense Program	Date:	March 2023	
Appropriation/Budget Activity 0400 / 7	R-1 Program Element (Number/Name) PE 0607384BP <i>I Chemical and Biological</i> <i>Defense (Operational Systems Developme</i> <i>nt)</i>	Project (Number/ MT7 / Mitigate (Op	,	
B. Accomplishments/Planned Programs (\$ in Millions)		FY 2022	FY 2023	FY 2024
Description: SNAPP Shelf Life Modernization: Studies required chemical defense countermeasures.	by the FDA and/or users to modernize or upgrade medical			
FY 2023 Plans: Continue SNAPP stability studies.				
FY 2024 Plans: Completing on-going stability activities and initiating New Drug A	pplication (NDA) package preparation for FDA submission.			
FY 2023 to FY 2024 Increase/Decrease Statement: In FY24 activities are completing due to the acceleration of the provident of	rogram.			
Title: 2) INATS CA - PB Tablet		-	3.664	0.36
Description: Pyridostigmine Bromide (PB) Extended Release Ta	ablet Development			
FY 2023 Plans: Continuing Extended Release Tablet Development.				
FY 2024 Plans: Continue Extended Release Tablet Development.				
FY 2023 to FY 2024 Increase/Decrease Statement: Decrease due to change in program/project schedule. In FY24 ad program in prior years.	ctivities are completing early due to the acceleration of the			
Title: 3) MODPROT DE		-	1.088	2.19
Description: Upgrades, improvements, and modernizations to fit	elded decontamination systems			
FY 2023 Plans: Continue to update technical data for spares and repair parts for Small Scale (JSTDS-SS) Technical Data Package (TDP). Contir efforts for M12A1 Power Driven Decontamination Apparatus (PD	nue to update technical references and validation/verification			

xhibit R-2A, RDT&E Project Jus	tification: PB	2024 Chemi	ical and Biolo	ogical Defen	se Program			-	Date: Ma	rch 2023	
Appropriation/Budget Activity 400 / 7				PE 06	07384BP / C	nent (Numb Chemical and nal Systems	,	-	(Number/Na litigate (Op S		
3. Accomplishments/Planned Pro	ograms (\$ in N	/lillions)							FY 2022	FY 2023	FY 2024
Complete the M12 Pressure Accun support, to include Technical Manu Performance Characterization Proje	al (TM) update										
FY 2023 to FY 2024 Increase/Dec ncrease due to change in program esting, which will conduct testing to General Purpose Decontaminant (0	/project sched	ule. The incr on TTPs for r	ecent progra	ams, such as	Joint Servi	ce Equipmer	nt Wipe (JSEW				
							rograms Sub	totals	-	5.098	3.074
C. Other Program Funding Summ	aanı (¢ in Milli	one)			-			I			
. Other Program Punding Summ		<u>0115)</u>	FY 2024	FY 2024	FY 2024					Cost To	
Line Item	FY 2022	FY 2023	Base	000	Total	FY 2025	FY 2026	FY 2027	<u>FY 2028</u>		
 DE7: Decontamination (Op Sys Dev) 	1.020	-	-	-	-	-	-	-	-	0.000	1.02
• MC5: Medical Chemical Defense (SDD)	38.936	-	-	-	-	-	-	-	-	0.000	38.930
MC7: Medical Chemical Defense (Op Sys Dev)	1.013	-	-	-	-	-	-	-	-	0.000	1.01
• MT5: <i>Mitigate (SDD)</i>	-	74.225	88.441	-	88.441	92.279	91.431	87.773	93.250	Continuing	Continuin
• JD0050: Decontamination Family Of Systems (DFoS)	7.797	4.795	6.062	-	6.062	8.673	8.820	16.518		Continuing	
• PHM040: Improved Nerve Agent Treatment Centrally Acting (INATS CA)	-	-	-	-	-	-	-	6.511	33.883	Continuing	Continuin

Remarks

D. Acquisition Strategy

IMPROVED NERVE AGENT TREATMENT CENTRALLY ACTING (INATS CA)

The INATS CA BA7 program consists of modernization efforts for the FDA-approved Soman Nerve Agent Pretreatment Pyridostigmine (SNAPP), a medical pretreatment against nerve agent poisoning, and the development of a novel pyridostigmine bromide (PB) once-a-day tablet that will allow the services an alternative to the currently used SNAPP product. Both efforts utilize contracts and Other Transactional Agreements (OTAs) in which the performer shall be responsible for conducting

PE 0607384BP: *Chemical and Biological Defense (Operati...* Chemical and Biological Defense Program

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and E	Biological Defense Program	Date: March 2023
Appropriation/Budget Activity 0400 / 7	R-1 Program Element (Number/Name) PE 0607384BP <i>I Chemical and Biological</i> <i>Defense (Operational Systems Developme</i> <i>nt)</i>	Project (Number/Name) MT7 / Mitigate (Op Sys Dev)
development and testing activities consistent with current Food and Dr the Office of Regulatory Affairs (ORA), to submit all relevant data and t and hold all approvals and/or licenses. The Soman Nerve Agent Pre-Treatment Pyridostigmine (SNAPP) effor from the joint service users for the FDA approved SNAPP product. Th regulations.	forms to the FDA, or in the case of the novel PB once- rt under INATS CA is a modernization effort for pyridos	a-day tablet, sponsor the product to the FD, stigmine bromide (PB) tablet requirements
MODERNIZATION DECONTAMINATION (MODPROT DE)		
MODPROT DE leverages mature technology from contractor developed systems. Modernization efforts will also use items developed by the G inserted into fielded systems. A combination of competitive and sole s be used to adapt previously developed components to modernize syst furnished improvements. The improvements will be added into the spe	Government that have transitioned from lower to higher source contracts to various industry vendors and project	technology readiness levels that can be ct orders to various Government activities w

Proposals (ECPs) and provided to the item managers.

Performing ivity & Location C Pharma : veland, OH heal rmaceuticals : ppauge, NY O Chem, Bio, , and Nuc ense (JPEO- RND) : Aberdeen ving Ground, MD I CBRN Medical,	Prior Years - -	FY 2 Cost 0.000 0.000	Award Date	Cost 0.150	Award Date Dec 2022 Dec 2022	FY 2 Ba Cost 0.330		FY 2 OC Cost		FY 2024 Total Cost	Cost To Complete	Total Cost	
ivity & Location C Pharma : veland, OH neal rmaceuticals : ppauge, NY O Chem, Bio, , and Nuc ense (JPEO- RND) : Aberdeen ving Ground, MD		Cost 0.000 0.000	Award	Cost 0.150	Award Date Dec 2022	Cost	Award Date						Target Value of Contract
veland, OH meal rmaceuticals : ppauge, NY O Chem, Bio, , and Nuc ense (JPEO- RND) : Aberdeen ving Ground, MD	-	0.000				0.330	Nov 2023	-		0 330			
rmaceuticals : ppauge, NY O Chem, Bio, , and Nuc ense (JPEO- RND) : Aberdeen <i>v</i> ing Ground, MD	-			2.935	Dec 2022					0.000	Continuing	Continuing	0.00
O Chem, Bio, , and Nuc ense (JPEO- RND) : Aberdeen <i>v</i> ing Ground, MD	-	0.000				0.329	Oct 2023	-		0.329	Continuing	Continuing	0.00
1 CBRN Medical,				0.000		0.040	Nov 2023	-		0.040	Continuing	Continuing	0.00
O-CBRND : Fort ick, MD	-	0.000		0.000		0.080	Nov 2023	-		0.080	Continuing	Continuing	0.00
ous : N/A	-	0.000		0.787	Nov 2022	1.735	Nov 2023	-		1.735	Continuing	Continuing	0.00
Subtotal	-	0.000		3.872		2.514		-		2.514	Continuing	Continuing	N//
	ſ	EV 2	022	EV 3	2023	FY 2 Ba	-	FY 2		FY 2024 Total			
Performing ivity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
ous : N/A	-	0.000		0.230	Nov 2022	0.329	Nov 2023	-		0.329	Continuing	Continuing	0.000
Subtotal	-	0.000		0.230		0.329		-		0.329	Continuing	Continuing	N/A
	vity & Location us : N/A Subtotal	vity & Location Years	Performing rity & Location Prior Years Cost us : N/A - 0.000 Subtotal - 0.000	vity & Location Years Cost Date us : N/A - 0.000 Subtotal - 0.000 ical Defense (Operati UN	Performing rity & Location Prior Years Cost Award Date Cost us : N/A - 0.000 0.230 Subtotal - 0.000 0.230 ical Defense (Operati UNCLASS	Performing rity & Location Prior Years Cost Award Date Cost Award Date us : N/A - 0.000 0.230 Nov 2022 Subtotal - 0.000 0.230 Vor 2022 Subtotal - 0.000 0.230 Vor 2022 Subtotal - 0.000 0.230 Vor 2022	FY 2022 FY 2023 Ba Performing rity & Location Prior Years Cost Award Date Award Cost Award Date Cost Award Date Cost Award Date Cost Award Date Cost Cost Award Date Cost Cost <thcost< th=""> <thcost< th=""> Cos</thcost<></thcost<>	FY 2022 FY 2023 Base Performing rity & Location Prior Years Cost Award Date Cost Award Date Award Date Award Date Award Date Award Date us : N/A - 0.000 0.230 Nov 2022 0.329 Nov 2023 Subtotal - 0.000 0.230 0.230 0.329 Image: Cost ical Defense (Operati UNCLASSIFIED	FY 2022 FY 2023 Base OC Performing rity & Location Prior Years Cost Award Date Cost Award Date Award Cost Award Date Award Cost Award Date Cost Award Cost Awar	FY 2022 FY 2023 Base OCO Performing rity & Location Prior Years Cost Award Date Award Cost Award Date Award Cost Award Date Aw	FY 2022 FY 2023 Base OCO Total Performing rity & Location Prior Years Cost Award Date Cost 0.329 Image: N/A Image: N	FY 2022 FY 2023 Base OCO Total Performing rity & Location Prior Years Cost Award Date Cost Award Date Cost Award Date Cost Date Cost Cos	FY 2022 FY 2023 Base OCO Total Performing rity & Location Prior Years Cost Award Date Cost Award Date Cost Award Date Cost Cost Cost Cost Total us : N/A - 0.000 0.230 Nov 2022 0.329 Nov 2023 - 0.329 Continuing Continuing Subtotal - 0.000 0.230 0.230 0.329 - - 0.329 Continuing Continuing ical Defense (Operati UNCLASSIFIED Volume Volume Volume Volume

Exhibit R-3, RDT&E F	Project C	ost Analysis: PB 2	024 Che	mical and	Biologica	al Defens	e Progran	n				Date:	March 20	023	
Appropriation/Budge 0400 / 7	et Activity	/				PE 060	7384BP /	Chemica	umber/Na al and Biol tems Dev	ogical		t (Numbe i <i>Aitigate (C</i>		ev)	
Management Service	es (\$ in M	illions)		FY 2	022	FY	2023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
INATS CA - PM/MS C - Management Services	Various	JPEO Chem, Bio, Rad, and Nuc Defense (JPEO- CBRND) : Aberdeen Proving Ground, MD	-	0.000		0.925	Dec 2022	0.096	Nov 2023	-		0.096	Continuing	Continuing	0.000
MODPROT DE - PM/MS C - Program Management Support	Various	Various : N/A	-	0.000		0.071	Nov 2022	0.135	Nov 2023	-		0.135	Continuing	Continuing	0.000
		Subtotal	-	0.000		0.996		0.231		-		0.231	Continuing	Continuing	N/A
			Prior Years	FY 2	022	FY	2023		2024 Ise		2024 CO	FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract
		Project Cost Totals	-	0.000		5.098		3.074		-		3.074	Continuing	Continuing	N/A

Remarks

Exhibit R-4, RDT&E Schedule Profile: PB 2024	Cherr	nical	and	Bio	logio	cal D)efe	nse l	Prog	gram												Date	e: Ma	arch	n 202	23		
Appropriation/Budget Activity 0400 / 7								PE (0607	gran 7384 e (Op	BP /	Che	emi	cal a	nd E	Biolo	gica	a/					er/N ′Op 、			1)		
		FY 2	2022			FY 2	2023	3		FY 2	2024			FY 2	2025			FY	202	5		FY 2	2027			FY 2	028	
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	-	3	4	1	2	3	4	1	2	3	4
INATS CA - MS B-Milestone B							1						1			1					1				1			
INATS CA - Clinical Trials																												
INATS CA - Manufacturing/Auto-Injector																												
INATS CA - Non-Clinical Studies																												
INATS CA - NDA Submission-New Drug Application Submission																												
INATS CA - FDA Approval-Food and Drug Administration Approval																												
INATS CA - SNAPP Modernization - BA7																												
INATS CA - PB Extended Release Tablet Development - BA7																												
MODPROT DE - M12A1 TM Update																												
MODPROT DE - M26 JSTDS-SS TDP																												
MODPROT DE - M26 JSTDS-SS Modernization																												
MODPROT DE - M12 Pressure Accumulator																												
MODPROT DE - M295 & M100 Performance Characterization																												

xhibit R-4A, RDT&E Schedule Details: PB 2024 Chemical and Biological	Defense Program			Date: Mare	ch 2023			
ppropriation/Budget Activity 400 / 7	PE 0607384BF	Element (Numbe P I Chemical and ational Systems	Project (Number/Name) MT7 / Mitigate (Op Sys Dev)					
S	Schedule Details				nd			
Events		Quarter	tart Year	Quarter	Year			
INATS CA - MS B-Milestone B		2	2022	2	2022			
INATS CA - Clinical Trials		1	2022	4	2024			
INATS CA - Manufacturing/Auto-Injector		1	2022	2	2025			
INATS CA - Non-Clinical Studies		1	2022	2	2025			
INATS CA - NDA Submission-New Drug Application Submission		1	2026	3	2026			
INATS CA - FDA Approval-Food and Drug Administration Approval		3	2026	1	2028			
INATS CA - SNAPP Modernization - BA7		1	2022	4	2025			
INATS CA - PB Extended Release Tablet Development - BA7		1	2023	1	2026			

MODPROT DE - M12A1 TM Update

MODPROT DE - M26 JSTDS-SS TDP

MODPROT DE - M26 JSTDS-SS Modernization

MODPROT DE - M295 & M100 Performance Characterization

MODPROT DE - M12 Pressure Accumulator

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program								Date: March 2023				
Appropriation/Budget Activity 0400 / 7					R-1 Program Element (Number/Name) I PE 0607384BP / Chemical and Biological 0				Project (Number/Name) CA7 I Contamination Avoidance (Op Sys Dev)			
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
CA7: Contamination Avoidance (Op Sys Dev)	-	12.244	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	12.244
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

The Project supports technology upgrade and refresh of fielded dismounted reconnaissance and detection systems that minimize chemical, biological, and The project supports technology upgrade and refresh of fielded dismounted reconnaissance and detection systems that minimize chemical, biological, and radiological (CBR) contamination and prevent further cross-contamination during operations. In FY2023, the CBDP RDT&E Projects have been restructured to align to the CBDP portfolio. CA7 efforts in FY2022 progress to the Understand (UN7) portfolio. This restructuring is intended to provide standardization and alignment across CBDP research, development and acquisition efforts.

Efforts included in this Project are:

(1) Enhanced Maritime Biological Detection (EMBD) **Progresses to UN7 in FY2023**, and
 (2) Modernization Sensors (MOD SEN) **Progresses to UN7 in FY2023**

The EMBD program will undertake engineering efforts to combat Diminishing Manufacturing Sources and Material Shortages (DMSMS) and maintain a stable production line. Specific efforts in FY24 include flash memory and in the Rapid Agent Aerosol Detector (RAAD), multiple circuit card electrical components and Developmental Testing (DT).

The MOD SEN program addresses obsolescence of critical equipment and functionality issues for the Services by establishing a modernization plan to integrate and incorporate advancements in technology for the Analytical Laboratory System Modification (ALS MOD), Common Analytical Laboratory System (CALS) Field Confirmatory Analytical Capability Set (FC ACS), CALS Theater Validation Integrated System (TV IS), CBRN Dismounted Reconnaissance System (DRS), and M8 Modernization. In FY24, MOD SEN supports the evaluation of components for technical refreshment of the CBRN DRS, CALS, ALS MOD, M8, and EMBD under UN7.

B. Accomplishments/Planned Programs (\$ in Millions)	FY 2022	FY 2023	FY 2024
Title: 1) EMBD	0.869	-	-
Description: Obsolescence and replacement efforts			
Title: 2) MOD SEN	11.375	-	-
Description: Sensors Modernization			

PE 0607384BP: *Chemical and Biological Defense (Operati...* Chemical and Biological Defense Program

Volume 4 - 472

Exhibit R-2A, RDT&E Project Justi	fication: PB	2024 Chem	ical and Biol	ogical Defen	se Program				Date: Ma	arch 2023	
Appropriation/Budget Activity 0400 / 7				PE 06	07384BP / C	nent (Numb Chemical and nal Systems	,	-	ct (Number/N Contamination	•	(Op Sys
B. Accomplishments/Planned Prog	grams (\$ in N	<u>Millions)</u>						[FY 2022	FY 2023	FY 2024
				Accon	nplishments	s/Planned P	rograms Sub	ototals	12.244	-	-
C. Other Program Funding Summa	ary (\$ in Milli	ons)									
• •	•		FY 2024	FY 2024	FY 2024					Cost To	1
Line Item	<u>FY 2022</u>	FY 2023	Base	000	Total	<u>FY 2025</u>	FY 2026	FY 202	27 FY 2028	Complete	Total Cos
 CA5: Contamination Avoidance (SDD) 	84.967	-	-	-	-	-	-			0.000	84.96
• CM7: Homeland Defense (Op Sys Dev)	1.463	-	-	-	-	-	-			0.000	1.46
• UN7: Understand (Op Sys Dev)	-	40.414	50.603	-	50.603	58.881	71.869	68.83	39 50.628	Continuing	Continuin
JS0005: Common Analytical Laboratory System (CALS)	48.258	30.530	7.167	-	7.167	-	-			0.000	
• MC0101: CBRN Dismounted Reconnaissance Systems (CBRN DRS)	21.611	47.324	60.492	-	60.492	64.556	37.802	23.29	92 -	Continuing	Continuin
SA0003: Enhanced Maritime Biological Detection (EMBD)	21.473	21.472	21.899	-	21.899	21.203	26.500	2.24	40 -	Continuing	Continuin
• SA0025: Analytical Laboratory System Modification (ALS MOD)	1.056	3.894	4.256	-	4.256	4.806	5.088	9.13	37 15.109	Continuing	Continuin

Remarks

D. Acquisition Strategy

ENHANCED MARITIME BIOLOGICAL DETECTION (EMBD)

The EMBD program uses a streamlined acquisition strategy and awarded a Full Rate Production (FRP) contract in 1QFY22 with options for production of EMBD kits and Obsolescence Support in Production (OSIP) to resolve diminishing sources and obsolescence issues. The FY24 OSIP Option will address major obsolescence problems identified by the prime contractor that could affect a stable production line and to ensure new EMBD hardware/software remains procurable, field upgradeable and backwards compatible with previously fielded units. The FY24 OSIP Option will undertake engineering efforts to resolve obsolescence of the flash memory in the Rapid Agent Aerosol Detector (RAAD), multiple circuit card electrical components and Developmental Testing (DT) of all new components.

MODERNIZATION SENSORS (MOD SEN)

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical a	and Biological Defense Program	Date: March 2023
Appropriation/Budget Activity 1400 / 7	R-1 Program Element (Number/Name) PE 0607384BP <i>I Chemical and Biological</i> <i>Defense (Operational Systems Developme</i> <i>nt)</i>	Project (Number/Name) CA7 I Contamination Avoidance (Op Sys Dev)
MOD SEN program uses a Commercial Off-The-Shelf (COTS)/Go programs. This strategy employs an Non-developmental Item ac component to solve obsolescence and technology update needs. and EMBD modernization activities. The program maintains base changes in requirements. This program modernizes the Joint For assessment and exploitation capabilities require a system modern	equisition concept to translate mission needs and emerging Current planned funding supports CALS TV-IS, FC-ACS, eline capabilities with obsolescence management, technolo rce to combat advancing threats and current capability gap	technology capabilities into a fieldable ALS MOD, CBRN DRS, M8 Modification, ogy insertions, and enhancements based on

Exhibit R-3, RDT&E	Project C	ost Analysis: PB 2	2024 Che	mical and	d Biologica	al Defens	e Prograr	n				Date:	March 20	23	
Appropriation/Budge 0400 / 7	et Activity	1				PE 060	7384BP /	ement (N Chemica ional Syst	l and Bio	, logical		(Number Contamina	r /Name) ition Avoid	ance (Op	o Sys
Product Developmer	nt (\$ in Mi	illions)		FY	2022	FY 2	023	FY 2 Ba			2024 CO	FY 2024 Total]		
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
EMBD - HW SB - Obsolescence Support in Production	C/CPIF	Various : N/A	-	0.469	Dec 2021	0.000		0.000		-		0.000	0.000	0.469	0.000
MOD SEN - HW C - Government Product Development Team Labor	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	-	1.285	Feb 2022	0.000		0.000		-		0.000	0.000	1.285	0.000
MOD SEN - HW C - System Modernization	C/FFP	FLIR Systems, Inc. : Elkridge, MD	-	6.817	Jan 2022	0.000		0.000		-		0.000	0.000	6.817	0.000
MOD SEN - SW C - Training Software	MIPR	CCDC AVIATION AND MISSILE CENTER : Huntsville, AL	-	0.121	Jul 2022	0.000		0.000		-		0.000	0.000	0.121	0.000
MOD SEN - HW C - Technology Readiness Evaluation	C/FFP	MRIGlobal : Kansas City, MO	-	0.712	Jul 2022	0.000		0.000		-		0.000	0.000	0.712	0.000
MOD SEN - HW C - Cost Estimating Support	C/FFP	DCS Corps : Alexandria, VA	-	0.034	Jul 2022	0.000		0.000		-		0.000	0.000	0.034	0.000
		Subtotal	-	9.438		0.000		0.000		-		0.000	0.000	9.438	N/A
Support (\$ in Million	s)			FY	2022	FY 2	023	FY 2 Ba			2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
MOD SEN - Test Support	MIPR	Various : N/A	-	0.232	Apr 2022	0.000		0.000		-		0.000	0.000	0.232	0.000
MOD SEN - Science and Engineering Support	C/FFP	Johns Hopkins University - Applied	-	0.191	Jul 2022	0.000		0.000		-		0.000	0.000	0.191	0.000

PE 0607384BP: *Chemical and Biological Defense (Operati...* Chemical and Biological Defense Program

Exhibit R-3, RDT&E	-	-	2024 Che	mical and	d Biologica		•				_	Date:	March 20	23	
Appropriation/Budg 0400 / 7	et Activity	/				PE 060	7384BP /	Chemica	umber/N al and Bio tems Dev	logical		(Number contamina	/ Name) tion Avoid	lance (Oj	o Sys
Support (\$ in Million	is)			FY	2022	FY 2	023	FY 2 Ba	-	FY 2 OC	2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
		Physics Laboratory : Laurel, MD													
MOD SEN - ES C - Engineering Support	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	-	0.046	Jul 2022	0.000		0.000		-		0.000	0.000	0.046	0.000
MOD SEN - ES C - Program OGA Support	Various	Various : N/A	-	0.071	Jul 2022	0.000		0.000		-		0.000	0.000	0.071	0.000
		Subtotal	-	0.540		0.000		0.000		-		0.000	0.000	0.540	N/A
Test and Evaluation	(\$ in Milli	ions)		FY	2022	FY 2	023	FY 2 Ba	-	FY 2 O	2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
EMBD - Obsolescence Support in Production testing and verification	C/CPIF	Various : N/A	-	0.252	Dec 2021	0.000		0.000		-		0.000	0.000	0.252	0.000
MOD SEN - DTE C - Information Assurance	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Armaments Center : Picatinny, NJ	-	0.279	Jul 2022	0.000		0.000		-		0.000	0.000	0.279	0.000
MOD SEN - DTE C - Component Test and Evaluation	MIPR	Aberdeen Test Center (ATC) : Aberdeen Proving Ground, MD	-	0.480	Apr 2022	0.000		0.000		-		0.000	0.000	0.480	0.000
		Subtotal	-	1.011	1	0.000		0.000		-	İ	0.000	0.000	1.011	N/A

PE 0607384BP: *Chemical and Biological Defense (Operati...* Chemical and Biological Defense Program

Exhibit R-3, RDT&E	Project C	ost Analysis: PB 2	024 Che	mical and	d Biologica	al Defense	e Prograi	n				Date:	March 20	23	
Appropriation/Budg 0400 / 7	et Activity	,				PE 0607	7384BP /	ement (N Chemica tional Syst	l and Bio	logical	-	t (Numbe i Contamina	r/ Name) tion Avoid	ance (Oj	o Sys
Management Servic	es (\$ in M	illions)		FY	2022	FY 2	023	FY 2 Ba			2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
EMBD - PM/MS S - Program Management Support	MIPR	Various : N/A	-	0.148	Dec 2021	0.000		0.000		-		0.000	0.000	0.148	0.000
MOD SEN - PM/MS C - Program Management Support	Various	Various : N/A	-	1.107	Oct 2021	0.000		0.000		-		0.000	0.000	1.107	0.000
		Subtotal	-	1.255		0.000		0.000		-		0.000	0.000	1.255	N/A
			Prior Years	FY	2022	FY 2	023	FY 2 Ba			2024 CO	FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract
		Project Cost Totals	-	12.244		0.000		0.000		-		0.000	0.000	12.244	N/A

Remarks

Exhibit R-4, RDT&E Schedule Profile: PB 2024 C	he	mic	al	and	Bio	olog	lica	I D)efe	ense	Pro	gra	m												Dat	: e: Ma	arch	ı 20	23		
Appropriation/Budget Activity 0400 / 7										ΡE	060)738	34BF	P10	Che	mic	al a	nbei and E ms E	Biolo	gica	1		710	•		per/N natio			ance	e (Oµ	o Sy
		F	Y 2	022	2		F`	Y 2	2023	3		F١	(202	24			FY	2025	;		FY	2020		<u> </u>	FY	2027	,		FY	2028	3
	1		2	3	4	1		2	3	4	1	2	2 3	6	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
EMBD - IOC-Initial Operational Capability																															
EMBD - FRP Production																											l				
EMBD - FOC-Full Operational Capability																															
MOD SEN - DT/OT for refreshed components and obsolescence management within MOD SEN																															

hibit R-4A, RDT&E Schedule Details: PB 2024 Chemical and Biological Defense Pro	ogram			Date: Marc	ch 2023
D0/7 PE 0607	yram Element (Numbe 384BP / Chemical and I (Operational Systems I	Biological		lumber/Nan Itamination A	n e) Avoidance (Op Sj
Schedule D	etails				
	64	~~+		E.	
Events	Sta Quarter				nd Year
Events EMBD - IOC-Initial Operational Capability	Sta Quarter 2	art Year 2023	(Ei Quarter 2	nd Year 2023
	Quarter	Year		Quarter	Year
EMBD - IOC-Initial Operational Capability	Quarter	Year 2023		Quarter 2	Year 2023

ppropriation/Budget Activity 400 / 7 COST (\$ in Millions)					1	Program			1		rch 2023	
COST (\$ in Millions)					PE 060738	am Elemen 84BP / Cher Operational	nical and B	iological		Number/Na omeland Def	me) ense (Op Sy	/s Dev)
· · · · · · · · · · · · · · · · · · ·	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
M7: Homeland Defense (Op ys Dev)	-	1.463	0.000	0.000	0.000	0.000	0.000	0.000	0.00	0 0.000	0.000	1.46
uantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		
1) Weapons of Mass Destruction The WMD CST program supports GOTS) analytical detection, prot CST Teams. Program efforts sup nanufacturer. In FY24 the WMD lata on the performance of the s . Accomplishments/Planned F	s the fielded tection, deco pport upgrac) CST progra ystem.	system up ntaminatio les of key o am continue	grade and c n and samp components es system-re	ngoing ass ling equipm of the WM	essment ar nent for surv D CST Prog	nd acquisitio vey in order gram that ha	on of comm to expand/ ave become	enhance the e obsolete, c	e operation or are no lo d hardwar	nal capabiliti onger being e to obtain c	es of the (57 supported b) WMD y the
itle: 1) WMD CST										1.463	-	
escription: System Upgrade ar	nd Support											-
					Accomplis	shments/Pl						-
							anned Pro	grams Sub	totals	1.463	-	-
. Other Program Funding Sum	nmary (\$ in I	<u> Millions)</u>		2024 FY	2024 F		anned Pro	grams Sub	totals	1.463	- Cost To	

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biologica	I Defense Program		Date: March 2023
Appropriation/Budget Activity	R-1 Program Element (Number/Name)	Project (N	umber/Name)
0400 / 7	PE 0607384BP I Chemical and Biological	CM7 I Hon	neland Defense (Op Sys Dev)
	Defense (Operational Systems Developme		
	nt)		

D. Acquisition Strategy

WMD - CIVIL SUPPORT TEAMS (WMD CST)

The Weapons of Mass Destruction Civil Support Team Program (WMD-CST) is a COTS based program that supports the evaluation of advancements in CBRN commercial off the shelf (COTS)/government-off-the-shelf (GOTS) equipment against the current technology baseline of equipment fielded to the (57) WMD CST Teams, this is to address analytical equipment obsolescence.

Exhibit R-3, RDT&E	Project C	ost Analysis: PB 2	2024 Cher	nical and	d Biologica	al Defense	e Prograr	n				Date:	March 20	23	
Appropriation/Budge 0400 / 7	et Activity	1				PE 0607	7384BP /	ement (N Chemica ional Syst	l and Bio	logical		: (Numbe i Homeland		(Op Sys	Dev)
Support (\$ in Million	s)		ſ	FY 2	2022	FY 2	023	FY 2 Ba			2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
WMD CST - ES C - Science & Engineering Support	MIPR	Various : N/A	0.096	0.250	Nov 2021	0.000		0.000		-		0.000	0.000	0.346	0.000
		Subtotal	0.096	0.250		0.000		0.000		-		0.000	0.000	0.346	N/A
Test and Evaluation	(\$ in Milli	ons)	ſ	FY 2	2022	FY 2	023	FY 2 Ba			2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
WMD CST - OTHT C - CBRN COTS Component	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	7.372	1.051	Feb 2022	0.000		0.000		-		0.000	0.000	8.423	0.000
		Subtotal	7.372	1.051		0.000		0.000		-		0.000	0.000	8.423	N/A
Management Servic	es (\$ in M	illions)		FY	2022	FY 2	023	FY 2 Ba			2024 CO	FY 2024 Total			-
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
WMD CST - PM/MS S - Program Management Support	MIPR	Various : N/A	2.625	0.162	Dec 2021	0.000		0.000		-		0.000	0.000	2.787	0.000
		Subtotal	2.625	0.162		0.000		0.000		-		0.000	0.000	2.787	N/A
			Prior Years		2022	FY 2	023	FY 2 Ba			2024 CO	FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract
		Project Cost Totals	10.093	1.463		0.000		0.000		-		0.000	0.000	11.556	N/A

PE 0607384BP: *Chemical and Biological Defense (Operati...* Chemical and Biological Defense Program

Exhibit R-3, RDT&E Project Cost Analysis: PB 2	2024 Che	mical and Biologic	al Defense Progra	m			Date:	March 20	23	
Appropriation/Budget Activity 0400 / 7			PE 0607384BP	ement (Number/N I Chemical and Bio tional Systems Dev	logical	Project (CM7 / Ho		r/Name) Defense	(Op Sys	Dev)
	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2 OC		FY 2024 Total	Cost To Complete	Total Cost	Target Value o Contrac

Remarks

xhibit R-4, RDT&E Schedule Profile: PB 20	24 Chemic	al and Bi	ologi	cal De	efense	Prog	ram									[Date	: Mar	ch 2	023		
ppropriation/Budget Activity 400 / 7					R- ' PE	1 Prog 0607 fense	jram E 384BF <i>(Oper</i>)	I Che	emica	al an	d Biol	ogica	1	Proj CM7	ject 7	(Nu Iome	mbe eland	er/Na d Def	me) ense	(Op	o Sys	Dev)
	F۱	2022		FY 2	023	F	TY 202	4	F	FY 20)25		FY	2026		F	FY 2	027			Y 202	8
	1 2	2 3 4	1	2	3 4	1	2 3	4	1	2	3 4	1	2	3	4	1	2	3	4 1		2 3	4
WMD CST - Upgrade Fielded Systems														· · ·								

ppropriation/Budget Activity 400 / 7	R-1 Program Element (Number PE 0607384BP <i>I Chemical and E</i> <i>Defense (Operational Systems D</i>	Biological	Project (Number/Nam CM7 / Homeland Defe	
	nt)			
Sc	chedule Details			
	Sta	rt	Er	nd
Events	Quarter	Year	Quarter	Year
WMD CST - Upgrade Fielded Systems	1	2022	4	2027
	Quarter 1			

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical and Biological Defense Program

EXINDIL R-ZA, RDT&E PTOJECT JU	Suncation		memicaran	iu piologica	a Delense	Fiogram				Dale. Mai	CH 2025	
Appropriation/Budget Activity 0400 / 7					PE 06073	ram Elemer 84BP <i>I Che</i> 70perational	mical and E	Biological		lumber/Nai ective Prote		Sys Dev)
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
C07: Collective Protection (Op Sys Dev)	-	9.645	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	9.64
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		
The effort included in this Project (1) Modernization Protection Collective Supply chain shortages by address mobile, transportable, fixed facility modernized, will continue to face program's requirements and scher key components to extend service	ective Protection we Protection sing obsole and shipb significantly dules. MO e life and er	on (MODPR escence iss oard CP sy increased DPROT CF nsure afford	OT CP) inc ues to the I stems witho cost and lo modernize able and pr	corporates a DoD /Joint S Dut the high ng lead tim es decades	a value eng Services fie cost of rec nes making old collecti	ineering app Ided Chemic Juiring a new the equipme ve protection	proach to ac cal Biologic v program c ent unafford	al and Radi of record. T able and ur	ological (CE he obsolesc procurable costs, shorte	BR) protection cence of crite to meet matering lead t	on portfolio tical equipm ajor weapor times, and u	for hent, if not h system hpdating
B. Accomplishments/Planned P	rograms (\$		<u>5)</u>						F۱		FY 2023	FY 2024
Title: 1) MODPROT CP										9.645	-	-
Description: Upgrades, improver	nents, and	modernizati	ons to field	ed CP syst	ems							
					Accompli	ishments/Pl	anned Pro	grams Sub	totals	9.645	-	-
C. Other Program Funding Sum	mary (\$ in	Millions)	FY	2024 FY	′ 2024 F	Y 2024					Cost To	
Line Item	<u>FY 20</u>	22 FY 2		Base	000		Y 2025	FY 2026	FY 2027	<u>FY 202</u> 8	Complete	Total Cos
CO5: Collective Protection (SDE PT7: Protect (Op Sys Dev)		88	-	-	-	- 26.818	- 22.815	- 15.490	- 14.193	-	0.000 Continuing	2.88

PE 0607384BP: *Chemical and Biological Defense (Operati...* Chemical and Biological Defense Program UNCLASSIFIED Page 56 of 91

R-1 Line #208

Volume 4 - 486

Date: March 2023

Exhibit R-2A, RDT&E Project Just	ification: PB	2024 Chemi	cal and Biolo	ogical Defen	se Program				Date: Ma	arch 2023	
Appropriation/Budget Activity 0400 / 7				PE 06	r ogram Eler 07384BP / C se (Operatio	Chemical and			Number/Na lective Prot	ame) tection (Op S	Sys Dev)
C. Other Program Funding Summ	ary (\$ in Milli	ons <u>)</u>									
			<u>FY 2024</u>	FY 2024	FY 2024					<u>Cost To</u>	
Line Item	FY 2022	FY 2023	Base	000	Total	<u>FY 2025</u>	FY 2026	<u>FY 2027</u>	FY 2028	Complete	Total Cost
JP1111: Joint Expeditionary Collective Protection (JECP)	22.719	30.737	-	-	-	3.000	3.750	-	-	Continuing	Continuing
PHM036: Modernization Protection Collective Protection (MODPROT CP)	1.385	1.385	-	-	-	-	-	1.375	2.517	Continuing	Continuing
<u>Remarks</u>											

D. Acquisition Strategy

MODERNIZATION PROTECTION COLLECTIVE PROTECTION (MODPROT CP)

Modernization Protection Collective Protection (MODPROT CP) leverages mature technology from contractor developed components to address and replace obsolete components of various fielded collective protection systems. Modernization efforts will also use items developed by the Government that have transitioned from lower to higher technology readiness levels that can be inserted into fielded systems. A combination of competitive and sole source contracts to various industry vendors and project orders to various Government activities will be used to adapt previously developed components to modernize systems. Robust component and system level testing to meet applicable military standards will validate both Government and contractor furnished improvements. The improvements will be added into the specific systems' updated Technical Data Packages (TDPs) to be used in Engineering Change Proposals (ECPs) and provided to the item managers.

					PE 0607	7384BP /	ement (Nu Chemica ional Syst	l and Biol	ogical	-	(Number ollective F	r/ Name) Protection	(Op Sys	Dev)	
in Mil	llions)		FY 2	2022	FY 2	023					FY 2024 Total				
ntract ethod Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract	
	Various : N/A	0.773	2.295	Nov 2021	0.000		0.000		-		0.000	0.000	3.068	0.000	
IIPR	Various : N/A	2.815	0.736	Nov 2021	0.000		0.000		-		0.000	0.000	3.551	0.000	
rinie	Indian Head : Indian Head, MD	1.909	3.021	Nov 2021	0.000		0.000		-		0.000	0.000	4.930	0.000	
	Subtotal	5.497	6.052		0.000		0.000		-		0.000	0.000	11.549	N/A	
			FY 2	2022	FY 2	023					FY 2024 Total				
ntract ethod Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract	
IIPR	Various : N/A	0.704	0.735	Dec 2021	0.000		0.000		-		0.000	0.000	1.439	0.000	
	Subtotal	0.704	0.735		0.000		0.000		-		0.000	0.000	1.439	N/A	
Millio	ons)		FY 2	2022	FY 2	023		-			FY 2024 Total				
ntract ethod Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract	
irious	Various : N/A	1.137	2.183	Nov 2021	0.000		0.000		-		0.000	0.000	3.320	0.000	
	Subtotal	1.137	2.183		0.000		0.000		-		0.000	0.000	3.320	N/A	
	tract thod fype rious IPR rious tract thod fype IPR IPR IPR	Activity & LocationTypeActivity & LocationActivity & LocationriousVarious : N/AIPRVarious : N/AriousIndian Head : Indian Head, MDriousIndian Head : Indian Head, MDTotalSubtotalActivity & LocationIPRVarious : N/ASubtotalIPRVarious : N/AIPRVarious : N/AMillions)SubtotalActivity & LocationVarious : N/AVarious : N/AVarious : N/AIPRVarious : N/A	Arract thod TypePerforming Activity & LocationPrior YearsriousVarious : N/A0.773IPRVarious : N/A2.815IPRIndian Head : Indian Head, MD1.909riousIndian Head : Indian Head, MD5.497tract thod TypePerforming Activity & LocationPrior YearsIPRVarious : N/A0.704IPRVarious : N/A0.704IPRVarious : N/A0.704Millions)Subtotal0.704tract thod TypePerforming Activity & LocationPrior YearsIPRVarious : N/A0.704Millions)Various : N/A0.704	tract thod Performing Activity & LocationPrior YearsCostriousVarious : N/A0.7732.295IPRVarious : N/A0.7732.295IPRVarious : N/A2.8150.736riousIndian Head : Indian Head, MD1.9093.021Subtotal5.497FY 2tract thod TypePerforming Activity & LocationPrior YearsIPRVarious : N/A0.7040.735IPRVarious : N/A0.7040.735Millions)Subtotal0.7040.735fract thod Performing Activity & LocationPrior YearsFY 2Millions)FY 2Subtotal0.704Various : N/A0.7040.735FY 2fract thodPerforming Activity & LocationPrior YearsMillions)FY 2Subtotal0.704Various : N/A1.1372.183	tract thract throd SuppePerforming Activity & LocationPrior YearsAward CostAward DateriousVarious : N/A0.7732.295Nov 2021IPRVarious : N/A2.8150.736Nov 2021IPRVarious : N/A2.8150.736Nov 2021riousIndian Head : Indian Head, MD1.9093.021Nov 2021tract throd TypeSubtotal5.4976.052FY 2022tract throd TypeMillions)Performing Activity & LocationPrior YearsAward CostMillions)Subtotal0.7040.735Dec 2021FY 2022tract throd TypePerforming Activity & LocationPrior YearsAward CostMillions)FY 2022tract throd TypePerforming Activity & LocationPrior YearsAward CostMillionsVarious : N/A1.1372.183Nov 2021	FY 2022FY 2in Millions)FY 2022FY 2itract thod VypePerforming Activity & LocationPrior YearsAward CostCostIndian riousN/A0.7732.295Nov 20210.000IPR riousVarious : N/A2.8150.736Nov 20210.000IPR riousIndian Head : Indian Head, MD1.9093.021Nov 20210.000Subtotal5.4976.0520.000FY 2022FY 2FY 2022FY 2Indian Head : Indian Head, MD1.9093.021Nov 20210.000Subtotal5.4976.0520.000FY 2022FY 2Itract thod PypePerforming Activity & LocationPrior YearsAward CostCostMillions)FY 2022FY 2Millions)FY 2022FY 2Itract thod TypePerforming Activity & LocationPrior YearsAward CostCostMillionsFY 2022FY 2Itract thodPerforming DatePrior CostAward DateCostMillionsItract YearsCostAward DateCostMillionsItract YearsCostAward DateCostMillionsItract YearsCostAward DateCost<	In Millions)FY 2022FY 2023trract thod Performing Activity & LocationPrior YearsAward DateAward DatePerforming Activity & LocationPrior YearsAward CostAward DateAward DateIPR riousVarious : N/A 0.773 2.295 Nov 2021 0.000 0.000 IPR riousIndian Head : Indian Head, MD 1.909 3.021 Nov 2021 0.000 FY 2022FY 2023FY 2022FY 2023Tract thod TypePerforming Activity & LocationPrior YearsAward CostAward DateAward DateIPR Various : N/A 0.704 0.735 Dec 2021 0.000 IPR Mullions)Subtotal 0.704 0.735 Dec 2021 0.000 FY 2022FY 2023Millions)FY 2022FY 2023Millions)FY 2022FY 2023Millions)FY 2022FY 2023MillionsYearsCostAward DateVarious : N/A 1.137 2.183 Nov 2021 0.000	In Millions)FY 2022FY 2023FY 2 Battract thod SuppoPerforming Activity & LocationPrior YearsCostAward DateCostAward DateCostPerforming Activity & LocationPrior YearsAward DateCostAward DateCostIPRVarious : N/A2.8150.736Nov 20210.0000.0000.000Indian Head : Indian Head, MD1.9093.021Nov 20210.0000.0000.000FY 2 0.000FY 2022FY 2 0.000Indian Head : Indian Head, MD1.9093.021Nov 20210.0000.000Subtotal5.4976.0520.0000.000FY 2022FY 2 0.000FY 2 0.000Award DateCostPerforming Activity & LocationPrior YearsCostAward DateCostAward DateCostMillions)Fy 2022Fy 2023Fy 2 BatFy 2 CostFy 2 DateFy 2 CostFy 2 CostF	In Millions)FY 2022FY 2023FY 2024 Basetract tract thod MypePerforming Activity & LocationPrior YearsAward DateCostAward DateAward CostAward DateAward CostAward DateAward CostAward DateAward CostAward DateAward CostAward DateIPR Various : N/A2.8150.736Nov 20210.0000.000IPR tract thod thed, MDFY 20210.0000.000O.000Indian Head : Indian Head, MD1.909 3.021Nov 2021 Nov 20210.0000.000Itract tract thod MypePerforming Activity & LocationFY 2022FY 2023FY 2024 BaseItract tract tract thodPerforming Activity & LocationPrior YearsAward CostAward DateIPR Various : N/A0.7040.735Dec 20210.000O.000IPT 2022FY 2023FY 2024 BaseIPT 2022 <td colsp<="" td=""><td>In Millions)FY 2022FY 2023FY 2024FY 2024FY 2023FY 2024FY 2024DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostFY 2024FY 2024FY 2024IPRVarious : N/A0.7040.735Dec 20210.0000.0000.000FY 2022FY 2023FY 2024FY 2024FY 2024IPRVarious : N/A0.7040.735Dec 20210.0000.000Utract throdPrior YaersCostAward DateCostAward DateCostIPRVarious : N/A0.7040.735Dec 20210.0000.000Utract throd</td><td>$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$</td><td>In Millions)FY 202FY 2023FY 2024 BaseFY 2024 TotalFY 2024 TotalIntract thract hype Activity & LocationPrior YearsCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostPior AwardFY 2024 DateFY 2024 CostFY 2024 DateFY 2024 CostCostAward DateCostAward DateCostPior CostO.000IPR Various : N/AAward D.004CostFY 2024 DateFY 2024 CostFY 2024 CostFY 2024 CostFY 2024 CostFY 2024 CostFY 2024 CostFY 2024 CostFY 2024 CostF</td><td>$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$</td><td>In Millions) FY 2022 FY 2023 FY 2024 Base FY 2024 OCO FY 2024 Total FY 2024 Total Performing Ype Performing Activity & Location Prior Years Award Cost Award Date Cost D.000 0.000 1.549 Various: N/A 0.704 0.735 Dec 2021 0.000 0.000 - 0.000 0.000 1.439 Millions)</td></td>	<td>In Millions)FY 2022FY 2023FY 2024FY 2024FY 2023FY 2024FY 2024DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostFY 2024FY 2024FY 2024IPRVarious : N/A0.7040.735Dec 20210.0000.0000.000FY 2022FY 2023FY 2024FY 2024FY 2024IPRVarious : N/A0.7040.735Dec 20210.0000.000Utract throdPrior YaersCostAward DateCostAward DateCostIPRVarious : N/A0.7040.735Dec 20210.0000.000Utract throd</td> <td>$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$</td> <td>In Millions)FY 202FY 2023FY 2024 BaseFY 2024 TotalFY 2024 TotalIntract thract hype Activity & LocationPrior YearsCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostPior AwardFY 2024 DateFY 2024 CostFY 2024 DateFY 2024 CostCostAward DateCostAward DateCostPior CostO.000IPR Various : N/AAward D.004CostFY 2024 DateFY 2024 CostFY 2024 CostFY 2024 CostFY 2024 CostFY 2024 CostFY 2024 CostFY 2024 CostFY 2024 CostF</td> <td>$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$</td> <td>In Millions) FY 2022 FY 2023 FY 2024 Base FY 2024 OCO FY 2024 Total FY 2024 Total Performing Ype Performing Activity & Location Prior Years Award Cost Award Date Cost D.000 0.000 1.549 Various: N/A 0.704 0.735 Dec 2021 0.000 0.000 - 0.000 0.000 1.439 Millions)</td>	In Millions)FY 2022FY 2023FY 2024FY 2024FY 2023FY 2024FY 2024DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostFY 2024FY 2024FY 2024IPRVarious : N/A0.7040.735Dec 20210.0000.0000.000FY 2022FY 2023FY 2024FY 2024FY 2024IPRVarious : N/A0.7040.735Dec 20210.0000.000Utract throdPrior YaersCostAward DateCostAward DateCostIPRVarious : N/A0.7040.735Dec 20210.0000.000Utract throd	$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	In Millions)FY 202FY 2023FY 2024 BaseFY 2024 TotalFY 2024 TotalIntract thract hype Activity & LocationPrior YearsCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostAward DateCostPior AwardFY 2024 DateFY 2024 CostFY 2024 DateFY 2024 CostCostAward DateCostAward DateCostPior CostO.000IPR Various : N/AAward D.004CostFY 2024 DateFY 2024 CostFY 2024 CostFY 2024 CostFY 2024 CostFY 2024 CostFY 2024 CostFY 2024 CostFY 2024 CostF	$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	In Millions) FY 2022 FY 2023 FY 2024 Base FY 2024 OCO FY 2024 Total FY 2024 Total Performing Ype Performing Activity & Location Prior Years Award Cost Award Date Cost D.000 0.000 1.549 Various: N/A 0.704 0.735 Dec 2021 0.000 0.000 - 0.000 0.000 1.439 Millions)

Exhibit R-3, RDT&E	Project C	ost Analysis: PB 2	2024 Cher	mical and	d Biologica	al Defens	e Prograi	n				Date:	March 20	23	
Appropriation/Budge 0400 / 7	et Activity	,				PE 060	7384BP /	ement (N Chemica ional Syst	al and Bio	logical		(Number ollective I	r/ Name) Protection	(Op Sys	Dev)
Management Service	es (\$ in M	illions)		FY	2022	FY 2	023	FY 2 Ba			2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
MODPROT CP - PM/MS C - Program Management Support	MIPR	Various : N/A	0.612	0.675	Nov 2021	0.000		0.000		-		0.000	0.000	1.287	0.000
		Subtotal	0.612	0.675		0.000		0.000		-		0.000	0.000	1.287	N/A
			Prior Years	FY	2022	FY 2	023	FY 2 Ba			2024 CO	FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract
	_	Project Cost Totals	7.950	9.645		0.000		0.000		-		0.000	0.000	17.595	N/A

Remarks

Exhibit R-4, RDT&E Schedule Profile: PB 2024 C	Chei	nica	al and	d Bio	logi	cal D	Defer	nse l	Prog	gram												Da	te:	Mar	ch 2	202	3		
Appropriation/Budget Activity 0400 / 7								PE (0607	7384	n El BP / berat	Che	emi	cal a	and	Biolo	ogic	al		oje 07 /							Op S	Sys I	Dev)
		FY	202	2		FY	2023	}		FY 2	2024	Ļ		FY	202	5		FY	202	26		FY	202	27		F	Y 2	028	
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	2 3	; 4	4	1	2	3	4
MODPROT CP - M93 GPFU Electro Magnetic Interference																											·		
MODPROT CP - Non Destructive (ND) Acceptance Leak Test CP Filters																													
MODPROT CP - Environmental M98 Guard Bed Testing																													
MODPROT CP - M49 Filter Modernization																													
MODPROT CP - Filter Prototype Design Analysis and Development																													
MODPROT CP - Collective Protection Training Development																													
MODPROT CP - M48A1 Filter Redesign																													
MODPROT CP - Collective Protection Modernization for Ships and Buildings																													
MODPROT CP - M14 Protective Entrance Modernization																													
MODPROT CP - Filter Prototype Laboratory Testing and Evaluation																													
MODPROT CP - Contaminated Filter Changeout Procedures																													
MODPROT CP - Filter Technical Design Package and Procurement of Filter Design Test Articles	t																												
MODPROT CP - Platform Interoperability Testing and Final Technical Design Package																													
MODPROT CP - Mobile Platform Filter Modernization																													

PE 0607384BP: *Chemical and Biological Defense (Operati...* Chemical and Biological Defense Program UNCLASSIFIED Page 60 of 91

R-1 Line #208

Appropriation/Budget Activity R-1 Program Element (Number/Name) Project (Number/Name) Project (Number/Name) 0400 / 7 PE 0607384BP / Chemical and Biological Defense (Operational Systems Developme nt) C07 / Collective Protection (Op Sys De Net) FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 FY 2027 FY 2028 1 2 3 4 1 2 <th>xhibit R-4, RDT&E Schedule Profile: PB 2</th> <th>024 Che</th> <th>emica</th> <th>al a</th> <th>nd B</th> <th>iol</th> <th>ogic</th> <th>al D</th> <th>)efe</th> <th>nse</th> <th>Pro</th> <th>grar</th> <th>n</th> <th></th> <th>C</th> <th>Date</th> <th>e: M</th> <th>arch</th> <th>202 ו</th> <th>23</th> <th></th> <th></th>	xhibit R-4, RDT&E Schedule Profile: PB 2	024 Che	emica	al a	nd B	iol	ogic	al D)efe	nse	Pro	grar	n											C	Date	e: M	arch	202 ו	23		
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4										PE Def	060	738	4BP	I C	hem	ical	and	d Bi	iolog	gica	1								(Op	Sys	Dev
			FY	20	22			FY :	202	3		FY	202	4		FY	20	25			FY	202	26	F	Y 2	2027	1		FY	2028	3
MODPROT CP - Filter Surveillance Testing		•	1 2		3 4	1	1	2	3	4	1	2	3	4	1	2	2 :	3	4	1	2	3	3 4	1	2	3	4	1	2	3	4
	MODPROT CP - Filter Surveillance Testin	g																													

Exhibit R-4A, RDT&E Schedule Details: PB 2024 Chemical and Biological Details	efense Program	Date: March 2023
Appropriation/Budget Activity 0400 / 7	R-1 Program Element (Number/Name) PE 0607384BP <i>I Chemical and Biological</i> <i>Defense (Operational Systems Developme</i> <i>nt)</i>	 umber/Name) ective Protection (Op Sys Dev)

Schedule Details

	Sta	art	Er	nd
Events	Quarter	Year	Quarter	Year
MODPROT CP - M93 GPFU Electro Magnetic Interference	1	2022	4	2022
MODPROT CP - Non Destructive (ND) Acceptance Leak Test CP Filters	1	2022	4	2022
MODPROT CP - Environmental M98 Guard Bed Testing	1	2022	4	2022
MODPROT CP - M49 Filter Modernization	1	2022	4	2022
MODPROT CP - Filter Prototype Design Analysis and Development	1	2022	4	2022
MODPROT CP - Collective Protection Training Development	1	2022	4	2022
MODPROT CP - M48A1 Filter Redesign	1	2022	4	2025
MODPROT CP - Collective Protection Modernization for Ships and Buildings	1	2022	4	2026
MODPROT CP - M14 Protective Entrance Modernization	1	2022	4	2022
MODPROT CP - Filter Prototype Laboratory Testing and Evaluation	1	2023	2	2023
MODPROT CP - Contaminated Filter Changeout Procedures	3	2022	4	2023
MODPROT CP - Filter Technical Design Package and Procurement of Filter Design Test Articles	1	2023	4	2023
MODPROT CP - Platform Interoperability Testing and Final Technical Design Package	1	2024	4	2024
MODPROT CP - Mobile Platform Filter Modernization	1	2025	4	2025
MODPROT CP - Filter Surveillance Testing	1	2025	4	2028

Exhibit R-2A, RDT&E Project Ju	stification:	PB 2024 (Chemical an	d Biologica	I Defense	Program				Date: Ma	rch 2023	
Appropriation/Budget Activity 0400 / 7					PE 06073	r am Elemer 84BP <i>I Che</i> Operational	mical and E	liological		lumber/Na contaminatio	me) on (Op Sys I	Dev)
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
DE7: <i>Decontamination (Op Sys</i> Dev)	-	1.020	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	1.02
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		
The effort included in this project (1) Modernization Protection Decoma Modernization Protection Deconta Decontamination System-Small S parts; the M12A1 Power Driven D publishing an updated Technical to expand wipe capabilities to inc	ontaminatio amination (M Scale (JSTD Decontamina Manual (TM	MODPROT S-SS) thro ation Appar 1); Conduct	DE) addres ugh validatio atus (PDDA biological e	sses obsole on and veri) by updati efficacy at re	escence an fication of ⁻ ng technica	d technical o Fechnical Ma al references	anual (TM) s and perfor	changes as ming the ne	well as tec ecessary va	hnical data Ilidation and	for spare ar d verification	nd repair before
3. Accomplishments/Planned P	rograms (\$	in Million	<u>s)</u>						F	(2022	FY 2023	FY 2024
Title: 1) MODPROT DE										1.020	-	-
Description: Upgrades, improver	ments, and i	modernizat	ions to field	ed deconta	mination sy	/stems						
					Accompli	shments/P	anned Pro	grams Sub	ototals	1.020	-	-
C. Other Program Funding Sum	mary (\$ in	Millions)	FY	2024 FY	2024 F	Y 2024					Cost To	
Line Item	<u>FY 20</u>	<u>22</u> <u>FY 2</u>		Base	000		Y 2025	FY 2026	<u>FY 2027</u>	<u>FY 2028</u>	Complete	Total Cos
 MT7: Mitigate (Op Sys Dev) JD0050: Decontamination Family Of Systems (DFoS) 	7.7			.074 .062	-	3.074 6.062	1.987 8.673	1.819 8.820	1.845 16.518		Continuing Continuing	
PE 0607384BP: Chemical and Bio	logical Defe	ense (Oner	əti	UN	CLASSI	FIFD						
Control and Biological Defense I	•				0 E (00)			R-1 Line #	208		Volu	ıme 4 - 493

Chemical and Biological Defense Program

Page 63 of 91

R-1 Line #208

Exhibit R-2A, RDT&E Project	Justification: PB	2024 Chemi	ical and Biol	ogical Defen	se Program				Date: Ma	rch 2023	
Appropriation/Budget Activity 0400 / 7	/			PE 06	r ogram Eler 07384BP / (se (Operatio	Chemical and	,		Number/Na contaminati	i me) ion (Op Sys	Dev)
C. Other Program Funding Su	<u>ımmary (\$ in Milli</u>	<u>ons)</u>	FY 2024	FY 2024	FY 2024					Cost To	
<u>Line Item</u> Remarks	<u>FY 2022</u>	<u>FY 2023</u>	Base	000	<u>Total</u>	<u>FY 2025</u>	<u>FY 2026</u>	<u>FY 2027</u>	<u>FY 2028</u>		Total Cost
D. Acquisition Strategy MODERNIZATION DECONTAI	MINATION (MODF	PROT DE)									

MODPROT DE leverages mature technology from contractor developed components to address and replace obsolete components of various fielded decontamination systems. Modernization efforts will also use items developed by the Government that have transitioned from lower to higher technology readiness levels that can be inserted into fielded systems. A combination of competitive and sole source contracts to various industry vendors and project orders to various Government activities will be used to adapt previously developed components to modernize systems. Robust component and system level testing will validate both Government and contractor furnished improvements. The improvements will be added into the specific system's updated Technical Data Packages (TDPs) to be used in Engineering Change Proposals (ECPs) and provided to the item managers.

Exhibit R-3, RDT&E F	Project C	ost Analysis: PB 2	024 Cher	mical and	l Biologica	al Defens	e Prograr	n				Date:	March 20	23	
Appropriation/Budge 0400 / 7	et Activity	1				PE 060	7384BP /	Chemica	umber/N al and Bio tems Dev	logical		i (Numbe i Decontami	r/ Name) Ination (Op	o Sys De	v)
Product Developmen	nt (\$ in M	illions)		FY 2	2022	FY 2	023	FY 2 Ba	2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
MODPROT DE - HW C - M26 Tech Data Package; Modernization Update / M12A1 TM Update, JSEW	MIPR	Various : N/A	0.365	0.534	Nov 2021	0.000		0.000		-		0.000	0.000	0.899	0.00
	<u>_</u>	Subtotal	0.365	0.534		0.000		0.000		-		0.000	0.000	0.899	N//
Support (\$ in Millions	s)		ſ	FY 2	2022	FY 2	023	FY 2 Ba	2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
MODPROT DE - DTE C - IPT, Engineering, Technical, Logistics Support	MIPR	Various : N/A	0.268	0.406	Oct 2021	0.000		0.000		-		0.000	0.000	0.674	0.00
		Subtotal	0.268	0.406		0.000		0.000		-		0.000	0.000	0.674	N//
Management Service	es (\$ in M	illions)	ſ	FY 2	2022	FY 2	023	FY 2 Ba	2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
MODPROT DE - PM/MS C - Program Management Support	Various	Various : N/A	-	0.080	Oct 2021	0.000		0.000		-		0.000	0.000	0.080	0.00
		Subtotal	-	0.080		0.000		0.000		-		0.000	0.000	0.080	N//
			Prior Years	FY 2	2022	FY 2	023	FY 2 Ba	2024 Ise		2024 CO	FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract
		Project Cost Totals	0.633	1.020		0.000		0.000		-		0.000	0.000	1.653	N//

PE 0607384BP: *Chemical and Biological Defense (Operati...* Chemical and Biological Defense Program

chibit R-4, RDT&E Schedule Profile: PB 2024	Cher	nica	al ar	nd B	Biolo	ogic	al [De	fens	se F	Pro	grar	n											Da	ate	e: Ma	arch	1 202	23			
opropriation/Budget Activity 00 / 7									P L	PE (060	738	4BP	lem I Cl ation	hem	nica	al ai	nd E	Biolo	gic	al			(Nun econt					5 5	Sys [Dev)
		FY	20	22			FY	20	23			FY	202	4		F	TY 2	025			FY	202	26	F	Y 2	2027	,		F	Y 20	28	
	1	2		3 4	4	1	2		3	4	1	2	3	4	1	I	2	3	4	1	2	3	3 4	1	2	3	4	1		2	3	4
MODPROT DE - M12A1 TM Update																																
MODPROT DE - M26 JSTDS-SS TDP																																
MODPROT DE - M26 JSTDS-SS Modernization																																
MODPROT DE - M12 Pressure Accumulator																																
MODPROT DE - M295 & M100 Performance Characterization																																

Appropriation/Budget ActivityR-1 Program Element (Number/Name)Project (Number/Name)0400 / 7PE 0607384BP / Chemical and Biological Defense (Operational Systems DevelopmeDE7 / Decontamination (Op Sys Dev)	Exhibit R-4A, RDT&E Schedule Details: PB 2024 Chemical and Biological	Defense Program	Date: March 2023
nt)		PE 0607384BP / Chemical and Biological	

Schedule Details

	St	art	E	nd
Events	Quarter	Year	Quarter	Year
MODPROT DE - M12A1 TM Update	1	2022	4	2023
MODPROT DE - M26 JSTDS-SS TDP	1	2022	4	2023
MODPROT DE - M26 JSTDS-SS Modernization	1	2022	4	2025
MODPROT DE - M12 Pressure Accumulator	1	2024	4	2024
MODPROT DE - M295 & M100 Performance Characterization	1	2024	4	2024

Exhibit R-2A, RDT&E Project J	ustification	: PB 2024 C	Chemical an	d Biologica	l Defense P	rogram				Date: Mare	ch 2023	
Appropriation/Budget Activity 0400 / 7					R-1 Progra PE 060738 <i>Defense (C</i> <i>nt)</i>	4BP / Cher	nical and B	iological	Project (N IP7 / Indivi		ne) tion (Op Sys	Dev)
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
IP7: Individual Protection (Op Sys Dev)	-	11.659	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	11.659
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

The project supports technology refresh of fielded individual protective equipment which enable the warfighter to operate in a contaminated CBR environment with little or no degradation to his/her performance. In FY2023, the CBDP RDT&E Projects have been restructured to align to the CBDP portfolio. IP7 efforts in FY2022 progress to the Protect (PT7) and Understand (UN7) portfolios. This restructuring is intended to provide standardization and alignment across CBDP research, development and acquisition efforts.

Efforts included in this Project are:

(1) Modernization Protection Individual Protection (MODPROT IP) **Progresses to PT7 in FY2023**, and
 (2) Special Purpose Unit Rapid Capability Development and Deployment (SPU RCDD) **Progresses to UN7 in FY2023**

Modernization Protection Individual Protection (MODPROT IP) addresses obsolescence issues with Individual Protective (IP) equipment and the need to modernize fielded IP with capabilities to meet or exceed the Services requirements. MODPROT IP will also conduct modernization efforts and reverse engineering of maintenance and repair procedures for the Joint Services Mask Leakage Tester (JSMLT). MODPROT IP will also provide mask and filter system upgrades and modernization of fielded protection systems to enhance respiratory and ocular protection resulting in an increased lethality of fighter aircraft by mitigating risk due to operationally unsuitable aircrew Chemical Biological Radiological Nuclear (CBRN) masks. Modernization efforts will include technical manual updates and a Logistics Demonstration for an updated, lightweight version of the Joint Protective Aircrew Ensemble (JPACE). Testing and analysis with aircraft will fully validate and refine new Tactics, Techniques and Procedures (TTPs) that allow aircrews to operate without restrictive CBRN protective equipment by determining time and techniques required to reduce cockpit hazards to acceptable levels by flushing with clean air. The impact of funding these programs will address modernization and obsolescence across the DoD IP portfolio to increase readiness, sustainability, reliability, and affordability of these systems.

SPU RCDD facilitates Joint Special Operations Command (JSOC) rapid response requirements to near-term and emergent chemical-biological defensive capabilities. This includes select elements from across the Special Operations Force (SOF) Enterprise such as CBRN Assessment Response Teams (CARTs) and other Joint Force enabling units such as the 20th Chemical, Biological, Radiological, Nuclear and Explosives Command. SPU RCDD mitigates risk across the Chemical Biological Defense Program (CBDP) by creating a portfolio of operationally-relevant CB capabilities that can be quickly transitioned in response to the articulated, emergent capability needs of the geographic combatant commanders. These objectives are met by the early transitioning of promising science and technologies (S&T); the focused conduct of combat evaluations and mission-oriented operational assessments to assess technological and mission suitability; and the active leveraging of existing Commercial-Off-The-Shelf (COTS) and Government-Off-The-Shelf (GOTS) products along with novel redesign approaches to optimize existing solutions to

Exhibit R-2A, RDT&E Project Justi	fication: PB	2024 Chemi	cal and Biol	ogical Defen	se Program				Date: Ma	arch 2023	
Appropriation/Budget Activity 1400 / 7				PE 06	r ogram Elen 07384BP / C se (Operatio	Chemical and	,	IP7 I In	t (Number/N dividual Prot		ys Dev)
new challenges supported by "buy-trunter and ground platform unmanned aerial and ground platform Biological ensembles that have gone SOF equipment to counter emerging	m sensor inte through req	gration, dev	elopment of	enhanced a	nd augmente	ed reality sys	stems, and m	nodernizat	tion of protec	tive Chemica	al and
B. Accomplishments/Planned Prog	grams (\$ in N	<u>/lillions)</u>							FY 2022	FY 2023	FY 2024
Title: 1) MODPROT IP									7.850	-	-
Description: Upgrades, improvement	nts, and mod	ernizations to	o fielded IP s	systems.							
Title: 2) SPU RCDD - System Model	rnization								3.809	-	-
Description: This line includes Prod across multiple commodity areas in c							dernize techr	nology			
				Accon	nplishments	s/Planned P	rograms Su	btotals	11.659	-	-
C. Other Program Funding Summa	ry (\$ in Milli	<u>ons)</u>								- · -	
			FY 2024	FY 2024	FY 2024					Cost To	
Line Item IP5: Individual Protection (SDD)	<u>FY 2022</u> 18.690	<u>FY 2023</u>	Base	000	<u>Total</u>	<u>FY 2025</u>	<u>FY 2026</u>	<u>FY 2027</u>		Complete 0.000	
• PT7: Protect (Op Sys Dev)	-	20.076	26.818	_	26.818	22.815	15.490	14.193		Continuing	
• UN5: Understand (SDD)	-	126.071	182.726	-	182.726	137.991	127.671	108.908		Continuing	
• UN7: Understand (Op Sys Dev)	-	40.414	50.603	-	50.603	58.881	71.869	68.839		Continuing	
• PHM018: SPU Rapid	10.834	9.914	49.455	-	49.455	20.689	20.180	24.216		Continuing	
Capability Development And Demo (SPU RCDD)											
Remarks											
D. Acquisition Strategy MODERNIZATION PROTECTION II	NDIVIDUAL F	PROTECTIO	N (MODPR	ot IP)							

Modernization Protection Individual Protection (MODPROT IP) leverages mature technology from contractor developed components to address and replace obsolete components of various fielded individual protection systems. Modernization efforts will also use items developed by the Government that have transitioned from lower to higher technology readiness levels that can be inserted into fielded systems. A combination of competitive and sole source contracts to various industry vendors and project orders to various Government activities will be used to adapt previously developed components to modernize systems. Robust component and system

PE 0607384BP: *Chemical and Biological Defense (Operati...* Chemical and Biological Defense Program

Exhibit R-2A, RDT&E Project Justification: PB 2024 Chemical an	nd Biological Defense Program	Date: March 2023
Appropriation/Budget Activity 0400 / 7	R-1 Program Element (Number/Name) PE 0607384BP <i>I Chemical and Biological</i> <i>Defense (Operational Systems Developme</i> <i>nt)</i>	Project (Number/Name) IP7 I Individual Protection (Op Sys Dev)
level testing will validate both Government and contractor furnished Package (TDP) to be used in Engineering Change Proposals (ECP		e specific system's updated Technical Dat
SPU RAPID CAPABILITY DEVELOPMENT AND DEPLOYMENT (SPU RCDD)	
The SPU RCDD overall acquisition strategy allows for rapid prototy to enhance mission success. The SPU RCDD will use technical ar and incorporate operationally-relevant system developments. This Delivery Indefinite Quantify Task Order and the Countering Weapor test assets. The SPU RCDD will use Government Agencies for pro	nd functional evaluations of currently fielded items to ider will be accomplished through competitive contracting vel ns of Mass Destruction Other Transaction Authority (CWI	tify materiel that requires modernization nicles such as Multiple Award Indefinite MD OTA) for the development of prototype

Exhibit R-3, RDT&E F	Project C	ost Analysis: PB 2	024 Chei	mical and	d Biologica	al Defens	e Prograr	n			_	Date:	March 20	23	
Appropriation/Budge 0400 / 7	t Activity	1				PE 060	7384BP /	Chemica	umber/N al and Bio tems Dev	logical	-	(Number dividual P	r/ Name) rotection (Op Sys I	Dev)
Product Developmen	nt (\$ in M	illions)		FY	2022	FY 2	2023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
MODPROT IP - HW C - Filter Prototypes & JSMLT Modernization	Various	Various : N/A	1.472	2.867	Nov 2021	0.000		0.000		-		0.000	0.000	4.339	0.000
SPU RCDD - HW C - EWAT Product Development	Various	MRIGlobal : Kansas City, MO	2.768	2.389	Dec 2021	0.000		0.000		-		0.000	0.000	5.157	0.000
SPU RCDD - HW S - Improved PPE Bag	C/CPFF	MRIGlobal : Kansas City, MO	-	0.127	Feb 2022	0.000		0.000		-		0.000	0.000	0.127	0.000
SPU RCDD - HW C - M-SCBA Product Development	C/CPFF	Advanced Technologies International : Summerville, SC	0.503	0.680	Mar 2022	0.000		0.000		-		0.000	0.000	1.183	0.000
		Subtotal	4.743	6.063		0.000		0.000		-		0.000	0.000	10.806	N/A
Support (\$ in Millions	s)			FY	2022	FY 2	2023		2024 Ise		2024 CO	FY 2024 Total]		
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
MODPROT IP - ES C - IPT, Engineering, Technical, Logistics Support	MIPR	Various : N/A	0.301	1.176	Oct 2021	0.000		0.000		-		0.000	0.000	1.477	0.000
		Subtotal	0.301	1.176		0.000		0.000		-		0.000	0.000	1.477	N/A
Test and Evaluation ((\$ in Milli	ons)		FY	2022	FY 2	2023		2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
MODPROT IP - DTE C - Fixed Wing Aircraft/Aircrew PPE Optimization Effort	MIPR	Various : N/A	-	1.800	Dec 2021	0.000		0.000		-		0.000	0.000	1.800	0.000

PE 0607384BP: *Chemical and Biological Defense (Operati...* Chemical and Biological Defense Program

Exhibit R-3, RDT&E	Project C	ost Analysis: PB 2	024 Cher	nical and	d Biologica	al Defens	e Prograr	n				Date:	March 20	23	
Appropriation/Budg 0400 / 7	et Activity	/				PE 060	7384BP /	Chemica	umber/Na al and Biol tems Dev	logical		: (Numbe i dividual P	r/ Name) rotection (Op Sys I	Dev)
Test and Evaluation	(\$ in Milli	ions)	ſ	FY 2	2022	FY 2	023	FY 2 Ba	-		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
MODPROT IP - DTE C - Filter Prototype Testing	MIPR	U.S. Army Combat Capabilities Development Command (DEVCOM) Chemical Biological Center (CBC) : Aberdeen Proving Ground, MD	1.005	1.419	Dec 2021	0.000		0.000		-		0.000	0.000	2.424	0.000
		Subtotal	1.005	3.219		0.000		0.000		-		0.000	0.000	4.224	N/A
Management Servic	es (\$ in M	lillions)	ſ	FY 2	2022	FY 2	023	FY 2 Ba	-		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
MODPROT IP - PM/MS C - Program Management Support	MIPR	Various : N/A	0.110	0.588	Jan 2022	0.000		0.000		-		0.000	0.000	0.698	0.000
SPU RCDD - PM/MS C - Program Management Support	Various	Various : N/A	1.556	0.613	Nov 2021	0.000		0.000		-		0.000	0.000	2.169	0.000
		Subtotal	1.666	1.201		0.000		0.000		-		0.000	0.000	2.867	N/A
			Prior Years	FY	2022	FY 2	023	FY 2 Ba	-		2024 CO	FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract

Remarks

PE 0607384BP: *Chemical and Biological Defense (Operati...* Chemical and Biological Defense Program

xhibit R-4, RDT&E Schedule Profile: PB 2024 C	her	nical	and	d Bio	ologio	cal [Defei	nse F	Prog	gram												Dat	e: M	arch	20	23		
Appropriation/Budget Activity 400 / 7								R-1 PE 0 Defe nt)	607	7384	BP /	Che	mic	al a	and I	Biolo	ogic	al					er/N Prot			Op S	Sys E	Dev)
		FY	2022	2		FY	2023	3		FY 2	024			FY 2	202	5		FY	202	6		FY	2027			FY 2	2028	
	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
MODPROT IP - Second Generation Filter & NIOSH DT																					-							
MODPROT IP - JSMLT Modernization																												
MODPROT IP - LJPACE TM Updates & LOGDEMO																												
MODPROT IP - MALO Shelf Life Extension Testing																												
MODPROT IP - Fixed Wing Aircraft/Aircrew PPE Optimization Effort																												
MODPROT IP - Maximum Age Study for JB2GU nFR Glove																												
MODPROT IP - Second Generation Filter ECP																												
MODPROT IP - CBIRF Class 3 Modernization																												
MODPROT IP - CRE PPE Modernization																												
MODPROT IP - Third Generation Filter Prototype DT																												
MODPROT IP - Third Generation Filter Technology ECP																												
SPU RCDD - Modernize CBRN Materiel																												
SPU RCDD - Develop Modular Self Contained Breathing Apparatus (MSCBA)																												
SPU RCDD - Develop Enhanced Warfighter Augmented Training (EWAT)																												
SPU RCDD - Prototype Novel CBRN Equipment																												

PE 0607384BP: *Chemical and Biological Defense (Operati...* Chemical and Biological Defense Program

E	chibit R-4, RDT&E Schedule Profile: PB 2024	Chei	mica	l and	l Bio	logic	cal D)efen	nse F	Prog	gram												Dat	e: N	larc	h 20	23		
	opropriation/Budget Activity 00 / 7							F	PE (0607	gran 7384 e (Op	BP /	Ch	emi	cal a	nd E	Biolo	, gica				•	umb dual			,	Ор	Sys	Dev)
			FY	2022	2		FY 2	2023			FY 2	2024			FY :	2025			FY :	2026	5		FY	202	7		FY	202	8
		1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
	SPU RCDD - Develop Low Temperature Plasma Mass Spectrometer (LTPMS)																												
	SPU RCDD - Develop Optimized CBRN Hydration System (OCHS)																												
	SPU RCDD - Develop Assault Respirator																												-
	SPU RCDD - Develop USSOCOM-specific UGV/UAS Sensor Integration																												

Exhibit R-4A, RDT&E Schedule Details: PB 2024 Chemical and Biological I	Defense Program	Date: March 2023
Appropriation/Budget Activity 0400 / 7	R-1 Program Element (Number/Name) PE 0607384BP / Chemical and Biological Defense (Operational Systems Developme nt)	Project (Number/Name) IP7 I Individual Protection (Op Sys Dev)

Schedule Details

	Sta	art	Er	nd
Events	Quarter	Year	Quarter	Year
MODPROT IP - Second Generation Filter & NIOSH DT	1	2022	4	2022
MODPROT IP - JSMLT Modernization	1	2022	4	2026
MODPROT IP - LJPACE TM Updates & LOGDEMO	1	2022	4	2022
MODPROT IP - MALO Shelf Life Extension Testing	1	2022	2	2022
MODPROT IP - Fixed Wing Aircraft/Aircrew PPE Optimization Effort	1	2023	4	2026
MODPROT IP - Maximum Age Study for JB2GU nFR Glove	2	2022	4	2022
MODPROT IP - Second Generation Filter ECP	1	2023	2	2023
MODPROT IP - CBIRF Class 3 Modernization	2	2024	4	2024
MODPROT IP - CRE PPE Modernization	2	2024	4	2024
MODPROT IP - Third Generation Filter Prototype DT	1	2025	4	2025
MODPROT IP - Third Generation Filter Technology ECP	1	2026	2	2026
SPU RCDD - Modernize CBRN Materiel	1	2022	4	2027
SPU RCDD - Develop Modular Self Contained Breathing Apparatus (MSCBA)	1	2022	4	2024
SPU RCDD - Develop Enhanced Warfighter Augmented Training (EWAT)	1	2022	4	2024
SPU RCDD - Prototype Novel CBRN Equipment	1	2022	4	2027
SPU RCDD - Develop Low Temperature Plasma Mass Spectrometer (LTPMS)	1	2022	4	2024
SPU RCDD - Develop Optimized CBRN Hydration System (OCHS)	1	2022	2	2023
SPU RCDD - Develop Assault Respirator	1	2022	4	2023
SPU RCDD - Develop USSOCOM-specific UGV/UAS Sensor Integration	1	2022	4	2023

Exhibit R-2A, RDT&E Project Ju	ustification	: PB 2024 C	Chemical an	d Biologica	l Defense P	rogram				Date: Mare	ch 2023	
Appropriation/Budget Activity 0400 / 7					PE 060738	a m Elemen 34BP <i>I Cher</i> Operational	nical and B	ological	Project (N IS7 / Inform		ne) ems (Op Sys	Dev)
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
IS7: Information Systems (Op Sys Dev)	-	14.589	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	14.589
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		

A. Mission Description and Budget Item Justification

This Project provides for the upgrade and modernization of fielded Information Systems. During this phase efforts will execute modernization, bug fixes, provide support at fielded locations, and maintain training and logistics support. In FY2023, the CBDP RDT&E Projects have been restructured to align to the CBDP portfolio. IS7 efforts in FY2022 progress to the Understand (UN7) portfolio. This restructuring is intended to provide standardization and alignment across CBDP research, development and acquisition efforts.

Efforts included in this Project are:

(1) Modernization Chemical Biological Radiological Nuclear Information Systems (MOD CBRN IS) ** Progresses to UN7 in FY2023**

MOD CBRN IS combines CBRN IS (Cloud), Joint Effects Model (JEM), the Joint Warning and Reporting Network (JWARN) and the Software Support Activity within one portfolio. MOD CBRN IS provides for the continuous engineering and sustainment efforts to modernize capabilities and conduct Post Deployment Software Support (PDSS) to fielded CBRN software programs. Activities include: software code updates and modernization to correct deficiencies; compliance with system architectural changes to ensure interoperability; cybersecurity updates ensuring compliance with policies and standards; test and evaluation to identify possible cybersecurity vulnerabilities; configuration management; software redistribution, documentation, and training. In FY24, MOD CBRN IS funding will be consolidated under CBRN Support to Command and Control (CSC2).

B. Accomplishments/Planned Prog	grams (\$ in N	<u> ////////////////////////////////////</u>							FY 2022	FY 2023	FY 2024
Title: 1) MOD CBRN IS									14.589	-	-
Description: CBRN Information Sys	tems Modern	ization									
				Accon	nplishments	s/Planned P	rograms Su	btotals	14.589	-	-
C. Other Program Funding Summa	ry (\$ in Milli	ons <u>)</u>									
			FY 2024	<u>FY 2024</u>	<u>FY 2024</u>					Cost To	<u>)</u>
Line Item	FY 2022	FY 2023	Base	000	<u>Total</u>	FY 2025	<u>FY 2026</u>	FY 202	27 FY 202	<u>3</u> Complete	Total Cos
• UN7: Understand (Op Sys Dev)	-	40.414	50.603	-	50.603	58.881	71.869	68.83	39 50.62	B Continuing	Continuing
PE 0607384BP: Chemical and Biolog	viaal Dafanaa	Oporati		UNCLAS							

PE 0607384BP: Chemical and Biological Defense (Operati... Chemical and Biological Defense Program UNCLASSIFIED Page 76 of 91

R-1 Line #208

Exhibit R-2A, RDT&E Project Jus	tification: PB	2024 Chemi	cal and Biol	ogical Defen	se Program				Date: Ma	rch 2023			
Appropriation/Budget Activity 0400 / 7	PE 06	rogram Eler 07384BP / C se (Operatio	Chemical and	,	Project (Number/Name) IS7 I Information Systems (Op Sys Dev)								
C. Other Program Funding Sumn	nary (\$ in Milli	ons <u>)</u>											
			<u>FY 2024</u>	<u>FY 2024</u>	FY 2024					Cost To			
Line Item	<u>FY 2022</u>	FY 2023	Base	000	<u>Total</u>	<u>FY 2025</u>	FY 2026	<u>FY 2027</u>	<u>FY 2028</u>	Complete	Total Cost		
 JS5230: Modernization 	0.611	0.656	-	-	-	-	-	-	-	0.000	1.267		
CBRN Information													
Systems (MOD CBRN IS)													
• SA0050: CBRN	1.750	11.803	2.186	-	2.186	2.257	2.366	2.451	2.549	Continuing	Continuing		
Support to C2 (CSC2)										U			
Remarks													

D. Acquisition Strategy

MODERNIZATION CBRN INFORMATION SYSTEMS (MOD CBRN IS)

MOD CBRN IS combines CBRN IS, Joint Effects Model (JEM), Joint Warning and Reporting Network(JWARN) and the Software Support Activity under one portfolio. The acquisition strategy utilizes a managed portfolio approach to align multiple capabilities in support of modernization of CBRN Information Systems. MOD CBRN IS leverages the concepts of CBRN Hazard Awareness and Understanding and the DISA milCloud Enterprise Services to integrate current CBRN capabilities and intelligence services, applications, and systems to provide increased situational awareness and decision support to commanders for CBRN defense. This strategy provides an integration platform and supports the implementation of CSC2 and other emerging technologies from advanced technology demonstrations (ATD) and experimental capability demonstrations (ECD). MOD CBRN IS provides for the continuous engineering and modernization of fielded information systems for JEM and JWARN and Next Generation hazard prediction, warning and reporting, and CBRN decision support tool applications. MOD CBRN IS utilizes the Agile software development and IT Box to provide for the continuous spiral development, and fielding of modular capability packages. In FY23, MOD CBRN IS will transition from IS7 to UN7.

EXHIBIT R-3, RDI &E I	Project C	ost Analysis: PB 2	:024 Che	mical and	Biologica	al Defens	e Prograr	n				Date:	March 202	23		
Appropriation/Budge 0400 / 7	et Activity	,		PE 060	7384BP /	ement (Ni Chemica ional Syst	l and Biol	Project (Number/Name) IS7 I Information Systems (Op Sys Dev)								
Product Developmer	nt (\$ in Mi	illions)		FY 2	2022	FY 2	023	FY 2 Bas			2024 CO	FY 2024 Total				
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract	
MOD CBRN IS - SW S - Modernization	Various	Various : N/A	-		Oct 2021	0.000		0.000		-		0.000	0.000	10.176	0.000	
		Subtotal	-	10.176		0.000		0.000		-		0.000	0.000	10.176	N/#	
Support (\$ in Millions)			ſ	FY 2	2022	FY 2	023	FY 2 Bas	-		2024 CO	FY 2024 Total				
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract	
MOD CBRN IS - ES S - milCloud Support	MIPR	Various : N/A	-	1.977	Oct 2021	0.000		0.000		-		0.000	0.000	1.977	0.000	
		Subtotal	-	1.977		0.000		0.000		-		0.000	0.000	1.977	N/A	
Test and Evaluation	(\$ in Milli	ons)		FY 2	2022	FY 2	023	FY 2 Bas			2024 CO	FY 2024 Total				
	Contract Method	Performing	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract	
Cost Category Item	& Type	Activity & Location											Complete	0000		
Cost Category Item MOD CBRN IS - OTHT S - System Testing	& Type MIPR	Various : N/A	-	0.803	Oct 2021	0.000		0.000		-		0.000	0.000	0.803	0.000	
MOD CBRN IS - OTHT S -		_	-	0.803 0.803	Oct 2021	0.000		0.000		-		0.000			0.000 N/A	
MOD CBRN IS - OTHT S -	MIPR	Various : N/A Subtotal	-				023		-	FY 2	2024 CO		0.000	0.803		
MOD CBRN IS - OTHT S - System Testing	MIPR	Various : N/A Subtotal	- - Prior Years	0.803		0.000	023 Award Date	0.000 FY 2	-	FY 2		0.000	0.000	0.803		
MOD CBRN IS - OTHT S - System Testing Management Service	MIPR es (\$ in M Contract Method	Various : N/A Subtotal illions) Performing		0.803 FY 2 Cost	2022 Award	0.000 FY 2	Award	0.000 FY 2 Ba	se Award	FY 2 OC	CO Award	0.000 FY 2024 Total	0.000 0.000 Cost To	0.803 0.803 Total	N/# Target Value of	

Exhibit R-3, RDT&E Project Cost Analysis: PB 2	024 Che	mical and Biologic	al Defens	e Prograr	m				Date:	March 20	23			
Appropriation/Budget Activity 0400 / 7	PE 060	ogram Ele 7384BP / e (Operat	Chemica	al and Bio	-	Project (Number/Name) IS7 I Information Systems (Op Sys Dev)								
	Prior Years	FY 2022	FY 2	2023	FY 2 Ba	2024 Ise	FY 2 OC		FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract		
Project Cost Totals	-	14.589	0.000		0.000		-		0.000	0.000	14.589	N/A		

Remarks

Exhibit R-4, RDT&E Schedule Profile: PB 2024 Chemical and Biological Defense Program										Date: March 2023																						
Appropriation/Budget Activity 0400 / 7							R-1 Program Element (Number/Name) PE 0607384BP <i>I Chemical and Biological</i> <i>Defense (Operational Systems Developme</i> <i>nt)</i>												a/	IS7 I Information Systems (Op Sys Dev)												
		F	Υź	2022				FY 2023			FY 2024			1		FY 2025			,		FY	202	6		F١	′ 20)27			FY	2028	
	1	I	2	3	4	1		2	3	4	1	2	3	4	•	1 2	2	3	4	1	2	3	4	1	2	2	3	4	1	2	3	4
MOD CBRN IS - Modernization																																
MOD CBRN IS - Continuous Engineering/SW Codes Updates																																
MOD CBRN IS - Cyber Security Compliance																																
MOD CBRN IS - Operating system architecture updates																																
MOD CBRN IS - Configuration Management and Test and Evaluation																																
MOD CBRN IS - Validation, Verification and Accreditation																																

Exhibit R-4A, RDT&E Schedule Details: PB 2024 Chemical and Biological E	efense Program	Date: March 2023
Appropriation/Budget Activity 0400 / 7	R-1 Program Element (Number/Name) PE 0607384BP <i>I Chemical and Biological</i> <i>Defense (Operational Systems Developme</i> <i>nt)</i>	Project (Number/Name) IS7 I Information Systems (Op Sys Dev)

Schedule Details

	St	art	E	nd
Events	Quarter	Year	Quarter	Year
MOD CBRN IS - Modernization	1	2022	4	2023
MOD CBRN IS - Continuous Engineering/SW Codes Updates	1	2022	4	2023
MOD CBRN IS - Cyber Security Compliance	1	2022	4	2023
MOD CBRN IS - Operating system architecture updates	1	2022	4	2023
MOD CBRN IS - Configuration Management and Test and Evaluation	1	2022	4	2023
MOD CBRN IS - Validation, Verification and Accreditation	1	2022	4	2023

		1 0 2024 0	Chemical and	a Biologica	1	•			1		rch 2023	
Appropriation/Budget Activity 0400 / 7					PE 060738	am Elemen 34BP / Chen Operational	nical and B	ological		(Number/Na ledical Biolog		e (Op Sys
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 202	7 FY 2028	Cost To Complete	Total Cost
MB7: Medical Biological Defense (Op Sys Dev)	-	3.726	0.000	0.000	0.000	0.000	0.000	0.000	0.0	0.00	0.000	3.72
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-				
Efforts in this Project include:												
(1) MODERNIZATION MEDICAL The MOD MED program supports devices, including FDA-approved emerging FDA-compliant technolo requirements (PMRs), and continu software configurations and addree B. Accomplishments/Planned Planned	improveme autoinjecto ogies and u ually mitigat essed efforts	ents to field rs and diag pdated mar tes cyberse s to mitigat	ed systems nostic equip nufacturing (curity risks. e obsolesce	and suppo oment, in or guidelines, In FY22, N	rts post-fiel der to mitig supports FI MOD MED o	ate obsoles DA-required continued ar	cence and post-marke	maintain fie eting commi security up	Ided cap itments (odates ar D transiti	abilities. It ex PMCs) and p d manageme oned to UN7.	ploits new an ost-marketin ent of hardwa	nd g are and
The MOD MED program supports devices, including FDA-approved emerging FDA-compliant technolo requirements (PMRs), and continu	improveme autoinjecto ogies and u ually mitigat essed efforts	ents to field rs and diag pdated mar tes cyberse s to mitigat	ed systems nostic equip nufacturing g ecurity risks. e obsolesce <u>s)</u>	and suppo oment, in or guidelines, In FY22, N	rts post-fiel der to mitig supports FI MOD MED o	ate obsoles DA-required continued ar	cence and post-marke	maintain fie eting commi security up	Ided cap itments (odates ar D transiti	abilities. It ex PMCs) and p d manageme oned to UN7.	ploits new ar ost-marketin ent of hardwa	nd g
The MOD MED program supports devices, including FDA-approved emerging FDA-compliant technolo requirements (PMRs), and continu software configurations and addre B. Accomplishments/Planned Pr <i>Title:</i> 1) MOD MED - Next General	improveme autoinjecto ogies and u ually mitigat essed efforts rograms (\$ ition Diagno	ents to field rs and diag pdated mar tes cyberse s to mitigat in Millions	ed systems nostic equip nufacturing (curity risks. e obsolesce <u>s)</u> n (NGDS) 1	and suppo oment, in or guidelines, In FY22, N nce and ma	rts post-fiel der to mitig supports FI MOD MED o	ate obsoles DA-required continued ar	cence and post-marke	maintain fie eting commi security up	Ided cap itments (odates ar D transiti	abilities. It ex PMCs) and p Id manageme oned to UN7. FY 2022	ploits new an ost-marketin ent of hardwa	nd g are and
The MOD MED program supports devices, including FDA-approved emerging FDA-compliant technolo requirements (PMRs), and continu software configurations and addre B. Accomplishments/Planned Pr	improveme autoinjecto ogies and u ually mitigat essed efforts rograms (\$ ition Diagno	ents to field rs and diag pdated mar tes cyberse s to mitigat in Millions	ed systems nostic equip nufacturing (curity risks. e obsolesce <u>s)</u> n (NGDS) 1	and suppo oment, in or guidelines, In FY22, N nce and ma	rts post-fiel der to mitig supports FI MOD MED o aintain field	ate obsoles DA-required continued ar	cence and i post-marke nnual cyber es. In FY23	maintain fie eting commi security up , MOD MEI	lded cap itments (odates ar D transiti	abilities. It ex PMCs) and p Id manageme oned to UN7. FY 2022	ploits new an ost-marketin ent of hardwa	nd g are and
The MOD MED program supports devices, including FDA-approved emerging FDA-compliant technolo requirements (PMRs), and continu software configurations and addre 3. Accomplishments/Planned Pi Title: 1) MOD MED - Next Genera Description: Maintain Fielded Sys	improveme autoinjecto ogies and u ually mitigat essed efforts rograms (\$ ntion Diagno stems / Obs	ents to field rs and diag pdated man tes cyberse s to mitigat in Millions ostic Syster solescence	ed systems nostic equip nufacturing g curity risks. e obsolesce <u>s)</u> n (NGDS) 1 Manageme	and suppo oment, in or guidelines, In FY22, M nce and ma nt	rts post-fiel der to mitig supports FI MOD MED d aintain field Accomplis	ate obsoles DA-required continued ar ed capabiliti	cence and i post-marke nnual cyber es. In FY23	maintain fie eting commi security up , MOD MEI	lded cap itments (odates ar D transiti	abilities. It ex PMCs) and p id manageme oned to UN7 FY 2022 3.726	ploits new ar ost-marketin ent of hardwa FY 2023 - -	nd g are and
The MOD MED program supports devices, including FDA-approved emerging FDA-compliant technolo requirements (PMRs), and continu software configurations and addre B. Accomplishments/Planned Pr Title: 1) MOD MED - Next General	improveme autoinjecto ogies and u ually mitigat essed efforts rograms (\$ ntion Diagno stems / Obs	ents to field rs and diag pdated mar tes cyberse s to mitigat in Millions ostic Syster solescence Millions) 22 FY 2	ed systems nostic equip nufacturing (curity risks. e obsolesce s) n (NGDS) 1 Manageme	and suppo oment, in or guidelines, In FY22, M nce and ma nt	rts post-fiel der to mitig supports FI MOD MED d aintain field Accomplis	ate obsoles DA-required continued ar ed capabiliti	cence and i post-marke nnual cyber es. In FY23 anned Prog	maintain fie eting commi security up , MOD MEI	lded cap itments (odates ar D transiti	abilities. It ex PMCs) and p of manageme oned to UN7. FY 2022 3.726 3.726	ploits new an ost-marketin ent of hardwa FY 2023	nd g are and FY 2024

PE 0607384BP: *Chemical and Biological Defense (Operati...* Chemical and Biological Defense Program UNCLASSIFIED Page 82 of 91

R-1 Line #208

Volume 4 - 512

Exhibit R-2A, RDT&E Project Justi	fication: PB	2024 Chemi	cal and Biol	ogical Defen	ise Program				Date: Ma	arch 2023	
Appropriation/Budget Activity 0400 / 7				PE 06	rogram Eler 07384BP / (se (Operatio	Chemical and	,		Number/Na edical Biolog	a me) gical Defens	e (Op Sys
C. Other Program Funding Summa	ary (\$ in Milli	<u>ons)</u>									
Line Item	FY 2022	FY 2023	FY 2024	<u>FY 2024</u> OCO	<u>FY 2024</u> Total	FY 2025	FY 2026	FY 2027	FY 2028	<u>Cost To</u>	Total Cost
• UN7: Understand (Op Sys Dev)	<u>F T 2022</u> -	40.414	<u>Base</u> 50.603	-	50.603	58.881	71.869	68.839			Continuing
<u>Remarks</u>											

D. Acquisition Strategy

MODERNIZATION MEDICAL (MOD MED)

MOD MED ensures system upgrades for both hardware and software track to latest updates, including cybersecurity, for the commercial devices from the original equipment manufacturer. MOD MED will also fund development of additional assays (i.e. tests), for fielded systems, to address emerging biological threats and diseases. MOD MED leverages an existing Indefinite Delivery/Indefinite Quantity (IDIQ) Delivery Order contract for required system upgrades and assay development.

Exhibit R-3, RDT&E F	Project C	ost Analysis: PB 2	2024 Che	mical and	Biologica	al Defens	e Prograr	n				Date:	March 20	23	
Appropriation/Budge 0400 / 7	et Activity	/				PE 060	7384BP /	ement (N Chemica ional Syst	al and Bio	logical		t (Numbe i Medical Bi	r/ Name) ological D	efense ((Op Sys
Product Developmer	nt (\$ in M	illions)		FY 2	2022	FY 2	023	FY 2 Ba	2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
MOD MED - Product Management	Various	Various : N/A	-	1.264	Dec 2021	0.000		0.000		-		0.000	0.000	1.264	0.000
MOD MED - HW C - Next Generation Diagnostic System 1 (NGDS 1)	C/CPFF	BioFire Diagnostics : Salt Lake City, UT	-	2.036	Jan 2022	0.000		0.000		-		0.000	0.000	2.036	0.000
		Subtotal	-	3.300		0.000		0.000		-		0.000	0.000	3.300	N/A
Support (\$ in Million	s)			FY 2	2022	FY 2	023	FY 2 Ba	2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
MOD MED - ES S - NGDS 1 - Technical Support	C/CPFF	Battelle Memorial Institute : Aberdeen, MD	-	0.095	May 2022	0.000		0.000		-		0.000	0.000	0.095	0.000
		Subtotal	-	0.095		0.000		0.000		-		0.000	0.000	0.095	N/A
Management Service	es (\$ in M	lillions)		FY 2	2022	FY 2	023	FY 2 Ba	2024 Ise		2024 CO	FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
MOD MED - PM/MS C - Management Services	Various	Various : N/A	-	0.331	Feb 2022	0.000		0.000		-		0.000	0.000	0.331	0.000
		Subtotal	-	0.331		0.000		0.000		-		0.000	0.000	0.331	N/A
			Prior Years	FY 2	2022	FY 2	023		2024 Ise		2024 CO	FY 2024 Total	Cost To Complete	Total Cost	Target Value of Contract
		Project Cost Totals		3.726		0.000		0.000		-		0.000	0.000	3.726	N/A

PE 0607384BP: *Chemical and Biological Defense (Operati...* Chemical and Biological Defense Program

Volume 4 - 514

khibit R-4, RDT&E Schedule Profile: PB 2024	Cher	nica	l an	nd Bi	olo	gica	al D	efer	se	Prog	grar	n								_,			Dat	e: M	larc	:h 20	23		
ppropriation/Budget Activity 100 / 7								ŀ	PE (060	738	i m E 4BP)pera	I Ch	emi	cal a	and I	Biolo	ogic	al								efen	se (0	Op S
		FY	202	22		F	Y 2	2023			FY	202	4		FY	202	5		FY	202	6		FY	2027	7		FY	2028	8
	1	2	3	3 4		1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
MOD MED - Diagnostic System Upgrades / Assay Development																													
MOD MED - NGDS 1 Tech Refresh																													
MOD MED - Autoinjector Post Marketing Commitments and Requirements (PMRs/ PMCs)																													

xhibit R-4A, RDT&E Schedule Details: PB 2024 Chemical and Biological Defense Progr	am		Date: Mare	ch 2023
PE 060738	am Element (Numbe 4BP / Chemical and Operational Systems I	Biological	Project (Number/Nar MB7 I Medical Biologi Dev)	,
Schedule Det		art	E	nd
Events	Quarter	Year	Quarter	Year
MOD MED - Diagnostic System Upgrades / Assay Development	1	2023	4	2028
MOD MED - NGDS 1 Tech Refresh	4	2023	4	2028
MOD MED - Autoinjector Post Marketing Commitments and Requirements (PMRs/ PMCs)	1	2023	4	2028

Exhibit R-2A, RDT&E Project Ju	suncation:	FD 2024 C			1				1	Date: Mar		
Appropriation/Budget Activity 0400 / 7					PE 060738	am Elemen 34BP / Cher Operational	nical and B	ological		lumber/Na dical Chem	me) ical Defense	(Op Sys
COST (\$ in Millions)	Prior Years	FY 2022	FY 2023	FY 2024 Base	FY 2024 OCO	FY 2024 Total	FY 2025	FY 2026	FY 2027	FY 2028	Cost To Complete	Total Cost
MC7: Medical Chemical Defense (Op Sys Dev)	-	1.013	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000	1.01
Quantity of RDT&E Articles	-	-	-	-	-	-	-	-	-	-		
A. Mission Description and Bud	aet Item Ju	stification										
The effort included in this Project	ic:											
(1) Improved Nerve Agent Treatm	ient System	-		⁻ S CA) **P	rogresses to	o MT7 in FY	2023**					
(1) Improved Nerve Agent Treatm B. Accomplishments/Planned Planned Pla	ient System	-		⁻ S CA) **P	rogresses to	o MT7 in FY	2023**		F		FY 2023	FY 2024
(1) Improved Nerve Agent Treatm <u>B. Accomplishments/Planned Pr</u> <i>Title:</i> 1) INATS CA	nent System rograms (\$	in Millions	5)			o MT7 in FY	2023**		F	7 2022 0.800	FY 2023	FY 2024
(1) Improved Nerve Agent Treatm B. Accomplishments/Planned Planned Pla	nent System rograms (\$	in Millions	5)			o MT7 in FY	2023**		F		FY 2023 -	FY 2024
(1) Improved Nerve Agent Treatm <u>B. Accomplishments/Planned Pr</u> <i>Title:</i> 1) INATS CA	nent System rograms (\$	in Millions	5)			o MT7 in FY	2023**		F		FY 2023 - -	FY 2024 -
 (1) Improved Nerve Agent Treatm <u>B. Accomplishments/Planned Planned Plante</u> <i>Title:</i> 1) INATS CA <i>Description:</i> Pyridostigmine Brom 	nent System rograms (\$ nide (PB) Ex	in Millions	s) elease Table	t Developr	nent			e medical	F\	0.800	FY 2023 - -	FY 2024 -
(1) Improved Nerve Agent Treatm <u>B. Accomplishments/Planned Pr</u> <i>Title:</i> 1) INATS CA <i>Description:</i> Pyridostigmine Bron <i>Title:</i> 2) INATS CA <i>Description:</i> SNAPP Shelf Life M	nent System rograms (\$ nide (PB) Ex	in Millions	s) elease Table	t Developr	nent nd/or users t		e or upgrad			0.800	FY 2023 - - -	FY 2024 - -
(1) Improved Nerve Agent Treatm <u>B. Accomplishments/Planned Pr</u> <i>Title:</i> 1) INATS CA <i>Description:</i> Pyridostigmine Bron <i>Title:</i> 2) INATS CA <i>Description:</i> SNAPP Shelf Life M	nent System rograms (\$ nide (PB) Ex lodernization es.	in Millions	s) elease Table	t Developr	nent nd/or users t	o moderniz	e or upgrad			0.800	FY 2023 - - -	FY 2024 - -
(1) Improved Nerve Agent Treatments. B. Accomplishments/Planned Printile: 1) INATS CA Description: Pyridostigmine Browner Title: 2) INATS CA Description: SNAPP Shelf Life Michaenical defense countermeasure C. Other Program Funding Summer	nent System rograms (\$ nide (PB) Ex- lodernization es. mary (\$ in N	in Millions ktended Re n: Studies r Millions)	s) elease Table required by f	the FDA ar	nent nd/or users t Accomplis	o modernizo shments/Pla	e or upgrad anned Prog	yrams Sub	totals	0.800	- - - <u>Cost To</u>	-
 (1) Improved Nerve Agent Treatm B. Accomplishments/Planned Planned P	nent System rograms (\$ nide (PB) Ex lodernization es.	in Millions ktended Re n: Studies r <u>Millions)</u> 22 FY 2	s) elease Table required by f	the FDA ar	nent nd/or users t Accomplis	o modernizo shments/Pla	e or upgrad anned Prog	yrams Sub		0.800	- - - <u>Cost To</u>	- - - - -
(1) Improved Nerve Agent Treatm B. Accomplishments/Planned Pr <i>Title:</i> 1) INATS CA <i>Description:</i> Pyridostigmine Brom <i>Title:</i> 2) INATS CA <i>Description:</i> SNAPP Shelf Life M chemical defense countermeasure <u>C. Other Program Funding Sum</u> <u>Line Item</u>	nent System rograms (\$ nide (PB) Ex- lodernization es. mary (\$ in M FY 202	in Millions atended Re n: Studies r Millions) 22 FY 2 36 - 74.	<u>FY 2</u> <u>225 88 8 </u>	the FDA ar	nent Accomplis	to modernize shments/Pla (2024 Total F -	e or upgrad anned Prog	yrams Sub	totals	0.800 0.213 1.013 FY 2028 - 93.250	- - - <u>Cost To</u> Complete	- - - - - - - - - - - - - - - - - - -

PE 0607384BP: *Chemical and Biological Defense (Operati...* Chemical and Biological Defense Program UNCLASSIFIED Page 87 of 91

R-1 Line #208

Volume 4 - 517

Exhibit R-2A, RDT&E Project Just	ification: PB	2024 Chem	ical and Biol	ogical Defen	se Program				Date: Ma	rch 2023	
Appropriation/Budget Activity 0400 / 7				PE 06	07384BP / (ment (Numb Chemical and onal Systems			Number/Na edical Chem		e (Op Sys
C. Other Program Funding Summ	ary (\$ in Milli	ons)		,							
			FY 2024	FY 2024	FY 2024					Cost To	-
<u>Line Item</u> • PHM040: Improved Nerve Agent Treatment Centrally Acting (INATS CA)	<u>FY 2022</u> -	<u>FY 2023</u> -	<u>Base</u> -	<u>000</u> -	<u>Total</u> -	<u>FY 2025</u> -	<u>FY 2026</u> -	<u>FY 2027</u> 6.511		Complete Continuing	
Remarks											
approvals and/or licenses. Upon F (FOC). The pyridostigmine bromide (PB) m				-		-	-				
The pyriodslightine brothide (FD) h	IUUEIIIIZALIUII			conducting	developmen		J activities to	generate ua			٦.

EXHIBIT R-3, RDI&E	Project C	ost Analysis: PB 2	024 Cher	nical and	l Biologica	al Defense	e Prograr	n				Date:	March 20	23	
Appropriation/Budge 0400 / 7	et Activity	,				PE 060	7384BP /	Chemica	umber/Na al and Biol tems Dev	, logical	-	(Number Medical Cl	r/ Name) hemical De	efense (C	Dp Sys
Product Developme	nt (\$ in Mi	llions)		FY 2	2022	FY 2	023	FY 2 Ba	-	FY 2 OC		FY 2024 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
INATS CA - Shelf Life Modernization (SNAPP)	C/CPFF	CMC Pharma : Cleveland, OH	0.449	0.196	Jun 2022	0.000		0.000		-		0.000	0.000	0.645	0.000
INATS CA - HW C - PB Extended Release	C/FFP	Amneal Pharmaceuticals : Hauppauge, NY	1.179	0.737	Nov 2021	0.000		0.000		-		0.000	0.000	1.916	0.000
		Subtotal	1.628	0.933		0.000		0.000		-		0.000	0.000	2.561	N/A
						ļ									
Management Service	es (\$ in M	illions)		FY 2	2022	FY 2	023	FY 2 Ba	-	FY 2 OC		FY 2024 Total			
Management Service	es (\$ in M Contract Method & Type	illions) Performing Activity & Location	Prior Years	FY 2 Cost	2022 Award Date	FY 2 Cost	023 Award Date		-				Cost To Complete	Total Cost	Target Value of Contract
Cost Category Item	Contract Method	Performing	-	Cost	Award		Award	Ba	se Award	00	Award	Total			•
Cost Category Item	Contract Method & Type	Performing Activity & Location JPEO Chem, Bio, Rad, and Nuc Defense (JPEO- CBRND) : Aberdeen	Years	Cost	Award Date	Cost	Award	Ba Cost	se Award	00	Award	Total Cost	Complete	Cost	Value of Contract
Management Service Cost Category Item INATS CA - Management Services	Contract Method & Type	Performing Activity & Location JPEO Chem, Bio, Rad, and Nuc Defense (JPEO- CBRND) : Aberdeen Proving Ground, MD	Years 0.126	Cost 0.080 0.080	Award Date	Cost 0.000	Award Date	Ba Cost 0.000	Se Award Date	OC Cost -	20 Award Date	Total Cost 0.000	Complete 0.000	Cost 0.206	Value of Contract

xhibit R-4, RDT&E Schedule Profile: PB 2024	Che	mica	al an	d B	iolo	gica	al D	Defe	ense	e Pro	ogra	m													Da	te: N	Var	rch	202	23		
ppropriation/Budget Activity 400 / 7									PE	1 Pr 5 060 efens	0738	34B	Ρ/	Che	mi	cal a	and	Biol	logic	al	Ν	-	I N	•		ber/ Ch			•	fens	se (C	Dp S
		FY	202	2		F	FY	202	3		FY	′ 2()24			FY	202	25		F	Y 20	26			FY	202	27			FY :	2028	
	1	2	2 3	4	<u>ا</u>	1	2	3	4	1 1	2	2	3	4	1	2	3	4	1		2	3	4	1	2	3	; ;	4	1	2	3	4
INATS CA - MS B-Milestone B																							l						l			
INATS CA - Clinical Trials																															-	
INATS CA - Manufacturing/Auto-Injector																																
INATS CA - Non-Clinical Studies																																
INATS CA - NDA Submission-New Drug Application Submission																																
INATS CA - FDA Approval-Food and Drug Administration Approval																														. <u> </u>		
INATS CA - SNAPP Modernization - BA7																																
INATS CA - PB Extended Release Tablet Development - BA7																																

chibit R-4A, RDT&E Schedule Details: PB 2024 Chemical and Biological	I Defense Program			Date: Ma	arch 2023
opropriation/Budget Activity 00 / 7	PE 0607384BF	Element (Numbe P I Chemical and rational Systems I	Biological	Project (Number/Na MC7 / Medical Chen Dev)	a me) nical Defense (Op Sys
S	Schedule Details	3			
		St	art		End
Events		Quarter	Year	Quarter	Year
INATS CA - MS B-Milestone B		2	2022	2	2022
INATS CA - Clinical Trials		1	2022	4	2024
INATS CA - Manufacturing/Auto-Injector		1	2022	2	2025
INATS CA - Non-Clinical Studies		1	2022	2	2025
INATS CA - NDA Submission-New Drug Application Submission		1	2026	3	2026
INATS CA - FDA Approval-Food and Drug Administration Approval		3	2026	1	2028
INATS CA - SNAPP Modernization - BA7		1	2022	4	2025
INATS CA - PB Extended Release Tablet Development - BA7		1	2023	1	2026

THIS PAGE INTENTIONALLY LEFT BLANK